FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Joshi, G
Petty, C
Wozniak, J
Faraone, SV
Spencer, AE
Woodworth, KY
Shelley-Abrahamson, R
McKillop, H
Furtak, SL
Biederman, J
AF Joshi, Gagan
Petty, Carter
Wozniak, Janet
Faraone, Stephen V.
Spencer, Andrea E.
Woodworth, K. Yvonne
Shelley-Abrahamson, Rachel
McKillop, Hannah
Furtak, Stephannie L.
Biederman, Joseph
TI A prospective open-label trial of paliperidone monotherapy for the
treatment of bipolar spectrum disorders in children and adolescents
SO PSYCHOPHARMACOLOGY
LA English
DT Article
DE Bipolar disorder; Paliperidone; Youth; Treatment
ID MANIA RATING-SCALE; METAANALYSIS; COMORBIDITY; RELIABILITY; RISPERIDONE;
PREDICTORS; SEVERITY; VALIDITY
AB Treatment studies for the management of pediatric bipolar disorder are limited.
This study evaluates the safety and efficacy of paliperidone monotherapy as an acute treatment of mania and related symptoms in youth with bipolar spectrum disorders.
An 8-week, prospective, open-label paliperidone monotherapy trial to assess effectiveness and tolerability in treating pediatric bipolar spectrum and related disorders (depression, psychosis, attention-deficit/hyperactivity disorder [ADHD]). Assessments included the Young Mania Rating Scale (YMRS), Clinical Global Impression scale (CGI), Children's Depression Rating Scale-Revised (CDRS-R), and Brief Psychiatric Rating Scale (BPRS). Adverse events were assessed through spontaneous self-reports, vital signs, weight monitoring, and laboratory analysis.
Fifteen youth with bipolar spectrum disorders (YMRS at entry: 32.8 +/- 6.1) were enrolled in the study and 11 (73 %) completed the 8-week trial. The total daily dose of paliperidone at study endpoint was 3 mg in 12 subjects and 6 mg in three subjects. Treatment with paliperidone was associated with statistically significant levels of improvement in mean YMRS scores (-18.7 +/- 13.9, p < 0.001) at endpoint. Paliperidone treatment also resulted in significant improvement in the severity of ADHD and psychotic symptoms. Although treatment with paliperidone was generally well tolerated and was not associated with clinically significant change in cardiovascular or metabolic parameters, increases in body weight (4.1 +/- 5.5 lb) were substantial.
Open-label paliperidone treatment appears to be beneficial in the treatment of bipolar spectrum disorders and associated conditions in youth. Future placebo-controlled studies are warranted to confirm these findings.
C1 [Joshi, Gagan; Petty, Carter; Wozniak, Janet; Spencer, Andrea E.; Woodworth, K. Yvonne; Shelley-Abrahamson, Rachel; McKillop, Hannah; Furtak, Stephannie L.; Biederman, Joseph] Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, Boston, MA 02114 USA.
[Joshi, Gagan; Wozniak, Janet; Spencer, Andrea E.; Biederman, Joseph] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Faraone, Stephen V.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA.
RP Biederman, J (reprint author), Massachusetts Gen Hosp, Clin & Res Program Pediat Psychopharmacol & Adult, 55 Fruit St,YAW 6900, Boston, MA 02114 USA.
EM jbiederman@partners.org
OI Faraone, Stephen/0000-0002-9217-3982
NR 33
TC 4
Z9 4
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0033-3158
J9 PSYCHOPHARMACOLOGY
JI Psychopharmacology
PD JUN
PY 2013
VL 227
IS 3
BP 449
EP 458
DI 10.1007/s00213-013-2970-7
PG 10
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 147IW
UT WOS:000319161100008
PM 23397049
ER
PT J
AU Sayegh, RR
Dohlman, CH
AF Sayegh, Rony R.
Dohlman, Claes H.
TI WIDE-ANGLE FUNDUS IMAGING THROUGH THE BOSTON KERATOPROSTHESIS
SO RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
LA English
DT Article
DE keratoprosthesis; optics; imaging; fundus; retina
ID PERMANENT KERATOPROSTHESIS; SILICONE OIL; MANAGEMENT; HYPOTONY; LESIONS;
EYES
AB Purpose: To explore the feasibility and compare the outcomes of three wide-angle fundus cameras for imaging the peripheral retina through the Type 1 Boston keratoprosthesis.
Methods: The noncontact Optos and the contact RetCam and Panoret wide-angle imaging systems were used to image the retina of eyes implanted with a keratoprosthesis. The failure-to-image rate, ease of acquisition, and quality of the images were noted, and the field of view was compared. Limitations and complications were recorded. Optos was then performed on patients referred for ultrasound B-scan evaluation, and the imaging findings were correlated.
Results: Retinal images with all three cameras were obtained on four eyes. Optos could be performed on all four eyes, RetCam on three, and Panoret on two. The field of view was comparable between the three different cameras. The best quality images were obtained with Optos. The external illumination of the Panoret made it impossible to image the only darkly pigmented individual in the series. Both contact devices failed to image another patient who was too agitated. Two patients had some ocular irritation from the coupling agent that resolved with replacement of the contact lens. Optos images were obtained on an additional six eyes, and findings correlated well with those on B-scan. Optos was superior to B-scan in an eye with silicone oil filling.
Conclusion: Wide-angle fundus imaging through the keratoprosthesis is possible, and all three cameras performed similarly. The good quality of pictures obtained with the noncontact Optos, as well as its ease of use, comfort, and safety make it a preferred choice. Optos complements B-scan in the examination of the peripheral retina through the keratoprosthesis, and it may even be superior in certain settings.
C1 [Sayegh, Rony R.; Dohlman, Claes H.] Harvard Univ, Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Sch Med, Boston, MA 02114 USA.
RP Dohlman, CH (reprint author), Massachusetts Eye & Ear Infirm, 243 Charles St, Boston, MA 02114 USA.
EM claes_dohlman@meei.harvard.edu
RI Sayegh, Rony/G-8777-2013
OI Sayegh, Rony/0000-0002-0119-4201
FU Massachusetts Eye and Ear Infirmary
FX Supported by the Keratoprosthesis Fund from the Massachusetts Eye and
Ear Infirmary.
NR 17
TC 3
Z9 3
U1 0
U2 6
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0275-004X
J9 RETINA-J RET VIT DIS
JI Retin.-J. Retin. Vitr. Dis.
PD JUN
PY 2013
VL 33
IS 6
BP 1188
EP 1192
DI 10.1097/IAE.0b013e3182869ec2
PG 5
WC Ophthalmology
SC Ophthalmology
GA 151IU
UT WOS:000319454700015
PM 23416513
ER
PT J
AU Singh, JA
Lewallen, DG
AF Singh, Jasvinder A.
Lewallen, David G.
TI Patient-level clinically meaningful improvements in activities of daily
living and pain after total hip arthroplasty: data from a large US
institutional registry
SO RHEUMATOLOGY
LA English
DT Article
DE pain; activity limitation; activities of daily living; function;
functional limitation; total hip replacement; arthroplasty; joint
replacement; outcomes; patient-reported outcomes; primary; revision
ID QUALITY-OF-LIFE; TOTAL KNEE ARTHROPLASTY; REVISION HIP; OUTCOMES;
QUESTIONNAIRE; EXPECTATIONS; PREDICTORS; RESPONSIVENESS; REPLACEMENT;
COMORBIDITY
AB Objective. To characterize patient-level clinically meaningful improvements in pain and limitation of key activities of daily living (ADLs) after primary or revision total hip arthroplasty (THA).
Methods. We analysed prospectively collected data from the Mayo Clinic Total Joint Registry to study clinically meaningful improvements in index hip pain severity and limitation in seven key ADLs (walking, climbing stairs, putting on shoes/socks, picking up objects, getting in/out of car, rising from a chair and sitting), from preoperative to 2- and 5-year post-THA.
Results. The primary THA cohort consisted of 6168 responders preoperatively, 5707 at 2 years and 3289 at 5 years postoperatively. The revision THA cohort consisted of 2063 responders preoperatively, 2682 at 2 years and 1627 at 5 years postoperatively. In the primary THA cohort, clinically meaningful pain reduction to mild or no hip pain at 2 years was reported by 94% with moderate and 91% with severe preoperative pain; respective proportions were 91% and 89% at 5-year follow-up. For revision THA, respective proportions were 84% and 77% at 2 years and 80% and 78% at 5 years. In the primary THA cohort, up to 4% with moderate and 17% with severe preoperative ADL limitation reported severe limitation in the respective activity 2 years post-primary THA; at 5 years, the respective proportions were up to 7% and 20%. Respective proportions for revision THA were up to 10% and 26% at 2 years and 13% and 30% at 5 years.
Conclusions. These comprehensive data for patient-level clinically meaningful improvements in pain and seven key ADLs can help patients set realistic goals for improvement after THA.
C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL USA.
[Singh, Jasvinder A.] Birmingham VA Med Ctr, Ctr Surg Med Acute Care Res & Transit C SMART, Birmingham, AL USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA.
[Singh, Jasvinder A.; Lewallen, David G.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA.
RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA.
EM jasvinder.md@gmail.com
OI singh, jasvinder/0000-0003-3485-0006
FU Mayo Clinic Orthopedic Surgery research funds, National Institutes of
Health (NIH) [1 KL2 RR024151-01]
FX This work was supported by research grants from the Mayo Clinic
Orthopedic Surgery research funds, National Institutes of Health (NIH)
Clinical Translational Science Award 1 KL2 RR024151-01 (Mayo Clinic
Center for Clinical and Translational Research) and the resources and
use of facilities at the Birmingham VA Medical Center, Birmingham, AL,
USA.
NR 28
TC 2
Z9 2
U1 0
U2 1
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 1462-0324
J9 RHEUMATOLOGY
JI RHEUMATOLOGY
PD JUN
PY 2013
VL 52
IS 6
BP 1109
EP 1118
DI 10.1093/rheumatology/kes416
PG 10
WC Rheumatology
SC Rheumatology
GA 151KS
UT WOS:000319460000019
PM 23382362
ER
PT J
AU Ayata, C
AF Ayata, Cenk
TI Spreading Depression and Neurovascular Coupling
SO STROKE
LA English
DT Article; Proceedings Paper
CT 28th Princeton Conference
CY MAY 17-19, 2012
CL Cincinnati, OH
DE brain injury; neurovascular coupling; spreading depression; stroke
ID BLOOD-FLOW RESPONSE; CEREBRAL-CORTEX; MIGRAINE; DEPOLARIZATIONS;
HYPOPERFUSION; RAT; HYPEREMIA; PERFUSION; SCOTOMAS; ISCHEMIA
C1 [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp,Stroke Serv, Dept Radiol,Neurovasc Res Lab,Dept Neurol, Charlestown, MA USA.
[Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Intens Care Unit, Charlestown, MA USA.
RP Ayata, C (reprint author), Massachusetts Gen Hosp, 149 13th St,Room 6408, Charlestown, MA 02129 USA.
EM cayata@partners.org
FU NINDS NIH HHS [NS061505, NS055104]
NR 24
TC 27
Z9 27
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2013
VL 44
IS 6
SU 1
BP S87
EP S89
DI 10.1161/STROKEAHA.112.680264
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 151KI
UT WOS:000319459000032
PM 23709742
ER
PT J
AU Bauer, KA
AF Bauer, Kenneth A.
TI Dabigatran, ROCKET Atrial Fibrillation, and Beyond Basic Science,
Mechanisms of Agents, Monitoring, and Reversal
SO STROKE
LA English
DT Article; Proceedings Paper
CT 28th Princeton Conference
CY MAY 17-19, 2012
CL Cincinnati, OH
DE apixaban; atrial fibrillation; dabigatran; international normalized
ratio; prothrombin time; rivaroxaban; vitamin K antagonists
ID NEWER ORAL ANTICOAGULANTS; PREVENT THROMBOEMBOLISM; 1ST-LINE AGENTS;
RISK-FACTORS; FACTOR XA; THROMBIN; STROKE; WARFARIN; RIVAROXABAN;
INHIBITORS
C1 Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
VA Boston Healthcare Syst, Boston, MA USA.
RP Bauer, KA (reprint author), Beth Israel Deaconess Med Ctr, 330 Brookline Ave, Boston, MA 02215 USA.
EM kbauer@bidmc.harvard.edu
NR 15
TC 5
Z9 6
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2013
VL 44
IS 6
SU 1
BP S38
EP S40
DI 10.1161/STROKEAHA.111.000387
PG 3
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 151KI
UT WOS:000319459000016
PM 23709725
ER
PT J
AU Biffi, A
Anderson, CD
Falcone, GJ
Kissela, B
Norrving, B
Tirschwell, DL
Selim, M
Brown, DL
Silliman, SL
Worrall, BB
Meschia, JF
Kidwell, CS
Broderick, JP
Greenberg, SM
Roquer, J
Lindgren, A
Slowik, A
Schmidt, R
Woo, D
Rosand, J
AF Biffi, Alessandro
Anderson, Christopher D.
Falcone, Guido J.
Kissela, Brett
Norrving, Bo
Tirschwell, David L.
Selim, Magdy
Brown, Devin L.
Silliman, Scott L.
Worrall, Bradford B.
Meschia, James F.
Kidwell, Chelsea S.
Broderick, Joseph P.
Greenberg, Steven M.
Roquer, Jaume
Lindgren, Arne
Slowik, Agnieszka
Schmidt, Reinhold
Woo, Daniel
Rosand, Jonathan
CA Int Stroke Genetics Consortium
TI Novel Insights Into the Genetics of Intracerebral Hemorrhage
SO STROKE
LA English
DT Article; Proceedings Paper
CT 28th Princeton Conference
CY MAY 17-19, 2012
CL Cincinnati, OH
C1 [Biffi, Alessandro; Anderson, Christopher D.; Falcone, Guido J.; Greenberg, Steven M.] Massachusetts Gen Hosp, Hemorrhag Stroke Res Grp, Boston, MA 02114 USA.
[Biffi, Alessandro; Anderson, Christopher D.; Falcone, Guido J.] Massachusetts Gen Hosp, Div Neurocrit Care & Emergency Neurol, Dept Neurol, Boston, MA 02114 USA.
[Biffi, Alessandro; Anderson, Christopher D.; Falcone, Guido J.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Biffi, Alessandro; Anderson, Christopher D.; Falcone, Guido J.] Broad Inst, Program Med & Populat Genet, Cambridge, MA USA.
[Kissela, Brett; Broderick, Joseph P.; Woo, Daniel] Univ Cincinnati, Coll Med, Dept Neurol, Cincinnati, OH USA.
[Norrving, Bo; Lindgren, Arne] Lund Univ, Dept Clin Sci Lund, Lund, Sweden.
[Norrving, Bo; Lindgren, Arne] Skane Univ Hosp, Dept Neurol, Lund, Sweden.
[Tirschwell, David L.] Univ Washington, Harborview Med Ctr, Stroke Ctr, Seattle, WA 98104 USA.
[Selim, Magdy] Beth Israel Deaconess Med Ctr, Dept Neurol, Boston, MA 02215 USA.
[Brown, Devin L.] Univ Michigan Hlth Syst, Dept Neurol, Stroke Program, Ann Arbor, MI USA.
[Silliman, Scott L.] Univ Florida, Coll Med, Dept Neurol, Jacksonville, FL USA.
[Worrall, Bradford B.] Univ Virginia Hlth Syst, Dept Neurol & Publ Hlth Sci, Charlottesville, VA USA.
[Meschia, James F.] Mayo Clin, Dept Neurol, Jacksonville, FL 32224 USA.
[Kidwell, Chelsea S.] Georgetown Univ, Med Ctr, Dept Neurol, Washington, DC 20007 USA.
Hosp del Mar, Inst Municipal Invest Med, Dept Neurol, Neurovasc Res Unit, Barcelona, Spain.
[Slowik, Agnieszka] Hosp del Mar, Inst Municipal Invest Med, Program Inflammat & Cardiovasc Disorders, Barcelona, Spain.
[Schmidt, Reinhold] Univ Autonoma Barcelona, Neurovasc Res Unit, Dept Neurol, E-08193 Barcelona, Spain.
[Schmidt, Reinhold] Univ Autonoma Barcelona, Program Inflammat & Cardiovasc Disorders, E-08193 Barcelona, Spain.
[Slowik, Agnieszka] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland.
[Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Graz, Austria.
RP Biffi, A (reprint author), Massachusetts Gen Hosp, CPZN 6818,Simches Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM biffi@chgr.mgh.harvard.edu
RI Falcone, Guido/L-2287-2016;
OI Falcone, Guido/0000-0002-6407-0302; Brown, Devin/0000-0002-9815-3421;
Norrving, Bo/0000-0002-8024-5096; Anderson,
Christopher/0000-0002-0053-2002; Kissela, Brett/0000-0002-9773-4013
FU NCATS NIH HHS [UL1 TR000077]; NINDS NIH HHS [R01 NS059727]
NR 0
TC 1
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2013
VL 44
IS 6
SU 1
BP S137
EP S137
DI 10.1161/STROKEAHA.113.001912
PG 1
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 151KI
UT WOS:000319459000052
PM 23709713
ER
PT J
AU Schwamm, LH
AF Schwamm, Lee H.
TI Measuring and Changing the Quality of Care via National Registries
SO STROKE
LA English
DT Article; Proceedings Paper
CT 28th Princeton Conference
CY MAY 17-19, 2012
CL Cincinnati, OH
DE quality improvement; registries; stroke
ID ACUTE ISCHEMIC-STROKE; GUIDELINES-STROKE; MEDICARE BENEFICIARIES;
PERFORMANCE-MEASURES; PLASMINOGEN-ACTIVATOR; 30-DAY MORTALITY; OUTCOMES;
ASSOCIATION; PROGRAM; NETWORK
C1 [Schwamm, Lee H.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Schwamm, LH (reprint author), Massachusetts Gen Hosp, Dept Neurol ACC 720, 55 Fruit St, Boston, MA 02114 USA.
EM lschwamm@partners.org
OI Schwamm, Lee/0000-0003-0592-9145
NR 26
TC 2
Z9 3
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2013
VL 44
IS 6
SU 1
BP S132
EP S135
DI 10.1161/STROKEAHA.111.000049
PG 4
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA 151KI
UT WOS:000319459000050
PM 23709711
ER
PT J
AU Olden, M
Teumer, A
Bochud, M
Pattaro, C
Kottgen, A
Turner, ST
Rettig, R
Chen, MH
Dehghan, A
Bastardot, F
Schmidt, R
Vollenweider, P
Schunkert, H
Reilly, MP
Fornage, M
Launer, LJ
Verwoert, GC
Mitchell, GF
Bis, JC
O'Donnell, CJ
Cheng, CY
Sim, X
Siscovick, DS
Coresh, J
Kao, WHL
Fox, CS
O'Seaghdha, CM
AF Olden, Matthias
Teumer, Alexander
Bochud, Murielle
Pattaro, Cristian
Koettgen, Anna
Turner, Stephen T.
Rettig, Rainer
Chen, Ming-Huei
Dehghan, Abbas
Bastardot, Francois
Schmidt, Reinhold
Vollenweider, Peter
Schunkert, Heribert
Reilly, Muredach P.
Fornage, Myriam
Launer, Lenore J.
Verwoert, Germaine C.
Mitchell, Gary F.
Bis, Joshua C.
O'Donnell, Christopher J.
Cheng, Ching-Yu
Sim, Xueling
Siscovick, David S.
Coresh, Josef
Kao, W. H. Linda
Fox, Caroline S.
O'Seaghdha, Conall M.
CA AortaGen
CARDIoGRAM
CHARGE Eye
CHARGE IMT
ICBP
NeuroCHARGE
CKDGen Consortia
TI Overlap Between Common Genetic Polymorphisms Underpinning Kidney Traits
and Cardiovascular Disease Phenotypes: The CKDGen Consortium
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Cardiovascular disease; chronic kidney disease; genomics;
single-nucleotide polymorphism (SNP)
ID GENOME-WIDE ASSOCIATION; GLOMERULAR-FILTRATION-RATE;
CORONARY-HEART-DISEASE; UNITED-STATES; RISK-FACTORS; CYSTATIN-C;
METAANALYSIS; MORTALITY; LOCI; ALBUMINURIA
AB Background: Chronic kidney disease is associated with cardiovascular disease. We tested for evidence of a shared genetic basis to these traits.
Study Design: We conducted 2 targeted analyses. First, we examined whether known single-nucleotide polymorphisms (SNPs) underpinning kidney traits were associated with a series of vascular phenotypes. Additionally, we tested whether vascular SNPs were associated with markers of kidney damage. Significance was set to 1.5 x 10(-4) (0.05/325 tests).
Setting & Participants: Vascular outcomes were analyzed in participants from the AortaGen (20,634), CARDIoGRAM (86,995), CHARGE Eye (15,358), CHARGE IMT (31,181), ICBP (69,395), and NeuroCHARGE (12,385) consortia. Tests for kidney outcomes were conducted in up to 67,093 participants from the CKDGen consortium.
Predictor: We used 19 kidney SNPs and 64 vascular SNPs.
Outcomes & Measurements: Vascular outcomes tested were blood pressure, coronary artery disease, carotid intima-media thickness, pulse wave velocity, retinal venular caliber, and brain white matter lesions. Kidney outcomes were estimated glomerular filtration rate and albuminuria.
Results: In general, we found that kidney disease variants were not associated with vascular phenotypes (127 of 133 tests were nonsignificant). The one exception was rs653178 near SH2B3 (SH2B adaptor protein 3), which showed direction-consistent association with systolic (P = 9.3 x 10(-10)) and diastolic (P = 1.6 x 10(-14)) blood pressure and coronary artery disease (P = 2.2 x 10(-6)), all previously reported. Similarly, the 64 SNPs associated with vascular phenotypes were not associated with kidney phenotypes (187 of 192 tests were nonsignificant), with the exception of 2 high-correlated SNPs at the SH2B3 locus (P = 1.06 x 10(-07) and P = 7.05 x 10(-08)).
Limitations: The combined effect size of the SNPs for kidney and vascular outcomes may be too low to detect shared genetic associations.
Conclusions: Overall, although we confirmed one locus (SH2B3) as associated with both kidney and cardiovascular disease, our primary findings suggest that there is little overlap between kidney and cardiovascular disease risk variants in the overall population. The reciprocal risks of kidney and cardiovascular disease may not be genetically mediated, but rather a function of the disease milieu itself. (c) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Olden, Matthias; Chen, Ming-Huei; O'Donnell, Christopher J.; Fox, Caroline S.; O'Seaghdha, Conall M.] NHLBI, Framingham Heart Study, Framingham, MA 01702 USA.
[Teumer, Alexander] Ernst Moritz Arndt Univ Greifswald, Interfac Inst Genet & Funct Genom, Greifswald, Germany.
[Bochud, Murielle] CHU Vaudois, Inst Social & Prevent Med IUMSP, Lausanne, Switzerland.
[Bochud, Murielle; Bastardot, Francois] Fac Biol & Med, Lausanne, Switzerland.
[Pattaro, Cristian] European Acad Bolzano Bozen EURAC, Inst Med Genet, Bolzano, Italy.
[Pattaro, Cristian] Med Univ Lubeck, D-23538 Lubeck, Germany.
[Koettgen, Anna; Kao, W. H. Linda] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA.
[Koettgen, Anna] Univ Hosp Freiburg, Div Renal, Freiburg, Germany.
[Turner, Stephen T.] Mayo Clin, Dept Internal Med, Div Nephrol & Hypertens, Rochester, MN USA.
[Rettig, Rainer] Ernst Moritz Arndt Univ Greifswald, Inst Physiol, Greifswald, Germany.
[Chen, Ming-Huei] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Dehghan, Abbas] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
[Dehghan, Abbas] NCHA, Leiden, Netherlands.
[Bastardot, Francois] CHU Vaudois, Dept Med, Lausanne, Switzerland.
[Schmidt, Reinhold] Med Univ Graz, Dept Neurol, Graz, Austria.
[Vollenweider, Peter] CHU Vaudois, Dept Internal Med, CH-1011 Lausanne, Switzerland.
[Schunkert, Heribert] Med Univ Lubeck, Med Klin 2, D-23538 Lubeck, Germany.
[Reilly, Muredach P.] Univ Penn, Perelman Sch Med, Cardiovasc Inst, Philadelphia, PA 19104 USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Brown Fdn Inst Mol Med, Houston, TX USA.
[Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Div Epidemiol, Sch Publ Hlth, Houston, TX USA.
[Launer, Lenore J.] NIA, Lab Epidemiol Demog & Biometry, Intramural Res Program, NIH, Bethesda, MD 20892 USA.
[Verwoert, Germaine C.] Erasmus MC, Dept Internal Med, Dept Epidemiol, Rotterdam, Netherlands.
[Mitchell, Gary F.] Cardiovasc Engn Inc, Norwood, MA USA.
[Bis, Joshua C.; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Bis, Joshua C.; Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA 98195 USA.
[Cheng, Ching-Yu] Singapore Eye Res Inst, Singapore, Singapore.
[Cheng, Ching-Yu] Saw Swee Hock Sch Publ Hlth, Singapore, Singapore.
[Cheng, Ching-Yu] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Ophthalmol, Singapore 117595, Singapore.
[Cheng, Ching-Yu] Duke NUS Grad Med Sch, Off Clin Sci, Ctr Quantitat Med, Singapore, Singapore.
[Sim, Xueling] Natl Univ Singapore, Yong Loo Lin Sch Med, Ctr Mol Epidemiol, Singapore 117595, Singapore.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Siscovick, David S.] Univ Washington, Dept Med, Seattle, WA USA.
[Coresh, Josef; Kao, W. H. Linda] Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD USA.
[Fox, Caroline S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Fox, Caroline S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP O'Seaghdha, CM (reprint author), NHLBI, Framingham Heart Study, 73 Mt Wayte Ave,Ste 2, Framingham, MA 01702 USA.
EM conall.o'seaghdha@nih.gov
RI Cheng, Ching-Yu/K-7017-2013; Bochud, Murielle/A-3981-2010; Colaus,
PsyColaus/K-6607-2013
OI Cheng, Ching-Yu/0000-0003-0655-885X; Bochud,
Murielle/0000-0002-5727-0218; Dehghan, Abbas/0000-0001-6403-016X;
FU NHLBI's Framingham Heart Study [N01-HC-25195]
FX This research was conducted in part using data and resources from the
Framingham Heart Study of the National Heart, Lung and Blood Institute
(NHLBI) of the National Institutes of Health and Boston University
School of Medicine. This work was supported in part by the NHLBI's
Framingham Heart Study (contract N01-HC-25195). Full information on
funding of the GWAS performed by the involved consortia is available in
the consortia's previously published articles. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 37
TC 15
Z9 15
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUN
PY 2013
VL 61
IS 6
BP 889
EP 898
DI 10.1053/j.ajkd.2012.12.024
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA 145FC
UT WOS:000318999200009
PM 23474010
ER
PT J
AU Sasaki, K
Anderson, E
Shankland, SJ
Nicosia, RF
AF Sasaki, Kotaro
Anderson, Eric
Shankland, Stuart J.
Nicosia, Roberto F.
TI Diffuse Proliferative Glomerulonephritis Associated With Cetuximab, an
Epidermal Growth Factor Receptor Inhibitor
SO AMERICAN JOURNAL OF KIDNEY DISEASES
LA English
DT Article
DE Immunoglobulin A (IgA); diffuse proliferative glomerulonephritis;
cetuximab
ID IGA NEPHROPATHY; DISEASE
AB Cetuximab is an epidermal growth factor receptor inhibitor used for advanced squamous cell carcinoma of the head and neck. We report an unusual case of diffuse proliferative and crescentic glomerulonephritis in a 67-year-old man in close temporal association with cetuximab treatment for recurrent oral squamous cell carcinoma. The patient presented with acute renal failure and nephrotic-range proteinuria. Kidney biopsy showed diffuse proliferative and focally crescentic glomerulonephritis associated with immunoglobulin A (IgA)-dominant immune-complex deposition within glomerular capillary walls and mesangium. The patient showed dramatic improvement in kidney function after discontinuation of cetuximab therapy and a short course of cyclophosphamide and steroid. The clinical outcome of this case suggests that cetuximab therapy may trigger or exacerbate IgA-mediated glomerular injury and warrants close monitoring of kidney function in patients treated with this epidermal growth factor receptor inhibitor. (c) 2013 by the National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.
C1 [Sasaki, Kotaro; Nicosia, Roberto F.] Univ Washington, Med Ctr, Dept Pathol, Seattle, WA 98195 USA.
[Anderson, Eric; Shankland, Stuart J.] Univ Washington, Med Ctr, Dept Nephrol, Seattle, WA 98195 USA.
[Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Pathol Serv, Seattle, WA USA.
[Nicosia, Roberto F.] VA Puget Sound Hlth Care Syst, Lab Med Serv, Seattle, WA USA.
RP Sasaki, K (reprint author), Univ Washington, Med Ctr, 1959 NE Pacific,Box 356100, Seattle, WA 98195 USA.
EM ksasaki@uw.edu
NR 9
TC 5
Z9 6
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-6386
J9 AM J KIDNEY DIS
JI Am. J. Kidney Dis.
PD JUN
PY 2013
VL 61
IS 6
BP 988
EP 991
DI 10.1053/j.ajkd.2013.01.008
PG 4
WC Urology & Nephrology
SC Urology & Nephrology
GA 145FC
UT WOS:000318999200021
PM 23474009
ER
PT J
AU van Setten, J
Isgum, I
Smolonska, J
Ripke, S
de Jong, PA
Oudkerk, M
de Koning, H
Lammers, JWJ
Zanen, P
Groen, HJM
Boezen, HM
Postma, DS
Wijmenga, C
Viergever, MA
Mali, WPTM
de Bakker, PIW
AF van Setten, Jessica
Isgum, Ivana
Smolonska, Joanna
Ripke, Stephan
de Jong, Pim A.
Oudkerk, Matthijs
de Koning, Harry
Lammers, Jan-Willem J.
Zanen, Pieter
Groen, Harry J. M.
Boezen, H. Marike
Postma, Dirkje S.
Wijmenga, Cisca
Viergever, Max A.
Mali, Willem P. Th. M.
de Bakker, Paul I. W.
TI Genome-wide association study of coronary and aortic calcification
implicates risk loci for coronary artery disease and myocardial
infarction
SO ATHEROSCLEROSIS
LA English
DT Article
DE Genetics; Calcium; Arteries; Atherosclerosis; Imaging
ID ALL-CAUSE MORTALITY; COMPUTED-TOMOGRAPHY; CHROMOSOME 9P21; POPULATION;
CALCIUM; PROTEIN; CELLS; INDIVIDUALS; PREDICTION; DEPOSITS
AB Arterial calcification is a well-known risk factor for coronary artery disease (CAD) and myocardial infarction (MI). We performed a genome-wide association study on coronary artery calcification and aortic calcification as intermediate traits for CAD/MI. We tested similar to 2.5 million SNPs for association with coronary artery calcification and aortic calcification in 2620 male individuals of the NELSON trial, who underwent chest CT scans. All participants were current or former heavy smokers. No SNPs were associated with aortic calcification on a genome-wide scale. The 9p21 locus was significantly associated with coronary artery calcification (rs1537370, P = 2.3 x 10(-11)). Since this locus corresponds to the strongest SNP association for CAD/MI, we tested 24 published and validated CAD/MI risk SNPs for association with arterial calcification. Besides the CAD/MI SNP at 9p21 (rs4977574, P = 3.1 x 10(-10)), two additional loci at ADAMTS7 (rs3825807, P = 6.5 x 10(-6)) and at PHACTR1 (rs12526453, P = 1.0 x 10(-3)) show a nominally significant association with coronary artery calcification with MI/CAD risk alleles increasing the degree of arterial calcification. The 9p21 locus was also nominally associated with aortic calcification (P = 3.2 x 10(-4)). These findings indicate that these CAD and MI risk loci are likely involved in arterial calcification. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [van Setten, Jessica; de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Med Genet, NL-3584 CG Utrecht, Netherlands.
[Isgum, Ivana; Viergever, Max A.] Univ Med Ctr Utrecht, Image Sci Inst, NL-3584 CG Utrecht, Netherlands.
[Smolonska, Joanna; Wijmenga, Cisca] Univ Groningen, Univ Med Ctr Groningen, Dept Human Genet, NL-9713 GZ Groningen, Netherlands.
[Smolonska, Joanna; Oudkerk, Matthijs; Wijmenga, Cisca] Univ Groningen, NL-9713 GZ Groningen, Netherlands.
[Ripke, Stephan] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Ripke, Stephan; de Bakker, Paul I. W.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[de Jong, Pim A.; Mali, Willem P. Th. M.] Univ Med Ctr Utrecht, Dept Radiol, NL-3584 CG Utrecht, Netherlands.
[Oudkerk, Matthijs] Univ Groningen, Univ Med Ctr Groningen, Dept Radiol Radiodiagnost, NL-9713 GZ Groningen, Netherlands.
[de Koning, Harry] Erasmus MC, Dept Publ Hlth, NL-3015 GE Rotterdam, Netherlands.
[Lammers, Jan-Willem J.; Zanen, Pieter] Univ Med Ctr Utrecht, Dept Resp Med, NL-3584 CG Utrecht, Netherlands.
[Groen, Harry J. M.; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, Dept Pulm Dis, NL-9713 GZ Groningen, Netherlands.
[Boezen, H. Marike] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 GZ Groningen, Netherlands.
[Boezen, H. Marike; Postma, Dirkje S.] Univ Groningen, Univ Med Ctr Groningen, GRIAC Res Inst, NL-9713 GZ Groningen, Netherlands.
[de Bakker, Paul I. W.] Univ Med Ctr Utrecht, Dept Epidemiol, NL-3584 CG Utrecht, Netherlands.
[de Bakker, Paul I. W.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Div Genet, Boston, MA 02115 USA.
RP de Bakker, PIW (reprint author), Univ Med Ctr Utrecht, Dept Epidemiol, Stratenum 0-310,POB 85500, NL-3508 GA Utrecht, Netherlands.
EM pdebakker@umcutrecht.nl
RI de Bakker, Paul/B-8730-2009; Wijmenga, Cisca/D-2173-2009; Isgum,
Ivana/H-8659-2014; Mali, Willem/I-1123-2014; Viergever, Max/J-1215-2014;
de Jong, Pim/G-7220-2014;
OI de Bakker, Paul/0000-0001-7735-7858; Isgum, Ivana/0000-0003-1869-5034;
Mali, Willem/0000-0003-4391-0904; de Jong, Pim/0000-0003-4840-6854;
Wijmenga, Cisca/0000-0002-5635-1614
FU Zorg Onderzoek Nederland-Medische Wetenschappen; KWF Kankerbestrijding;
Stichting Centraal Fonds Reserves van Voormalig Vrijwillige
Ziekenfondsverzekeringen; G. Ph. Verhagen Foundation; Rotterdam
Oncologic Thoracic Study Group; Erasmus Trust Fund; Foundation against
Cancer; Flemish League against Cancer; ITEA2 (project Care4Me); Lokaal
Gezondheids Overleg (LOGO) Leuven; Lokaal Gezondheids Overleg (LOGO)
Hageland; Roche Diagnostics; European Union [201379]; Philips
Healthcare; AstraZeneca; Chiesi; GSK; Nycomed; Boehringer Ingelheim;
TEVA
FX This study is supported by Zorg Onderzoek Nederland-Medische
Wetenschappen, KWF Kankerbestrijding, Stichting Centraal Fonds Reserves
van Voormalig Vrijwillige Ziekenfondsverzekeringen, G. Ph. Verhagen
Foundation, Rotterdam Oncologic Thoracic Study Group, Erasmus Trust
Fund, Foundation against Cancer, Flemish League against Cancer, ITEA2
(project Care4Me), and Lokaal Gezondheids Overleg (LOGO) Leuven and
Hageland. Roche Diagnostics provided an unrestricted research grant.
Siemens Germany provided four digital workstations and accompanying
software but had no other role in the study. COPACETIC (COPD Pathology:
Addressing Critical gaps, Early Treatment & Diagnosis and Innovative
Concepts) is funded by the European Union FP7 program (grant number:
201379).; Harry de Koning is a paid member of the medical advisory board
of Roche Diagnostics. Max A. Viergever has received several
institutional grants from Philips Healthcare (but none directly related
to the subject matter of the present article). Dirkje S. Postma has
received an unrestricted research grant from AstraZeneca and Chiesi.
Travel to the European Respiratory Society and American Thoracic Society
has been partially funded by AstraZeneca, Chiesi, GSK, Nycomed.
Consulting fees (for work by D. S. P.) were given to the University of
Groningen by AstraZeneca, Boehringer Ingelheim, Chiesi, GSK, Nycomed and
TEVA.
NR 30
TC 31
Z9 31
U1 0
U2 12
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2013
VL 228
IS 2
BP 400
EP 405
DI 10.1016/j.atherosclerosis.2013.02.039
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 145SI
UT WOS:000319037200018
PM 23561647
ER
PT J
AU Alele, JD
Luttrell, LM
Hollis, BW
Luttrell, DK
Hunt, KJ
AF Alele, Jimmy D.
Luttrell, Louis M.
Hollis, Bruce W.
Luttrell, Deirdre K.
Hunt, Kelly J.
CA VADT Study Grp
TI Relationship between vitamin D status and incidence of vascular events
in the Veterans Affairs Diabetes Trial
SO ATHEROSCLEROSIS
LA English
DT Article
DE Diabetes mellitus; Cardiovascular outcomes; Epidemiology; Vitamin D;
Prospective cohort study
ID ISCHEMIC-HEART-DISEASE; SMOOTH-MUSCLE-CELLS; CARDIOVASCULAR-DISEASE;
MYOCARDIAL-INFARCTION; 25-HYDROXYVITAMIN D; D DEFICIENCY;
ENDOTHELIAL-CELLS; D INSUFFICIENCY; BLOOD-PRESSURE; RISK
AB Objective: Few studies have examined the relationship between vitamin D levels and incident cardiovascular events in large well-characterized patient cohorts. Therefore, our objective was to determine if low vitamin D levels predicted vascular complications of diabetes.
Methods: Prospective analysis of 936 veterans with type 2 diabetes (59.7 +/- 8.4 years, 96.9% male) who participated in the Veteran Affairs Diabetes Trial (VADT) was conducted. 25(OH)-vitamin D was measured a median of two years after entry and participants were subsequently followed 3.7 years. Hazard ratios (HRs) were calculated for cardiovascular endpoints in relation to 25(OH)-vitamin D quartile. For microvascular endpoints, logistic regression was used to calculate odds ratios.
Results: After adjusting for age, minority status, treatment arm and history of prior event, individuals in the lowest vitamin D quartile (i.e., 1-15.9 ng/ml) were at similar risk of MI [HR = 1.13 (95% CI: 0.53, 2.42)], CHD [HR = 0.87 (95% CI: 0.49, 1.55)], congestive heart failure [HR = 1.44 (95% CI: 0.67, 3.06)], and death from any cause [HR = 1.04 (95% CI: 0.53, 2.04)] as individuals in the highest vitamin D quartile (i.e., 29.9-77.2 ng/ml). Similarly, there were no differences in the odds associated with retinopathy or renal disease onset or progression in the lowest versus highest vitamin D quartile.
Conclusions: These data indicate that vitamin D status had no significant impact on the incidence of vascular events in a cohort of high-risk veterans with diabetes in which traditional risk factors were managed according to current treatment guidelines. (C) 2013 Elsevier Ireland Ltd. All rights reserved.
C1 [Alele, Jimmy D.; Luttrell, Louis M.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Hollis, Bruce W.; Luttrell, Deirdre K.] Med Univ S Carolina, Dept Pediat, Charleston, SC 29425 USA.
[Hunt, Kelly J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC 29425 USA.
[Luttrell, Louis M.; Hunt, Kelly J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29401 USA.
RP Hunt, KJ (reprint author), Med Univ S Carolina, Dept Publ Hlth Sci, 135 Cannon St,Suite 302,POB 250835, Charleston, SC 29425 USA.
EM huntke@musc.edu
FU American Heart Association [AHA0755466U]; Research Service of the
Charleston SC VA Medical Center; Department of Veterans Affairs,
Veterans Health Administration, Office of Research and Development
FX This work was supported by American Heart Association Grant-in-Aid
AHA0755466U (L.M.L.) and the Research Service of the Charleston SC VA
Medical Center. This material is based upon work supported in part by
the Department of Veterans Affairs, Veterans Health Administration,
Office of Research and Development. The funding source had no
involvement in the study design; in the collection, analysis or
interpretation of data; in the writing of the report; or in the decision
to submit the article for publication. The views expressed in this
article are those of the authors and do not necessarily reflect the
position or policy of the Department of Veterans Affairs or the United
States government.
NR 35
TC 10
Z9 11
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0021-9150
J9 ATHEROSCLEROSIS
JI Atherosclerosis
PD JUN
PY 2013
VL 228
IS 2
BP 502
EP 507
DI 10.1016/j.atherosclerosis.2013.03.024
PG 6
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 145SI
UT WOS:000319037200034
PM 23608249
ER
PT J
AU Amin, J
Puglisi, A
Clarke, J
Milton, J
Wang, MH
Paranal, RM
Bradner, JE
Spencer, J
AF Amin, Jahangir
Puglisi, Antonino
Clarke, James
Milton, John
Wang, Minghua
Paranal, Ronald M.
Bradner, James E.
Spencer, John
TI A cyclodextrin-capped histone deacetylase inhibitor
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE HDAC Inhibitors; Cyclodextrin conjugates; Molecular modelling; Cancer
ID CANCER-CELLS; DELIVERY; ACID
AB We have synthesized a beta-cyclodextrin (beta CD)-capped histone deacetylase (HDAC) inhibitor 3 containing an alkyl linker and a zinc-binding hydroxamic acid motif. Biological evaluation (HDAC inhibition studies) of 3 enabled us to establish the effect of replacing an aryl cap (in SAHA (vorinostat,)) 1 by a large saccharidic scaffold "cap''. HDAC inhibition was observed for 3, to a lesser extent than SAHA, and rationalized by molecular docking into the active site of HDAC8. However, compound 3 displayed no cellular activity. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Amin, Jahangir; Puglisi, Antonino; Spencer, John] Univ Sussex, Sch Life Sci, Dept Chem, Brighton BN1 9QJ, E Sussex, England.
[Puglisi, Antonino; Clarke, James; Milton, John] Oxford Nanopore Technol Ltd, Oxford OX4 4GA, England.
[Wang, Minghua] Univ Toronto, Terrence Donnelly Ctr Cellular & Biomol Res, Toronto, ON M5S 3E1, Canada.
[Paranal, Ronald M.; Bradner, James E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Amin, J (reprint author), Univ Sussex, Sch Life Sci, Dept Chem, Brighton BN1 9QJ, E Sussex, England.
EM j.amin@sussex.ac.uk; antonino.puglisi@nanopore-tech.com
RI spencer, john/C-2156-2008
OI spencer, john/0000-0001-5231-8836
FU Oxford Nanopore Technology Ltd
FX Oxford Nanopore Technology Ltd is thanked for funding. The EPSRC Mass
Spectrometry Service (Swansea University) is thanked for HRMS
measurements.
NR 22
TC 3
Z9 3
U1 0
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 1
PY 2013
VL 23
IS 11
BP 3346
EP 3348
DI 10.1016/j.bmcl.2013.03.084
PG 3
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 144XR
UT WOS:000318976100044
PM 23591111
ER
PT J
AU Wang, CN
Moseley, CK
Carlin, SM
Wilson, CM
Neelamegam, R
Hooker, JM
AF Wang, Changning
Moseley, Christian K.
Carlin, Stephen M.
Wilson, Colin M.
Neelamegam, Ramesh
Hooker, Jacob M.
TI Radiosynthesis and evaluation of [C-11] EMPA as a potential PET tracer
for orexin 2 receptors
SO BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Orexin; EMPA; PET radiotracer; Brain; Carbon-11
ID CLUSTER HEADACHE; ANTAGONISTS; EXPRESSION; SLEEP; IMMUNOREACTIVITY;
IDENTIFICATION; ASSOCIATION; SECRETION; LEPTIN; CELLS
AB EMPA is a selective antagonist of orexin 2 (OX2) receptors. Previous literature with [H-3]-EMPA suggest that it may be used as an imaging agent for OX2 receptors; however, brain penetration is known to be modest. To evaluate the potential of EMPA as a PET radiotracer in non-human primate (as a step to imaging in man), we radiolabeled EMPA with carbon-11. Radiosynthesis of [C-11] N-ethyl-2-(N-(6-methoxypyridin- 3-yl)-2-methylphenylsulfonamido)-N-(pyridin-3-ylmethyl) acetamide ([C-11] EMPA), and evaluation as a potential PET tracer for OX2 receptors is described. Synthesis of an appropriate non-radioactive O-desmethyl precursor was achieved from EMPA with sodium iodide and chlorotrimethylsilane. Selective O-methylation using [C-11] CH3I in the presence of cesium carbonate in DMSO at room temp afforded [C-11] EMPA in 1.5-2.5% yield (non-decay corrected relative to trapped [C-11] CH3I at EOS) with >= 95% chemical and radiochemical purities. The total synthesis time was 34-36 min from EOB. Studies in rodent suggested that uptake in tissue was dominated by nonspecific binding. However, [C-11] EMPA also showed poor uptake in both rats and baboon as measured with PET imaging. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Wang, Changning; Moseley, Christian K.; Carlin, Stephen M.; Wilson, Colin M.; Neelamegam, Ramesh; Hooker, Jacob M.] Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Charlestown, MA 02129 USA.
RP Hooker, JM (reprint author), Harvard Univ, Sch Med, Athinoula A Martinos Ctr Biomed Imaging, Massachusetts Gen Hosp,Dept Radiol, Bldg 149,13th St,Suite 2301, Charlestown, MA 02129 USA.
EM hooker@nmr.mgh.harvard.edu
OI Hooker, Jacob/0000-0002-9394-7708
FU National Institute of Biomedical Imaging and Bioengineering (NIBIB);
National Institutes of Health; NIH Shared Instrumentation Grant Program;
High-End Instrumentation Grant Program [S10RR017208, S10RR026666,
S10RR022976, S10RR019933, S10RR029495]
FX This research was carried out at the Athinoula A. Martinos Center for
Biomedical Imaging at the Massachusetts General Hospital, using
resources provided by the Center for Functional Neuroimaging
Technologies, P41EB015896, a P41 Regional Resource supported by the
National Institute of Biomedical Imaging and Bioengineering (NIBIB),
National Institutes of Health. This work also involved the use of
instrumentation supported by the NIH Shared Instrumentation Grant
Program and/or High-End Instrumentation Grant Program; specifically,
Grant numbers: S10RR017208, S10RR026666, S10RR022976, S10RR019933,
S10RR029495. We would like to thank members of the Hooker laboratory for
helpful discussions. The authors are grateful to Joseph Mandeville, Grae
Arabsz, Shirley Hsu, and Helen Deng for assistance during NHP imaging.
NR 29
TC 6
Z9 6
U1 0
U2 11
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0960-894X
J9 BIOORG MED CHEM LETT
JI Bioorg. Med. Chem. Lett.
PD JUN 1
PY 2013
VL 23
IS 11
BP 3389
EP 3392
DI 10.1016/j.bmcl.2013.03.079
PG 4
WC Chemistry, Medicinal; Chemistry, Organic
SC Pharmacology & Pharmacy; Chemistry
GA 144XR
UT WOS:000318976100054
PM 23601709
ER
PT J
AU Carlson, KF
Barnes, JE
Hagel, EM
Taylor, BC
Cifu, DX
Sayer, NA
AF Carlson, Kathleen F.
Barnes, Joan E.
Hagel, Emily M.
Taylor, Brent C.
Cifu, David X.
Sayer, Nina A.
TI Sensitivity and specificity of traumatic brain injury diagnosis codes in
United States Department of Veterans Affairs administrative data
SO BRAIN INJURY
LA English
DT Article
DE Clinical coding; epidemiology; ICD-9-CM; public health surveillance;
traumatic brain injury; validity
ID CASE ASCERTAINMENT; WAR VETERANS; HEAD-INJURY; VALIDITY; ACCURACY;
AFGHANISTAN; PREVALENCE; IRAQ; ADMISSIONS; SERVICES
AB Objective: To examine the validity of using International Classification of Diseases (ICD) diagnosis codes from United States Department of Veterans Affairs (VA) data to describe prevalence of traumatic brain injury (TBI) among military veterans.
Methods: VA clinicians complete a standardized TBI evaluation to determine whether veterans' deployment exposures resulted in TBI. Clinician-confirmed cases and non-cases of TBI were used as recorded on the evaluation as the criterion standard against which to evaluate three series of TBI-related ICD diagnosis codes in national VA datasets. Focusing on codes used within VA, measures of validity were calculated and correlates of discordance examined, including patient characteristics, region and time. Secondarily, it was examined whether TBI codes can differentiate mild from more severe TBI cases.
Results: Of 49 962 veterans with completed TBI evaluations, 29 534 (59%) received clinician-confirmed TBI diagnoses. Sensitivity of the VA series of codes was 70%, specificity was 82% and concordance was 75%. Concordance varied by region, but not by patient characteristics or time. Codes were not useful for distinguishing mild TBI.
Conclusion: Estimates of TBI prevalence in military veterans are important for national programme development and resource distribution. Estimates derived from ICD diagnosis codes in administrative data should take potential misclassification into account.
C1 [Carlson, Kathleen F.] Portland VA Med Ctr, Portland Ctr Study Chron Comorbid Mental & Phys D, Portland, OR USA.
[Carlson, Kathleen F.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97201 USA.
[Barnes, Joan E.; Hagel, Emily M.; Taylor, Brent C.; Sayer, Nina A.] Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Taylor, Brent C.; Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA.
[Cifu, David X.] Vet Hlth Adm, Phys Med & Rehabil Serv, Richmond, VA USA.
[Cifu, David X.] Hunter Holmes McGuire VA Med Ctr, Phys Med & Rehabil Serv, Richmond, VA USA.
[Cifu, David X.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA.
[Sayer, Nina A.] Univ Minnesota, Sch Med, Dept Psychiat, Minneapolis, MN 55455 USA.
RP Carlson, KF (reprint author), Portland VA Med Ctr R&D 66, Portland Ctr Study Chron Comorbid Mental & Phys D, 3715 SW US Vet Hosp Rd, Portland, OR 97239 USA.
EM kathleen.carlson@va.gov
RI Taylor, Brent/A-8069-2009; Sayer, Nina/E-3249-2016
OI Taylor, Brent/0000-0002-2140-8377;
FU United States Department of Veterans Affairs, Veterans Health
Administration, Health Services Research and Development Service [CDA
08-025]
FX This work was supported by a career development award from the United
States Department of Veterans Affairs, Veterans Health Administration,
Health Services Research and Development Service (CDA 08-025). The
opinions expressed in this article are those of the authors and do not
necessarily reflect the position or policy of the Department of Veterans
Affairs or the United States government. The authors report no conflicts
of interest.
NR 53
TC 8
Z9 8
U1 0
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2013
VL 27
IS 6
BP 640
EP 650
DI 10.3109/02699052.2013.771795
PG 11
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 143QO
UT WOS:000318882500002
PM 23514276
ER
PT J
AU Wong, WW
Chan, ST
Tang, KW
Meng, F
Tong, KY
AF Wong, Wan-Wa
Chan, Suk-Tak
Tang, Kwok-Wing
Meng, Fei
Tong, Kai-Yu
TI Neural correlates of motor impairment during motor imagery and motor
execution in sub-cortical stroke
SO BRAIN INJURY
LA English
DT Article
DE Stroke; motor imagery; functional MRI; brain activation
ID MENTAL PRACTICE; UPPER-LIMB; FUNCTIONAL REORGANIZATION; PREMOTOR CORTEX;
RECOVERY; MOVEMENTS; ORGANIZATION; HUMANS; MRI; REPRESENTATIONS
AB Objective: This study aims at identifying the neural substrates for motor execution (ME) and motor imagery (MI) in patients after stroke and their correlations with functional outcomes.
Methods: 10 chronic stroke patients with left sub-cortical lesions and 10 unimpaired subjects were recruited. Their cortical processes were studied when they were asked to perform ME and MI unimanually using their unaffected and affected wrists during fMRI.
Results: From correlation results, the supplementary motor area (SMA), its activation volume and congruence in functional neuroanatomy associated with ME and MI using affected wrist positively correlated with motor performance. During ME of the affected wrist, the precuneus, its activation volume and congruence in functional neuroanatomy between patient and unimpaired groups showed a negative correlation, while, in non-primary motor areas, the hemispheric balance of premotor cortex and the congruence in functional neuroanatomy of contralesional inferior parietal lobule between patient and unimpaired groups showed a positive correlation with motor performance.
Conclusions: The non-primary motor-related areas were revealed to play a critical role in determining motor outcomes after left sub-cortical stroke, which was demonstrated in the stroke patients. In particular, SMA might be the key neural substrate associated with motor recovery.
C1 [Wong, Wan-Wa; Meng, Fei; Tong, Kai-Yu] Hong Kong Polytech Univ, Interdisciplinary Div Biomed Engn, Hong Kong, Hong Kong, Peoples R China.
[Chan, Suk-Tak] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02114 USA.
[Tang, Kwok-Wing] Queen Elizabeth Hosp, Dept Diagnost Radiol & Imaging, Hong Kong, Hong Kong, Peoples R China.
[Meng, Fei] Tsinghua Univ, Dept Biomed Engn, Beijing 100084, Peoples R China.
RP Tong, KY (reprint author), Hong Kong Polytech Univ, Interdisciplinary Div Biomed Engn, Hong Kong, Hong Kong, Peoples R China.
EM k.y.tong@polyu.edu.hk
RI Tong, Raymond Kai-yu/C-3546-2009; Chan, Suk-tak/G-5846-2015
OI Tong, Raymond Kai-yu/0000-0003-4375-653X;
FU Research Grants Council of Hong Kong [GRF 5318/09E]
FX This project was supported by a grant from the Research Grants Council
of Hong Kong (GRF 5318/09E). The authors report no conflicts of
interest. The authors alone are responsible for the content and writing
of the paper.
NR 47
TC 3
Z9 5
U1 1
U2 7
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2013
VL 27
IS 6
BP 651
EP 663
DI 10.3109/02699052.2013.771796
PG 13
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 143QO
UT WOS:000318882500003
PM 23514275
ER
PT J
AU Mannix, RC
Zhang, J
Berglass, J
Qui, JH
Whalen, MJ
AF Mannix, Rebekah C.
Zhang, Jimmy
Berglass, Jacqueline
Qui, Jianhua
Whalen, Michael J.
TI Beneficial effect of amyloid beta after controlled cortical impact
SO BRAIN INJURY
LA English
DT Article
DE Traumatic brain injury; beta amyloid
ID TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; PROTEIN DEPOSITION;
PRECURSOR PROTEIN; PEPTIDE; MICE; TRANSMISSION; INHIBITION; MODULATION;
PLASTICITY
AB Background: Worse functional outcomes after controlled cortical impact (CCI) in Bace1(-/-) mice have previously been demonstrated. This study investigated whether reconstitution of amyloid-beta (A beta) after CCI in Bace1(-/-) animals would reverse the detrimental effect of Bace1 deletion.
Methods: Bace1(-/-) and wild type Bace1(+/+) (C57Bl/ 6) mice were subjected to CCI (n = 14-23/ group) or sham injury (n= 6/ group). After injury, mice underwent intracerebroventricular injections of A beta(40) (n=23 Bace1(-/-) and 17 Bace1(+/+) per group) or vehicle (n=14 Bace1(-/-) and 22 Bace1(+/+) per group). Functional outcomes were assessed with wire grip (motor) and Morris water maze (spatial memory). Soluble A beta levels were assessed at 24 hours and 21 days after CCI. Lesion volume was assessed 21 days after injury.
Results: At 24 hours after injury, A beta-treated Bace1(-/-) mice had A beta(40) levels similar to vehicle-treated Bace1(+/+) mice, but by 21 days after injury there were no differences between A beta-treated versus vehicle-treated Bace1(-/-) mice. Reconstitution with A beta(40) improved motor but not spatial memory or histopathological outcome in injured Bace1(-/-) mice. In contrast, treatment with A beta(40) worsened motor performance in Bace1(+/+) mice.
Conclusions: The data suggest A beta(40) may have some beneficial effects after CCI in young adult mice and that therapies targeting BACE should be approached cautiously.
C1 [Mannix, Rebekah C.; Berglass, Jacqueline] Harvard Univ, Sch Med, Dept Med, Div Emergency Med,Childrens Hosp Boston, Boston, MA 02115 USA.
[Mannix, Rebekah C.; Zhang, Jimmy; Berglass, Jacqueline; Qui, Jianhua; Whalen, Michael J.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurosci Ctr, Charlestown, MA USA.
[Zhang, Jimmy; Qui, Jianhua; Whalen, Michael J.] Harvard Univ, Dept Pediat, Massachusetts Gen Hosp, Sch Med, Charlestown, MA USA.
RP Mannix, RC (reprint author), Childrens Hosp, 300 Longwood Ave, Boston, MA 02115 USA.
EM rebekah.mannix@childrens.harvard.edu
FU Charles Hood Foundation (RCM); NINDS [5RO1NS047447]
FX This work was supported by grants from Charles Hood Foundation (RCM) and
NINDS 5RO1NS047447 (MJW).
NR 21
TC 2
Z9 2
U1 0
U2 2
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0269-9052
J9 BRAIN INJURY
JI Brain Inj.
PD JUN
PY 2013
VL 27
IS 6
BP 743
EP 748
DI 10.3109/02699052.2013.771797
PG 6
WC Neurosciences; Rehabilitation
SC Neurosciences & Neurology; Rehabilitation
GA 143QO
UT WOS:000318882500012
PM 23672448
ER
PT J
AU Ayata, C
AF Ayata, Cenk
TI Pearls and pitfalls in experimental models of spreading depression
SO CEPHALALGIA
LA English
DT Article
DE Spreading depression; migraine; aura; animal models
ID CEREBRAL-BLOOD-FLOW; HEMIPLEGIC MIGRAINE TYPE-1; IN-VIVO; TRIGEMINAL
NUCLEUS; RAT; SUSCEPTIBILITY; MICE; ANESTHETICS; THRESHOLD; MOUSE
AB Background: Spreading depression (SD) is the electrophysiological substrate of migraine aura and a potential trigger for headache. Since its discovery by Leao in 1944, SD has transformed from being viewed as an epiphenomenon into a therapeutic target relevant in the pathophysiology of migraine and brain injury.
Aim: Despite decades of research, the underpinnings of SD are still poorly understood, hampering our efforts to selectively block its initiation and spread. Experimental models have nevertheless been useful to measure the likelihood of SD occurrence (i.e. SD susceptibility) and characterize genetic, physiological and pharmacological modulation of SD in search of potential therapies, such as in migraine prophylaxis and stroke. Here, I review experimental SD susceptibility endpoints and surrogates, and minimum essential model requirements to improve their utility in drug screening.
Conclusion: A critical reappraisal of strengths and caveats of experimental models of SD susceptibility is needed to set standards and improve data quality, interpretation and reconciliation.
C1 [Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol,Neurovasc Res Lab, Charlestown, MA 02129 USA.
[Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Stroke Serv, Charlestown, MA 02129 USA.
[Ayata, Cenk] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Neurol,Neurosci Intens Care Unit, Charlestown, MA 02129 USA.
RP Ayata, C (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 149 13th St,Room 6408, Charlestown, MA 02129 USA.
EM cayata@partners.org
FU United States National Institutes of Health (NIH) [NS061505]; Andrew
David Heitman Neuroendovascular Research Fund from the Andrew David
Heitman Foundation
FX This work was funded in part by the United States National Institutes of
Health (NIH) (NS061505) and the Andrew David Heitman Neuroendovascular
Research Fund from the Andrew David Heitman Foundation.
NR 67
TC 11
Z9 11
U1 0
U2 11
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0333-1024
J9 CEPHALALGIA
JI Cephalalgia
PD JUN
PY 2013
VL 33
IS 8
SI SI
BP 604
EP 613
DI 10.1177/0333102412470216
PG 10
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 142NV
UT WOS:000318805000010
PM 23671256
ER
PT J
AU Vannini, P
Hedden, T
Huijbers, W
Ward, A
Johnson, KA
Sperling, RA
AF Vannini, Patrizia
Hedden, Trey
Huijbers, Willem
Ward, Andrew
Johnson, Keith A.
Sperling, Reisa A.
TI The Ups and Downs of the Posteromedial Cortex: Age- and Amyloid-Related
Functional Alterations of the Encoding/Retrieval Flip in Cognitively
Normal Older Adults
SO CEREBRAL CORTEX
LA English
DT Article
DE aging; amyloid; encoding; functional MRI; retrieval
ID PITTSBURGH-COMPOUND-B; ALZHEIMERS-DISEASE; PARIETAL DEACTIVATION;
EPISODIC MEMORY; DEFAULT NETWORK; CEREBRAL-CORTEX; IN-VIVO; DEPOSITION;
ACTIVATION; BRAIN
AB Neural networks supporting memory function decline with increasing age. Accumulation of amyloid-, a histopathological finding in Alzheimers disease, is a likely contributor. Posteromedial cortices (PMCs) are particularly vulnerable to early amyloid pathology and play a role in both encoding and retrieval processes. The extent to which aging and amyloid influence the ability to modulate activity between these processes within the PMC was investigated by combining positron emission tomography-amyloid imaging with functional magnetic resonance imaging in cognitively normal older and young adults. Young subjects exhibited a marked decrease in activity during encoding and an increase during retrieval (also known as encoding/retrieval flip). Impaired ability to modulate activity was associated with increasing age, greater amyloid burden, and worse memory performance. In contrast, the hippocampus showed increased activity during both encoding and retrieval, which was not related to these variables. These findings support a specific link between amyloid pathology and neural dysfunction in PMC and elucidate the underpinnings of age-related memory dysfunction.
C1 [Vannini, Patrizia; Hedden, Trey; Huijbers, Willem; Ward, Andrew; Johnson, Keith A.; Sperling, Reisa A.] Massachusetts Gen Hosp, Gerontol Res Unit, Boston, MA 02129 USA.
[Vannini, Patrizia; Huijbers, Willem; Sperling, Reisa A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Psychiat, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Ward, Andrew; Johnson, Keith A.; Sperling, Reisa A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Neurol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Hedden, Trey; Johnson, Keith A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med,Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Boston, MA 02129 USA.
[Vannini, Patrizia; Huijbers, Willem; Johnson, Keith A.; Sperling, Reisa A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Neurol,Ctr Alzheimer Res & Treatment, Boston, MA 02115 USA.
[Vannini, Patrizia] Karolinska Univ, Huddinge Hosp, Karolinska Inst, Dept Neurobiol Care Sci & Soc,Div Clin Geriatr, SE-14186 Stockholm, Sweden.
RP Vannini, P (reprint author), Massachusetts Gen Hosp, Gerontol Res Unit, 149 13th St,Suite 2691, Boston, MA 02129 USA.
EM patrizia@nmr.mgh.harvard.edu
OI Ward, Andrew/0000-0001-6948-4814
FU European Union [FP7-PEOPLE-2007-4-1-IOF]; Swedish Brain Foundation;
Swedish Society for Medicine; European Molecular Biology Organization
[ALTF 318-2011]; National Institutes of Health [K24 AG035007, R01
AG027435-S1, P01AG036694, P50AG00513421]; American Health Assistance
Foundation
FX This work was supported by the Marie Curie Fellowship:
FP7-PEOPLE-2007-4-1-IOF from the European Union [P. V.], the Swedish
Brain Foundation and Swedish Society for Medicine [P. V.], the European
Molecular Biology Organization: ALTF 318-2011 [W.H], the National
Institutes of Health: K24 AG035007 [R. A. S.], R01 AG027435-S1 [R. A. S
and K.A.J.], P01AG036694 [R. A. S. and K.A.J.], P50AG00513421 [R. A. S.
and K.A.J.], and the American Health Assistance Foundation [R.A.S.].
NR 51
TC 10
Z9 10
U1 0
U2 4
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1047-3211
J9 CEREB CORTEX
JI Cereb. Cortex
PD JUN
PY 2013
VL 23
IS 6
BP 1317
EP 1328
DI 10.1093/cercor/bhs108
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 140IZ
UT WOS:000318649100006
PM 22586140
ER
PT J
AU Harshman, LC
Barbeau, S
McMillian, A
Srinivas, S
AF Harshman, Lauren C.
Barbeau, Sarah
McMillian, Alex
Srinivas, Sandy
TI A Phase II Study of Bevacizumab and Everolimus as Treatment for
Refractory Metastatic Renal Cell Carcinoma
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Bevacizumab; Everolimus; Horizontal blockade; Metastatic renal cell
carcinoma; Treatment refractory
ID ENDOTHELIAL GROWTH-FACTOR; INTERFERON-ALPHA; DOUBLE-BLIND; TRIAL;
CANCER; SUNITINIB; SORAFENIB; EFFICACY; SAFETY; TEMSIROLIMUS
AB Agents that target hypoxia-inducible factor pathways have achieved significant improvements in outcomes for patients with metastatic renal cell carcinoma. We investigated horizontal blockade with the combination of bevacizumab and everolimus. The median progression-free survival was less than expected with bevacizumab monotherapy, and 40% of 10 were discontinued for toxicity. The combination was toxic, and the efficacy achieved did not support its combined use over sequential administration.
Background: Agents that inhibit the vascular endothelial growth factor (VEGF) and mammalian target of rapamycin (mTOR) pathways in metastatic renal cell carcinoma (mRCC) prolong progression-free survival (PFS), but durable complete responses are rare. Combinations of these cytostatic therapies have great potential to improve efficacy and to escape tumoral resistance mechanisms, but supra-additive toxicity is a valid concern. We investigated whether horizontal blockade with the combination of bevacizumab, a monoclonal antibody to VEGF-A, and of everolimus, an oral mTOR inhibitor, improved PFS in patients with clear cell mRCC who had received prior VEGF blockade. Methods: In this phase II investigator-initiated study, 10 of 30 planned patients were enrolled. Bevacizumab 10 mg/kg was administered intravenously every 14 days. Everolimus was orally dosed at 10 mg daily. The patients were treated until disease progression or unacceptable toxicity. The primary endpoint was PFS. Results: The median age was 55 years. The majority of patients were white men with an Eastern Cooperative Oncology Group performance status of 1 (80%) and intermediate risk disease by Memorial Sloan-Kettering Cancer Center criteria (70%). All the patients had received 1 prior VEGF inhibitor. The median PFS in the 10 evaluable patients was 5.1 months, which was less than the expected historical control of bevacizumab monotherapy at 6 months. The median overall survival was 21 months. The best response was a partial response in 1 patient and stable disease in 9. Forty percent of the patients were discontinued from the study due to toxicity. Conclusions: In our experience, the combination of bevacizumab and everolimus was toxic. The efficacy achieved did not support its combined use over sequential administration. Ongoing randomized studies will definitively evaluate the combination's efficacy and tolerability. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Harshman, Lauren C.; Barbeau, Sarah; Srinivas, Sandy] Stanford Sch Med, Stanford Canc Inst, Div Oncol, Stanford, CA USA.
[McMillian, Alex] Stanford Univ, Div Stat, Stanford, CA 94305 USA.
RP Harshman, LC (reprint author), Dana Farber Canc Inst, 450 Brookline Ave,1230 DANA, Boston, MA 02215 USA.
EM laurenc_harshman@dfci.harvard.edu
FU Genentech; Novartis; Bristol-Myers Squibb; Pfizer
FX Genentech and Novartis provided drug and funding for the nonstandard of
care clinical costs of this study. We thank John Allen for his
assistance in the creation of the figures, and Deb Bouvier, Oncore
specialist, for her work in the preparation of the cumulative data for
the patient demographic and toxicity tables.; L. C. Harshman has served
as a consultant for Novartis and Pfizer. She has received research
funding from Bristol-Myers Squibb, Novartis, and Genentech. S. Srinivas
has served as a consultant for Pfizer, Novartis, and Genentech. She has
received research funding from Pfizer, Novartis, and Genentech. The
remaining authors have stated that they have no conflicts of interest.
NR 32
TC 14
Z9 15
U1 1
U2 9
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1558-7673
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD JUN
PY 2013
VL 11
IS 2
BP 100
EP 106
DI 10.1016/j.clgc.2012.12.002
PG 7
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 143EK
UT WOS:000318849100006
PM 23352238
ER
PT J
AU Rini, BI
Rouge, TD
Harzstark, AL
Michaelson, MD
Liu, G
Grunwald, V
Ingrosso, A
Tortorici, MA
Bycott, P
Kim, S
Bloom, J
Motzer, RJ
AF Rini, Brian I.
Rouge, Thibault de La Motte
Harzstark, Andrea L.
Michaelson, M. Dror
Liu, Glenn
Gruenwald, Viktor
Ingrosso, Antonella
Tortorici, Michael A.
Bycott, Paul
Kim, Sinil
Bloom, Joanna
Motzer, Robert J.
TI Five-Year Survival in Patients With Cytokine-Refractory Metastatic Renal
Cell Carcinoma Treated With Axitinib
SO CLINICAL GENITOURINARY CANCER
LA English
DT Article
DE Long-term survival; Pharmacokinetics; Tyrosine kinase inhibitor;
Vascular endothelial growth factor receptor inhibitor
ID LONG-TERM RESPONSE; PHASE-II; JAPANESE PATIENTS; TARGETED AGENTS; SOLID
TUMORS; SORAFENIB; SUNITINIB; TRIAL; EFFICACY; CANCER
AB This report presents an update of overall survival data retrospectively collected from a phase II study of axitinib in patients with cytokine-refractory metastatic renal cell carcinoma. The 5-year overall survival rate was 20.6%. A post hoc analysis showed improved clinical outcomes in patients with peak post-first-dose axitinib plasma concentrations within a specific range.
Background: In a phase II study of axitinib for cytokine-refractory metastatic renal cell carcinoma, median overall survival (OS) was 29.9 months (95% CI, 20.3 to not estimable months). Patients and Methods: Long-term survival data were collected retrospectively from 52 patients with cytokine-refractory metastatic renal cell carcinoma who received axitinib in a completed phase II study (protocol 1), 11 of whom enrolled in a continuing access protocol (protocol 2), for the current observational study (protocol 3). In a post hoc analysis, the patients were grouped into quartiles based on cycle 1 day 1, 1- to 2-hour post-dose axitinib plasma levels to explore the impact of drug exposure on efficacy. Results: The 5-year survival rate was 20.6% (95% CI, 10.9%-32.4%), with a median follow-up of 5.9 years. Frequent all-grade adverse events were fatigue (n = 38; 73.1%), diarrhea (n = 34; 65.4%), hypertension (n = 33; 63.5%), and nausea (n = 33; 63.5%). Quartile 3 patients (axitinib level, 45.2-56.4 ng/mL; n = 12) had the best clinical outcome: objective response rate 82%, median progression-free survival (PFS) 28.3 months, and median OS that was not reached after 5 years. Conclusions: Axitinib was well tolerated and provided an estimated 5-year survival rate of 20.6% for cytokine-refractory metastatic renal cell carcinoma. Exploratory analyses showed numerically higher objective response rate and longer OS and PFS in patients who achieved post-first-dose axitinib plasma concentrations within a specific range. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Rini, Brian I.] Cleveland Clin, Taussig Canc Inst, Dept Solid Tumor Oncol, Cleveland, OH 44195 USA.
[Rouge, Thibault de La Motte] Hop La Pitie Salpetriere, Dept Med Oncol, Paris, France.
[Harzstark, Andrea L.] Univ Calif San Francisco, Dept Med, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
[Michaelson, M. Dror] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Liu, Glenn] Univ Wisconsin, Dept Med, Carbone Canc Ctr, Madison, WI USA.
[Gruenwald, Viktor] Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany.
[Ingrosso, Antonella] Pfizer Oncol, Milan, Italy.
[Tortorici, Michael A.; Bycott, Paul; Kim, Sinil] Pfizer Oncol, San Diego, CA USA.
[Bloom, Joanna] United Biosource Corp, Envis Grp, Southport, Qld, Australia.
[Motzer, Robert J.] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
RP Rini, BI (reprint author), Cleveland Clin, Main Campus,Mail Code R35,9500 Euclid Ave, Cleveland, OH 44195 USA.
EM rinib2@ccf.org
OI Michaelson, Dror/0000-0001-9249-6338
FU Pfizer Inc.; Pfizer
FX We thank Cynthia Kancler and Patricia Stephenson for statistical support
and Karen Maksin for study coordination and data review. This study was
sponsored by Pfizer Inc.; B. Rini, M. Michaelson, and R. Motzer have
received research funding from Pfizer and acted as consultants for
Pfizer. T. de La Motte Rouge has received honoraria from Pfizer and
Roche. G. Liu has received research funding from Pfizer. V. Grunwald has
acted as a consultant for Pfizer, Novartis, GlaxoSmithKline, Roche, and
Aveo, and has received honoraria from Pfizer, Novartis, GlaxoSmithKline,
and Roche. A. Ingrosso, M. Tortorici, P. Bycott, and S. Kim are
employees of and own stock in Pfizer. J. Bloom is an employee of UBC
Scientific Solutions who was a paid consultant to Pfizer in connection
with the development of this manuscript. A. Harzstark has stated that
she has no conflicts of interest.
NR 33
TC 17
Z9 17
U1 0
U2 4
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1558-7673
J9 CLIN GENITOURIN CANC
JI Clin. Genitourin. Cancer
PD JUN
PY 2013
VL 11
IS 2
BP 107
EP 114
DI 10.1016/j.clgc.2012.12.004
PG 8
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 143EK
UT WOS:000318849100007
PM 23391371
ER
PT J
AU Brandt, CP
Zvolensky, MJ
Bonn-Miller, MO
AF Brandt, Charles P.
Zvolensky, Michael J.
Bonn-Miller, Marcel O.
TI Distress Tolerance, Emotion Dysregulation, and Anxiety and Depressive
Symptoms Among HIV+ Individuals
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Emotion dysregulation; Distress tolerance; HIV; AIDS; Anxiety;
Depression
ID HUMAN-IMMUNODEFICIENCY-VIRUS; SUBSTANCE USE DISORDERS; QUALITY-OF-LIFE;
PANIC DISORDER; REGULATION DIFFICULTIES; TRANSMISSION RISK; NEGATIVE
AFFECT; HEALTH-STATUS; DAILY SMOKERS; SELF-REPORT
AB The current study examined the mediational effects of emotion dysregulation in terms of the relation between perceived distress tolerance and anxiety and depressive symptoms among HIV+ individuals. Participants included 176 HIV+ adults (21.6 % female, M (age) = 48.40 years, SD = 8.66). Results indicated that distress tolerance was significantly related to greater depressive and anxiety symptoms. Results also indicated that emotion dysregulation mediated this association. The observed findings were evident above and beyond the variance accounted for by CD4 T-cell count, ethnicity, gender, education level, and cannabis use status. The results are discussed in terms of the potential explanatory utility of perceived distress tolerance and emotion dysregulation in terms of psychological well-being among HIV+ individuals.
C1 [Brandt, Charles P.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA.
[Bonn-Miller, Marcel O.] Philadelphia VA Med Ctr, Ctr Excellence Subst Abuse Treatment & Educ, Philadelphia, PA 19104 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA 94025 USA.
[Bonn-Miller, Marcel O.] VA Palo Alto Hlth Care Syst, Ctr Hlth Care Evaluat, Menlo Pk, CA 94025 USA.
RP Brandt, CP (reprint author), Univ Houston, Dept Psychol, 126 Heyne Bldg, Houston, TX 77204 USA.
EM cpbrandt1@gmail.com; Marcel.Bonn-Miller@va.gov
NR 72
TC 10
Z9 10
U1 2
U2 17
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD JUN
PY 2013
VL 37
IS 3
BP 446
EP 455
DI 10.1007/s10608-012-9497-9
PG 10
WC Psychology, Clinical
SC Psychology
GA 142SI
UT WOS:000318817000004
ER
PT J
AU Magidson, JF
Listhaus, AR
Seitz-Brown, CJ
Anderson, KE
Lindberg, B
Wilson, A
Daughters, SB
AF Magidson, Jessica F.
Listhaus, Alyson R.
Seitz-Brown, C. J.
Anderson, Katelyn E.
Lindberg, Briana
Wilson, Alexis
Daughters, Stacey B.
TI Rumination Mediates the Relationship Between Distress Tolerance and
Depressive Symptoms Among Substance Users
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Distress tolerance; Depressive symptoms; Rumination; Brooding;
Reflection; Substance use
ID DIALECTICAL BEHAVIOR-THERAPY; RESPONSE STYLES THEORY; MAJOR DEPRESSION;
DISCOMFORT INTOLERANCE; PROBLEMATIC ALCOHOL; ANXIETY SENSITIVITY;
COLLEGE-STUDENTS; INVENTORY-II; LIFE EVENTS; GENDER
AB Distress tolerance has been implicated in the emergence of internalizing symptomatology, notably depressive symptoms. However, few studies have tested potential mechanisms underlying the relationship between distress tolerance and depressive symptoms, and further, this has not been tested among substance users, who commonly experience both low distress tolerance and elevated depressive symptoms. The current study focused on the construct of rumination, which has been suggested to be a coping response to stress associated with substance use and depression. Two forms of rumination, brooding and reflection, were tested as potential mediators of the relationship between distress tolerance and self-reported depressive symptoms among 128 individuals entering substance abuse treatment. Brooding (i.e., to overly focus on symptoms of distress) mediated the relationship between distress tolerance and depressive symptoms. However, reflection (i.e., to attempt to gain insight into problems) was unrelated to distress tolerance. Findings suggest the important role of brooding as a mechanism underlying the relationship between distress tolerance and depressive symptomatology.
C1 [Magidson, Jessica F.; Listhaus, Alyson R.; Seitz-Brown, C. J.; Anderson, Katelyn E.; Lindberg, Briana; Wilson, Alexis] Univ Maryland, Dept Behav & Community Hlth, College Pk, MD 20742 USA.
[Magidson, Jessica F.] Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Daughters, Stacey B.] Univ N Carolina, Dept Psychol, Chapel Hill, NC USA.
RP Magidson, JF (reprint author), Harvard Univ, Sch Med, Dept Psychiat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM jmagidson@partners.org; daughter@email.unc.edu
FU NIDA NIH HHS [F31 DA026679, R01 DA026424, R01 DA022974]
NR 71
TC 9
Z9 9
U1 2
U2 23
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD JUN
PY 2013
VL 37
IS 3
BP 456
EP 465
DI 10.1007/s10608-012-9488-x
PG 10
WC Psychology, Clinical
SC Psychology
GA 142SI
UT WOS:000318817000005
PM 23729916
ER
PT J
AU Gibbons, C
Stirman, SW
DeRubeis, RJ
Newman, CF
Beck, AT
AF Gibbons, Carly R.
Stirman, Shannon Wiltsey
DeRubeis, Robert J.
Newman, Cory F.
Beck, Aaron T.
TI Research Setting Versus Clinic Setting: Which Produces Better Outcomes
in Cognitive Therapy for Depression?
SO COGNITIVE THERAPY AND RESEARCH
LA English
DT Article
DE Cognitive therapy; Depression; Effectiveness
ID PSYCHOTHERAPY-RESEARCH; BEHAVIOR THERAPY; METAANALYSIS; DISORDERS; CARE;
PHARMACOTHERAPY; INVENTORY
AB To compare the outcomes of cognitive therapy for depression under controlled and clinically representative conditions, while holding several therapist and clinical assessment factors constant. Treatment outcomes for a sample of 23 adults with a primary diagnosis of Major Depressive Disorder who received cognitive therapy in an outpatient clinic were compared with outcomes of 18 clients who were treated in the cognitive therapy condition of a large, multi-site randomized clinical trial of treatments for depression. All participants had been treated by one of two therapists who served as clinicians in both settings. Individuals in the two samples were diagnostically and demographically similar (approximately 50 % Female, 83 % White). A variety of client characteristics, assessed prior to treatment, as well as the outcomes of treatment, were examined. Significantly superior treatment outcomes were observed in the individuals treated in the research study, relative to clients in the outpatient clinic, and the difference was not accounted for by intake characteristics. Individuals treated by the therapists in the RCT experienced almost three times as much improvement in depressive symptoms as clients seen in the outpatient setting. If replicated, the findings suggest that differences exist between treatment outcomes in research and outpatient settings and that these differences may not simply be due to therapist experience and training, or differences in patient populations. Future research should further examine the impact of fidelity monitoring, treatment expectation and motivation, and the duration and timing of treatment protocols on clinical outcomes.
C1 [Stirman, Shannon Wiltsey] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Stirman, Shannon Wiltsey] Boston Univ, Boston, MA 02215 USA.
[DeRubeis, Robert J.; Newman, Cory F.; Beck, Aaron T.] Univ Penn, Philadelphia, PA 19104 USA.
RP Stirman, SW (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
EM sws@bu.edu
OI Wiltsey Stirman, Shannon/0000-0001-9917-5078
FU NIMH NIH HHS [R10 MH055875, R25 MH080916, R37 MH047383, R00 MH080100]
NR 30
TC 5
Z9 5
U1 0
U2 28
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0147-5916
J9 COGNITIVE THER RES
JI Cogn. Ther. Res.
PD JUN
PY 2013
VL 37
IS 3
BP 605
EP 612
DI 10.1007/s10608-012-9499-7
PG 8
WC Psychology, Clinical
SC Psychology
GA 142SI
UT WOS:000318817000020
PM 23710102
ER
PT J
AU Yonekawa, Y
Jakobiec, FA
Zakka, FR
Kim, N
AF Yonekawa, Yoshihiro
Jakobiec, Frederick A.
Zakka, Fouad R.
Kim, Nancy
TI Keratinizing Cyst of the Lacrimal Punctum
SO CORNEA
LA English
DT Article
DE keratinizing cyst; lacrimal punctum; canaliculus
ID DIAGNOSIS; TUMORS
AB Purpose: To describe the clinical and histopathologic features of the first reported punctal keratinizing cyst.
Methods: Observational case report with clinical findings and paraffin-embedded tissue stained with hematoxylin and eosin.
Results: A 54-year-old man presented with an outpouching in the region of the left upper lacrimal punctum. Microscopic examination revealed a cyst filled with needle-like keratin located in the proximal subpunctal canaliculus, with a small, mostly effaced punctal orifice with focal extrusion of keratin. The epithelial wall was composed of a crenellated, multilaminar, keratinizing squamous epithelium. There was no associated inflammation or foreign bodies.
Conclusions: To the best of our knowledge, a punctal canalicular cyst, or any ectasia of the canaliculus or the lacrimal sac, has never before been reported primarily to contain keratin. As a new entity, this report broadens the differential diagnosis for lesions of the lacrimal drainage system.
C1 Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Jakobiec, FA (reprint author), Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, David G Cogan Lab Ophthalm Pathol, Suite 328,243 Charles St, Boston, MA 02114 USA.
EM fred_jakobiec@meei.harvard.edu
NR 12
TC 4
Z9 4
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD JUN
PY 2013
VL 32
IS 6
BP 883
EP 885
DI 10.1097/ICO.0b013e3182847917
PG 3
WC Ophthalmology
SC Ophthalmology
GA 144VB
UT WOS:000318967800035
PM 23471084
ER
PT J
AU Sayegh, RR
Kouyoumjian, PB
Vedula, GG
Nottage, JM
Nirankari, VS
AF Sayegh, Rony R.
Kouyoumjian, Paul B.
Vedula, Geetha G.
Nottage, Jennifer M.
Nirankari, Verinder S.
TI Cocaine-Assisted Epithelial Debridement for the Treatment of Anterior
Basement Membrane Dystrophy
SO CORNEA
LA English
DT Article
DE anterior basement membrane dystrophy; cocaine; debridement; epithelial
basement membrane dystrophy; map-dot-fingerprint dystrophy
ID RECURRENT CORNEAL EROSIONS; STROMAL PUNCTURE; KERATECTOMY; RABBIT
AB Purpose: To describe a method of epithelial debridement with the adjunctive use of topical cocaine for the treatment of symptomatic anterior basement membrane dystrophy (ABMD).
Methods: Retrospective consecutive chart review. Symptomatic patients with ABMD were treated with 4% topical cocaine followed by epithelial debridement. Preoperative and postoperative best-corrected visual acuities (BCVA), topography, subjective symptoms, complications, and evidence of disease recurrence were recorded.
Results: Thirty-three eyes of 27 patients were included. The average follow-up duration was 5 years (range, 1.3 months to 8 years). Fourteen patients (17 eyes) presented with recurrent erosion symptoms (group 1) and 13 patients (16 eyes) presented with reduced visual acuity from irregular astigmatism (group 2). Only 1 patient from group 1 experienced symptomatic recurrence of the corneal erosion. In this group, BCVA improved from a mean of 20/45 preoperatively to 20/38 at the last follow-up visit. In group 2, BCVA improved from a mean of 20/63 preoperatively to 20/32 at the last follow-up visit. No major recurrences were noted at the last follow-up visit in this group. No residual effect from the application of cocaine was noted in any of the eyes. Significant postoperative corneal haze occurred in 1 eye.
Conclusions: Topical cocaine-assisted epithelial debridement offers a simple and inexpensive method for treating patients with ABMD who experience recurrent corneal erosions and/or irregular astigmatism resulting in decreased visual acuity.
C1 [Sayegh, Rony R.; Kouyoumjian, Paul B.; Nottage, Jennifer M.; Nirankari, Verinder S.] Univ Maryland, Sch Med, Dept Ophthalmol & Visual Sci, Baltimore, MD 21201 USA.
[Sayegh, Rony R.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Vedula, Geetha G.] Cleveland Clin Florida, Weston, FL USA.
[Nottage, Jennifer M.; Nirankari, Verinder S.] Eye Consultants Maryland, Baltimore, MD USA.
RP Nirankari, VS (reprint author), 21 Crossroads Dr,Suite 425, Owings Mills, MD 21117 USA.
EM vnirankari@aol.com
RI Sayegh, Rony/G-8777-2013
OI Sayegh, Rony/0000-0002-0119-4201
NR 22
TC 3
Z9 4
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0277-3740
J9 CORNEA
JI Cornea
PD JUN
PY 2013
VL 32
IS 6
BP 889
EP 892
DI 10.1097/ICO.0b013e318288ad4d
PG 4
WC Ophthalmology
SC Ophthalmology
GA 144VB
UT WOS:000318967800037
PM 23591147
ER
PT J
AU Lee, EQ
Nayak, L
Wen, PY
Reardon, DA
AF Lee, Eudocia Q.
Nayak, Lakshmi
Wen, Patrick Y.
Reardon, David A.
TI Treatment Options in Newly Diagnosed Glioblastoma
SO CURRENT TREATMENT OPTIONS IN NEUROLOGY
LA English
DT Review
DE Glioblastoma; Temozolomide; Radiation; Bevacizumab; Treatment; Newly
diagnosed; Carmustine polymer wafers
ID PHASE-III TRIAL; RADIATION-THERAPY; ADJUVANT TEMOZOLOMIDE; MALIGNANT
GLIOMA; RADIOTHERAPY; SURVIVAL; CHEMOTHERAPY; BEVACIZUMAB; CONCOMITANT;
MULTIFORME
AB Regardless of MGMT status, standard of care for a patient with newly diagnosed glioblastoma (GBM), age a parts per thousand currency sign70 years, and adequate functional status is radiation and concurrent temozolomide followed by adjuvant temozolomide. For elderly patients, recent studies have suggested that standard radiation, hypofractionated radiation, or single agent temozolomide are acceptable treatment options. Randomized phase III studies of bevacizumab in combination with radiation and temozolomide for newly diagnosed GBM have completed accrual. Preliminary results reveal a clear progression-free survival benefit. Overall survival appears unchanged although follow-up has not fully matured and cross-over to bevacizumab upon progression among control patients may limit definitive conclusions. Although bevacizumab in the upfront setting may be considered for a subset of patients, it should not be used routinely in newly diagnosed patients until final results are available. Clinical trials evaluating promising therapeutics given in combination with standard temozolomide chemoradiation are critically needed.
C1 [Lee, Eudocia Q.; Nayak, Lakshmi; Wen, Patrick Y.; Reardon, David A.] Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, Boston, MA 02215 USA.
RP Lee, EQ (reprint author), Dana Farber Brigham & Womens Canc Ctr, Ctr Neurooncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM david_reardon@dfci.harvard.edu
FU Up To Date and Continuum
FX Eudocia Q. Lee has served on an advisory board for Novartis and has been
paid for manuscript preparation by Up To Date and Continuum.
NR 31
TC 6
Z9 6
U1 0
U2 10
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1092-8480
J9 CURR TREAT OPTION NE
JI Curr. Treat. Options Neurol.
PD JUN
PY 2013
VL 15
IS 3
BP 281
EP 288
DI 10.1007/s11940-013-0226-9
PG 8
WC Clinical Neurology
SC Neurosciences & Neurology
GA 143YU
UT WOS:000318906300004
PM 23553038
ER
PT J
AU Taylor, J
Gerstner, ER
AF Taylor, Jennie
Gerstner, Elizabeth R.
TI Anti-Angiogenic Therapy in High-Grade Glioma (Treatment and Toxicity)
SO CURRENT TREATMENT OPTIONS IN NEUROLOGY
LA English
DT Review
DE Glioma; High-grade glioma; Anti-angiogenic; Treatment; VEGF; Vasogenic
edema; Targeted therapy; Bevacizumab
ID RECURRENT MALIGNANT GLIOMA; ENDOTHELIAL GROWTH-FACTOR; BEVACIZUMAB PLUS
IRINOTECAN; BRAIN-TUMOR CONSORTIUM; PHASE-II; GLIOBLASTOMA-MULTIFORME;
ANTIANGIOGENIC THERAPY; RADIATION NECROSIS; CANCER-PATIENTS; TRIAL
AB Malignant gliomas continue to have a very poor prognosis and treatment responses at recurrence are very limited. Though anti-angiogenic therapy has not yet been shown to extend overall survival in this patient population, there is likely substantial benefit to reducing vasogenic edema, allowing for temporary improvement in neurologic function, and minimizing the side effects of prolonged corticosteroid use. A trial of bevacizumab should be considered in those with worsening vasogenic cerebral edema such as seen in recurrent malignant gliomas, radiation necrosis, or progressive brain metastases. However, not all patients respond to anti-angiogenic treatment and if no radiographic or clinical responses are seen, then patients are not likely to benefit from further infusions. Though it is commonly well tolerated, some side effects, while rare, may be life threatening, and should be discussed with patients and their families. These discussions should also outline the goals of initiating therapy and when treatment should be stopped.
C1 [Taylor, Jennie; Gerstner, Elizabeth R.] Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Ctr Canc, Boston, MA 02114 USA.
RP Taylor, J (reprint author), Massachusetts Gen Hosp, Stephen E & Catherine Pappas Ctr Neurooncol, Ctr Canc, Yawkey 9E,55 Fruit St, Boston, MA 02114 USA.
EM egerstner@partners.org
FU NCI NIH HHS [R01 CA129371, U01 CA154601]
NR 59
TC 7
Z9 8
U1 0
U2 7
PU CURRENT MEDICINE GROUP
PI PHILADELPHIA
PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA
SN 1092-8480
EI 1534-3138
J9 CURR TREAT OPTION NE
JI Curr. Treat. Options Neurol.
PD JUN
PY 2013
VL 15
IS 3
BP 328
EP 337
DI 10.1007/s11940-013-0224-y
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA 143YU
UT WOS:000318906300008
PM 23417315
ER
PT J
AU Jain, R
Jain, D
Liu, Q
Bartosinska, B
Wang, J
Schumann, D
Kauschke, SG
Eickelmann, P
Piemonti, L
Gray, NS
Lammert, E
AF Jain, R.
Jain, D.
Liu, Q.
Bartosinska, B.
Wang, J.
Schumann, D.
Kauschke, S. G.
Eickelmann, P.
Piemonti, L.
Gray, N. S.
Lammert, E.
TI Pharmacological inhibition of Eph receptors enhances glucose-stimulated
insulin secretion from mouse and human pancreatic islets
SO DIABETOLOGIA
LA English
DT Article
DE Compound; Eph; Ephrin; Glucose tolerance; Insulin secretion; Pancreatic
islets
ID BETA-CELL; APOPTOSIS; IMATINIB; MICE
AB Type 2 diabetes is characterised by impaired glucose-stimulated insulin secretion (GSIS) from pancreatic islets. Since erythropoietin-producing hepatoma (Eph)-ephrin bidirectional signalling fine-tunes GSIS from pancreatic beta cells, we investigated Eph receptor tyrosine kinases (RTK) as potential drug targets for selectively increasing GSIS.
Insulin secretion assays were carried out using mouse and human pancreatic islets as well as mouse insulinoma (MIN6) cells in the presence or absence of two Eph RTK inhibitors. Furthermore, the most potent inhibitor was injected into mice to evaluate its effects on glucose tolerance and plasma insulin levels.
We showed that the Eph RTK inhibitors selectively increased GSIS from MIN6 cells as well as mouse and human islets. Our results also showed that the insulin secretory effects of these compounds required Eph-ephrin signalling. Finally, pharmacological inhibition of Eph receptor signalling improved glucose tolerance in mice.
We showed for the first time that Eph RTKs represent targets for small molecules to selectively increase GSIS and improve glucose tolerance.
C1 [Jain, R.; Jain, D.; Bartosinska, B.; Lammert, E.] Univ Dusseldorf, Inst Metab Physiol, D-40225 Dusseldorf, Germany.
[Jain, R.; Jain, D.; Bartosinska, B.; Lammert, E.] Univ Dusseldorf, German Diabet Ctr, D-40225 Dusseldorf, Germany.
[Liu, Q.; Wang, J.; Gray, N. S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schumann, D.; Kauschke, S. G.; Eickelmann, P.] Boehringer Ingelheim Pharma GmbH & Co KG, Cardiometab Dis Res, Biberach, Germany.
[Piemonti, L.] Ist Sci San Raffaele, Diabet Res Inst HSR DRI, Beta Cell Biol Unit, I-20132 Milan, Italy.
[Lammert, E.] Max Planck Inst Mol Cell Biol & Genet, Dresden, Germany.
RP Lammert, E (reprint author), Univ Dusseldorf, Inst Metab Physiol, Univ Str 1, D-40225 Dusseldorf, Germany.
EM Lammert@uni-duesseldorf.de
OI Schumann, Desiree/0000-0002-1172-7438; Piemonti,
Lorenzo/0000-0002-2172-2198; liu, qing song/0000-0002-7829-2547
FU CRC [590]; German Center for Diabetes Research (DZD e.V.) of the Federal
Ministry for Education and Research (BMBF)
FX R. Jain and E. Lammert were supported by CRC 590. E. Lammert and D. Jain
were supported by the German Center for Diabetes Research (DZD e.V.) of
the Federal Ministry for Education and Research (BMBF).
NR 20
TC 6
Z9 6
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2013
VL 56
IS 6
BP 1350
EP 1355
DI 10.1007/s00125-013-2877-1
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 142HI
UT WOS:000318787600017
PM 23475368
ER
PT J
AU Aranda, J
Motiejunaite, R
Silva, P
Aiello, LP
Kazlauskas, A
AF Aranda, J.
Motiejunaite, R.
Silva, P.
Aiello, L. P.
Kazlauskas, A.
TI Regression activity that is naturally present in vitreous becomes
ineffective as patients develop proliferative diabetic retinopathy
SO DIABETOLOGIA
LA English
DT Article
DE Basic science; Endothelium; Microvascular disease; Retinopathy
ID ENDOTHELIAL GROWTH-FACTOR; LYSOPHOSPHATIDIC ACID LPA; ANGIOGENIC FACTOR;
CELL-SURVIVAL; AUTOTAXIN; NEOVASCULARIZATION; INHIBITION; ACTIVATION;
MECHANISMS; MOTOGEN
AB The realisation that targeting agents in the vitreous is an effective approach to treating patients with diabetic retinopathy (DR) has increased awareness that changes in the composition/bioactivity of the vitreous is a contributor to the pathogenesis of DR. The overall goal of this study was to test the hypothesis that the vitreous has regression activity, and that lysophosphatidic acid (LPA) contributes to such activity. LPA is a bioactive phospholipid present in many biological fluids, and has been recently appreciated for its ability to promote regression of blood vessels.
Vitreous-mediated regression was monitored on tubes organised from primary retinal endothelial cells or neovessels that sprouted from retinal explants. LPA was quantified radioenzymatically.
Bovine and human vitreous promoted regression of retinal explant vessels and of tubes organised from primary retinal endothelial cells. LPA was a substantial component of this regression activity. Comparing the regression activities of vitreous from patients with different stages of DR revealed that, as patients developed proliferative diabetic retinopathy (PDR), vitreous lost its ability to promote regression, even though the amount of LPA did not change. The underlying mechanism was a PDR-vitreous-mediated insensitivity to LPA, which could be overcome pharmacologically.
Our findings suggest that a decline in the responsiveness to regression factors such as LPA, which are naturally present in the vitreous, contributes to the pathogenesis of PDR.
C1 [Aranda, J.; Motiejunaite, R.; Kazlauskas, A.] Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Motiejunaite, R.] Vilnius State Univ, Dept Biochem & Biophys, Vilnius, Lithuania.
[Silva, P.; Aiello, L. P.] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Kazlauskas, A (reprint author), Massachusetts Eye & Ear Infirm, Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM Andrius_kazlauskas@meei.harvard.edu
FU JDRF [I-2008-905]; National Institutes of Health [EY018344]; Pew Latin
American Fellows Program in the Biomedical Sciences; American Diabetes
Association Mentor-based Minority Fellowship [7-09-MI-04]; Fundacion
Mexico en Harvard
FX Grant Numbers and Sources of Support: I-2008-905 and EY018344 from JDRF
and National Institutes of Health, respectively, to A. Kazlauskas; Pew
Latin American Fellows Program in the Biomedical Sciences, American
Diabetes Association Mentor-based Minority Fellowship 7-09-MI-04 and
Fundacion Mexico en Harvard to J. Aranda.
NR 47
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0012-186X
J9 DIABETOLOGIA
JI Diabetologia
PD JUN
PY 2013
VL 56
IS 6
BP 1444
EP 1453
DI 10.1007/s00125-013-2884-2
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 142HI
UT WOS:000318787600028
PM 23508305
ER
PT J
AU Lederlin, M
Bauman, G
Eichinger, M
Dinkel, J
Brault, M
Biederer, J
Puderbach, M
AF Lederlin, Mathieu
Bauman, Grzegorz
Eichinger, Monika
Dinkel, Julien
Brault, Mathilde
Biederer, Juergen
Puderbach, Michael
TI Functional MRI using Fourier decomposition of lung signal:
Reproducibility of ventilation- and perfusion-weighted imaging in
healthy volunteers
SO EUROPEAN JOURNAL OF RADIOLOGY
LA English
DT Article
DE Lung; Magnetic resonance imaging; Perfusion; Ventilation
ID DUAL-ENERGY TECHNIQUE; COMPUTED-TOMOGRAPHY; INITIAL-EXPERIENCE;
PULMONARY-EMBOLISM; PROTON MRI; CT; FLOW
AB Purpose: To assess the reproducibility of Fourier decomposition (FD) based ventilation-and perfusion-weighted lung MRI.
Methods: Sixteen healthy volunteers were examined on a 1.5 T whole-body MR-scanner with 4-6 sets of coronal slices over the chest volume with a non-contrast enhanced steady-state free precession sequence. The identical protocol was repeated after 24 h. Reconstructed perfusion-and ventilation-weighted images were obtained through non-rigid registration and FD post-processing of images. Analysis of signal in segmented regions of interest was performed for both native and post-processed data. Two blinded chest radiologists rated image quality of perfusion-and ventilation-weighted images using a 3-point scale.
Results: Reproducibility of signal between the two time points was very good with intra-class correlation coefficients of 0.98, 0.94 and 0.86 for native, perfusion-and ventilation-weighted images, respectively. Perfusion-and ventilation-weighted images were of overall good quality with proportions of diagnostic images of 87-95% and 69-75%, respectively. Lung signal decreased from posterior to anterior slices with image quality of ventilation-weighted images in anterior areas rated worse than in posterior or perfusion-weighted images. Inter-and intra-observer agreement of image quality was good for perfusion and ventilation.
Conclusions: The study demonstrates high reproducibility of ventilation-and perfusion-weighted FD lung MRI. (C) 2012 Elsevier Ireland Ltd. All rights reserved.
C1 [Lederlin, Mathieu; Biederer, Juergen] Univ Heidelberg Hosp, Dept Radiol, D-69120 Heidelberg, Germany.
[Lederlin, Mathieu] Univ Hosp Bordeaux, Dept Thorac & Cardiovasc Imaging, F-33600 Pessac, France.
[Bauman, Grzegorz] German Canc Res Ctr, Div Med Phys Radiol, D-69120 Heidelberg, Germany.
[Eichinger, Monika; Dinkel, Julien; Puderbach, Michael] German Canc Res Ctr, Div Radiol, D-69120 Heidelberg, Germany.
[Dinkel, Julien] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Brault, Mathilde] Univ Bordeaux Segalen, Methodol Unit Support Res USMR, F-33076 Bordeaux, France.
[Puderbach, Michael] Heidelberg Univ, Clin Intervent Radiol, Chest Clin, D-69126 Heidelberg, Germany.
[Puderbach, Michael] Heidelberg Univ, Clin Diagnost Radiol, Chest Clin, D-69126 Heidelberg, Germany.
RP Bauman, G (reprint author), German Canc Res Ctr, Div Med Phys Radiol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.
EM mathieu.lederlin@chu-bordeaux.fr; g.bauman@dkfz.de; m.eichinger@dkfz.de;
julien.dinkel@googlemail.com; mathilde.brault@isped.u-bordeaux2.fr;
juergen.biederer@uni-heidelberg.de; m.puderbach@dkfz.de
RI Biederer, Juergen/E-4545-2010
NR 30
TC 14
Z9 14
U1 0
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0720-048X
J9 EUR J RADIOL
JI Eur. J. Radiol.
PD JUN
PY 2013
VL 82
IS 6
BP 1015
EP 1022
DI 10.1016/j.ejrad.2012.12.003
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 143ZL
UT WOS:000318908300027
PM 23295084
ER
PT J
AU Toro, ML
Koontz, AM
Cooper, RA
AF Toro, Maria Luisa
Koontz, Alicia M.
Cooper, Rory A.
TI The Impact of Transfer Setup on the Performance of Independent
Wheelchair Transfers
SO HUMAN FACTORS
LA English
DT Article
DE activities of daily living; accessibility standards; wheeled mobility;
wheelchair; disability
ID SPINAL-CORD-INJURY; USERS; INDIVIDUALS; SHOULDER; IMPINGEMENT;
KINEMATICS
AB Objective: The aim of this study was to determine how selected environmental factors affect transfers and to compare our results to the Americans with Disabilities Act Accessibility Guidelines (ADAAG).
Background: Few data are available to support standards development related to transfers in the built environment.
Method: Participants were 120 wheeled mobility device (WMD) users who transferred to and from a modular transfer station that consisted of a height-adjustable platform with a lateral grab bar, optional obstacle to the transfer, and an optional height-adjustable front grab bar. Maximum and minimum vertical heights of the transfer surface, maximum gap distance between the WMD and transfer surface, grab bar use, and WMD space needs were recorded.
Results: The 95th percentile lowest and highest heights attained were similar to the median WMD seat-to-floor height (56 cm). We found that 42% (47/113) could not perform a transfer with the obstacle present. Participants transferred higher when the front grab bar was added to the setup (p = .005) and higher and lower with the front grab bar than without it when the obstacle was present in the setup (p = .003 and p = .005, respectively). We found that 95% of participants performed a transfer across an 8.9-cm gap. ADAAG recommendations fall short for the height and clear-space needs of the 50th-percentile WMD users.
Conclusion: Revisions concerning transfer heights, gaps, clear spaces, and grab bar heights are necessary to make transfers more accessible to WMD users.
Application: The data will be used to revise the guidelines related to transfers and to enable designers and engineers to create an environment that is more accessible.
C1 [Toro, Maria Luisa; Koontz, Alicia M.; Cooper, Rory A.] Dept Vet Affairs, Human Engn Res Labs, Pittsburgh, PA USA.
RP Koontz, AM (reprint author), VA Pittsburgh Hlth Care Syst, Human Engn Res Labs, 6425 Penn Ave,Suite 400 151R-B, Pittsburgh, PA 15206 USA.
EM akoontz@pitt.edu
FU Department of Education (NIDRR), United States Access Board
[H133E070024, 84.133E]
FX The authors are also affiliated with the University of Pittsburgh,
Pittsburgh, Pennsylvania. Funding for this study was provided by the
Department of Education (NIDRR), United States Access Board Grant
H133E070024 and Project No. 84.133E. This material is the result of work
supported with resources and the use of facilities at the Human
Engineering Research Laboratories, VA Pittsburgh Healthcare System. The
contents do not represent the views of the Department of Veterans
Affairs or the U. S. government.
NR 29
TC 2
Z9 2
U1 3
U2 10
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0018-7208
J9 HUM FACTORS
JI Hum. Factors
PD JUN
PY 2013
VL 55
IS 3
BP 567
EP 580
DI 10.1177/0018720812460549
PG 14
WC Behavioral Sciences; Engineering, Industrial; Ergonomics; Psychology,
Applied; Psychology
SC Behavioral Sciences; Engineering; Psychology
GA 144MF
UT WOS:000318942900009
PM 23829031
ER
PT J
AU Graber, CJ
Madaras-Kelly, K
Jones, MM
Neuhauser, MM
Goetz, MB
AF Graber, Christopher J.
Madaras-Kelly, Karl
Jones, Makoto M.
Neuhauser, Melinda M.
Goetz, Matthew Bidwell
TI Unnecessary Antimicrobial Use in the Context of Clostridium difficile
Infection: A Call to Arms for the Veterans Affairs Antimicrobial
Stewardship Task Force
SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY
LA English
DT Letter
C1 [Graber, Christopher J.; Goetz, Matthew Bidwell] Vet Affairs VA Greater Los Angeles Healthcare Sys, Infect Dis Sect, Los Angeles, CA USA.
[Graber, Christopher J.; Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Madaras-Kelly, Karl] Boise VA Med Ctr, Serv Pharm, Boise, ID USA.
[Madaras-Kelly, Karl] Idaho State Univ, Coll Pharm, Meridian, ID USA.
[Jones, Makoto M.] VA Salt Lake City Hlth Care Syst, IDEAS Ctr, Salt Lake City, UT USA.
[Jones, Makoto M.] Univ Utah, Div Epidemiol, Salt Lake City, UT USA.
[Neuhauser, Melinda M.] Dept VA Pharm Benefits Management Serv, Hines, IL USA.
RP Graber, CJ (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Infect Dis Sect, 11301 Wilshire Blvd,111-F, Los Angeles, CA 90073 USA.
EM christopher.graber@va.gov
OI Goetz, Matthew/0000-0003-4542-992X
NR 6
TC 4
Z9 4
U1 0
U2 3
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0899-823X
J9 INFECT CONT HOSP EP
JI Infect. Control Hosp. Epidemiol.
PD JUN
PY 2013
VL 34
IS 6
BP 651
EP 653
DI 10.1086/670640
PG 5
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA 142AB
UT WOS:000318766800023
PM 23651905
ER
PT J
AU Burgio, KL
Newman, DK
Rosenberg, MT
Sampselle, C
AF Burgio, K. L.
Newman, D. K.
Rosenberg, M. T.
Sampselle, C.
TI Impact of behaviour and lifestyle on bladder health
SO INTERNATIONAL JOURNAL OF CLINICAL PRACTICE
LA English
DT Review
ID URINARY-TRACT SYMPTOMS; BENIGN PROSTATIC HYPERPLASIA;
NUTRITION-EXAMINATION-SURVEY; OVERACTIVE BLADDER; CIGARETTE-SMOKING;
RISK-FACTORS; STRESS-INCONTINENCE; FLUID INTAKE; CANCER RISK; CHRONIC
CONSTIPATION
AB Bladder conditions, including UTI, UI, and bladder cancer, are highly prevalent and affect a wide range of populations. There are a variety of modifiable behavioral and lifestyle factors that influence bladder health. Some factors, such as smoking and obesity, increase the risk or severity of bladder conditions, whereas other factors, such as pelvic floor muscle exercise, are protective. Although clinical practice may be assumed to be the most appropriate ground for education on behavioral and lifestyle factors that influence bladder health, it is also crucial to extend these messages into the general population through public health interventions to reach those who have not yet developed bladder conditions and to maximize the prevention impact of these behaviors. Appropriate changes in these factors have the potential for an enormous impact on bladder health if implemented on a population-based level.
C1 [Burgio, K. L.] Dept Vet Affairs Med Ctr, Birmingham, AL USA.
[Burgio, K. L.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Newman, D. K.] Univ Penn, Perelman Sch Med, Div Urol, Philadelphia, PA 19104 USA.
[Rosenberg, M. T.] Midmichigan Hlth Ctr, Jackson, MI USA.
[Sampselle, C.] Univ Michigan, Sch Nursing, Div Hlth Promot & Risk Reduct, Ann Arbor, MI 48109 USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Geriatr Res Educ & Clin Ctr, 700 South 19th St, Birmingham, AL 35233 USA.
EM kburgio@uabmc.edu
FU Pfizer Inc.
FX Funding for two expert panel meetings on bladder health, at which this
manuscript was conceptualised, was provided by Pfizer Inc. Editorial
assistance was provided by Nicole Lodowski of Pfizer Inc and Colin P.
Mitchell, PhD, of Complete Healthcare Communications, Inc. and was
funded by Pfizer Inc.
NR 100
TC 8
Z9 8
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1368-5031
J9 INT J CLIN PRACT
JI Int. J. Clin. Pract.
PD JUN
PY 2013
VL 67
IS 6
BP 495
EP 504
DI 10.1111/ijcp.12143
PG 10
WC Medicine, General & Internal; Pharmacology & Pharmacy
SC General & Internal Medicine; Pharmacology & Pharmacy
GA 146BJ
UT WOS:000319063500005
PM 23679903
ER
PT J
AU Sylvia, LG
Hay, A
Ostacher, MJ
Miklowitz, DJ
Nierenberg, AA
Thase, ME
Sachs, GS
Deckersbach, T
Perlis, RH
AF Sylvia, Louisa G.
Hay, Aleena
Ostacher, Michael J.
Miklowitz, David J.
Nierenberg, Andrew A.
Thase, Michael E.
Sachs, Gary S.
Deckersbach, Thilo
Perlis, Roy H.
TI Association Between Therapeutic Alliance, Care Satisfaction, and
Pharmacological Adherence in Bipolar Disorder
SO JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
LA English
DT Article
DE therapeutic alliance; clinical practice; medication adherence; bipolar
disorder; treatment
ID TREATMENT ENHANCEMENT PROGRAM; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW;
MEDICATION ADHERENCE; MENTAL-HEALTH; STEP-BD; TREATMENT NONADHERENCE;
SPECTRUM DISORDERS; PRACTICE MODEL; I-DISORDER; DSM-IV
AB Objectives: We sought to understand the association of specific aspects of care satisfaction, such as patients' perceived relationship with their psychiatrist and access to their psychiatrist and staff, and therapeutic alliance with participants' likelihood to adhere to their medication regimens among patients with bipolar disorder.
Methods: We examined data from the multicenter Systematic Treatment Enhancement Program for Bipolar Disorder, an effectiveness study investigating the course and treatment of bipolar disorder. We expected that participants (n = 3037) with positive perceptions of their relationship with their psychiatrist and quality of psychopharmacologic care, as assessed by the Helping Alliance Questionnaire and Care Satisfaction Questionnaire, would be associated with better medication adherence. We utilized logistic regression models controlling for already established factors associated with poor adherence.
Results: Patients' perceptions of collaboration, empathy, and accessibility were significantly associated with adherence to treatment in individuals with bipolar disorder completing at least 1 assessment. Patients' perceptions of their psychiatrists' experience, as well as of their degree of discussing medication risks and benefits, were not associated with medication adherence.
Conclusions: Patients' perceived therapeutic alliance and treatment environment impact their adherence to pharmacotherapy recommendations. This study may enable psychopharmacologists' practices to be structured to maximize features associated with greater medication adherence.
C1 [Sylvia, Louisa G.; Nierenberg, Andrew A.; Sachs, Gary S.; Deckersbach, Thilo] Massachusetts Gen Hosp, Bipolar Clin & Res Program, Boston, MA 02114 USA.
[Sylvia, Louisa G.; Nierenberg, Andrew A.; Sachs, Gary S.; Deckersbach, Thilo; Perlis, Roy H.] Harvard Univ, Sch Med, Boston, MA USA.
[Sylvia, Louisa G.; Nierenberg, Andrew A.; Sachs, Gary S.; Deckersbach, Thilo; Perlis, Roy H.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Hay, Aleena] Yale Univ, Dept Psychol, New Haven, CT 06520 USA.
[Ostacher, Michael J.] Stanford Univ, Dept Psychiat & Behav Sci, Sch Med, Stanford, CA 94305 USA.
[Miklowitz, David J.] Univ Calif Los Angeles, Dept Psychiat & Behav Sci, Semel Inst, Los Angeles, CA 90024 USA.
[Thase, Michael E.] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.
RP Sylvia, LG (reprint author), Bipolar Clin & Res Program, 50 Staniford St,Suite 580, Boston, MA 02114 USA.
EM lsylvia2@partners.org
OI Ostacher, Michael/0000-0003-0353-7535
FU National Institute of Mental Health [N01MH80001]; NIH; NIA; Janssen
Pharmaceuticals; Forest Research Institute; Shire Development Inc;
Medtronic; Cyberonics; Northstar; MGH from NIMH; PamLabs; Pfizer
Pharmaceuticals; Shire; NIMH; Eli Lilly and Company; GlaxoSmithKline;
Sepracor, Inc.; Abbott Laboratories; AstraZeneca Pharmaceuticals;
Bristol-Myers Squibb; Memory Pharmaceuticals; Novartis Pharmaceuticals;
Pfizer; Repligen; Concordant Rater Systems
FX This study was supported in part by the National Institute of Mental
Health Contract N01MH80001.; As of July 1st, 2012, the authors disclose
the following: Dr Sylvia is a consultant for Concordant Rater Systems.
In the past 2 years, Dr Ostacher has served on advisory/consulting
boards of Pfizer and Schering Plough (now Merck); he has received
speaking fees from AstraZeneca, Bristol-Myers Squibb, Eli Lilly &
Company, and Pfizer. Dr Deckersbach's research has been funded by the
National Institute of Mental Health (NIMH), NARSAD, TSA, and OCF. He has
received honoraria, consultation fees and/or royalties from Medacorp,
Massachusetts General Hospital (MGH) Psychiatry Academy, BrainCells Inc,
Systems Research and Applications Corporation, Boston University, the
Catalan Agency for Health Technology Assessment and Research, the
National Association of Social Workers Massachusetts, and Oxford
University Press. He has also participated in research funded by NIH,
NIA, Janssen Pharmaceuticals, The Forest Research Institute, Shire
Development Inc, Medtronic, Cyberonics, and Northstar. DrMiklowitz does
not have any support or funding to disclose. Dr Nierenberg is a full
time employee of the MGH. In the past 12 months (as of June 21, 2010),
he has served as a consultant to the Appliance Computing Inc (Mindsite)
and Brandeis University. Through the MGH Clinical Trials Network and
Institute (CTNI), he has consulted for Brain Cells, Inc; Dianippon
Sumitomo/Sepracor; Labopharm; Merck; Methylation Science; Novartis, PGx
Health, Shire; Schering-Plough; Targacept; and Takeda/Lundbeck
Pharmaceuticals. He received grant/research support through MGH from
NIMH, PamLabs, Pfizer Pharmaceuticals, and Shire. He received honoraria
from Belvior Publishing, Hillside Hospital, American Society for
Clinical Psychopharmacology, Columbia University, IMEDEX, MJ Consulting,
New York State, MBL Publishing, Physicians Postgraduate Press, SciMed,
SUNY Buffalo, University of Wisconsin, and the University of Pisa. Dr
Nierenberg is a presenter for the MGH Psychiatry Academy (MGHPA). The
education programs conducted by the MGHPA were supported through
Independent Medical Education grants from the following pharmaceutical
companies: in 2008 AstraZeneca, Eli Lilly, and Janssen Pharmaceuticals;
and in 2009 AstraZeneca, Eli Lilly, and Bristol-Myers Squibb. No speaker
bureaus or boards since 2003. He is on the advisory boards of Appliance
Computing, Inc; Brain Cells, Inc; Eli Lilly and Company; and Takeda/
Lundbeck and Targacept. Dr Nierenberg owns stock options in Appliance
Computing, Inc, and Brain Cells, Inc. Through MGH, he is named for
copyrights to the Clinical Positive Affect Scale and the MGH Structured
Clinical Interview for the Montgomery-A ~ sberg Depression Scale
exclusively licensed to the CTNI. Ms Hay is a consultant for GENOMIND.
Dr Thase has received federal funding from the NIMH. Dr Thase has
received research support from Eli Lilly and Company, GlaxoSmithKline,
and Sepracor, Inc. Dr Thase has provided scientific consultation to
AstraZeneca; Bristol-Myers Squibb Company; Eli Lilly & Co; Forest
Laboratories; GlaxoSmithKline; MedAvante, Inc; Neuronetics, Inc;
Novartis; Otsuka; OrthoMcNeil Pharmaceuticals; Pfizer (formerly Wyeth
Ayerst Pharmaceuticals); Schering-Plough; Shire US Inc; Supernus
Pharmaceuticals; Takeda (Lundbeck); and Transcept Pharmaceuticals. Dr
Thase has been a member of the speakers' bureaus for AstraZeneca,
Bristol-Myers Squibb Company, Eli Lilly & Co, and Pfizer (formerly Wyeth
Ayerst Pharmaceuticals).; Dr Thase has equity holdings in MedAvante,
Inc, and receives royalty income from American Psychiatric Publishing,
Inc; Guilford Publications; Herald House; and W. W. Norton & Company.
His wife is employed as the senior medical director for Advogent
(Advogent does business with BMS and Pfizer/ Wyeth). Over his lifetime,
Dr Sachs has served as a member of the speakers' bureaus for Abbott
Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli
Lilly & Co, GlaxoSmithKline, Janssen Pharmaceuticals, Memory
Pharmaceuticals, Novartis Pharmaceuticals, Pfizer, Sanofi-Aventis, and
Wyeth. Dr Sachs has received research support from Abbott Laboratories,
AstraZeneca Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly & Co,
GlaxoSmithKline, Janssen Pharmaceuticals, Memory Pharmaceuticals, the
NIMH, Novartis Pharmaceuticals, Pfizer, Repligen, Shire, and Wyeth. In
his lifetime, Dr Sachs has served on advisory/consulting boards of
Abbott Laboratories, AstraZeneca Pharmaceuticals, Bristol-Myers Squibb,
Cephalon, CNS Response, Elan Pharmaceuticals, Memory Pharmaceuticals,
Merck, Novartis Pharmaceuticals, Organon, Otsuka, Pfizer, Schering
Plough, Sepracor, Repligen, Sanofi-Aventis, Shire, Sigma-Tau, Solvay
Pharmaceuticals, and Wyeth. Dr Sachs and his spouse own stock in
Concordant Rater Systems. In the past 12 months, Dr Sachs has received
research support from GlaxoSmithKline, the NIMH, and Repligen. In the
past 12 months, Dr Sachs has served on the advisory/ consulting boards
of AstraZeneca Pharmaceuticals, BristolMyers Squibb, Cephalon,
Concordant Rater Systems, Janssen Pharmaceuticals, Merck, Otsuka,
Pfizer, Schering Plough, Sepracor, and Repligen. Dr Perlis receives
speaker's bureau/ consulting fees from AstraZeneca, Eli Lilly & Co,
Proteus Biomedical, and Concordant Rater Systems. Dr Perlis receives
royalties and has a patent for the Concordant Rater Systems.
NR 56
TC 9
Z9 10
U1 4
U2 15
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0271-0749
J9 J CLIN PSYCHOPHARM
JI J. Clin. Psychopharmacol.
PD JUN
PY 2013
VL 33
IS 3
BP 343
EP 350
DI 10.1097/JCP.0b013e3182900c6f
PG 8
WC Pharmacology & Pharmacy; Psychiatry
SC Pharmacology & Pharmacy; Psychiatry
GA 143MK
UT WOS:000318871400009
PM 23609394
ER
PT J
AU Fong, ZV
Tan, WP
Lavu, H
Kennedy, EP
Mitchell, DG
Koniaris, LG
Sauter, PK
Rosato, EL
Yeo, CJ
Winter, JM
AF Fong, Zhi Ven
Tan, Wei Phin
Lavu, Harish
Kennedy, Eugene P.
Mitchell, Donald G.
Koniaris, Leonidas G.
Sauter, Patricia K.
Rosato, Ernest L.
Yeo, Charles J.
Winter, Jordan M.
TI Preoperative Imaging for Resectable Periampullary Cancer:
Clinicopathologic Implications of Reported Radiographic Findings
SO JOURNAL OF GASTROINTESTINAL SURGERY
LA English
DT Article
DE Periampullary cancers; Computed tomography; Pancreatic ductal
adenocarcinoma
ID MULTIDETECTOR CT ANGIOGRAPHY; SPIRAL COMPUTED-TOMOGRAPHY;
PANCREATIC-CANCER; ENDOSCOPIC ULTRASONOGRAPHY; DUCTAL ADENOCARCINOMA;
SINGLE-INSTITUTION; HELICAL CT; CARCINOMA; HEAD; INVOLVEMENT
AB High-resolution, multiphase, computed tomography (CT) is a standard preoperative test prior to pancreatectomy, yet the clinical significance of routinely reported findings remains unknown.
We identified patients who underwent a pancreaticoduodenectomy for a periampullary adenocarcinoma (PA) over the previous 5 years and had a pancreas protocol CT at our institution. Clinicopathologic implications of reported CT findings were evaluated.
There were 155 pancreatic ductal adenocarcinomas (PDA) and 47 non-pancreatic PAs. No mass was visualized on CT in 6 % of PDAs and 23 % of non-pancreatic PA. A size discrepancy of a parts per thousand yen1 cm between radiographic and pathologic tumor diameters was observed in 40 % of PAs, with CT underestimating the size in most instances (75 %). Radiographically enlarged lymph nodes were not associated with true lymph node metastases in PDAs (70 % lymph node positive cases were enlarged on CT vs 74 % lymph node negative, p = 0.5), but were associated with a preoperatively placed biliary endoprosthesis (63 % with endoprosthesis were enlarged vs 37 % no endoprosthesis, p = 0.013). Major visceral vessel involvement on CT was not associated with a vascular resection (3 % with CT vessel involvement vs 2 % without, p = 0.8) or a positive uncinate resection margin (24 vs 20 %, respectively, p = 0.6).
While dedicated pancreas protocol CT provides unprecedented detail, the test may lead to overinterpretation of the extent of disease in some instances. A radiographic suggestion of enlarged lymph nodes and vascular involvement does not necessarily preclude exploration with curative intent. CTs with local disease should be reported in an objective template and carefully reviewed by a multidisciplinary group of surgeons, radiologists, and oncologists to avoid missing an opportunity for neoadjuvant therapy or cure by resection.
C1 [Fong, Zhi Ven] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Tan, Wei Phin; Lavu, Harish; Kennedy, Eugene P.; Koniaris, Leonidas G.; Sauter, Patricia K.; Rosato, Ernest L.; Yeo, Charles J.; Winter, Jordan M.] Thomas Jefferson Univ, Dept Surg, Jefferson Pancreas Biliary & Related Canc Ctr, Philadelphia, PA 19107 USA.
[Mitchell, Donald G.] Thomas Jefferson Univ, Dept Radiol, Jefferson Pancreas Biliary & Related Canc Ctr, Philadelphia, PA 19107 USA.
[Winter, Jordan M.] Thomas Jefferson Univ, Dept Surg, Philadelphia, PA 19107 USA.
RP Winter, JM (reprint author), Thomas Jefferson Univ, Dept Surg, 1025 Walnut St,Coll Bldg,Suite 605, Philadelphia, PA 19107 USA.
EM Jordan.winter@jefferson.edu
NR 47
TC 4
Z9 5
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1091-255X
J9 J GASTROINTEST SURG
JI J. Gastrointest. Surg.
PD JUN
PY 2013
VL 17
IS 6
BP 1098
EP 1106
DI 10.1007/s11605-013-2181-x
PG 9
WC Gastroenterology & Hepatology; Surgery
SC Gastroenterology & Hepatology; Surgery
GA 143XF
UT WOS:000318901800011
PM 23553385
ER
PT J
AU Patenaude, AF
DeMarco, TA
Peshkin, BN
Valdimarsdottir, H
Garber, JE
Schneider, KA
Hewitt, L
Hamilton, J
Tercyak, KP
AF Patenaude, Andrea Farkas
DeMarco, Tiffani A.
Peshkin, Beth N.
Valdimarsdottir, Heiddis
Garber, Judy E.
Schneider, Katherine A.
Hewitt, Larissa
Hamilton, Jennifer
Tercyak, Kenneth P.
TI Talking to Children About Maternal BRCA1/2 Genetic Test Results: A
Qualitative Study of Parental Perceptions and Advice
SO JOURNAL OF GENETIC COUNSELING
LA English
DT Article
DE BRCA1/2; Genetic testing; Family communication; Hereditary
breast/ovarian cancer; Prevention
ID BREAST-CANCER; MUTATION CARRIERS; RISK; SUPPORT; COMMUNICATION;
INFORMATION; DISCLOSURE; MOTHERS; NEEDS; TELL
AB Family communication is the primary, initial means of educating the next, at-risk generation about hereditary cancer risk. In this study, in-depth parent narratives provided self-report of motivations, planning, satisfactions and regrets associated with sharing or not sharing maternal BRCA1/2 test results with young children and advice for parents considering disclosure and for genetic counselors. Interviews were conducted with 32 mothers tested for BRCA1/2 with children ages 8-21 years and 24 of their co-parents; interview narratives were analyzed qualitatively. Parents were concerned with both protecting and educating children about hereditary cancer risk. They expressed confidence that parents can constructively convey genetic information to minor children. Telling relieved most parents and satisfied a sense of parental duty. Parents strongly advised child-specific, age-appropriate tailoring of genetic information and emphasized conveying the positive, preventive utility of genetic information to children. Immunizing effects of disclosure were viewed as providing forewarning about and preparation for possible later family cancer diagnoses. Parents choosing not to tell children were advised to consider future disclosure. Narratives about parental sharing of BRCA1/2 test results with minor children support the feasibility of parental discussion of maternal genetic test results to the next at-risk generation. Results suggest development of intervention tools for parents would support decision-making and family communication and potentially reduce parental worry and regret. Recommendations are made for more active involvement by genetic counselors with tested parents around the topic of delivery of genetic information to children.
C1 [Patenaude, Andrea Farkas; Garber, Judy E.; Schneider, Katherine A.; Hewitt, Larissa] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
[DeMarco, Tiffani A.; Peshkin, Beth N.; Tercyak, Kenneth P.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Valdimarsdottir, Heiddis] Mt Sinai Sch Med, Icahn Med Inst, New York, NY 10029 USA.
[Valdimarsdottir, Heiddis] Univ Reykjavik, Reykjavik, Iceland.
[Hamilton, Jennifer] Milton Acad, Milton, MA 02186 USA.
RP Patenaude, AF (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM andrea_patenaude@dfci.harvard.edu
FU National Human Genome Research Institute, National Institutes of Health
[R01HG002686]
FX This work was funded by grant #R01HG002686 (to Kenneth P. Tercyak,
Ph.D.) from the Ethical, Legal, and Social Implications Research Program
of the National Human Genome Research Institute, National Institutes of
Health. The authors would like to thank Kathleen McNaughton, Ph.D. who
ably conducted the research interviews.
NR 29
TC 10
Z9 10
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1059-7700
J9 J GENET COUNS
JI J. Genet. Couns.
PD JUN
PY 2013
VL 22
IS 3
BP 303
EP 314
DI 10.1007/s10897-012-9549-z
PG 12
WC Genetics & Heredity
SC Genetics & Heredity
GA 140XR
UT WOS:000318690300003
ER
PT J
AU Pursnani, A
Tawakol, A
AF Pursnani, Amit
Tawakol, Ahmed
TI PET/CT imaging of myocardial blood flow and arterial calcium: Putting
the pieces together
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Editorial Material
ID CORONARY CALCIUM; PERFUSION; DISEASE; INDIVIDUALS; TRIAL
C1 [Pursnani, Amit; Tawakol, Ahmed] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
RP Tawakol, A (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
EM atawakol@partners.org
FU NHLBI NIH HHS [T32 HL076136, K24 HL113128]
NR 12
TC 1
Z9 1
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD JUN
PY 2013
VL 20
IS 3
BP 331
EP 333
DI 10.1007/s12350-013-9702-6
PG 3
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 145GS
UT WOS:000319003800005
PM 23512168
ER
PT J
AU Vijayakumar, J
Subramanian, S
Singh, P
Corsini, E
Fontanez, S
Lawler, M
Kaplan, R
Brady, TJ
Hoffmann, U
Tawakol, A
AF Vijayakumar, Jayanthi
Subramanian, Sharath
Singh, Parmanand
Corsini, Erin
Fontanez, Sara
Lawler, Meredith
Kaplan, Rebecca
Brady, Thomas J.
Hoffmann, Udo
Tawakol, Ahmed
TI Arterial inflammation in bronchial asthma
SO JOURNAL OF NUCLEAR CARDIOLOGY
LA English
DT Article
DE PET; bronchial asthma; aorta; inflammation; atherosclerosis
ID POSITRON-EMISSION-TOMOGRAPHY; C-REACTIVE PROTEIN;
CORONARY-HEART-DISEASE; ATHEROSCLEROTIC PLAQUE INFLAMMATION; OBSTRUCTIVE
PULMONARY-DISEASE; LUNG-FUNCTION; CARDIOVASCULAR-DISEASE; SYSTEMIC
INFLAMMATION; FDG-PET; RISK
AB Bronchial asthma is a chronic inflammatory condition associated with increased cardiovascular (CV) events. Here, we assess arterial inflammation, using 18F-fluorodeoxyglucose positron emission tomography/computed tomography imaging (FDG-PET/CT), in patients with bronchial asthma and low to intermediate Framingham risk scores (FRS).
A total of 102 patients underwent FDG-PET/CT imaging for clinical indications. Thirty-four patients (mean age 54.9 +/- A 16.1) with mild asthma and no known atherosclerotic disease were compared to 2 non-asthmatic groups. The first control group (n = 34) were matched by age, gender, and FRS. The second control group (n = 34) had clinical atherosclerosis and were matched by gender. Thereafter, arterial FDG uptake on PET images was determined, while blinded to patient identifiers.
Target-to-background-ratio (TBR) in the aorta was higher in asthmatics vs non-asthmatic FRS-matched controls (1.96 +/- A 0.26 vs 1.76 +/- A 0.20; P < .001). The aortic TBR remained elevated in asthmatics vs non-asthmatic controls after adjusting traditional CV risk factors (P < .001). An inverse correlation was observed between FDG uptake and lung function, FEV1 (P = .02) and peak flow (P = .03).
Bronchial asthma is associated with increased arterial inflammation beyond that estimated by current risk stratification tools. Further studies are required to evaluate whether attenuation of systemic inflammation will decrease CV events.
C1 [Vijayakumar, Jayanthi; Subramanian, Sharath; Singh, Parmanand; Corsini, Erin; Fontanez, Sara; Lawler, Meredith; Kaplan, Rebecca; Brady, Thomas J.; Hoffmann, Udo; Tawakol, Ahmed] Massachusetts Gen Hosp, Cardiac MR PET CT Program, Boston, MA 02114 USA.
[Vijayakumar, Jayanthi; Subramanian, Sharath; Singh, Parmanand; Kaplan, Rebecca; Hoffmann, Udo] Massachusetts Gen Hosp, Cardiovasc Imaging Div, Boston, MA 02114 USA.
[Brady, Thomas J.] Massachusetts Gen Hosp, Nucl Med & Mol Imaging Div, Dept Imaging, Boston, MA 02114 USA.
[Tawakol, Ahmed] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Tawakol, Ahmed] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Tawakol, A (reprint author), Massachusetts Gen Hosp, Cardiac MR PET CT Program, 165 Cambridge St,Suite 400, Boston, MA 02114 USA.
EM atawakol@partners.org
NR 57
TC 14
Z9 14
U1 1
U2 3
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-3581
J9 J NUCL CARDIOL
JI J. Nucl. Cardiol.
PD JUN
PY 2013
VL 20
IS 3
BP 385
EP 395
DI 10.1007/s12350-013-9697-z
PG 11
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 145GS
UT WOS:000319003800011
PM 23526296
ER
PT J
AU Chan, MP
Duncan, LM
Nazarian, RM
AF Chan, May P.
Duncan, Lyn M.
Nazarian, Rosalynn M.
TI Subcutaneous Sweet syndrome in the setting of myeloid disorders: A case
series and review of the literature
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Review
DE myelodysplastic syndrome; myeloid leukemia; neutrophilic dermatosis;
neutrophilic panniculitis; subcutaneous; Sweet syndrome
ID FEBRILE NEUTROPHILIC DERMATOSIS; COLONY-STIMULATING FACTOR;
ERYTHEMA-NODOSUM; PYODERMA GANGRENOSUM; ACUTE-LEUKEMIA; MYELODYSPLASTIC
SYNDROMES; LOBULAR PANNICULITIS; HISTOPATHOLOGIC SPECTRUM; BULLOUS
PYODERMA; ID REACTION
AB Background: The association of neutrophilic dermatoses with myeloid disorders is well known, but neutrophilic panniculitis in the same setting has only been reported infrequently.
Objective: We aimed to better characterize these lesions clinically and histologically, and to provide a comprehensive differential diagnosis and appropriate diagnostic approach.
Methods: The pathology archives were searched for cases of neutrophilic panniculitis in patients with myeloid disorders. Clinical history and histologic features were studied. Similar cases in the English-language literature were reviewed.
Results: Five biopsy specimens from 4 patients and 11 previous case reports were identified. All patients presented with erythematous tender nodules typically involving the extremities. Most were accompanied by fevers, and resolved either spontaneously or with steroids. Histologically, the subcutaneous neutrophilic infiltrates demonstrated lobular or, less frequently, septal patterns with minimal dermal involvement. Leukocytoclasis, fat necrosis, reactive stromal fibroblasts, and mild reticular dermal edema were each seen in at least 3 of our 5 biopsy specimens. No myeloid blasts, vascular changes, or non-Miescher granulomas were observed. No micro-organisms were identified in the skin nodules.
Limitations: This study is limited by the small number of cases.
Conclusions: Based on the fairly consistent clinical and histologic findings, neutrophilic panniculitis occurring in the setting of myeloid disorders is best classified as subcutaneous Sweet syndrome after exclusion of infectious panniculitis, id reaction, and leukemia cutis. These lesions may be associated with myeloid disorders, or induced by chemotherapy or other medications.
C1 [Chan, May P.] Univ Michigan, Ctr Med, Dept Pathol, Ann Arbor, MI 48109 USA.
[Chan, May P.] Univ Michigan, Ctr Med, Dept Dermatol, Ann Arbor, MI 48109 USA.
[Duncan, Lyn M.; Nazarian, Rosalynn M.] Massachusetts Gen Hosp, Dermatopathol Unit, Pathol Serv, Boston, MA 02114 USA.
RP Chan, MP (reprint author), Univ Michigan, Ctr Med, Dept Pathol, Room M3261,1301 Catherine St, Ann Arbor, MI 48109 USA.
EM mpchan@med.umich.edu
OI Nazarian, Rosalynn/0000-0003-4003-7193
NR 56
TC 11
Z9 14
U1 0
U2 6
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2013
VL 68
IS 6
BP 1006
EP 1015
DI 10.1016/j.jaad.2012.12.954
PG 10
WC Dermatology
SC Dermatology
GA 143ZW
UT WOS:000318909600034
PM 23399459
ER
PT J
AU Dellavalle, RP
AF Dellavalle, Robert P.
TI Internet dermatology resources
SO JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
LA English
DT Editorial Material
ID INFORMATION
C1 [Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Denver, CO USA.
RP Dellavalle, RP (reprint author), 1055 Clermont St,Box 165, Denver, CO 80220 USA.
EM robert.dellavalle@ucdenver.edu
RI Dellavalle, Robert/L-2020-2013
OI Dellavalle, Robert/0000-0001-8132-088X
NR 7
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0190-9622
J9 J AM ACAD DERMATOL
JI J. Am. Acad. Dermatol.
PD JUN
PY 2013
VL 68
IS 6
BP 1039
EP 1039
DI 10.1016/j.jaad.2012.09.006
PG 1
WC Dermatology
SC Dermatology
GA 143ZW
UT WOS:000318909600039
PM 23680195
ER
PT J
AU Cheng, JW
Rozenblatt-Rosen, O
Paulson, KG
Nghiem, P
DeCaprio, JA
AF Cheng, Jingwei
Rozenblatt-Rosen, Orit
Paulson, Kelly G.
Nghiem, Paul
DeCaprio, James A.
TI Merkel Cell Polyomavirus Large T Antigen Has Growth-Promoting and
Inhibitory Activities
SO JOURNAL OF VIROLOGY
LA English
DT Article
ID TUMOR-SUPPRESSOR PROTEINS; JC VIRUS; RETINOBLASTOMA FAMILY; BK VIRUS;
CARCINOMA; TRANSFORMATION; SIMIAN-VIRUS-40; P53; IDENTIFICATION;
ONCOPROTEIN
AB Merkel cell carcinoma (MCC) is a rare and aggressive form of skin cancer. In at least 80% of all MCC, Merkel cell polyomavirus (MCPyV) DNA has undergone clonal integration into the host cell genome, and most tumors express the MCPyV large and small T antigens. In all cases of MCC reported to date, the integrated MCPyV genome has undergone mutations in the large T antigen. These mutations result in expression of a truncated large T antigen that retains the Rb binding or LXCXE motif but deletes the DNA binding and helicase domains. However, the transforming functions of full-length and truncated MCPyV large T antigen are unknown. We compared the transforming activities of full-length, truncated, and alternatively spliced 57kT forms of MCPyV large T antigen. MCPyV large T antigen could bind to Rb but was unable to bind to p53. Furthermore, MCPyV-truncated large T antigen was more effective than full-length and 57kT large T antigen in promoting the growth of human and mouse fibroblasts. In contrast, expression of the MCPyV large T antigen C-terminal 100 residues could inhibit the growth of several different cell types. These data imply that the deletion of the C terminus of MCPyV large T antigen found in MCC serves not only to disrupt viral replication but also results in the loss of a distinct growth-inhibitory function intrinsic to this region.
C1 [Cheng, Jingwei; Rozenblatt-Rosen, Orit; DeCaprio, James A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Cheng, Jingwei; DeCaprio, James A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
Univ Washington, Div Dermatol, Dept Med, Seattle, WA 98195 USA.
[Paulson, Kelly G.; Nghiem, Paul] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA.
RP DeCaprio, JA (reprint author), Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
EM james_decaprio@dfci.harvard.edu
RI Nghiem, Paul/A-9210-2011; Paulson, Kelly/E-5761-2010
OI Nghiem, Paul/0000-0003-2784-963X; Paulson, Kelly/0000-0002-0033-3708
FU Public Health Service [R01CA162522, K24-CA139052, P01CA050661,
RO1CA93804, R01CA63113]; Claudia Adams Barr Program in Innovative Basic
Cancer Research at the Dana-Farber Cancer Institute
FX This work was supported in part by Public Health Service grants
R01CA162522 and K24-CA139052 to P.N. and P01CA050661, RO1CA93804, and
R01CA63113 to J.A.D. We gratefully acknowledge the support of the
Claudia Adams Barr Program in Innovative Basic Cancer Research at the
Dana-Farber Cancer Institute to J.A.D.
NR 46
TC 29
Z9 29
U1 1
U2 11
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0022-538X
J9 J VIROL
JI J. Virol.
PD JUN
PY 2013
VL 87
IS 11
BP 6118
EP 6126
DI 10.1128/JVI.00385-13
PG 9
WC Virology
SC Virology
GA 143ZF
UT WOS:000318907500006
PM 23514892
ER
PT J
AU Weinstock, M
Ghobrial, IM
AF Weinstock, Matthew
Ghobrial, Irene M.
TI Extramedullary multiple myeloma
SO LEUKEMIA & LYMPHOMA
LA English
DT Review
DE Multiple myeloma; extramedullary; plasmacytoma
ID BONE-MARROW-TRANSPLANTATION; SOFT-TISSUE PLASMACYTOMAS;
CENTRAL-NERVOUS-SYSTEM; PRESENTING FEATURES; PLUS DEXAMETHASONE;
DISEASE; THALIDOMIDE; EXPRESSION; RELAPSE; IMMUNOGLOBULIN
AB Extramedullary disease (EMD), defined as a clonal plasmacytic infiltrate at anatomic sites distant from the bone marrow or adjacent soft tissue in a patient with underlying multiple myeloma, is present in a significant percentage of patients with multiple myeloma at some point during the course of their disease. The exact prevalence of EMD, however, has not been reproducibly described, with some series citing EMD in 6% of patients with myeloma, and others up to 20%. EMD is therefore an uncommon, but by no means rare, manifestation of multiple myeloma. Further observational series have suggested that EMD is a highly aggressive disease entity, with clinical behavior distinct from marrow-restricted myeloma. This article summarizes the current research on EMD and examines the opportunity for further research into the pathogenic, immunologic, cytogenetic, clinical, therapeutic and prognostic features of this hitherto poorly understood disease entity.
C1 [Weinstock, Matthew] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Ghobrial, Irene M.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Ghobrial, IM (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM irene_ghobrial@dfci.harvard.edu
FU Multiple Myeloma Research Foundation; NIH [R01CA154648, R01CA133799]
FX This work was supported in part by the Multiple Myeloma Research
Foundation, and NIH R01CA154648, R01CA133799.
NR 36
TC 9
Z9 10
U1 0
U2 5
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD JUN
PY 2013
VL 54
IS 6
BP 1135
EP 1141
DI 10.3109/10428194.2012.740562
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA 142OI
UT WOS:000318806400007
PM 23210572
ER
PT J
AU Van Etten, RA
Mauro, M
Radich, JP
Goldman, JM
Saglio, G
Jamieson, C
Soverini, S
Gambacorti-Passerini, C
Hehlmann, R
Martinelli, G
Perrotti, D
Scadden, DT
Skorski, T
Tefferi, A
Mughal, TI
AF Van Etten, Richard A.
Mauro, Michael
Radich, Jerald P.
Goldman, John M.
Saglio, Giuseppe
Jamieson, Catriona
Soverini, Simona
Gambacorti-Passerini, Carlo
Hehlmann, Ruediger
Martinelli, Giovanni
Perrotti, Danilo
Scadden, David T.
Skorski, Tomasz
Tefferi, Ayalew
Mughal, Tariq I.
TI Advances in the biology and therapy of chronic myeloid leukemia:
proceedings from the 6th Post-ASH International Chronic Myeloid Leukemia
and Myeloproliferative Neoplasms Workshop
SO LEUKEMIA & LYMPHOMA
LA English
DT Review
DE Chronic myelogenous leukemia; dasatinib; imatinib mesylate; nilotinib;
tyrosine kinase inhibitor
ID DIAGNOSED CHRONIC-PHASE; TYROSINE KINASE INHIBITORS; CHRONIC MYELOGENOUS
LEUKEMIA; BCR-ABL EXPRESSION; STEM-CELLS; FOLLOW-UP; T315I MUTANT;
IMATINIB; BCR-ABL1; TRIAL
AB Following the 53rd annual meeting of the American Society of Hematology (ASH) in San Diego in December 2011, a group of clinical and laboratory investigators convened for the 6th Post-ASH International Workshop on Chronic Myeloid Leukemia (CML) and Myeloproliferative Neoplasms (MPN). The Workshop took place on 13-14 December at the Estancia, La Jolla, California, USA. This report summarizes the most recent advances in the biology and therapy of CML that were presented at the ASH meeting and discussed at the Workshop. Preclinical studies focused on the CML stem cell and its niche, and on early results of deep sequencing of CML genomes. Clinical advances include updates on second- and third-generation tyrosine kinase inhibitors (TKIs), molecular monitoring, TKI discontinuation studies and new therapeutic agents. A report summarizing the pertinent advances in MPN has been published separately.
C1 [Van Etten, Richard A.] Tufts Med Ctr, Boston, MA 02111 USA.
[Mauro, Michael] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Radich, Jerald P.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Goldman, John M.] Univ London Imperial Coll Sci Technol & Med, London, England.
[Saglio, Giuseppe] Univ Turin, Orbassano, Italy.
[Jamieson, Catriona] Univ Calif San Diego, La Jolla, CA 92093 USA.
[Soverini, Simona; Martinelli, Giovanni] Univ Bologna, Bologna, Italy.
[Gambacorti-Passerini, Carlo] Univ Monza, Monza, Italy.
[Hehlmann, Ruediger] Univ Mannheim, D-68131 Mannheim, Germany.
[Perrotti, Danilo] Ohio State Univ, Columbus, OH 43210 USA.
[Scadden, David T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Scadden, David T.] Harvard Univ, Sch Med, Boston, MA USA.
[Skorski, Tomasz] Temple Univ, Philadelphia, PA 19122 USA.
[Tefferi, Ayalew] Mayo Clin, Rochester, MN USA.
[Mughal, Tariq I.] Univ Colorado, Denver, CO 80202 USA.
RP Van Etten, RA (reprint author), Tufts Med Ctr, Mol Oncol Res Inst, 800 Washington St,Box 5609, Boston, MA 02111 USA.
EM Rvanetten@tuftsmedicalcenter.org
RI Perrotti, Danilo/E-3852-2011; SOVERINI, SIMONA/A-3608-2016
OI GAMBACORTI PASSERINI, CARLO/0000-0001-6058-515X; SOVERINI,
SIMONA/0000-0002-4508-0353
FU Incyte Corporation; NIH [CA0905756, CA134458, CA123014]
FX This Workshop and related activities were made possible by an
unrestricted educational grant from Incyte Corporation, and by the
Alpine Oncology Foundation who received unrestricted support from Sanofi
Oncology, Bristol-Myers Squibb and YM Bioscience. Special thanks go to
Alpa Parmar and Susannne Blassingale for their help, and to the
Postgraduate Institute for Medicine for CME accreditation. Preparation
of this manuscript was supported in part by NIH grants CA0905756 to
R.A.V. and CA134458 and CA123014 to T.S.
NR 60
TC 6
Z9 7
U1 0
U2 6
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 1042-8194
J9 LEUKEMIA LYMPHOMA
JI Leuk. Lymphoma
PD JUN
PY 2013
VL 54
IS 6
BP 1151
EP 1158
DI 10.3109/10428194.2012.745524
PG 8
WC Oncology; Hematology
SC Oncology; Hematology
GA 142OI
UT WOS:000318806400009
PM 23121619
ER
PT J
AU Seo, YK
Mirkheshti, N
Song, CS
Kim, S
Dodds, S
Ahn, SC
Christy, B
Mendez-Meza, R
Ittmann, MM
Abboud-Werner, S
Chatterjee, B
AF Seo, Young-Kyo
Mirkheshti, Nooshin
Song, Chung S.
Kim, Soyoung
Dodds, Sherry
Ahn, Soon C.
Christy, Barbara
Mendez-Meza, Rosario
Ittmann, Michael M.
Abboud-Werner, Sherry
Chatterjee, Bandana
TI SULT2B1b Sulfotransferase: Induction by Vitamin D Receptor and Reduced
Expression in Prostate Cancer
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID HUMAN HYDROXYSTEROID SULFOTRANSFERASE; ACTIVITY IN-VITRO; CHOLESTEROL
SULFOTRANSFERASE; 1,25-DIHYDROXYVITAMIN D-3; ANDROGEN RECEPTOR; BINDING
PROTEIN; CELLS; ACID; PROMOTER; ENZYMES
AB An elevated tumor tissue androgen level, which reactivates androgen receptor in recurrent prostate cancer, arises from the intratumor synthesis of 5 alpha-dihydrotestosterone through use of the precursor steroid dehydroepiandrosterone (DHEA) and is fueled by the steroidogenic enzymes 3 beta-hydroxysteroid dehydrogenase (3 beta-HSD1), aldoketoreductase (AKR1C3), and steroid 5-alpha reductase, type 1 (SRD5A1) present in cancer tissue. Sulfotransferase 2B1b (SULT2B1b) (in short, SULT2B) is a prostate-expressed hydroxysteroid SULT that converts cholesterol, oxysterols, and DHEA to 3 beta-sulfates. DHEA metabolism involving sulfonation by SULT2B can potentially interfere with intraprostate androgen synthesis due to reduction of free DHEA pool and, thus, conversion of DHEA to androstenedione. Here we report that in prostatectomy specimens from treatment-naive patients, SULT2B expression is markedly reduced in malignant tissue (P < .001, Mann-Whitney U test) compared with robust expression in adjacent nonmalignant glands. SULT2B was detected in formalin-fixed specimens by immunohistochemistry on individual sections and tissue array. Immunoblotting of protein lysates of frozen cancer and matched benign tissue confirmed immunohistochemistry results. An in-house-developed rabbit polyclonal antibody against full-length human SULT2B was validated for specificity and used in the analyses. Ligand-activated vitamin D receptor induced the SULT2B1 promoter in vivo in mouse prostate and increased SULT2B mRNA and protein levels in vitro in prostate cancer cells. A vitamin D receptor/retinoid X receptor-alpha-bound DNA element (with a DR7 motif) mediated induction of the transfected SULT2B1 promoter in calcitriol-treated cells. SULT2B knockdown caused an increased proliferation rate of prostate cancer cells upon stimulation by DHEA. These results suggest that the tumor tissue SULT2B level may partly control prostate cancer growth, and its induction in a therapeutic setting may inhibit disease progression.
C1 [Seo, Young-Kyo; Mirkheshti, Nooshin; Song, Chung S.; Kim, Soyoung; Dodds, Sherry; Ahn, Soon C.; Christy, Barbara; Chatterjee, Bandana] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
[Mendez-Meza, Rosario; Abboud-Werner, Sherry] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78245 USA.
[Ittmann, Michael M.] Baylor Coll Med, Dept Pathol & Immunol, Houston, TX 77030 USA.
[Chatterjee, Bandana] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
RP Chatterjee, B (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
EM chatterjee@uthscsa.edu
FU Department of Veterans Affairs (VA) Merit Review [1I01BX000280]; VA
Senior Research Career Scientist Award; National Institute of Aging
(NIA/NIH) RO1 [AG-10486, AG-19660]; Morrison Trust Foundation; American
Cancer Research Foundation; Translational Resource Supplement, UTHSCSA
[CTSA5UL1RR025767-04]; Antibody Core, UTHSCSA [P30 CA54174]; Dan L.
Duncan Cancer Center Human Tissue Acquisition and Pathology Core, Baylor
College of Medicne [P30 CA1251230]
FX This work was supported by Department of Veterans Affairs (VA) Merit
Review 1I01BX000280 and VA Senior Research Career Scientist Award (to B.
C.), National Institute of Aging (NIA/NIH) RO1 (AG-10486 and AG-19660),
and pilot grants (Morrison Trust Foundation and American Cancer Research
Foundation). Partial support came from Translational Resource Supplement
(CTSA5UL1RR025767-04) and Antibody Core (P30 CA54174), UTHSCSA, and the
Dan L. Duncan Cancer Center Human Tissue Acquisition and Pathology Core
(P30 CA1251230), Baylor College of Medicne.
NR 43
TC 10
Z9 10
U1 0
U2 7
PU ENDOCRINE SOC
PI CHEVY CHASE
PA 8401 CONNECTICUT AVE, SUITE 900, CHEVY CHASE, MD 20815-5817 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2013
VL 27
IS 6
BP 925
EP 939
DI 10.1210/me.2012-1369
PG 15
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 147XT
UT WOS:000319205300006
PM 23579488
ER
PT J
AU Saxena, A
Kessinger, CW
Thompson, B
McCarthy, JR
Iwamoto, Y
Lin, CP
Jaffer, FA
AF Saxena, Amit
Kessinger, Chase W.
Thompson, Brian
McCarthy, Jason R.
Iwamoto, Yoshiko
Lin, Charles P.
Jaffer, Farouc A.
TI High-Resolution Optical Mapping of Inflammatory Macrophages Following
Endovascular Arterial Injury
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE Inflammation; Vascular injury; Molecular imaging; Intravital microscopy;
Macrophage; Nanoparticle; Restenosis; Percutaneous coronary
intervention; Fluorescence
ID LASER-SCANNING MICROSCOPY; VASCULAR INJURY; IN-VIVO; CORONARY
ANGIOPLASTY; INTIMAL HYPERPLASIA; MICE REVEALS; ATHEROSCLEROSIS;
LEUKOCYTE; INFILTRATION; ACTIVATION
AB Inflammation following arterial injury mediates vascular restenosis, a leading cause of cardiovascular morbidity. Here we utilize intravital microscopy (IVM) and a dextran-coated nanosensor to spatially map inflammatory macrophages in vivo following endovascular injury of murine carotid arteries.
C57Bl/6 mice (n = 23) underwent endovascular guidewire carotid arterial injury. At day 14 or day 28 post-injury, mice underwent fluorescence IVM, 24 h after injection with the near-infrared fluorescent macrophage nanosensor CLIO-VT680. Adventitial collagen was concomitantly imaged using second harmonic generation (SHG) IVM. Correlative fluorescence microscopy and immunohistochemistry were performed.
Two-plane IVM reconstructions detected macrophage inflammation in the arterial wall that was elevated at day 14 compared to day 28 animals (P < 0.05). SHG-based collagen imaging of the outer arterial wall facilitated analysis of the macrophage-rich, inflamed neointima. Histological analyses and fluorescence microscopy data demonstrated increased macrophage infiltration in day 14 compared to day 28 neointima.
We demonstrate that the macrophage response to arterial injury can be imaged in vivo using IVM-based molecular imaging, and shows a higher macrophage influx at day 14 compared to day 28 post-injury.
C1 [Saxena, Amit; Kessinger, Chase W.; Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Cardiol Div, Boston, MA 02114 USA.
[Thompson, Brian; Lin, Charles P.; Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
[McCarthy, Jason R.; Iwamoto, Yoshiko; Lin, Charles P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Syst Biol, Boston, MA 02114 USA.
[Jaffer, Farouc A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Mol Imaging Res, Boston, MA 02114 USA.
RP Jaffer, FA (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiovasc Res Ctr,Cardiol Div, Room 3206,Simches Res Bldg,185 Cambridge St, Boston, MA 02114 USA.
EM fjaffer@mgh.harvard.edu
OI Jaffer, Farouc/0000-0001-7980-384X
FU American Heart Association [0830352N]; Howard Hughes Medical Institute;
NIH/NHLBI [R01 HL-108229, T32 HL-076136]
FX We thank Elazer Edelman, MD PhD for helpful discussions. Study funding
was provided by the American Heart Association Scientist Development
Grant #0830352N, Howard Hughes Medical Institute Career Development
Award, and NIH/NHLBI R01 HL-108229. CWK was supported by NIH/NHLBI T32
HL-076136.
NR 30
TC 8
Z9 8
U1 0
U2 17
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD JUN
PY 2013
VL 15
IS 3
BP 282
EP 289
DI 10.1007/s11307-012-0599-2
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 142JZ
UT WOS:000318794800006
PM 23090852
ER
PT J
AU Cheng, G
Alavi, A
Lim, E
Werner, TJ
Del Bello, CV
Akers, SR
AF Cheng, Gang
Alavi, Abass
Lim, Esther
Werner, Thomas J.
Del Bello, Catherine V.
Akers, Scott R.
TI Dynamic Changes of FDG Uptake and Clearance in Normal Tissues
SO MOLECULAR IMAGING AND BIOLOGY
LA English
DT Article
DE FDG PET; SUV; Time course; Delayed imaging; Normal tissues
ID POINT F-18-FDG PET; POSITRON-EMISSION-TOMOGRAPHY; SOLITARY PULMONARY
NODULES; HEPATOCELLULAR-CARCINOMA; HEPATIC METASTASES;
COLORECTAL-CANCER; BREAST-CANCER; TIME; LIVER; MALIGNANCY
AB This study aims to evaluate dynamic 2-deoxy-2-[F-18]fluoro-d-glucose (FDG) uptake in normal tissues.
Thirty male patients underwent FDG positron emission tomography (PET)/computed tomography imaging at 1, 2, and 3 h after tracer injection. Standardized uptake values (SUV) were obtained in regions of interest of normal tissues.
The aorta (blood pool), liver, and spleen FDG activity demonstrated significantly and continuously decreased activity from 1 to 2 and 2 to 3 h, while FDG uptake in the lungs, pancreas, lymph nodes, and skeletal muscle decreased from 1 to 2 h only. In contrast, the left ventricular myocardium demonstrated two patterns of dynamic changes: myocardium with higher FDG uptake (SUVmax a parts per thousand yenaEuro parts per thousand 3.25) on the initial images had more remarkable increased activity on the delayed images, while myocardium with lower FDG uptake (SUVmax < 3.25) on the initial imaging had no increased uptake on delayed imaging. Increased FDG uptake was also observed in the bones on the delayed images. No significant changes of FDG uptake were noted in the parotid gland, thyroid gland, and prostate gland.
These findings may help nuclear medicine physicians when comparing images performed at different time points, when using FDG uptake in internal reference regions as a relative indicator of FDG uptake in a specific lesion, and when reading a delayed FDG PET imaging.
C1 [Cheng, Gang; Lim, Esther; Del Bello, Catherine V.; Akers, Scott R.] Philadelphia VA Med Ctr, Dept Radiol, Philadelphia, PA 19104 USA.
[Alavi, Abass; Werner, Thomas J.] Hosp Univ Penn, Dept Radiol, Philadelphia, PA 19104 USA.
RP Cheng, G (reprint author), Philadelphia VA Med Ctr, Dept Radiol, 3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM gangcheng99@yahoo.com; akerssco@me.com
FU Department of Veterans Affairs (VISN 4 CPPF grant)
FX This study was supported in part by a grant from the Department of
Veterans Affairs (VISN 4 CPPF grant).
NR 28
TC 29
Z9 29
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1536-1632
J9 MOL IMAGING BIOL
JI Mol. Imaging. Biol.
PD JUN
PY 2013
VL 15
IS 3
BP 345
EP 352
DI 10.1007/s11307-012-0600-0
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA 142JZ
UT WOS:000318794800013
PM 23090853
ER
PT J
AU Taylor, JJ
Borckardt, JJ
Canterberry, M
Li, XB
Hanlon, CA
Brown, TR
George, MS
AF Taylor, Joseph J.
Borckardt, Jeffrey J.
Canterberry, Melanie
Li, Xingbao
Hanlon, Colleen A.
Brown, Truman R.
George, Mark S.
TI Naloxone-Reversible Modulation of Pain Circuitry by Left Prefrontal rTMS
SO NEUROPSYCHOPHARMACOLOGY
LA English
DT Article
DE pain modulation; rTMS; endogenous opioids; analgesia; imaging;
prefrontal cortex
ID TRANSCRANIAL MAGNETIC STIMULATION; NORMAL HUMAN CORTEX; PERIAQUEDUCTAL
GRAY; CYTOARCHITECTONIC DEFINITION; CORTICAL PROJECTIONS; ENDOGENOUS
OPIOIDS; HEALTHY-VOLUNTEERS; PLACEBO ANALGESIA; AREAS 9; DEPRESSION
AB A 20-minute session of 10 Hz repetitive transcranial magnetic stimulation (rTMS) of Brodmann Area (BA) nine of the left dorsolateral prefrontal cortex (DLPFC) can produce analgesic effects on postoperative and laboratory-induced pain. This analgesia is blocked by pretreatment with naloxone, a mu-opioid antagonist. The purpose of this sham-controlled, double-blind, crossover study was to identify the neural circuitry that underlies the analgesic effects of left DLPFC rTMS, and to examine how the function of this circuit, including midbrain and medulla, changes during opioid blockade. Fourteen healthy volunteers were randomized to receive intravenous saline or naloxone immediately before sham and real left DLPFC rTMS on the same experimental visit. One week later, each participant received the novel pretreatment but the same stimulation paradigm. Using short sessions of heat on capsaicin-sensitized skin, hot allodynia was assessed during 3 Tesla functional magnetic resonance imaging (fMRI) scanning at baseline, post-sham rTMS, and post-real rTMS. Data were analyzed using whole-brain voxel-based analysis, as well as time series extractions from anatomically-defined regions of interest representing midbrain and medulla. Consistent with previous findings, real rTMS significantly reduced hot allodynia pain ratings. This analgesia was associated with elevated blood oxygenation-level dependent (BOLD) signal in BAs 9 and 10, and diminished BOLD signal in the anterior cingulate, thalamus, midbrain, and medulla during pain. Naloxone pretreatment largely abolished rTMS-induced analgesia, as well as rTMS-induced attenuation of BOLD signal response to painful stimuli throughout pain processing regions, including midbrain and medulla. These preliminary results suggest that left DLPFC rTMS drives top-down opioidergic analgesia.
C1 [Taylor, Joseph J.; Borckardt, Jeffrey J.; Canterberry, Melanie; Li, Xingbao; Hanlon, Colleen A.; George, Mark S.] Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, Charleston, SC 29414 USA.
[Brown, Truman R.] Med Univ S Carolina, Dept Radiol, Ctr Biomed Imaging, Charleston, SC 29414 USA.
[George, Mark S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Taylor, JJ (reprint author), Med Univ S Carolina, Dept Psychiat, Brain Stimulat Lab, 67 President St,Room 504 North, Charleston, SC 29414 USA.
EM taylorjj@musc.edu
FU NIDA [1F30DA033748-01]; Center for Biomedical Imaging (CBI) at the
Medical University of South Carolina; [T32DA007288]; [K01DA0267756]
FX We thank Kathryn Beaver, RN and Tracey Greene, RN for their assistance
in conducting this study. JJT is funded by 1F30DA033748-01 (NIDA) and a
Grant-In-Kind from the Center for Biomedical Imaging (CBI) at the
Medical University of South Carolina. MC is funded by T32DA007288. CH is
funded by K01DA0267756. A Clinical Trail Agreement with Neuronetics
provided the TMS treatment cards used to drive laboratory owned TMS
machines in this study.
NR 50
TC 17
Z9 17
U1 0
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0893-133X
J9 NEUROPSYCHOPHARMACOL
JI Neuropsychopharmacology
PD JUN
PY 2013
VL 38
IS 7
BP 1189
EP 1197
DI 10.1038/npp.2013.13
PG 9
WC Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA 146UV
UT WOS:000319120000005
PM 23314221
ER
PT J
AU Wright, JL
Plymate, SR
Porter, MP
Gore, JL
Lin, DW
Hu, E
Zeliadt, SB
AF Wright, J. L.
Plymate, S. R.
Porter, M. P.
Gore, J. L.
Lin, D. W.
Hu, E.
Zeliadt, S. B.
TI Hyperglycemia and prostate cancer recurrence in men treated for
localized prostate cancer
SO PROSTATE CANCER AND PROSTATIC DISEASES
LA English
DT Article
DE hyperglycemia; biochemical recurrence; veterans' affairs
ID INSULIN-RESISTANCE; LUNG-CANCER; MORTALITY; OBESITY; VETERANS; DATABASE;
OUTCOMES; BREAST; RISK
AB BACKGROUND: Obesity is consistently linked with prostate cancer (PCa) recurrence and mortality, though the mechanism is unknown. Impaired glucose regulation, which is common among obese individuals, has been hypothesized as a potential mechanism for PCa tumor growth. In this study, we explore the relationship between serum glucose at time of treatment and risk of PCa recurrence following initial therapy.
METHODS: The study group comprised 1734 men treated with radical prostatectomy (RP) or radiation therapy (RT) for localized PCa between 2001-2010. Serum glucose levels closest to date of diagnosis were determined. PCa recurrence was determined based on PSA progression (nadir PSA + 2 for RT; PSA >= 0.2 for RP) or secondary therapy. Multivariate Cox regression was performed to determine whether glucose level was associated with biochemical recurrence after adjusting for age, race, body mass index, comorbidity, diagnosis of diabetes, Gleason Sum, PSA, treatment and treatment year.
RESULTS: Recurrence was identified in 16% of men over a mean follow-up period of 41 months (range 1-121 months). Those with elevated glucose (>= 100 mg/dl) had a 50% increased risk of recurrence (HR 1.5, 95% CI: 1.1-2.0) compared with those with a normal glucose level (< 100 mg/dl). This effect was seen in both those undergoing RP (HR 1.9, 95% CI: 1.0-3.6) and those treated with RT (HR 1.4, 95% CI: 1.0-2.0).
CONCLUSIONS: Glucose levels at the time of PCa diagnosis are an independent predictor of PCa recurrence for men undergoing treatment for localized disease.
C1 [Wright, J. L.; Porter, M. P.; Gore, J. L.; Lin, D. W.] Univ Washington, Dept Urol, Sch Med, Seattle, WA 98195 USA.
[Wright, J. L.; Porter, M. P.] VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA.
[Wright, J. L.; Gore, J. L.; Lin, D. W.; Zeliadt, S. B.] Fred Hutchinson Canc Res Ctr, Div Publ Hlth Sci, Seattle, WA 98104 USA.
[Plymate, S. R.] Univ Washington, Dept Med, Sch Med, Seattle, WA 98195 USA.
[Plymate, S. R.; Hu, E.; Zeliadt, S. B.] VA Puget Sound Hlth Care Syst, Hlth Serv Res & Dev, Seattle, WA USA.
[Plymate, S. R.; Hu, E.; Zeliadt, S. B.] VA Puget Sound Hlth Care Syst, GRECC, Seattle, WA USA.
RP Wright, JL (reprint author), Univ Washington, Dept Urol, Sch Med, 1959 NE Pacific,Box 356510, Seattle, WA 98195 USA.
EM jlwright@uw.edu
OI Gore, John/0000-0002-2847-5062
FU NIH from the National Cancer Institute [P50CA097186]; Fred Hutchinson
Cancer Research Center
FX This study was supported by NIH grants: P50CA097186 from the National
Cancer Institute; with additional support from the Fred Hutchinson
Cancer Research Center. This material is the result of work supported by
resources from the VA Puget Sound Health Care System, Seattle,
Washington.
NR 29
TC 13
Z9 14
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 1365-7852
J9 PROSTATE CANCER P D
JI Prostate Cancer Prostatic Dis.
PD JUN
PY 2013
VL 16
IS 2
BP 204
EP 208
DI 10.1038/pcan.2013.5
PG 5
WC Oncology; Urology & Nephrology
SC Oncology; Urology & Nephrology
GA 144UJ
UT WOS:000318965800014
PM 23459096
ER
PT J
AU Drummond, JB
Tucholski, J
Haroutunian, V
Meador-Woodruff, JH
AF Drummond, Jana B.
Tucholski, Janusz
Haroutunian, Vahram
Meador-Woodruff, James H.
TI Transmembrane AMPA receptor regulatory protein (TARP) dysregulation in
anterior cingulate cortex in schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE AMPA receptor auxiliary protein; Glutamate receptor; Trafficking;
Postmortem; Human
ID IONOTROPIC GLUTAMATE RECEPTORS; MESSENGER-RNA EXPRESSION; PREFRONTAL
CORTEX; SYNAPTIC PLASTICITY; AUXILIARY SUBUNITS; ELDERLY SCHIZOPHRENICS;
DECREASED EXPRESSION; CORNICHON PROTEINS; POSTMORTEM BRAIN;
BINDING-PROTEINS
AB The glutamate hypothesis of schizophrenia proposes that abnormal glutamatergic neurotransmission occurs in this illness, and a major contribution may involve dysregulation of the AMPA subtype of ionotropic glutamate receptor (AMPAR). Transmembrane AMPAR regulatory proteins (TARPs) form direct associations with AMPARs to modulate the trafficking and biophysical functions of these receptors, and their dysregulation may alter the localization and activity of AMPARs, thus having a potential role in the pathophysiology of schizophrenia. We performed comparative quantitative real-time PCR and Western blot analysis to measure transcript (schizophrenia, N = 25; comparison subjects, N = 25) and protein (schizophrenia, N = 36; comparison subjects, N = 33) expression of TARPs (gamma subunits 1-8) in the anterior cingulate cortex (ACC) in schizophrenia and a comparison group. TARP expression was also measured in frontal cortex of rats chronically treated with haloperidol decanoate (28.5 mg/kg every three weeks for nine months) to determine the effect of antipsychotic treatment on the expression of these molecules. We found decreased transcript expression of TARP gamma-8 in schizophrenia. At the protein level, gamma-3 and gamma-5 were increased, while gamma-4, gamma-7 and gamma-8 were decreased in schizophrenia. No changes in any of the molecules were noted in the frontal cortex of haloperidol-treated rats. TARPs are abnormally expressed at transcript and protein levels in ACC in schizophrenia, and these changes are likely due to the illness and not to the antipsychotic treatment. Alterations in the expression of TARPs may contribute to the pathophysiology of schizophrenia, and represent a potential mechanism of glutamatergic dysregulation in this illness. (c) 2013 Elsevier B.V. All rights reserved.
C1 [Drummond, Jana B.; Tucholski, Janusz; Meador-Woodruff, James H.] Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, Birmingham, AL 35294 USA.
[Haroutunian, Vahram] James J Peters Vet Adm, Dept Psychiat, Mt Sinai Sch Med, Bronx, NY 10468 USA.
RP Drummond, JB (reprint author), Univ Alabama Birmingham, Dept Psychiat & Behav Neurobiol, CIRC 589A,1719 6th Ave South, Birmingham, AL 35294 USA.
EM jdrummond@uab.edu
FU NIH [MH53327, MH066392]
FX Funding for this study was provided by NIH grants: MH53327 (JHMW) and
MH066392 (VH).
NR 74
TC 11
Z9 12
U1 0
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2013
VL 147
IS 1
BP 32
EP 38
DI 10.1016/j.schres.2013.03.010
PG 7
WC Psychiatry
SC Psychiatry
GA 145VN
UT WOS:000319047100004
PM 23566497
ER
PT J
AU Smucny, J
Olincy, A
Eichman, LC
Lyons, E
Tregellas, JR
AF Smucny, Jason
Olincy, Ann
Eichman, Lindsay C.
Lyons, Emma
Tregellas, Jason R.
TI Early sensory processing deficits predict sensitivity to distraction in
schizophrenia
SO SCHIZOPHRENIA RESEARCH
LA English
DT Article
DE Schizophrenia; Attention; Distraction; P50
ID P50 SUPPRESSION; REACTION-TIME; ATTENTIONAL PERFORMANCE; SUSTAINED
ATTENTION; AUDITORY MISMATCH; NEGATIVE SYMPTOMS; HIPPOCAMPAL;
PERCEPTION; ABNORMALITIES; ACTIVATION
AB Patients with schizophrenia frequently report difficulties paying attention during important tasks, because they are distracted by noise in the environment. The neurobiological mechanism underlying this problem is, however, poorly understood. The goal of this study was to determine if early sensory processing deficits contribute to sensitivity to distracting noise in schizophrenia. To that end, we examined the effect of environmentally relevant distracting noise on performance of an attention task in 19 patients with schizophrenia and 22 age and gender-matched healthy comparison subjects. Using electroencephalography, P50 auditory gating ratios also were measured in the same subjects and were examined for their relationship to noise-induced changes in performance on the attention task. Positive symptoms also were evaluated in patients. Distracting noise caused a greater increase in reaction time in patients, relative to comparison subjects, on the attention task. Higher P50 auditory gating ratios also were observed in patients. P50 gating ratio significantly correlated with the magnitude of noise-induced increase in reaction time. Noise-induced increase in reaction time was associated with delusional thoughts in patients. P50 ratios were associated with delusional thoughts and hallucinations in patients. In conclusion, the observation of noise effects on attention in patients is consistent with subjective reports from patients. The observed relationship between noise effects on reaction time and P50 auditory gating supports the hypothesis that early inhibitory processing deficits may contribute to susceptibility to distraction in the illness. (C) 2013 Elsevier B. V. All rights reserved.
C1 [Smucny, Jason; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Neurosci Program, Aurora, CO 80045 USA.
[Smucny, Jason; Olincy, Ann; Eichman, Lindsay C.; Lyons, Emma; Tregellas, Jason R.] Denver VA Med Ctr, Denver, CO USA.
[Smucny, Jason; Olincy, Ann; Eichman, Lindsay C.; Lyons, Emma; Tregellas, Jason R.] Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA.
RP Smucny, J (reprint author), Univ Colorado Anschutz Med Campus, Dept Psychiat, Aurora, CO 80045 USA.
EM Jason.Smucny@ucdenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Smucny, Jason/0000-0001-5656-7987
FU VA Biomedical Laboratory and Clinical Science Research and Development
Service; National Association for Research in Schizophrenia and
Affective Disorders (NARSAD); Blowitz-Ridgeway Foundation
FX This research was supported by the VA Biomedical Laboratory and Clinical
Science Research and Development Service, the National Association for
Research in Schizophrenia and Affective Disorders (NARSAD) and the
Blowitz-Ridgeway Foundation.
NR 39
TC 23
Z9 23
U1 3
U2 7
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0920-9964
J9 SCHIZOPHR RES
JI Schizophr. Res.
PD JUN
PY 2013
VL 147
IS 1
BP 196
EP 200
DI 10.1016/j.schres.2013.03.025
PG 5
WC Psychiatry
SC Psychiatry
GA 145VN
UT WOS:000319047100030
PM 23590872
ER
PT J
AU Van Loon, K
Wigler, D
Niedzwiecki, D
Venook, AP
Fuchs, C
Blanke, C
Saltz, L
Goldberg, RM
Meyerhardt, JA
AF Van Loon, Katherine
Wigler, Devin
Niedzwiecki, Donna
Venook, Alan P.
Fuchs, Charles
Blanke, Charles
Saltz, Leonard
Goldberg, Richard M.
Meyerhardt, Jeffrey A.
TI Comparison of Dietary. and Lifestyle Habits Among Stage III and
Metastatic Colorectal Cancer Patients: Findings from CALGB 89803 and
CALGB 80405
SO CLINICAL COLORECTAL CANCER
LA English
DT Article
DE Colon cancer; Chemotherapy; Nutrition; Exercise; Behavioral patterns
ID BODY-MASS INDEX; PHYSICAL-ACTIVITY QUESTIONNAIRE; COLON-CANCER; ADJUVANT
CHEMOTHERAPY; SUPPLEMENT USE; BREAST-CANCER; SURVIVAL; DIAGNOSIS;
RECURRENCE; REPRODUCIBILITY
AB Self-administered questionnaires were completed by patients undergoing chemotherapy for stage Ill colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). We describe the prevalence of a wide-range of health-related dietary patterns and lifestyle behaviors among colorectal cancer patients with stage Ill and metastatic disease and report notable similarities in these 2 cohorts.
Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m(2)). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Van Loon, Katherine; Venook, Alan P.] UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94115 USA.
[Wigler, Devin; Fuchs, Charles; Meyerhardt, Jeffrey A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Niedzwiecki, Donna] Duke Univ, Dept Biostat & Bioinformat, Durham, NC USA.
[Blanke, Charles] Univ British Columbia, Div Med Oncol, British Columbia Canc Agcy, Vancouver, BC V5Z 1M9, Canada.
[Saltz, Leonard] Mem Sloan Kettering Canc Ctr, Gastrointestinal Oncol Serv, New York, NY 10021 USA.
[Goldberg, Richard M.] Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
[Goldberg, Richard M.] Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Inst, Columbus, OH 43210 USA.
RP Van Loon, K (reprint author), UCSF, Helen Diller Family Comprehens Canc Ctr, 1600 Divisadero St,UCSF Box 1770, San Francisco, CA 94115 USA.
EM katherine.vanloon@ucsf.edu
RI Goldberg , Richard/M-1311-2013;
OI Saltz, Leonard/0000-0001-8353-4670
FU National Cancer Institute [CA31946, CA33601]; Pfizer Oncology;
Sanofi-Aventis; Bristol-Myers Squibb; [R01CA118553]; [R01CA14922];
[P50 CA127003]
FX The research for CALGB 89803 and 80405 was supported, in part, by grants
from the National Cancer Institute (CA31946) to the Cancer and Leukemia
Group B (Monica M. Bertagnolli, MD, Chair) and to the CALGB Statistical
Center (Daniel J. Sargent, PhD, CA33601), and support from Pharmacia &
Upjohn Company, now Pfizer Oncology, Sanofi-Aventis, and Bristol-Myers
Squibb. These analyses were also supported by R01CA118553 (PI, Fuchs),
R01CA14922 (PI, Meyerhardt), and P50 CA127003 (PI, Fuchs). The content
of this manuscript is solely the responsibility of the authors and does
not necessarily represent the official views of the National Cancer
Institute.
NR 39
TC 6
Z9 6
U1 0
U2 9
PU CIG MEDIA GROUP, LP
PI DALLAS
PA 3500 MAPLE AVENUE, STE 750, DALLAS, TX 75219-3931 USA
SN 1533-0028
EI 1938-0674
J9 CLIN COLORECTAL CANC
JI Clin. Colorectal Canc.
PD JUN
PY 2013
VL 12
IS 2
BP 95
EP 102
DI 10.1016/j.clcc.2012.11.002
PG 8
WC Oncology
SC Oncology
GA 142WW
UT WOS:000318829300003
PM 23317558
ER
PT J
AU Baidal, JAW
Price, SN
Gonzalez-Suarez, E
Gillman, MW
Mitchell, K
Rifas-Shiman, SL
Horan, CM
Gortmaker, SL
Taveras, EM
AF Baidal, Jennifer A. Woo
Price, Sarah N.
Gonzalez-Suarez, Elizabeth
Gillman, Matthew W.
Mitchell, Kathleen
Rifas-Shiman, Sheryl L.
Horan, Christine M.
Gortmaker, Steven L.
Taveras, Elsie M.
TI Parental Perceptions of a Motivational Interviewing-Based Pediatric
Obesity Prevention Intervention
SO CLINICAL PEDIATRICS
LA English
DT Article
DE obesity; parental perceptions; motivational interviewing; intervention;
child; preschool
ID RANDOMIZED CONTROLLED-TRIAL; HEALTH-CARE SETTINGS; PHYSICIAN
COMMUNICATION; PATIENT-SATISFACTION; PRESCHOOL-CHILDREN; CHILDHOOD
OBESITY; OVERWEIGHT; RACE/ETHNICITY; ADOLESCENTS; PROGRAM
AB Motivational interviewing (MI) shows promise for pediatric obesity prevention, but few studies address parental perceptions of MI. The aim of this study was to identify correlates of parental perceptions of helpfulness of and satisfaction with a MI-based pediatric obesity prevention intervention. We studied 253 children 2 to 6 years of age in the intervention arm of High Five for Kids, a primary care-based randomized controlled trial. In multivariable models, parents born outside the United States (odds ratio [OR] = 8.81; 95% confidence interval [CI] = 2.44, 31.8), with lower household income (OR = 3.60; 95% CI = 1.03, 12.55), and with higher BMI (OR = 2.86; 95% CI = 1.07, 7.65) were more likely to perceive MI-based visits as helpful in improving children's obesity-related behaviors after the first year of the intervention. Parents of female (vs male), black (vs white), and Latino (vs white) children had lower intervention satisfaction. Our findings underscore the importance of tailoring pediatric obesity prevention efforts to target populations.
C1 [Baidal, Jennifer A. Woo] Childrens Hosp Boston, Boston, MA 02115 USA.
[Baidal, Jennifer A. Woo; Price, Sarah N.; Gillman, Matthew W.; Rifas-Shiman, Sheryl L.; Horan, Christine M.; Taveras, Elsie M.] Harvard Univ, Sch Med, Boston, MA USA.
[Baidal, Jennifer A. Woo; Price, Sarah N.; Gillman, Matthew W.; Rifas-Shiman, Sheryl L.; Horan, Christine M.; Taveras, Elsie M.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Gonzalez-Suarez, Elizabeth] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mitchell, Kathleen] Harvard Vanguard Med Associates, Watertown, MA USA.
[Gortmaker, Steven L.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
RP Baidal, JAW (reprint author), Childrens Hosp Boston, Div Gastroenterol & Nutr, 300 Longwood Ave, Boston, MA 02115 USA.
EM Jennifer.WooBaidal@childrens.harvard.edu
FU US National Institutes of Health [HD 050966]
FX The author(s) disclosed receipt of the following financial support for
the research, authorship, and/or publication of this article: This study
was supported by a grant from the US National Institutes of Health (HD
050966).
NR 37
TC 3
Z9 3
U1 6
U2 22
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0009-9228
J9 CLIN PEDIATR
JI Clin. Pediatr.
PD JUN
PY 2013
VL 52
IS 6
BP 540
EP 548
DI 10.1177/0009922813483170
PG 9
WC Pediatrics
SC Pediatrics
GA 140JY
UT WOS:000318651600009
ER
PT J
AU Montecucco, F
Cea, M
Bauer, I
Soncini, D
Caffa, I
Lasiglie, D
Nahimana, A
Uccelli, A
Bruzzone, S
Nencioni, A
AF Montecucco, Fabrizio
Cea, Michele
Bauer, Inga
Soncini, Debora
Caffa, Irene
Lasiglie, Denise
Nahimana, Aimable
Uccelli, Antonio
Bruzzone, Santina
Nencioni, Alessio
TI Nicotinamide Phosphoribosyltransferase (NAMPT) Inhibitors as
Therapeutics: Rationales, Controversies, Clinical Experience
SO CURRENT DRUG TARGETS
LA English
DT Article
DE NAD; NAMPT; sirtuins; cancer; inflammation; cardiovascular disorders;
chemotaxis; angiogenesis
ID COLONY-ENHANCING FACTOR; NAD BIOSYNTHESIS INHIBITOR; POTENT
ANTITUMOR-ACTIVITY; HUMAN LEUKEMIA-CELLS; CANCER-CELLS; IN-VITRO;
PHARMACOLOGICAL INHIBITION; HEMATOLOGIC MALIGNANCIES; CAROTID
ATHEROSCLEROSIS; ENZYMATIC-ACTIVITY
AB Nicotinamide adenine dinucleotide (NAD(+)) biosynthesis from nicotinamide is used by mammalian cells to replenish their NAD(+) stores and to avoid unwanted nicotinamide accumulation. Pharmacological inhibition of nicotinamide phosphoribosyltransferase (NAMPT), the key enzyme in this biosynthetic pathway, almost invariably leads to intracellular NAD(+) depletion and, when protracted, to ATP shortage and cell demise. Cancer cells and activated immune cells express high levels of NAMPT and are highly susceptible to NAMPT inhibitors, as shown by the activity of these agents in models of malignant and inflammatory disorders. As the spectrum of conditions which could benefit from pharmacological NAMPT inhibition becomes broader, the mechanisms accounting for their activity are also eventually becoming apparent, including the induction of autophagy and the impairment of Ca2+- and NF-kappa B-dependent signaling. Here, we discuss the rationales for exploiting NAMPT inhibitors in cancer and inflammatory diseases and provide an overview of the preclinical and clinical studies in which these agents have been evaluated.
C1 [Montecucco, Fabrizio; Cea, Michele; Bauer, Inga; Soncini, Debora; Caffa, Irene; Lasiglie, Denise; Nencioni, Alessio] Univ Genoa, Dept Internal Med, I-16132 Genoa, Italy.
[Montecucco, Fabrizio] Univ Geneva, Dept Med Specialties, Fdn Med Res, Div Cardiol, Geneva, Switzerland.
[Cea, Michele] Harvard Univ, Sch Med, LeBow Inst Myeloma Therapeut, Boston, MA USA.
[Cea, Michele] Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Ctr Multiple Myeloma Res, Boston, MA 02115 USA.
[Nahimana, Aimable] Univ Lausanne Hosp, Serv Hematol, Lausanne, Switzerland.
[Uccelli, Antonio] Univ Genoa, Dept Neurol Ophtalmol & Genet, I-16132 Genoa, Italy.
[Uccelli, Antonio; Nencioni, Alessio] IRCCS AOU San Martino IST, I-16132 Genoa, Italy.
[Bruzzone, Santina] Univ Genoa, Biochem Sect, Dept Expt Med, I-16132 Genoa, Italy.
RP Nencioni, A (reprint author), Univ Genoa, Dept Internal Med, Room 221,Vle Benedetto XV 6, I-16132 Genoa, Italy.
EM alessio.nencioni@unige.it
RI Bruzzone, Santina/A-4264-2015; Montecucco, Fabrizio/K-8543-2016
OI Bruzzone, Santina/0000-0003-2034-3716; Montecucco,
Fabrizio/0000-0003-0823-8729
FU Associazione Italiana per la Ricerca sul Cancro (AIRC) [6108]; European
Seventh Framework Program (PANACREAS) [256986]; Ministero della Salute
[GR-2008-1135635]; Fondazione Italiana Sclerosi Multipla (FISM);
Compagnia di San Paolo; University of Genoa
FX A.N. is supported in part by the Associazione Italiana per la Ricerca
sul Cancro (AIRC, Code 6108, to A.N.), by the European Seventh Framework
Program (project number 256986, PANACREAS, to A.N.), by the Ministero
della Salute (GR-2008-1135635 to A.N.), by the Fondazione Italiana
Sclerosi Multipla (FISM), by the Compagnia di San Paolo, and by the
University of Genoa.
NR 92
TC 21
Z9 22
U1 0
U2 16
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1389-4501
J9 CURR DRUG TARGETS
JI Curr. Drug Targets
PD JUN
PY 2013
VL 14
IS 6
BP 637
EP 643
PG 7
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 140XE
UT WOS:000318689000003
PM 23531116
ER
PT J
AU Drakaki, A
McDermott, DF
AF Drakaki, Alexandra
McDermott, David F.
TI Novel Immunotherapies in GU Malignancies
SO CURRENT ONCOLOGY REPORTS
LA English
DT Article
DE Renal cell carcinoma; Bladder cancer; Prostate cancer; Immunotherapy;
Targeted therapy; PD-1 antibody; CTLA-4 antibody; Combination strategies
ID RENAL-CELL CARCINOMA; RESISTANT PROSTATE-CANCER; PHASE-III TRIAL;
METASTATIC UROTHELIAL CANCER; DOSE-ESCALATION TRIAL; INTERFERON-ALPHA;
DOUBLE-BLIND; GM-CSF; COMBINATION THERAPY; MEMBRANE ANTIGEN
AB Despite the development of several novel therapies in recent years, genitourinary (GU) malignancies remain associated with significant morbidity and mortality. An improved understanding of how the immune system responds to cancer has led to the clinical development of several targeted immunotherapies. Data from recent clinical trials suggests that these agents might improve the prognosis of patients with advanced GU malignancies. This review article will discuss the current state of immunotherapy and describe future directions in combination therapy and biomarker development for cancers of the kidney, bladder and prostate.
C1 [Drakaki, Alexandra] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[McDermott, David F.] Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Kidney Canc Program, Boston, MA 02215 USA.
RP McDermott, DF (reprint author), Harvard Univ, Sch Med, Dana Farber Harvard Canc Ctr, Kidney Canc Program, 330 Brookline Ave,MASCO 428, Boston, MA 02215 USA.
EM adrakaki@bidmc.harvard.edu; dmcdermo@bidmc.harvard.edu
NR 73
TC 2
Z9 2
U1 0
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1523-3790
J9 CURR ONCOL REP
JI Curr. Oncol. Rep.
PD JUN
PY 2013
VL 15
IS 3
BP 224
EP 231
DI 10.1007/s11912-013-0306-8
PG 8
WC Oncology
SC Oncology
GA 139FX
UT WOS:000318568500009
PM 23519772
ER
PT J
AU Brady, PC
Stanic, AK
Styer, AK
AF Brady, Paula C.
Stanic, Aleksandar K.
Styer, Aaron K.
TI Uterine fibroids and subfertility: an update on the role of myomectomy
SO CURRENT OPINION IN OBSTETRICS & GYNECOLOGY
LA English
DT Review
DE fibroids; infertility; myomectomy; pregnancy; subfertility
ID LAPAROSCOPIC MYOMECTOMY; EMBRYO IMPLANTATION; INTRAMURAL FIBROIDS;
PREGNANCY RATE; INFERTILITY; WOMEN; PERISTALSIS; CONCEPTION; FERTILITY;
OUTCOMES
AB Purpose of review
Uterine fibroids, the most common neoplasm of reproductive-aged women, can have a significant impact on quality of life, and may affect fertility and pregnancy outcomes. Although it is generally accepted that submucosal fibroids are of clinical significance, the effect of intramural and subserosal fibroids, and the benefit of surgical removal remains an area of active debate. Because of this controversy, this article will review current evidence for an association of fibroids and subfertility, and assess the impact of surgical management on fertility outcomes.
Recent findings
Recent analyses of patients with intramural fibroids have reported an increase in pregnancy loss and reduction in pregnancy and live birth rates. However, when analyzing studies with high quality diagnostic methods for assessing the endometrial cavity, no significant impact on reproductive outcomes was observed, and no benefit of myomectomy was consistently demonstrated. Myomectomy for submucosal fibroids greater than 2 cm and for intramural fibroids distorting the endometrial contour likely confers improvement of fertility outcome.
Summary
Submucosal fibroid location and distortion of the endometrial cavity (either submucosal or deeply infiltrating intramural fibroids) are most predictive of impaired fertility and probable benefit of surgical removal, and warrant consideration of myomectomy in the subfertile patient.
C1 [Brady, Paula C.; Stanic, Aleksandar K.; Styer, Aaron K.] Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Brady, Paula C.; Stanic, Aleksandar K.; Styer, Aaron K.] Harvard Univ, Sch Med, Boston, MA USA.
[Stanic, Aleksandar K.; Styer, Aaron K.] Massachusetts Gen Hosp, Vincent Reprod Med & IVF, Boston, MA 02114 USA.
RP Styer, AK (reprint author), Massachusetts Gen Hosp, Vincent Dept Obstet & Gynecol, Vincent Reprod Med & IVF, Yaw 10A,55 Fruit St, Boston, MA 02114 USA.
EM astyer@partners.org
OI Brady, Paula/0000-0002-2225-1148; Stanic-Kostic,
Aleksandar/0000-0003-1946-6436
NR 29
TC 13
Z9 15
U1 0
U2 10
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1040-872X
J9 CURR OPIN OBSTET GYN
JI Curr. Opin. Obstet. Gynecol.
PD JUN
PY 2013
VL 25
IS 3
BP 255
EP 259
DI 10.1097/GCO.0b013e3283612188
PG 5
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA 141UM
UT WOS:000318752000013
PM 23562956
ER
PT J
AU Pau, CT
Keefe, CC
Welt, CK
AF Pau, Cindy Ta
Keefe, Candace C.
Welt, Corrine K.
TI Cigarette smoking, nicotine levels and increased risk for metabolic
syndrome in women with polycystic ovary syndrome
SO GYNECOLOGICAL ENDOCRINOLOGY
LA English
DT Article
DE Cotinine; hyperandrogenism; insulin resistance; testosterone;
triglycerides
ID IMPAIRED GLUCOSE-TOLERANCE; INSULIN-RESISTANCE; HEPATIC LIPASE;
LIFE-STYLE; PREVALENCE; LIPOPROTEIN; TESTOSTERONE; PREDICTORS; COTININE;
SMOKERS
AB Women with polycystic ovary syndrome (PCOS) are at risk for metabolic syndrome, which may be exacerbated by smoking. We hypothesized that smoking worsens androgen levels and the metabolic profile in women with PCOS. PCOS smokers (n = 47) and non-smokers (n = 64) and control smokers (n = 30) and non-smokers (n = 28), aged 18-45 years, underwent anthropomorphic measurements, pelvic ultrasound and blood sampling. Smokers had higher cotinine (801 +/- 83 versus <11 nmol/L; smokers versus non-smokers, respectively; p<0.001) and nicotine levels (37 +/- 4 versus 512 mu mol/L; p<0.001). Triglyceride levels were higher in women with PCOS who smoked compared to non-smokers (1.55 +/- 0.18 versus 0.95 +/- 0.08 mmol/L; p<0.001), even when adjusted for BMI. Metabolic syndrome was more common in smokers with PCOS compared to non-smokers with PCOS and smokers who were controls (28.6 versus 3.6%; p = 0.02). There were no differences in reproductive parameters including androgen levels. Cotinine (r = 0.3; p<0.001) and nicotine levels (r = 0.2; p = 0.005) correlated with triglycerides. Nicotine levels also correlated with pulse rate (r = 0.2; p = 0.02) and waist: hip ratio (WHR; r = 0.2; p = 0.02). Taken together, smoking may worsen the already high risk for metabolic syndrome in women with PCOS.
C1 [Pau, Cindy Ta; Keefe, Candace C.; Welt, Corrine K.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02114 USA.
RP Welt, CK (reprint author), Massachusetts Gen Hosp, BHX 511,55 Fruit St, Boston, MA 02114 USA.
EM cwelt@partners.org
OI Welt, Corrine/0000-0002-8219-5504
FU National Institutes of Health [1R01HD065029, ADA 1-10-CT-57, 1 UL1
RR025758]; Harvard Clinical and Translational Science Center; National
Center for Research Resources [M01-RR-01066]; Flight Attendant Medical
Research Institute
FX This work was supported by the National Institutes of Health
1R01HD065029 (CKW), ADA 1-10-CT-57 (CKW), 1 UL1 RR025758 Harvard
Clinical and Translational Science Center, M01-RR-01066 from the
National Center for Research Resources and the Flight Attendant Medical
Research Institute.
NR 24
TC 6
Z9 6
U1 0
U2 6
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 0951-3590
J9 GYNECOL ENDOCRINOL
JI Gynecol. Endocrinol.
PD JUN
PY 2013
VL 29
IS 6
BP 551
EP 555
DI 10.3109/09513590.2013.788634
PG 5
WC Endocrinology & Metabolism; Obstetrics & Gynecology
SC Endocrinology & Metabolism; Obstetrics & Gynecology
GA 140IN
UT WOS:000318647900007
PM 23656383
ER
PT J
AU Lebrun-Harris, LA
Baggett, TP
Jenkins, DM
Sripipatana, A
Sharma, R
Hayashi, AS
Daly, CA
Ngo-Metzger, Q
AF Lebrun-Harris, Lydie A.
Baggett, Travis P.
Jenkins, Darlene M.
Sripipatana, Alek
Sharma, Ravi
Hayashi, A. Seiji
Daly, Charles A.
Ngo-Metzger, Quyen
TI Health Status and Health Care Experiences among Homeless Patients in
Federally Supported Health Centers: Findings from the 2009 Patient
Survey
SO HEALTH SERVICES RESEARCH
LA English
DT Article
DE Community health centers; homeless persons; health status; health
services utilization; access to care; primary care
ID PSYCHOLOGICAL DISTRESS; BEHAVIORAL-MODEL; SCREENING SCALES; URBAN
HOMELESS; MENTAL-HEALTH; MEDICAL-CARE; HOUSED POOR; ADULTS; POPULATION;
SERVICES
AB Objective To examine health status and health care experiences of homeless patients in health centers and to compare them with their nonhomeless counterparts. Data Sources/Study Setting Nationally representative data from the 2009 Health Center Patient Survey. Study Design Cross-sectional analyses were limited to adults (n=2,683). We compared sociodemographic characteristics, health conditions, access to health care, and utilization of services among homeless and nonhomeless patients. We also examined the independent effect of homelessness on health care access and utilization, as well as factors that influenced homeless patients' health care experiences. Data Collection Computer-assisted personal interviews were conducted with health center patients. Principal Findings Homeless patients had worse health statuslifetime burden of chronic conditions, mental health problems, and substance use problemscompared with housed respondents. In adjusted analyses, homeless patients had twice the odds as housed patients of having unmet medical care needs in the past year (OR=1.98, 95 percent CI: 1.243.16) and twice the odds of having an ED visit in the past year (OR=2.00, 95 percent CI: 1.372.92). Conclusions There is an ongoing need to focus on the health issues that disproportionately affect homeless populations. Among health center patients, homelessness is an independent risk factor for unmet medical needs and ED use.
C1 [Lebrun-Harris, Lydie A.; Sripipatana, Alek; Sharma, Ravi; Hayashi, A. Seiji; Daly, Charles A.; Ngo-Metzger, Quyen] US Hlth Resources & Serv Adm, US Dept HHS, Bur Primary Hlth Care, Rockville, MD 20857 USA.
[Baggett, Travis P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston Hlth Care Homeless Program, Boston, MA USA.
[Jenkins, Darlene M.] Natl Hlth Care Homeless Council, Nashville, TN USA.
RP Lebrun-Harris, LA (reprint author), US Hlth Resources & Serv Adm, US Dept HHS, Bur Primary Hlth Care, 5600 Fishers Lane 6A-55, Rockville, MD 20857 USA.
EM llebrun@hrsa.gov
FU Health Resources and Services Administration (HRSA) of the U.S.
Department of the Health and Human Services (HHS)
FX Joint Acknowledgment/Disclosure Statement: The authors acknowledge the
financial support of this study by the Health Resources and Services
Administration (HRSA) of the U.S. Department of the Health and Human
Services (HHS). The views expressed in this article are those of the
authors and do not necessarily reflect the official policies of HHS or
HRSA, nor does mention of the department or agency imply endorsement by
the U.S. government.
NR 34
TC 27
Z9 27
U1 1
U2 23
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-9124
J9 HEALTH SERV RES
JI Health Serv. Res.
PD JUN
PY 2013
VL 48
IS 3
BP 992
EP 1017
DI 10.1111/1475-6773.12009
PG 26
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA 141BR
UT WOS:000318700900006
PM 23134588
ER
PT J
AU Shapiro, GI
McCallum, S
Adams, LM
Sherman, L
Weller, S
Swann, S
Keer, H
Miles, D
Muller, T
LoRusso, P
AF Shapiro, Geoffrey I.
McCallum, Stewart
Adams, Laurel M.
Sherman, Laurie
Weller, Steve
Swann, Suzanne
Keer, Harold
Miles, Dale
Mueller, Thomas
LoRusso, Patricia
TI A Phase 1 dose-escalation study of the safety and pharmacokinetics of
once-daily oral foretinib, a multi-kinase inhibitor, in patients with
solid tumors
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Foretinib; Multi-kinase inhibitor; Solid tumors; GSK 1363089; XL880
ID HEPATOCYTE GROWTH-FACTOR; C-MET; HEPATOCELLULAR-CARCINOMA; INVASIVE
GROWTH; EXPRESSION; CANCER; ANGIOGENESIS; METASTASIS; RECEPTORS;
PROGNOSIS
AB Foretinib is an oral multi-kinase inhibitor targeting MET, vascular endothelial growth factor receptor (VEGFR)-2, RON, KIT, and AXL kinases. In this Phase 1, open-label, non-randomized study, foretinib was administered once daily at doses of 60 mg, 80 mg, 100 mg, or 120 mg for 28 days. The primary objectives were to determine the maximum tolerated dose (MTD) and assess the safety and tolerability of the daily oral administration schedule. Secondary objectives included pharmacokinetics, pharmacodynamics, and assessment of tumor response. Patients had histologically confirmed metastatic or unresectable solid tumors for which no standard treatments existed and all received oral foretinib once daily. Dose escalation was planned as a conventional "3 + 3" design with an expansion at the MTD for collection of additional safety and pharmacokinetic information. Thirty-seven patients were treated across four dose levels. The MTD was established as 80 mg foretinib. Dose-limiting toxicities were hypertension, dehydration, and diarrhea. The most common adverse events included fatigue, hypertension, nausea, and diarrhea. Twenty-three of 31 patients (74 %) had a best response of stable disease. No patient had a confirmed partial or complete response. At the MTD, steady state was achieved by approximately 2 weeks, with average post-dose time to maximum concentration, peak concentration, and trough concentration of 4 h, 46 ng/mL, and 24 ng/mL, respectively. In patients treated at the MTD, soluble MET and VEGF-A plasma levels significantly increased (P < 0.003) and soluble VEGFR2 plasma levels significantly decreased from baseline (P < 0.03). The MTD of foretinib bisphosphate salt was determined to be 80 mg once daily.
C1 [Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Shapiro, Geoffrey I.] Harvard Univ, Sch Med, Boston, MA USA.
[McCallum, Stewart; Sherman, Laurie; Swann, Suzanne] GlaxoSmithKline, Collegeville, PA USA.
[Adams, Laurel M.; Weller, Steve] GlaxoSmithKline, Durham, NC USA.
[Keer, Harold; Miles, Dale; Mueller, Thomas] Exelixis, San Francisco, CA USA.
[LoRusso, Patricia] Barbara Ann Karmanos Canc Inst, Detroit, MI USA.
[Adams, Laurel M.] GlaxoSmithKline, Oncol Res & Dev, Durham, NC USA.
RP Adams, LM (reprint author), GlaxoSmithKline, Oncol Res & Dev, Durham, NC USA.
EM laurel.m.adams@gsk.com
FU GlaxoSmithKline [NCT00743067]; Exelixis Inc.; GlaxoSmithKline; Exelixis
FX We thank the patients, their families, and caregivers, and all of the
personnel who contributed to the patient care and data collection for
study MET111648. Funding for this study was provided by GlaxoSmithKline
(NCT00743067) and Exelixis Inc. Editorial support in the form of
assembling the first draft, collating author comments, copyediting, and
fact checking was provided by Susannah Chang at WynneWords, LLC
(Wynnewood, PA); final formatting, review, and submission assistance was
provided by MediTech Media, UK and was funded by GlaxoSmithKline;
Geoffrey I. Shapiro and Patricia LoRusso received research funding from
GlaxoSmithKline and Exelixis for the study. Stewart McCallum, Laurel M.
Adams, Laurie Sherman, Steve Weller, and Suzanne Swann are all
compensated employees of GlaxoSmithKline and own company stock. Dale
Miles is a compensated employee of Exelixis and owns company stock. At
the time of the study Harold Keer and Thomas Muller were compensated
employees of Exelixis and still own company stock.
NR 28
TC 17
Z9 17
U1 0
U2 10
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD JUN
PY 2013
VL 31
IS 3
BP 742
EP 750
DI 10.1007/s10637-012-9881-z
PG 9
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA 140MA
UT WOS:000318657000027
PM 23054208
ER
PT J
AU Henrich, TJ
Hu, ZX
Li, JZ
Sciaranghella, G
Busch, MP
Keating, SM
Gallien, S
Lin, NH
Giguel, FF
Lavoie, L
Ho, VT
Armand, P
Soiffer, RJ
Sagar, M
LaCasce, AS
Kuritzkes, DR
AF Henrich, Timothy J.
Hu, Zixin
Li, Jonathan Z.
Sciaranghella, Gaia
Busch, Michael P.
Keating, Sheila M.
Gallien, Sebastien
Lin, Nina H.
Giguel, Francoise F.
Lavoie, Laura
Ho, Vincent T.
Armand, Philippe
Soiffer, Robert J.
Sagar, Manish
LaCasce, Ann S.
Kuritzkes, Daniel R.
TI Long-Term Reduction in Peripheral Blood HIV Type 1 Reservoirs Following
Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation
SO JOURNAL OF INFECTIOUS DISEASES
LA English
DT Article
DE HIV-1; viral reservoirs; hematopoietic stem cell transplantation; HIV-1
persistence; CCR5; reduced-intensity allogeneic stem cell
transplantation
ID IMMUNODEFICIENCY-VIRUS TYPE-1; BONE-MARROW-TRANSPLANTATION; LOW-LEVEL
VIREMIA; HIGH-DOSE THERAPY; ANTIRETROVIRAL THERAPY; PLASMA VIREMIA;
INFECTION; LYMPHOMA; EVOLUTION; RESPONSES
AB Background. The long-term impact of allogeneic hematopoietic stem cell transplantation (HSCT) on human immunodeficiency virus type 1 (HIV-1) reservoirs in patients receiving combination antiretroviral therapy (cART) is largely unknown.
Methods. We studied the effects of a reduced-intensity conditioning allogeneic HSCT from donors with wild-type-CCR5(+) cells on HIV-1 peripheral blood reservoirs in 2 patients heterozygous for the ccr5 delta 32 mutation. In-depth analyses of the HIV-1 reservoir size in peripheral blood, coreceptor use, and specific antibody responses were performed on samples obtained before and up to 3.5 years after HSCT receipt.
Results. Although HIV-1 DNA was readily detected in peripheral blood mononuclear cells (PBMCs) before and 2-3 months after HSCT receipt, HIV-1 DNA and RNA were undetectable in PBMCs, CD4(+) T cells, or plasma up to 21 and 42 months after HSCT. The loss of detectable HIV-1 correlated temporally with full donor chimerism, development of graft-versus-host disease, and decreases in HIV-specific antibody levels.
Conclusions. The ability of donor cells to engraft without evidence of ongoing HIV-1 infection suggests that HIV-1 replication may be fully suppressed during cART and does not contribute to maintenance of viral reservoirs in peripheral blood in our patients. HSCTs with wild-type-CCR5(+) donor cells can lead to a sustained reduction in the size of the peripheral reservoir of HIV-1.
C1 [Henrich, Timothy J.; Hu, Zixin; Li, Jonathan Z.; Gallien, Sebastien; Sagar, Manish; Kuritzkes, Daniel R.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Henrich, Timothy J.; Hu, Zixin; Li, Jonathan Z.; Lin, Nina H.; Ho, Vincent T.; Armand, Philippe; Soiffer, Robert J.; Sagar, Manish; LaCasce, Ann S.; Kuritzkes, Daniel R.] Harvard Univ, Sch Med, Boston, MA USA.
[Sciaranghella, Gaia] Ragon Inst MGH MIT Harvard, Boston, MA USA.
[Lin, Nina H.; Giguel, Francoise F.; Lavoie, Laura] Massachusetts Gen Hosp, Divsis Infect Dis, Boston, MA 02114 USA.
[Ho, Vincent T.; Armand, Philippe; Soiffer, Robert J.; LaCasce, Ann S.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Busch, Michael P.; Keating, Sheila M.] Blood Syst Res Inst, San Francisco, CA USA.
[Busch, Michael P.; Keating, Sheila M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Gallien, Sebastien] Hop St Louis, Paris, France.
RP Henrich, TJ (reprint author), 65 Landsdowne St,Partners Res Bldg,Rm 435, Cambridge, MA 02139 USA.
EM thenrich@partners.org
RI Gallien, Sebastien/F-9930-2015
OI Gallien, Sebastien/0000-0002-8033-0936
FU National Institutes of Health/National Institute of Allergy and
Infectious Disease [1K23AI098480-01A1, UM1 AI068636, P30 AI060354];
Foundation for AIDS Research [108466 52 RGRL, U19 AI096109]; Bill and
Melinda Gates Foundation [OPP1017716]; Gilead; Merck
FX This work was supported by the National Institutes of Health/National
Institute of Allergy and Infectious Disease (grants 1K23AI098480-01A1;
UM1 AI068636 [to the AIDS Clinical Trials Group Virology Support
Laboratory], P30 AI060354 [to the Harvard CFAR Program in Therapeutics],
the Foundation for AIDS Research (amfAR Grant# 108466 52 RGRL), and U19
AI096109 [to the DARE Collaboratory]) and the Bill and Melinda Gates
Foundation (global health grant OPP1017716).; D. R. K. is a consultant
to and has received honoraria from Abbott, Boehringer-Ingelheim,
Bristol-Myers Squibb, Gilead, GlaxoSmithKline, InnoVirVax, Koronis,
Merck, Roche, Roxane, Sangamo, and ViiV; grant support from Gilead and
Merck; and speaking honoraria from Gilead. All other authors report no
potential conflicts.
NR 43
TC 114
Z9 115
U1 2
U2 18
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0022-1899
J9 J INFECT DIS
JI J. Infect. Dis.
PD JUN 1
PY 2013
VL 207
IS 11
BP 1694
EP 1702
DI 10.1093/infdis/jit086
PG 9
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA 139EA
UT WOS:000318563200010
PM 23460751
ER
PT J
AU Brandt, CP
Gonzalez, A
Grover, KW
Zvolensky, MJ
AF Brandt, Charles P.
Gonzalez, Adam
Grover, Kristin W.
Zvolensky, Michael J.
TI The Relation Between Emotional Dysregulation and Anxiety and Depressive
Symptoms, Pain-Related Anxiety, and HIV-Symptom Distress Among Adults
with HIV/AIDS
SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT
LA English
DT Article
DE HIV/AIDS; Depression; ANXIETY; Emotion dysregulation; Pain anxiety;
Symptom distress; Anxiety sensitivity
ID QUALITY-OF-LIFE; HUMAN-IMMUNODEFICIENCY-VIRUS; REGULATION DIFFICULTIES;
INITIAL VALIDATION; CIGARETTE SMOKERS; PANIC-ATTACKS; STIGMA SCALE;
SENSITIVITY; PEOPLE; SAMPLE
AB The current study investigated the relations between emotional dysregulation and anxiety and depressive symptoms, pain-related anxiety, and HIV-symptom distress among individuals living with HIV/AIDS. This research is important in its explanatory value regarding the unique effects of emotional dysregulation as it relates to psychological and disease-specific distress given high rates of distress specific to HIV infection (e.g. medicatin side-effects, stigma). Participants included 164 adults (17.1 % female, Mage = 48.40, SD = 9.57) with HIV/AIDS. Results indicated that emotional dysregulation was significantly and positively related to anxiety and depressive symptoms, pain-related anxiety, and HIV-symptom distress. All emotional dyregulation effects were evidenced above and beyond the variance accounted for by demographic and HIV-specific characteristics, and the main effects of anxiety sensitivity and distress intolerance. Findings are discussed in terms of the importance of emotional dysregulation in negative affective experiences within the HIV/AIDS population.
C1 [Brandt, Charles P.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA.
[Gonzalez, Adam] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Gonzalez, Adam] Harvard Univ, Sch Med, Boston, MA USA.
[Gonzalez, Adam] SUNY Stony Brook, Dept Psychiat & Behav Sci, Stony Brook, NY 11794 USA.
[Grover, Kristin W.] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA.
RP Brandt, CP (reprint author), Univ Houston, Dept Psychol, Houston, TX 77204 USA.
EM cpbrandt1@gmail.com
NR 50
TC 10
Z9 10
U1 2
U2 15
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0882-2689
J9 J PSYCHOPATHOL BEHAV
JI J. Psychopathol. Behav. Assess.
PD JUN
PY 2013
VL 35
IS 2
BP 197
EP 204
DI 10.1007/s10862-012-9329-y
PG 8
WC Psychology, Clinical
SC Psychology
GA 139HE
UT WOS:000318571900007
ER
PT J
AU Vujanovic, AA
Hart, AS
Potter, CM
Berenz, EC
Niles, B
Bernstein, A
AF Vujanovic, Anka A.
Hart, Ashley S.
Potter, Carrie M.
Berenz, Erin C.
Niles, Barbara
Bernstein, Amit
TI Main and Interactive Effects of Distress Tolerance and Negative Affect
Intensity in Relation to PTSD Symptoms among Trauma-Exposed Adults
SO JOURNAL OF PSYCHOPATHOLOGY AND BEHAVIORAL ASSESSMENT
LA English
DT Article
DE Distress tolerance; Affect intensity; PTSD; Trauma
ID POSTTRAUMATIC-STRESS-DISORDER; SELF-REPORT MEASURE; ANXIETY SENSITIVITY;
FUNCTIONAL IMPAIRMENT; SEVERITY; SCALE; RELIABILITY; VALIDATION; EMOTION
AB The present investigation evaluated the main and interactive effects of distress tolerance and negative affect intensity in relation to posttraumatic stress disorder (PTSD) symptom severity and symptom cluster severity. Participants were 190 trauma-exposed adults (52.6 % women; M (age) = 25.3 years, SD = 11.4) recruited from the community. Distress tolerance (i.e., perceived ability to withstand distressing emotional states) demonstrated significant incremental associations with global PTSD symptom severity as well as Re-Experiencing, Emotional Numbing, and Hyperarousal symptom cluster severity. Negative affect intensity (i.e., perceived intensity of negative emotional responses) demonstrated significant incremental associations with each of the PTSD symptom outcomes. Moreover, the incremental interactive effect of distress tolerance and negative affect intensity was significantly associated with PTSD symptom severity as well as PTSD-Emotional Numbing symptom cluster severity. These incremental effects were evident after accounting for the variance explained by anxiety sensitivity (i.e., fear of anxiety-related sensations). Post hoc probing analyses supported the moderating role of negative affect intensity in the association between distress tolerance and PTSD symptom severity, such that low levels of distress tolerance, in the context of elevated levels of negative affect intensity, were associated with the greatest levels of PTSD symptoms.
C1 [Vujanovic, Anka A.] Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, Houston, TX 77021 USA.
[Hart, Ashley S.] Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA.
[Hart, Ashley S.] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
[Potter, Carrie M.] Temple Univ, Philadelphia, PA 19122 USA.
[Berenz, Erin C.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[Niles, Barbara] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Niles, Barbara] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Bernstein, Amit] Univ Haifa, IL-31999 Haifa, Israel.
RP Vujanovic, AA (reprint author), Univ Texas Hlth Sci Ctr Houston, Dept Psychiat & Behav Sci, 2800 South MacGregor Way, Houston, TX 77021 USA.
EM anka.vujanovic@gmail.com
FU NIDA NIH HHS [F31 DA021006]; NIMH NIH HHS [F31 MH073205, F31 MH080453]
NR 35
TC 9
Z9 9
U1 2
U2 13
PU SPRINGER/PLENUM PUBLISHERS
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0882-2689
J9 J PSYCHOPATHOL BEHAV
JI J. Psychopathol. Behav. Assess.
PD JUN
PY 2013
VL 35
IS 2
BP 235
EP 243
DI 10.1007/s10862-012-9325-2
PG 9
WC Psychology, Clinical
SC Psychology
GA 139HE
UT WOS:000318571900011
PM 24431482
ER
PT J
AU Duggan, MJ
Mejaddam, AY
Beagle, J
deMoya, MA
Velmahosa, GC
Alam, HB
Rago, A
Zugates, G
Busold, R
Freyman, T
Sharma, U
King, DR
AF Duggan, Michael J.
Mejaddam, Ali Y.
Beagle, John
deMoya, Marc A.
Velmahosa, George C.
Alam, Hasan B.
Rago, Adam
Zugates, Greg
Busold, Rany
Freyman, Toby
Sharma, Upma
King, David R.
TI Development of a lethal, closed-abdomen grade V hepato-portal injury
model in non-coagulopathic swine
SO JOURNAL OF SURGICAL RESEARCH
LA English
DT Article
DE Swine; Lethal hemorrhage; Animal; Resuscitation; Closed cavity; Liver
injury; Portal vein injury
ID DECREASES BLOOD-LOSS; FIBRIN SEALANT DRESSINGS; OPERATION-IRAQI-FREEDOM;
RECOMBINANT FACTOR VIIA; LIVER-INJURIES; ABDOMINAL INSUFFLATION;
HEMORRHAGE CONTROL; HEMOSTATIC AGENT; HEMODYNAMIC-RESPONSE;
RESUSCITATION VOLUME
AB Background: Hemorrhage within an intact abdominal cavity remains a leading cause of preventable death on the battlefield. Despite this need, there is no existing closed-cavity animal model to assess new hemostatic agents for the preoperative control of intra-abdominal hemorrhage.
Methods: We developed a novel, lethal liver injury model in non-coagulopathic swine by strategic placement of two wire loops in the medial liver lobes including the hepatic and portal veins. Distraction resulted in grade V liver laceration with hepato-portal injury, massive bleeding, and severe hypotension. Crystalloid resuscitation was started once mean arterial pressure (MAP) fell below 65 mmHg. Monitoring continued for up to 180 min.
Results: We demonstrated 90% lethality (9/10) in swine receiving injury and fluid resuscitation, with a mean survival time of 43 min. Previous efforts in our laboratory to develop a consistently lethal swine model of abdominal solid organs, including preemptive anticoagulation, a two-hit injury with controlled hemorrhage prior to liver trauma, and the injury described above without resuscitation, consistently failed to result in lethal injury.
Conclusion: This model can be used to screen other interventions for pre hospital control of noncompressible. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Duggan, Michael J.; Mejaddam, Ali Y.; Beagle, John; deMoya, Marc A.; Velmahosa, George C.; Alam, Hasan B.; King, David R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Trauma Emergency Surg & Surg Crit C, Boston, MA 02114 USA.
[Rago, Adam; Zugates, Greg; Busold, Rany; Freyman, Toby; Sharma, Upma] Arsenal Med Inc, Watertown, MA USA.
RP King, DR (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Trauma, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM dking3@partners.org
OI King, David/0000-0003-1028-1478
FU DARPA [W911NF-10-C-0089]
FX This research was entirely supported by DARPA under contract no:
W911NF-10-C-0089.
NR 42
TC 14
Z9 14
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0022-4804
J9 J SURG RES
JI J. Surg. Res.
PD JUN 1
PY 2013
VL 182
IS 1
BP 101
EP 107
DI 10.1016/j.jss.2012.07.048
PG 7
WC Surgery
SC Surgery
GA 139WU
UT WOS:000318616500023
PM 22921917
ER
PT J
AU Chung, JY
Lee, DH
Park, JH
Lee, MK
Kang, DW
Min, J
Kim, DI
Jeong, DH
Kim, NK
Meyerhardt, JA
Jones, LW
Jeon, JY
AF Chung, Jae Youn
Lee, Dong Hoon
Park, Ji-Hye
Lee, Mi Kyung
Kang, Dong-Woo
Min, Jihee
Kim, Dong-Il
Jeong, Duck Hyoun
Kim, Nam Kyu
Meyerhardt, Jeffrey A.
Jones, Lee W.
Jeon, Justin Y.
TI Patterns of physical activity participation across the cancer trajectory
in colorectal cancer survivors
SO SUPPORTIVE CARE IN CANCER
LA English
DT Article
DE Physical activity; Exercise; Cancer trajectory; Colorectal cancer
ID QUALITY-OF-LIFE; POPULATION-BASED SAMPLE; BODY-MASS INDEX; EXERCISE;
PREFERENCES; DIAGNOSIS; HEALTH; IMPACT; INTERVENTION; CHEMOTHERAPY
AB The purpose of the present study was to explore the participation in physical activity (PA) by colorectal cancer survivors across cancer trajectories and based on selected demographic and medical variables.
A total of 431 participants were surveyed individually at the Shinchon Severance Hospital, Seoul, Korea, to determine their PA levels before diagnosis, during treatment and after completion of cancer treatment.
Percentage of survivors meeting American College of Sports Medicine guideline significantly reduced from 27 % before diagnosis to 10 % during treatment due to reduced strenuous intensity PA (28.8 +/- 106.2 vs 11.8 +/- 95.9 min, p = 0.042), while total PA and mild intensity PA did not change. Total (187.2 +/- 257.7 vs. 282.6 +/- 282.0 min, p < 0.001) and mild (99.1 +/- 191.5 vs. 175.1 +/- 231.2 min, p < 0.001) intensity PA significantly increased after the completion of treatments compared with their PA level before diagnosis. Further analyses showed that age (more vs. equal or less than 60 years) and chemotherapy (chemotherapy vs. no chemotherapy) significantly influenced the level of physical activity (p = 0.004). Survivors who were older or received chemotherapy increased their total PA and mild intensity PA after the completion of treatment more than those who did not receive chemotherapy.
The level and the pattern of physical activity by colorectal cancer survivors differed across cancer trajectories, which were significantly influenced by age and adjuvant chemotherapy.
C1 [Chung, Jae Youn; Lee, Dong Hoon; Park, Ji-Hye; Lee, Mi Kyung; Kang, Dong-Woo; Min, Jihee; Kim, Dong-Il; Jeon, Justin Y.] Yonsei Univ, Dept Sport & Leisure Studies, Seoul 120749, South Korea.
[Jeong, Duck Hyoun; Kim, Nam Kyu] Yonsei Univ, Coll Med, Dept Surg, Seoul 120749, South Korea.
[Meyerhardt, Jeffrey A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jones, Lee W.] Duke Canc Inst, Durham, NC USA.
RP Jeon, JY (reprint author), Yonsei Univ, Dept Sport & Leisure Studies, 134 Seodaemun Gu, Seoul 120749, South Korea.
EM jjeon@yonsei.ac.kr
OI Kim, Nam-Kyu/0000-0003-0639-5632; Kim, Dong-Il/0000-0003-4434-799X
FU national research foundation of Korea (NRF) [2011-0004892]; National R &
D program for Cancer Control, Ministry of Health and Welfare, Republic
of Korea [1120230]
FX The current study was supported by the national research foundation of
Korea (NRF)(No. 2011-0004892) and the National R & D program for Cancer
Control, Ministry of Health and Welfare, Republic of Korea (No.
1120230).
NR 31
TC 6
Z9 6
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0941-4355
J9 SUPPORT CARE CANCER
JI Support. Care Cancer
PD JUN
PY 2013
VL 21
IS 6
BP 1605
EP 1612
DI 10.1007/s00520-012-1703-5
PG 8
WC Oncology; Health Care Sciences & Services; Rehabilitation
SC Oncology; Health Care Sciences & Services; Rehabilitation
GA 138OA
UT WOS:000318516700011
PM 23292698
ER
PT J
AU Torgerson, CM
Irimia, A
Leow, AD
Bartzokis, G
Moody, TD
Jennings, RG
Alger, JR
Van Horn, JD
Altshuler, LL
AF Torgerson, Carinna M.
Irimia, Andrei
Leow, Alex D.
Bartzokis, George
Moody, Teena D.
Jennings, Robin G.
Alger, Jeffry R.
Van Horn, John Darrell
Altshuler, Lori L.
TI DTI tractography and white matter fiber tract characteristics in
euthymic bipolar I patients and healthy control subjects
SO BRAIN IMAGING AND BEHAVIOR
LA English
DT Article
DE Diffusion tensor imaging (DTI); White matter (WM); Bipolar disorder
(BD); Tractography; Tract length; Fiber density
ID DIFFUSION TENSOR TRACTOGRAPHY; MILD COGNITIVE IMPAIRMENT; AUTISM
SPECTRUM DISORDER; MAGNETIC-RESONANCE; CORPUS-CALLOSUM; UNCINATE
FASCICULUS; FRONTAL-LOBE; ABNORMALITIES; INTEGRITY; SCHIZOPHRENIA
AB With the introduction of diffusion tensor imaging (DTI), structural differences in white matter (WM) architecture between psychiatric populations and healthy controls can be systematically observed and measured. In particular, DTI-tractography can be used to assess WM characteristics over the entire extent of WM tracts and aggregated fiber bundles. Using 64-direction DTI scanning in 27 participants with bipolar disorder (BD) and 26 age-and-gender-matched healthy control subjects, we compared relative length, density, and fractional anisotrophy (FA) of WM tracts involved in emotion regulation or theorized to be important neural components in BD neuropathology. We interactively isolated 22 known white matter tracts using region-of-interest placement (TrackVis software program) and then computed relative tract length, density, and integrity. BD subjects demonstrated significantly shorter WM tracts in the genu, body and splenium of the corpus callosum compared to healthy controls. Additionally, bipolar subjects exhibited reduced fiber density in the genu and body of the corpus callosum, and in the inferior longitudinal fasciculus bilaterally. In the left uncinate fasciculus, however, BD subjects exhibited significantly greater fiber density than healthy controls. There were no significant differences between groups in WM tract FA for those tracts that began and ended in the brain. The significance of differences in tract length and fiber density in BD is discussed.
C1 [Torgerson, Carinna M.; Irimia, Andrei; Van Horn, John Darrell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, Los Angeles, CA 90095 USA.
[Leow, Alex D.] Univ Illinois, Dept Bioengn, Dept Psychiat, Chicago, IL 60612 USA.
[Leow, Alex D.] Community Psychiat Associates, Chicago, IL 60612 USA.
[Bartzokis, George; Moody, Teena D.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA.
[Jennings, Robin G.; Altshuler, Lori L.] Univ Calif San Diego, ADCS Imaging Core, San Diego, CA 92037 USA.
[Alger, Jeffry R.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA.
[Altshuler, Lori L.] VA Greater Los Angeles Healthcare Syst, West Los Angeles Healthcare Ctr, Dept Psychiat, Los Angeles, CA USA.
RP Torgerson, CM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Lab Neuro Imaging LONI, 635 Charles E Young Dr S, Los Angeles, CA 90095 USA.
EM carinnat@gmail.com
RI Irimia, Andrei/B-8275-2008; Bartzokis, George/K-2409-2013; Leow,
Alex/K-3236-2014
OI Irimia, Andrei/0000-0002-9254-9388; Leow, Alex/0000-0002-5660-8651
FU National Institute of Mental Health [R21MH086104, R21MH085944]; HF
Foundation
FX This work was supported by grants to LLA from the National Institute of
Mental Health (R21MH086104, R21MH085944) and a generous donation from
the HF Foundation.
NR 70
TC 16
Z9 16
U1 1
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1931-7557
J9 BRAIN IMAGING BEHAV
JI Brain Imaging Behav.
PD JUN
PY 2013
VL 7
IS 2
BP 129
EP 139
DI 10.1007/s11682-012-9202-3
PG 11
WC Neuroimaging
SC Neurosciences & Neurology
GA 136NY
UT WOS:000318369800004
PM 23070746
ER
PT J
AU Griffin, JD
Guerin, A
Chen, L
Macalalad, AR
Luo, JY
Ionescu-Ittu, R
Wu, EQ
AF Griffin, James D.
Guerin, Annie
Chen, Lei
Macalalad, Alexander R.
Luo, Jiayuan
Ionescu-Ittu, Raluca
Wu, Eric Qiong
TI Comparing nilotinib with dasatinib as second-line therapies in patients
with chronic myelogenous leukemia resistant or intolerant to imatinib -
a retrospective chart review analysis
SO CURRENT MEDICAL RESEARCH AND OPINION
LA English
DT Review
DE Dasatinib; Nilotinib; Progression; Survival; Treatment changes
ID CHRONIC MYELOID-LEUKEMIA; CHRONIC-PHASE; COMORBIDITY INDEX; FOLLOW-UP;
ADHERENCE
AB Introduction:
This study compared progression, progression-free survival (PFS), overall survival (OS), and treatment changes among chronic myelogenous leukemia patients in chronic phase (CML-CP) receiving nilotinib or dasatinib as second-line therapy.
Patients and methods:
Information on CML-CP patients switched from imatinib to nilotinib or dasatinib as second-line therapy was collected retrospectively from 122 US hematologists and oncologists through an online medical chart review. Progression, PFS, and OS were compared using multivariate Cox proportional hazard models, and treatment changes using chi-square tests.
Results:
Of 597 imatinib resistant or intolerant patients, 301 initiated nilotinib and 296 dasatinib as second-line therapy. Nilotinib was associated with a lower risk of progression (hazard ratio [HR] = 0.27; p = 0.021) and longer PFS (HR = 0.48; p = 0.030) than dasatinib, with a median follow-up time of 11 months for nilotinib and 10 months for dasatinib. Nilotinib patients had a lower estimated hazard of mortality than dasatinib patients, though not statistically significant (HR = 0.46; p = 0.067). When treatment changes were classified by the physicians' justifications, fewer nilotinib patients had treatment changes due to ineffectiveness (2.0% vs. 5.1%, p = 0.041) or drug holidays due to intolerance (0.0% vs. 1.7%, p = 0.024) than dasatinib patients.
Conclusions:
Among CML-CP patients in this retrospective chart review who switched from imatinib to either nilotinib or dasatinib, nilotinib was associated with a significantly lower risk of progression and longer PFS than dasatinib. Nilotinib patients were also less likely than dasatinib patients to subsequently have treatment changes due to ineffectiveness or drug holidays due to intolerance. These findings could be subject to unobserved confounders.
C1 [Griffin, James D.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Guerin, Annie; Macalalad, Alexander R.; Luo, Jiayuan; Ionescu-Ittu, Raluca; Wu, Eric Qiong] Anal Grp Inc, Montreal, PQ H3B 4W5, Canada.
[Chen, Lei] Novartis Pharmaceut, E Hanover, NJ USA.
RP Guerin, A (reprint author), Anal Grp Inc, 1000 Rue Gauchetiere Ouest,Bur 1200, Montreal, PQ H3B 4W5, Canada.
EM aguerin@analysisgroup.com
FU Novartis Pharmaceuticals Corporation; Novartis Pharmaceuticals
FX L.C. is an employee of Novartis Pharmaceuticals Corporation. E.Q.W.,
A.G., A.R.M., J.L., and R.I.-I. are employees of Analysis Group Inc.,
which has received consultancy fees from Novartis Pharmaceuticals
Corporation to conduct this study. J.D.G. is a consultant for Novartis
Pharmaceuticals Corporation and receives research support from Novartis
Pharmaceuticals.
NR 19
TC 4
Z9 4
U1 2
U2 9
PU INFORMA HEALTHCARE
PI LONDON
PA TELEPHONE HOUSE, 69-77 PAUL STREET, LONDON EC2A 4LQ, ENGLAND
SN 0300-7995
J9 CURR MED RES OPIN
JI Curr. Med. Res. Opin.
PD JUN
PY 2013
VL 29
IS 6
BP 623
EP 631
DI 10.1185/03007995.2013.789012
PG 9
WC Medicine, General & Internal; Medicine, Research & Experimental
SC General & Internal Medicine; Research & Experimental Medicine
GA 136KH
UT WOS:000318360300005
PM 23517347
ER
PT J
AU DePalma, G
Xu, HP
Covinsky, KE
Craig, BA
Stallard, E
Thomas, J
Sands, LP
AF DePalma, Glen
Xu, Huiping
Covinsky, Kenneth E.
Craig, Bruce A.
Stallard, Eric
Thomas, Joseph, III
Sands, Laura P.
TI Hospital Readmission Among Older Adults Who Return Home With Unmet Need
for ADL Disability
SO GERONTOLOGIST
LA English
DT Article
DE Activities of daily living; Insufficient help
ID ALL-CAUSE HOSPITALIZATION; FUNCTIONAL OUTCOMES; ELDERLY-PEOPLE;
HEART-FAILURE; ACUTE-CARE; COMMUNITY; DISCHARGE; CONSEQUENCES;
ASSISTANCE; ADMISSIONS
AB Purpose: This study determined whether returning to the community from a recent hospitalization with unmetactivities of daily living (ADL) need was associated with probability of readmission. Methods: A total of 584 respondents to the 1994, 1999, and/or 2004 National Long-Term Care Surveys (NLTCS) who were hospitalized within 90 days prior to the interview and reported ADL disability at the time of the interview were considered for analysis. Medicare claims linked to the NLTCS provided information about hospital episodes, so those enrolled in Health Maintenance Organizations or Veterans Affairs Medical Centers were not included (n = 62), resulting in a total sample size of 522. ADL disability was defined as needing human help or equipment to complete the task. Unmet ADL need was defined as receiving inadequate or no help for one or more ADL disabilities. Disability that began within 90 days of the interview was considered new disability. Results: After adjusting for demographic, health, and functioning characteristics, unmet ADL need was associated with increased risk for hospital readmission (HR: 1.37, 95% CI: 1.03-1.82). Risk of readmission was greater for those with unmet need for new disabilities than those with unmet need for disabilities that were present before the index hospitalization (HR: 1.66, 95% CI: 1.01-2.73). Implications: Many older patients are discharged from the hospital with ADL disability. Those who report unmet need for new ADL disabilities after they return home from the hospital are particularly vulnerable to readmission. Patients' functional needs after discharge should be carefully evaluated and addressed.
C1 [DePalma, Glen; Craig, Bruce A.] Purdue Univ, Dept Stat, W Lafayette, IN 47907 USA.
[Xu, Huiping] Indiana Univ Sch Med, Dept Biostat, Indianapolis, IN USA.
[Covinsky, Kenneth E.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA 94143 USA.
[Stallard, Eric] Duke Univ, Ctr Populat Hlth & Aging, Durham, NC USA.
[Thomas, Joseph, III] Purdue Univ, Coll Pharm, Ctr Aging & Life Course, Regenstrief Ctr Healthcare Engn,Ctr Hlth Outcomes, W Lafayette, IN 47907 USA.
[Sands, Laura P.] Purdue Univ, Sch Nursing, W Lafayette, IN 47907 USA.
[Sands, Laura P.] Purdue Univ, Ctr Aging & Life Course, W Lafayette, IN 47907 USA.
RP Sands, LP (reprint author), Purdue Univ, Sch Nursing, 502 N Univ St, W Lafayette, IN 47907 USA.
EM lsands@purdue.edu
RI Sands, Laura/E-8919-2015; Craig, Bruce/D-5797-2017
OI Sands, Laura/0000-0003-2446-4486; Craig, Bruce/0000-0001-9346-467X
FU NIA NIH HHS [R01 AG034160, R01AG034160]
NR 32
TC 21
Z9 23
U1 2
U2 19
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD JUN
PY 2013
VL 53
IS 3
BP 454
EP 461
DI 10.1093/geront/gns103
PG 8
WC Gerontology
SC Geriatrics & Gerontology
GA 137UP
UT WOS:000318464000010
PM 22859438
ER
PT J
AU Leutwyler, H
Hubbard, EM
Jeste, DV
Vinogradov, S
AF Leutwyler, Heather
Hubbard, Erin M.
Jeste, Dilip V.
Vinogradov, Sophia
TI "We're Not Just Sitting on the Periphery": A Staff Perspective of
Physical Activity in Older Adults With Schizophrenia
SO GERONTOLOGIST
LA English
DT Article
DE Schizophrenia; Grounded theory
ID SERIOUS MENTAL-ILLNESS; HEALTH; EXERCISE; INTERVENTION; DISABILITY;
QUALITY; LIFE
AB Targeted physical activity interventions to improve the poor physical function of older adults with schizophrenia are necessary but currently not available. Given disordered thought processes and institutionalization, it is likely that older adults with schizophrenia have unique barriers and facilitators to physical activity. It is necessary to consider the perspective of the mental health staff about barriers and facilitators to physical activity to design a feasible intervention. Purpose of This Study: To describe the perceptions of mental health staff about barriers and facilitators to engage in physical activities that promote physical function among older adults with schizophrenia. Design and Method: We conducted qualitative interviews with 23 mental health staff that care for older adults with schizophrenia. The data were collected and analyzed with grounded theory methodology. Results: The participants were interested in promoting physical activity with older adults with schizophrenia. Facilitators and barriers to physical activity identified were mental health, role models and rewards, institutional factors, and safety. Implications: In order to design successful physical activity interventions for this population, the intervention may need to be a routine part of the mental health treatment program and patients may need incentives to participate. Staff should be educated that physical activity may provide the dual benefit of physical and mental health treatment.
C1 [Leutwyler, Heather; Hubbard, Erin M.] Univ Calif San Francisco, Dept Physiol Nursing, San Francisco, CA 94143 USA.
[Jeste, Dilip V.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA.
[Vinogradov, Sophia] Univ Calif San Francisco, Dept Psychiat, San Francisco VA Med Ctr, San Francisco, CA 94143 USA.
RP Leutwyler, H (reprint author), Univ Calif San Francisco, Dept Physiol Nursing, 2 Koret Way,N631A,Box 0610, San Francisco, CA 94143 USA.
EM heather.leutwyler@nursing.ucsf.edu
FU NCRR NIH HHS [KL2RR024130]; NIMH NIH HHS [R01 MH094151]; NINR NIH HHS
[P30-NR011934-0]
NR 35
TC 13
Z9 13
U1 0
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0016-9013
J9 GERONTOLOGIST
JI Gerontologist
PD JUN
PY 2013
VL 53
IS 3
BP 474
EP 483
DI 10.1093/geront/gns092
PG 10
WC Gerontology
SC Geriatrics & Gerontology
GA 137UP
UT WOS:000318464000012
PM 22936534
ER
PT J
AU Zantek, ND
Hsu, P
Refaai, MA
Ledford-Kraemer, M
Meijer, P
Van Cott, EM
AF Zantek, N. D.
Hsu, P.
Refaai, M. A.
Ledford-Kraemer, M.
Meijer, P.
Van Cott, E. M.
TI Factor VII assay performance: an analysis of the North American
Specialized Coagulation Laboratory Association proficiency testing
results
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Article
DE Factor VII; thromboplastin; external quality control of diagnostic
assays and tests; North American specialized coagulation laboratory
association
ID CLINICAL BLEEDING SEVERITY; DEFICIENCY; DISORDERS
AB The performance of factor VII (FVII) assays currently used by clinical laboratories was examined in North American Specialized Coagulation Laboratory Association (NASCOLA) proficiency tests. Data from 12 surveys conducted between 2008 and 2010, involving 20 unique specimens plus four repeat-tested specimens, were analyzed. The number of laboratories per survey was 4954 with a total of 1224 responses. Numerous reagent/instrument combinations were used. For FVII>80 or <40U/dL, 99.5% of results (859/863) were correctly classified by laboratories as normal/abnormal. Classification of specimens with 4073U/dL FVII was heterogeneous. Interlaboratory precision was better for normal specimens (coefficient of variation (CV) 10.7%) than for FVII<20U/dL (CV 33.1%), with a mean CV of 17.2% per specimen. Intralaboratory precision for repeated specimens demonstrated no significant difference between the paired survey results (mean absolute difference 2.55.0U/dL). For specimens with FVII >50U/dL, among commonly used methods, one thromboplastin and one calibrator produced results 56U/dL higher and another thromboplastin and calibrator produced results 56U/dL lower than all other methods, and human thromboplastin differed from rabbit by +7.6U/dL. Preliminary evidence suggests these differences could be due to the calibrator. For FVII <50U/dL, differences among the commonly used reagents and calibrators were generally not significant.
C1 [Zantek, N. D.] Univ Minnesota, Dept Lab Med & Pathol, Minneapolis, MN 55455 USA.
[Hsu, P.] Hofstra North Shore Long Isl Jewish Sch Med, Dept Pathol & Lab Med, Lake Success, NY USA.
[Refaai, M. A.] Univ Rochester, Sch Med & Dent, Dept Pathol & Lab Med, Rochester, NY USA.
[Ledford-Kraemer, M.] CLOT ED, Islamorada, FL USA.
[Meijer, P.] ECAT Fdn, Leiden, Netherlands.
[Van Cott, E. M.] Massachusetts Gen Hosp, Dept Pathol, Div Clin Labs, Boston, MA 02114 USA.
RP Van Cott, EM (reprint author), Massachusetts Gen Hosp GRJ235, Coagulat Lab, 55 Fruit St, Boston, MA 02114 USA.
NR 7
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD JUN
PY 2013
VL 35
IS 3
SI SI
BP 314
EP 321
DI 10.1111/ijlh.12083
PG 8
WC Hematology
SC Hematology
GA 131GM
UT WOS:000317980800013
PM 23590660
ER
PT J
AU Hasserjian, RP
AF Hasserjian, R. P.
TI Acute myeloid leukemia: advances in diagnosis and classification
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Review
DE Acute myeloid leukemia; cytogenetics; mutations; bone marrow;
myelodysplastic syndrome
ID ACUTE PROMYELOCYTIC LEUKEMIA; MYELODYSPLASIA-RELATED CHANGES;
PROGNOSTIC-SIGNIFICANCE; GENE-MUTATIONS; CYTOGENETIC ABNORMALITIES;
MULTILINEAGE DYSPLASIA; POOR-PROGNOSIS; GROUP-B; AML; NUCLEOPHOSMIN
AB Acute myeloid leukemia is an aggressive myeloid neoplasm characterized by 20% myeloblasts in the blood or bone marrow. Current treatment strategies for acute myeloid leukemia are based on both patient-related parameters such as age and performance status as well as the intrinsic characteristics of particular disease subtypes. Subtyping of acute myeloid leukemia requires an integration of information from the patient's clinical history (such as any prior preleukemic myeloid neoplasm or cytotoxic potentially leukemogenic therapy), the leukemia morphology, cytogenetic findings, and the mutation status of particular genes (NPM1, FLT3, and CEBPA). In recent years, a barrage of information has become available regarding gene mutations that occur in acute myeloid leukemia and their influence on prognosis. Future therapies for acute myeloid leukemia will increasingly rely on the genetic signatures of individual leukemias and will adjust therapy to the predicted disease aggressiveness as well as employ therapies targeted against particular deregulated genetic pathways. This article reviews current standards for diagnosing and classifying acute myeloid leukemia according to the 2008 WHO Classification. Data that have subsequently accumulated regarding newly characterized gene mutations are also presented. It is anticipated that future leukemia classifications will employ a combination of karyotypic features and the gene mutation pattern to stratify patients to increasingly tailored treatment plans.
C1 Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Hasserjian, RP (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 02114 USA.
EM rhasserjian@partners.org
NR 34
TC 14
Z9 15
U1 0
U2 27
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD JUN
PY 2013
VL 35
IS 3
SI SI
BP 358
EP 366
DI 10.1111/ijlh.12081
PG 9
WC Hematology
SC Hematology
GA 131GM
UT WOS:000317980800019
PM 23590662
ER
PT J
AU Tong, MJ
Brugeaud, A
Edge, ASB
AF Tong, Mingjie
Brugeaud, Aurore
Edge, Albert S. B.
TI Regenerated Synapses Between Postnatal Hair Cells and Auditory Neurons
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE synaptic regeneration; auditory neurons; hair cells; VGLUT3;
neurotrophins
ID SPIRAL GANGLION NEURONS; VESICULAR GLUTAMATE TRANSPORTER-3; IN-VITRO;
POSTSYNAPTIC PROTEINS; RIBBON SYNAPSE; HEARING-LOSS; MUTANT MICE;
TIME-COURSE; EAR; NEUROTROPHINS
AB Regeneration of synaptic connections between hair cells and spiral ganglion neurons would be required to restore hearing after neural loss. Here we demonstrate by immunohistochemistry the appearance of afferent-like cochlear synapses in vitro after co-culture of de-afferented organ of Corti with spiral ganglion neurons from newborn mice. The glutamatergic synaptic complexes at the ribbon synapse of the inner hair cell contain markers for presynaptic ribbons and postsynaptic densities. We found postsynaptic density protein PSD-95 at the contacts between hair cells and spiral ganglion neurons in newly formed synapses in vitro. The postsynaptic proteins were directly facing the CtBP2-positive presynaptic ribbons of the hair cells. BDNF and NT-3 promoted afferent synaptogenesis in vitro. Direct juxtaposition of the postsynaptic densities with the components of the preexisting ribbon synapse indicated that growing fibers recognized components of the presynaptic sites. Initiation of cochlear synaptogenesis appeared to be influenced by glutamate release from the hair cell ribbons at the presynaptic site since the synaptic regeneration was impaired in glutamate vesicular transporter 3 mutant mice. These insights into cochlear synaptogenesis could be relevant to regenerative approaches for neural loss in the cochlea.
C1 [Tong, Mingjie; Brugeaud, Aurore; Edge, Albert S. B.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Tong, Mingjie; Brugeaud, Aurore; Edge, Albert S. B.] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Edge, Albert S. B.] Harvard Univ, Div Hlth Sci & Technol, Program Speech & Hearing Biosci & Technol, Cambridge, MA 02139 USA.
[Edge, Albert S. B.] MIT, Cambridge, MA 02139 USA.
RP Edge, ASB (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM alber-t_edge@meei.harvard.edu
FU National Institute on Deafness and other Communicative Disorders [RO1
DC007174, P30 DC05209]
FX We thank Robert Edwards and Rebecca Seal (University of California, San
Francisco) for the VGLUT3 knockout mouse. This work was supported by
grants from the National Institute on Deafness and other Communicative
Disorders (RO1 DC007174 and P30 DC05209).
NR 51
TC 20
Z9 21
U1 0
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
J9 JARO-J ASSOC RES OTO
JI JARO
PD JUN
PY 2013
VL 14
IS 3
BP 321
EP 329
DI 10.1007/s10162-013-0374-3
PG 9
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 138IL
UT WOS:000318502100003
PM 23423560
ER
PT J
AU Lewis, RF
Nicoucar, K
Gong, WS
Haburcakova, C
Merfeld, DM
AF Lewis, Richard F.
Nicoucar, Keyvan
Gong, Wangsong
Haburcakova, Csilla
Merfeld, Daniel M.
TI Adaptation of Vestibular Tone Studied with Electrical Stimulation of
Semicircular Canal Afferents
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE vestibular; nystagmus; compensation; adaptation; electrical stimulation
ID VESTIBULOOCULAR REFLEX; GUINEA-PIG; UNILATERAL LABYRINTHECTOMY;
DISCHARGE REGULARITY; SQUIRREL-MONKEY; COMPENSATION; RECOVERY;
PROSTHESIS; PLASTICITY; NEURONS
AB Damage to one vestibular labyrinth or nerve causes a central tone imbalance, reflected by prominent spontaneous nystagmus. Central adaptive mechanisms eliminate the nystagmus over several days, and the mechanisms underlying this process have received extensive study. The characteristics of vestibular compensation when the tone imbalance is presented gradually or repeatedly have never been studied. We used high-frequency electrical stimulation of semicircular canal afferents to generate a vestibular tone imbalance and recorded the nystagmus produced when the stimulation was started abruptly or gradually and when it was repeatedly cycled on and off. In the acute-onset protocol, brisk nystagmus occurred when stimulation started, gradually resolved within 1 day, and reversed direction when the stimulation was stopped after 1 week. Repeated stimulation cycles resulted in progressively smaller nystagmus responses. In the slow-onset protocol, minimal nystagmus occurred while the stimulation ramped-up to its maximum rate over 12 h, but a reversal still occurred when the stimulation was stopped after 1 week, and repeated stimulation cycles did not affect this pattern. The absence of nystagmus during the 12 h ramp of stimulation demonstrates that central vestibular tone can rebalance relatively quickly, and the reduction in the stimulation-off nystagmus with repeated cycles of the acute-onset but not the slow-onset stimulation suggests that dual-state adaptation may have occurred with the former paradigm but not the latter.
C1 [Lewis, Richard F.; Nicoucar, Keyvan; Gong, Wangsong; Haburcakova, Csilla; Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Lewis, Richard F.; Nicoucar, Keyvan; Haburcakova, Csilla; Merfeld, Daniel M.] Harvard Univ, Sch Med, Boston, MA USA.
[Lewis, Richard F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Lewis, RF (reprint author), Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
EM Richard_lewis@meei.harvard.edu
FU Geneva Charity Foundation; Swiss Foundation [PASMP3-123225]; Swiss
National Science Foundation; National Institute of Deafness and Other
Communication Disorders [DC-6909, DC-8362, DC-8167]; European Commission
[225929]
FX We thank S. Fukuda, M. Saginaw, and J-P Guyot. This work was supported
by the Geneva Charity Foundation "Valeria Rossi di Montelera" and the
Swiss Foundation for Fellowships in Medicine and Biology (PASMP3-123225)
in collaboration with the Swiss National Science Foundation (K.
Nicoucar); by the National Institute of Deafness and Other Communication
Disorders Grants DC-6909 and DC-8362 to R. F. Lewis and DC-8167 to D. M.
Merfeld; and by the European Commission contract 225929 to D. M.
Merfeld.
NR 36
TC 8
Z9 8
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
J9 JARO-J ASSOC RES OTO
JI JARO
PD JUN
PY 2013
VL 14
IS 3
BP 331
EP 340
DI 10.1007/s10162-013-0376-1
PG 10
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 138IL
UT WOS:000318502100004
PM 23423561
ER
PT J
AU Hancock, KE
Chung, Y
Delgutte, B
AF Hancock, Kenneth E.
Chung, Yoojin
Delgutte, Bertrand
TI Congenital and Prolonged Adult-Onset Deafness Cause Distinct
Degradations in Neural ITD Coding with Bilateral Cochlear Implants
SO JARO-JOURNAL OF THE ASSOCIATION FOR RESEARCH IN OTOLARYNGOLOGY
LA English
DT Article
DE binaural hearing; congenital deafness; inferior colliculus; cochlear
implants; ITD
ID MEDIAL SUPERIOR OLIVE; INTRACOCHLEAR ELECTRICAL-STIMULATION;
EXPERIENCE-DEPENDENT PLASTICITY; BINAURAL RESPONSE PROPERTIES;
INTERAURAL TIME DIFFERENCES; CAT INFERIOR COLLICULUS; LOW-FREQUENCY
NEURONS; AUDITORY-NERVE; SOUND LOCALIZATION; TEMPORAL RESOLUTION
AB Bilateral cochlear implant (CI) users perform poorly on tasks involving interaural time differences (ITD), which are critical for sound localization and speech reception in noise by normal-hearing listeners. ITD perception with bilateral CI is influenced by age at onset of deafness and duration of deafness. We previously showed that ITD coding in the auditory midbrain is degraded in congenitally deaf white cats (DWC) compared to acutely deafened cats (ADC) with normal auditory development (Hancock et al., J. Neurosci, 30:14068). To determine the relative importance of early onset of deafness and prolonged duration of deafness for abnormal ITD coding in DWC, we recorded from single units in the inferior colliculus of cats deafened as adults 6 months prior to experimentation (long-term deafened cats, LTDC) and compared neural ITD coding between the three deafness models. The incidence of ITD-sensitive neurons was similar in both groups with normal auditory development (LTDC and ADC), but significantly diminished in DWC. In contrast, both groups that experienced prolonged deafness (LTDC and DWC) had broad distributions of best ITDs around the midline, unlike the more focused distributions biased toward contralateral-leading ITDs present in both ADC and normal-hearing animals. The lack of contralateral bias in LTDC and DWC results in reduced sensitivity to changes in ITD within the natural range. The finding that early onset of deafness more severely degrades neural ITD coding than prolonged duration of deafness argues for the importance of fitting deaf children with sound processors that provide reliable ITD cues at an early age.
C1 [Hancock, Kenneth E.; Chung, Yoojin; Delgutte, Bertrand] Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
[Hancock, Kenneth E.; Chung, Yoojin; Delgutte, Bertrand] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Delgutte, Bertrand] MIT, Elect Res Lab, Cambridge, MA 02139 USA.
RP Hancock, KE (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, Boston, MA 02114 USA.
EM ken_hancock@meei.harvard.edu
OI , /0000-0003-1349-9608; Chung, Yoojin/0000-0002-8772-5308
FU NIDCD [R01 DC005775, P30 DC005209]
FX We are grateful to Dr. David Ryugo for providing deaf white cats from
his colony and to Connie Miller for the expert surgical assistance. We
would also like to thank Evan Foss and Ishmael Stefanov-Wagner for
development of custom current sources, based on a design generously
shared by Chris van den Honert. This work was supported by NIDCD Grants
R01 DC005775 and P30 DC005209.
NR 73
TC 8
Z9 8
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1525-3961
J9 JARO-J ASSOC RES OTO
JI JARO
PD JUN
PY 2013
VL 14
IS 3
BP 393
EP 411
DI 10.1007/s10162-013-0380-5
PG 19
WC Neurosciences; Otorhinolaryngology
SC Neurosciences & Neurology; Otorhinolaryngology
GA 138IL
UT WOS:000318502100008
PM 23462803
ER
PT J
AU Etingen, B
LaVela, SL
Miskevics, S
Goldstein, B
AF Etingen, Bella
LaVela, Sherri L.
Miskevics, Scott
Goldstein, Barry
TI Health Information During the H1N1 Influenza Pandemic: Did the Amount
Received Influence Infection Prevention Behaviors?
SO JOURNAL OF COMMUNITY HEALTH
LA English
DT Article
DE H1N1 influenza; Vaccine; Pandemic; Veteran; Spinal cord injuries
ID RISK PERCEPTION; VACCINE UPTAKE; NETHERLANDS; A(H1N1); PREPAREDNESS
AB In the wake of uncertainty due to the H1N1 influenza pandemic, amount and sources of H1N1-related information were examined in a cohort at high-risk for respiratory complications. Factors associated with adequate amount of information were identified. A cross-sectional mailed survey was conducted in 2010 with veterans with spinal cord injuries and disorders. Bivariate comparisons assessed adequate H1N1-realted information versus not enough and too much. Multivariate regression identified variables associated with receipt of adequate information. A greater proportion who received adequate versus not enough information received H1N1 vaccination (61.87 vs. 48.49 %, p < 0.0001). A greater proportion who received adequate versus too much information received seasonal vaccination (84.90 vs. 71.02 %, p < 0.0001) and H1N1 vaccination (61.87 vs. 42.45 %, p < 0.0001). Variables associated with greater odds of receiving adequate information included being white, a college graduate, and having VA health professionals as their primary information source. Receiving adequate information was associated with lower odds of staying home with flu/flu-like symptoms, and higher odds of H1N1 vaccine receipt and wearing a facemask. Receiving appropriate amounts of information from valid sources may impact adherence to infection control recommendations during pandemics. Findings can be used to facilitate efforts ensuring information is received by high-risk populations.
C1 [Etingen, Bella; LaVela, Sherri L.; Miskevics, Scott] Hines VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Etingen, Bella; LaVela, Sherri L.; Miskevics, Scott; Goldstein, Barry] Hines VA Hosp, Spinal Cord Injury Qual Enhancement Res Initiat, Hines, IL 60141 USA.
[LaVela, Sherri L.] Northwestern Univ, Feinberg Sch Med, Inst Healthcare Studies, Chicago, IL 60611 USA.
[Goldstein, Barry] VA Puget Sound Healthcare Syst, Seattle, WA USA.
[Goldstein, Barry] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
RP Etingen, B (reprint author), Hines VA Hosp, Ctr Management Complex Chron Care, 5000 S 5th Ave 151H, Hines, IL 60141 USA.
EM Bella.Etingen@va.gov
NR 20
TC 2
Z9 2
U1 1
U2 18
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0094-5145
J9 J COMMUN HEALTH
JI J. Community Health
PD JUN
PY 2013
VL 38
IS 3
BP 443
EP 450
DI 10.1007/s10900-012-9647-8
PG 8
WC Health Policy & Services; Public, Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA 136PJ
UT WOS:000318373500005
PM 23269499
ER
PT J
AU Harris, E
McNamara, P
Durso, R
AF Harris, Erica
McNamara, Patrick
Durso, Raymon
TI Apathy in Patients With Parkinson Disease as a Function of Side of Onset
SO JOURNAL OF GERIATRIC PSYCHIATRY AND NEUROLOGY
LA English
DT Article
DE apathy; Parkinson's disease; dopamine; side of onset; dementia
ID ANXIETY STRESS SCALES; BASAL GANGLIA; RATING-SCALE; COGNITIVE
IMPAIRMENT; SYMPTOM ONSET; DEPRESSION; AWARENESS; ASYMMETRY; PREDICTION;
INVENTORY
AB Background: In previous studies among patients with Parkinson disease (PD) who were administered the Apathy Evaluation Scale (AES), between 12% and 51% evidenced clinically significant apathy. Although apathy is a risk factor for dementia, its causes and clinical correlates have not been adequately studied. In particular, side of onset of disease, though a likely predictor of apathy and dementia, has not been thoroughly investigated. Methods: A total of 30 mid-stage patients with PD and 35 community-dwelling elderly control patients (CPs) were administered the AES (self version) along with a battery of cognitive and neuropsychiatric assessments. Persons close to patients with PD and CPs completed the AES-other (informant) version about the patient or CP. Multiple linear regression analysis examined predictors of apathy severity after controlling for mood, levodopa dosage equivalents (LDEs), gender, age, and disease severity (Hoehn-Yahr [H-Y] stage). Results: Patients with right-onset disease more frequently exhibited apathy and evidenced significantly higher total AES scores than left-onset patients with PD or CPs (P < .03). Of all the patients, 42% with right-onset PD versus 11.1% of the patients with left-onset PD exhibited clinically significant levels of apathy. There were no differences for self versus informant scores for right-onset patients with PD. The AES scores were not correlated with depression, stress, anxiety, LDEs, gender, age, and H-Y stage. There were no gender differences for any AES variables. Conclusion: Clinically significant levels of apathy are much more likely to occur in patients with right-onset disease. These patients may be at greater risk of PD-related dementia.
C1 [Harris, Erica] USN, Dept Behav Sci & Epidemiol, Hlth Res Ctr, San Diego, CA 92106 USA.
[McNamara, Patrick; Durso, Raymon] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[McNamara, Patrick; Durso, Raymon] VA Boston Healthcare Syst, Dept Neurol, Boston, MA USA.
[McNamara, Patrick] Northcent Univ, Prescott Valley, AZ USA.
RP Harris, E (reprint author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.
EM Erica.Harris@med.navy.mil
FU National Institute on Deafness and Other Communication Disorders; Office
of Research and Development, Medical Research Service, Department of
Veterans Affairs
FX Both the Boston University Medical Center (BUMC) and Boston Veterans
Affairs Medical Center (VAMC) institutional review boards approved this
study. Some material contained within this manuscript was previously
published in Harris, E. Neurocognition and self-regulation of the
agentic self in patients with Parkinson's disease (Doctoral
dissertation). Boston University, Boston, MA; 2011. Dr Harris owns the
copyright to this material. This study is based upon work supported, in
part, by the Office of Research and Development, Medical Research
Service, Department of Veterans Affairs.; The author(s) disclosed
receipt of the following financial support for the research, authorship,
and/or publication of this article: This work was supported by the
National Institute on Deafness and Other Communication Disorders.
Competing Interests. There are no competing interests among any of the
authors, financial or otherwise.
NR 68
TC 8
Z9 8
U1 2
U2 14
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 0891-9887
J9 J GERIATR PSYCH NEUR
JI J. Geriatr. Psychiatry Neurol.
PD JUN
PY 2013
VL 26
IS 2
BP 95
EP 104
DI 10.1177/0891988713481267
PG 10
WC Geriatrics & Gerontology; Clinical Neurology; Psychiatry
SC Geriatrics & Gerontology; Neurosciences & Neurology; Psychiatry
GA 135LN
UT WOS:000318289700005
PM 23584852
ER
PT J
AU Peralta, CA
Weekley, CC
Li, YM
Shlipak, MG
AF Peralta, Carmen A.
Weekley, Cristin C.
Li, Yongmei
Shlipak, Michael G.
TI Occult chronic kidney disease among persons with hypertension in the
United States: data from the national health and nutrition surveys
1988-1994 and 1999-2002
SO JOURNAL OF HYPERTENSION
LA English
DT Article
DE albumin-to-creatinine ratio; chronic kidney disease; cystatin C;
National Health and Nutrition Examination Survey
ID GLOMERULAR-FILTRATION-RATE; HIGH BLOOD-PRESSURE; CYSTATIN-C; SERUM
CREATININE; CARDIOVASCULAR EVENTS; NHANES; NEPHROSCLEROSIS; ALBUMINURIA;
ASSOCIATION; POPULATION
AB Objectives: Hypertension guidelines recommend screening for chronic kidney disease (CKD) using serum creatinine and urine dipstick; this strategy may lead to misclassification. Persons with occult CKD [i.e. missed by creatinine but detected by cystatin C or albumin-to-creatinine ratio (ACR)] have higher risks for death, cardiovascular events, and end-stage renal disease.
Methods: We studied occult CKD prevalence among nondiabetic, hypertensive adults in National Health and Nutrition Examination Survey 1988-1994 (N = 2088) and 1999-2002 (N = 737). We defined occult CKD as estimated glomerular filtration rate by cystatin C (eGFRcys) less than 60 ml/min per 1.73 m(2) and/or ACR at least 30 mg/g among persons with eGFRcreat more than 60 ml/min per 1.73 m(2). We studied occult CKD prevalence by either marker, stratified by age, race/ethnicity, and assessed clinical predictors associated with occult CKD presence.
Results: In 1988-1994, occult CKD was prevalent among 25% of nondiabetic hypertensive persons, and it was 22% in 1999-2002. Each marker's ability to detect occult CKD varied by age and race. Cystatin C detected occult CKD among 8.9% of persons more than 65 years, and among 3.8% of whites. ACR detected occult CKD among 9.3% of persons less than 45 years, 16.6% of Blacks, and 20.6% of Mexican-Americans. In multivariate models, each decade of advancing age was associated with a higher occult CKD prevalence by cystatin C (OR 3.1, 95% CI 2.5-3.8) in 1988-1994 and 1999-2002 (OR 2.9, 1.8-4.6).
Conclusion: Current hypertension guidelines may fail to detect a large proportion of high-risk individuals with CKD who can be identified by cystatin C or ACR. Future studies are needed to evaluate targeted use of multimarker renal panels among hypertensives.
C1 [Peralta, Carmen A.; Weekley, Cristin C.; Shlipak, Michael G.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Weekley, Cristin C.; Li, Yongmei; Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA.
RP Peralta, CA (reprint author), 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM carmenalicia.peralta@ucsf.edu
FU National Institutes of Diabetes and Digestive and Kidney Diseases
[1K23SK082793-01]; Robert Wood Johnson Harold Amos award
FX C.A.P. is funded by the National Institutes of Diabetes and Digestive
and Kidney Diseases 1K23SK082793-01 and a Robert Wood Johnson Harold
Amos award. These funding sources had no involvement in the design or
execution of this study.
NR 23
TC 4
Z9 6
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0263-6352
J9 J HYPERTENS
JI J. Hypertens.
PD JUN
PY 2013
VL 31
IS 6
BP 1196
EP 1202
DI 10.1097/HJH.0b013e328360ae2d
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 138XC
UT WOS:000318543900020
PM 23640605
ER
PT J
AU Lucas, MR
AF Lucas, Michele Roberta
TI What Brain Tumor Patients and Their Families Have Taught Me
SO JOURNAL OF NEUROSCIENCE NURSING
LA English
DT Article
DE brain tumor; cognitive deficits; mental health; short-term memory loss
AB The purpose of this article is to identify the experience of the patient with a World Health Organization grade III/IV and IV/IV brain tumor, and that of their family, to best understand how to treat them. It is the cumulative input of hundreds of patients and family members seen over a 20-year career of specialization at two teaching hospitals. No patient who has been diagnosed with a brain tumor, whether low grade, high grade, or benign, escapes totally unharmed because tumor existence, surgical removal, and/or toxicity of treatment combine to cause varying degrees of brain injury. Additional considerations are the variables of tumor location within the brain, the age of the patient, their premorbid intellectual capacity, and their fear and anxiety, for full understanding of the impact and the complexity of the tumor and treatment on the individual patient. The mental health provider's mandate in caring for this population is threefold: first, provide hope in what patients feel is a hopeless situation; second, serve as witness to their experience and acknowledge and validate the changes and loses that occur; and third, create empowerment in what seems a helpless situation. For the purposes of this article, further reference to brain tumors will be World Health Organization grade III/IVand IV/IV.
C1 [Lucas, Michele Roberta] Massachusetts Gen Hosp, Pappas Ctr Neurooncol, Boston, MA 02114 USA.
EM michelelucas1@verizon.net
NR 0
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0888-0395
J9 J NEUROSCI NURS
JI J. Neurosci. Nurs.
PD JUN
PY 2013
VL 45
IS 3
BP 171
EP 175
DI 10.1097/JNN.0b013e31828a40f6
PG 5
WC Clinical Neurology; Nursing
SC Neurosciences & Neurology; Nursing
GA 138BO
UT WOS:000318483500009
PM 23636071
ER
PT J
AU Lima, XT
Minnillo, R
Spencer, JM
Kimball, AB
AF Lima, X. T.
Minnillo, R.
Spencer, J. M.
Kimball, A. B.
TI Psoriasis prevalence among the 2009 AAD National Melanoma/Skin Cancer
Screening Program participants
SO JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
LA English
DT Article
ID POPULATION; ARTHRITIS; EPIDEMIOLOGY; COMMON
AB Background Validated epidemiological estimates of the prevalence of skin diseases remain an unmet challenge. Most patients in many health care systems do not see dermatologists for skin problems. Assessments based on claims data or self-report are likely to contain substantial misclassification. Population-based in-person dermatological exams have proven impractical because of the number of patients required. However, in the US, there is a large skin cancer screening program where volunteer dermatologists assess almost 100 000 people annually. Objective To evaluate the utility of this program for the assessment of other diseases. Methods Information concerning prior diagnosis of psoriasis, type of insurance and physician's current assessment of psoriasis was captured as part of the American Academy of Dermatology National Melanoma/Skin Cancer Screening Program. A modified form was provided to a subset of participant sites. Overall and subgroup prevalence of psoriasis was analysed. Crude and adjusted results are presented for comparison to the US population. Results Among the 2991 participants, 86% answered the self-report psoriasis question. A previous diagnosis of psoriasis was reported by 5.1% of them. This proportion was greater than the prevalence of physician documented diagnosis of psoriasis (2.8%). Analyses with different assumptions to account for missing values and weighting based on US population estimates yielded prevalence values ranging from 1.2% to 3.4%. Conclusion This project, although limited by missing data, is consistent with previous findings that psoriasis prevalence is between 2.2% and 4.6% in the US. It demonstrates the potential to evaluate prevalence of other skin conditions through existing national activities.
C1 [Lima, X. T.; Kimball, A. B.] Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin, Boston, MA 02114 USA.
[Minnillo, R.] Soc Investigat Dermatol, Cleveland, OH USA.
[Spencer, J. M.] Amer Acad Dermatol, Melanoma Skin Canc Comm, St Petersburg, FL USA.
RP Kimball, AB (reprint author), Massachusetts Gen Hosp, Clin Unit Res Trials & Outcomes Skin, Boston, MA 02114 USA.
EM harvardskinstudies@partners.org
FU Society for Investigative Dermatology
FX Partial support was provided by the Society for Investigative
Dermatology and administrative support was provided by the American
Academy of Dermatology.
NR 11
TC 12
Z9 12
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0926-9959
J9 J EUR ACAD DERMATOL
JI J. Eur. Acad. Dermatol. Venereol.
PD JUN
PY 2013
VL 27
IS 6
BP 680
EP 685
DI 10.1111/j.1468-3083.2012.04531.x
PG 6
WC Dermatology
SC Dermatology
GA 140FB
UT WOS:000318638700003
PM 22471885
ER
PT J
AU Caretti, V
Jansen, MHA
van Vuurden, DG
Lagerweij, T
Bugiani, M
Horsman, I
Wessels, H
van der Valk, P
Cloos, J
Noske, DP
Vandertop, WP
Wesseling, P
Wurdinger, T
Hulleman, E
Kaspers, GJL
AF Caretti, V.
Jansen, M. H. A.
van Vuurden, D. G.
Lagerweij, T.
Bugiani, M.
Horsman, I.
Wessels, H.
van der Valk, P.
Cloos, J.
Noske, D. P.
Vandertop, W. P.
Wesseling, P.
Wurdinger, T.
Hulleman, E.
Kaspers, G. J. L.
TI Implementation of a multi-institutional diffuse intrinsic pontine glioma
autopsy protocol and characterization of a primary cell culture
SO NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY
LA English
DT Article
DE autopsy; brain neoplasms; brainstem neoplasms; cells cultured; disease
models animal; pontine glioma
ID STEREOTACTIC BIOPSY; CLINICAL-TRIALS; IN-VIVO; CHILDREN; TUMORS; LINES;
GLIOBLASTOMAS; CHILDHOOD; MODELS; GROWTH
AB V. Caretti, M. H. A. Jansen, D. G. van Vuurden, T. Lagerweij, M. Bugiani, I. Horsman, H. Wessels, P. van der Valk, J. Cloos, D. P. Noske, W. P. Vandertop, P. Wesseling, T. Wurdinger, E. Hulleman and G. J. L. Kaspers (2013) Neuropathology and Applied Neurobiology39, 426436 Implementation of a multi-institutional diffuse intrinsic pontine glioma autopsy protocol and characterization of a primary cell culture Aims: Diffuse intrinsic pontine glioma (DIPG) is a fatal paediatric malignancy. Tumour resection is not possible without serious morbidity and biopsies are rarely performed. The resulting lack of primary DIPG material has made preclinical research practically impossible and has hindered the development of new therapies for this disease. The aim of the current study was to address the lack of primary DIPG material and preclinical models by developing a multi-institutional autopsy protocol. Methods: An autopsy protocol was implemented in the Netherlands to obtain tumour material within a brief post mortem interval. A team of neuropathologists and researchers was available at any time to perform the autopsy and process the material harvested. Whole brain autopsy was performed and primary DIPG material and healthy tissue were collected from all affected brain areas. Finally, the study included systematic evaluation by parents. Results: Five autopsies were performed. The mean time interval between death and time of autopsy was 3h (range 24). All tumours were graded as glioblastoma. None of the parents regretted their choice to participate, and they all derived comfort in donating tissue of their child in the hope to help future DIPG patients. In addition, we developed and characterized one of the first DIPG cell cultures from post mortem material. Conclusion: Here we show that obtaining post mortem DIPG tumour tissue for research purposes is feasible with short delay, and that the autopsy procedure is satisfying for participating parents and can be suitable for the development of preclinical DIPG models.
C1 [Caretti, V.; Jansen, M. H. A.; van Vuurden, D. G.; Lagerweij, T.; Cloos, J.; Hulleman, E.; Kaspers, G. J. L.] Vrije Univ Amsterdam, Med Ctr, Dept Pediat Oncol, NL-1081 HZ Amsterdam, Netherlands.
[Caretti, V.; Lagerweij, T.; Noske, D. P.; Vandertop, W. P.; Wurdinger, T.] Vrije Univ Amsterdam, Med Ctr, Neurosurg Ctr Amsterdam, NL-1081 HZ Amsterdam, Netherlands.
[Caretti, V.; Jansen, M. H. A.; van Vuurden, D. G.; Lagerweij, T.; Noske, D. P.; Wurdinger, T.; Hulleman, E.] Vrije Univ Amsterdam, Med Ctr, Neurooncol Res Grp, NL-1081 HZ Amsterdam, Netherlands.
[Bugiani, M.; van der Valk, P.; Wesseling, P.] Vrije Univ Amsterdam, Med Ctr, Dept Pathol, NL-1081 HZ Amsterdam, Netherlands.
[Horsman, I.; Wessels, H.] Vrije Univ Amsterdam, Med Ctr, Dept Clin Genet, NL-1081 HZ Amsterdam, Netherlands.
[Wesseling, P.] Radboud Univ Nijmegen, Med Ctr, Dept Pathol, NL-6525 ED Nijmegen, Netherlands.
[Wurdinger, T.] Massachusetts Gen Hosp, Dept Neurol, Mol Neurogenet Unit, Boston, MA 02114 USA.
[Wurdinger, T.] Harvard Univ, Sch Med, Boston, MA USA.
RP Jansen, MHA (reprint author), Vrije Univ Amsterdam, Med Ctr, Room PK 4x027,De Boelelaan 1118, NL-1081 HZ Amsterdam, Netherlands.
EM mh.jansen@vumc.nl
RI Wesseling, P./H-8114-2014;
OI Wesseling, P./0000-0001-5453-5201; Lagerweij, Tonny/0000-0003-1043-7452;
Van Vuurden, Dannis/0000-0002-1364-9007
FU Semmy Foundation; Semmy foundation fund
FX Diffuse intrinsic pontine glioma research at our institution would have
been impossible without the generous donations of the brain tissue
material by parents and the support of the Semmy Foundation. We thank
the Dutch Childhood Oncology Group for critically reviewing the autopsy
research protocol. Further we thank our colleagues Dr C. E.
Catsman-Berrevoets and Dr R. Reddingius (Erasmus Medical Center
Rotterdam), Dr J.H. Schieving and Dr C. E. Gidding (Radboud University
Nijmegen Medical Centre), Dr J.M. Fock and Dr E.S.J.M. de Bont
(University Medical Center Groningen) and Dr I. M. Snoeck (Juliana
Children's Hospital The Hague) for referring patients for autopsy. DIPG
research is funded by the Semmy foundation fund. The sponsors had no
role in the preparation and execution of the study and/or manuscript.
NR 31
TC 8
Z9 8
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0305-1846
J9 NEUROPATH APPL NEURO
JI Neuropathol. Appl. Neurobiol.
PD JUN
PY 2013
VL 39
IS 4
BP 426
EP 436
DI 10.1111/j.1365-2990.2012.01294.x
PG 11
WC Clinical Neurology; Neurosciences; Pathology
SC Neurosciences & Neurology; Pathology
GA 137HI
UT WOS:000318425900009
PM 22845849
ER
PT J
AU Hemingway, M
Morrissey, L
AF Hemingway, Maureen
Morrissey, Lisa
TI Development of a Complex Orientation Program for Multidisciplinary
Training
SO AORN JOURNAL
LA English
DT Article
DE orientation; multidisciplinary education; information technology;
simulation
AB Providing complex orientation and multidisciplinary training for perioperative personnel of a newly constructed health care facility with new surgical suites proved both challenging and valuable to nurse leaders. Despite the need for such training, a program to teach groups across all disciplines regarding technological advances specific to the OR and to orient them to a new facility did not exist previously. To address this, we developed a multiphase educational initiative that involved orientation, technology training, and multidisciplinary simulation. The project required extensive planning, high-level collaboration, and use of the hospital's information technology systems, all while staff members continued to provide care for patients undergoing surgically complex procedures. The successful implementation of this program ensured that staff members were proficient in new OR technology and oriented to the new facility before occupancy began. (C) AORN, Inc, 2013.
C1 [Hemingway, Maureen; Morrissey, Lisa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Hemingway, M (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 2
TC 0
Z9 0
U1 2
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0001-2092
J9 ASSOC OPER ROOM NURS
JI AORN J.
PD JUN
PY 2013
VL 97
IS 6
BP 718
EP 727
DI 10.1016/j.aorn.2013.04.011
PG 10
WC Nursing
SC Nursing
GA V42XV
UT WOS:000209647400010
PM 23722036
ER
PT J
AU Gray, PJ
Efstathiou, JA
AF Gray, Phillip J.
Efstathiou, Jason A.
TI Proton Beam Radiation Therapy for Prostate Cancer-Is the Hype (and the
Cost) Justified?
SO CURRENT UROLOGY REPORTS
LA English
DT Article
DE Prostate cancer; Proton beam therapy; Particle therapy; IMRT;
Comparative effectiveness; Cost
ID INTENSITY-MODULATED RADIOTHERAPY; RANDOMIZED CONTROLLED-TRIAL; LATE
RECTAL TOXICITY; PHASE-II; CONFORMAL RADIOTHERAPY; DOSE-ESCALATION;
BOOST THERAPY; PHOTON; RISK; TESTOSTERONE
AB Although in use for over 40 years, proton beam therapy for prostate cancer has only recently come under public scrutiny, due to its increased cost compared to other forms of treatment. While the last decade has seen a rapid accumulation of evidence to suggest that proton beam therapy is both safe and effective in this disease site, a rigorous comparison to other radiotherapy techniques has not yet been completed. In this review, we provide an in-depth look at the evidence both supporting and questioning proton beam therapy's future role in the treatment of prostate cancer, with emphasis on its history, physical properties, comparative clinical and cost effectiveness, advances in its delivery and future promise.
C1 [Gray, Phillip J.] Harvard Radiat Oncol Program, Boston, MA USA.
[Efstathiou, Jason A.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
RP Efstathiou, JA (reprint author), Massachusetts Gen Hosp, Dept Radiat Oncol, 100 Blossom St,Cox 3, Boston, MA 02114 USA.
EM jefstathiou@partners.org
NR 64
TC 5
Z9 5
U1 2
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1527-2737
J9 CURR UROL REP
JI Curr. Urol. Rep.
PD JUN
PY 2013
VL 14
IS 3
BP 199
EP 208
DI 10.1007/s11934-013-0320-2
PG 10
WC Urology & Nephrology
SC Urology & Nephrology
GA AI1FK
UT WOS:000336595500006
PM 23546839
ER
PT J
AU Quinones, AR
Liang, J
Ye, W
AF Quinones, Ana R.
Liang, Jersey
Ye, Wen
TI DIFFERENCES IN DIABETES MELLITUS ONSET FOR OLDER BLACK, WHITE, AND
MEXICAN AMERICANS
SO ETHNICITY & DISEASE
LA English
DT Article
DE Ethnic Differences; Diabetes Mellitus Incidence; Discrete-Time Survival
Analysis
ID RISK-FACTORS; HEALTH; PREVALENCE; DISEASE; ADULTS; COHORT
AB Objectives: Our research examines the differences in estimated odds of developing diabetes mellitus for White, Black, and Mexican Americans age 51 and over for a period of 11 years.
Design, Setting, and Participants: Longitudinal data came from 14,783 respondents of the Health and Retirement Study (1995-2006) who reported being diabetes-free at the first time period. Discrete-time survival models were used to analyze ethnic variations in the probability of developing diabetes.
Main Outcome Measure: Estimated odds of developing diabetes mellitus.
Results: The odds of newly diagnosed diabetes increased between 1995 and 2006, with 11% cumulative incidence for all study participants. The probability of incident diabetes among Black Americans was .01 during the period of 1995/96-1998, which increased to .03 during 1998-2000 and remained at .03 throughout subsequent periods, with cumulative incidence over the 11 years at 12%. In contrast, for Mexican Americans the probability more than doubled from .02 in 1995/96-1998 to .05 in 2004-2006, with cumulative incidence at 19%. White Americans had 11% cumulative incidence during the 11 year period.
Conclusions: Relative to White Americans, Mexican Americans had significantly elevated odds of developing diabetes throughout the 11-year period of observation even after controlling for differences in demographic, socioeconomic, and time-varying health characteristics.
C1 [Quinones, Ana R.] Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, Portland, OR 97239 USA.
[Quinones, Ana R.] Portland VA Med Ctr, Portland, OR USA.
[Liang, Jersey] Univ Michigan, Dept Hlth Management & Policy, Ann Arbor, MI 48109 USA.
[Ye, Wen] Univ Michigan, Dept Biostat, Ann Arbor, MI 48109 USA.
RP Quinones, AR (reprint author), Oregon Hlth & Sci Univ, Dept Publ Hlth & Prevent Med, 3181 SW Sam Jackson Pk Rd,CB669, Portland, OR 97239 USA.
EM quinones@ohsu.edu
FU National Institute On Aging [F31-AG029783, R36AG031570, R01-AG015124,
R01-AG028116]
FX This research was supported by the National Institute On Aging grants
F31-AG029783 and R36AG031570 (Ana Quinones, PI), R01-AG015124 and
R01-AG028116 (Jersey Liang, PI). The content is solely the
responsibility of the author and does not necessarily represent the
official views of the National Institute on Aging or the National
Institutes of Health. We thank Joan Bennett, Xiao Xu, and Alexis Dinno.
NR 21
TC 2
Z9 2
U1 2
U2 2
PU INT SOC HYPERTENSION BLACKS-ISHIB
PI ATLANTA
PA 100 AUBURN AVE NE STE 401, ATLANTA, GA 30303-2527 USA
SN 1049-510X
EI 1945-0826
J9 ETHNIC DIS
JI Ethn. Dis.
PD SUM
PY 2013
VL 23
IS 3
BP 310
EP 315
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AQ7QV
UT WOS:000343015200007
PM 23914416
ER
PT J
AU Talbert, J
Chan, ED
AF Talbert, Janet
Chan, Edward D.
TI The association between body shape and nontuberculous mycobacterial lung
disease
SO EXPERT REVIEW OF RESPIRATORY MEDICINE
LA English
DT Editorial Material
DE bronchiectasis; environmental mycobacteria; Marfan syndrome;
nontuberculous mycobacteria; pectus excavatum; scoliosis
ID SHPRINTZEN-GOLDBERG SYNDROME; PULMONARY-DISEASE; MARFANS-SYNDROME; AVIUM
COMPLEX; INFECTION; MUTATIONS; TUBERCULOSIS; ANOMALIES; DOMINANT; GROWTH
C1 [Talbert, Janet] Univ Colorado Denver, Natl Jewish Hlth, Dept Med, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Denver Vet Affairs Med Ctr, Denver, CO 80217 USA.
[Chan, Edward D.] Univ Colorado Denver, Dept Med, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Natl Jewish Hlth, Cell Biol Program, Denver, CO USA.
[Chan, Edward D.] Univ Colorado Denver, Div Pulm Sci & Crit Care Med, Denver, CO USA.
RP Chan, ED (reprint author), Univ Colorado Denver, Denver Vet Affairs Med Ctr, Anschutz Med Campus, Denver, CO 80217 USA.
EM chane@njhealth.org
NR 31
TC 2
Z9 2
U1 1
U2 1
PU EXPERT REVIEWS
PI LONDON
PA UNITEC HOUSE, 3RD FL, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON N3 1QB,
ENGLAND
SN 1747-6348
EI 1747-6356
J9 EXPERT REV RESP MED
JI Expert Rev. Respir. Med.
PD JUN
PY 2013
VL 7
IS 3
BP 201
EP 204
DI 10.1586/ERS.13.23
PG 4
WC Respiratory System
SC Respiratory System
GA AI8RF
UT WOS:000337190100002
PM 23734642
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI PEGYLATED INTERFERON ALFA, NITAZOXANIDE, TELAPREVIR, RIBAVIRIN, IN
GENOTYPE 1 UNDERGOING PRIOR EXPERIENCED CHC-A RANDOMIZED PLACEBO CONTROL
CLINICAL PILOT TRIAL (INTRIGUE-C)
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
[Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A183
EP A184
DI 10.1136/gutjnl-2013-304907.417
PG 3
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600311
ER
PT J
AU Basu, P
Shah, NJ
Farhat, S
Siriki, R
Mittimanj, K
Rahaman, M
Atluri, S
AF Basu, P.
Shah, N. J.
Farhat, S.
Siriki, R.
Mittimanj, K.
Rahaman, M.
Atluri, S.
TI RESTLESS LEG SYNDROME, (RLS) IS ASSOCIATED WITH HEPATIC ENCEPHALOPATHY
(HE) IN DECOMPENSATED CIRRHOSIS. A CLINICAL PILOT STUDY
SO GUT
LA English
DT Meeting Abstract
CT Annual General Meeting of the British-Society-of-Gastroenterology
CY JUN 24-27, 2013
CL Glasgow, SCOTLAND
SP British Soc Gastroenterol
C1 [Basu, P.; Farhat, S.] Columbia Sch Phys & Surg, New York, NY USA.
[Basu, P.; Siriki, R.; Mittimanj, K.; Rahaman, M.; Atluri, S.] Forest Hills Hosp, Hofstra North Shore LIJ Sch Med, Flushing, NY USA.
[Shah, N. J.] James J Peters VA Med Ctr, Mt Sinai Sch Med, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0017-5749
EI 1468-3288
J9 GUT
JI Gut
PD JUN
PY 2013
VL 62
SU 1
BP A182
EP A183
DI 10.1136/gutjnl-2013-304907.415
PG 2
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AA6SF
UT WOS:000331227600309
ER
PT J
AU Devkota, S
AF Devkota, Suzanne
TI Dietary Manipulation of the Gut Microbiota and Its Implications for
Tailored Therapies.
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Meeting Abstract
C1 [Devkota, Suzanne] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
EM Suzanne.Devkota@joslin.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JUN
PY 2013
VL 49
SU 1
MA A-2
BP S5
EP S5
PG 1
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA V41LL
UT WOS:000209547600012
ER
PT J
AU Izard, J
AF Izard, Jacques
TI Diversity, Networking and Metabolic Potential of the Digestive Tract of
the Healthy Individuals.
SO IN VITRO CELLULAR & DEVELOPMENTAL BIOLOGY-ANIMAL
LA English
DT Meeting Abstract
C1 [Izard, Jacques] Harvard Univ, Sch Dent Med Cambridge, Forsyth Inst, Dept Microbiol, Cambridge, MA 02138 USA.
EM jizard@forsyth.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1071-2690
EI 1543-706X
J9 IN VITRO CELL DEV-AN
JI In Vitro Cell. Dev. Biol.-Anim.
PD JUN
PY 2013
VL 49
SU 1
MA A-3
BP S5
EP S6
PG 2
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA V41LL
UT WOS:000209547600013
ER
PT J
AU Januzzi, J
Felker, GM
AF Januzzi, James L., Jr.
Felker, G. Michael
TI Surfing the Biomarker Tsunami at JACC: Heart Failure
SO JACC-HEART FAILURE
LA English
DT Editorial Material
DE atrial fibrillation; heart failure; natriuretic peptides
C1 [Januzzi, James L., Jr.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Felker, G. Michael] Duke Univ, Med Ctr, Durham, NC USA.
RP Januzzi, J (reprint author), Massachusetts Gen Hosp, 32 Fruit St,Yawkey 5984, Boston, MA 02114 USA.
EM jjanuzzi@partners.org
NR 8
TC 14
Z9 14
U1 0
U2 0
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD JUN
PY 2013
VL 1
IS 3
BP 213
EP 215
DI 10.1016/j.jchf.2013.03.007
PG 3
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V41GU
UT WOS:000209535500005
PM 24621872
ER
PT J
AU Kwan, GF
Bukhman, AK
Miller, AC
Ngoga, G
Mucumbitsi, J
Bavuma, C
Dusabeyezu, S
Rich, ML
Mutabazi, F
Mutumbira, C
Ngiruwera, JP
Amoroso, C
Ball, E
Fraser, HS
Hirschhorn, LR
Farmer, P
Rusingiza, E
Bukhman, G
AF Kwan, Gene F.
Bukhman, Alice K.
Miller, Ann C.
Ngoga, Gedeon
Mucumbitsi, Joseph
Bavuma, Charlotte
Dusabeyezu, Symaque
Rich, Michael L.
Mutabazi, Francis
Mutumbira, Cadet
Ngiruwera, Jean Paul
Amoroso, Cheryl
Ball, Ellen
Fraser, Hamish S.
Hirschhorn, Lisa R.
Farmer, Paul
Rusingiza, Emmanuel
Bukhman, Gene
TI A Simplified Echocardiographic Strategy for Heart Failure Diagnosis and
Management Within an Integrated Noncommunicable Disease Clinic at
District Hospital Level for Sub-Saharan Africa
SO JACC-HEART FAILURE
LA English
DT Article
DE cardiomyopathy; epidemiology; global health; health policy; hypertensive
heart disease; noncommunicable disease; rheumatic heart disease
AB Objectives This study sought to describe a decentralized strategy for heart failure diagnosis and management and report the clinical epidemiology at district hospitals in rural Rwanda.
Background Heart failure contributes significantly to noncommunicable disease burden in sub-Saharan Africa. Specialized care is provided primarily at referral hospitals by physicians, limiting patients' access. Simplifying clinical strategies can facilitate decentralization of quality care to the district hospital level and improve care delivery.
Methods Heart failure services were established within integrated advanced noncommunicable disease clinics in 2 rural district hospitals in Rwanda. Nurses, supervised by physicians, were trained to use simplified diagnostic and treatment algorithms including echocardiography with diagnoses confirmed by a cardiologist. Data on 192 heart failure patients treated between November 2006 and March 2011 were reviewed from an electronic medical record.
Results In our study population, the median age was 35 years, 70% were women, 63% were subsistence farmers, and 6% smoked tobacco. At entry, 47% had New York Heart Association class III or IV functional status. Of children age <18 years (n = 54), rheumatic heart disease (48%), congenital heart disease (39%), and dilated cardiomyopathy (9%) were the leading diagnoses. Among adults (n = 138), dilated cardiomyopathy (54%), rheumatic heart disease (25%), and hypertensive heart disease (8%) were most common. During follow-up, 62% were retained in care, whereas 9% died and 29% were lost to follow-up.
Conclusions In rural Rwanda, the causes of heart failure are almost exclusively nonischemic even though patients often present with advanced symptoms. Training nurses, supervised by physicians, in simplified protocols and basic echocardiography is 1 approach to integrated, decentralized care for this vulnerable population. (c) 2013 by the American College of Cardiology Foundation
C1 [Kwan, Gene F.; Bukhman, Alice K.; Rich, Michael L.; Fraser, Hamish S.; Hirschhorn, Lisa R.; Farmer, Paul; Bukhman, Gene] Brigham & Womens Hosp, Dept Med, Div Global Hlth Equ, Boston, MA 02115 USA.
[Kwan, Gene F.] Boston Med Ctr, Dept Med, Sect Cardiol, Boston, MA USA.
[Miller, Ann C.; Fraser, Hamish S.; Hirschhorn, Lisa R.; Farmer, Paul; Bukhman, Gene] Harvard Univ, Sch Med, Dept Global Hlth & Social Med, Boston, MA 02115 USA.
[Ngoga, Gedeon; Bavuma, Charlotte; Amoroso, Cheryl; Rusingiza, Emmanuel] Inshuti Mu Buzima, Rwinkwavu, Rwanda.
[Mucumbitsi, Joseph] King Faisal Hosp, Dept Paediat, Kigali, Rwanda.
[Bavuma, Charlotte] Ctr Hosp Univ Kigali, Dept Internal Med, Endocrinol Unit, Kigali, Rwanda.
[Bavuma, Charlotte; Dusabeyezu, Symaque; Mutabazi, Francis; Mutumbira, Cadet; Ngiruwera, Jean Paul; Rusingiza, Emmanuel; Bukhman, Gene] Minist Hlth, Kigali, Rwanda.
[Rich, Michael L.; Amoroso, Cheryl; Ball, Ellen; Fraser, Hamish S.; Hirschhorn, Lisa R.; Farmer, Paul; Bukhman, Gene] Partners Hlth, Boston, MA USA.
[Rusingiza, Emmanuel] Ctr Hosp Univ Kigali, Pediat Cardiol Unit, Dept Pediat, Kigali, Rwanda.
[Bukhman, Gene] VA Boston Healthcare Syst, Boston, MA USA.
RP Bukhman, G (reprint author), Harvard Univ, Sch Med, Dept Global Hlth & Social Med, 641 Huntington Ave, Boston, MA 02115 USA.
EM gbukhman@pih.org
RI Fraser, Hamish/E-3773-2013;
OI Kwan, Gene/0000-0002-0929-6800
NR 24
TC 12
Z9 12
U1 0
U2 1
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 2213-1779
EI 2213-1787
J9 JACC-HEART FAIL
JI JACC-Heart Fail.
PD JUN
PY 2013
VL 1
IS 3
BP 230
EP 236
DI 10.1016/j.jchf.2013.03.006
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA V41GU
UT WOS:000209535500008
PM 24621875
ER
PT J
AU Coleman, RE
Lipton, A
Costa, L
Cook, RJ
Lee, KA
Saad, F
Brown, JE
Terpos, E
Major, PP
Kohno, N
Smith, M
Body, JJ
AF Coleman, Robert E.
Lipton, Allan
Costa, Luis
Cook, Richard J.
Lee, Ker-Ai
Saad, Fred
Brown, Janet E.
Terpos, Evangelos
Major, Pierre P.
Kohno, Norio
Smith, Matthew
Body, Jean-Jacques
TI Possible survival benefits from zoledronic acid treatment in patients
with bone metastases from solid tumours and poor prognostic features-An
exploratory analysis of placebo-controlled trials
SO JOURNAL OF BONE ONCOLOGY
LA English
DT Article
DE Breast cancer; Non-small cell lung cancer; N-telopeptide of type I
collagen; Prostate cancer; Survival; Zoledronic acid
AB Background: Zoledronic acid (ZOL) is an important component of therapy for patients with metastatic bone disease (MBD) to reduce the risk of skeletal-related events (SREs). We evaluated overall survival (OS) in patients with MBD secondary to solid tumours included in placebocontrolled ZOL trials.
Patients and methods: Exploratory analyses were performed using databases from three randomised trials of ZOL versus placebo. 1126 patients (ZOL, n=731; placebo, n=395) with complete baseline data for 18 predefined parameters were evaluated for OS. Relative risks (RRs) with 95% confidence intervals were assessed using stratified and adjusted Cox regression models. Baseline covariates defining patient populations with significantly different effects of ZOL treatment on OS (identified by stepwise backward elimination) were included in multivariate models.
Results: Although OS was similar between the overall treatment groups, ZOL significantly improved OS in the subset of patients (n=423; 38%) with elevated baseline NTX ( >= 100 nmol/mmol creatinine; RR, 0.692; P=.0028). Notably, this effect was independent of SRE prevention. Additional covariates associated with OS benefits with ZOL (e.g., low albumin, SRE history, elevated lactate dehydrogenase, shorter cancer duration) were characteristic of advanced disease.
Conclusion: These exploratory analyses suggest a beneficial effect of ZOL on OS in patients with highly aggressive or advanced MBD. (C) 2013 Elsevier GmbH. All rights reserved.
C1 [Coleman, Robert E.; Brown, Janet E.] Univ Sheffield, Weston Pk Hosp, Canc Clin Trials Ctr, Canc Res Ctr,Dept Oncol, Sheffield S10 2SJ, S Yorkshire, England.
[Lipton, Allan] Penn State Milton S Hershey Med Ctr, Coll Med, Hershey, PA USA.
[Costa, Luis] Inst Mol Med, Clin & Translat Oncol Res Unit, Lisbon, Portugal.
[Cook, Richard J.; Lee, Ker-Ai] Univ Waterloo, Dept Stat & Actuarial Sci, Waterloo, ON N2L 3G1, Canada.
[Saad, Fred] Univ Montreal, Notre Dame Hosp, Ctr Hosp, Div Urol, Montreal, PQ H3C 3J7, Canada.
[Brown, Janet E.] St James Hosp, Canc Res UK Ctr, Dept Oncol & Clin Res, Leeds, W Yorkshire, England.
[Terpos, Evangelos] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece.
[Major, Pierre P.] McMaster Univ, Juravinski Canc Ctr, Dept Oncol, Div Med Oncol, Hamilton, ON, Canada.
[Kohno, Norio] Tokyo Med Univ, Div Breast Oncol, Tokyo 1608402, Japan.
[Smith, Matthew] Massachusetts Gen Hosp, Ctr Canc, Genitourinary Malignancies Program, Boston, MA USA.
[Body, Jean-Jacques] ULB, Univ Hosp Brugmann, Dept Med, Brussels, Belgium.
RP Coleman, RE (reprint author), Univ Sheffield, Weston Pk Hosp, Canc Clin Trials Ctr, Dept Oncol,Acad Unit Clin Oncol, Whitham Rd, Sheffield S10 2SJ, S Yorkshire, England.
EM r.e.coleman@sheffield.ac.uk
FU Novartis Pharmaceuticals Corporation
FX This work, including medical editorial assistance, was supported by
Novartis Pharmaceuticals Corporation.
NR 35
TC 4
Z9 4
U1 0
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 2212-1366
EI 2212-1374
J9 J BONE ONCOL
JI J. Bone Oncol.
PD JUN
PY 2013
VL 2
IS 2
BP 70
EP 76
DI 10.1016/j.jbo.2013.01.002
PG 7
WC Oncology
SC Oncology
GA V37LN
UT WOS:000209277400002
PM 26909273
ER
PT J
AU Chuang, SK
Lee, CT
AF Chuang, Sung-Kiang
Lee, Chun-Teh
TI Short Implants Might be a Predictable Treatment Alternative to Long
Implants Which Often Require Additional Augmentation Procedures
SO JOURNAL OF EVIDENCE-BASED DENTAL PRACTICE
LA English
DT Editorial Material
AB Selection Criteria
This systematic review included studies of short implant placement with length <= 8.5 mm in posterior partially edentulous patients. All restorations were fixed prostheses, including single or multiple crowns. No patients in these studies were medically compromised. The study types included in this review could be randomized clinical trials or prospective or retrospective controlled or non-controlled clinical trials providing data about short implant length, diameter, surgical site, surface texture, and survival rate. The studies with unclear data of short implants were excluded. A total of 1354 articles were found in the initial electronic and manual searches. Of these, 33 articles fit the criteria. These final articles documented the results with 3573 short implants. In different types of statistical analysis or comparison, various numbers of implants were included from these studies.
Key Study Factor
The systematic review was designed to evaluate the implant survival outcome of short implants placed in posterior partially edentulous patients with fixed restorations. Other factors in short implants were also evaluated, for example, implant diameter and length. The survival results of short implants were compared with those for long implants.
Main Outcome Measure
Life table analysis with interval survival rate (ISR) and cumulative survival rate (CSR) was done for short and long implant groups. The survival rates were also analyzed in subgroups: short implants (diameter < 4.8 mm); wide-short implants (diameter >= 4.8 mm); and short implants of different lengths (5-8.5 mm). Risk ratios of implant failure in short and long implant groups were analyzed.
Main Results
The results demonstrated an ISR of 98.5% to 100% and a CSR of 97.9% to 98.5% in short implants with 1 to 5 years of follow-up. The majority (71%) of implant failures occurred before loading. The life table analysis demonstrated similar survival rate between short implants (length <= 8.5 mm) and long implants (length > 8.5 mm) and short (diameter < 4.8 mm) and short-wide (diameter >= 4.8 mm) implants. Meta-analysis was performed to analyze risk ratio of failure in short and long implants from studies, including a comparison of short versus long implants as the objective (6 of 33 studies). The risk ratios were also analyzed by the frost plots in the other 24 studies. There was no statistical heterogeneity in the two risk ratio evaluations (p = 0.07 and 0.30, respectively). Short implants with varying lengths (5-8.5 mm) had ISRs and CSRs higher than 95% over 1 to 4 years of followup except 5-mm short implants, which had 89.9% CSR with 2 to 4 years of follow-up.
Conclusions
The survival rate of short implants in posterior partial edentulism was high and not related to implant surface, design, or width. Short implants might be a predictable alternative to long implants, which often require additional augmentation procedures.
C1 [Chuang, Sung-Kiang] Massachusetts Gen Hosp, Oral & Maxillofacial Surg, Boston, MA 02114 USA.
[Chuang, Sung-Kiang] Harvard Univ, Sch Dent Med, Dept Oral & Maxillofacial Surg, Boston, MA 02115 USA.
[Lee, Chun-Teh] Harvard Univ, Sch Dent Med, Periodontol, Boston, MA 02115 USA.
RP Chuang, SK (reprint author), Massachusetts Gen Hosp, Oral & Maxillofacial Surg, Boston, MA 02114 USA.
EM sungkiangchuang@gmail.com
NR 11
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER INC
PI SAN DIEGO
PA 525 B STREET, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 1532-3382
EI 1532-3390
J9 J EVID-BASED DENT PR
JI J. Evid.-Based Dent. Pract.
PD JUN
PY 2013
VL 13
IS 2
BP 45
EP 46
DI 10.1016/j.jebdp.2013.04.010
PG 2
WC Dentistry, Oral Surgery & Medicine
SC Dentistry, Oral Surgery & Medicine
GA V40IJ
UT WOS:000209472000003
PM 23773463
ER
PT J
AU Makanji, HS
Zhao, M
Mudgal, CS
Jupiter, JB
Ring, D
AF Makanji, H. S.
Zhao, M.
Mudgal, C. S.
Jupiter, J. B.
Ring, D.
TI Correspondence between clinical presentation and electrophysiological
testing for potential carpal tunnel syndrome
SO JOURNAL OF HAND SURGERY-EUROPEAN VOLUME
LA English
DT Article
DE Carpal tunnel; clinical diagnosis; electrophysiology
ID IDIOPATHIC ARM PAIN; NERVE-CONDUCTION; DECOMPRESSION; SPECIFICITY;
SENSITIVITY; VALIDATION; SEVERITY; PREDICT
AB The diagnosis of carpal tunnel syndrome (CTS) is often applied in the absence of objectively verifiable pathophysiology (i.e. electrophysiologically normal carpal tunnel syndrome). The primary purpose of this study was to determine whether depressive symptoms, heightened illness concern, and pain catastrophizing are associated with an absence of electrophysiological abnormalities. The secondary purpose was to examine the correspondence between the Levine scale, the CTS-6, and electrophysiological abnormalities. Ninety-eight participants completed validated questionnaires assessing psychosocial factors at the initial visit, and surgeons recorded clinical data and their confidence that the diagnosis was carpal tunnel syndrome. Symptoms and signs that are characteristic of carpal tunnel syndrome (e.g. the CTS-6 and Levine scale) significantly, but incompletely coincided with electrophysiological testing. Psychological factors did not help distinguish patients with normal and abnormal objective testing and it remains unclear if symptoms that do not coincide with abnormal tests represent very mild, immeasurable median nerve dysfunction or a different illness altogether. Future studies should address whether outcomes are superior and resource utilization is optimized when surgery is offered based on symptoms and signs (e.g. the CTS-6) or when surgery is offered on the basis of measurable pathophysiology.
C1 [Makanji, H. S.; Zhao, M.; Mudgal, C. S.; Jupiter, J. B.; Ring, D.] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
RP Ring, D (reprint author), Massachusetts Gen Hosp, Yawkey 2100,55 Fruit St, Boston, MA 02114 USA.
EM dring@partners.org
NR 23
TC 10
Z9 11
U1 0
U2 2
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1753-1934
EI 2043-6289
J9 J HAND SURG-EUR VOL
JI J. Hand Surg.-Eur. Vol.
PD JUN
PY 2013
VL 38
IS 5
BP 489
EP 495
DI 10.1177/1753193412461860
PG 7
WC Orthopedics; Surgery
SC Orthopedics; Surgery
GA AF3DY
UT WOS:000334592900006
PM 23027833
ER
PT J
AU Karakis, I
Pathmanathan, J
Chang, R
Cook, EF
Cash, SS
Cole, AJ
AF Karakis, I.
Pathmanathan, J.
Chang, R.
Cook, E. F.
Cash, S. S.
Cole, A. J.
TI The prognostic value of electroencephalographic asymmetries for the
development of pharmaco-resistance in medication-naive patients with
idiopathic generalized epilepsies
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
C1 Emory Univ, Sch Med, Atlanta, GA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2013
VL 260
SU 1
MA O233
BP S15
EP S15
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA V36DR
UT WOS:000209194000036
ER
PT J
AU Rannikmae, K
Kalaria, RN
Greenberg, SM
Chui, HC
Schmitt, FA
Sudlow, CLM
AF Rannikmaee, K.
Kalaria, R. N.
Greenberg, S. M.
Chui, H. C.
Schmitt, F. A.
Sudlow, C. L. M.
TI Association between APOE genotype and cerebral amyloid angiopathy
(CAA)-related vasculopathic changes: collaborative metaanalysis
SO JOURNAL OF NEUROLOGY
LA English
DT Meeting Abstract
C1 Univ Edinburgh, Edinburgh, Midlothian, Scotland.
Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ So Calif, Los Angeles, CA USA.
Univ Kentucky, Lexington, KY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER HEIDELBERG
PI HEIDELBERG
PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY
SN 0340-5354
EI 1432-1459
J9 J NEUROL
JI J. Neurol.
PD JUN
PY 2013
VL 260
SU 1
MA O299
BP S40
EP S41
PG 2
WC Clinical Neurology
SC Neurosciences & Neurology
GA V36DR
UT WOS:000209194000102
ER
PT J
AU Schestatsky, P
Morales-Quezada, L
Fregni, F
AF Schestatsky, Pedro
Morales-Quezada, Leon
Fregni, Felipe
TI Simultaneous EEG Monitoring During Transcranial Direct Current
Stimulation
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Behavior; Issue 76; Medicine; Neuroscience; Neurobiology; Anatomy;
Physiology; Biomedical Engineering; Psychology; electroencephalography;
electroencephalogram; EEG; transcranial direct current stimulation;
tDCS; noninvasive brain stimulation; neuromodulation; closed-loop
system; brain; imaging; clinical techniques
AB Transcranial direct current stimulation (tDCS) is a technique that delivers weak electric currents through the scalp. This constant electric current induces shifts in neuronal membrane excitability, resulting in secondary changes in cortical activity. Although tDCS has most of its neuromodulatory effects on the underlying cortex, tDCS effects can also be observed in distant neural networks. Therefore, concomitant EEG monitoring of the effects of tDCS can provide valuable information on the mechanisms of tDCS. In addition, EEG findings can be an important surrogate marker for the effects of tDCS and thus can be used to optimize its parameters. This combined EEG-tDCS system can also be used for preventive treatment of neurological conditions characterized by abnormal peaks of cortical excitability, such as seizures. Such a system would be the basis of a non-invasive closed-loop device. In this article, we present a novel device that is capable of utilizing tDCS and EEG simultaneously. For that, we describe in a step-by-step fashion the main procedures of the application of this device using schematic figures, tables and video demonstrations. Additionally, we provide a literature review on clinical uses of tDCS and its cortical effects measured by EEG techniques.
C1 [Schestatsky, Pedro] Univ Fed Rio Grande do Sul, Programa Posgrad Ciencias Med, BR-90046900 Porto Alegre, RS, Brazil.
[Schestatsky, Pedro] Coordenacao Aperfeicoamento Pessoal Nivel Super C, Kobe, Hyogo, Japan.
[Schestatsky, Pedro; Morales-Quezada, Leon; Fregni, Felipe] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat,Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
[Schestatsky, Pedro; Morales-Quezada, Leon; Fregni, Felipe] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
[Morales-Quezada, Leon] De Montfort Univ, Leicester LE1 9BH, Leics, England.
RP Fregni, F (reprint author), Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Lab Neuromodulat,Dept Phys Med & Rehabil, Cambridge, MA 02138 USA.
EM fregni.felipe@mgh.harvard.edu
FU CAPES, Brazil; CIMIT
FX P.S. received funding support from CAPES, Brazil. This work was
partially supported with a grant from CIMIT. The authors are also
grateful to Uri Fligil for his technical assistance and to Olivia Gozel
and Noelle Chiavetta for their help in editing this manuscript.
NR 40
TC 9
Z9 9
U1 2
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2013
IS 76
AR UNSP e50426
DI 10.3791/50426
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RF
UT WOS:000209227800045
ER
PT J
AU Shahid, M
Buys, ES
AF Shahid, Mohd
Buys, Emmanuel S.
TI Assessing Murine Resistance Artery Function Using Pressure Myography
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Physiology; Issue 76; Biomedical Engineering; Medicine; Biophysics;
Bioengineering; Anatomy; Cardiology; Hematology; Vascular Diseases;
Cardiovascular System; mice; resistance arteries; pressure myography;
myography; myograph; NO-cGMP signaling; signaling; animal model
AB Pressure myograph systems are exquisitely useful in the functional assessment of small arteries, pressurized to a suitable transmural pressure. The near physiological condition achieved in pressure myography permits in-depth characterization of intrinsic responses to pharmacological and physiological stimuli, which can be extrapolated to the in vivo behavior of the vascular bed. Pressure myograph has several advantages over conventional wire myographs. For example, smaller resistance vessels can be studied at tightly controlled and physiologically relevant intraluminal pressures. Here, we study the ability of 3rd order mesenteric arteries (3-4 mm long), preconstricted with phenylephrine, to vaso-relax in response to acetylcholine. Mesenteric arteries are mounted on two cannulas connected to a pressurized and sealed system that is maintained at constant pressure of 60 mmHg. The lumen and outer diameter of the vessel are continuously recorded using a video camera, allowing real time quantification of the vasoconstriction and vasorelaxation in response to phenylephrine and acetylcholine, respectively.
To demonstrate the applicability of pressure myography to study the etiology of cardiovascular disease, we assessed endothelium-dependent vascular function in a murine model of systemic hypertension. Mice deficient in the alpha(1) subunit of soluble guanylate cyclase (sGC alpha(-/-)(1)) are hypertensive when on a 129S6 (S6) background (sGC alpha(-/-S6)(1)) but not when on a C57BL/6 (B6) background (sGC alpha(-/-B6)(1)). Using pressure myography, we demonstrate that sGC alpha(1)-deficiency results in impaired endothelium-dependent vasorelaxation. The vascular dysfunction is more pronounced in sGC alpha(-/-S6)(1) than in sGC alpha(-/-B6)(1) mice, likely contributing to the higher blood pressure in sGC alpha(-/-S6)(1) than in sGC alpha(-/-B6)(1) mice.
Pressure myography is a relatively simple, but sensitive and mechanistically useful technique that can be used to assess the effect of various stimuli on vascular contraction and relaxation, thereby augmenting our insight into the mechanisms underlying cardiovascular disease.
C1 [Shahid, Mohd; Buys, Emmanuel S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res,Dept Anesthesia Crit, Cambridge, MA 02138 USA.
RP Shahid, M (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Anesthesia Ctr Crit Care Res,Dept Anesthesia Crit, Cambridge, MA 02138 USA.
EM MShahid@partners.org
FU American Heart Association [10SDG2610313]; Harvard Medical School
FX This work was supported by Scientist Development Grant 10SDG2610313 from
the American Heart Association (to E. S. Buys), and an Eleanor and Miles
Shore 50th Anniversary Fellowship program for Scholars in Medicine from
Harvard Medical School (to E. S. Buys).
NR 14
TC 1
Z9 1
U1 3
U2 4
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2013
IS 76
AR UNSP e50328
DI 10.3791/50328
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RF
UT WOS:000209227800027
ER
PT J
AU Sharp, JA
Blower, MD
AF Sharp, Judith A.
Blower, Mike D.
TI Production of Xenopus tropicalis Egg Extracts to Identify
Microtubule-associated RNAs
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Molecular Biology; Issue 76; Genetics; Developmental Biology;
Biochemistry; Bioengineering; Cellular Biology; RNA; Messenger; Stored;
RNA Processing; Post-Transcriptional; Xenopus; microtubules; egg
extract; purification; RNA localization; mRNA; Xenopus tropicalis; eggs;
animal model
AB Many organisms localize mRNAs to specific subcellular destinations to spatially and temporally control gene expression. Recent studies have demonstrated that the majority of the transcriptome is localized to a nonrandom position in cells and embryos. One approach to identify localized mRNAs is to biochemically purify a cellular structure of interest and to identify all associated transcripts. Using recently developed high-throughput sequencing technologies it is now straightforward to identify all RNAs associated with a subcellular structure. To facilitate transcript identification it is necessary to work with an organism with a fully sequenced genome. One attractive system for the biochemical purification of subcellular structures are egg extracts produced from the frog Xenopus laevis. However, X. laevis currently does not have a fully sequenced genome, which hampers transcript identification. In this article we describe a method to produce egg extracts from a related frog, X. tropicalis, that has a fully sequenced genome. We provide details for microtubule polymerization, purification and transcript isolation. While this article describes a specific method for identification of microtubule-associated transcripts, we believe that it will be easily applied to other subcellular structures and will provide a powerful method for identification of localized RNAs.
C1 [Sharp, Judith A.; Blower, Mike D.] Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
[Sharp, Judith A.; Blower, Mike D.] Harvard Univ, Dept Genet, Sch Med, Cambridge, MA 02138 USA.
RP Blower, MD (reprint author), Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA.
EM blower@molbio.mgh.harvard.edu
NR 27
TC 0
Z9 0
U1 1
U2 1
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2013
IS 76
AR UNSP e50434
DI 10.3791/50434
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA V36RF
UT WOS:000209227800047
ER
PT J
AU Altundal, Y
Sajo, E
Makrigiorgos, G
Ngwa, W
AF Altundal, Y.
Sajo, E.
Makrigiorgos, G.
Ngwa, W.
TI Customizable Radiotherapy Enhancement (CuRE) for Retinal Diseases Using
Nanoparticles
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Altundal, Y.; Sajo, E.] Univ Massachusetts, Lowell, MA USA.
[Makrigiorgos, G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ngwa, W.] Brigham & Womans Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814736
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849901587
ER
PT J
AU Beddar, S
Deye, J
Romeijn, E
Mackie, T
Paganetti, H
Jin, J
McGuire, S
AF Beddar, S.
Deye, J.
Romeijn, E.
Mackie, T.
Paganetti, H.
Jin, J.
McGuire, S.
TI Grantsmanship and Funding
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Beddar, S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Deye, J.] NCI, Bethesda, MD 20892 USA.
[Romeijn, E.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Mackie, T.] Univ Wisconsin, Madison, WI USA.
[Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Jin, J.] Henry Ford Hosp Syst, Detroit, MI USA.
[McGuire, S.] Univ Iowa, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4815615
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849900027
ER
PT J
AU Bentefour, E
Samuel, D
Testa, M
Lu, H
AF Bentefour, E.
Samuel, D.
Testa, M.
Lu, H.
TI Methods and Device for Dose Based Proton Radiography
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Bentefour, E.] IBA, Louvain, Belgium.
[Samuel, D.] Catholic Univ Louvain, B-1348 Louvain, Walloon Brabant, Belgium.
[Testa, M.] Massachussetts Gen Hosp, Boston, MA USA.
[Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814880
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902136
ER
PT J
AU Daartz, J
Winey, B
Bussiere, M
Gierga, D
Crawford, B
Sedlacek, D
Cotter, C
AF Daartz, J.
Winey, B.
Bussiere, M.
Gierga, D.
Crawford, B.
Sedlacek, D.
Cotter, C.
TI Evaluation of the ArcCheck Device for Patient-Specific Quality Assurance
in Step-And-Shoot IMRT for Single-Fraction Spinal SBRT
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Daartz, J.; Winey, B.; Bussiere, M.; Gierga, D.; Crawford, B.; Sedlacek, D.; Cotter, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814867
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902122
ER
PT J
AU Daartz, J
Winey, B
Bussiere, M
Gierga, D
Crawford, B
Sedlacek, D
Cotter, C
AF Daartz, J.
Winey, B.
Bussiere, M.
Gierga, D.
Crawford, B.
Sedlacek, D.
Cotter, C.
TI Evaluation of the ArcCheck Device for Patient-Specific Quality Assurance
in Step-And-Shoot IMRT for Single-Fraction Spinal SBRT
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Daartz, J.; Winey, B.; Bussiere, M.; Gierga, D.; Crawford, B.; Sedlacek, D.; Cotter, C.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902123
ER
PT J
AU Gueorguiev, G
Sharp, G
Mahd, M
Turcotte, J
Crawford, B
AF Gueorguiev, G.
Sharp, G.
Mahd, M.
Turcotte, J.
Crawford, B.
TI A Protocol for 3D IMRT Quality Assurance of Prostate Radiotherapy
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Gueorguiev, G.; Mahd, M.] Univ Massachusetts Lowell, Lowell, MA USA.
[Gueorguiev, G.; Sharp, G.; Turcotte, J.; Crawford, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814624
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849901463
ER
PT J
AU Hacker, F
Friesen, S
Mannarino, E
Wagar, M
Lewis, J
Lyatskaya, Y
AF Hacker, F.
Friesen, S.
Mannarino, E.
Wagar, M.
Lewis, J.
Lyatskaya, Y.
TI A Total Imaging Test Sequence to Determine the Isocenter Coordinates of
Multi-Modality Imaging Systems On a Stereotactic Linac Relative to the
Radiation Isocenter
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Hacker, F.; Friesen, S.; Mannarino, E.; Wagar, M.; Lewis, J.; Lyatskaya, Y.] Brigham & Women & Apos S Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Hacker, F.; Friesen, S.; Mannarino, E.; Wagar, M.; Lewis, J.; Lyatskaya, Y.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814570
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902193
ER
PT J
AU Jia, X
Schuemann, J
Paganetti, H
Jiang, S
AF Jia, X.
Schuemann, J.
Paganetti, H.
Jiang, S.
TI Development of GPMC V2.0, a GPU-Based Monte Carlo Dose Calculation
Package for Proton Radiotherapy
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Jia, X.; Jiang, S.] Univ Calif San Diego, Ctr Adv Radiotherapy Technol, La Jolla, CA 92093 USA.
[Schuemann, J.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4815619
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849900031
ER
PT J
AU Kim, S
Park, Y
Lee, J
Choi, K
Ye, S
AF Kim, S.
Park, Y.
Lee, J.
Choi, K.
Ye, S.
TI Double-Ends Quasi-Breath-Hold (DE-QBH) Technique for Respiratory Motion
Management
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Kim, S.] Mayo Clin, Jacksonville, FL 32224 USA.
[Park, Y.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lee, J.; Choi, K.; Ye, S.] Seoul Natl Univ, Seoul, South Korea.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814792
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902041
ER
PT J
AU Lee, J
Park, Y
Choi, K
Ye, S
AF Lee, J.
Park, Y.
Choi, K.
Ye, S.
TI Assessment of 2D / 3D Intra-Fractional Tumor Motion for
Respiratory-Gated Radiotherapy
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Lee, J.; Choi, K.; Ye, S.] Seoul Natl Univ, Grad Sch Convergence Sci & Technol, Dept Transdisciplinary Studies, Program Biomed Radiat Sci, Suwon, South Korea.
[Lee, J.; Choi, K.] Seoul Natl Univ Hosp, Biomed Res Inst, Seoul 110744, South Korea.
[Lee, J.; Choi, K.] Seoul Natl Univ, Med Res Ctr, Inst Radiat Med, Seoul, South Korea.
[Park, Y.] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Ye, S.] Seoul Natl Univ Hosp, Dept Radiat Oncol, Seoul 110744, South Korea.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814760
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902004
ER
PT J
AU Testa, M
Min, C
Schuemann, J
Verburg, J
Lu, H
Paganetti, H
AF Testa, M.
Min, C.
Schuemann, J.
Verburg, J.
Lu, H.
Paganetti, H.
TI A Novel Technique for In-Vivo and Real-Time Range Verification Based On
the Characteristic Prompt Gamma Time-Structure of Passively Modulated
Proton Beams
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Testa, M.; Min, C.; Schuemann, J.; Verburg, J.; Lu, H.; Paganetti, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4815637
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849900051
ER
PT J
AU Winey, B
Wolfgang, J
Speier, C
Crawford, B
AF Winey, B.
Wolfgang, J.
Speier, C.
Crawford, B.
TI Evaluating Treatment Couch Dosimetric Effects in Spine SBRT Treatment
Planning
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Winey, B.; Wolfgang, J.; Speier, C.; Crawford, B.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Winey, B.; Wolfgang, J.; Speier, C.; Crawford, B.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814614
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849901452
ER
PT J
AU Wolf, R
Paganetti, H
Flanz, J
AF Wolf, R.
Paganetti, H.
Flanz, J.
TI Assessing Quality Assurance of Proton Scattering Nozzles Using Monte
Carlo
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Wolf, R.; Paganetti, H.; Flanz, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814559
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849902181
ER
PT J
AU Wuu, C
Xu, Y
Qian, X
Admovics, J
Cascio, E
Lu, H
AF Wuu, C.
Xu, Y.
Qian, X.
Admovics, J.
Cascio, E.
Lu, H.
TI 3-D Dosimetric Assessment for a Proton Pencil Beam by Optical CT
Scanning of Plastic Radiochromic Dosimeters
SO MEDICAL PHYSICS
LA English
DT Meeting Abstract
C1 [Wuu, C.; Qian, X.] Columbia Univ, New York, NY USA.
[Xu, Y.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
[Admovics, J.] Rider Univ, Lawrenceville, NJ 08648 USA.
[Cascio, E.; Lu, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Xu, Andy/C-7753-2016
OI Xu, Andy/0000-0002-0763-9953
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC PHYSICISTS MEDICINE AMER INST PHYSICS
PI MELVILLE
PA STE 1 NO 1, 2 HUNTINGTON QUADRANGLE, MELVILLE, NY 11747-4502 USA
SN 0094-2405
J9 MED PHYS
JI Med. Phys.
PD JUN
PY 2013
VL 40
IS 6
DI 10.1118/1.4814494
PG 2
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI4QM
UT WOS:000336849901438
ER
PT J
AU Vujanovic, AA
Farris, SG
Harte, CB
Smits, JAJ
Zvolensky, MJ
AF Vujanovic, Anka A.
Farris, Samantha G.
Harte, Christopher B.
Smits, Jasper A. J.
Zvolensky, Michael J.
TI Smoking status and exercise in relation to PTSD symptoms: A test among
trauma-exposed adults
SO MENTAL HEALTH AND PHYSICAL ACTIVITY
LA English
DT Article
DE PTSD; Trauma; Exercise; Cigarette smoking
AB The present investigation examined the interactive effect of cigarette smoking status (i.e., regular smoking vs. non-smoking) and weekly exercise (i.e., weekly metabolic equivalent) in terms of post-traumatic stress (PTSD) symptom severity among a community sample of trauma-exposed adults. Participants included 86 trauma-exposed adults (58.1% female; M-age = 24.3). Approximately 59.7% of participants reported regular (>= 10 cigarettes per day) daily smoking over the past year. The interactive effect of smoking status by weekly exercise was significantly associated with hyperarousal and avoidance symptom cluster severity (p <= .05). These effects were evident above and beyond number of trauma types and gender, as well as the respective main effects of smoking status and weekly exercise. Follow-up tests indicated support for the moderating role of exercise on the association between smoking and PTSD symptoms, such that the highest levels of PTSD symptoms were observed among regular smokers reporting low weekly exercise levels. Theoretical and clinical implications of the findings are discussed. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Vujanovic, Anka A.] Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Psychiat & Behav Sci, Houston, TX 77021 USA.
[Farris, Samantha G.; Zvolensky, Michael J.] Univ Houston, Dept Psychol, Houston, TX 77204 USA.
[Harte, Christopher B.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Smits, Jasper A. J.] So Methodist Univ, Dept Psychol, Dallas, TX 75206 USA.
RP Vujanovic, AA (reprint author), Univ Texas Hlth Sci Ctr Houston, Sch Med, Dept Psychiat & Behav Sci, 2800 South MacGregor Way, Houston, TX 77021 USA.
EM anka.vujanovic@gmail.com; samantha.g.farris@gmail.com;
c.b.harte@gmail.com; jsmits@mail.smu.edu; mjzvolen@central.uh.edu
RI Smits, Jasper/A-4350-2008;
OI Smits, Jasper/0000-0001-7128-9807; Harte,
Christopher/0000-0002-8097-7369; Smits, Jasper/0000-0003-1633-9693
FU [1 F31 DA021006-02]
FX This work was supported, in part, by a grant awarded to Anka A.
Vujanovic (1 F31 DA021006-02). The views expressed here are of those of
the authors and do not necessarily reflect those of the US Department of
Veterans Affairs.
NR 53
TC 4
Z9 4
U1 3
U2 5
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1755-2966
J9 MENT HEALTH PHYS ACT
JI Ment. Health Phys. Act.
PD JUN
PY 2013
VL 6
IS 2
BP 132
EP 138
DI 10.1016/j.mhpa.2012.12.001
PG 7
WC Psychiatry
SC Psychiatry
GA V36SH
UT WOS:000209230500011
ER
PT J
AU Nash, WP
Carper, TLM
Mills, MA
Au, T
Goldsmith, A
Litz, BT
AF Nash, William P.
Carper, Teresa L. Marino
Mills, Mary Alice
Au, Teresa
Goldsmith, Abigail
Litz, Brett T.
TI Psychometric Evaluation of the Moral Injury Events Scale
SO MILITARY MEDICINE
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC EVENTS; WAR VETERANS; COMBAT;
CRITERION; SYMPTOMS; VALIDITY; ANXIETY; IMPACT; PTSD
AB Literature describing the phenomenology of the stress of combat suggests that war-zone experiences may lead to adverse psychological outcomes such as post-traumatic stress disorder not only because they expose persons to life threat and loss but also because they may contradict deeply held moral and ethical beliefs and expectations. We sought to develop and validate a measure of potentially morally injurious events as a necessary step toward studying moral injury as a possible adverse consequence of combat. We administered an 11-item, self-report Moral Injury Events Scale to active duty Marines 1 week and 3 months following war-zone deployment. Two items were eliminated because of low item-total correlations. The remaining 9 items were subjected to an exploratory factor analysis, which revealed two latent factors that we labeled perceived transgressions and perceived betrayals; these were confirmed via confirmatory factor analysis on an independent sample. The overall Moral Injury Events Scale and its two subscales had favorable internal validity, and comparisons between the 1-week and 3-month data suggested good temporal stability. Initial discriminant and concurrent validity were also established. Future research directions were discussed.
C1 [Nash, William P.] Boston VA Res Inst, Boston, MA 02130 USA.
[Carper, Teresa L. Marino] Orlando VA Med Ctr, Orlando, FL 32803 USA.
[Carper, Teresa L. Marino] Univ Cent Florida, Coll Med, Orlando, FL 32816 USA.
[Mills, Mary Alice; Au, Teresa; Litz, Brett T.] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Mills, Mary Alice; Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
[Au, Teresa] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
[Goldsmith, Abigail] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92093 USA.
[Goldsmith, Abigail] VA San Diego Healthcare Syst, San Diego, CA 92161 USA.
[Litz, Brett T.] Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA 02130 USA.
[Litz, Brett T.] Natl Ctr PTSD, Behav Sci Div, Boston, MA 02130 USA.
RP Nash, WP (reprint author), Boston VA Res Inst, Boston, MA 02130 USA.
FU VA Health Services Research and Development; Headquarters Marine Corps;
Naval Health Research Center
FX This research was supported by grants from VA Health Services Research
and Development, Naval Health Research Center, and Headquarters Marine
Corps.
NR 54
TC 20
Z9 20
U1 1
U2 6
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD JUN
PY 2013
VL 178
IS 6
BP 646
EP 652
DI 10.7205/MILMED-D-13-00017
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7TZ
UT WOS:000340805200009
PM 23756071
ER
PT J
AU Kern, RS
Zarate, R
Glynn, SM
Turner, LR
Smith, KM
Mitchell, SS
Becker, DR
Drake, RE
Kopelowicz, A
Tovey, W
Liberman, RP
AF Kern, Robert S.
Zarate, Roberto
Glynn, Shirley M.
Turner, Luana R.
Smith, Kellie M.
Mitchell, Sharon S.
Becker, Deborah R.
Drake, Robert E.
Kopelowicz, Alex
Tovey, Wendi
Liberman, Robert P.
TI A Demonstration Project Involving Peers as Providers of Evidence-Based,
Supported Employment Services
SO PSYCHIATRIC REHABILITATION JOURNAL
LA English
DT Article
DE peer support; supported employment; schizophrenia; psychiatric
rehabilitation
AB Objective: The present demonstration project involved development of a training program designed to teach recovering consumers employed as peer advocates how to provide evidence-based supported employment services to consumers with severe mental illness. Methods: A training curriculum was developed to teach the core competencies of the Individual Placement and Support (IPS) model of supported employment. Three peers participated in training and provided work outcome data from their caseloads. Assessments were conducted of peers' competence in implementing IPS and effectiveness in promoting job placements. Peer competency was assessed by the following: (a) a formal IPS fidelity review performed by two external reviewers to evaluate service implementation, and (b) the Kansas Employment Specialist Job Performance Evaluation, an objective measure of employment specialist attitudes and skills. Program efficacy was assessed by examining the number of job placements and corresponding tenure. Results: The fidelity review revealed that peers met IFS standards of implementation on 7 of 14 items assessing service delivery. The Kansas scale results revealed attitudes to be a relative strength and job performance competency ratings fell in the average to above average range across skill areas assessed (e.g., vocational assessment, job development). Thirty-three percent of consumers from the peers' caseloads got competitive jobs; mean tenure was 26.1 weeks. Conclusions and Implications for Practice: This demonstration project provides a starting point for future efforts aimed at expanding the role of peers as providers of evidence-based mental health services and provides a measured degree of optimism that this is a realistic, attainable goal.
C1 [Kern, Robert S.; Zarate, Roberto; Glynn, Shirley M.; Turner, Luana R.; Smith, Kellie M.; Mitchell, Sharon S.; Kopelowicz, Alex; Liberman, Robert P.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90073 USA.
[Kern, Robert S.; Glynn, Shirley M.] Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, Los Angeles, CA 90073 USA.
[Becker, Deborah R.; Drake, Robert E.] Dartmouth Coll, Dartmouth Psychiat Res Ctr, Dept Psychiat, Geisel Sch Med, Hanover, NH 03755 USA.
[Kopelowicz, Alex] San Fernando Mental Hlth Ctr, Granada Hills, CA USA.
[Tovey, Wendi] Los Angeles Cty Dept Mental Hlth, Los Angeles, CA USA.
RP Kern, RS (reprint author), Univ Calif Los Angeles, VA Greater Angeles Healthcare Syst, 11301 Wilshire Blvd MIRECC 210 A,Bldg 210, Los Angeles, CA 90073 USA.
EM rkern@ucla.edu
OI kopelowicz, alex/0000-0002-1728-4105
FU NIMH [R01 MH082939]; VA Merit Award; Los Angeles County Department of
Mental Health
FX We thank each of the peers for their dedication and tireless effort in
working towards becoming a supported employment specialist under the IPS
model. This project was supported in part by NIMH grant R01 MH082939 and
a VA Merit Award received by R. Kern (Principal Investigator), and the
Los Angeles County Department of Mental Health. Special thanks go to
Marvin Southard, DSW who had the foresight to realize the rehabilitative
potential of persons with serious mental illnesses to recover and become
employed by his own agency to serve others with SMI using an
evidence-based, person-centered model of supported employment.
NR 40
TC 11
Z9 11
U1 4
U2 16
PU CENTER PSYCHIATRIC REHABILITATION
PI BOSTON
PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA
SN 1095-158X
EI 1559-3126
J9 PSYCHIATR REHABIL J
JI Psychiatr. Rehabil. J.
PD JUN
PY 2013
VL 36
IS 2
BP 99
EP 107
DI 10.1037/h0094987
PG 9
WC Psychiatry; Rehabilitation
SC Psychiatry; Rehabilitation
GA V36ST
UT WOS:000209231700007
PM 23750760
ER
PT J
AU Tang, XN
Liu, LP
Koike, MA
Yenari, MA
AF Tang, Xian Nan
Liu, Liping
Koike, Maya A.
Yenari, Midori A.
TI Mild Hypothermia Reduces Tissue Plasminogen Activator-Related Hemorrhage
and Blood Brain Barrier Disruption After Experimental Stroke
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Article
AB Therapeutic hypothermia has shown neuroprotective promise, but whether it can be used to improve outcome in stroke has yet to be determined in patients. Recombinant tissue plasminogen activator (rt-PA) is only given to a minority of patients with acute ischemic stroke, and is not without risk, namely significant brain hemorrhage. We explored whether mild hypothermia, in combination with rt-PA, influences the safety of rt-PA. Mice were subjected to middle cerebral artery occlusion (MCAO) using a filament model, followed by 24 hours reperfusion. Two paradigms were studied. In the first paradigm, cooling and rt-PA treatment began at the same time upon reperfusion, whereas in the second paradigm, cooling began soon after ischemia onset, and rt-PA began after re-warming and upon reperfusion. Experimental groups included: tPA treatment at normothermia (37 degrees C), rt-PA treatment at hypothermia (33 degrees C), no rt-PA at normothermia, and no rt-PA treatment at hypothermia. Infarct size, neurological deficit scores, blood brain barrier (BBB) permeability, brain hemorrhage, and expression of endogenous tissue plasminogen activator (tPA) and its inhibitor, plasminogen activator inhibitor (PAI-1) were assessed. For both paradigms, hypothermia reduced infarct size and neurological deficits compared to normothermia, regardless of whether rt-PA was given. rt-PA treatment increased brain hemorrhage and BBB disruption compared to normothermia, and this was prevented by cooling. However, mortality was higher when rt-PA and cooling were administered at the same time, beginning 1-2 hours post MCAO. Endogenous tPA expression was reduced in hypothermic mice, whereas PAI-1 levels were unchanged by cooling. In the setting of rt-PA treatment, hypothermia reduces brain hemorrhage, and BBB disruption, suggesting that combination therapy with mild hypothermia and rt-PA appears safe.
C1 [Tang, Xian Nan; Liu, Liping; Koike, Maya A.; Yenari, Midori A.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94121 USA.
[Tang, Xian Nan; Liu, Liping; Koike, Maya A.; Yenari, Midori A.] San Francisco VA Med Ctr, Neurol Serv, San Francisco, CA USA.
[Liu, Liping] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China.
RP Yenari, MA (reprint author), Univ Calif San Francisco, Dept Neurol, 4150 Clement St, San Francisco, CA 94121 USA.
EM yenari@alum.mit.edu
FU National Institutes of Health [NS40516]; Veteran's Merit Award
FX This work was supported by grants from National Institutes of Health
(NS40516) and Veteran's Merit Award to M.Y. Grants to M.Y. were
administered by Northern California Institute for Research and
Education, and supported by resources of Veterans Affairs Medical
Center, San Francisco, California.
NR 57
TC 10
Z9 10
U1 0
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD JUN 1
PY 2013
VL 3
IS 2
BP 74
EP 83
DI 10.1089/ther.2013.0010
PG 10
WC Critical Care Medicine
SC General & Internal Medicine
GA V38PL
UT WOS:000209355200007
PM 23781399
ER
PT J
AU Guanci, MM
AF Guanci, Mary McKenna
TI Clinical Q & A: Translating Therapeutic Temperature Management from
Theory to Practice
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Letter
C1 Massachusetts Gen Hosp, Neurosci Intens Care, Boston, MA 02114 USA.
RP Guanci, MM (reprint author), Massachusetts Gen Hosp, Neurosci Intens Care, Boston, MA 02114 USA.
NR 40
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD JUN 1
PY 2013
VL 3
IS 2
BP 100
EP 100
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA V38PL
UT WOS:000209355200011
ER
PT J
AU McCauley, JL
Back, SE
Brady, KT
AF McCauley, Jenna L.
Back, Sudie E.
Brady, Kathleen T.
TI Pilot of a brief, web-based educational intervention targeting safe
storage and disposal of prescription opioids
SO ADDICTIVE BEHAVIORS
LA English
DT Article
DE Prescription opioid misuse; Web; Computer; Primary care; Dental
ID RANDOMIZED CONTROLLED-TRIAL; NONMEDICAL USE; NONCANCER PAIN; DRUG-ABUSE;
VALIDATION; PREVENTION; ADOLESCENTS; DEPENDENCE; DIVERSION; INTERNET
AB Prescription opioid misuse has been declared an American epidemic and a significant proportion of misused opioids are diverted from legitimate prescriptions. Patient education,regarding appropriate use and the dangers of misuse has been identified as a key intervention target. The current study presents findings from the open pilot of a patient-tailored, brief, web-based intervention designed to improve knowledge of safe medication use, storage and disposal.
Methods: Subjects were 62 treatment-seeking outpatients at two diverse outpatient health clinics (dental and pain management) who were prescribed an opioid medication. Subjects completed an online assessment of risk factors for prescription opioid misuse and the 15-minute Script Safety intervention. Knowledge and misuse behaviors were assessed at baseline, immediately post intervention (knowledge only) and at one-week and one-month follow up. Knowledge regarding safe prescription opioid use, storage and disposal improved significantly from pre to post intervention and was sustained at follow up (% correct from baseline to one-month follow up: unsafe to retain unused pills, 66.1% vs. 96.5%; unsafe to borrow pills from family/friends, 87.1% vs. 98.2%; best to store pills in cool, dry, secure location, 45.2% vs. 89.5%; not recommended to use expired medications, 75.8% vs. 96.5%; not recommended to flush all medications down the toilet, 45.2% vs. 82.5%, ps<.01). Reductions in self-reported misuse behaviors were also observed. Although preliminary, the findings highlight the potential utility of integrating brief, web-based educational interventions in community and primary health care settings. Published by Elsevier Ltd.
C1 [McCauley, Jenna L.; Back, Sudie E.; Brady, Kathleen T.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Back, Sudie E.; Brady, Kathleen T.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
RP McCauley, JL (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, Clin Neurosci Div, 125 Doughty St,Suite 140, Charleston, SC 29425 USA.
EM mccaule@musc.edu
FU South Carolina Clinical & Translational Research (SCTR) Institute;
Medical University of South Carolina; NIH/NCRR [UL1RR029882-02];
National Institute on Drug Abuse [K23 DA021228]
FX This study was supported by the South Carolina Clinical & Translational
Research (SCTR) Institute, with an academic home at the Medical
University of South Carolina, NIH/NCRR Grant number UL1RR029882-02
(KTB), and grant K23 DA021228 (SEB) from the National Institute on Drug
Abuse. Funding agencies had no role in the study design, collection,
analysis or interpretation of the data, writing the manuscript, or the
decision to submit the paper for publication.
NR 35
TC 16
Z9 16
U1 2
U2 15
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0306-4603
J9 ADDICT BEHAV
JI Addict. Behav.
PD JUN
PY 2013
VL 38
IS 6
BP 2230
EP 2235
DI 10.1016/j.addbeh.2013.01.019
PG 6
WC Psychology, Clinical; Substance Abuse
SC Psychology; Substance Abuse
GA 135YC
UT WOS:000318325600005
PM 23501140
ER
PT J
AU Golberg, A
Bei, M
Sheridan, RL
Yarmush, ML
AF Golberg, Alexander
Bei, Marianna
Sheridan, Robert L.
Yarmush, Martin L.
TI Regeneration and control of human fibroblast cell density by
intermittently delivered pulsed electric fields
SO BIOTECHNOLOGY AND BIOENGINEERING
LA English
DT Article
DE fibroblasts; irreversible electroporation; intermittently delivered
pulsed electric fields; cell density control; proliferative scarring
ID GROWTH-FACTOR-BETA; HYPERTROPHIC SCAR; ELECTROPORATION; PREVENTION;
TAMOXIFEN; SKIN; PARAMETERS; WOUNDS; TISSUE
AB Proliferative scarring is a human disease with neither available effective treatment nor relevant animal model. One of the hypotheses for scar formation involves deregulation of fibroblast signaling and delayed apoptosis. Here, we introduce a new chemical-free method for fibroblast density control in culture by intermittently delivered pulsed electric fields (IDPEF), which cause irreversible damage to cell membranes. Using 5100 pulses with electric field strength of 150V/mm, pulse duration 70 mu s, and frequency of 1Hz, we investigated the effects of PEF application on growth, death, and regeneration of normal human dermal fibroblasts in culture. We found that the fraction of fibroblasts that survive depends on the number of pulses applied and follows a Weibull distribution. We have successfully developed an IDPEF protocol that controls fibroblasts density in culture. Specifically, through application of IDPEF every 72h for 12 days, we maintain a normal human dermal fibroblast density in the 3.1 +/- 0.2x1051.4 +/- 0.2x105cell/mL range. Our results suggest that IDPEFs may prove useful as a non-chemical method for fibroblast density control in human wound healing. Biotechnol. Bioeng. 2013; 110: 17591768. (c) 2013 Wiley Periodicals, Inc.
C1 [Golberg, Alexander; Bei, Marianna; Yarmush, Martin L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
[Golberg, Alexander; Bei, Marianna; Yarmush, Martin L.] Shriners Burn Inst, Boston, MA 02114 USA.
[Bei, Marianna] Forsyth Inst, Ctr Regenerat Dev Biol, Cambridge, MA USA.
[Sheridan, Robert L.] Massachusetts Gen Hosp, Shriners Burns Inst, Sumner Redstone Burn Ctr, Boston, MA 02114 USA.
[Yarmush, Martin L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
RP Yarmush, ML (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med, Boston, MA 02114 USA.
EM ireis@sbi.org
FU MGH [85120-BOS]
FX We acknowledge Dr. Fangjing Wang for assistance with the cell culture
experiments and Prof. Micha Peleg from University of Massachusetts at
Amherst for a valuable discussion on cell growth and survival kinetics.
We acknowledge MGH Fund for Medical Discovery for an ECOR postdoctoral
fellowship award and Shriners Grant # 85120-BOS for the support of this
study.
NR 56
TC 4
Z9 4
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0006-3592
J9 BIOTECHNOL BIOENG
JI Biotechnol. Bioeng.
PD JUN
PY 2013
VL 110
IS 6
BP 1759
EP 1768
DI 10.1002/bit.24831
PG 10
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA 132ZS
UT WOS:000318107800022
PM 23297079
ER
PT J
AU Feng, JQ
Clinkenbeard, EL
Yuan, BZ
White, KE
Drezner, MK
AF Feng, Jian Q.
Clinkenbeard, Erica L.
Yuan, Baozhi
White, Kenneth E.
Drezner, Marc K.
TI Osteocyte regulation of phosphate homeostasis and bone mineralization
underlies the pathophysiology of the heritable disorders of rickets and
osteomalacia
SO BONE
LA English
DT Review
DE Osteocyte; Rickets; Osteomalacia; Fibroblast growth factor-23; PHEX;
DMP1
ID DOMINANT HYPOPHOSPHATEMIC RICKETS; AUTOSOMAL RECESSIVE HYPOPHOSPHATEMIA;
X-LINKED HYPOPHOSPHATEMIA; HYP MICE; PEX GENE; IN-VIVO; DMP1; PHENOTYPE;
FGF23; MUTATIONS
AB Although recent studies have established that osteocytes function as secretory cells that regulate phosphate metabolism, the biomolecular mechanism(s) underlying these effects remain incompletely defined. However, investigations focusing on the pathogenesis of X-linked hypophosphatemia (XLH), autosomal dominant hypophosphatemic rickets (ADHR), and autosomal recessive hypophosphatemic rickets (ARHR), heritable disorders characterized by abnormal renal phosphate wasting and bone mineralization, have clearly implicated FGF23 as a central factor in osteocytes underlying renal phosphate wasting, documented new molecular pathways regulating FGF23 production, and revealed complementary abnormalities in osteocytes that regulate bone mineralization. The seminal observations leading to these discoveries were the following: 1) mutations in FGF23 cause ADHR by limiting cleavage of the bioactive intact molecule, at a subtilisin-like protein convertase (SPC) site, resulting in increased circulating FGF23 levels and hypophosphatemia; 2) mutations in DMP1 cause ARHR, not only by increasing serum FGF23, albeit by enhanced production and not limited cleavage, but also by limiting production of the active DMP1 component, the C-terminal fragment, resulting in dysregulated production of Dial and beta-catenin, which contributes to impaired bone mineralization; and 3) mutations in PHEX cause XLH both by altering FGF23 proteolysis and production and causing dysregulated production of Dial and p-catenin, similar to abnormalities in ADHR and ARHR, but secondary to different central pathophysiological events. These discoveries indicate that ADHR, XLH, and ARHR represent three related heritable hypophosphatemic diseases that arise from mutations in, or dysregulation of, a single common gene product, FGF23 and, in ARHR and XLH, complimentary DMP1 and PHEX directed events that contribute to abnormal bone mineralization.
This article is part of a Special Issue entitled "The Osteocyte". (C) 2013 Elsevier Inc. All rights reserved.
C1 [Feng, Jian Q.] Baylor Coll Dent, Texas A&M Hlth Sci Ctr, Dept Biomed Sci, Dallas, TX 75246 USA.
[Clinkenbeard, Erica L.; White, Kenneth E.] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Yuan, Baozhi; Drezner, Marc K.] Univ Wisconsin, Dept Med, Madison, WI 53792 USA.
[Yuan, Baozhi; Drezner, Marc K.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res & Educ Ctr, Madison, WI 53792 USA.
RP White, KE (reprint author), Indiana Univ Sch Med, Dept Med & Mol Genet, 975 West Walnut St,IB 130, Indianapolis, IN 46202 USA.
EM kenewhit@iu.edu; mkd@medicine.wisc.edu
FU NIH [AR27032, 2UL1TR000427, DE018486, DK063934, AR059278];
Sanofi-Genzyme
FX This work was funded by NIH grants to MK Drezner (AR27032,
2UL1TR000427), JQ Feng (DE018486), and KE White (DK063934, AR059278) and
a GRIP Award from Sanofi-Genzyme to KE White.
NR 49
TC 32
Z9 33
U1 1
U2 19
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2013
VL 54
IS 2
SI SI
BP 213
EP 221
DI 10.1016/j.bone.2013.01.046
PG 9
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131NJ
UT WOS:000318000100006
PM 23403405
ER
PT J
AU Wesseling-Perry, K
Juppner, H
AF Wesseling-Perry, Katherine
Jueppner, Harald
TI The osteocyte in CKD: New concepts regarding the role of FGF23 in
mineral metabolism and systemic complications
SO BONE
LA English
DT Review
DE Osteocytes; FGF23; Chronic kidney disease; Secondary hyperparathyroidism
ID CHRONIC KIDNEY-DISEASE; GROWTH-FACTOR 23; CHRONIC-RENAL-FAILURE;
SMOOTH-MUSCLE-CELLS; INTERMITTENT CALCITRIOL THERAPY; CORONARY-ARTERY
CALCIFICATION; LEFT-VENTRICULAR HYPERTROPHY; VITAMIN-D METABOLISM;
MATRIX GLA PROTEIN; PARATHYROID-HORMONE
AB The identification of elevated circulating levels of the osteocytic protein fibroblast growth factor 23 (FGF23) in patients with chronic kidney disease (CKD), along with recent data linking these values to the pathogenesis of secondary hyperparathyroidism and to systemic complications, has changed the approach to the pathophysiology and treatment of disordered bone and mineral metabolism in renal failure. It now appears that osteocyte biology is altered very early in the course of CKD and these changes have implications for bone biology, as well as for progressive cardiovascular and renal disease. Since circulating FGF23 values are influenced by therapies used to treat secondary hyperparathyroidism, the effects of different therapeutic paradigms on FGF23 have important implications for mineral metabolism as well as for morbidity and mortality. Further studies are critically needed to identify the initial trigger for abnormalities of skeletal mineralization and turnover as well as the potential effects that current therapeutic options may have on osteocyte biology.
This article is part of a Special Issue entitled "The Osteocyte". (C) 2012 Elsevier Inc. All rights reserved.
C1 [Wesseling-Perry, Katherine] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Jueppner, Harald] Harvard Univ, Sch Med, Boston, MA USA.
[Jueppner, Harald] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Wesseling-Perry, K (reprint author), Dept Pediat, Div Nephrol, A2-383 MDCC,650 Charles Young Dr, Los Angeles, CA 90095 USA.
EM kwesseling@mednet.ucla.edu
FU NIDDK NIH HHS [K23 DK080984]
NR 86
TC 8
Z9 11
U1 0
U2 17
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2013
VL 54
IS 2
SI SI
BP 222
EP 229
DI 10.1016/j.bone.2012.10.008
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131NJ
UT WOS:000318000100007
PM 23079136
ER
PT J
AU Bellido, T
Saini, V
Pajevic, PD
AF Bellido, Teresita
Saini, Vaibhav
Pajevic, Paola Divieti
TI Effects of PTH on osteocyte function
SO BONE
LA English
DT Review
DE Osteocyte; PTH; PTH receptor; Sclerostin; RANKL; FGF23
ID FIBROBLAST GROWTH FACTOR-23; HEMATOPOIETIC STEM-CELLS; FGF23
GENE-EXPRESSION; PARATHYROID-HORMONE; BONE-FORMATION; PRIMARY
HYPERPARATHYROIDISM; IN-VITRO; PTH/PTHRP RECEPTOR; SCLEROSTIN LEVELS;
INTERMITTENT PTH
AB Osteocytes are ideally positioned to detect and respond to mechanical and hormonal stimuli and to coordinate the function of osteoblasts and osteoclasts. However, evidence supporting the involvement of osteocytes in specific aspects of skeletal biology has been limited mainly due to the lack of suitable experimental approaches. Few crucial advances in the field in the past several years have markedly increased our understanding of the function of osteocytes. The development of osteocytic cell lines initiated a plethora of in vitro studies that have provided insights into the unique biology of osteocytes and continue to generate novel hypotheses. Genetic approaches using promoter fragments that direct gene expression to osteocytes allowed the generation of mice with gain or loss of function of particular genes revealing their role in osteocyte function. Furthermore, evidence that Sost/sclerostin is expressed primarily in osteocytes and inhibits bone formation by osteoblasts, fueled research, attempting to identify regulators of this gene as well as other osteocyte products that impact the function of osteoblasts and osteoclasts. The discovery that parathyroid hormone (PTH), a central regulator of bone homeostasis, inhibits sclerostin expression generated a cascade of studies that revealed that osteocytes are crucial target cells of the actions of PTH. This review highlights these investigations and discusses their significance for advancing our understanding of the mechanisms by which osteocytes regulate bone homeostasis and for developing therapies for bone diseases targeting osteocytes.
This article is part of a Special Issue entitled "The Osteocyte". (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bellido, Teresita] Indiana Univ Sch Med, Dept Anat & Cell Biol, Indianapolis, IN 46202 USA.
[Bellido, Teresita] Indiana Univ Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA.
[Saini, Vaibhav; Pajevic, Paola Divieti] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Saini, Vaibhav; Pajevic, Paola Divieti] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Bellido, T (reprint author), Indiana Univ Sch Med, Dept Anat & Cell Biol, 635 Barnhill Dr,MS5035, Indianapolis, IN 46202 USA.
EM tbellido@iupui.edu; divieti@helix.mgh.harvard.edu
FU BLRD VA [I01 BX002104]; NIDDK NIH HHS [R01 DK079161, R01 DK076007]
NR 75
TC 38
Z9 42
U1 1
U2 30
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
J9 BONE
JI Bone
PD JUN
PY 2013
VL 54
IS 2
SI SI
BP 250
EP 257
DI 10.1016/j.bone.2012.09.016
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131NJ
UT WOS:000318000100011
PM 23017659
ER
PT J
AU Kalajzic, I
Matthews, BG
Torreggiani, E
Harris, MA
Pajevic, PD
Harris, SE
AF Kalajzic, Ivo
Matthews, Brya G.
Torreggiani, Elena
Harris, Marie A.
Pajevic, Paola Divieti
Harris, Stephen E.
TI In vitro and in vivo approaches to study osteocyte biology
SO BONE
LA English
DT Review
DE Osteocyte; Cell lines; Transgenic mice; Dmp1; Cre-recombinase; GFP
ID GREEN FLUORESCENT PROTEIN; DENTIN MATRIX PROTEIN-1; FUNCTIONAL
GAP-JUNCTIONS; FLUID-FLOW; BONE-FORMATION; CELL-LINE;
PARATHYROID-HORMONE; OSTEOCLAST FORMATION; MONOCLONAL-ANTIBODY;
OSTEOBLASTIC CELLS
AB Osteocytes, the most abundant cell population of the bone lineage, have been a major focus in the bone research field in recent years. This population of cells that resides within mineralized matrix is now thought to be the mechanosensory cell in bone and plays major roles in the regulation of bone formation and resorption. Studies of osteocytes had been impaired by their location, resulting in numerous attempts to isolate primary osteocytes and to generate cell lines representative of the osteocytic phenotype. Progress has been achieved in recent years by utilizing in vivo genetic technology and generation of osteocyte directed transgenic and gene deficiency mouse models.
We will provide an overview of the current in vitro and in vivo models utilized to study osteocyte biology. We discuss generation of osteocyte-like cell lines and isolation of primary osteocytes and summarize studies that have utilized these cellular models to understand the functional role of osteocytes. Approaches that attempt to selectively identify and isolate osteocytes using fluorescent protein reporters driven by regulatory elements of genes that are highly expressed in osteocytes will be discussed.
In addition, recent in vivo studies utilizing overexpression or conditional deletion of various genes using dentin matrix protein (Dmp1) directed Cre recombinase are outlined. In conclusion, evaluation of the benefits and deficiencies of currently used cell lines/genetic models in understanding osteocyte biology underlines the current progress in this field. The future efforts will be directed towards developing novel in vitro and in vivo models that would additionally facilitate in understanding the multiple roles of osteocytes.
This article is part of a Special Issue entitled "The Osteocyte". (C) 2012 Elsevier Inc. All rights reserved.
C1 [Kalajzic, Ivo; Matthews, Brya G.; Torreggiani, Elena] Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, Farmington, CT 06032 USA.
[Harris, Marie A.; Harris, Stephen E.] Univ Texas Hlth Sci Ctr San Antonio, Sch Dent, Dept Periodont, San Antonio, TX 78299 USA.
[Pajevic, Paola Divieti] Massachusetts Gen Hosp, Endocrine Unit, Boston, MA 02114 USA.
[Pajevic, Paola Divieti] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Kalajzic, I (reprint author), Univ Connecticut, Ctr Hlth, Dept Reconstruct Sci, MC 3705,263 Farmington Ave, Farmington, CT 06032 USA.
EM ikalaj@neuron.uchc.edu
RI Matthews, Brya/B-9812-2013; Torreggiani, Elena/J-6404-2016
OI Matthews, Brya/0000-0002-4145-4696; Torreggiani,
Elena/0000-0001-7874-2002
FU NIH/NIAMS [AR059315]
FX We would like to thank Dr. Jerry Feng for providing us with 10 kb
Dmp1-Cre mice. The loading of bone tubes is a result of collaboration
with Dan Nicollela at Southwest Research Institute in San Antonio, TX.
We thank Dr. Teresita Bellido and Dr. Lilian Plotkin for their important
comments and suggestions. This work was supported by NIH/NIAMS grant
AR059315 to IK.
NR 118
TC 32
Z9 34
U1 3
U2 29
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 8756-3282
EI 1873-2763
J9 BONE
JI Bone
PD JUN
PY 2013
VL 54
IS 2
SI SI
BP 296
EP 306
DI 10.1016/j.bone.2012.09.040
PG 11
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 131NJ
UT WOS:000318000100017
PM 23072918
ER
PT J
AU Lin, E
Bredella, MA
Gerweck, AV
Landa, M
Schoenfeld, D
Utz, AL
Miller, KK
AF Lin, E.
Bredella, M. A.
Gerweck, A. V.
Landa, M.
Schoenfeld, D.
Utz, A. L.
Miller, K. K.
TI Effects of growth hormone withdrawal in obese premenopausal women
SO CLINICAL ENDOCRINOLOGY
LA English
DT Article
ID PLACEBO-CONTROLLED TRIAL; BODY-COMPOSITION; GH DEFICIENCY;
CARDIOVASCULAR RISK; VISCERAL FAT; RESONANCE SPECTROSCOPY; ABDOMINAL
ADIPOSITY; ADULTS; MEN; HYPOPITUITARISM
AB Objective We previously reported improved body composition and cardiovascular risk markers plus a small decrease in glucose tolerance with GH administration vs placebo for 6months to abdominally obese premenopausal women. The objective of this study was to determine whether the effects of GH treatment on cardiovascular risk markers, body composition and glucose tolerance in obese women persist 6months after GH withdrawal. Design and patients Fifty abdominally obese premenopausal women completed a trial of rhGH vs placebo for 6months; thirty-nine women completed a subsequent 6-month withdrawal observation period. Measurements IGF-I, body composition by CT, 1H-MRS and DXA, serum cardiovascular risk markers, oral glucose tolerance test (OGTT). Results IGF-I standard deviation scores (SDS) within the GH group were 1 center dot 7 +/- 0 center dot 1 (pretreatment),0 center dot 1 +/- 0 center dot 3 (after 6months of GH) and 1 center dot 7 +/- 0 center dot 1 (6months post-GH withdrawal). Six months after GH withdrawal, total abdominal and subcutaneous adipose tissue, total fat, trunk fat, trunk/extremity fat, hsCRP, apoB, LDL, and tPA were higher than at the 6-month (GH discontinuation) timepoint (P0 center dot 05). All body composition and cardiovascular risk markers that had improved with GH returned to baseline levels by 6months after GH discontinuation, as did fasting and 2-h OGTT glucose levels. Conclusion The effects of GH administration to abdominally obese premenopausal women have a short time-course. The beneficial effects on body composition and cardiovascular risk markers, and the side effect of altered glucose tolerance returned to pretreatment levels after GH withdrawal. There was no suppression of endogenous IGF-I levels, which returned to baseline after GH withdrawal.
C1 [Lin, E.; Gerweck, A. V.; Landa, M.; Miller, K. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Bredella, M. A.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Schoenfeld, D.] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
[Utz, A. L.] Vanderbilt, Pituitary Ctr, Nashville, TN USA.
RP Miller, KK (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Bulfinch 457B, Boston, MA 02114 USA.
EM KKMiller@partners.org
FU National Institutes of Health [R01 HL-077674, UL1 RR-025758, K23
RR-23090, T32 DK007028]
FX This work was supported in part by National Institutes of Health Grants
R01 HL-077674, UL1 RR-025758, K23 RR-23090, and T32 DK007028.
NR 23
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0300-0664
J9 CLIN ENDOCRINOL
JI Clin. Endocrinol.
PD JUN
PY 2013
VL 78
IS 6
BP 914
EP 919
DI 10.1111/cen.12102
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA 133AW
UT WOS:000318110800016
PM 23146135
ER
PT J
AU Haritha, AT
Wood, KH
Hoef, LWV
Knight, DC
AF Haritha, Abhishek T.
Wood, Kimberly H.
Hoef, Lawrence W. Ver
Knight, David C.
TI Human trace fear conditioning: right-lateralized cortical activity
supports trace-interval processes
SO COGNITIVE AFFECTIVE & BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE fMRI; Learning; Conditioning; Trace; Prefrontal; Parietal; Emotion;
Fear; Skin conductance
ID MEDIAL PREFRONTAL CORTEX; WORKING-MEMORY MAINTENANCE; HUMAN AMYGDALA
ACTIVITY; HIPPOCAMPAL INVOLVEMENT; BRAIN ACTIVATION; FUNCTIONAL MRI;
HUMAN DELAY; AWARENESS; FMRI; ACQUISITION
AB Pavlovian conditioning requires the convergence and simultaneous activation of neural circuitry that supports conditioned stimulus (CS) and unconditioned stimulus (US) processes. However, in trace conditioning, the CS and US are separated by a period of time called the trace interval, and thus do not overlap. Therefore, determining brain regions that support associative learning by maintaining a CS representation during the trace interval is an important issue for conditioning research. Prior functional magnetic resonance imaging (fMRI) research has identified brain regions that support trace-conditioning processes. However, relatively little is known about whether this activity is specific to the trace CS, the trace interval, or both periods of time. The present study was designed to disentangle the hemodynamic response produced by the trace CS from that associated with the trace interval, in order to identify learning-related activation during these distinct components of a trace-conditioning trial. Trace-conditioned activity was observed within dorsomedial prefrontal cortex (PFC), dorsolateral PFC, insula, inferior parietal lobule (IPL), and posterior cingulate (PCC). Each of these regions showed learning-related activity during the trace CS, while trace-interval activity was only observed within a subset of these areas (i.e., dorsomedial PFC, PCC, right dorsolateral PFC, right IPL, right superior/middle temporal gyrus, and bilateral insula). Trace-interval activity was greater in right than in left dorsolateral PFC, IPL, and superior/middle temporal gyrus. These findings indicate that components of the prefrontal, cingulate, insular, and parietal cortices support trace-interval processes, as well as suggesting that a right-lateralized fronto-parietal circuit may play a unique role in trace conditioning.
C1 [Haritha, Abhishek T.] Univ Alabama Birmingham, Dept Biol, Birmingham, AL 35294 USA.
[Wood, Kimberly H.; Knight, David C.] Univ Alabama Birmingham, Dept Psychol, Birmingham, AL 35294 USA.
[Hoef, Lawrence W. Ver] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Hoef, Lawrence W. Ver] Birmingham VA Med Ctr, Birmingham, AL USA.
RP Knight, DC (reprint author), CIRC 235H,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM knightdc@uab.edu
FU University of Alabama at Birmingham Faculty Development Grant Program;
Civitan International Research Center
FX A.T.H. and K. H. W. contributed equally to this work. This research was
supported by the University of Alabama at Birmingham Faculty Development
Grant Program and the Civitan International Research Center.
NR 60
TC 6
Z9 6
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1530-7026
EI 1531-135X
J9 COGN AFFECT BEHAV NE
JI Cogn. Affect. Behav. Neurosci.
PD JUN
PY 2013
VL 13
IS 2
BP 225
EP 237
DI 10.3758/s13415-012-0142-6
PG 13
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 131II
UT WOS:000317986100002
PM 23263840
ER
PT J
AU Leonardi, S
Stebbins, A
Lopes, RD
Lokhnygina, Y
Todd, M
Bhatt, DL
Stone, GW
Lincoff, AM
Dauerman, HL
Gibson, CM
White, HD
Parikh, KH
Gruberg, L
Herrmann, HC
McLaurin, BT
Goodman, SG
Mahaffey, KW
AF Leonardi, Sergio
Stebbins, Amanda
Lopes, Renato D.
Lokhnygina, Yuliya
Todd, Meredith
Bhatt, Deepak L.
Stone, Gregg W.
Lincoff, A. Michael
Dauerman, Harold L.
Gibson, C. Michael
White, Harvey D.
Parikh, Keyur H.
Gruberg, Luis
Herrmann, Howard C.
McLaurin, Brent T.
Goodman, Shaun G.
Mahaffey, Kenneth W.
TI Quantification of the effect of clopidogrel on enzymatic infarct size
related to a percutaneous coronary intervention in patients with acute
coronary syndromes: insights from the CHAMPION percutaneous coronary
intervention trial
SO CORONARY ARTERY DISEASE
LA English
DT Article
DE acute coronary syndrome; clopidogrel; enzymatic infarct size;
percutaneous coronary intervention
ID CREATINE KINASE-MB; MYOCARDIAL-INFARCTION; PHOSPHOKINASE ACTIVITY;
PLATELET INHIBITION; PCI; OUTCOMES; PRETREATMENT; CANGRELOR;
ASSOCIATION; DEFINITION
AB Objectives Using data from the CHAMPION percutaneous coronary intervention (PCI), we determined the relationship between clopidogrel started at least 5 days before PCI (maintenance of clopidogrel) and PCI-related enzymatic infarct size.
Background Clopidogrel is recommended in patients with acute coronary syndrome (ACS) managed with PCI, but its effect on PCI-related myonecrosis in contemporary patients has not been quantified.
Patients and methods Patients with ACS (with or without ST-segment elevation) who underwent PCI and had at least three creatine kinase-MB (CK-MB) samples after PCI were included. Enzymatic infarct size was defined as the peak CK-MB concentration indexed by its upper limit of normal. Associations between maintenance clopidogrel and enzymatic infarct size were explored using multivariable linear regression (with and without missing data imputation) and propensity score analysis using inverse probability weighting.
Results Of 8877 patients randomized, 6327 (71.3%) were included (median age 61 years, 73% male, 13% ACS with ST-segment elevation). Of these 6327 patients, 2015 (31.8%) were on maintenance clopidogrel. After multivariable adjustment, maintenance clopidogrel was associated with a reduction in enzymatic infarct size {beta = -0.63; 47% decrease in peak CK-MB [95% confidence interval (CI) 35, 56%]}. Multivariable linear regression with multiple imputations and inverse probability weighting propensity score analysis yielded similar results, with maintenance clopidogrel associated with 44% (95% CI 33, 53%) and 29% (95% CI 24, 33%) infarct size reductions.
Conclusion In this subgroup analysis of modern ACS patients, clopidogrel maintenance was independently associated with smaller enzymatic infarct size after PCI. These results are consistent with previous observations suggesting a benefit of clopidogrel on the procedural outcome and quantify this benefit. Coron Artery Dis 24:321-327 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Leonardi, Sergio] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Cardiol, Durham, NC 27705 USA.
[Lopes, Renato D.; Mahaffey, Kenneth W.] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Med, Durham, NC 27705 USA.
[Lokhnygina, Yuliya] Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Biostat & Bioinformat, Durham, NC 27705 USA.
[Stebbins, Amanda] Duke Univ, Med Ctr, Duke Clin Res Inst, Clin Trials Stat Grp, Durham, NC 27705 USA.
[Lokhnygina, Yuliya] Medicines Co, Parsippany, NJ USA.
[Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, VA Boston Healthcare Syst, Dept Med,Med Sch, Boston, MA 02115 USA.
[Gibson, C. Michael] Beth Israel Deaconess Med Ctr, Div Cardiol, Boston, MA 02215 USA.
[Stone, Gregg W.] Cardiovasc Res Fdn, New York, NY USA.
[Gruberg, Luis] SUNY Stony Brook, Med Ctr, Div Cardiovasc Med, Stony Brook, NY 11794 USA.
[Lincoff, A. Michael] Cleveland Clin, Coordinating Ctr Clin Res, Dept Cardiovasc Med, Cleveland, OH 44106 USA.
[Dauerman, Harold L.] Univ Vermont, Coll Med, Dept Med, Burlington, VT 05405 USA.
[Herrmann, Howard C.] Hosp Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
[McLaurin, Brent T.] AnMed Hlth, Anderson, SC USA.
[Leonardi, Sergio] Fdn IRCCS Policlin S Matteo, Pavia, Italy.
[White, Harvey D.] Auckland City Hosp, Green Lane Cardiovasc Serv, Auckland, New Zealand.
[Parikh, Keyur H.] Care Inst Med Sci, Ahmadabad, Gujarat, India.
[Goodman, Shaun G.] Canadian Heart Res Ctr, Div Cardiol, Dept Med, Toronto, ON, Canada.
[Goodman, Shaun G.] St Michaels Hosp, Toronto, ON M5B 1W8, Canada.
RP Leonardi, S (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Dept Cardiol, 2400 Pratt St,Room 0311 Terrace Level, Durham, NC 27705 USA.
EM sergio.leonardi@dm.duke.edu
OI Leonardi, Sergio/0000-0002-4800-6132
FU Bristol-Myers Squibb; Amarin; Astra Zeneca; Eisai; Ethicon; Medtronic;
Sanofi-Aventis; Medicines Company; Roche; Tekeda; Eli Lilly; Regado;
BMS; Merck; Novartis; Pfizer; Vivus; Abbott Vascular; Abbott; Angel
Medical Corporation; Baxter Healthcare; Genetech Inc.; Johnson & Johnson
Corporation; Lantheus Medical Imaging; Merck Co.; Roche Diagnostics;
Volcano Corp.; Walk Vascular; Atrium Medical System; Stealth Peptides
Inc.; St Jude Medical; NIH; Johnson Johnson; Schering Plough; Merck
Sharpe and Dohme; GSK; Daiichi Sankyo Pharma Development; Edwards
Lifesciences; Gore; Medicines Co., Siemens Medical
FX The CHAMPION PCI trial and the current analyses were funded by The
Medicines Company. The sponsor played no role in the conception and
design of the paper, but contributed to the interpretation of the
results.; Renato D. Lopes: Consultancy from Boehringer Ingelheim, Bayer,
Janssen, and Pfizer; grant support from Bristol-Myers Squibb.; Deepak L.
Bhatt: Advisory Board: Medscape Cardiology; Board of Directors: Boston
VA Research Institute, Society of Chest Pain Centers; Chair: American
Heart Association Get With The Guidelines Science Subcommittee;
Honoraria: American College of Cardiology (Editor, Clinical Trials,
Cardiosource), Duke Clinical Research Institute (clinical trial steering
committees), Slack Publications (Chief Medical Editor, Cardiology Today
Intervention), WebMD (CME steering committees); Other: Senior Associate
Editor, Journal of Invasive Cardiology; Research Grants: Amarin, Astra
Zeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic, Sanofi-Aventis,
The Medicines Company; Unfunded Research: FlowCo, PLx Pharma, Takeda.;
A. Michael Lincoff: Consultancy for Astra Zeneca, Roche, Ikaria, Merck,
Janseen, CSL Behring; grant support to institution from Roche, Tekeda,
Eli Lilly, Regado, Astra Zeneca, BMS, Merck, Novartis, Pfizer, Vivus.;
Harold L. Dauerman: Grant support from Abbott Vascular and Medtronic;
consulting fee/honorarium from The Medicines Company.; C. Michael
Gibson: Grant support and payment for development of educational
presentations from The Medicines Company; consultancy from Biogen Idec,
CSL Behring, GlaxoSmithKline, Genetech Inc., Ischemix Inc., Janssen
Pharmaceuticals, Johnson & Johnson Corporation, Merck & Co., Ortho
McNeil, Portola Pharmaceuticals Inc., Regado Biosciences, St Jude
Medical, The Medicines Company, Bayer Corp., Beacon BioSciences, ICON
Clinical Research, Bristol-Myers Squibb, Daiichi Sankyo Company Inc.,
Cytori Therapeutics, Eli Lilly & Co., ICON Medical Imaging,
Sanofi-Aventis Corporation; and grant support for his institution from
Abbott, Angel Medical Corporation, Baxter Healthcare, Genetech Inc.,
Johnson & Johnson Corporation, Lantheus Medical Imaging, Merck & Co.,
Roche Diagnostics, Volcano Corp., Walk Vascular, Atrium Medical System,
Bayer Corp., Ikaria Inc., Janssen Pharmaceuticals, Portola
Pharmaceuticals, Sanofi-Aventis, Stealth Peptides Inc., St Jude Medical;
royalties from UpToDate and Pocket Medicine.; Harvey D. White:
Consultancy (advisory boards) for Merck Sharpe and Dohme, Regardo
Biosciences; grant support from Sanofi-Aventis, Eli Lilly, Medicines
Company, NIH, Pfizer, Roche, Johnson & Johnson, Schering Plough, Merck
Sharpe and Dohme, Astra Zeneca, GSK, Daiichi Sankyo Pharma Development,
Bristol-Myers Squibb.; H. Herrmann: Consultant for Edwards Lifesciences,
St Jude Medical, Siemens Medical; grant support from Abbott Vascular,
Edwards Lifesciences, St Jude Medical, Medtronic, Gore, and Medicines
Co., Siemens Medical; stock/stock options from Microinterventional
Devices.
NR 27
TC 0
Z9 1
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0954-6928
J9 CORONARY ARTERY DIS
JI Coronary Artery Dis.
PD JUN
PY 2013
VL 24
IS 4
BP 321
EP 327
DI 10.1097/MCA.0b013e32835f2fbd
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 133QQ
UT WOS:000318154600010
PM 23442944
ER
PT J
AU Verkman, AS
Synder, D
Tradtrantip, L
Thiagarajah, JR
Anderson, MO
AF Verkman, Alan S.
Synder, David
Tradtrantip, Lukmanee
Thiagarajah, Jay R.
Anderson, Marc O.
TI CFTR Inhibitors
SO CURRENT PHARMACEUTICAL DESIGN
LA English
DT Article
DE Chloride channels; cystic fibrosis; diarrhea; polycystic kidney disease;
drug discovery
ID POLYCYSTIC KIDNEY-DISEASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; GREEN
FLUORESCENT PROTEIN; INTESTINAL FLUID SECRETION; SMALL-MOLECULE
CORRECTORS; AGE-DEPENDENT DIARRHEA; CYSTIC-FIBROSIS; CHLORIDE-CHANNEL;
ION-TRANSPORT; ANTIDIARRHEAL EFFICACY
AB The cystic fibrosis transmembrane conductance regulator (CFTR) protein is a cAMP-regulated Cl- channel whose major function is to facilitate epithelial fluid secretion. Loss-of-function mutations in CFTR cause the genetic disease cystic fibrosis. CFTR is required for transepithelial fluid transport in certain secretory diarrheas, such as cholera, and for cyst expansion in autosomal dominant polycystic kidney disease. High-throughput screening has yielded CFTR inhibitors of the thiazolidinone, glycine hydrazide and quinoxalinedione chemical classes. The glycine hydrazides target the extracellular CFTR pore, whereas the thiazolidinones and quinoxalinediones act at the cytoplasmic surface. These inhibitors have been widely used in cystic fibrosis research to study CFTR function at the cell and organ levels. The most potent CFTR inhibitor has IC50 of approximately 4 nM. Studies in animal models support the development of CFTR inhibitors for antisecretory therapy of enterotoxin-mediated diarrheas and polycystic kidney disease.
C1 [Verkman, Alan S.; Synder, David; Tradtrantip, Lukmanee; Thiagarajah, Jay R.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.
[Verkman, Alan S.; Synder, David; Tradtrantip, Lukmanee; Thiagarajah, Jay R.] Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA.
[Thiagarajah, Jay R.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Anderson, Marc O.] San Francisco State Univ, Dept Chem & Biochem, San Francisco, CA 94132 USA.
RP Verkman, AS (reprint author), Univ Calif San Francisco, 1246 Hlth Sci East Tower, San Francisco, CA 94143 USA.
EM Alan.Verkman@ucsf.edu
FU NIH; Cystic Fibrosis Foundation
FX We wish to thank former contributors in our lab to CFTR inhibitor
research, including Dr. Tonghui Ma for small-molecule screening, Dr
Sujatha Jayaraman for assay development, Dr. Nitin Sonawane for
synthetic chemistry, and Drs. Baoxue Yang, Dan Zhao, Byung-Ju Jin,
Chenyuan Yao and Wan Namkung for biological studies. Our CFTR inhibitor
work has been funded by the NIH and Cystic Fibrosis Foundation.
NR 78
TC 5
Z9 5
U1 1
U2 21
PU BENTHAM SCIENCE PUBL LTD
PI SHARJAH
PA EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB
EMIRATES
SN 1381-6128
J9 CURR PHARM DESIGN
JI Curr. Pharm. Design
PD JUN
PY 2013
VL 19
IS 19
BP 3529
EP 3541
PG 13
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA 133RN
UT WOS:000318157300018
PM 23331030
ER
PT J
AU Wen, LS
Anderson, PD
Stagelund, S
Sullivan, AF
Camargo, CA
AF Wen, Leana S.
Anderson, Philip D.
Stagelund, Soren
Sullivan, Ashley F.
Camargo, Carlos A., Jr.
TI National survey of emergency departments in Denmark
SO EUROPEAN JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE Denmark; emergency department classification; emergency medicine
administration; international emergency medicine
AB Objectives Emergency departments (EDs) are the basic unit of emergency medicine, but often differ in fundamental features. We sought to describe and characterize EDs in Denmark.
Methods All EDs open 24/7 to the general public were surveyed using the National ED Inventories survey instrument (http://www.emnet-nedi.org). ED staff were asked about ED characteristics with reference to the calendar year 2008.
Results Twenty-eight EDs participated (82% response). All were located in hospitals. Less than half [43%, 95% confidence interval (CI) 24-63%] were independent departments. Thirty-nine percent (95% CI 22-59%) had a contiguous layout, with medical and surgical care provided in one area. The vast majority of EDs saw both adults and children; only 10% saw adults only and none saw children only. The median number of annual visits was 32 000 (interquartile range, 14700-47 000). The majority (68%, 95% CI 47-89%) believed that their ED was at good balance or capacity, with 22% responding that they were under capacity and 9% reporting overcapacity. Technological resources were generally available, with the exception of dedicated computed tomography scanners and negative-pressure rooms. Almost all common emergencies were identified as being treatable 24/7 in the EDs.
Conclusion Although there is some variation in their layout and characteristics, most Danish EDs have a high degree of resource availability and are able to treat common emergencies. As Denmark seeks to reform emergency care through ED consolidation, this national survey helps to establish a benchmark for future comparisons. European Journal of Emergency Medicine 20:205-209 (c) 2013 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.
C1 [Wen, Leana S.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Harvard Affiliated Emergency Med Residency, Dept Emergency Med, Boston, MA 02114 USA.
[Anderson, Philip D.] Beth Israel Deaconess Med Ctr, Dept Emergency Med, Boston, MA 02215 USA.
[Sullivan, Ashley F.; Camargo, Carlos A., Jr.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Stagelund, Soren] Rigshosp, DK-2100 Copenhagen, Denmark.
RP Camargo, CA (reprint author), Massachusetts Gen Hosp, Dept Emergency Med, 326 Cambridge St,Suite 410, Boston, MA 02114 USA.
EM ccamargo@partners.org
OI Wen, Leana/0000-0003-0259-0537
NR 16
TC 4
Z9 4
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0969-9546
J9 EUR J EMERG MED
JI Eur. J. Emerg. Med.
PD JUN
PY 2013
VL 20
IS 3
BP 205
EP 209
DI 10.1097/MEJ.0b013e328354dd09
PG 5
WC Emergency Medicine
SC Emergency Medicine
GA 133QV
UT WOS:000318155200011
PM 22668810
ER
PT J
AU Mooney, JJ
Samson, JA
McHale, NL
Pappalarado, KM
Alpert, JE
Schildkraut, JJ
AF Mooney, John J.
Samson, Jacqueline A.
McHale, Nancy L.
Pappalarado, Kathleen M.
Alpert, Jonathan E.
Schildkraut, Joseph J.
TI Increased Gs alpha within blood cell membrane lipid microdomains in some
depressive disorders: An exploratory study
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Major depressive disorder; Adenylate cyclase; Gs alpha subunit; Membrane
lipid rafts
ID GUANINE-NUCLEOTIDE-BINDING; INDUCED HETEROLOGOUS DESENSITIZATION;
HORMONE-RELEASING HORMONE; ADENYLATE-CYCLASE; MAJOR DEPRESSION;
CYCLIC-AMP; G-PROTEIN; MONONUCLEAR LEUKOCYTES; REGULATORY COMPONENT;
RAFT DOMAINS
AB The stimulatory guanine nucleotide binding protein Gs couples many cellular receptors to adenylate cyclase, and the Gs alpha subunit activates all 9 isoforms of the adenylate cyclase catalytic unit to produce the enzyme product cyclicAMP or cAMP. In prefrontal cortex and cerebellum of unipolar depressive suicides, Rasenick and colleagues have found increased concentrations of Gs alpha in membrane lipid microdomains (Donati et al., 2008), where the ensconced Gs alpha is less likely to activate adenylate cyclase by receptor and postreceptor pathways (Allen et al., 2005, 2009).
We report that a group of 7 depressed patients (DP-1) had (1) reduced activation of platelet receptor-stimulated adenylate cyclase by both prostaglandins E2 and D2 compared to controls, and (2) reduced postreceptor stimulation of adenylate cyclase by aluminum fluoride ion in both platelets and mononuclear leukocytes when compared to both another group of depressed patients (DP-2, n = 17) and to controls (n = 21). Our observations in the blood cells of the group DP-1 support the findings of Donati et al. (2008), and they reflect the importance of this interaction between the activated Gs alpha subunit and membrane lipid microdomains in the pathophysiology and treatment of some major depressive disorders. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Mooney, John J.; Schildkraut, Joseph J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Samson, Jacqueline A.] McLean Hosp, Belmont, MA 02478 USA.
[McHale, Nancy L.] Smithers Viscient LLC, Dept Chem, Wareham, MA 02571 USA.
[Pappalarado, Kathleen M.] Associates Cape Cod Inc, Beacon Diagnost, Falmouth, MA 02536 USA.
[Alpert, Jonathan E.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Mooney, John J.; Samson, Jacqueline A.; Alpert, Jonathan E.; Schildkraut, Joseph J.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
RP Mooney, JJ (reprint author), Beth Israel Deaconess Med Ctr, Dept Psychiat, 330 Brookline Ave Rabb 2, Boston, MA 02215 USA.
EM jmooney@bidmc.harvard.edu
FU NIMH [MH-15413]; Abbott Laboratories; Alkermes; Lichtwer Pharma GmbH;
Lorex Pharmaceuticals; Aspect Medical Systems; Astra-Zeneca;
Bristol-Myers Squibb Company; Cephalon; Cyberonics; Eli Lilly Company;
Forest Pharmaceuticals Inc.; GlaxSmithKline; J&J Pharmaceuticals;
Novartis; Organon Inc.; PamLab LLC; Pfizer, Inc.; Pharmavite LLC; Roche;
Sanofi/Synthelabo; Solvay Pharmaceuticals Inc.; Wyeth-Ayerst
Laboratories; Belvoir Publishing
FX Funding for this study was provided by NIMH Grant Number MH-15413. The
NIMH had no further role in study design, in the collection, analysis,
and interpretation of data, in the writing of the report, and the
decision to submit the report for publication.; Research support: Abbott
Laboratories, Alkermes, Lichtwer Pharma GmbH, Lorex Pharmaceuticals,
Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb Company,
Cephalon, Cyberonics, Eli Lilly & Company, Forest Pharmaceuticals Inc.,
GlaxSmithKline, J&J Pharmaceuticals, Novartis, Organon Inc., PamLab LLC,
Pfizer, Inc., Pharmavite LLC, Roche, Sanofi/Synthelabo, Solvay
Pharmaceuticals Inc., and Wyeth-Ayerst Laboratories. JE Alpert has
participated on advisory boards for or consulted to: Eli Lilly &
Company, PamLab LCC, and Pharmavite LLC. JE Alpert has received
speakers' honoraria from Eli Lilly & Company, Xian-Janssen, Organon, MGH
Psychiatry Academy/Reed Medical Education and Primedia and from the
American Psychiatric Association, and has received editorial fees from
Belvoir Publishing. All other authors declare that they have no
conflicts of interest related to the work in this article.
NR 48
TC 1
Z9 1
U1 1
U2 5
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2013
VL 47
IS 6
BP 706
EP 711
DI 10.1016/j.jpsychires.2013.02.005
PG 6
WC Psychiatry
SC Psychiatry
GA 135ZH
UT WOS:000318328700002
PM 23490066
ER
PT J
AU Strauss, GP
Horan, WP
Kirkpatrick, B
Fischer, BA
Keller, WR
Miski, P
Buchanan, RW
Green, MF
Carpenter, WT
AF Strauss, Gregory P.
Horan, William P.
Kirkpatrick, Brian
Fischer, Bernard A.
Keller, William R.
Miski, Pinar
Buchanan, Robert W.
Green, Michael F.
Carpenter, William T., Jr.
TI Deconstructing negative symptoms of schizophrenia: Avolition-apathy and
diminished expression clusters predict clinical presentation and
functional outcome
SO JOURNAL OF PSYCHIATRIC RESEARCH
LA English
DT Article
DE Schizophrenia; Negative symptoms; Avolition; Apathy; Emotion; Blunted
affect
ID DEFICIT SYNDROME SCHIZOPHRENIA; NONDEFICIT SCHIZOPHRENIA; DIFFERENTIAL
PATTERNS; ASSESSMENT INTERVIEW; FACTORIAL STRUCTURE; FLAT AFFECT; SCALE;
VALIDATION; MEDICATION; SCHEDULE
AB Background: Previous studies indicate that negative symptoms reflect a separable domain of pathology from other symptoms of schizophrenia. However, it is currently unclear whether negative symptoms themselves are multi-faceted, and whether sub-groups of patients who display unique negative symptom profiles can be identified.
Methods: A data-driven approach was used to examine the heterogeneity of negative symptom presentations in two samples: Study 1 included 199 individuals with schizophrenia assessed with a standard measure of negative symptoms and Study 2 included 169 individuals meeting criteria for deficit schizophrenia (i.e., primary and enduring negative symptoms) assessed with a specialized measure of deficit symptoms. Cluster analysis was used to determine whether different groups of patients with distinct negative symptoms profiles could be identified.
Results: Across both studies, we found evidence for two distinctive negative symptom sub-groups: one group with predominantly Avolition-Apathy (AA) symptoms and another with a predominantly Diminished Expression (DE) profile. Follow-up discriminant function analyses confirmed the validity of these groups. AA and DE negative symptom sub-groups significantly differed on clinically relevant external validators, including measures of functional outcome, premorbid adjustment, clinical course, disorganized symptoms, social cognition, sex, and ethnicity.
Conclusions: These results suggest that distinct subgroups of patients with elevated AA or DE can be identified within the broader diagnosis of schizophrenia and that these subgroups show clinically meaningful differences in presentation. Additionally, AA tends to be associated with poorer outcomes than DE, suggesting that it may be a more severe aspect of psychopathology. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Strauss, Gregory P.; Fischer, Bernard A.; Keller, William R.; Miski, Pinar; Buchanan, Robert W.; Carpenter, William T., Jr.] Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, Baltimore, MD 21228 USA.
[Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
[Fischer, Bernard A.; Buchanan, Robert W.; Carpenter, William T., Jr.] VA Maryland Hlth Care Syst, Vet Affairs Capital Network VISN Mental Illness R, Baltimore, MD USA.
[Kirkpatrick, Brian] Texas A&M Coll Med, Dept Psychiat, Scott & White Healthcare, Temple, TX USA.
RP Strauss, GP (reprint author), Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Dept Psychiat, POB 21247, Baltimore, MD 21228 USA.
EM gstrauss@mprc.umaryland.edu
FU NIH [MH043292, P30MH068580]; UpToDate Incorporated
FX The current studies were supported in part by NIH Grants: MH043292 (M.F.
Green PI) and P30MH068580 (W.T. Carpenter PI). Study sponsors had no
role in study design, data collection, analysis and interpretation; the
writing of the report; and in the decision to submit the paper for
publication.; Dr. Carpenter served as a consultant for Genentech, Astra
Zeneca, and Merck. Dr. Green has served as a consultant for Abbott
laboratories, Amgen, and Shire. Dr. Kirkpatrick has served as a
consultant for Sunovion, Abbott, Boehringer Ingelheim. Dr Buchanan is on
the advisory boards of Amgen, Janssen Pharmaceuticals, Inc., NuPathe,
Inc., Pfizer, and Roche, and has served as a consultant to Abbott,
Amgen, EnVivo, and Pfizer. Dr. Buchanan is also a DSMB member for Pfizer
and Otsuka. Drs. Fischer receives royalties from UpToDate Incorporated.
Drs. Strauss, Horan, Keller, Miski report no financial relationships
with commercial interests.
NR 66
TC 78
Z9 78
U1 3
U2 33
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-3956
J9 J PSYCHIATR RES
JI J. Psychiatr. Res.
PD JUN
PY 2013
VL 47
IS 6
BP 783
EP 790
DI 10.1016/j.jpsychires.2013.01.015
PG 8
WC Psychiatry
SC Psychiatry
GA 135ZH
UT WOS:000318328700012
PM 23453820
ER
PT J
AU Naylor, DE
Liu, HT
Niquet, J
Wasterlain, CG
AF Naylor, David E.
Liu, Hantao
Niquet, Jerome
Wasterlain, Claude G.
TI Rapid surface accumulation of NMDA receptors increases glutamatergic
excitation during status epilepticus
SO NEUROBIOLOGY OF DISEASE
LA English
DT Article
DE NMDA receptor trafficking; Status epilepticus; Epilepsy; Hippocampus;
Synaptic excitation
ID METHYL-D-ASPARTATE; SUSTAINING STATUS EPILEPTICUS; PROTEIN-KINASE-C;
LONG-TERM POTENTIATION; PROLONGED STATUS EPILEPTICUS; LIMBIC STATUS
EPILEPTICUS; GABA(A) RECEPTORS; RAT HIPPOCAMPUS; SUBUNIT COMPOSITION;
AMPA RECEPTORS
AB After 1 h of lithium-pilocarpine status epilepticus (SE), immunocytochemical labeling of NMDA receptor NR1 subunits reveals relocation of subunits from the interior to the cell surface of dentate gyrus granule cells and CA3 pyramidal cells. Simultaneously, an increase in NMDA-miniature excitatory postsynaptic currents (mEPSC) as well as an increase in NMDA receptor-mediated tonic currents is observed in hippocampal slices after SE. Mean-variance analysis of NMDA-mEPSCs estimates that the number of functional postsynaptic NMDA receptors per synapse increases 38% during SE, and antagonism by ifenprodil suggests that an increase in the surface representation of NR2B-containing NMDA receptors is responsible for the augmentation of both the phasic and tonic excitatory currents with SE. These results provide a potential mechanism for an enhancement of glutamatergic excitation that maintains SE and may contribute to excitotoxic injury during SE. Therapies that directly antagonize NMDA receptors may be a useful therapeutic strategy during refractory SE. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Naylor, David E.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Dept Neurol, Torrance, CA 90509 USA.
[Naylor, David E.; Liu, Hantao; Niquet, Jerome; Wasterlain, Claude G.] Vet Adm Greater Los Angeles Healthcare Syst, Dept Neurol, Los Angeles, CA USA.
[Wasterlain, Claude G.] Univ Calif Los Angeles, Brain Res Inst, Torrance, CA 90509 USA.
[Naylor, David E.; Liu, Hantao; Niquet, Jerome; Wasterlain, Claude G.] Univ Calif Los Angeles, Dept Neurol, Torrance, CA 90509 USA.
RP Naylor, DE (reprint author), Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Vet Adm Greater Angeles Healthcare Syst, 1000 West Carson St Bldg N-25 Neurol 432, Torrance, CA 90509 USA.
EM dnaylor@ucla.edu
FU Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center;
VA Career Development Award; NINDS [N13515]
FX Support provided by the Los Angeles Biomedical Research Institute at
Harbor-UCLA Medical Center and a VA Career Development Award to D.N. and
by NINDS (N13515) to C.W.
NR 119
TC 34
Z9 35
U1 0
U2 15
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0969-9961
J9 NEUROBIOL DIS
JI Neurobiol. Dis.
PD JUN
PY 2013
VL 54
BP 225
EP 238
DI 10.1016/j.nbd.2012.12.015
PG 14
WC Neurosciences
SC Neurosciences & Neurology
GA 132EZ
UT WOS:000318052000022
PM 23313318
ER
PT J
AU Maleki, N
Brawn, J
Barmettler, G
Borsook, D
Becerra, L
AF Maleki, Nasim
Brawn, Jennifer
Barmettler, Gabi
Borsook, David
Becerra, Lino
TI Pain response measured with arterial spin labeling
SO NMR IN BIOMEDICINE
LA English
DT Article
DE pain; MRI; functional MRI; arterial spin labeling; arterial spin
tagging; perfusion; hemodynamics; blood flow
ID CEREBRAL-BLOOD-FLOW; BRAIN MECHANISMS; RADIO-FREQUENCY; RAT-BRAIN;
PERFUSION; FMRI; MRI; STIMULATION; QUANTIFICATION; MODULATION
AB The majority of functional MRI studies of pain processing in the brain use the blood oxygenation level-dependent (BOLD) imaging approach. However, the BOLD signal is complex as it depends on simultaneous changes in blood flow, vascular volume and oxygen metabolism. Arterial spin labeling (ASL) perfusion imaging is another imaging approach in which the magnetically labeled arterial water is used as an endogenous tracer that allows for direct measurement of cerebral blood flow. In this study, we assessed the pain response in the brain using a pulsed-continuous arterial spin labeling (pCASL) approach and a thermal stimulation paradigm. Using pCASL, response to noxious stimulation was detected in somatosensory cortex, anterior cingulate cortex, anterior insula, hippocampus, amygdala, thalamus and precuneus, consistent with the pain response activation patterns detected using the BOLD imaging approach. We suggest that pCASL is a reliable alternative for functional MRI pain studies in conditions in which blood flow, volume or oxygen extraction are altered or compromised. Copyright (c) 2013 John Wiley & Sons, Ltd.
C1 [Maleki, Nasim; Brawn, Jennifer; Barmettler, Gabi; Borsook, David; Becerra, Lino] Boston Childrens Hosp, PAIN Grp, Dept Anesthesia, Waltham, MA 02453 USA.
[Maleki, Nasim; Brawn, Jennifer; Barmettler, Gabi; Borsook, David; Becerra, Lino] Harvard Univ, Sch Med, Boston, MA USA.
[Borsook, David; Becerra, Lino] McLean Hosp, Dept Psychiat, PAIN Grp, Boston, MA USA.
[Borsook, David; Becerra, Lino] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Charlestown, MA USA.
[Borsook, David; Becerra, Lino] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Radiol, Charlestown, MA USA.
RP Maleki, N (reprint author), Boston Childrens Hosp, PAIN Grp, 9 Hope Ave, Waltham, MA 02453 USA.
EM nasim.maleki@childrens.harvard.edu
FU National Institutes of Health (NIH) [K24 NS064050, R01 NS056195]
FX This work was supported by grants from the National Institutes of Health
(NIH) [K24 NS064050 (National Institute of Neurological Disorders and
Stroke, NINDS) and R01 NS056195 (NINDS)] to DB.
NR 43
TC 6
Z9 6
U1 2
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0952-3480
J9 NMR BIOMED
JI NMR Biomed.
PD JUN
PY 2013
VL 26
IS 6
BP 664
EP 673
DI 10.1002/nbm.2911
PG 10
WC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
SC Biophysics; Radiology, Nuclear Medicine & Medical Imaging; Spectroscopy
GA 134RJ
UT WOS:000318231700008
PM 23319440
ER
PT J
AU Park, JR
Bagatell, R
London, WB
Maris, JM
Cohn, SL
Mattay, KM
Hogarty, M
AF Park, Julie R.
Bagatell, Rochelle
London, Wendy B.
Maris, John M.
Cohn, Susan L.
Mattay, Katherine M.
Hogarty, Michael
CA COG Neuroblastoma Comm
TI Children's Oncology Group's 2013 blueprint for research: Neuroblastoma
SO PEDIATRIC BLOOD & CANCER
LA English
DT Review
DE children; malignancies; neuroblastoma
ID HIGH-RISK NEUROBLASTOMA; STEM-CELL TRANSPLANTATION; MYCN GENE
AMPLIFICATION; STAGE-IV NEUROBLASTOMA; PHASE-I; REFRACTORY
NEUROBLASTOMA; N-MYC; MYELOABLATIVE CHEMOTHERAPY; METASTATIC
NEUROBLASTOMA; SPONTANEOUS REGRESSION
AB Estimated 5-year survival rates for patients with non-high-risk and high-risk neuroblastoma are 90% and 50%, respectively. Recent clinical trials have shown excellent outcomes with reduced therapy for non-high-risk disease. For patients with high-risk neuroblastoma treated with chemoradiotherapy, surgery, and stem cell transplantation, the addition of anti-disialoganglioside (GD2) immunotherapy plus cytokines improves survival. Upcoming trials will study the incorporation of targeted radionuclide therapy prior to myeloablative chemotherapy into high-risk treatment. Phase 2 trials will investigate druggable target(s) including mTOR inhibition and GD2-directed therapy in combination with chemotherapy for patients with recurrent neuroblastoma, and ALK inhibition for those with ALK-aberrant tumors. Pediatr Blood Cancer 2013; 60: 985993. (c) 2013 Wiley Periodicals, Inc.
C1 [Park, Julie R.] Univ Washington, Sch Med, Seattle Childrens Hosp, Seattle, WA USA.
[Park, Julie R.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Bagatell, Rochelle; Maris, John M.; Hogarty, Michael] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Bagatell, Rochelle; Maris, John M.; Hogarty, Michael] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[London, Wendy B.] Boston Childrens Hosp, Boston, MA USA.
[London, Wendy B.] Dana Farber Harvard Canc Ctr, Boston, MA USA.
[Cohn, Susan L.] Univ Chicago, Chicago, IL 60637 USA.
[Mattay, Katherine M.] Univ Calif San Francisco, Sch Med, San Francisco, CA USA.
[Mattay, Katherine M.] UCSF Benioff Childrens Hosp, San Francisco, CA USA.
RP Park, JR (reprint author), Seattle Childrens Hosp, Div Pediat Hematol & Oncol, 4800 Sandpoint Way NE,Mailstop B6553, Seattle, WA 98106 USA.
EM julie.park@seattlechildrens.org
OI Cohn, Susan/0000-0001-5749-7650
NR 121
TC 73
Z9 82
U1 5
U2 27
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
EI 1545-5017
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
IS 6
BP 985
EP 993
DI 10.1002/pbc.24433
PG 9
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 130QV
UT WOS:000317934800027
PM 23255319
ER
PT J
AU Dome, JS
Fernandez, CV
Mullen, EA
Kalapurakal, JA
Geller, JI
Huff, V
Gratias, EJ
Dix, DB
Ehrlich, PF
Khanna, G
Malogolowkin, MH
Anderson, JR
Naranjo, A
Perlman, EJ
AF Dome, Jeffrey S.
Fernandez, Conrad V.
Mullen, Elizabeth A.
Kalapurakal, John A.
Geller, James I.
Huff, Vicki
Gratias, Eric J.
Dix, David B.
Ehrlich, Peter F.
Khanna, Geetika
Malogolowkin, Marcio H.
Anderson, James R.
Naranjo, Arlene
Perlman, Elizabeth J.
CA COG Renal Tumors Comm
TI Children's Oncology Group's 2013 blueprint for research: Renal tumors
SO PEDIATRIC BLOOD & CANCER
LA English
DT Review
DE clear cell sarcoma; malignant rhabdoid tumor; renal cell carcinoma;
Wilms tumor
ID NATIONAL WILMS-TUMOR; ADVERSE PROGNOSTIC-FACTOR; CELL LUNG-CANCER;
FAVORABLE-HISTOLOGY; GENE-EXPRESSION; CLINICAL-FEATURES; INITIAL
TREATMENT; PEDIATRIC CANCER; RHABDOID TUMOR; ACTINOMYCIN-D
AB Renal malignancies are among the most prevalent pediatric cancers. The most common is favorable histology Wilms tumor (FHWT), which has 5-year overall survival exceeding 90%. Other pediatric renal malignancies, including anaplastic Wilms tumor, clear cell sarcoma, malignant rhabdoid tumor, and renal cell carcinoma, have less favorable outcomes. Recent clinical trials have identified gain of chromosome 1q as a prognostic marker for FHWT. Upcoming studies will evaluate therapy adjustments based on this and other novel biomarkers. For high-risk renal tumors, new treatment regimens will incorporate biological therapies. A research blueprint, viewed from the perspective of the Children's Oncology Group, is presented. Pediatr Blood Cancer 2013; 60: 9941000. (c) 2012 Wiley Periodicals, Inc.
C1 [Dome, Jeffrey S.] Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Div Oncol, Washington, DC 20010 USA.
[Fernandez, Conrad V.] IWK Hlth Ctr, Div Pediat Hematol Oncol, Halifax, NS, Canada.
[Mullen, Elizabeth A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kalapurakal, John A.] Ann & Robert H Lurie Childrens Hosp Chicago, Dept Radiat Oncol, Chicago, IL USA.
[Geller, James I.] Cincinnati Childrens Hosp Med Ctr, Div Oncol, Canc & Blood Dis Inst, Cincinnati, OH USA.
[Huff, Vicki] Univ Texas MD Anderson Canc Ctr, Dept Genet, Houston, TX 77030 USA.
[Gratias, Eric J.] Univ Tennessee, Coll Med, Childrens Hosp Erlanger, Div Hematol Oncol, Chattanooga, TN USA.
[Dix, David B.] British Columbia Childrens Hosp, Vancouver, BC V6H 3V4, Canada.
[Ehrlich, Peter F.] Univ Michigan, CS Mott Childrens Hosp, Dept Pediat Surg, Ann Arbor, MI 48109 USA.
[Khanna, Geetika] Washington Univ, Sch Med, Mallinckrodt Inst Radiol, St Louis, MO USA.
[Malogolowkin, Marcio H.] Childrens Hosp Wisconsin, Div Hematol Oncol Bone Marrow Transplant, Milwaukee, WI 53201 USA.
[Anderson, James R.] Univ Nebraska Med Ctr, Omaha, NE USA.
[Naranjo, Arlene] Univ Florida, Coll Med, Dept Biostat, Gainesville, FL USA.
[Naranjo, Arlene] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Biostat, Gainesville, FL USA.
[Perlman, Elizabeth J.] Northwestern Univ, Dept Pathol, Feinberg Sch Med, Chicago, IL 60611 USA.
[Perlman, Elizabeth J.] Robert H Lurie Canc Ctr, Chicago, IL USA.
RP Dome, JS (reprint author), Childrens Natl Med Ctr, Ctr Canc & Blood Disorders, Div Oncol, 111 Michigan Ave NW, Washington, DC 20010 USA.
EM jdome@childrensnational.org
FU National Institutes of Health [CA54498, CA42326]; Children's Oncology
Group [CA98543, CA98413, CA114766]
FX The research was supported by grants from the National Institutes of
Health to the National Wilms Tumor Study Group (CA54498 and CA42326) and
the Children's Oncology Group (CA98543, CA98413, and CA114766).
NR 62
TC 29
Z9 29
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
IS 6
BP 994
EP 1000
DI 10.1002/pbc.24419
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 130QV
UT WOS:000317934800028
PM 23255438
ER
PT J
AU Sung, L
Zaoutis, T
Ullrich, NJ
Johnston, D
Dupuis, L
Ladas, E
AF Sung, Lillian
Zaoutis, Theo
Ullrich, Nicole J.
Johnston, Donna
Dupuis, Lee
Ladas, Elena
CA Children's Oncology Grp Canc
TI Children's Oncology Group's 2013 blueprint for research: Cancer control
and supportive care
SO PEDIATRIC BLOOD & CANCER
LA English
DT Review
DE cancer control; cognition; infection; supportive care
ID QUALITY-OF-LIFE; ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA;
SCALE CHIMES CHILD; CONTENT VALIDITY; MORTALITY; UNDERSTANDABILITY;
ACCEPTABILITY; CHEMOTHERAPY; INFECTIONS
AB In cancer control research, the objective is to reduce overall morbidity and mortality by decreasing acute and delayed treatment-related toxicities in all children with cancer. To date, the Children's Oncology Group (COG) has focused on infection, neurocognition, quality of life (QoL), and nutrition/antiemetics. COG is conducting randomized controlled trials (RCTs) to determine prophylaxis strategies that will reduce infections in high-risk populations. Two RCTs are determining if modafinil or computerized cognitive training improve cognitive functioning in pediatric brain tumor patients. QoL is being assessed in acute leukemia patients. Improved supportive care outcomes will only occur when the most effective interventions are established. Pediatr Blood Cancer 2013; 60: 10271030. (c) 2012 Wiley Periodicals, Inc.
C1 [Sung, Lillian; Dupuis, Lee] Hosp Sick Children, Dept Haematol Oncol, Toronto, ON M5G 1X8, Canada.
[Sung, Lillian] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
[Zaoutis, Theo] Childrens Hosp Philadelphia, Div Infect Dis, Philadelphia, PA 19104 USA.
[Ullrich, Nicole J.] Boston Childrens Hosp, Dept Neurol, Boston, MA USA.
[Ullrich, Nicole J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Johnston, Donna] Childrens Hosp Eastern Ontario, Dept Hematol Oncol, Ottawa, ON K1H 8L1, Canada.
[Dupuis, Lee] Hosp Sick Children, Dept Pharm, Toronto, ON M5G 1X8, Canada.
[Ladas, Elena] Columbia Univ, Med Ctr, Dept Pediat Oncol, New York, NY USA.
RP Sung, L (reprint author), Hosp Sick Children, Div Haematol Oncol, 555 Univ Ave, Toronto, ON M5G 1X8, Canada.
EM lillian.sung@sickkids.ca
OI Dupuis, L.Lee/0000-0002-7699-1061
FU Statistics and Data Center Grant [U10 CA98413]; CCOP [U10 CA95861];
Division of Cancer Prevention; Canadian Institutes of Health Research;
[U10 CA98543]
FX Grant sponsor: Chair's Grant; Grant number: U10 CA98543; Grant sponsor:
Statistics and Data Center Grant; Grant number: U10 CA98413; Grant
sponsor: CCOP; Grant number: U10 CA95861; Grant sponsor: Division of
Cancer Prevention; Grant sponsor: Canadian Institutes of Health
Research.
NR 34
TC 10
Z9 10
U1 0
U2 12
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
IS 6
BP 1027
EP 1030
DI 10.1002/pbc.24426
PG 4
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 130QV
UT WOS:000317934800033
PM 23255159
ER
PT J
AU Noll, RB
Patel, SK
Embry, L
Hardy, KK
Pelletier, W
Annett, RD
Patenaude, A
Lown, EA
Sands, SA
Barakat, LP
AF Noll, Robert B.
Patel, Sunita K.
Embry, Leanne
Hardy, Kristina K.
Pelletier, Wendy
Annett, Robert D.
Patenaude, Andrea
Lown, E. Anne
Sands, Stephen A.
Barakat, Lamia P.
CA COG Behav Sci Comm
TI Children's Oncology Group's 2013 blueprint for research: Behavioral
science
SO PEDIATRIC BLOOD & CANCER
LA English
DT Review
DE behavioral science; children; clinical trials; malignancies; pediatric
cancer
ID CHILDHOOD-CANCER SURVIVORS; PSYCHOSOCIAL ASSESSMENT-TOOL; ACUTE
LYMPHOBLASTIC-LEUKEMIA; WORKING-MEMORY; PEDIATRIC CANCER; BRAIN-TUMORS;
SUSTAINED ATTENTION; HEALTH BEHAVIORS; ADULT SURVIVORS; RISK
AB Behavioral science has long played a central role in pediatric oncology clinical service and research. Early work focused on symptom relief related to side effects of chemotherapy and pain management related to invasive medical procedures. As survival rates improved, the focused has shifted to examination of the psychosocial impact, during and after treatment, of pediatric cancer and its treatment on children and their families. The success of the clinical trials networks related to survivorship highlights an even more critical role in numerous domains of psychosocial research and care. Within the cooperative group setting, the field of behavioral science includes psychologists, social workers, physicians, nurses, and parent advisors. The research agenda of this group of experts needs to focus on utilization of psychometrically robust measures to evaluate the impact of treatment on children with cancer and their families during and after treatment ends. Over the next 5 years, the field of behavioral science will need to develop and implement initiatives to expand use of standardized neurocognitive and behavior batteries; increase assessment of neurocognition using technology; early identification of at-risk children/families; establish standards for evidence-based psychosocial care; and leverage linkages with the broader behavioral health pediatric oncology community to translate empirically supported research clinical trials care to practice. Pediatr Blood Cancer 2013; 60: 10481054. (c) 2012 Wiley Periodicals, Inc.
C1 [Noll, Robert B.] Univ Pittsburgh, Dept Pediat, Med Ctr, Pittsburgh, PA 15260 USA.
[Patel, Sunita K.] City Hope Med Ctr, Dept Populat Sci, Duarte, CA USA.
[Patel, Sunita K.] City Hope Med Ctr, Dept Pediat, Duarte, CA USA.
[Patel, Sunita K.] City Hope Med Ctr, Dept Support Care Med, Duarte, CA USA.
[Embry, Leanne] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, San Antonio, TX 78229 USA.
[Hardy, Kristina K.] Childrens Natl Med Ctr, Neuropsychol Div, Washington, DC 20010 USA.
[Pelletier, Wendy] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
[Annett, Robert D.] Univ New Mexico, Dept Pediat, Hlth Sci Ctr, Albuquerque, NM 87131 USA.
[Patenaude, Andrea] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lown, E. Anne] Alcohol Res Grp, Emeryville, CA USA.
[Lown, E. Anne] Univ Calif San Francisco, Dept Family Hlth Care Nursing, San Francisco, CA 94143 USA.
[Sands, Stephen A.] Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA.
[Sands, Stephen A.] Columbia Univ Coll Phys & Surg, Dept Psychiat, New York, NY 10032 USA.
[Barakat, Lamia P.] Childrens Hosp Philadelphia, Div Oncol, Philadelphia, PA 19104 USA.
[Barakat, Lamia P.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA.
RP Noll, RB (reprint author), Dept Pediat, Child Dev Unit, 3420 5th Ave, Pittsburgh, PA 15217 USA.
EM nollrb2@upmc.edu
OI Hardy, Kristina/0000-0002-5479-5043
NR 49
TC 12
Z9 12
U1 1
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
IS 6
BP 1048
EP 1054
DI 10.1002/pbc.24421
PG 7
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 130QV
UT WOS:000317934800037
PM 23255478
ER
PT J
AU Abraham, A
Alsultan, A
Jeng, M
Rodriguez-Galindo, C
Campbell, PK
AF Abraham, Allistair
Alsultan, Abdulrahman
Jeng, Michael
Rodriguez-Galindo, Carlos
Campbell, Patrick K.
TI Clofarabine salvage therapy for refractory high-risk langerhans cell
histiocytosis
SO PEDIATRIC BLOOD & CANCER
LA English
DT Article
DE clofarabine; Langerhans cell histiocytosis
ID LEUKEMIA; TRANSPLANTATION
AB Pediatric patients with refractory multisystem Langerhans cell histiocytosis (LCH) have a poor prognosis despite aggressive chemotherapy. Salvage therapy with cytarabine and cladribine has shown promise as an effective treatment but is associated with significant toxicity. A previous report described two patients with refractory LCH who had a rapid response to single-agent clofarabine with minimal toxicity. In this report, we describe four children with refractory, risk-organ-positive LCH who were treated with clofarabine and provide follow-up for the two previously reported cases. The results support development of a formal trial evaluating clofarabine as front-line salvage for refractory LCH. Pediatr Blood Cancer 2013; 60: E19E22. (c) 2012 Wiley Periodicals, Inc.
C1 [Abraham, Allistair; Campbell, Patrick K.] St Jude Childrens Res Hosp, Dept Oncol, Memphis, TN 38105 USA.
[Alsultan, Abdulrahman] King Saud Univ, Coll Med, Riyadh 11461, Saudi Arabia.
[Jeng, Michael] Stanford Univ, Dept Pediat, Sch Med, Stanford, CA 94305 USA.
[Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
RP Campbell, PK (reprint author), St Jude Childrens Res Hosp, Dept Oncol, 262 Danny Thomas Pl, Memphis, TN 38105 USA.
EM patrick.campbell@stjude.org
OI Jeng, Michael/0000-0001-8200-8484
FU American Lebanese Syrian Associated Charities (ALSAC)
FX Grant sponsor: American Lebanese Syrian Associated Charities (ALSAC).
NR 14
TC 14
Z9 16
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
IS 6
BP E19
EP E22
DI 10.1002/pbc.24436
PG 4
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 130QV
UT WOS:000317934800007
PM 23255383
ER
PT J
AU Rosell, A
Agin, V
Rahman, M
Morancho, A
Ali, C
Koistinaho, J
Wang, XY
Vivien, D
Schwaninger, M
Montaner, J
AF Rosell, Anna
Agin, Veronique
Rahman, Mahbubur
Morancho, Anna
Ali, Carine
Koistinaho, Jari
Wang, Xiaoying
Vivien, Denis
Schwaninger, Markus
Montaner, Joan
TI Distal Occlusion of the Middle Cerebral Artery in Mice: Are We Ready to
Assess Long-Term Functional Outcome?
SO TRANSLATIONAL STROKE RESEARCH
LA English
DT Article
DE Ischemia; Mouse; Distal MCAO; Functional outcome
ID COGNITIVE DEFICITS; ISCHEMIC-STROKE; MOUSE; SENSORIMOTOR; RECOVERY;
MODELS; REPERFUSION; MECHANISMS; EXPRESSION; PROTECTS
AB Rodent animal models of stroke are widely used with brain ischemia inducible by various occlusion methods. Permanent or transient occlusion of the distal portion of the middle cerebral artery (MCAO) offers a reproducible model with low mortality rates, and it is the most likely model of choice for mid- and long-term studies to assess neurorepair or long-term effects of neuroprotective drugs. Therefore, a measurable and stable neurological assessment would be required to evaluate sensorimotor and cognitive deficits at short and long terms as suggested by the Stroke Therapy Academic Industry Roundtable preclinical recommendations. We review the usefulness of different tests used to measure functional outcome after distal MCAO in mice and further sustain these data with our own multilaboratories' experience. Results show that several tests were suitable to detect neurological deterioration at short term. Grip strength and latency to move have shown some usefulness at long term, with important differences between strains, while less clear are the data for the corner test. Important strain differences in terms of infarct volume are also reported in this study. Statistical power analysis and sample size calculation of our data confirmed the value of grip strength and latency to move tests but suggest that larger sample size would be required. In conclusion, there are no robust data supporting the use of a specific behavior test to assess long-term functional outcome after distal MCAO in mice. This is an important limitation since translational basic research should provide data to help further clinical trial evaluation. New multicenter studies with larger sample size and specific mouse strains are needed to confirm the validity of tests, such as the corner, latency to move or grip strength.
C1 [Rosell, Anna; Morancho, Anna; Montaner, Joan] Univ Autonoma Barcelona, Neurovasc Res Lab, Vall dHebron Res Inst, Barcelona 08035, Spain.
[Rosell, Anna; Morancho, Anna; Montaner, Joan] Univ Autonoma Barcelona, Dept Neurol, Vall dHebron Res Inst, Barcelona 08035, Spain.
[Agin, Veronique; Ali, Carine; Vivien, Denis] Univ Caen Basse Normandie, INSERM UMR S U919, Serine Proteases & Pathophysiol Neurovasc Unit, GIP CYCERON, Caen, France.
[Rahman, Mahbubur; Schwaninger, Markus] Med Univ Lubeck, Inst Expt & Clin Pharmacol & Toxicol, D-23538 Lubeck, Germany.
[Koistinaho, Jari] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, Kuopio, Finland.
[Wang, Xiaoying] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Neuroprotect Res Lab,Dept Neurol & Radiol,Neurosc, Boston, MA USA.
RP Rosell, A (reprint author), Univ Autonoma Barcelona, Neurovasc Res Lab, Vall dHebron Res Inst, PasseigValldHebron 119-129, Barcelona 08035, Spain.
EM anna.rosell@vhir.org
RI Morancho Retana, Anna/K-8804-2014; Montaner, Joan/D-3063-2015; IBIS,
NEUROVASCULAR/O-1855-2015;
OI Morancho Retana, Anna/0000-0001-9059-3206; Rahman, Md.
Mahbubur/0000-0003-3027-0354; VIVIEN, DENIS/0000-0002-7636-2185
FU Spanish Ministry of Health (Instituto de Salud Carlos III) [CP09/00265,
PI10/00694]; INSERM; French Ministry of Research and Technology;
Regional Council of Lower Normandy; European Union [201024, 202213];
ERANET-NEURON program from the Ministerio de Economia y Competitividad
[2011-1352]
FX A.R. is supported by the Miguel Servet program (CP09/00265) from the
Spanish Ministry of Health (Instituto de Salud Carlos III). V.A., C.A.
and D.V. works are supported by INSERM, French Ministry of Research and
Technology, and Regional Council of Lower Normandy. The research leading
to these results has received funding from the European Union's Seventh
Framework Program (FP7/2007-2013) under grant agreements No. 201024 and
202213 (European Stroke Network), the Spanish Ministry of Health
(Instituto de Salud Carlos III, grant agreement No. PI10/00694, and
RETICS program, RENEVAS network), and the ERANET-NEURON program from the
Ministerio de Economia y Competitividad (grant agreement No. 2011-1352).
NR 41
TC 17
Z9 17
U1 1
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1868-4483
J9 TRANSL STROKE RES
JI Transl. Stroke Res.
PD JUN
PY 2013
VL 4
IS 3
BP 297
EP 307
DI 10.1007/s12975-012-0234-1
PG 11
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA 136XU
UT WOS:000318397800003
PM 24323300
ER
PT J
AU Wilson, LB
Tregellas, JR
Slason, E
Pasko, BE
Hepburn, S
Rojas, DC
AF Wilson, Lisa B.
Tregellas, Jason R.
Slason, Erin
Pasko, Bryce E.
Hepburn, Susan
Rojas, Donald C.
TI Phonological processing in first-degree relatives of individuals with
autism: An fMRI study
SO HUMAN BRAIN MAPPING
LA English
DT Review
DE functional magnetic resonance imaging (fMRI); autism spectrum disorders
(ASD); broad autism phenotype (BAP); phonology; priming; nonword
repetition
ID FUNCTIONAL MAGNETIC-RESONANCE; SUPERIOR TEMPORAL GYRUS; VOXEL-BASED
MORPHOMETRY; VERBAL WORKING-MEMORY; PERVASIVE DEVELOPMENTAL DISORDERS;
POSITRON-EMISSION-TOMOGRAPHY; VISUAL WORD RECOGNITION;
SCHOOL-AGE-CHILDREN; LANGUAGE IMPAIRMENT; SPECTRUM DISORDERS
AB Autism spectrum disorders (ASD) are complex neurodevelopmental disorders. Twin studies have provided heritability estimates as high as 90% for idiopathic ASD. Further evidence for the spectrum's heritability is provided by the presence of the broad autism phenotype (BAP) in unaffected first-degree relatives. Language ability, specifically phonological processing, is proposed to be a core BAP trait. To date, however, no functional neuroimaging investigations of phonological processing in relatives of individuals with ASD have been undertaken. We conducted a functional magnetic resonance imaging (fMRI) study in parents of children with ASD utilizing a priming task probing implicit phonological processing. In our condition that placed heavier demands on phonological recoding, parents exhibited greater hemodynamic responses than controls in a network of cortical regions involved in phonological processing. Across conditions, parents exhibited enhanced priming-induced response suppression suggesting compensatory neural processing. A nonword repetition test used in previous studies of relatives was also administered. Correlations between this measure and our functional measures also suggested compensatory processing in parents. Regions exhibiting atypical responses in parents included regions previously implicated in the spectrum's language impairments and found to exhibit structural abnormalities in a parent study. These results suggest a possible neurobiological substrate of the phonological deficits proposed to be a core BAP trait. However, these results should be considered preliminary. No previous fMRI study has investigated phonological processing in ASD, so replication is required. Furthermore, interpretation of our fMRI results is limited by the fact that the parent group failed to exhibit behavioral evidence of phonological impairments. Hum Brain Mapp, 2013. (c) 2012 Wiley Periodicals, Inc.
C1 [Wilson, Lisa B.; Tregellas, Jason R.; Slason, Erin; Pasko, Bryce E.; Hepburn, Susan; Rojas, Donald C.] Univ Colorado Denver, Dept Psychiat, Aurora, CO 80045 USA.
[Tregellas, Jason R.] Denver VA Med Ctr, Res Serv, Dept Psychiat, Denver, CO USA.
RP Rojas, DC (reprint author), Univ Colorado Denver, Dept Psychiat, 13001 East 17th Pl, Aurora, CO 80045 USA.
EM don.rojas@ucdenver.edu
RI Tregellas, Jason/J-3637-2015;
OI Rojas, Don/0000-0001-6560-9616; Hepburn, Susan/0000-0002-8545-3804
FU Autism Speaks [2090]; Autism Speaks Weatherstone [6291]; National
Institutes of Health (NIH) [PHS R01 MH082020]; NIH/NCRR Colorado CTSI
[TL1 RR025778]; National Institute of Child Health and Human Development
(NICHHD) [HD041697]
FX Contract grant sponsor: Autism Speaks; Contract grant number: 2090;
Contract grant sponsor: Autism Speaks Weatherstone; Contract grant
number: 6291; Contract grant sponsor: National Institutes of Health
(NIH); Contract grant number: PHS R01 MH082020; Contract grant sponsor:
NIH/NCRR Colorado CTSI; Contract grant number: TL1 RR025778; Contract
grant sponsor: National Institute of Child Health and Human Development
(NICHHD); Contract grant number: HD041697.
NR 146
TC 6
Z9 7
U1 8
U2 44
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1065-9471
J9 HUM BRAIN MAPP
JI Hum. Brain Mapp.
PD JUN
PY 2013
VL 34
IS 6
BP 1447
EP 1463
DI 10.1002/hbm.22001
PG 17
WC Neurosciences; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA 129QA
UT WOS:000317855400016
PM 22419478
ER
PT J
AU Bergman, ME
Benzer, JK
Kabins, AH
Bhupatkar, A
Panina, D
AF Bergman, Mindy E.
Benzer, Justin K.
Kabins, Adam H.
Bhupatkar, Alok
Panina, Daria
TI An event-based perspective on the development of commitment
SO HUMAN RESOURCE MANAGEMENT REVIEW
LA English
DT Article
DE Commitment; Events; Organizational commitment; Values
ID PERSON-ORGANIZATION FIT; NORMATIVE COMMITMENT; JOB-SATISFACTION;
INTEGRATIVE MODEL; WORK COMMITMENT; MOTIVATION; BEHAVIOR; CONSTRUCTS;
IDENTIFICATION; COMPLEMENTARY
AB This paper proposes a new perspective on the development of commitment. We propose that organizational events are evaluated relative to a person's values to determine whether the person fits or misfits the organization. The fit information is then organized into commitment elements, which reflect the extent to which workplace events fit (relative to misfit) a particular value across events over time. We propose that elements are organized around values, not events, such that values are the main effect and events are the moderators of said effect on elements. Elements are, in turn, formative indicators of the latent commitment construct. They are the proximal causes of commitment. Multiple elements contribute to a single commitment and they are weighted via the value hierarchy. Our perspective contributes to the literature by: (a) being developmental; (b) focusing on events; and, (c) having implications for both within-person and between-person questions about commitment development. (C) 2012 Elsevier Inc. All rights reserved.
C1 [Bergman, Mindy E.; Kabins, Adam H.] Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
[Benzer, Justin K.] VA Boston Healthcare Syst, Boston, MA USA.
[Benzer, Justin K.] Boston Univ, Boston, MA 02215 USA.
[Panina, Daria] Texas A&M Univ, Dept Management, College Stn, TX 77843 USA.
RP Bergman, ME (reprint author), Texas A&M Univ, Dept Psychol, College Stn, TX 77843 USA.
EM mindybergman@tamu.edu
OI Bergman, Mindy/0000-0002-4529-4925; Benzer, Justin/0000-0001-5151-2127
NR 56
TC 2
Z9 2
U1 4
U2 19
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1053-4822
EI 1873-7889
J9 HUM RESOUR MANAGE R
JI Hum. Resour. Manage. Rev.
PD JUN
PY 2013
VL 23
IS 2
BP 148
EP 160
DI 10.1016/j.hrmr.2012.07.005
PG 13
WC Management
SC Business & Economics
GA 130AT
UT WOS:000317885800003
ER
PT J
AU Tevaarwerk, AJ
Lee, JW
Sesto, ME
Buhr, KA
Cleeland, CS
Manola, J
Wagner, LI
Chang, VTS
Fisch, MJ
AF Tevaarwerk, A. J.
Lee, J. W.
Sesto, M. E.
Buhr, K. A.
Cleeland, C. S.
Manola, J.
Wagner, L. I.
Chang, V. T. S.
Fisch, M. J.
TI Employment outcomes among survivors of common cancers: the Symptom
Outcomes and Practice Patterns (SOAPP) study
SO JOURNAL OF CANCER SURVIVORSHIP-RESEARCH AND PRACTICE
LA English
DT Article
DE Cancer survivor; Post-cancer employment; Work disability; Survivor
symptom burden; Return to work
ID QUALITY-OF-LIFE; RETURN-TO-WORK; BREAST-CANCER; PROSTATE-CANCER;
PROSPECTIVE COHORT; REHABILITATION; DIAGNOSIS; PAIN; MODERATE; FATIGUE
AB Risk factors for employment difficulties after cancer diagnosis are incompletely understood, and interventions to improve post-cancer employment remain few. New targets for intervention are needed.
We assessed a cohort of 530 nonmetastatic cancer patients (aged a parts per thousand currency signaEuro parts per thousand 65 years, > 6 months from diagnosis, off chemo- or radiotherapy) from the observational multi-site Symptom Outcomes and Practice Patterns study. Participants reported employment change, current employment, and symptoms. Groups were based on employment at survey (working full- or part-time versus not working) and whether there had been a change due to illness (yes versus no). The predictive power of symptom interference with work was evaluated for employment group (working stably versus no longer working). Race/ethnicity, gender, cancer type, therapy, and time since diagnosis were also assessed. Association between employment group and specific symptoms was examined.
The cohort was largely non-Hispanic white (76 %), female (85 %), and diagnosed with breast cancer (75 %); 24 % reported a change in employment. On multivariable analysis, participants with at least moderate symptom interference were more likely to report no longer working than their less effected counterparts (odds ratio (OR) = 8.0, 95 % CI, 4.2-15.4), as were minority participants compared with their non-Hispanic white counterparts (OR = 3.2, 95 % CI, 1.8-5.6). Results from the multiple regression model indicated the combination of fatigue (OR = 2.3, 95 % CI, 1.1-4.7), distress (OR = 3.9, 95 % CI, 1.7-9.0), and dry mouth (OR = 2.6, 95 % CI, 1.1-6.2) together with race/ethnicity and time since diagnosis adequately accounted for employment group.
Our findings support the hypothesis that residual symptom burden is related to post-cancer employment: Residual symptoms may be targets for intervention to improve work outcomes among cancer survivors.
This analysis examines whether increased symptom burden is associated with a change to not working following a cancer diagnosis. We also examined individual symptoms to assess which symptoms were most strongly associated with not working after a cancer diagnosis. Our hope is that we will be able to use this information to both screen survivors post-active treatment as well as target high-risk symptoms for further and more aggressive intervention, in an attempt to improve post-cancer work outcomes.
C1 [Tevaarwerk, A. J.] Univ Wisconsin, Carbone Comprehens Canc Ctr, Madison, WI 53705 USA.
[Lee, J. W.; Manola, J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Sesto, M. E.] Univ Wisconsin, Madison, WI 53706 USA.
[Buhr, K. A.] Univ Wisconsin, Madison, WI 53726 USA.
[Cleeland, C. S.; Fisch, M. J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Wagner, L. I.] Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
[Chang, V. T. S.] VA New Jersey Hlth Care Syst, E Orange, NJ USA.
RP Tevaarwerk, AJ (reprint author), Univ Wisconsin, Carbone Comprehens Canc Ctr, 1111 Highland Ave,Room 6037, Madison, WI 53705 USA.
EM at4@medicine.wisc.edu
FU Institute of Clinical and Translational Research KL2 Scholar grant
[9U54TR00021]; National Cancer Institute, National Institutes of Health
[CA3403, CA21076, CA17145, CA15488]; Department of Health and Human
Services
FX All authors report no financial disclosures. Dr. Tevaarwerk is supported
by an Institute of Clinical and Translational Research KL2 Scholar
grant, 9U54TR00021.; This study was conducted by the Eastern Cooperative
Oncology Group (Robert L. Comis, M. D.) and supported in part by Public
Health Service Grants CA3403, CA21076, CA17145, and CA15488, and from
the National Cancer Institute, National Institutes of Health, and the
Department of Health and Human Services. Its contents are solely the
responsibility of the authors and do not necessarily represent the
official views of the National Cancer Institute.
NR 70
TC 11
Z9 11
U1 4
U2 19
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1932-2259
J9 J CANCER SURVIV
JI J. Cancer Surviv.-Res. Pract.
PD JUN
PY 2013
VL 7
IS 2
BP 191
EP 202
DI 10.1007/s11764-012-0258-2
PG 12
WC Oncology; Social Sciences, Biomedical
SC Oncology; Biomedical Social Sciences
GA 129SP
UT WOS:000317862900003
PM 23378060
ER
PT J
AU Meisenhelder, JB
Schaeffer, NJ
Younger, J
Lauria, M
AF Meisenhelder, Janice Bell
Schaeffer, Nancy J.
Younger, Jerry
Lauria, Marisa
TI Faith and Mental Health in an Oncology Population
SO JOURNAL OF RELIGION & HEALTH
LA English
DT Article
DE Faith; Mental health; Cancer; Oncology; Spirituality
ID QUALITY-OF-LIFE; ADVANCED CANCER-PATIENTS; MEDICAL OUTCOMES;
TERMINALLY-ILL; SPIRITUAL CARE; RELIGIOSITY; DEPRESSION; GOD;
RELIGIOUSNESS; ASSOCIATIONS
AB This study compares faith attitudes versus behaviors for their relationship to mental health in current cancer patients and survivors. This cross-sectional survey of ambulatory patients included Hodge's intrinsic religious motivation scale, Benson & Spilka's concept of God scale, frequency of prayer, and the mental health subscale of the MOS SF-36. One hundred and fifty-eighty patients, mostly women with breast cancer, completed questionnaires (92% return). Mental health was positively related to a concept of a loving God (P < .001) and negatively related to the concept of a stern God (P < .002). Mental health was unrelated to goal of treatment (cure vs. chemotherapy/palliation), frequency of prayer, intrinsic faith motivation, or physical pain. Viewing God as loving was strongly related to better mental health, even in the presence of a poor prognosis or pain.
C1 [Meisenhelder, Janice Bell] MGH Inst Hlth Profess, Sch Nursing, Boston, MA USA.
[Schaeffer, Nancy J.] Massachusetts Gen Hosp, Ctr Canc, Med Oncol Unit, Boston, MA USA.
[Younger, Jerry] Harvard Univ, Sch Med, Boston, MA USA.
[Younger, Jerry] Massachusetts Gen Hosp, Ctr Canc, Gillett Ctr Breast Canc, Boston, MA USA.
[Lauria, Marisa] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Meisenhelder, JB (reprint author), 36 1st Ave, Boston, MA 02129 USA.
EM jmeisenhelder@mghihp.edu
NR 41
TC 2
Z9 2
U1 2
U2 29
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0022-4197
J9 J RELIG HEALTH
JI J. Relig. Health
PD JUN
PY 2013
VL 52
IS 2
BP 505
EP 513
DI 10.1007/s10943-011-9497-1
PG 9
WC Public, Environmental & Occupational Health; Religion
SC Public, Environmental & Occupational Health; Religion
GA 126NV
UT WOS:000317625500014
PM 21573903
ER
PT J
AU Elborai, Y
Blanchette, A
Maher, O
Lehmann, L
Lee, M
AF Elborai, Yasser
Blanchette, Andrew
Maher, Ossama
Lehmann, Leslie
Lee, Michelle
TI RENAL AND BONE MARROW TOXICITY IN PEDIATRIC HSCT PATIENTS ON ACYCLOVIR
PROPHYLAXIS
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Elborai, Yasser; Blanchette, Andrew; Maher, Ossama; Lehmann, Leslie; Lee, Michelle] Harvard Univ, Boston Childerns Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
SU 2
BP S13
EP S13
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 131HY
UT WOS:000317984800042
ER
PT J
AU Green, A
Langholz, B
Chintagumpala, M
Chevez-Barrios, P
Albert, D
Eagle, R
Rodriguez-Galindo, C
AF Green, Adam
Langholz, Bryan
Chintagumpala, Murali
Chevez-Barrios, Patricia
Albert, Daniel
Eagle, Ralph, Jr.
Rodriguez-Galindo, Carlos
TI RACE, ETHNICITY, AND INSURANCE STATUS CORRELATE WITH PATHOLOGICAL RISK
IN RETINOBLASTOMA: A CHILDREN'S ONCOLOGY GROUP (COG) STUDY
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Green, Adam; Langholz, Bryan; Chintagumpala, Murali; Chevez-Barrios, Patricia; Albert, Daniel; Eagle, Ralph, Jr.; Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
SU 2
BP S6
EP S7
PG 2
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 131HY
UT WOS:000317984800021
ER
PT J
AU Kentsis, A
Burns, M
Eisenberg, A
Ahmed, S
Gaewsky, L
Bradwin, G
He, Y
Naranjo, A
Gadd, S
Warren, P
Rodriguez-Galindo, C
Dome, J
Perlman, E
Steen, H
Mullen, E
AF Kentsis, Alex
Burns, Melissa
Eisenberg, Amy
Ahmed, Saima
Gaewsky, Lyvia
Bradwin, Gary
He, Ying
Naranjo, Arlene
Gadd, Samantha
Warren, Peter
Rodriguez-Galindo, Carlos
Dome, Jeffrey
Perlman, Elizabeth
Steen, Hanno
Mullen, Elizabeth
TI PROHIBITIN IS A PROGNOSTIC MARKER OF TREATMENT FAILURE AND THERAPEUTIC
TARGET TO BLOCK CHEMOTHERAPY RESISTANCE IN WILMS TUMOR
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Kentsis, Alex; Burns, Melissa; Eisenberg, Amy; Ahmed, Saima; Gaewsky, Lyvia; Bradwin, Gary; He, Ying; Naranjo, Arlene; Gadd, Samantha; Warren, Peter; Rodriguez-Galindo, Carlos; Dome, Jeffrey; Perlman, Elizabeth; Steen, Hanno; Mullen, Elizabeth] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
SU 2
BP S3
EP S3
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 131HY
UT WOS:000317984800010
ER
PT J
AU Shulman, D
Lehmann, L
AF Shulman, David
Lehmann, Leslie
TI INCIDENCE AND CAUSES OF HOSPITAL READMISSION FOR PEDIATRIC PATIENTS
UNDERGOING HEMATOIETIC CELL TRANSPLANT
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Shulman, David; Lehmann, Leslie] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
SU 2
BP S12
EP S12
PG 1
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 131HY
UT WOS:000317984800039
ER
PT J
AU Yi, J
Kesselheim, J
Kamihara, J
Davies, K
Van Hoff, J
Silverman, L
Mullen, E
AF Yi, Joanna
Kesselheim, Jennifer
Kamihara, Junne
Davies, Kimberly
Van Hoff, Jack
Silverman, Lewis
Mullen, Elizabeth
TI SYNCHRONOUS OCCURRENCE OF ACUTE LYMPHOBLASTIC LEUKEMIA AND WILMS TUMOR
IN TWO PATIENTS-UNDERLYING ETIOLOGY AND COMBINED TREATMENT PLAN
SO PEDIATRIC BLOOD & CANCER
LA English
DT Meeting Abstract
C1 [Yi, Joanna; Kesselheim, Jennifer; Kamihara, Junne; Davies, Kimberly; Van Hoff, Jack; Silverman, Lewis; Mullen, Elizabeth] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1545-5009
J9 PEDIATR BLOOD CANCER
JI Pediatr. Blood Cancer
PD JUN
PY 2013
VL 60
SU 2
BP S52
EP S53
PG 2
WC Oncology; Hematology; Pediatrics
SC Oncology; Hematology; Pediatrics
GA 131HY
UT WOS:000317984800180
ER
PT J
AU Gong, B
Pan, Y
Vempati, P
Zhao, W
Knable, L
Ho, L
Wang, J
Sastre, M
Ono, K
Sauve, AA
Pasinetti, GM
AF Gong, Bing
Pan, Yong
Vempati, Prashant
Zhao, Wei
Knable, Lindsay
Ho, Lap
Wang, Jun
Sastre, Magdalena
Ono, Kenjiro
Sauve, Anthony A.
Pasinetti, Giulio M.
TI Nicotinamide riboside restores cognition through an upregulation of
proliferator-activated receptor-gamma coactivator 1 alpha regulated
beta-secretase 1 degradation and mitochondrial gene expression in
Alzheimer's mouse models
SO NEUROBIOLOGY OF AGING
LA English
DT Article
DE Nicotinamide riboside; Alzheimer's disease; beta-secretase (BACE1);
Promotes peroxisome proliferator-activated receptor (PPAR)-gamma
coactivator 1 (PGC)-1 alpha; Ubiquitin-proteasome system; Mitochondrial
metabolism; Synaptic plasticity; Long-term potentiation
ID PERMEABILITY TRANSITION; SYNAPTIC FUNCTION; OXIDATIVE STRESS; TRANSGENIC
MICE; DISEASE; PGC-1-ALPHA; NAD(+); SIRT1; MECHANISM; DEMENTIA
AB Nicotinamide adenine dinucleotide (NAD)(+), a coenzyme involved in redox activities in the mitochondrial electron transport chain, has been identified as a key regulator of the lifespan-extending effects, and the activation of NAD(+) expression has been linked with a decrease in beta-amyloid (A beta) toxicity in Alzheimer's disease (AD). Nicotinamide riboside (NR) is a NAD(+) precursor, it promotes peroxisome proliferator-activated receptor-gamma coactivator 1 (PGC)-1 alpha expression in the brain. Evidence has shown that PGC-1 alpha is a crucial regulator of A beta generation because it affects beta-secretase (BACE1) degradation. In this study we tested the hypothesis that NR treatment in an AD mouse model could attenuate A beta toxicity through the activation of PGC-1 alpha-mediated BACE1 degradation. Using the Tg2576 AD mouse model, using in vivo behavioral analyses, biochemistry assays, small hairpin RNA (shRNA) gene silencing and electrophysiological recording, we found (1) dietary treatment of Tg2576 mice with 250 mg/kg/day of NR for 3 months significantly attenuates cognitive deterioration in Tg2576 mice and coincides with an increase in the steady-state levels of NAD(+) in the cerebral cortex; (2) application of NR to hippocampal slices (10 mu M) for 4 hours abolishes the deficits in long-term potentiation recorded in the CA1 region of Tg2576 mice; (3) NR treatment promotes PGC-1 alpha expression in the brain coinciding with enhanced degradation of BACE1 and the reduction of A beta production in Tg2576 mice. Further in vitro studies confirmed that BACE1 protein content is decreased by NR treatment in primary neuronal cultures derived from Tg2576 embryos, in which BACE1 degradation was prevented by PGC-1 alpha-shRNA gene silencing; and (4) NR treatment and PGC-1 alpha overexpression enhance BACE1 ubiquitination and proteasomal degradation. Our studies suggest that dietary treatment with NR might benefit AD cognitive function and synaptic plasticity, in part by promoting PGC-1 alpha-mediated BACE1 ubiquitination and degradation, thus preventing A beta production in the brain. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Gong, Bing; Pan, Yong; Vempati, Prashant; Zhao, Wei; Knable, Lindsay; Ho, Lap; Wang, Jun; Ono, Kenjiro; Pasinetti, Giulio M.] Mt Sinai Sch Med, Dept Neurol, Ctr Excellence Novel Approaches Neurotherapeut, New York, NY 10029 USA.
[Pasinetti, Giulio M.] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA.
[Sastre, Magdalena] Univ London Imperial Coll Sci Technol & Med, Div Brain Sci, London, England.
[Sauve, Anthony A.] Weill Cornell Med Coll, Dept Pharmacol, New York, NY USA.
RP Pasinetti, GM (reprint author), Mt Sinai Sch Med, Dept Neurol, 1468 Madison Ave, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
FU Veterans Administration, US National Institutes of Health; Alzheimer's
Association [IIRG-08-89354]
FX The studies described here were supported in part from a grant from the
Veterans Administration by the US National Institutes of Health grants
to G. M. P. and by grant from Alzheimer's Association (IIRG-08-89354) to
B. G. The authors thank Dr Ottavio Arancio (Columbia University) for his
advice on the reported electrophysiological recording and thank Ms.
Amanda Bilski for assisting in preparation of the manuscript.
NR 34
TC 53
Z9 54
U1 3
U2 50
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0197-4580
J9 NEUROBIOL AGING
JI Neurobiol. Aging
PD JUN
PY 2013
VL 34
IS 6
BP 1581
EP 1588
DI 10.1016/j.neurobiolaging.2012.12.005
PG 8
WC Geriatrics & Gerontology; Neurosciences
SC Geriatrics & Gerontology; Neurosciences & Neurology
GA 123UQ
UT WOS:000317417100008
PM 23312803
ER
PT J
AU Townsend, E
Chastain, PA
AF Townsend, Elise
Chastain, Patricia Anne
TI Commentary on "Reliability and Validity of the TIMPSI for Infants With
Spinal Muscular Atrophy Type I"
SO PEDIATRIC PHYSICAL THERAPY
LA English
DT Editorial Material
C1 [Townsend, Elise] Massachusetts Gen Hosp, MGH Inst Hlth Profess, Boston, MA 02114 USA.
[Townsend, Elise] Massachusetts Gen Hosp, Pediat Neuromuscular Clin, Boston, MA 02114 USA.
[Chastain, Patricia Anne] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Townsend, E (reprint author), Massachusetts Gen Hosp, MGH Inst Hlth Profess, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0898-5669
J9 PEDIATR PHYS THER
JI Pediatr. Phys. Ther.
PD SUM
PY 2013
VL 25
IS 2
BP 149
EP 149
DI 10.1097/PEP.0b013e31828a23c8
PG 1
WC Pediatrics; Rehabilitation
SC Pediatrics; Rehabilitation
GA 123GO
UT WOS:000317376600005
ER
PT J
AU Hernandez-Diaz, S
Su, YC
Mitchell, AA
Kelley, KE
Calafat, AM
Hauser, R
AF Hernandez-Diaz, Sonia
Su, Yung-Cheng
Mitchell, Allen A.
Kelley, Katherine E.
Calafat, Antonia M.
Hauser, Russ
TI Medications as a potential source of exposure to phthalates among women
of childbearing age
SO REPRODUCTIVE TOXICOLOGY
LA English
DT Article
DE Phthalate; Toxicology; Medications; Mesalamine; Male reproductive system
ID N-BUTYL PHTHALATE; SEXUAL-DIFFERENTIATION; ANOGENITAL DISTANCE; MALE
INFANTS; HUMAN URINE; MALE-RAT; METABOLITES; POPULATION
AB Objective: To evaluate the association between the use of medications potentially containing phthalates and urinary concentrations of specific phthalate metabolites around conception.
Methods: Women enrolled in the Environment and Reproductive Health project from 2006 to 2009 completed questionnaires about the use of medications and provided multiple urine samples before and after conception. We compared the mean urinary concentration of phthalate metabolites between users of phthalate containing medications and a matched unexposed control group.
Results: One woman used Asacol (R) (mesalamine), which utilizes dibutyl phthalate (DBP) as a delayed release coating material, and had a mean urinary concentration of the main DBP metabolite 200 times higher than the controls (8176 mu g/L vs. 37.5 mu g/L). The three users of stool softeners had a higher concentration of the main diethyl phthalate (DEP) metabolite (8636 mu g/L vs. 714.2 mu g/L). Neither the three additional Prilosec (R) (omeprazole) users nor one cyclobenzaprine user had higher urinary concentration than controls.
Conclusion: Selected medications may be important sources of DBP and DEP exposures around conception. (C) 2013 Elsevier Inc. All rights reserved.
C1 [Hernandez-Diaz, Sonia; Su, Yung-Cheng; Hauser, Russ] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Su, Yung-Cheng] Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, Dalin Township 622, Chiayi County, Taiwan.
[Mitchell, Allen A.; Kelley, Katherine E.] Boston Univ, Slone Epidemiol Ctr, Boston, MA 02215 USA.
[Calafat, Antonia M.] Ctr Dis Control & Prevent, Natl Ctr Environm Hlth, Atlanta, GA USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth HSPH, Dept Environm Hlth Occupat & Environm Med, Boston, MA 02115 USA.
[Hauser, Russ] Harvard Univ, Sch Publ Hlth HSPH, Program Epidemiol, Boston, MA 02115 USA.
[Hauser, Russ] Massachusetts Gen Hosp, Vincent Mem Obstet & Gynecol Serv, Boston, MA 02114 USA.
RP Su, YC (reprint author), Buddhist Tzu Chi Dalin Gen Hosp, Emergency Dept, 2 Minsheng Rd, Dalin Township 622, Chiayi County, Taiwan.
EM drsu119@gmail.com
OI Mitchell, Allen/0000-0003-0950-6799
FU National Institute of Environmental Health Sciences (NIEHS) [ES009718,
ES00002]; National Institute of Child Health and Human Development
[RO1HD059861]; Pfizer; ASISA
FX National Institute of Environmental Health Sciences (NIEHS) (grant
numbers: ES009718 and ES00002) and by the National Institute of Child
Health and Human Development (grant number RO1HD059861); The findings
and conclusions in this report are those of the authors and do not
necessarily represent the views of the U.S. Centers for Disease Control
and Prevention. The Pharmacoepidemiology Program at the Harvard School
of Public Health is supported by training grants from Pfizer and ASISA.
The Slone Epidemiology Center receives unrelated research support from
various pharmaceutical manufacturers, some of which may market products
containing phthalates.
NR 19
TC 19
Z9 20
U1 1
U2 29
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0890-6238
J9 REPROD TOXICOL
JI Reprod. Toxicol.
PD JUN
PY 2013
VL 37
BP 1
EP 5
DI 10.1016/j.reprotox.2013.01.001
PG 5
WC Reproductive Biology; Toxicology
SC Reproductive Biology; Toxicology
GA 121OM
UT WOS:000317254100001
PM 23333816
ER
PT J
AU Binder, F
Hayakawa, M
Choo, MK
Sano, Y
Park, JM
AF Binder, Flora
Hayakawa, Morisada
Choo, Min-Kyung
Sano, Yasuyo
Park, Jin Mo
TI Interleukin-4-induced beta-catenin regulates the conversion of
macrophages to multinucleated giant cells
SO MOLECULAR IMMUNOLOGY
LA English
DT Article
DE Macrophage; Cytokine; Beta-catenin
ID COLONY-STIMULATING FACTOR; IL-4 PRODUCTION; I INTERFERON; FUSION;
POLARIZATION; RESPONSES; ACTIVATION; BASOPHILS; MECHANISM; INFECTION
AB The cytokine interleukin-4 (IL-4) exerts pleiotropic effects on macrophages as it plays a key role in the immune response to infectious agents, allergens, and vaccines. Macrophages exposed to IL-4 drastically change their gene expression and metabolic state to adjust to new functional requirements. IL-4 also induces macrophages to fuse together and form multinucleated giant cells (MGCs). MGC formation is associated with chronic inflammation resulting from persistence of pathogenic microorganisms or foreign materials in tissues. Very little is known, however, about the mechanisms regulating IL-4-induced macrophage-to-MGC conversion. We observed a dramatic increase in beta-catenin protein but not mRNA amount in mouse macrophages following exposure to IL-4. To investigate the role of beta-catenin in macrophages, we generated mice with a myeloid cell-specific deletion of the beta-catenin gene. Ablation of beta-catenin expression did not affect the viability of macrophages or impair expression of known IL-4-inducible genes. Intriguingly, beta-catenin-deficient macrophages incubated with IL-4 formed MGCs with markedly greater efficiency than wild-type macrophages. Similar increases in multinucleated cell formation were detected in the peritoneal cavity of myeloid cell-specific beta-catenin knockout mice injected with chitin, which is known to induce endogenous IL-4 production. Our findings reveal beta-catenin as a novel regulator of macrophage responses to IL-4, and suggest that therapeutic modulation of its expression or function may help enhance the effectiveness or ameliorate the pathology of IL-4-driven immune responses. (C) 2012 Elsevier Ltd. All rights reserved.
C1 [Binder, Flora; Hayakawa, Morisada; Choo, Min-Kyung; Sano, Yasuyo; Park, Jin Mo] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA 02129 USA.
[Binder, Flora; Hayakawa, Morisada; Choo, Min-Kyung; Sano, Yasuyo; Park, Jin Mo] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Binder, Flora] Univ Grenoble 1, Unite Format & Rech Pharm, F-38706 La Tronche, France.
RP Park, JM (reprint author), Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, 149 13th St, Charlestown, MA 02129 USA.
EM jmpark@cbrc2.mgh.harvard.edu
FU US National Institutes of Health [AI070999]
FX This study was supported by the US National Institutes of Health grant
AI070999 (J.M.P.). F.B. was a recipient of a Bourse de mobilite
internationale etudiante Explo'ra sup - Region Rhone-Alpes.
NR 39
TC 3
Z9 3
U1 0
U2 45
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0161-5890
J9 MOL IMMUNOL
JI Mol. Immunol.
PD JUN
PY 2013
VL 54
IS 2
BP 157
EP 163
DI 10.1016/j.molimm.2012.12.004
PG 7
WC Biochemistry & Molecular Biology; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 094HP
UT WOS:000315253900007
PM 23287596
ER
PT J
AU Qi, W
Hosseini, A
Tsai, TY
Li, JS
Rubash, HE
Li, GA
AF Qi, Wei
Hosseini, Ali
Tsai, Tsung-Yuan
Li, Jing-Sheng
Rubash, Harry E.
Li, Guoan
TI In vivo kinematics of the knee during weight bearing high flexion
SO JOURNAL OF BIOMECHANICS
LA English
DT Article
DE In vivo knee kinematics; Cartilage contact; High flexion
ID POSTERIOR CRUCIATE LIGAMENT; LIVING KNEE; JOINT KINEMATICS; DEEP
FLEXION; MOVEMENT; CONTACT; MRI; OSTEOARTHRITIS; ARTHROPLASTY; WALKING
AB Achieving high flexion is an objective of contemporary total knee arthoplasty; however little is known on the knee biomechanics at high flexion under weight-bearing conditions. This study investigates the 6DOF kinematics and tibiofemoral cartilage contact biomechanics of the knee during weight-bearing flexion from full extension to maximal flexion. Eight knees from seven healthy subjects with no history of injuries or chronic pain were recruited. The knees were MRI scanned to create 3D models of the tibia and femur, including their articular cartilage surfaces. The subjects were then imaged using a dual fluoroscopic image system while performing a weight-bearing quasi-static single-legged lunge from full extension to maximal flexion. The 6DOF kinematics and the articular cartilage contact locations were measured along the flexion path of the knee. The result indicated that the internal tibial rotation increased sharply at low flexion angles (full extension to 30 degrees), maintained a small variation in the middle range of flexion (30-120 degrees, and then sharply increased again at high flexion angles (120 degrees to maximal flexion). The contact point moved similarly in the medial and lateral compartments before 120 degrees of flexion, but less on the medial compartment at high flexion angles. The results indicated that the knee motion could not be described using one character in the entire range of flexion, especially in high flexion. The knee kinematic data in the entire range of flexion of the knee could be instrumental for designing new knee prostheses to achieve physical high flexion and improving rehabilitation protocols after knee injuries. (C) 2013 Elsevier Ltd. All rights reserved.
C1 [Qi, Wei; Hosseini, Ali; Tsai, Tsung-Yuan; Li, Jing-Sheng; Rubash, Harry E.; Li, Guoan] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bioengn Lab,Dept Orthopaed Surg, Boston, MA 02114 USA.
[Qi, Wei] Chinese Peoples Liberat Army Gen Hosp, Dept Orthopaed Surg, Beijing 100853, Peoples R China.
RP Li, GA (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Bioengn Lab,Dept Orthopaed Surg, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM GLI1@PARTNERS.ORG
OI Tsai, Tsung-Yuan/0000-0003-1522-2987
FU National Institutes of Health [R01 AR055612]; Chinese PLA General
Hospital
FX The authors gratefully acknowledge the support of the National
Institutes of Health (R01 AR055612), and the scholarship provided by the
Chinese PLA General Hospital.
NR 35
TC 18
Z9 19
U1 1
U2 23
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0021-9290
J9 J BIOMECH
JI J. Biomech.
PD MAY 31
PY 2013
VL 46
IS 9
BP 1576
EP 1582
DI 10.1016/j.jbiomech.2013.03.014
PG 7
WC Biophysics; Engineering, Biomedical
SC Biophysics; Engineering
GA 170CQ
UT WOS:000320827700014
PM 23591448
ER
PT J
AU Gilkeson, GS
Mashmoushi, AK
Ruiz, P
Caza, TN
Perl, A
Oates, JC
AF Gilkeson, Gary S.
Mashmoushi, Ahmad K.
Ruiz, Phillip
Caza, Tiffany N.
Perl, Andras
Oates, Jim C.
TI Endothelial Nitric Oxide Synthase Reduces Crescentic and Necrotic
Glomerular Lesions, Reactive Oxygen Production, and MCP1 Production in
Murine Lupus Nephritis
SO PLOS ONE
LA English
DT Article
ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; SUPEROXIDE-PRODUCTION; OXIDATIVE
STRESS; REDOX REGULATION; GENETIC-ANALYSIS; MICE; ERYTHEMATOSUS; CELLS;
TETRAHYDROBIOPTERIN; INHIBITION
AB Systemic lupus erythematosus, in both animal models and in humans, is characterized by autoantibody production followed by immune complex deposition in target tissues. Ensuing target organ damage is modulated by reactive intermediates, including reactive nitrogen and oxygen species, through as of now incompletely understood mechanisms. Endothelial nitric oxide synthase is known to impact vascular reactivity; however its impact on reactive intermediate production and inflammatory renal disease is less well defined. In this study, we assessed the impact of endothelial nitric oxide synthase (eNOS) on disease in lupus prone MRL/lpr mice. Mice lacking eNOS developed earlier more severe disease with decreased survival. eNOS deficient mice died sooner and developed significantly more glomerular crescents, necrosis, inflammatory infiltrates and vasculitis, indicating a role for eNOS in modulating these renal lesions. Immune complex deposition was similar between groups, indicating the impact of eNOS is distal to antibody/complement glomerular deposition. Urinary nitric oxide production was decreased in the eNOS deficient mice, while proteinuria was increased. Urinary monocyte chemotactic protein-1 was also increased in the knockout mice. CD4+ T cells from MRL/lpr mice demonstrated mitochondrial hyperpolarization, increased nitric oxide and superoxide production and increased calcium flux compared to B6 control mice. Deficiency of eNOS resulted in decreased nitric oxide and mitochondrial calcium levels but had no effect on mitochondrial hyperpolarization. Renal cortices from MRL/lpr mice that are eNOS deficient demonstrated increased superoxide production, which was blocked by both nitric oxide synthase and NADPH oxidase inhibitors. These studies thus demonstrate a key role for eNOS in modulating renal disease in lupus prone MRL/lpr mice. The impact appears to be mediated by effects on superoxide production in the kidney, impacting downstream mediators such as monocyte chemotactic protein-1. These results suggest that modulation of eNOS may be a novel therapeutic approach to treating lupus nephritis.
C1 [Gilkeson, Gary S.; Mashmoushi, Ahmad K.; Oates, Jim C.] Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
[Gilkeson, Gary S.; Oates, Jim C.] Ralph H Johnson VA Med Ctr, Med Serv, Charleston, SC USA.
[Ruiz, Phillip] Univ Miami, Miller Sch Med, Dept Surg & Pathol, Transplant Labs & Immunopathol, Miami, FL 33136 USA.
[Caza, Tiffany N.; Perl, Andras] SUNY Upstate Med Univ, Dept Med, Div Rheumatol, Syracuse, NY 13210 USA.
RP Oates, JC (reprint author), Med Univ S Carolina, Dept Med, Div Rheumatol & Immunol, Charleston, SC 29425 USA.
EM oatesjc@musc.edu
OI Perl, Andras/0000-0002-5017-1348
FU Medical University of SC Clinical and Translational Science Award (NIH)
[UL1TR000062]; National Institutes of Health [R01-AR045476,
T32-GM008716, AI048079, AI072648]; Alliance for Lupus Research; Central
New York Community Foundation
FX This work was supported by the Medical University of SC Clinical and
Translational Science Award (NIH grant UL1TR000062) and National
Institutes of Health grant numbers R01-AR045476 and T32-GM008716. This
work was supported in part by grants AI048079 and AI072648 from the
National Institutes of Health, the Alliance for Lupus Research, and the
Central New York Community Foundation
(http://grants.nih.gov/grants/oer.htm). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 43
TC 9
Z9 10
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e64650
DI 10.1371/journal.pone.0064650
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900072
PM 23741359
ER
PT J
AU Glass, K
Huttenhower, C
Quackenbush, J
Yuan, GC
AF Glass, Kimberly
Huttenhower, Curtis
Quackenbush, John
Yuan, Guo-Cheng
TI Passing Messages between Biological Networks to Refine Predicted
Interactions
SO PLOS ONE
LA English
DT Article
ID GENE-EXPRESSION DATA; REGULATORY NETWORKS; TRANSCRIPTIONAL NETWORKS;
SACCHAROMYCES-CEREVISIAE; CELL-CYCLE; GENOMIC DATA; CHIP-CHIP; S-PHASE;
INFERENCE; YEAST
AB Regulatory network reconstruction is a fundamental problem in computational biology. There are significant limitations to such reconstruction using individual datasets, and increasingly people attempt to construct networks using multiple, independent datasets obtained from complementary sources, but methods for this integration are lacking. We developed PANDA (Passing Attributes between Networks for Data Assimilation), a message-passing model using multiple sources of information to predict regulatory relationships, and used it to integrate protein-protein interaction, gene expression, and sequence motif data to reconstruct genome-wide, condition-specific regulatory networks in yeast as a model. The resulting networks were not only more accurate than those produced using individual data sets and other existing methods, but they also captured information regarding specific biological mechanisms and pathways that were missed using other methodologies. PANDA is scalable to higher eukaryotes, applicable to specific tissue or cell type data and conceptually generalizable to include a variety of regulatory, interaction, expression, and other genome-scale data. An implementation of the PANDA algorithm is available at www.sourceforge.net/projects/panda-net.
C1 [Glass, Kimberly; Quackenbush, John; Yuan, Guo-Cheng] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Glass, Kimberly; Huttenhower, Curtis; Quackenbush, John; Yuan, Guo-Cheng] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
RP Yuan, GC (reprint author), Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM gcyuan@jimmy.harvard.edu
OI Huttenhower, Curtis/0000-0002-1110-0096
FU National Heart, Lung and Blood Institute [1P01HL105339, R01HL111759];
National Science Foundation [NSF DBI-1053486]; Claudia Adams Barr Award
FX This work was supported, in part, by the grants 1P01HL105339 and
R01HL111759 from the National Heart, Lung and Blood Institute as well as
NSF DBI-1053486 from the National Science Foundation. This research was
supported by a Claudia Adams Barr Award to GY. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 58
TC 15
Z9 15
U1 1
U2 10
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR UNSP e64832
DI 10.1371/journal.pone.0064832
PG 14
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900115
PM 23741402
ER
PT J
AU Jeselsohn, RM
Werner, L
Regan, MM
Fatima, A
Gilmore, L
Collins, LC
Beck, AH
Bailey, ST
He, HH
Buchwalter, G
Brown, M
Iglehart, JD
Richardson, A
Come, SE
AF Jeselsohn, Rinath M.
Werner, Lillian
Regan, Meredith M.
Fatima, Aquila
Gilmore, Lauren
Collins, Laura C.
Beck, Andrew H.
Bailey, Shannon T.
He, Housheng Hansen
Buchwalter, Gilles
Brown, Myles
Iglehart, J. Dirk
Richardson, Andrea
Come, Steven E.
TI Digital Quantification of Gene Expression in Sequential Breast Cancer
Biopsies Reveals Activation of an Immune Response
SO PLOS ONE
LA English
DT Article
ID CORE NEEDLE-BIOPSY; ESTROGEN-RECEPTOR; GROWTH-FACTOR; TUMOR;
ANASTROZOLE; TAMOXIFEN; TRIAL; PROLIFERATION; CHEMOTHERAPY; INFLAMMATION
AB Advancements in molecular biology have unveiled multiple breast cancer promoting pathways and potential therapeutic targets. Large randomized clinical trials remain the ultimate means of validating therapeutic efficacy, but they require large cohorts of patients and are lengthy and costly. A useful approach is to conduct a window of opportunity study in which patients are exposed to a drug pre-surgically during the interval between the core needle biopsy and the definitive surgery. These are non-therapeutic studies and the end point is not clinical or pathological response but rather evaluation of molecular changes in the tumor specimens that can predict response. However, since the end points of the non-therapeutic studies are biologic, it is critical to first define the biologic changes that occur in the absence of treatment. In this study, we compared the molecular profiles of breast cancer tumors at the time of the diagnostic biopsy versus the definitive surgery in the absence of any intervention using the Nanostring nCounter platform. We found that while the majority of the transcripts did not vary between the two biopsies, there was evidence of activation of immune related genes in response to the first biopsy and further investigations of the immune changes after a biopsy in early breast cancer seem warranted.
C1 [Jeselsohn, Rinath M.; Bailey, Shannon T.; He, Housheng Hansen; Buchwalter, Gilles; Brown, Myles] Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
[Jeselsohn, Rinath M.; Bailey, Shannon T.; He, Housheng Hansen; Buchwalter, Gilles; Brown, Myles] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Jeselsohn, Rinath M.; Bailey, Shannon T.; He, Housheng Hansen; Buchwalter, Gilles; Brown, Myles] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA 02115 USA.
[Werner, Lillian; Regan, Meredith M.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Werner, Lillian; Regan, Meredith M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Fatima, Aquila; Iglehart, J. Dirk; Richardson, Andrea] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02115 USA.
[Gilmore, Lauren; Collins, Laura C.; Beck, Andrew H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Pathol, Boston, MA 02215 USA.
[Iglehart, J. Dirk] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Surg, Boston, MA 02215 USA.
[Richardson, Andrea] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Pathol, Boston, MA 02215 USA.
[Come, Steven E.] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Breast Med Oncol Program, Boston, MA 02215 USA.
RP Brown, M (reprint author), Dana Farber Canc Inst, Ctr Funct Canc Epigenet, Boston, MA 02115 USA.
EM myles_brown@dfci.harvard.edu; scome@bidmc.harvard.edu
RI Bailey, Shannon/B-8045-2014;
OI Brown, Myles/0000-0002-8213-1658
FU National Cancer Institute (NCI): DF/HCC SPORE in Breast Cancer [P50
CA089393, P01CA080111]
FX This study was supported by the National Cancer Institute (NCI): DF/HCC
SPORE in Breast Cancer (P50 CA089393) and P01CA080111. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 37
TC 5
Z9 5
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e64225
DI 10.1371/journal.pone.0064225
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900020
PM 23741308
ER
PT J
AU Venkatesh, KK
Becker, JE
Kumarasamy, N
Nakamura, YM
Mayer, KH
Losina, E
Swaminathan, S
Flanigan, TP
Walensky, RP
Freedberg, KA
AF Venkatesh, Kartik K.
Becker, Jessica E.
Kumarasamy, Nagalingeswaran
Nakamura, Yoriko M.
Mayer, Kenneth H.
Losina, Elena
Swaminathan, Soumya
Flanigan, Timothy P.
Walensky, Rochelle P.
Freedberg, Kenneth A.
TI Clinical Impact and Cost-Effectiveness of Expanded Voluntary HIV Testing
in India
SO PLOS ONE
LA English
DT Article
ID 1ST-LINE ANTIRETROVIRAL THERAPY; OBSERVATIONAL DATABASE;
DEVELOPING-COUNTRIES; SOUTHERN INDIA; COTE-DIVOIRE; SCALING-UP; VIRAL
LOAD; INFECTION; TRANSMISSION; METAANALYSIS
AB Background: Despite expanding access to antiretroviral therapy (ART), most of the estimated 2.3 to 2.5 million HIV-infected individuals in India remain undiagnosed. The questions of whom to test for HIV and at what frequency remain unclear.
Methods: We used a simulation model of HIV testing and treatment to examine alternative HIV screening strategies: 1) current practice, 2) one-time, 3) every five years, and 4) annually; and we applied these strategies to three population scenarios: 1) the general Indian population ("national population''), i.e. base case (HIV prevalence 0.29%; incidence 0.032/100 person-years [PY]); 2) high-prevalence districts (HIV prevalence 0.8%; incidence 0.088/100 PY), and 3) high-risk groups (HIV prevalence 5.0%; incidence 0.552/100 PY). Cohort characteristics reflected Indians reporting for HIV testing, with a median age of 35 years, 66% men, and a mean CD4 count of 305 cells/mu l. The cost of a rapid HIV test was $3.33. Outcomes included life expectancy, HIV-related direct medical costs, incremental cost-effectiveness ratios (ICERs), and secondary transmission benefits. The threshold for "cost-effective" was defined as 3x the annual per capita GDP of India ($3,900/year of life saved [YLS]), or for "very cost-effective" was <1x the annual per capita GDP ($1,300/YLS).
Results: Compared to current practice, one-time screening was very cost-effective in the national population (ICER: $1,100/YLS), high-prevalence districts (ICER: $800/YLS), and high-risk groups (ICER: $800/YLS). Screening every five years in the national population (ICER: $1,900/YLS) and annual screening in high-prevalence districts (ICER: $1,900/YLS) and high-risk groups (ICER: $1,800/YLS) were also cost-effective. Results were most sensitive to costs of care and linkage-to-care.
Conclusions: In India, voluntary HIV screening of the national population every five years offers substantial clinical benefit and is cost-effective. Annual screening is cost-effective among high-risk groups and in high-prevalence districts nationally. Routine HIV screening in India should be implemented.
C1 [Venkatesh, Kartik K.; Flanigan, Timothy P.] Brown Univ, Miriam Hosp, Alpert Med Sch, Dept Med,Div Infect Dis, Providence, RI USA.
[Becker, Jessica E.] Yale Univ, Sch Med, New Haven, CT USA.
[Kumarasamy, Nagalingeswaran] YR Gaitonde Ctr AIDS Res & Educ, Madras, Tamil Nadu, India.
[Mayer, Kenneth H.] Fenway Hlth, Boston, MA USA.
[Mayer, Kenneth H.] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Dept Med, Boston, MA 02215 USA.
[Swaminathan, Soumya] Indian Council Med Res, TB Res Ctr, Dept Clin Res, Madras, Tamil Nadu, India.
[Swaminathan, Soumya] WHO, CH-1211 Geneva, Switzerland.
[Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Nakamura, Yoriko M.; Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nakamura, Yoriko M.; Walensky, Rochelle P.; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Dept Med, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Walensky, Rochelle P.] Brigham & Womens Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Mayer, Kenneth H.; Losina, Elena; Walensky, Rochelle P.; Freedberg, Kenneth A.] Harvard Univ, Sch Med, Ctr AIDS Res, Boston, MA USA.
[Freedberg, Kenneth A.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Freedberg, Kenneth A.] Boston Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA USA.
[Losina, Elena] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA USA.
RP Freedberg, KA (reprint author), Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
EM kfreedberg@partners.org
OI Walensky, Rochelle P./0000-0002-8795-379X
FU National Institute of Allergy and Infectious Diseases [R01 AI058736]
FX The Cost-effectiveness of Prevention AIDS Complications -
International(CEPAC-I) Group is funded by National Institute of Allergy
and Infectious Diseases (Grant no. National Institute of Allergy and
Infectious Diseases, R01 AI058736). The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 61
TC 12
Z9 12
U1 0
U2 3
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 31
PY 2013
VL 8
IS 5
AR e64604
DI 10.1371/journal.pone.0064604
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 156DC
UT WOS:000319799900061
PM 23741348
ER
PT J
AU Feng, L
Sharma, A
Slaughter, A
Jena, N
Koh, Y
Shkriabai, N
Larue, RC
Patel, PA
Mitsuya, H
Kessl, JJ
Engelman, A
Fuchs, JR
Kvaratskhelia, M
AF Feng, Lei
Sharma, Amit
Slaughter, Alison
Jena, Nivedita
Koh, Yasuhiro
Shkriabai, Nikolozi
Larue, Ross C.
Patel, Pratiq A.
Mitsuya, Hiroaki
Kessl, Jacques J.
Engelman, Alan
Fuchs, James R.
Kvaratskhelia, Mamuka
TI The A128T Resistance Mutation Reveals Aberrant Protein Multimerization
as the Primary Mechanism of Action of Allosteric HIV-1 Integrase
Inhibitors
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID SMALL-MOLECULE INHIBITORS; COACTIVATOR P75; DNA INTEGRATION; LEDGF/P75;
REPLICATION; DOMAIN; DRUGS; MODE; SITE
AB Allosteric HIV-1 integrase (IN) inhibitors (ALLINIs) are a very promising new class of anti-HIV-1 agents that exhibit a multimodal mechanism of action by allosterically modulating IN multimerization and interfering with IN-lens epithelium-derived growth factor (LEDGF)/p75 binding. Selection of viral strains under ALLINI pressure has revealed an A128T substitution in HIV-1 IN as a primary mechanism of resistance. Here, we elucidated the structural and mechanistic basis for this resistance. The A128T substitution did not affect the hydrogen bonding between ALLINI and IN that mimics the IN-LEDGF/p75 interaction but instead altered the positioning of the inhibitor at the IN dimer interface. Consequently, the A128T substitution had only a minor effect on the ALLINI IC50 values for IN-LEDGF/p75 binding. Instead, ALLINIs markedly altered the multimerization of IN by promoting aberrant higher order WT (but not A128T) IN oligomers. Accordingly, WT IN catalytic activities and HIV-1 replication were potently inhibited by ALLINIs, whereas the A128T substitution in IN resulted in significant resistance to the inhibitors both in vitro and in cell culture assays. The differential multimerization of WT and A128T INs induced by ALLINIs correlated with the differences in infectivity of HIV-1 progeny virions. We conclude that ALLINIs primarily target IN multimerization rather than IN-LEDGF/p75 binding. Our findings provide the structural foundations for developing improved ALLINIs with increased potency and decreased potential to select for drug resistance.
C1 [Feng, Lei; Sharma, Amit; Slaughter, Alison; Shkriabai, Nikolozi; Larue, Ross C.; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, Columbus, OH 43210 USA.
[Feng, Lei; Sharma, Amit; Slaughter, Alison; Shkriabai, Nikolozi; Larue, Ross C.; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Jena, Nivedita; Patel, Pratiq A.; Fuchs, James R.] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA.
[Koh, Yasuhiro; Mitsuya, Hiroaki] Kumamoto Univ, Sch Med, Dept Hematol, Kumamoto 8608556, Japan.
[Koh, Yasuhiro; Mitsuya, Hiroaki] Kumamoto Univ, Sch Med, Dept Infect Dis, Kumamoto 8608556, Japan.
[Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Engelman, Alan] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
RP Kvaratskhelia, M (reprint author), Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, 500 West 12th Ave, Columbus, OH 43210 USA.
EM kvaratskhelia.1@osu.edu
RI Kessl, Jacques/J-6073-2015
FU National Institutes of Health [AI081581, AI062520, GM103368, AI097044]
FX This work was supported, in whole or in part, by National Institutes of
Health Grants AI081581 and AI062520 (to M. K.), GM103368 (to A. E. and
M. K.), AI097044 (to J.J.K. and J.R.F.).
NR 27
TC 29
Z9 29
U1 1
U2 6
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 31
PY 2013
VL 288
IS 22
BP 15813
EP 15820
DI 10.1074/jbc.M112.443390
PG 8
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 156LA
UT WOS:000319822300035
PM 23615903
ER
PT J
AU Sun, Q
Gao, WT
Loughran, P
Shapiro, R
Fan, J
Billiar, TR
Scott, MJ
AF Sun, Qian
Gao, Wentao
Loughran, Patricia
Shapiro, Rick
Fan, Jie
Billiar, Timothy R.
Scott, Melanie J.
TI Caspase 1 Activation Is Protective against Hepatocyte Cell Death by
Up-regulating Beclin 1 Protein and Mitochondrial Autophagy in the
Setting of Redox Stress
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID HEMORRHAGIC-SHOCK; REPERFUSION INJURY; RAT HEPATOCYTES; NITRIC-OXIDE;
IN-VIVO; HYPOXIA; LIVER; DYSFUNCTION; MOUSE; INFLAMMATION
AB Caspase 1 activation can be induced by oxidative stress, which leads to the release of the proinflammatory cytokines IL1 beta and IL18 in myeloid cells and a potentially damaging inflammatory response. However, little is known about the role of caspase 1 in non-immune cells, such as hepatocytes, that express and activate the inflammasome but do not produce a significant amount of IL1 beta/IL18. Here we demonstrate that caspase 1 activation protects against cell death after redox stress induced by hypoxia/reoxygenation in hepatocytes. Mechanistically, we show that caspase 1 reduces mitochondrial respiration and reactive oxygen species by increasing mitochondrial autophagy and subsequent clearance of mitochondria in hepatocytes after hypoxia/reoxygenation. Caspase 1 increases autophagic flux through up-regulating autophagy initiator beclin 1 during redox stress and is an important cell survival factor in hepatocytes. We find that during hemorrhagic shock with resuscitation, an in vivo mouse model associated with severe hepatic redox stress, caspase 1 activation is also protective against liver injury and excessive oxidative stress through the up-regulation of beclin 1. Our findings suggest an alternative role for caspase 1 activation in promoting adaptive responses to oxidative stress and, more specifically, in limiting reactive oxygen species production and damage in cells and tissues where IL1 beta/IL18 are not highly expressed.
C1 [Sun, Qian; Gao, Wentao; Loughran, Patricia; Shapiro, Rick; Fan, Jie; Billiar, Timothy R.; Scott, Melanie J.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15213 USA.
[Sun, Qian] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA 15213 USA.
[Loughran, Patricia] Univ Pittsburgh, Ctr Biol Imaging, Pittsburgh, PA 15213 USA.
[Fan, Jie] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA 15213 USA.
RP Scott, MJ (reprint author), Univ Pittsburgh, Dept Surg, NW607 MUH,3459 5th Ave, Pittsburgh, PA 15213 USA.
EM scottm@upmc.edu
RI Sun, Qian/E-8130-2015
OI Sun, Qian/0000-0002-1121-5344
FU National Institutes of Health [R01-HL-079669, P50-GM053789]; Surgical
Infection Society
FX This work was supported, in whole or in part, by National Institutes of
Health Grants R01-HL-079669 (to J. F.) and P50-GM053789 (to T. R. B.).
This work was also supported by the Surgical Infection Society (to M.
S.).
NR 42
TC 26
Z9 26
U1 1
U2 17
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 31
PY 2013
VL 288
IS 22
BP 15947
EP 15958
DI 10.1074/jbc.M112.426791
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 156LA
UT WOS:000319822300047
PM 23589298
ER
PT J
AU Mansour, MK
Tam, JM
Khan, NS
Seward, M
Davids, PJ
Puranam, S
Sokolovska, A
Sykes, DB
Dagher, Z
Becker, C
Tanne, A
Reedy, JL
Stuart, LM
Vyas, JM
AF Mansour, Michael K.
Tam, Jenny M.
Khan, Nida S.
Seward, Michael
Davids, Peter J.
Puranam, Sravanthi
Sokolovska, Anna
Sykes, David B.
Dagher, Zeina
Becker, Christine
Tanne, Antoine
Reedy, Jennifer L.
Stuart, Lynda M.
Vyas, Jatin M.
TI Dectin-1 Activation Controls Maturation of beta-1,3-Glucan-containing
Phagosomes
SO JOURNAL OF BIOLOGICAL CHEMISTRY
LA English
DT Article
ID ORGAN TRANSPLANT RECIPIENTS; INVASIVE FUNGAL-INFECTIONS; BETA-GLUCAN
RECOGNITION; CANDIDA-ALBICANS; DENDRITIC CELLS; RECEPTOR DECTIN-1;
LECTIN RECEPTORS; INNATE IMMUNITY; HOST-DEFENSE; SYK KINASE
AB Elimination of fungal pathogens by phagocytes requires phagosome maturation, a process that involves the recruitment and fusion of intracellular proteins. The role of Dectin-1, a beta-1,3-glucan receptor, critical for fungal recognition and triggering of Th17 responses, to phagosomal maturation has not been defined. We show that GFP-Dectin-1 translocates to the fungal phagosome, but its signal decays after 2 h. Inhibition of acidification results in retention of GFP-Dectin-1 to phagosome membranes highlighting the requirement for an acidic pH. Following beta-1,3-glucan recognition, GFP-Dectin-1 undergoes tyrosine phosphorylation by Src kinases with subsequent Syk activation. Our results demonstrate that Syk is activated independently of intraphagosomal pH. Inhibition of Src or Syk results in prolonged retention of GFP-Dectin-1 to the phagosome signifying a link between Syk and intraphagosomal pH. beta-1,3-glucan phagosomes expressing a signaling incompetent Dectin-1 failed to mature as demonstrated by prolonged Dectin-1 retention, presence of Rab5B, failure to acquire LAMP-1 and inability to acidify. Phagosomes containing Candida albicans also require Dectin-1-dependent Syk activation for phagosomal maturation. Taken together, these results support a model where Dectin-1 not only controls internalization of beta-1,3-glucan containing cargo and triggers proinflammatory cytokines, but also acts as a master regulator for subsequent phagolysosomal maturation through Syk activation.
C1 [Mansour, Michael K.; Tam, Jenny M.; Khan, Nida S.; Seward, Michael; Davids, Peter J.; Puranam, Sravanthi; Dagher, Zeina; Reedy, Jennifer L.; Vyas, Jatin M.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Sokolovska, Anna; Becker, Christine; Tanne, Antoine; Stuart, Lynda M.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Sykes, David B.] Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
[Mansour, Michael K.; Tam, Jenny M.; Sykes, David B.; Reedy, Jennifer L.; Vyas, Jatin M.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
[Davids, Peter J.] Bowdoin Coll, Brunswick, ME 04011 USA.
[Puranam, Sravanthi] MIT, Cambridge, MA 02143 USA.
[Stuart, Lynda M.] Broad Inst MIT & Harvard Univ, Cambridge, MA 02143 USA.
RP Vyas, JM (reprint author), Massachusetts Gen Hosp, Dept Med, Div Infect Dis, 55 Fruit St,Gray Jackson Bldg Room 504, Boston, MA 02114 USA.
EM jvyas@partners.org
RI Vyas, Jatin/Q-1627-2016
OI Vyas, Jatin/0000-0002-9985-9565
FU National Institutes of Health [NIAID T32-AI007061-35, NIAID R01AI079198,
NIAID 1R01AI092084]; Leukemia & Lymphoma Society; Alex's Lemonade Stand
Foundation
FX This work was supported, in whole or in part, by National Institutes of
Health Grants NIAID T32-AI007061-35 (to M. K. M. and J. L. R.), NIAID
R01AI079198 (to L. M. S.), and NIAID 1R01AI092084 (to J. M. V.).;
Supported by The Leukemia & Lymphoma Society and Alex's Lemonade Stand
Foundation.
NR 46
TC 23
Z9 23
U1 0
U2 12
PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA
SN 0021-9258
J9 J BIOL CHEM
JI J. Biol. Chem.
PD MAY 31
PY 2013
VL 288
IS 22
BP 16043
EP 16054
DI 10.1074/jbc.M113.473223
PG 12
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 156LA
UT WOS:000319822300055
PM 23609446
ER
PT J
AU McGuire, AL
Joffe, S
Koenig, BA
Biesecker, BB
McCullough, LB
Blumenthal-Barby, JS
Caulfield, T
Terry, SF
Green, RC
AF McGuire, Amy L.
Joffe, Steven
Koenig, Barbara A.
Biesecker, Barbara B.
McCullough, Laurence B.
Blumenthal-Barby, Jennifer S.
Caulfield, Timothy
Terry, Sharon F.
Green, Robert C.
TI Ethics and Genomic Incidental Findings
SO SCIENCE
LA English
DT Editorial Material
C1 [McGuire, Amy L.; McCullough, Laurence B.; Blumenthal-Barby, Jennifer S.] Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
[Joffe, Steven] Harvard Univ, Dana Farber Canc Inst, Boston Childrens Hosp, Sch Med,Dept Pediat Oncol,Dept Med, Boston, MA 02215 USA.
[Koenig, Barbara A.] Univ Calif San Francisco, Inst Hlth & Aging, Dept Anthropol Hist & Social Med, Dept Social & Behav Sci, San Francisco, CA 94143 USA.
[Biesecker, Barbara B.] NHGRI, Social & Behav Res Branch, Bethesda, MD 20892 USA.
[Caulfield, Timothy] Univ Alberta, Hlth Law Inst, Edmonton, AB T6G 2H5, Canada.
[Terry, Sharon F.] Genet Alliance, Washington, DC 20008 USA.
[Green, Robert C.] Brigham & Womens Hosp, Dept Med, Div Genet, Boston, MA 02115 USA.
[Green, Robert C.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP McGuire, AL (reprint author), Baylor Coll Med, Ctr Med Eth & Hlth Policy, Houston, TX 77030 USA.
EM amcguire@bcm.edu; steven_joffe@dfci.harvard.edu
OI Joffe, Steven/0000-0002-0667-7384
FU Intramural NIH HHS; NCI NIH HHS [CA154517, R01 CA154517, R01-CA154517];
NHGRI NIH HHS [P20 HG007243, HG003178, HG005092, HG006485, HG006492,
HG006500, HG006612-02, HG006615, HG02213, R01 HG002213, R01 HG003178,
R01 HG005092, R01 HG006615, R21 HG006612, U01 HG006485, U01 HG006492,
U01 HG006500]
NR 11
TC 86
Z9 87
U1 2
U2 19
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 31
PY 2013
VL 340
IS 6136
BP 1047
EP 1048
DI 10.1126/science.1240156
PG 2
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154HJ
UT WOS:000319664500024
PM 23686340
ER
PT J
AU Bar-Peled, L
Chantranupong, L
Cherniack, AD
Chen, WW
Ottina, KA
Grabiner, BC
Spear, ED
Carter, SL
Meyerson, M
Sabatini, DM
AF Bar-Peled, Liron
Chantranupong, Lynne
Cherniack, Andrew D.
Chen, Walter W.
Ottina, Kathleen A.
Grabiner, Brian C.
Spear, Eric D.
Carter, Scott L.
Meyerson, Matthew
Sabatini, David M.
TI A Tumor Suppressor Complex with GAP Activity for the Rag GTPases That
Signal Amino Acid Sufficiency to mTORC1
SO SCIENCE
LA English
DT Article
ID HOMOZYGOUS DELETION REGION; HUMAN-CHROMOSOME 3P21.3; PTEN-DEFICIENT;
GROWTH-CONTROL; SENSITIVITY; INHIBITION; ACTIVATION; RAGULATOR;
AUTOPHAGY; TARGET
AB The mTOR complex 1 (mTORC1) pathway promotes cell growth in response to many cues, including amino acids, which act through the Rag guanosine triphosphatases (GTPases) to promote mTORC1 translocation to the lysosomal surface, its site of activation. Although progress has been made in identifying positive regulators of the Rags, it is unknown if negative factors also exist. Here, we identify GATOR as a complex that interacts with the Rags and is composed of two subcomplexes we call GATOR1 and -2. Inhibition of GATOR1 subunits (DEPDC5, Nprl2, and Nprl3) makes mTORC1 signaling resistant to amino acid deprivation. In contrast, inhibition of GATOR2 subunits (Mios, WDR24, WDR59, Seh1L, and Sec13) suppresses mTORC1 signaling, and epistasis analysis shows that GATOR2 negatively regulates DEPDC5. GATOR1 has GTPase-activating protein (GAP) activity for RagA and RagB, and its components are mutated in human cancer. In cancer cells with inactivating mutations in GATOR1, mTORC1 is hyperactive and insensitive to amino acid starvation, and such cells are hypersensitive to rapamycin, an mTORC1 inhibitor. Thus, we identify a key negative regulator of the Rag GTPases and reveal that, like other mTORC1 regulators, Rag function can be deregulated in cancer.
C1 [Bar-Peled, Liron; Chantranupong, Lynne; Chen, Walter W.; Ottina, Kathleen A.; Grabiner, Brian C.; Sabatini, David M.] Whitehead Inst Biomed Res, Cambridge, MA 02142 USA.
[Bar-Peled, Liron; Chantranupong, Lynne; Chen, Walter W.; Ottina, Kathleen A.; Grabiner, Brian C.; Sabatini, David M.] MIT, Dept Biol, Cambridge, MA 02142 USA.
[Bar-Peled, Liron; Chantranupong, Lynne; Chen, Walter W.; Ottina, Kathleen A.; Grabiner, Brian C.; Sabatini, David M.] Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Sabatini, David M.] MIT, Howard Hughes Med Inst, Dept Biol, Cambridge, MA 02139 USA.
[Cherniack, Andrew D.; Carter, Scott L.; Meyerson, Matthew; Sabatini, David M.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA 02142 USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Meyerson, Matthew] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Spear, Eric D.] Johns Hopkins Univ, Sch Med, Dept Cell Biol, Baltimore, MD 21205 USA.
RP Sabatini, DM (reprint author), Whitehead Inst Biomed Res, 9 Cambridge Ctr, Cambridge, MA 02142 USA.
EM sabatini@wi.mit.edu
FU NIH [CA103866, AI47389]; Department of Defense [W81XWH-07-0448];
National Cancer Institute (NIH) [U24CA143867]; David H. Koch Graduate
Fellowship Fund; NSF; Harvard-MIT Health, Sciences, and Technology IDEA2
program; American Cancer Society
FX We thank all members of the Sabatini lab fur helpful suggestions, E.
Spooner fur the mass spectrometric analysis of samples, and N. Kory for
technical assistance. This work was supported by grants from the NIH
(CA103866 and AI47389) and Department of Defense (W81XWH-07-0448) to
D.M.S. and the National Cancer Institute (NIH) (U24CA143867) to M.M. and
awards from the David H. Koch Graduate Fellowship Fund to L.B.-P.; the
NSF Graduate Research Fellowship Program to L.C.; the Harvard-MIT
Health, Sciences, and Technology IDEA2 program to W.W.C.; and
the American Cancer Society to B.C.G. D.M.S. is an investigator of the
Howard Hughes Medical Institute.
NR 26
TC 215
Z9 236
U1 9
U2 60
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 31
PY 2013
VL 340
IS 6136
BP 1100
EP 1106
DI 10.1126/science.1232044
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154HJ
UT WOS:000319664500046
PM 23723238
ER
PT J
AU Koff, WC
Burton, DR
Johnson, PR
Walker, BD
King, CR
Nabel, GJ
Ahmed, R
Bhan, MK
Plotkin, SA
AF Koff, Wayne C.
Burton, Dennis R.
Johnson, Philip R.
Walker, Bruce D.
King, Charles R.
Nabel, Gary J.
Ahmed, Rafi
Bhan, Maharaj K.
Plotkin, Stanley A.
TI Accelerating Next-Generation Vaccine Development for Global Disease
Prevention
SO SCIENCE
LA English
DT Review
ID IMMUNODEFICIENCY-VIRUS TYPE-1; T-CELL RESPONSES; NEUTRALIZING
ANTIBODIES; HUMAN IMMUNOLOGY; HIV-1 VACCINE; MYCOBACTERIUM-TUBERCULOSIS;
IMMUNOSTIMULATORY DNA; REVERSE VACCINOLOGY; DENDRITIC CELLS; INNATE
IMMUNITY
AB Vaccines are among the greatest successes in the history of public health. However, past strategies for vaccine development are unlikely to succeed in the future against major global diseases such as AIDS, tuberculosis, and malaria. For such diseases, the correlates of protection are poorly defined and the pathogens evade immune detection and/or exhibit extensive genetic variability. Recent advances have heralded in a new era of vaccine discovery. However, translation of these advances into vaccines remains impeded by lack of understanding of key vaccinology principles in humans. We review these advances toward vaccine discovery and suggest that for accelerating successful vaccine development, new human immunology based clinical research initiatives be implemented with the goal of elucidating and more effectively generating vaccine-induced protective immune responses.
C1 [Koff, Wayne C.; King, Charles R.] Int AIDS Vaccine Initiat IAVI, New York, NY 10004 USA.
[Burton, Dennis R.] Dept Immunol & Microbial Sci, La Jolla, CA 92037 USA.
[Burton, Dennis R.] IAVI Neutralizing Antibody Ctr, La Jolla, CA 92037 USA.
[Burton, Dennis R.] Scripps Res Inst, La Jolla, CA 92037 USA.
[Johnson, Philip R.] Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
[Burton, Dennis R.; Walker, Bruce D.] Rayon Inst Massachusetts Gen Hosp Massachusetts I, Cambridge, MA 02129 USA.
[Walker, Bruce D.] Howard Hughes Med Inst, Chevy Chase, MD 20815 USA.
[Nabel, Gary J.] Sanofi Aventis, Cambridge, MA 02139 USA.
[Ahmed, Rafi] Emory Univ, Sch Med, Emory Vaccine Ctr, Atlanta, GA 30329 USA.
[Bhan, Maharaj K.] Govt India, Dept Biotechnol, New Delhi, India.
[Plotkin, Stanley A.] Univ Penn, Philadelphia, PA 19104 USA.
[Plotkin, Stanley A.] Vaxconsult, Doylestown, PA 18902 USA.
[Burton, Dennis R.; Walker, Bruce D.; Ahmed, Rafi] Scripps Res Inst, Ctr HIV AIDS Vaccine Immunol & Immunogen Discover, La Jolla, CA 92037 USA.
RP Koff, WC (reprint author), Int AIDS Vaccine Initiat IAVI, New York, NY 10004 USA.
EM wkoff@iavi.org
RI Chiang, Vincent, Ming-Hsien/D-4312-2016
OI Chiang, Vincent, Ming-Hsien/0000-0002-2029-7863
FU U.S. Agency for International Development (USAID); Bill & Melinda Gates
Foundation (BMGF); International AIDS Vaccine Initiative (IAVI);
National Institutes of Health (NIH); Centers for HIV/AIDS Vaccine
Immunology and Immunogen Discovery (CHAVI-ID); National Institute of
Allergy and Infectious Diseases (NIAID); NIH
FX This work was supported by the network of IAVI donors, including, the
U.S. Agency for International Development (USAID) and the Bill & Melinda
Gates Foundation (BMGF) (W.C.K and C.R.K); the International AIDS
Vaccine Initiative (IAVI) and the National Institutes of Health (NIH)
(P.R.J.); the Centers for HIV/AIDS Vaccine Immunology and Immunogen
Discovery (CHAVI-ID), with funding from the National Institute of
Allergy and Infectious Diseases (NIAID), part of NIH (D.R.B., R.A, and
B.D.W). Additionally, S.A.P is a paid scientific advisor and consultant
for Sanofi, GlaxoSmithKline, Novartis, Merck, Pfizer, Medimmune, Inovio
Pharmaceuticals, Dynavax, and Glycovaxyn, and B.D.W. is a paid
scientific advisor and consultant for Merck, Bristol-Myers Squibb, and
Globe Immune. The authors also wish to thank S. Glass, L. Gieber, O.
Shmaidenko, M. Dees, and B. Hayes for their administrative support.
NR 87
TC 90
Z9 93
U1 9
U2 91
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
EI 1095-9203
J9 SCIENCE
JI Science
PD MAY 31
PY 2013
VL 340
IS 6136
AR 1232910
DI 10.1126/science.1232910
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 154HJ
UT WOS:000319664500035
PM 23723240
ER
PT J
AU Peraino, JS
Schenk, M
Zhang, HP
Li, GY
Hermanrud, CE
Neville, DM
Sachs, DH
Huang, CA
Duran-Struuck, R
Wang, ZR
AF Peraino, Jaclyn Stromp
Schenk, Marian
Zhang, Huiping
Li, Guoying
Hermanrud, Christina E.
Neville, David M., Jr.
Sachs, David H.
Huang, Christene A.
Duran-Struuck, Raimon
Wang, Zhirui
TI A truncated diphtheria toxin based recombinant porcine CTLA-4 fusion
toxin
SO JOURNAL OF IMMUNOLOGICAL METHODS
LA English
DT Article
DE Fusion toxin; Diphtheria toxin; Porcine CTLA-4; Porcine antigen
presenting cell; Pichia pastoris expression
ID PICHIA-PASTORIS; MINIATURE SWINE; IN-VIVO; IMMUNOTOXIN; EXPRESSION;
PATHWAY
AB Targeted cell therapies are possible through the generation of recombinant fusion proteins that combine a toxin, such as diphtheria toxin (DT), with an antibody or other molecule that confers specificity. Upon binding of the fusion protein to the cell of interest, the diphtheria toxin is internalized which results in protein synthesis inhibition and subsequent cell death. We have recently expressed and purified the recombinant soluble porcine CTLA-4 both with and without N-glycosylation in yeast Pichia pastoris for in vivo use in our preclinical swine model. The glycosylated and non-N-glycosylated versions of this recombinant protein each bind to a porcine CD80 expressing B-cell lymphoma line (LCL13271) with equal affinity (K-D = 13 nM). In this study we have linked each of the glycosylated and non-N-glycosylated soluble porcine CTLA-4 proteins to the truncated diphtheria toxin DT390 through genetic engineering yielding three versions of the porcine CTLA-4 fusion toxins: 1) monovalent glycosylated soluble porcine CTLA-4 fusion toxin; 2) monovalent non-N-glycosylated soluble porcine CTLA-4 fusion toxin and 3) bivalent non-N-glycosylated soluble porcine CTLA-4 fusion toxin. Protein synthesis inhibition analysis demonstrated that while all three fusion toxins are capable of inhibiting protein synthesis in vitro, the non-N-glycosylated porcine CTLA-4 isoforms function most efficiently. Binding analysis using flow cytometry of the porcine CTLA-4 fusion toxins to LCL13271 cells also demonstrated that the non-N-glycosylated porcine CTLA-4 isoforms bind to these cells with higher affinity compared to the glycosylated fusion toxin. The monovalent non-N-glycosylated porcine CTLA-4 fusion toxin was tested in vivo. NSG (NOD/SCID IL-2 receptor gamma(-)/(-)) mice were injected with porcine CD80(+) LCL13271 tumor cells. All animals succumbed to tumors and those treated with the monovalent non-N-glycosylated porcine CTLA-4 fusion toxin survived longer based on a symptomatic scoring system compared to the untreated controls. This recombinant protein may therefore provide a novel approach for in vivo depletion of porcine antigen presenting cells (APCs) for studies investigating the induction of transplantation tolerance, autoimmune disease and cancer treatment. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Peraino, Jaclyn Stromp; Schenk, Marian; Zhang, Huiping; Li, Guoying; Hermanrud, Christina E.; Sachs, David H.; Huang, Christene A.; Duran-Struuck, Raimon; Wang, Zhirui] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02129 USA.
[Peraino, Jaclyn Stromp; Schenk, Marian; Zhang, Huiping; Li, Guoying; Hermanrud, Christina E.; Sachs, David H.; Huang, Christene A.; Duran-Struuck, Raimon; Wang, Zhirui] Harvard Univ, Sch Med, Boston, MA USA.
[Peraino, Jaclyn Stromp; Zhang, Huiping; Li, Guoying; Hermanrud, Christina E.; Sachs, David H.; Huang, Christene A.; Wang, Zhirui] DF HCC MGH Recombinant Prot Express & Purificat C, Boston, MA USA.
[Neville, David M., Jr.] Angimmune LLC, Bethesda, MD 20814 USA.
RP Wang, ZR (reprint author), Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Bldg 149-6113,13th St, Boston, MA 02129 USA.
EM zhirui.wang@tbrc.mgh.harvard.edu
FU Dana Farber/Harvard Cancer Center Core development grant; NIH
[R01AI084657]
FX The work was supported in part by the Dana Farber/Harvard Cancer Center
Core development grant and NIH grant R01AI084657 (CAH). We would like to
thank Dr. Arlene H. Sharpe for the critical discussion regarding project
design.
NR 13
TC 4
Z9 4
U1 1
U2 12
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0022-1759
J9 J IMMUNOL METHODS
JI J. Immunol. Methods
PD MAY 31
PY 2013
VL 391
IS 1-2
BP 103
EP 111
DI 10.1016/j.jim.2013.02.015
PG 9
WC Biochemical Research Methods; Immunology
SC Biochemistry & Molecular Biology; Immunology
GA 137WA
UT WOS:000318467700011
PM 23470981
ER
PT J
AU Florez, JC
Shepard, JAO
Kradin, RL
AF Florez, Jose C.
Shepard, Jo-Anne O.
Kradin, Richard L.
TI Case 17-2013: A 56-Year-Old Woman with Poorly Controlled Diabetes
Mellitus and Fatigue
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID CUSHINGS-SYNDROME; EXPERIENCE; DIAGNOSIS
C1 [Florez, Jose C.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Shepard, Jo-Anne O.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Kradin, Richard L.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Florez, Jose C.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Shepard, Jo-Anne O.] Harvard Univ, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Kradin, Richard L.] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Florez, JC (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
FU Pfizer; Eli Lilly; Novartis; AGFA
FX Dr. Florez reports receiving consulting fees from Pfizer, Eli Lilly, and
Novartis. Dr. Shepard reports receiving consulting fees through her
institution from AGFA and serving as an expert witness on behalf of
physicians in legal cases involving chest imaging. Dr. Kradin reports
serving as an expert witness on behalf of patients in cases involving
asbestos and lung disease. No other potential conflict of interest
relevant to this article was reported.
NR 13
TC 2
Z9 2
U1 0
U2 3
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 30
PY 2013
VL 368
IS 22
BP 2126
EP 2136
DI 10.1056/NEJMcpc1215971
PG 11
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153AT
UT WOS:000319574200012
PM 23697472
ER
PT J
AU Treon, SP
Hunter, ZR
AF Treon, Steven P.
Hunter, Zachary R.
TI A new era for Waldenstrom macroglobulinemia: MYD88 L265P
SO BLOOD
LA English
DT Editorial Material
ID SOMATIC MUTATION
C1 [Treon, Steven P.; Hunter, Zachary R.] Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
[Treon, Steven P.; Hunter, Zachary R.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Treon, SP (reprint author), Dana Farber Canc Inst, Bing Ctr Waldenstroms Macroglobulinemia, Boston, MA 02115 USA.
OI Hunter, Zachary/0000-0002-1689-1691
NR 11
TC 21
Z9 22
U1 1
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
EI 1528-0020
J9 BLOOD
JI Blood
PD MAY 30
PY 2013
VL 121
IS 22
BP 4434
EP 4436
DI 10.1182/blood-2013-04-494849
PG 5
WC Hematology
SC Hematology
GA 184ML
UT WOS:000321894100003
PM 23723443
ER
PT J
AU Commisso, C
Davidson, SM
Soydaner-Azeloglu, RG
Parker, SJ
Kamphorst, JJ
Hackett, S
Grabocka, E
Nofal, M
Drebin, JA
Thompson, CB
Rabinowitz, JD
Metallo, CM
Vander Heiden, MG
Bar-Sagi, D
AF Commisso, Cosimo
Davidson, Shawn M.
Soydaner-Azeloglu, Rengin G.
Parker, Seth J.
Kamphorst, Jurre J.
Hackett, Sean
Grabocka, Elda
Nofal, Michel
Drebin, Jeffrey A.
Thompson, Craig B.
Rabinowitz, Joshua D.
Metallo, Christian M.
Vander Heiden, Matthew G.
Bar-Sagi, Dafna
TI Macropinocytosis of protein is an amino acid supply route in
Ras-transformed cells
SO NATURE
LA English
DT Article
ID MASS ISOTOPOMER DISTRIBUTIONS; K-RAS; GLUTAMINE-METABOLISM; H-RAS;
CANCER; SRC; FIBROBLASTS; CARCINOMA; PATHWAYS; GROWTH
AB Macropinocytosis is a highly conserved endocytic process by which extracellular fluid and its contents are internalized into cells through large, heterogeneous vesicles known as macropinosomes. Oncogenic Ras proteins have been shown to stimulate macropinocytosis but the functional contribution of this uptake mechanism to the transformed phenotype remains unknown(1-3). Here we show that Ras-transformed cells use macropinocytosis to transport extracellular protein into the cell. The internalized protein undergoes proteolytic degradation, yielding amino acids including glutamine that can enter central carbon metabolism. Accordingly, the dependence of Ras-transformed cells on free extracellular glutamine for growth can be suppressed by the macropinocytic uptake of protein. Consistent with macropinocytosis representing an important route of nutrient uptake in tumours, its pharmacological inhibition compromises the growth of Ras-transformed pancreatic tumour xenografts. These results identify macropinocytosis as a mechanism by which cancer cells support their unique metabolic needs and point to the possible exploitation of this process in the design of anticancer therapies.
C1 [Commisso, Cosimo; Soydaner-Azeloglu, Rengin G.; Grabocka, Elda; Bar-Sagi, Dafna] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
[Davidson, Shawn M.; Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Davidson, Shawn M.; Vander Heiden, Matthew G.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Parker, Seth J.; Metallo, Christian M.] Univ Calif San Diego, Dept Bioengn, La Jolla, CA 92093 USA.
[Kamphorst, Jurre J.; Hackett, Sean; Nofal, Michel; Rabinowitz, Joshua D.] Princeton Univ, Carl Icahn Lab, Lewis Sigler Inst Integrat Genom, Princeton, NJ 08544 USA.
[Drebin, Jeffrey A.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
[Thompson, Craig B.] Mem Sloan Kettering Canc Ctr, Canc Biol & Genet Program, New York, NY 10065 USA.
[Vander Heiden, Matthew G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Bar-Sagi, D (reprint author), NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA.
EM dafna.bar-sagi@nyumc.org
OI Kamphorst, Jurre/0000-0002-2042-5474
FU National Institutes of Health (NIH) [R01CA055360, 5 P30CA016087-32];
Canadian Institutes of Health Research; AACR provided by the Pancreatic
Cancer Action Network; Burroughs Wellcome Fund; Damon Runyon Cancer
Research Foundation; Smith Family; Stern family; Broad Institute;
National Cancer Institute [P01-CA117969, P30-CA14051-39]; Hope Funds for
Cancer Research Fellowship [HFCR-11-03-01]; Stand Up To Cancer (SU2C)
Pancreatic Cancer Dream Team Award; NICHD
FX We are grateful to members of the Bar-Sagi laboratory for their comments
and discussions, and N. Fehrenbacher and M. Philips for sharing cell
lines. This work was supported National Institutes of Health (NIH) grant
R01CA055360 to D.B.-S. C.C. was supported by a Canadian Institutes of
Health Research postdoctoral fellowship and an AACR postdoctoral
fellowship provided by the Pancreatic Cancer Action Network. M.G.V.H.
acknowledges support from the Burroughs Wellcome Fund, the Damon Runyon
Cancer Research Foundation, the Smith Family, the Stern family, the
Broad Institute and the National Cancer Institute (P01-CA117969 and
P30-CA14051-39). J.J.K. was supported by a Hope Funds for Cancer
Research Fellowship (HFCR-11-03-01). C.B.T., J.A.D. and J.D.R.
acknowledge support by the Stand Up To Cancer (SU2C) Pancreatic Cancer
Dream Team Award. All animal care and procedures were approved by the
Institutional Animal Care and Use Committee at NYU School of Medicine.
The Histopathology Core of NYU School of Medicine is partially supported
by the National Institutes of Health (grant 5 P30CA016087-32). Troma I,
an antibody that recognizes CK8, was contributed by P. Brulet and R.
Kemler and made available by the Developmental Studies Hybridoma Bank
under the auspices of the NICHD.
NR 31
TC 229
Z9 229
U1 7
U2 73
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0028-0836
J9 NATURE
JI Nature
PD MAY 30
PY 2013
VL 497
IS 7451
BP 633
EP +
DI 10.1038/nature12138
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 152UF
UT WOS:000319556100047
PM 23665962
ER
PT J
AU Steensma, DP
AF Steensma, David P.
TI The Beginning of the End of the Beginning in Cancer Genomics
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
ID ACUTE MYELOID-LEUKEMIA; TYROSINE KINASE; RESISTANCE; MUTATIONS; THERAPY
C1 [Steensma, David P.] Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Div Hematol Malignancies, Boston, MA 02115 USA.
OI Steensma, David/0000-0001-5130-9284
NR 12
TC 12
Z9 12
U1 0
U2 0
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 30
PY 2013
VL 368
IS 22
BP 2138
EP 2140
DI 10.1056/NEJMe1303816
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 153AT
UT WOS:000319574200013
PM 23634995
ER
PT J
AU Bandyopadhyay, M
Kono, M
Rohrer, B
AF Bandyopadhyay, Mausumi
Kono, Masahiro
Rohrer, Baerbel
TI Explant cultures of Rpe65(-/-) mouse retina: a model to investigate cone
opsin trafficking
SO MOLECULAR VISION
LA English
DT Article
ID NEUROTROPHIN RECEPTOR TRKB; ORGAN-CULTURE; PHARMACOLOGICAL MANIPULATION;
TEMPORAL EXPRESSION; 9-CIS-RETINOIC ACID; INVERSE AGONISTS; CELL-DEATH;
RD MOUSE; RHODOPSIN; PHOTORECEPTOR
AB Purpose: In the absence of 11-cis retinal (e.g., Rpe65(-/-)), the chromophore for all pigments, cone opsins are mislocalized in vivo. Using the systemic application of 11-cis retinal, appropriate protein localization can be promoted. Here, we asked whether explant cultures of Rpe65(-/-) mouse retina are amenable to screening retinoids for their ability to promote opsin trafficking.
Methods: Retina-retinal pigment epithelium (RPE) cultures were prepared from 7-day-old Rpe65(-/-) Rho(-/-) or wild-type pups and cultured for 11 days. Explants were treated with retinoids throughout this period. Ultraviolet (UV)-opsin trafficking was analyzed by immunohistochemistry and quantitative image analysis, while its messenger RNA expression was examined by quantitative real-time PCR, and the interaction of retinoids with UV-opsin was probed in transducing-activation assays.
Results: In wild-type explant cultures, UV-opsin was restricted to the outer segments, whereas in those derived from Rpe65(-/-) Rho(-/-) mice, opsin trafficking was impaired. In Rpe65(-/-) Rho(-/-) explants, administration of 11-cis retinal, 11-cis retinol or retinoic acid (RA) reversed the opsin trafficking phenotype. RA analogs designed to act by binding to the retinoic acid receptor or the retinoid X-receptor, however, had no effect. RA was shown to interact with the UV-cone opsin, demonstrated by its ability to effect ligand-dependent activation of transducin by UV-cone opsin. All compounds tested increased cone opsin messenger RNA expression.
Conclusions: Cone-opsin trafficking defects were replicated in Rpe65(-/-) Rho(-/-) retina-RPE cultures, and were reversed by 11-cis retinal treatment. Comparing the effects of different retinoids on their ability to promote UV-opsin trafficking to outer segments confirmed the critical role of agents that bind in the retinoid binding pocket. Retinoids that act as transcription factors, however, were ineffective. Thus, organ cultures may be a powerful low-throughput screening tool to identify novel compounds to promote cone survival.
C1 [Bandyopadhyay, Mausumi; Kono, Masahiro; Rohrer, Baerbel] Med Univ S Carolina, Dept Ophthalmol, Charleston, SC 29425 USA.
[Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Res Serv 151, Charleston, SC USA.
RP Rohrer, B (reprint author), Med Univ S Carolina, Dept Ophthalmol, 167 Ashley Ave, Charleston, SC 29425 USA.
EM rohrer@musc.edu
FU National Institutes of Health from the Extramural Research Facilities
Program of the National Center for Research Resources [C06 RR015455];
National Institutes of Health [R01EY04939, R01EY019515]; Hope for
Vision, Washington, DC; Research to Prevent Blindness (RPB), Inc., New
York, NY
FX We thank Dr. Rosalie Crouch for helpful discussions, Patrice Goletz for
expert assistance on the transducin assays and Dr. Luanna Bartholomew
for critical review. The animal studies were conducted in a facility
constructed with support from the National Institutes of Health through
a grant (C06 RR015455) from the Extramural Research Facilities Program
of the National Center for Research Resources. This work was supported
in part by the National Institutes of Health (R01EY04939, BR and
R01EY019515, MK); Hope for Vision, Washington, DC (BR); and an
unrestricted grant to MUSC from Research to Prevent Blindness (RPB),
Inc., New York, NY. BR is a RPB Olga Keith Wiess Scholar.
NR 53
TC 3
Z9 3
U1 0
U2 4
PU MOLECULAR VISION
PI ATLANTA
PA C/O JEFF BOATRIGHT, LAB B, 5500 EMORY EYE CENTER, 1327 CLIFTON RD, N E,
ATLANTA, GA 30322 USA
SN 1090-0535
J9 MOL VIS
JI Mol. Vis.
PD MAY 29
PY 2013
VL 19
BP 1149
EP 1157
PG 9
WC Biochemistry & Molecular Biology; Ophthalmology
SC Biochemistry & Molecular Biology; Ophthalmology
GA 158QW
UT WOS:000319988400006
PM 23734084
ER
PT J
AU Gupta, K
Trautner, BW
AF Gupta, Kalpana
Trautner, Barbara W.
TI Diagnosis and management of recurrent urinary tract infections in
non-pregnant women
SO BMJ-BRITISH MEDICAL JOURNAL
LA English
DT Review
ID ESCHERICHIA-COLI STRAINS; YOUNG-WOMEN; ASYMPTOMATIC BACTERIURIA;
POSTMENOPAUSAL-WOMEN; PREMENOPAUSAL WOMEN; UNCOMPLICATED CYSTITIS;
CONTROLLED-TRIAL; PRIMARY-CARE; RISK-FACTORS; DOUBLE-BLIND
C1 [Gupta, Kalpana] VA Boston Healthcare Syst, Dept Med, Boston, MA 02132 USA.
[Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02132 USA.
[Gupta, Kalpana] Vet Hlth Adm, Off Publ Hlth, Natl Ctr Occupat Hlth & Infect Control, Gainesville, FL 32608 USA.
[Trautner, Barbara W.] Baylor Coll Med, Michael E DeBakey Vet Affairs VA Med Ctr, Hlth Serv Res & Dev HSR&D Ctr Excellence, Houston, TX 77030 USA.
[Trautner, Barbara W.] Baylor Coll Med, Dept Med, Infect Dis Sect, Houston, TX 77030 USA.
RP Gupta, K (reprint author), VA Boston Healthcare Syst, Dept Med, Boston, MA 02132 USA.
EM Kalpana.Gupta@va.gov
FU Department of Veterans Affairs; VHA National Center for Patient Safety;
VA HSRD IIR [09-104]; NIH [DK092293]; VA HSR&D Houston Center of
Excellence [HFP-090-20]
FX KG is supported by the Department of Veterans Affairs and in part by the
VHA National Center for Patient Safety. BWT is funded by VA HSR&D IIR
09-104 and NIH DK092293; her work was also partly supported by the VA
HSR&D Houston Center of Excellence (HFP-090-20). The views expressed
reflect those of the authors and not necessarily those of the Department
of Veterans Affairs (VA)/Baylor College of Medicine.
NR 46
TC 8
Z9 8
U1 2
U2 14
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1756-1833
J9 BMJ-BRIT MED J
JI BMJ-British Medical Journal
PD MAY 29
PY 2013
VL 346
AR f3140
DI 10.1136/bmj.f3140
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA 158DG
UT WOS:000319948200006
PM 23719637
ER
PT J
AU Hoy, JL
Haeger, PA
Constable, JRL
Arias, RJ
McCallum, R
Kyweriga, M
Davis, L
Schnell, E
Wehr, M
Castillo, PE
Washbourne, P
AF Hoy, Jennifer L.
Haeger, Paola A.
Constable, John R. L.
Arias, Renee J.
McCallum, Raluca
Kyweriga, Michael
Davis, Lawrence
Schnell, Eric
Wehr, Michael
Castillo, Pablo E.
Washbourne, Philip
TI Neuroligin1 Drives Synaptic and Behavioral Maturation through
Intracellular Interactions
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID MORRIS WATER MAZE; AUTISM SPECTRUM DISORDERS; D-ASPARTATE RECEPTORS;
NMDA RECEPTORS; GLUTAMATERGIC SYNAPSES; INHIBITORY SYNAPSES; OBJECT
RECOGNITION; BURST STIMULATION; MOUSE MODEL; MICE
AB In vitro studies suggest that the intracellular C terminus of Neuroligin1 (NL1) could play a central role in the maturation of excitatory synapses. However, it is unknown how this activity affects synapses in vivo, and whether it may impact the development of complex behaviors. To determine how NL1 influences the state of glutamatergic synapses in vivo, we compared the synaptic and behavioral phenotypes of mice overexpressing a full-length version of NL1 (NL1FL) with mice overexpressing a version missing part of the intracellular domain (NL1 Delta C). We show that overexpression of full-length NL1 yielded an increase in the proportion of synapses with mature characteristics and impaired learning and flexibility. In contrast, the overexpression of NL1 Delta C increased the number of excitatory postsynaptic structures and led to enhanced flexibility in mnemonic and social behaviors. Transient overexpression of NL1FL revealed that elevated levels are not necessary to maintain synaptic and behavioral states altered earlier in development. In contrast, overexpression of NL1FL in the fully mature adult was able to impair normal learning behavior after 1 month of expression. These results provide the first evidence that NL1 significantly impacts key developmental processes that permanently shape circuit function and behavior, as well as the function of fully developed neural circuits. Overall, these manipulations of NL1 function illuminate the significance of NL1 intracellular signaling in vivo, and enhance our understanding of the factors that gate the maturation of glutamatergic synapses and complex behavior. This has significant implications for our ability to address disorders such as autism spectrum disorders.
C1 [Hoy, Jennifer L.; Constable, John R. L.; Arias, Renee J.; McCallum, Raluca; Kyweriga, Michael; Wehr, Michael; Washbourne, Philip] Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
[Haeger, Paola A.; Castillo, Pablo E.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.
[Schnell, Eric] Portland VA Med Ctr, Portland, OR 97239 USA.
[Schnell, Eric] Oregon Hlth & Sci Univ, Dept Anesthesiol & Perioperat Med, Portland, OR 97239 USA.
[Davis, Lawrence] Univ Oregon, Dept Phys, Eugene, OR 97403 USA.
RP Washbourne, P (reprint author), 1254 Univ Oregon, Inst Neurosci, Eugene, OR 97403 USA.
EM pwash@uoneuro.uoregon.edu
RI Kyweriga, Michael/H-3226-2013;
OI Kyweriga, Michael/0000-0003-3511-6292; Schnell, Eric/0000-0002-5623-5015
FU National Institute of Neurological Disorders and Stroke [R01 NS065795];
Autism Speaks [1368]; National Institute of Mental Health [R01
MH081935]; American Psychological Association [DPN T32 MH18882-22];
National Science Foundation [GK-12]; Oregon Center for Optics;
Biomedical Sciences Chile; Becas Chile
FX This work was supported by National Institute of Neurological Disorders
and Stroke R01 NS065795 and Autism Speaks 1368 to P.W., by National
Institute of Mental Health R01 MH081935 to P.E.C., the American
Psychological Association DPN T32 MH18882-22 to J.L.H, National Science
Foundation GK-12 program to L.D., and the Oregon Center for Optics to
J.L.H. and L.D.P.A.H. is a PEW Latin American Fellow in the Biomedical
Sciences and Becas Chile recipient. We thank Keith Beadle for
establishing the immunolabeling technique in thinly sectioned brain
tissue; Sheryl Moy (University of North Carolina) for excellent guidance
in conducting the appropriate behavioral tests and initial
characterization of our transgenic mice, and providing critical feedback
on this manuscript; Cris Niell and Victoria Herman for providing
comments on previous versions of this manuscript; Gary Westbrook (OHSU)
for generously providing his lab's reagents and support; Miriam Deutsch
(University of Oregon Physics Department) for providing lab support for
extended data analysis techniques; Shawn Brown and Sebastien Valverde
for technical assistance in preparation of synaptosomal fractions and
Western blot generation; and Sebastien Valverde and Leah Deblander for
additional assistance in training mice in the water maze and social
tasks.
NR 77
TC 5
Z9 5
U1 0
U2 10
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 29
PY 2013
VL 33
IS 22
BP 9364
EP 9384
DI 10.1523/JNEUROSCI.4660-12.2013
PG 21
WC Neurosciences
SC Neurosciences & Neurology
GA 152XV
UT WOS:000319566300014
PM 23719805
ER
PT J
AU Lewis, RF
Haburcakova, C
Gong, WS
Lee, D
Merfeld, D
AF Lewis, Richard F.
Haburcakova, Csilla
Gong, Wangsong
Lee, Daniel
Merfeld, Daniel
TI Electrical Stimulation of Semicircular Canal Afferents Affects the
Perception of Head Orientation
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID GALVANIC VESTIBULAR STIMULATION; USE INTERNAL-MODELS; VESTIBULOOCULAR
REFLEX; SQUIRREL-MONKEY; EYE-MOVEMENTS; RHESUS-MONKEYS; ROLL-TILT;
MOTION; NERVE; PROSTHESIS
AB Patients with vestibular dysfunction have visual, perceptual, and postural deficits. While there is considerable evidence that a semicircular canal prosthesis that senses angular head velocity and stimulates canal ampullary nerves can improve vision by augmenting the vestibulo-ocular reflex, no information is available regarding the potential utility of a canal prosthesis to improve perceptual deficits. In this study, we investigated the possibility that electrical stimulation of canal afferents could be used to modify percepts of head orientation. Two rhesus monkeys were trained to align a light bar parallel to gravity, and were tested in the presence and absence of electrical stimulation provided by an electrode implanted in the right posterior canal. While the monkeys aligned the light bar close to the true earth-vertical without stimulation, when the right posterior canal was stimulated their responses deviated toward their left ear, consistent with a misperception of head tilt toward the right. The deviation of the light bar from the earth-vertical exceeded the torsional deviation of the eyes, indicating that the perceptual changes were not simply visual in origin. Eye movements recorded during electrical stimulation in the dark were consistent with isolated activation of right posterior canal afferents, with no evidence of otolith stimulation. These results demonstrate that electrical stimulation of canal afferents affects the perception of head orientation, and therefore suggest that motion-modulated stimulation of canal afferents by a vestibular prosthesis could potentially improve vestibular percepts in patients lacking normal vestibular function.
C1 [Lewis, Richard F.; Haburcakova, Csilla; Gong, Wangsong; Merfeld, Daniel] Harvard Univ, Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Lewis, Richard F.; Lee, Daniel; Merfeld, Daniel] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Lewis, Richard F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA.
RP Lewis, RF (reprint author), 243 Charles St, Boston, MA 02114 USA.
EM Richard_lewis@meei.harvard.edu
FU NIH [DC6909, DC8362]
FX This research was supported by NIH Grants DC6909 and DC8362. We thank
Dr. Ruth Anne Eatock for comments on the manuscript.
NR 38
TC 8
Z9 8
U1 3
U2 8
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 29
PY 2013
VL 33
IS 22
BP 9530
EP 9535
DI 10.1523/JNEUROSCI.0112-13.2013
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA 152XV
UT WOS:000319566300028
PM 23719819
ER
PT J
AU Moslehi, J
Cheng, SS
AF Moslehi, Javid
Cheng, Susan
TI Cardio-Oncology: It Takes Two to Translate
SO SCIENCE TRANSLATIONAL MEDICINE
LA English
DT Editorial Material
ID ANGIOGENESIS
C1 [Moslehi, Javid; Cheng, Susan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiooncol Program,Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Moslehi, J (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Cardiooncol Program,Dana Farber Canc Inst, Boston, MA 02115 USA.
EM jmoslehi@partners.org; scheng3@partners.org
NR 10
TC 4
Z9 4
U1 0
U2 2
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1946-6234
J9 SCI TRANSL MED
JI Sci. Transl. Med.
PD MAY 29
PY 2013
VL 5
IS 187
AR 187fs20
DI 10.1126/scitranslmed.3006490
PG 3
WC Cell Biology; Medicine, Research & Experimental
SC Cell Biology; Research & Experimental Medicine
GA 152XU
UT WOS:000319566200002
PM 23720578
ER
PT J
AU Landau, DA
Wu, CJ
AF Landau, Dan A.
Wu, Catherine J.
TI Chronic lymphocytic leukemia: molecular heterogeneity revealed by
high-throughput genomics
SO GENOME MEDICINE
LA English
DT Review
ID B-CELL LYMPHOCYTOSIS; ACUTE LYMPHOBLASTIC-LEUKEMIA; RECURRENT MUTATIONS;
CLONAL EVOLUTION; SPLICING FACTOR; PROGNOSTIC-FACTORS; DNA METHYLATION;
WALDENSTROMS MACROGLOBULINEMIA; CLINICAL-SIGNIFICANCE; SIGNALING PATHWAY
AB Chronic lymphocytic leukemia (CLL) has been consistently at the forefront of genetic research owing to its prevalence and the accessibility of sample material. Recently, genome-wide technologies have been intensively applied to CLL genetics, with remarkable progress. Single nucleotide polymorphism arrays have identified recurring chromosomal aberrations, thereby focusing functional studies on discrete genomic lesions and leading to the first implication of somatic microRNA disruption in cancer. Next-generation sequencing (NGS) has further transformed our understanding of CLL by identifying novel recurrently mutated putative drivers, including the unexpected discovery of somatic mutations affecting spliceosome function. NGS has further enabled in-depth examination of the transcriptional and epigenetic changes in CLL that accompany genetic lesions, and has shed light on how different driver events appear at different stages of disease progression and clonally evolve with relapsed disease. In addition to providing important insights into disease biology, these discoveries have significant translational potential. They enhance prognosis by highlighting specific lesions associated with poor clinical outcomes (for example, driver events such as mutations in the splicing factor subunit gene SF3B1) or with increased clonal heterogeneity (for example, the presence of subclonal driver mutations). Here, we review new genomic discoveries in CLL and discuss their possible implications in the era of precision medicine.
C1 [Landau, Dan A.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA.
[Landau, Dan A.] Broad Inst, Cambridge, MA 02142 USA.
[Landau, Dan A.] Yale Canc Ctr, Dept Hematol, New Haven, CT 06510 USA.
[Landau, Dan A.] Univ Paris Diderot, F-75013 Paris, France.
[Wu, Catherine J.] Dana Farber Canc Inst, Div Med Oncol, Boston, MA 02215 USA.
[Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02215 USA.
RP Wu, CJ (reprint author), Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA.
EM cwu@partners.org
FU American Society of Hematology (Research Award for Fellows-in-Training);
American Cancer Society; Blavatnik Family Foundation; Lymphoma Research
Foundation; NHLBI [1RO1HL103532-01, 1RO1HL116452-01]; NCI
[1R01CA155010-01A1]; Leukemia Lymphoma Translational Research Program
Award; AACR SU2C Innovative Research Grant
FX DAL acknowledges support from the American Society of Hematology
(Research Award for Fellows-in-Training) and the American Cancer
Society. CJW acknowledges support from the Blavatnik Family Foundation,
the Lymphoma Research Foundation, NHLBI (1RO1HL103532-01;
1RO1HL116452-01) and NCI (1R01CA155010-01A1), and is a recipient of a
Leukemia Lymphoma Translational Research Program Award and an AACR SU2C
Innovative Research Grant.
NR 121
TC 15
Z9 15
U1 2
U2 14
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1756-994X
J9 GENOME MED
JI Genome Med.
PD MAY 29
PY 2013
VL 5
AR 47
DI 10.1186/gm451
PG 13
WC Genetics & Heredity
SC Genetics & Heredity
GA 152WW
UT WOS:000319563500001
PM 23731665
ER
PT J
AU Davis, SC
Samkoe, KS
Tichauer, KM
Sexton, KJ
Gunn, JR
Deharvengt, SJ
Hasan, T
Pogue, BW
AF Davis, Scott C.
Samkoe, Kimberley S.
Tichauer, Kenneth M.
Sexton, Kristian J.
Gunn, Jason R.
Deharvengt, Sophie J.
Hasan, Tayyaba
Pogue, Brian W.
TI Dynamic dual-tracer MRI-guided fluorescence tomography to quantify
receptor density in vivo
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE molecular imaging; oncology; optical imaging; engineered proteins;
spectroscopy
ID EPIDERMAL-GROWTH-FACTOR; DIFFUSE OPTICAL TOMOGRAPHY; BINDING-AFFINITY;
SOLID TUMORS; CANCER; THERAPY; MODEL; QUANTIFICATION; EVOLUTION;
MEDICINE
AB The up-regulation of cell surface receptors has become a central focus in personalized cancer treatment; however, because of the complex nature of contrast agent pharmacokinetics in tumor tissue, methods to quantify receptor binding in vivo remain elusive. Here, we present a dual-tracer optical technique for noninvasive estimation of specific receptor binding in cancer. A multispectral MRI-coupled fluorescence molecular tomography system was used to image the uptake kinetics of two fluorescent tracers injected simultaneously, one tracer targeted to the receptor of interest and the other tracer a nontargeted reference. These dynamic tracer data were then fit to a dual-tracer compartmental model to estimate the density of receptors available for binding in the tissue. Applying this approach to mice with deep-seated gliomas that overexpress the EGF receptor produced an estimate of available receptor density of 2.3 +/- 0.5 nM (n = 5), consistent with values estimated in comparative invasive imaging and ex vivo studies.
C1 [Davis, Scott C.; Tichauer, Kenneth M.; Sexton, Kristian J.; Gunn, Jason R.; Pogue, Brian W.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
[Samkoe, Kimberley S.; Pogue, Brian W.] Geisel Sch Med Dartmouth, Dept Surg, Hanover, NH 03755 USA.
[Deharvengt, Sophie J.] Geisel Sch Med Dartmouth, Dept Pathol, Hanover, NH 03755 USA.
[Tichauer, Kenneth M.] Illinois Inst Technol, Dept Biomed Engn, Chicago, IL 60616 USA.
[Hasan, Tayyaba; Pogue, Brian W.] Harvard Univ, Massachusetts Gen Hosp, Wellman Ctr Photomed, Sch Med, Boston, MA 02114 USA.
RP Davis, SC (reprint author), Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA.
EM scott.c.davis@dartmouth.edu
FU National Institutes of Health [R01CA109558, R01CA156177, U54CA151662];
Department of Defense [W81XWH-09-1-0661]
FX This work was funded by National Institutes of Health Grants R01CA109558
(to S. C. D. and B. W. P.), R01CA156177 (K. S. S., J.R.G., T. H., and B.
W. P.), and U54CA151662 (to K. M. T., K.J.S., and B. W. P.) as well as
Department of Defense Award W81XWH-09-1-0661 (to S.C.D.).
NR 51
TC 34
Z9 34
U1 4
U2 25
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 28
PY 2013
VL 110
IS 22
BP 9025
EP 9030
DI 10.1073/pnas.1213490110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 165RC
UT WOS:000320500000068
PM 23671066
ER
PT J
AU Rizvi, I
Gurkan, UA
Tasoglu, S
Alagic, N
Celli, JP
Mensah, LB
Mai, ZM
Demirci, U
Hasan, T
AF Rizvi, Imran
Gurkan, Umut A.
Tasoglu, Savas
Alagic, Nermina
Celli, Jonathan P.
Mensah, Lawrence B.
Mai, Zhiming
Demirci, Utkan
Hasan, Tayyaba
TI Flow induces epithelial-mesenchymal transition, cellular heterogeneity
and biomarker modulation in 3D ovarian cancer nodules
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE tumor microenvironment; stress response; molecular targets; combination
therapies; photodynamic therapy
ID GROWTH-FACTOR RECEPTOR; CARCINOMA ASCITES SPHEROIDS; PHASE-II TRIAL;
GENE-EXPRESSION; PHOTODYNAMIC THERAPY; MALIGNANT BREAST; IN-VITRO;
TRANSLATIONAL CONTROL; EXTRACELLULAR-MATRIX; NUCLEAR-ORGANIZATION
AB Seventy-five percent of patients with epithelial ovarian cancer present with advanced-stage disease that is extensively disseminated intraperitoneally and prognosticates the poorest outcomes. Primarily metastatic within the abdominal cavity, ovarian carcinomas initially spread to adjacent organs by direct extension and then disseminate via the transcoelomic route to distant sites. Natural fluidic streams of malignant ascites triggered by physiological factors, including gravity and negative subdiaphragmatic pressure, carry metastatic cells throughout the peritoneum. We investigated the role of fluidic forces as modulators of metastatic cancer biology in a customizable microfluidic platform using 3D ovarian cancer nodules. Changes in the morphological, genetic, and protein profiles of biomarkers associated with aggressive disease were evaluated in the 3D cultures grown under controlled and continuous laminar flow. A modulation of biomarker expression and tumor morphology consistent with increased epithelial-mesenchymal transition, a critical step in metastatic progression and an indicator of aggressive disease, is observed because of hydrodynamic forces. The increase in epithelial-mesenchymal transition is driven in part by a posttranslational up-regulation of epidermal growth factor receptor (EGFR) expression and activation, which is associated with the worst prognosis in ovarian cancer. A flow-induced, transcriptionally regulated decrease in E-cadherin protein expression and a simultaneous increase in vimentin is observed, indicating increased metastatic potential. These findings demonstrate that fluidic streams induce a motile and aggressive tumor phenotype. The microfluidic platform developed here potentially provides a flow-informed framework complementary to conventional mechanism-based therapeutic strategies, with broad applicability to other lethal malignancies.
C1 [Rizvi, Imran; Alagic, Nermina; Celli, Jonathan P.; Mensah, Lawrence B.; Mai, Zhiming; Hasan, Tayyaba] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed,Dept Dermatol, Boston, MA 02114 USA.
[Gurkan, Umut A.; Tasoglu, Savas; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Biomed Engn,Bioacoust Microelectrome, Boston, MA 02114 USA.
[Gurkan, Umut A.; Tasoglu, Savas; Demirci, Utkan] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Infect Dis,Bioacoust Microelectromec, Boston, MA 02114 USA.
[Celli, Jonathan P.] Univ Massachusetts, Dept Phys, Boston, MA 02125 USA.
[Demirci, Utkan; Hasan, Tayyaba] Harvard Univ, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Demirci, Utkan; Hasan, Tayyaba] MIT, Cambridge, MA 02139 USA.
RP Demirci, U (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Biomed Engn,Bioacoust Microelectrome, Boston, MA 02114 USA.
EM udemirci@rics.bwh.harvard.edu; thasan@mgh.harvard.edu
OI Gurkan, Umut/0000-0002-0331-9960; Rizvi, Imran/0000-0001-9673-4700
FU National Institutes of Health [K99CA155045, R21-HL112114, R21-AI087107,
R01AI081534, R01EB015776, R01CA158415, R01CA160998, 5PO1CA084203];
Eleanor and Miles Shore Scholars in Medicine Program; National Science
Foundation [1150733]
FX We thank Drs. Patricia Donahoe and Marcela del Carmen for valuable
guidance, feedback, and clinical perspective; Dr. Bryan Spring for
assistance with the immunofluorescence protocol and fluorescence
imaging; Michael Glidden for assistance with image processing; and Drs.
Maxim Olchanyi and Bala Sundaram for useful conversations regarding
interpretation of fractal geometries in image data. This work was
supported by National Institutes of Health Grants K99CA155045 (to
J.P.C.); R21-HL112114, R21-AI087107, R01AI081534, and R01EB015776 (to
U.D.); and R01CA158415, R01CA160998, and 5PO1CA084203 (to T.H.); and by
the Eleanor and Miles Shore Scholars in Medicine Program (J.P.C.). U.D.
is the recipient of National Science Foundation CAREER Award 1150733.
NR 98
TC 36
Z9 38
U1 4
U2 47
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 28
PY 2013
VL 110
IS 22
BP E1974
EP E1983
DI 10.1073/pnas.1216989110
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 165RC
UT WOS:000320500000003
PM 23645635
ER
PT J
AU Guyenet, SJ
Nguyen, HT
Hwang, BH
Schwartz, MW
Baskin, DG
Thaler, JP
AF Guyenet, Stephan J.
Nguyen, Hong T.
Hwang, Bang H.
Schwartz, Michael W.
Baskin, Denis G.
Thaler, Joshua P.
TI High-fat diet feeding causes rapid, non-apoptotic cleavage of caspase-3
in astrocytes
SO BRAIN RESEARCH
LA English
DT Article
DE Glia; Astrocytes; Apoptosis; Obesity; Neuron injury; Hypothalamus
ID POSTNATAL EXCITOTOXIC DAMAGE; FIBRILLARY ACIDIC PROTEIN; TRAUMATIC
BRAIN-INJURY; SPINAL-CORD-INJURY; REACTIVE ASTROCYTES; CELL-DEATH;
KAPPA-B; ACTIVATION; OBESITY; MICE
AB Astrocytes respond to multiple forms of central nervous system (CNS) injury by entering a reactive state characterized by morphological changes and a specific pattern of altered protein expression. Termed astrogliosis, this response has been shown to strongly influence the injury response and functional recovery of CNS tissues. This pattern of CNS inflammation and injury associated with astrogliosis has recently been found to occur in the energy homeostasis centers of the hypothalamus during diet-induced obesity (DIO) in rodent models, but the characterization of the astrocyte response remains incomplete. Here, we report that astrocytes in the mediobasal hypothalamus respond robustly and rapidly to purified high-fat diet (HFD) feeding by cleaving caspase-3, a protease whose cleavage is often associated with apoptosis. Although obesity develops in HFD-fed rats by day 14, caspase-3 cleavage occurs by day 3, prior to the development of obesity, suggesting the possibility that it could play a causal role in the hypothalamic neuropathology and fat gain observed in DIO. Caspase-3 cleavage is not associated with an increase in the rate of apoptosis, as determined by TUNEL staining, suggesting it plays a non-apoptotic role analogous to the response to excitotoxic neuron injury. Our results indicate that astrocytes in the mediobasal hypothalamus respond rapidly and robustly to HFD feeding, activating caspase-3 in the absence of apoptosis, a process that has the potential to influence the course of DIO. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Guyenet, Stephan J.; Nguyen, Hong T.; Hwang, Bang H.; Schwartz, Michael W.; Baskin, Denis G.; Thaler, Joshua P.] Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, Seattle, WA 98109 USA.
[Hwang, Bang H.; Baskin, Denis G.] VA Puget Sound Hlth Care Syst, Dept Vet Affairs Puget Sound Hlth Care Syst, Off Res & Dev, Seattle, WA 98108 USA.
RP Thaler, JP (reprint author), Univ Washington, Diabet & Obes Ctr Excellence, Div Metab Endocrinol & Nutr, UW Med South Lake Union,Dept Med, 850 Republican St,Box 358055, Seattle, WA 98109 USA.
EM guyenet@uw.edu; hongtng@uw.edu; bhhwang@uw.edu; mschwart@uw.edu;
baskindg@uw.edu; jpthaler@uw.edu
FU National Institutes of Health (NIH) [T32DK007247, F32DK091989, DK088872,
DK017047, P30DK017047, DK068384, DK083042, DK052989]; Department of
Veterans Affairs Senior Research Career Scientist Award at the Veterans
Affairs Puget Sound Health Care System; Biomedical Research Core
Programs Cellular and Molecular Imaging Core of the University of
Washington NIH/NIDDK Diabetes Research Center
FX This work was supported by a National Institutes of Health (NIH)
Fellowship Training Program Award (T32DK007247), an NIH National
Research Service Award (F32DK091989) to S.G., an NIH Career Development
Award (DK088872), an NIH-funded Diabetes Research Center Pilot and
Feasibility award (DK017047) to J.T., the NIH-funded University of
Washington Nutrition Obesity Research Center and Diabetes Research
Center (Grant P30DK017047 to D.B.), and NIH Grants DK068384, DK083042,
and DK052989 to M.S.; This work was also supported by resources from the
Office of Research and Development, Medical Research Service, Department
of Veterans Affairs, including the Merit Review Research Program and the
Research Enhancement Award Program. D.B. is the recipient of a
Department of Veterans Affairs Senior Research Career Scientist Award at
the Veterans Affairs Puget Sound Health Care System. Additional support
came from the Biomedical Research Core Programs Cellular and Molecular
Imaging Core of the University of Washington NIH/NIDDK Diabetes Research
Center.
NR 36
TC 11
Z9 12
U1 0
U2 10
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 28
PY 2013
VL 1512
BP 97
EP 105
DI 10.1016/j.brainres.2013.03.033
PG 9
WC Neurosciences
SC Neurosciences & Neurology
GA 160AG
UT WOS:000320087800010
PM 23548599
ER
PT J
AU Liang, OD
Lu, JY
Nombela-Arrieta, C
Zhong, J
Zhao, L
Pivarnik, G
Mondal, S
Chai, L
Silberstein, LE
Luo, HR
AF Liang, Olin D.
Lu, Jiayun
Nombela-Arrieta, Cesar
Zhong, Jia
Zhao, Li
Pivarnik, Gregory
Mondal, Subhanjan
Chai, Li
Silberstein, Leslie E.
Luo, Hongbo R.
TI Deficiency of Lipid Phosphatase SHIP Enables Long-Term Reconstitution of
Hematopoietic Inductive Bone Marrow Microenvironment
SO DEVELOPMENTAL CELL
LA English
DT Article
ID STEM-CELL NICHE; PROGENITOR CELLS; HOST ORIGIN; MOUSE; MAINTENANCE;
MICE; DIFFERENTIATION; TRANSPLANTATION; PROLIFERATION; REGENERATION
AB A dysfunctional bone marrow (BM) microenvironment is thought to contribute to the development of hematologic diseases. However, functional replacement of pathologic BM microenvironment through BM transplantation has not been possible. Furthermore, the study of hematopoietic inductive BM microenvironment is hampered by the lack of a functional nonhematopoietic reconstitution system. Here, we show that a deficiency of SH2-containing inosito1-5'-phosphatase-1 (SHIP) in a nonhematopoietic host microenvironment enables its functional reconstitution by wild-type donor cells. This microenvironment reconstitution normalizes hematopoiesis in peripheral blood and BM and alleviates pathology of spleen and lung in the SHIP-deficient recipients. SHIP-deficient BM contains a significantly smaller population of multipotent stromal cells with distinct properties, which may contribute to the reconstitution by wild-type cells. We further demonstrate that it is the nonhematopoietic donor cells that are responsible for the reconstitution. Thus, we have established a nonhematopoietic BM microenvironment reconstitution system to functionally study specific cell types in hematopoietic niches.
C1 [Liang, Olin D.; Lu, Jiayun; Nombela-Arrieta, Cesar; Zhong, Jia; Zhao, Li; Pivarnik, Gregory; Mondal, Subhanjan; Chai, Li; Silberstein, Leslie E.; Luo, Hongbo R.] Harvard Univ, Sch Med, Dept Pathol, Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Liang, Olin D.; Lu, Jiayun; Nombela-Arrieta, Cesar; Zhong, Jia; Zhao, Li; Pivarnik, Gregory; Mondal, Subhanjan; Chai, Li; Silberstein, Leslie E.; Luo, Hongbo R.] Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA.
[Liang, Olin D.; Lu, Jiayun; Nombela-Arrieta, Cesar; Zhong, Jia; Zhao, Li; Pivarnik, Gregory; Mondal, Subhanjan; Silberstein, Leslie E.; Luo, Hongbo R.] Childrens Hosp, Stem Cell Program, Boston, MA 02115 USA.
[Liang, Olin D.; Lu, Jiayun; Nombela-Arrieta, Cesar; Zhong, Jia; Zhao, Li; Pivarnik, Gregory; Mondal, Subhanjan; Silberstein, Leslie E.; Luo, Hongbo R.] Childrens Hosp, Dept Lab Med, Boston, MA 02115 USA.
[Chai, Li] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Luo, HR (reprint author), Harvard Univ, Sch Med, Dept Pathol, Harvard Stem Cell Inst, Boston, MA 02115 USA.
EM hongbo.luo@childrens.harvard.edu
OI Nombela-Arrieta, Cesar/0000-0003-0415-259X
FU National Institutes of Health (NIH) [HL066987]; Human Frontiers in
Science Program; NIH [HL085100, A1076471, HL092020, GM076084]; American
Cancer Society
FX We thank Jia Zhong and Li Zhao for maintaining the mice and Nick
Calderone for histology services. O.D.L. and J.L. are supported by
National Institutes of Health (NIH) training grant HL066987 (L.E.S.).
C.N.-A. is the recipient of a long-term postdoctoral fellowship from the
Human Frontiers in Science Program. H.R.L. is supported by NIH grants
HL085100, A1076471, HL092020, and GM076084 and a research scholar grant
from the American Cancer Society. O.D.L. conducted all experiments with
assistance from J.L. C.N.-A. and G.P. conducted the laser scanning
cytometry study. S.M., L.C., and L.E.S. advised on experiments and data
interpretation. O.D.L. and H.R.L. were responsible for conceiving this
study, interpreting the data, and preparing the manuscript.
NR 58
TC 3
Z9 3
U1 1
U2 5
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1534-5807
J9 DEV CELL
JI Dev. Cell
PD MAY 28
PY 2013
VL 25
IS 4
BP 333
EP 349
DI 10.1016/j.devcel.2013.04.016
PG 17
WC Cell Biology; Developmental Biology
SC Cell Biology; Developmental Biology
GA 157JM
UT WOS:000319892400005
PM 23725762
ER
PT J
AU Chaiyachati, KH
Loveday, M
Lorenz, S
Lesh, N
Larkan, LM
Cinti, S
Friedland, GH
Haberer, JE
AF Chaiyachati, Krisda H.
Loveday, Marian
Lorenz, Stephen
Lesh, Neal
Larkan, Lee-Megan
Cinti, Sandro
Friedland, Gerald H.
Haberer, Jessica E.
TI A Pilot Study of an mHealth Application for Healthcare Workers: Poor
Uptake Despite High Reported Acceptability at a Rural South African
Community-Based MDR-TB Treatment Program
SO PLOS ONE
LA English
DT Article
ID ACTIVE ANTIRETROVIRAL THERAPY; CLUSTER-RANDOMIZED-TRIAL; XDR-TB;
ADHERENCE; HIV; INTERVENTION; SYMPTOMS; MODEL
AB Introduction: As the South African province of KwaZulu-Natal addresses a growing multidrug-resistant tuberculosis (MDR-TB) epidemic by shifting care and treatment from trained specialty centers to community hospitals, delivering and monitoring MDR-TB therapy has presented new challenges. In particular, tracking and reporting adverse clinical events have been difficult for mobile healthcare workers (HCWs), trained health professionals who travel daily to patient homes to administer and monitor therapy. We designed and piloted a mobile phone application (Mobilize) for mobile HCWs that electronically standardized the recording and tracking of MDR-TB patients on low-cost, functional phones.
Objective: We assess the acceptability and feasibility of using Mobilize to record and submit adverse events forms weekly during the intensive phase of MDR-TB therapy and evaluate mobile HCW perceptions throughout the pilot period.
Methods: All five mobile HCWs at one site were trained and provided with phones. Utilizing a mixed-methods evaluation, mobile HCWs' usage patterns were tracked electronically for seven months and analyzed. Qualitative focus groups and questionnaires were designed to understand the impact of mobile phone technology on the work environment.
Results: Mobile HCWs submitted nine of 33 (27%) expected adverse events forms, conflicting with qualitative results in which mobile HCWs stated that Mobilize improved adverse events communication, helped their daily workflow, and could be successfully expanded to other health interventions. When presented with the conflict between their expressed views and actual practice, mobile HCWs cited forgetfulness and believed patients should take more responsibility for their own care.
Discussion: This pilot experience demonstrated poor uptake by HCWs despite positive responses to using mHealth. Though our results should be interpreted cautiously because of the small number of mobile HCWs and MDR-TB patients in this study, we recommend carefully exploring the motivations of HCWs and technologic enhancements prior to scaling new mHealth initiatives in resource poor settings.
C1 [Chaiyachati, Krisda H.; Friedland, Gerald H.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Chaiyachati, Krisda H.; Friedland, Gerald H.] Tugela Ferry Care & Res Collaborat TF CARES, Tugela Ferry, South Africa.
[Loveday, Marian] MRC, Hlth Syst Res Unit, Cape Town, South Africa.
[Loveday, Marian] Univ KwaZulu Natal, Discipline Publ Hlth Med, Durban, South Africa.
[Lorenz, Stephen] Massachusetts Gen Hosp, Comp Sci Lab, Boston, MA 02114 USA.
[Lesh, Neal] Dimagi Inc, Charlestown, MA USA.
[Larkan, Lee-Megan] KwaZulu Natal Dept Hlth, Greytown, South Africa.
[Cinti, Sandro] Univ Michigan, Sch Med, Ann Arbor, MI USA.
[Cinti, Sandro] Vet Affairs Ann Arbor Hlth Syst, Ann Arbor, MI USA.
[Haberer, Jessica E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Chaiyachati, KH (reprint author), Yale Univ, Sch Med, New Haven, CT 06520 USA.
EM Krisda.Chaiyachati@yale.edu
RI Loveday, Marian/M-8016-2013; Emchi, Karma/Q-1952-2016
OI Loveday, Marian/0000-0001-9205-9314;
FU Infectious Disease Society of America through the Medical Scholars
Program; International Institute at the University of Michigan
FX We received financial support from the Infectious Disease Society of
America through the Medical Scholars Program and the International
Institute at the University of Michigan through the Individual
Fellowship Award. Neither the Infectious Disease Society of American nor
the International Institute at the University of Michigan had any role
in the design or conduct of the study; collection, management, analysis,
or interpretation of the data; or preparation, review or approval of the
manuscript.
NR 33
TC 21
Z9 21
U1 2
U2 29
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 28
PY 2013
VL 8
IS 5
AR e64662
DI 10.1371/journal.pone.0064662
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 155FM
UT WOS:000319733000076
PM 23724075
ER
PT J
AU McCloud, RF
Jung, M
Gray, SW
Viswanath, K
AF McCloud, R. F.
Jung, M.
Gray, S. W.
Viswanath, K.
TI Class, race and ethnicity and information avoidance among cancer
survivors
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE health information avoidance; health communication; health disparities;
communication inequalities
ID HEALTH INFORMATION; SEEKING BEHAVIOR; BREAST-CANCER; STYLES;
DETERMINANTS; POPULATION; PREDICTORS
AB Background: Information seeking may increase cancer survivors' ability to make decisions and cope with the disease, but many also avoid cancer information after diagnosis. The social determinants and subsequent communication barriers that lead to avoidance have not been explored. The purpose of this study is to examine the influence of social determinants on information avoidance among cancer survivors.
Methods: We examined how health information avoidance is associated with structural and individual factors in a mail-based survey of 519 cancer survivors. Factor analysis was conducted to determine barriers to obtaining cancer information, and multivariable logistic regression models by gender were run to analyze social determinants of avoidance from an intersectional approach.
Results: Participants who were younger, female, had greater debt and lower income, and had difficulty finding suitable information were more likely to avoid information. The probability of information avoidance increased when survivors reported barriers to information use or comprehension.
Conclusion: These results indicate that survivors' information avoidance may be driven, in part, by social determinants, particularly among those at the intersection of multiple social status categories. Customized strategies are needed that maximize the likelihood that information will be used by vulnerable groups such as those from a lower socioeconomic position.
C1 [McCloud, R. F.; Viswanath, K.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[McCloud, R. F.; Jung, M.; Gray, S. W.; Viswanath, K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jung, M.] Dongduk Womens Univ, Seoul, South Korea.
[Gray, S. W.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP McCloud, RF (reprint author), Harvard Univ, Sch Publ Hlth, 665 Huntington Ave, Boston, MA 02115 USA.
EM Rachel_Faulkenberry@dfci.harvard.edu
OI Jung, Minsoo/0000-0003-3317-6507
FU NIH grant [R25 CA057711]; Lance Armstrong Foundation
FX This project was supported by NIH grant number R25 CA057711. Its
contents are solely the responsibility of the authors and do not
necessarily represent the official views of the NIH.; This work was
supported by the Lance Armstrong Foundation to K. Viswanath (PI).
NR 32
TC 7
Z9 7
U1 4
U2 18
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 28
PY 2013
VL 108
IS 10
BP 1949
EP 1956
DI 10.1038/bjc.2013.182
PG 8
WC Oncology
SC Oncology
GA 152WE
UT WOS:000319561300005
PM 23681189
ER
PT J
AU Hirata, H
Ueno, K
Nakajima, K
Tabatabai, ZL
Hinoda, Y
Ishii, N
Dahiya, R
AF Hirata, H.
Ueno, K.
Nakajima, K.
Tabatabai, Z. L.
Hinoda, Y.
Ishii, N.
Dahiya, R.
TI Genistein downregulates onco-miR-1260b and inhibits Wnt-signalling in
renal cancer cells
SO BRITISH JOURNAL OF CANCER
LA English
DT Article
DE Genistein; miR-1260b; RCC; Dkk2; sFRP1; Smad4; real-time RT-PCR; MTS
assay; invasion assay; apoptosis; FACS; western blot; 3 ' UTR luciferase
assay; TOPflash
ID BETA-CATENIN; TUMOR-SUPPRESSOR; CARCINOMA; THERAPY; EXPRESSION;
DIAGNOSIS
AB Background: Wnt-signalling has an important role in renal cancer and it is modulated by genistein in other cancers. Recently, microRNAs (miRNAs) have emerged as new regulators of gene expression. Thus, we focused on miRNAs to examine the regulatory mechanism of genistein on the Wnt-signalling pathway in renal cell carcinoma (RCC).
Methods: Initially, we investigated the effect of genistein on Wnt-signalling (TOPflash reporter assay (TCF reporter assays)) in renal cancer cells, and using microarray identified candidate miRNAs whose expression was decreased by genistein. We performed functional analyses and investigated the relationship between miRNA expression and renal cancer patient outcomes. We also did 3'UTR luciferase assays to look at direct miRNA regulation of Wnt-signalling-related genes.
Results: Genistein promoted apoptosis while inhibiting RCC cell proliferation and invasion. Genistein also decreased TCF reporter activity in RCC cells. We found that miR-1260b was highly expressed and significantly downregulated by genistein in RCC cells. The expression of miR-1260b was significantly higher in renal cancer tissues compared with normal, and significantly related to overall shorter survival. In addition, miR-1260b promoted renal cancer cell proliferation and invasion in RCC cells. The 3'UTR luciferase activity of target genes (sFRP1, Dkk2, Smad4) was significantly decreased and their protein expression significantly upregulated in miR-1260b inhibitor-transfected renal cancer cells.
Conclusion: Our data suggest that genistein inhibited Wnt-signalling by regulating miR-1260b expression in renal cancer cells.
C1 [Hirata, H.; Ueno, K.; Dahiya, R.] San Francisco VA Med Ctr, Dept Urol, San Francisco, CA 94121 USA.
[Hirata, H.; Ueno, K.; Tabatabai, Z. L.; Dahiya, R.] Univ Calif San Francisco, San Francisco, CA 94121 USA.
[Nakajima, K.; Ishii, N.] Toho Univ, Fac Med, Dept Urol, Tokyo, Japan.
[Tabatabai, Z. L.] San Francisco VA Med Ctr, Dept Pathol, San Francisco, CA 94121 USA.
[Hinoda, Y.] Yamaguchi Univ, Grad Sch Med, Dept Oncol & Lab Med, Yamaguchi, Japan.
RP Dahiya, R (reprint author), San Francisco VA Med Ctr, Dept Urol, 4150 Clement St, San Francisco, CA 94121 USA.
EM rdahiya@urology.ucsf.edu
FU National Center for Research Resources of the National Institutes of
Health [RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123]; VA Merit
Review; VA Program Project; Yamada Science Foundation
FX We thank Dr Roger Erickson for his support and assistance with the
preparation of the manuscript. This study was supported by National
Center for Research Resources of the National Institutes of Health
through Grant Number RO1CA138642, RO1CA130860, RO1CA160079, I01BX001123,
VA Merit Review, VA Program Project (PI: R Dahiya) and Yamada Science
Foundation.
NR 26
TC 30
Z9 33
U1 0
U2 8
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0007-0920
J9 BRIT J CANCER
JI Br. J. Cancer
PD MAY 28
PY 2013
VL 108
IS 10
BP 2070
EP 2078
DI 10.1038/bjc.2013.173
PG 9
WC Oncology
SC Oncology
GA 152WE
UT WOS:000319561300021
PM 23591200
ER
PT J
AU Kumar, V
Patel, N
Van Houzen, N
Saini, N
AF Kumar, Vishesh
Patel, Neha
Van Houzen, Nathan
Saini, Neeraj
TI Brugada-Type Electrocardiographic Changes Induced by Fever
SO CIRCULATION
LA English
DT Editorial Material
C1 [Kumar, Vishesh] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Patel, Neha] Brockton Hosp, Signature Healthcare, Dept Hospitalist Med, Brockton, MA USA.
[Van Houzen, Nathan] North Shore Med Ctr, Div Cardiol, Salem, MA USA.
[Saini, Neeraj] North Shore Med Ctr, Dept Internal Med, Salem, MA USA.
RP Kumar, V (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,Suite 5-210, Boston, MA 02114 USA.
EM Kumar.Vishesh@mgh.harvard.edu
NR 2
TC 2
Z9 2
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 28
PY 2013
VL 127
IS 21
BP 2145
EP 2146
DI 10.1161/CIRCULATIONAHA.112.000901
PG 2
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 152CJ
UT WOS:000319507100013
PM 23716383
ER
PT J
AU Amin, AP
Bachuwar, A
Reid, KJ
Chhatriwalla, AK
Salisbury, AC
Yeh, RW
Kosiborod, M
Wang, TY
Alexander, KP
Gosch, K
Cohen, DJ
Spertus, JA
Bach, RG
AF Amin, Amit P.
Bachuwar, Alok
Reid, Kimberly J.
Chhatriwalla, Adnan K.
Salisbury, Adam C.
Yeh, Robert W.
Kosiborod, Mikhail
Wang, Tracy Y.
Alexander, Karen P.
Gosch, Kensey
Cohen, David J.
Spertus, John A.
Bach, Richard G.
TI Nuisance Bleeding With Prolonged Dual Antiplatelet Therapy After Acute
Myocardial Infarction and its Impact on Health Status
SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
LA English
DT Article
DE clopidogrel; dual antiplatelet therapy; EuroQOL; nuisance bleeding;
quality of life
ID ACUTE CORONARY SYNDROMES; ST-SEGMENT-ELEVATION; RANDOMIZED MULTICENTER
TRIAL; ADVERSE OUTCOMES; CLOPIDOGREL; INTERVENTION; PREDICTORS;
REGISTRY; RISK; PCI
AB Objectives The purpose of this study was to examine the incidence of nuisance bleeding after AMI and its impact on QOL.
Background Prolonged dual antiplatelet therapy (DAPT) is recommended after acute myocardial infarction (AMI) to reduce ischemic events, but it is associated with increased rates of major and minor bleeding. The incidence of even lesser degrees of post-discharge "nuisance" bleeding with DAPT and its impact on quality of life (QOL) are unknown.
Methods Data from the 24-center TRIUMPH (Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status) study of 3,560 patients, who were interviewed at 1, 6, and 12 months after AMI, were used to investigate the incidence of nuisance bleeding (defined as Bleeding Academic Research Consortium type 1). Baseline characteristics associated with "nuisance" bleeding and its association with QOL, as measured by the EuroQol 5 Dimension visual analog scale, and subsequent re-hospitalization were examined.
Results Nuisance (Bleeding Academic Research Consortium type 1) bleeding occurred in 1,335 patients (37.5%) over the 12 months after AMI. After adjusting for baseline bleeding and mortality risk, ongoing DAPT was the strongest predictor of nuisance bleeding (rate ratio [RR]: 1.44, 95% confidence interval [CI]: 1.17 to 1.76 at 1 month; RR: 1.89, 95% CI: 1.35 to 2.65 at 6 months; and RR: 1.39, 95% CI: 1.08 to 1.79 at 12 months; p < 0.01 for all comparisons). Nuisance bleeding at 1 month was independently associated with a decrement in QOL at 1 month (-2.81 points on EuroQol 5 Dimension visual analog scale; 95% CI: 1.09 to 5.64) and nonsignificantly toward higher re-hospitalization (hazard ratio: 1.20; 95% CI: 0.95 to 1.52).
Conclusions Nuisance bleeding is common in the year after AMI, associated with ongoing use of DAPT, and independently associated with worse QOL. Improved selection of patients for prolonged DAPT may help minimize the incidence and adverse consequences of nuisance bleeding. (C) 2013 by the American College of Cardiology Foundation
C1 [Amin, Amit P.; Bachuwar, Alok; Bach, Richard G.] Washington Univ, Cardiovasc Div, Sch Med, St Louis, MO 63110 USA.
[Amin, Amit P.; Bachuwar, Alok; Bach, Richard G.] Barnes Jewish Hosp, St Louis, MO 63110 USA.
[Reid, Kimberly J.; Chhatriwalla, Adnan K.; Salisbury, Adam C.; Kosiborod, Mikhail; Gosch, Kensey; Cohen, David J.; Spertus, John A.] St Lukes Mid Amer Heart Inst, Kansas City, MO USA.
[Chhatriwalla, Adnan K.; Salisbury, Adam C.; Kosiborod, Mikhail; Cohen, David J.; Spertus, John A.] Univ Missouri, Kansas City, MO 64110 USA.
[Yeh, Robert W.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA.
[Wang, Tracy Y.; Alexander, Karen P.] Duke Univ, Med Ctr, Div Cardiol, Durham, NC 27710 USA.
RP Bach, RG (reprint author), Washington Univ, Cardiovasc Div, Sch Med, Campus Box 8086,660 South Euclid Ave, St Louis, MO 63110 USA.
EM rbach@dom.wustl.edu
FU National Heart, Lung, and Blood Institute [P50 HL077113]; American Heart
Association; National Center for Advancing Translational Sciences of the
National Institutes of Health [UL1TR000448, KL2TR000450, TL1TR000449];
National Cancer Institute of the National Institutes of Health
[1KM1CA156708-01]; Harvard Clinical Research Institute; Medtronic
Minimed; Gilead Sciences; Genentech; Sanofi-Aventis; GluMetrics Inc.;
Bristol-Myers Squibb; Daiichi Sankyo; Heartscape Technologies; Eli Lilly
Company; Schering Plough/Merck; Gilead; Boston Scientific; Medtronic;
Abbott Vascular; Eli Lilly; Daichi Sankyo; Accumetrix; BMS/Sanofi;
Schering-Plough; AstraZeneca; Edwards Lifesciences; Cordis; BMS
FX The TRIUMPH study was funded by P50 HL077113 from the National Heart,
Lung, and Blood Institute, and support for these analyses was provided
by an award from the American Heart Association Pharmaceutical Round
Table and David and Stevie Spina. Dr. Amin is funded via a comparative
effectiveness research KM1 career development award from the Clinical
and Translational Science Award program of the National Center for
Advancing Translational Sciences of the National Institutes of Health,
Grants UL1TR000448, KL2TR000450, and TL1TR000449, and the National
Cancer Institute of the National Institutes of Health, Grant
1KM1CA156708-01. Dr. Yeh has received research funding from the Harvard
Clinical Research Institute. Dr. Kosiborod has received research grant
support from Medtronic Minimed, Gilead Sciences, Genentech,
Sanofi-Aventis, and GluMetrics Inc.; and serves as a consultant and is
on the advisory board for Medtronic Minimed, Gilead Sciences, Genentech,
Boehringer Ingelheim, CardioMEMS, and Hoffmann-La Roche Ltd. Dr. Wang is
a consultant for ACCF and Medeo; lectures for AstraZeneca; and has
received research grant support from Bristol-Myers Squibb, Daiichi
Sankyo, Heartscape Technologies, Eli Lilly & Company, Sanofi-Aventis,
Schering Plough/Merck, and Gilead. Dr. Cohen serves as a consultant and
is on the advisory board of AstraZeneca and Janssen Pharmaceuticals; has
received research grant support from Boston Scientific, Medtronic,
Abbott Vascular, Eli Lilly, Daichi Sankyo, Accumetrix, BMS/Sanofi,
Schering-Plough, AstraZeneca, and Edwards Lifesciences; has received
consulting fees from Cordis and Medtronic; and has received speaking
honoraria from Eli Lilly and The Medicines Company. Dr. Spertus is the
Principal Investigator of a contract from the American College of
Cardiology Foundation to serve as an Analytic Center for the National
Cardiovascular Data Registry; has an equity position in Health Outcomes
Sciences; and has served as a consultant to Eli Lilly & Company, United
Healthcare, Genentech, Amgen, Abbott Vascular, EvaHeart, and St. Jude
Medical. Dr. Bach is a consultant to and a member of the clinical event
committee activity to Hoffmann-La Roche Ltd. and Pfizer and has received
research support from AstraZeneca, BMS, Eli Lilly & Company, and
Schering Plough/Merck. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
NR 31
TC 19
Z9 19
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0735-1097
J9 J AM COLL CARDIOL
JI J. Am. Coll. Cardiol.
PD MAY 28
PY 2013
VL 61
IS 21
BP 2130
EP 2138
DI 10.1016/j.jacc.2013.02.044
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA 148TD
UT WOS:000319269500003
PM 23541975
ER
PT J
AU Moore, VD
Letai, A
AF Moore, Victoria Del Gaizo
Letai, Anthony
TI BH3 profiling - Measuring integrated function of the mitochondrial
apoptotic pathway to predict cell fate decisions
SO CANCER LETTERS
LA English
DT Review
DE Apoptosis; Mitochondria; BH3-only; BH3; BCL-2
ID BCL-2 FAMILY-MEMBERS; BH3-ONLY PROTEINS; CHROMOSOMAL BREAKPOINT;
ANTIAPOPTOTIC BCL-2; BAX; DEATH; LEUKEMIA; ABT-737; THERAPEUTICS;
MAINTENANCE
AB Apoptosis is a form of programmed cell death that is controlled at the mitochondrion by the BCL-2 family of proteins. While much has been learned about the structure and function of these proteins over the past two decades, the important goal of predicting cell fate decisions in response to toxic stimuli is largely unrealized. BH3 profiling is a functional approach that can be used to predict cellular responses to stimuli based on measuring the response of mitochondria to perturbation by a panel of BH3 domain peptides. BH3 profiling has proven useful in identifying and understanding cellular dependence on individual anti-apoptotic proteins like BCL-2 or MCL-1. Consequently, it can also be used to predict cellular response to chemotherapy agents such as ABT-737 that target these individual proteins. (C) 2012 Published by Elsevier Ireland Ltd.
C1 [Moore, Victoria Del Gaizo] Elon Univ, Dept Chem, Elon, NC 27244 USA.
[Letai, Anthony] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Letai, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Mayer 430,450 Brookline Ave, Boston, MA 02215 USA.
EM anthony_letai@dfci.harvard.edu
OI Del Gaizo Moore, Victoria/0000-0002-6317-7693
NR 34
TC 18
Z9 18
U1 1
U2 10
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3835
EI 1872-7980
J9 CANCER LETT
JI Cancer Lett.
PD MAY 28
PY 2013
VL 332
IS 2
SI SI
BP 202
EP 205
DI 10.1016/j.canlet.2011.12.021
PG 4
WC Oncology
SC Oncology
GA 136QJ
UT WOS:000318378200011
ER
PT J
AU Walter, LC
Fung, KZ
Kirby, KA
Shi, Y
Espaldon, R
O'Brien, S
Freedland, SJ
Powell, AA
Hoffman, RM
AF Walter, Louise C.
Fung, Kathy Z.
Kirby, Katharine A.
Shi, Ying
Espaldon, Roxanne
O'Brien, Sarah
Freedland, Stephen J.
Powell, Adam A.
Hoffman, Richard M.
TI Five-Year Downstream Outcomes Following Prostate-Specific Antigen
Screening in Older Men
SO JAMA INTERNAL MEDICINE
LA English
DT Article
ID SERVICES TASK-FORCE; UNITED-STATES; RADICAL PROSTATECTOMY; CANCER
MORTALITY; RANDOMIZED-TRIAL; MEDICARE; RECOMMENDATION; POPULATION;
BIOPSY; LUNG
AB Importance: Despite ongoing controversies surrounding prostate-specific antigen (PSA) screening, many men 65 years or older undergo screening. However, few data exist that quantify the chain of events following screening in clinical practice to better inform decisions.
Objective: To quantify 5-year downstream outcomes following a PSA screening result exceeding 4.0 ng/mL in older men.
Design and Setting: Longitudinal cohort study in the national Veterans Affairs health care system.
Participants: In total, 295 645 men 65 years or older who underwent PSA screening in the Veterans Affairs health care system in 2003 and were followed up for 5 years using national Veterans Affairs and Medicare data.
Main Outcome Measures: Among men whose index screening PSA level exceeded 4.0 ng/mL, we determined the number who underwent prostate biopsy, were diagnosed as having prostate cancer, were treated for prostate cancer, and were treated for prostate cancer and were alive at 5 years according to baseline characteristics. Biopsy and treatment complications were also assessed.
Results: In total, 25 208 men (8.5%) had an index PSA level exceeding 4.0 ng/mL. During the 5-year follow-up period, 8313 men (33.0%) underwent at least 1 prostate biopsy, and 5220 men (62.8%) who underwent prostate biopsy were diagnosed as having prostate cancer, of whom 4284 (82.1%) were treated for prostate cancer. Performance of prostate biopsy decreased with advancing age and worsening comorbidity (P < .001), whereas the percentage treated for biopsy-detected cancer exceeded 75% even among men 85 years or older, those with a Charlson-Deyo Comorbidity Index of 3 or higher, and those having low-risk cancer. Among men with biopsy-detected cancer, the risk of death from non-prostate cancer causes increased with advancing age and worsening comorbidity (P < .001). In total, 468 men (5.6%) had complications within 7 days after prostate biopsy. Complications of prostate cancer treatment included new urinary incontinence in 584 men (13.6%) and new erectile dysfunction 588 men (13.7%).
Conclusions and Relevance: Performance of prostate biopsy is uncommon in older men with abnormal screening PSA levels and decreases with advancing age and worsening comorbidity. However, once cancer is detected on biopsy, most men undergo immediate treatment regardless of advancing age, worsening comorbidity, or low-risk cancer. Understanding downstream outcomes in clinical practice should better inform individualized decisions among older men considering PSA screening.
C1 [Walter, Louise C.; Fung, Kathy Z.; Kirby, Katharine A.; Shi, Ying; Espaldon, Roxanne; O'Brien, Sarah] San Francisco Vet Affairs VA Med Ctr, Div Geriatr, San Francisco, CA USA.
[Walter, Louise C.; Fung, Kathy Z.; Kirby, Katharine A.; Shi, Ying; Espaldon, Roxanne; O'Brien, Sarah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Freedland, Stephen J.] Duke Univ, Durham VA Med Ctr, Durham, NC USA.
[Freedland, Stephen J.] Duke Univ, Duke Prostate Ctr, Durham, NC USA.
[Powell, Adam A.] Univ Minnesota, Minneapolis VA Hlth Care Syst, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA.
[Powell, Adam A.] Univ Minnesota, Dept Med, Minneapolis, MN USA.
[Hoffman, Richard M.] Univ New Mexico, New Mexico VA Hlth Care Syst, Albuquerque, NM 87131 USA.
[Hoffman, Richard M.] Univ New Mexico, Dept Med, Albuquerque, NM 87131 USA.
RP Walter, LC (reprint author), San Francisco VA Med Ctr, Div Geriatr, Mail Code 181G,4150 Clement St, San Francisco, CA 94121 USA.
EM Louise.Walter@ucsf.edu
FU National Cancer Institute at the National Institutes of Health [R01
CA134425]; National Institute on Aging at the National Institutes of
Health [K24AG041180]; Veterans Affairs Career Development Award Program
[CDA 08-024]; New Mexico Veterans Affairs Health Care System
FX This work was supported by grant R01 CA134425 from the National Cancer
Institute at the National Institutes of Health (Drs Walter, Freedland,
Powell, and Hoffman), by grant K24AG041180 from the National Institute
on Aging at the National Institutes of Health (Dr Walter), by grant CDA
08-024 from the Veterans Affairs Career Development Award Program (Dr
Powell), and by the New Mexico Veterans Affairs Health Care System (Dr
Hoffman).
NR 49
TC 12
Z9 15
U1 0
U2 4
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 27
PY 2013
VL 173
IS 10
BP 866
EP 873
DI 10.1001/jamainternmed.2013.323
PG 8
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159KR
UT WOS:000320044800007
PM 23588999
ER
PT J
AU Weiner, RB
Wood, MJ
Pellikka, PA
AF Weiner, Rory B.
Wood, Malissa J.
Pellikka, Patricia A.
TI Repeated Testing and Appropriate Use of Echocardiography
SO JAMA INTERNAL MEDICINE
LA English
DT Letter
C1 [Weiner, Rory B.; Wood, Malissa J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Pellikka, Patricia A.] Mayo Clin, Dept Cardiovasc Dis & Internal Med, Rochester, MN 55905 USA.
RP Pellikka, PA (reprint author), Mayo Clin, Dept Cardiovasc Dis & Internal Med, 200 1st St SW, Rochester, MN 55905 USA.
EM pellikka.patricia@mayo.edu
NR 5
TC 0
Z9 0
U1 1
U2 1
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 515 N STATE ST, CHICAGO, IL 60654-0946 USA
SN 2168-6106
J9 JAMA INTERN MED
JI JAMA Intern. Med.
PD MAY 27
PY 2013
VL 173
IS 10
BP 935
EP 935
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 159KR
UT WOS:000320044800034
PM 23712411
ER
PT J
AU Liu, R
Rallo, R
Weissleder, R
Tassa, C
Shaw, S
Cohen, Y
AF Liu, Rong
Rallo, Robert
Weissleder, Ralph
Tassa, Carlos
Shaw, Stanley
Cohen, Yoram
TI Nano-SAR Development for Bioactivity of Nanoparticles with
Considerations of Decision Boundaries
SO SMALL
LA English
DT Article
DE nanomaterials; bioactivity screening; nano-SAR; decision boundaries
ID METAL-OXIDE NANOPARTICLES; TITANIUM-DIOXIDE NANOPARTICLES; SILICA
NANOPARTICLES; APPLICABILITY DOMAIN; AQUATIC ENVIRONMENT; HUMAN HEALTH;
TOXICITY; SIZE; NANOMATERIALS; CYTOTOXICITY
AB The development of classification nano-structureactivity Relationships (nano-SARs) of nanoparticle (NP) bioactivity is presented with the aim of demonstrating the integration of multiparametric toxicity/bioactivity assays to arrive at statistically meaningful class definitions (i.e., bioactivity/inactivity endpoints), as well as the implications of nano-SAR applicability domains and decision boundaries. Nano-SARs are constructed based on a dataset of 44 iron oxide core nanoparticles (NPs), used in molecular imaging and nano-sensing, containing bioactivity profiles for four cell types and four different assays. Class definitions are developed on the basis of hit' (i.e., significant bioactivity) identification analysis and self-organizing map based consensus clustering; these class definitions enable construction of nano-SARs of a high classification accuracy (>78%) with different NP descriptor combinations that include primary size, spin-lattice and spin-spin relaxivities, and zeta potentials. Analysis of the nano-SAR performance for different class definitions suggests that H4 (i.e., class with at least four hits) is a reasonable endpoint (from a regulatory' viewpoint) for keeping the level of false negatives (i.e., incorrect labeling of bioactive NPs as inactive) low. The establishment of a quantitative nano-SAR applicability domain is demonstrated, making use of a probability density with the H4 class definition and naive Bayesian classifier (NBC) model (with spin-lattice relaxivity and zeta potential as descriptors). Decision boundaries are determined for the above H4/NBC nano-SAR for different acceptance levels of false negative to false positive predictions, illustrating a practical approach that may assist in regulatory decision making with a consideration of reducing the likelihood of identifying bioactive NPs as being inactive.
C1 [Liu, Rong; Rallo, Robert; Cohen, Yoram] Univ Calif Los Angeles, Ctr Environm Implicat Nanotechnol, Calif Nanosyst Inst, Los Angeles, CA 90095 USA.
[Liu, Rong; Cohen, Yoram] Univ Calif Los Angeles, Chem & Biomol Engn Dept, Los Angeles, CA 90095 USA.
[Rallo, Robert] Univ Rovira & Virgili, Dept Engn Informat & Matemat, Tarragona 43007, Catalunya, Spain.
[Weissleder, Ralph; Tassa, Carlos; Shaw, Stanley] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph; Tassa, Carlos; Shaw, Stanley] Harvard Univ, Sch Med, Boston, MA 02115 USA.
RP Cohen, Y (reprint author), Univ Calif Los Angeles, Ctr Environm Implicat Nanotechnol, Calif Nanosyst Inst, Los Angeles, CA 90095 USA.
EM yoram@ucla.edu
RI Cohen, Yoram/M-8802-2014; Rallo, Robert/F-4703-2010
OI Cohen, Yoram/0000-0002-0756-4699; Rallo, Robert/0000-0003-3812-4458
FU National Science Foundation and the Environmental Protection Agency
[DBI-0830117]; CICYT [CTQ2009-14627]; Generalitat de Catalunya
[2009SGR-01529]; EU Commission (OSIRIS) [037017]; NHLBI (NIH)
[HHSN268201000044C]
FX This material is based upon work supported by the National Science
Foundation and the Environmental Protection Agency under Cooperative
Agreement Number DBI-0830117. Any opinions, findings, and conclusions or
recommendations expressed in this material are those of the author(s)
and do not necessarily reflect the views of the National Science
Foundation or the Environmental Protection Agency. This work has not
been subjected to EPA review and no official endorsement should be
inferred. R.R. acknowledges support provided by CICYT (Project
CTQ2009-14627), Generalitat de Catalunya (2009SGR-01529) and the EU
Commission (OSIRIS, Contract No. 037017). R.W. and S.S. acknowledge
support from contract HHSN268201000044C from NHLBI (NIH).
NR 88
TC 25
Z9 25
U1 3
U2 34
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA POSTFACH 101161, 69451 WEINHEIM, GERMANY
SN 1613-6810
EI 1613-6829
J9 SMALL
JI Small
PD MAY 27
PY 2013
VL 9
IS 9-10
SI SI
BP 1842
EP 1852
DI 10.1002/smll.201201903
PG 11
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary; Physics, Applied;
Physics, Condensed Matter
SC Chemistry; Science & Technology - Other Topics; Materials Science;
Physics
GA 146FT
UT WOS:000319076000038
PM 23423856
ER
PT J
AU Liang, ST
Cuevas, G
Tizani, S
Salas, T
Liu, HJ
Li, BJ
Habib, SL
AF Liang, Sitai
Cuevas, Gabriela
Tizani, Shaza
Salas, Tiffanie
Liu, Huijuan
Li, Baojie
Habib, Samy L.
TI Novel mechanism of regulation of fibrosis in kidney tumor with tuberous
sclerosis
SO MOLECULAR CANCER
LA English
DT Article
DE Angiomyolipoma; Fibrosis; alpha-SMA; YY1 and TSC
ID REPAIR ENZYME OGG1; TSC2 GAP ACTIVITY; 3-KINASE/AKT PATHWAY; COMPLEX;
GENE; ANGIOMYOLIPOMAS; EXPRESSION; RAT; LYMPHANGIOLEIOMYOMATOSIS;
PHOSPHORYLATION
AB Background: Deficiency in tuberin results in activation the mTOR pathway and leads to accumulation of cell matrix proteins. The mechanisms by which tuberin regulates fibrosis in kidney angiomyolipomas (AMLs) of tuberous sclerosis patients are not fully known.
Method: In the present study, we investigated the potential role of tuberin/mTOR pathway in the regulation of cell fibrosis in AML cells and kidney tumor tissue from tuberous sclerosis complex (TSC) patients.
Results: AML cells treated with rapamycin shows a significant decrease in mRNA and protein expression as well as in promoter transcriptional activity of alpha-smooth muscle actin (alpha-SMA) compared to untreated cells. In addition, cells treated with rapamycin significantly decreased the protein expression of the transcription factor YY1. Rapamycin treatment also results in the redistribution of YY1 from the nucleus to cytoplasm in AML cells. Moreover, cells treated with rapamycin resulted in a significant reduce of binding of YY1 to the alpha SMA promoter element in nuclear extracts of AML cells. Kidney angiomyolipoma tissues from TSC patients showed lower levels of tuberin and higher levels of phospho-p70S6K that resulted in higher levels of mRNA and protein of alpha SMA expression compared to control kidney tissues. In addition, most of the alpha-SMA staining was identified in the smooth muscle cells of AML tissues. YY1 was also significantly increased in tumor tissue of AMLs compared to control kidney tissue suggesting that YY1 plays a major role in the regulation of alpha SMA.
Conclusions: These data comprise the first report to provide one mechanism whereby rapamycin might inhibit the cell fibrosis in kidney tumor of TSC patients.
C1 [Habib, Samy L.] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA.
[Liu, Huijuan; Li, Baojie] Shanghai Jiao Tong Univ, Bio X Inst, Key Lab Genet Dev & Neuropsychiat Disorders, Minist Educ, Shanghai 200030, Peoples R China.
[Liang, Sitai; Cuevas, Gabriela; Tizani, Shaza; Salas, Tiffanie; Habib, Samy L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Cell & Struct Biol, San Antonio, TX 78229 USA.
RP Habib, SL (reprint author), South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Dept, San Antonio, TX USA.
EM habib@uthscsa.edu
FU American Heart Association; American Diabetes Association; Merit Review
Award from South Texas Veterans Healthcare System
FX This work was supported in part by grants from the American Heart
Association, American Diabetes Association and Merit Review Award from
South Texas Veterans Healthcare System (to S.L.H.).
NR 30
TC 2
Z9 2
U1 1
U2 2
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 25
PY 2013
VL 12
AR 49
DI 10.1186/1476-4598-12-49
PG 11
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 163IG
UT WOS:000320328900001
PM 23705901
ER
PT J
AU Teerlink, JR
Metra, M
AF Teerlink, John R.
Metra, Marco
CA RELAX-AHF Investigators
TI Not time to RELAX in acute heart failure Reply
SO LANCET
LA English
DT Letter
ID SERELAXIN; TRIAL; AHF
C1 [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
[Teerlink, John R.] Univ Calif San Francisco, Sch Med, San Francisco, CA 94121 USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
RP Teerlink, JR (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
EM john.teerlink@ucsf.edu
NR 5
TC 0
Z9 0
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0140-6736
J9 LANCET
JI Lancet
PD MAY 25
PY 2013
VL 381
IS 9880
BP 1813
EP 1814
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 151EO
UT WOS:000319443700021
PM 23706796
ER
PT J
AU Kampa-Schittenhelm, KM
Heinrich, MC
Akmut, F
Rasp, KH
Illing, B
Dohner, H
Dohner, K
Schittenhelm, MM
AF Kampa-Schittenhelm, Kerstin Maria
Heinrich, Michael Charles
Akmut, Figen
Rasp, Katharina Henriette
Illing, Barbara
Doehner, Hartmut
Doehner, Konstanze
Schittenhelm, Marcus Matthias
TI Cell cycle-dependent activity of the novel dual PI3K-MTORC1/2 inhibitor
NVP-BGT226 in acute leukemia
SO MOLECULAR CANCER
LA English
DT Article
DE Leukemia; PI3K; AKT; NVP-BEZ235; NVP-BGT226
ID ACUTE MYELOID-LEUKEMIA; GASTROINTESTINAL STROMAL TUMOR; ACUTE
LYMPHOBLASTIC-LEUKEMIA; C-KIT; TYROSINE KINASE; PATHWAY ACTIVATION;
THERAPEUTIC TARGET; MAMMALIAN TARGET; ADULT PATIENTS; CANCER CELLS
AB Background: Dysregulation of the PI3Kinase/AKT pathway is involved in the pathogenesis of many human malignancies. In acute leukemia, the AKT pathway is frequently activated, however mutations in the PI3K/AKT pathway are uncommon. In some cases, constitutive AKT activation can be linked to gain-of-function tyrosine kinase (TK) mutations upstream of the PI3K/AKT pathway. Inhibitors of the PI3K/AKT pathway are attractive candidates for cancer drug development, but so far clinical efficacy of PI3K inhibitors against various neoplasms has been moderate. Furthermore, specific MTORC1 inhibitors, acting downstream of AKT, have the disadvantage of activating AKT via feed-back mechanisms. We now evaluated the antitumor efficacy of NVP-BGT226, a novel dual pan-PI3K and MTORC1/2 inhibitor, in acute leukemia.
Methods: Native leukemia blasts were stained to analyze for AKT phosphorylation levels on a flow cytometer. Efficacy of NVP-BGT226 in comparison to a second dual inhibitor, NVP-BEZ235, was determined with regard to cellular proliferation, autophagy, cell cycle regulation and induction of apoptosis in in vitro and ex vivo cellular assays as well as on the protein level. An isogenic AKT-autoactivated Ba/F3 model, different human leukemia cell lines as well as native leukemia patient blasts were studied. Isobologram analyses were set up to calculate for (super) additive or antagonistic effects of two agents.
Results: We show, that phosphorylation of AKT is frequently augmented in acute leukemia. NVP-BGT226 as well as NVP-BEZ235 profoundly and globally suppress AKT signaling pathways, which translates into potent antiproliferative effects. Furthermore, NVP-BGT226 has potent proapoptotic effects in vitro as well as in ex vivo native blasts. Surprisingly and in contrast, NVP-BEZ235 leads to a profound G1/G0 arrest preventing significant induction of apoptosis. Combination with TK inhibitors, which are currently been tested in the treatment of acute leukemia subtypes, overcomes cell cycle arrest and results in (super) additive proapoptotic effects for NVP-BGT226 - but also for NVP-BEZ235. Importantly, mononuclear donor cells show lower phospho-AKT expression levels and consequently, relative insensitivity towards dual PI3K-MTORC1/2 inhibition.
Conclusions: Our data suggest a favorable antileukemic profile for NVP-BGT226 compared to NVP-BEZ235 - which provides a strong rationale for clinical evaluation of the dual PI3K-MTORC1/2 inhibitor NVP-BGT226 in acute leukemia.
C1 [Kampa-Schittenhelm, Kerstin Maria; Akmut, Figen; Rasp, Katharina Henriette; Illing, Barbara; Schittenhelm, Marcus Matthias] Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, D-72076 Tubingen, Germany.
[Heinrich, Michael Charles] Portland VA Med Ctr, Portland, OR USA.
[Heinrich, Michael Charles] OHSU Knight Canc Inst, Portland, OR USA.
[Doehner, Hartmut; Doehner, Konstanze] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.
RP Schittenhelm, MM (reprint author), Univ Tubingen Hosp, Dept Hematol Oncol Rheumatol Immunol & Pulmol, Otfried Muller Str 10, D-72076 Tubingen, Germany.
EM marcus.schittenhelm@med.uni-tuebingen.de
FU Deutsche Forschungsgemeinschaft; University of Tubingen; Deutsche
Krebshilfe Foundation; fortune-Program of the Tubingen Medical Faculty
[1490-0-0, 11836-0-0]; IZKF Program of the Medical Faculty Tubingen;
Jose Carreras Scholarship Program; Ludwig Hiermaier Foundation of the
Comprehensive Cancer Center Tubingen; Department of Veterans Affairs;
Leukemia and Lymphoma Society; GIST Cancer Research Fund; Life Raft
Group
FX We acknowledge support by Deutsche Forschungsgemeinschaft and Open
Access Publishing Fund of the University of Tubingen.; In part by the
Deutsche Krebshilfe Foundation (MMS, KKS), the fortune-Program of the
Tubingen Medical Faculty (Nr. 1490-0-0, MMS and 11836-0-0, KMK), the
IZKF Program of the Medical Faculty Tubingen (MMS) and the Jose Carreras
Scholarship Program (KKS), the Ludwig Hiermaier Foundation of the
Comprehensive Cancer Center Tubingen (MMS), a Merit Review Grant from
the Department of Veterans Affairs (MCH) and a grant from the Leukemia
and Lymphoma Society (MCH), GIST Cancer Research Fund (MCH) and the Life
Raft Group (MCH).
NR 56
TC 21
Z9 22
U1 0
U2 10
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1476-4598
J9 MOL CANCER
JI Mol. Cancer
PD MAY 24
PY 2013
VL 12
AR 46
DI 10.1186/1476-4598-12-46
PG 18
WC Biochemistry & Molecular Biology; Oncology
SC Biochemistry & Molecular Biology; Oncology
GA 168SA
UT WOS:000320724800001
PM 23705826
ER
PT J
AU Kelly, L
Bryan, K
Kim, SY
Janeway, KA
Killian, JK
Schildhaus, HU
Miettinen, M
Helman, L
Meltzer, PS
van de Rijn, M
Debiec-Rychter, M
O'Sullivan, M
AF Kelly, Lorna
Bryan, Kenneth
Kim, Su Young
Janeway, Katherine A.
Killian, J. Keith
Schildhaus, Hans-Ulrich
Miettinen, Markku
Helman, Lee
Meltzer, Paul S.
van de Rijn, Matt
Debiec-Rychter, Maria
O'Sullivan, Maureen
CA NIH Pediat Wild-type GIST Clin
TI Post-Transcriptional Dysregulation by miRNAs Is Implicated in the
Pathogenesis of Gastrointestinal Stromal Tumor [GIST]
SO PLOS ONE
LA English
DT Article
ID HEPATOCELLULAR-CARCINOMA CELLS; MICRORNA EXPRESSION PROFILE;
GENE-EXPRESSION; CARNEY TRIAD; UNIPARENTAL DISOMY; DOWN-REGULATION; KIT
ACTIVATION; ANATOMIC SITE; WILD-TYPE; MUTATIONS
AB In contrast to adult mutant gastrointestinal stromal tumors [GISTs], pediatric/wild-type GISTs remain poorly understood overall, given their lack of oncogenic activating tyrosine kinase mutations. These GISTs, with a predilection for gastric origin in female patients, show limited response to therapy with tyrosine kinase inhibitors and generally pursue a more indolent course, but still may prove fatal. Defective cellular respiration appears to underpin tumor development in these wild-type cases, which as a group lack expression of succinate dehydrogenase [SDH] B, a surrogate marker for respiratory chain metabolism. Yet, only a small subset of the wild-type tumors show mutations in the genes coding for the SDH subunits [SDHx]. To explore additional pathogenetic mechanisms in these wild-type GISTs, we elected to investigate post-transcriptional regulation of these tumors by conducting microRNA (miRNA) profiling of a mixed cohort of 73 cases including 18 gastric pediatric wild-type, 25 (20 gastric, 4 small bowel and 1 retroperitoneal) adult wild-type GISTs and 30 gastric adult mutant GISTs. By this approach we have identified distinct signatures for GIST subtypes which correlate tightly with clinico-pathological parameters. A cluster of miRNAs on 14q32 show strikingly different expression patterns amongst GISTs, a finding which appears to be explained at least in part by differential allelic methylation of this imprinted region. Small bowel and retroperitoneal wild-type GISTs segregate with adult mutant GISTs and express SDHB, while adult wildtype gastric GISTs are dispersed amongst adult mutant and pediatric wild-type cases, clustering in this situation on the basis of SDHB expression. Interestingly, global methylation analysis has recently similarly demonstrated that these wild-type, SDHB-immunonegative tumors show a distinct pattern compared with KIT and PDGFRA mutant tumors, which as a rule do express SDHB. All cases with Carney triad within our cohort cluster together tightly.
C1 [Kelly, Lorna; O'Sullivan, Maureen] Trinity Coll Dublin, Sch Med, Dept Histopathol, Dublin, Ireland.
[Kelly, Lorna; O'Sullivan, Maureen] Our Ladys Childrens Hosp, Natl Childrens Res Ctr, Dublin, Ireland.
[Bryan, Kenneth] TEAGASC, Anim & Grassland Res & Innovat Ctr, Dunsany, Meath, Ireland.
[Kim, Su Young; Killian, J. Keith; Miettinen, Markku; Helman, Lee; Meltzer, Paul S.] NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
[Janeway, Katherine A.] Dana Farber Canc Inst, Dept Pediat Hematol Oncol, Boston, MA 02115 USA.
[Janeway, Katherine A.] Childrens Hosp, Boston, MA 02115 USA.
[Schildhaus, Hans-Ulrich] Univ Cologne, Inst Pathol, Med Ctr, Cologne, Germany.
[van de Rijn, Matt] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA.
[Debiec-Rychter, Maria] Catholic Univ Louvain, Dept Human Genet, B-3000 Louvain, Belgium.
[Debiec-Rychter, Maria] Univ Hosp, Louvain, Belgium.
RP O'Sullivan, M (reprint author), Trinity Coll Dublin, Sch Med, Dept Histopathol, Dublin, Ireland.
EM maureen.osullivan@tcd.ie
OI Bryan, Kenneth/0000-0002-9550-8354
FU Medical Research Charities Group; Health Research Board of Ireland;
Children's Medical and Research Foundation; GIST Cancer Awareness
Foundation [GCAF]; Life Raft Group; Fonds voor Wetenschappelijk
Onderzoek Vlaanderen [G.0286.05 MD-R]
FX Funding was obtained from the Medical Research Charities Group
(http://www.mrcg.ie/) and Health Research Board of Ireland
(http://www.hrb.ie) (MO'S), The Children's Medical and Research
Foundation (http://www.cmrf.org) (MO'S), the GIST Cancer Awareness
Foundation [GCAF] (http://www.gistawareness.org/)(MO'S), and research
grants from the Life Raft Group (http://www.liferaftgroup.org/)(MD-R)
and from the Fonds voor Wetenschappelijk Onderzoek Vlaanderen
(http://www.fwo.be/)(grant # G.0286.05 MD-R). The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 59
TC 14
Z9 15
U1 0
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 24
PY 2013
VL 8
IS 5
AR e64102
DI 10.1371/journal.pone.0064102
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 150JB
UT WOS:000319385300026
PM 23717541
ER
PT J
AU Veeraraghavalu, K
Zhang, C
Miller, S
Hefendehl, JK
Rajapaksha, TW
Ulrich, J
Jucker, M
Holtzman, DM
Tanzi, RE
Vassar, R
Sisodia, SS
AF Veeraraghavalu, Karthikeyan
Zhang, Can
Miller, Sean
Hefendehl, Jasmin K.
Rajapaksha, Tharinda W.
Ulrich, Jason
Jucker, Mathias
Holtzman, David M.
Tanzi, Rudolph E.
Vassar, Robert
Sisodia, Sangram S.
TI Comment on "ApoE-Directed Therapeutics Rapidly Clear beta-Amyloid and
Reverse Deficits in AD Mouse Models"
SO SCIENCE
LA English
DT Editorial Material
ID FAMILIAL ALZHEIMERS-DISEASE; TRANSGENIC MICE
C1 [Veeraraghavalu, Karthikeyan; Sisodia, Sangram S.] Univ Chicago, Dept Neurobiol, Chicago, IL 60637 USA.
[Zhang, Can; Miller, Sean; Tanzi, Rudolph E.] Massachusetts Gen Hosp, Massachusetts Gen Inst Neurodegenerat Dis, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
[Zhang, Can; Miller, Sean; Tanzi, Rudolph E.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
[Hefendehl, Jasmin K.; Jucker, Mathias] Univ Tubingen, German Ctr Neurodegenerat Dis, Hertie Inst Clin Brain Res, Dept Cellular Neurol, D-72076 Tubingen, Germany.
[Rajapaksha, Tharinda W.; Vassar, Robert] Northwestern Univ, Feinberg Sch Med, Dept Cell & Mol Biol, Chicago, IL 60611 USA.
[Ulrich, Jason; Holtzman, David M.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA.
[Holtzman, David M.] Washington Univ, Sch Med, Hope Ctr Neurol Dis, St Louis, MO 63110 USA.
[Holtzman, David M.] Washington Univ, Sch Med, Charles F & Joanne Knight Alzheimers Dis Res Ctr, St Louis, MO 63110 USA.
RP Jucker, M (reprint author), Univ Tubingen, German Ctr Neurodegenerat Dis, Hertie Inst Clin Brain Res, Dept Cellular Neurol, Otfried Muller Str 27, D-72076 Tubingen, Germany.
EM mathias.jucker@uni-tuebingen.de; holtzman@neuro.wustl.edu;
tanzi@helix.mgh.harvard.edu; r-vassar@northwestern.edu;
ssisodia@bsd.uchicago.edu
NR 9
TC 63
Z9 63
U1 0
U2 29
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 0036-8075
J9 SCIENCE
JI Science
PD MAY 24
PY 2013
VL 340
IS 6135
AR 1235505
DI 10.1126/science.1235505
PG 3
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149TK
UT WOS:000319344100024
PM 23704555
ER
PT J
AU Bender, SL
Sherry, NA
Masia, R
AF Bender, Suzanne L.
Sherry, Nicole A.
Masia, Ricard
TI Case 16-2013: A 12-Year-Old Girl with Irritability, Hypersomnia, and
Somatic Symptoms
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID COGNITIVE-BEHAVIORAL THERAPY; AUTOIMMUNE ADDISONS-DISEASE; RANDOMIZED
CONTROLLED-TRIAL; SSRI-RESISTANT DEPRESSION; SUBJECTIVE HEALTH-STATUS;
CELIAC-DISEASE; ADRENAL INSUFFICIENCY; DEHYDROEPIANDROSTERONE
REPLACEMENT; UNIPOLAR DEPRESSION; MENTAL-DISORDERS
C1 [Bender, Suzanne L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Sherry, Nicole A.] Massachusetts Gen Hosp, Dept Pediat, Boston, MA 02114 USA.
[Masia, Ricard] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Bender, Suzanne L.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Sherry, Nicole A.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Masia, Ricard] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Bender, SL (reprint author), Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
FU MacroGenics
FX Dr. Sherry reports receiving consulting fees and grant support through
her institution from MacroGenics. No other potential conflict of
interest relevant to this article was reported.
NR 48
TC 2
Z9 2
U1 0
U2 5
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 23
PY 2013
VL 368
IS 21
BP 2015
EP 2024
DI 10.1056/NEJMcpc1208145
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148TJ
UT WOS:000319270200005
PM 23697517
ER
PT J
AU Oh-hora, M
Komatsu, N
Pishyareh, M
Feske, S
Hori, S
Taniguchi, M
Rao, A
Takayanagi, H
AF Oh-hora, Masatsugu
Komatsu, Noriko
Pishyareh, Mojgan
Feske, Stefan
Hori, Shohei
Taniguchi, Masaru
Rao, Anjana
Takayanagi, Hiroshi
TI Agonist-Selected T Cell Development Requires Strong T Cell Receptor
Signaling and Store-Operated Calcium Entry
SO IMMUNITY
LA English
DT Article
ID NEGATIVE SELECTION; POSITIVE SELECTION; CA2+ ENTRY; TGF-BETA; IN-VIVO;
INTRAEPITHELIAL LYMPHOCYTES; CD4+8+ THYMOCYTES; CHANNEL FUNCTION;
TRANSGENIC MICE; NKT CELLS
AB T cell receptor (TCR) signaling driven by interaction of the TCR with specific complexes of self-peptide and the major histocompatibility complex determines T cell fate in thymic development. However, the signaling pathway through which TCR signal strength regulates distinct T cell lineages remains unknown. Here we have used mice lacking the endoplasmic reticulum Ca2+ sensors stromal interaction molecule 1 (STIM1) and STIM2 to show that STIM-induced store-operated Ca2+ entry is not essential for thymic development of conventional TCR alpha beta(+) T cells but is specifically required for the development of agonist-selected T cells (regulatory T cells, invariant natural killer T cells, and TCR alpha beta(+) CD8 alpha alpha(+) intestinal intraepithelial lymphocytes). The severe impairment of agonist-selected T cell development is mainly due to a defect in interleukin-2 (IL-2) or IL-15 signaling. Thus, STIM1 and STIM2-mediated store-operated Ca2+ influx, leading to efficient activation of NFAT (nuclear factor of activated T cells), is critical for the postselection maturation of agonist-selected T cells.
C1 [Oh-hora, Masatsugu; Komatsu, Noriko; Takayanagi, Hiroshi] Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, Tokyo 1138549, Japan.
[Oh-hora, Masatsugu; Pishyareh, Mojgan; Rao, Anjana] Harvard Univ, Sch Med, Childrens Hosp, Dept Pathol,Immune Dis Inst, Boston, MA 02115 USA.
[Oh-hora, Masatsugu; Pishyareh, Mojgan; Rao, Anjana] Harvard Univ, Sch Med, Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Oh-hora, Masatsugu; Komatsu, Noriko; Takayanagi, Hiroshi] Int Res Ctr Mol Sci Tooth & Bone Dis, Global Ctr Excellence GCOE Program, Bunkyo Ku, Tokyo 1138549, Japan.
[Oh-hora, Masatsugu] Japan Sci & Technol Agcy JST, Precursory Res Embryon Sci & Technol PRESTO Progr, Bunkyo Ku, Tokyo 1138549, Japan.
[Feske, Stefan] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA.
[Hori, Shohei] RIKEN, Res Ctr Allergy & Immunol, Res Unit Immune Homeostasis, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
[Taniguchi, Masaru] RIKEN, Res Ctr Allergy & Immunol, Lab Immune Regulat, Tsurumi Ku, Yokohama, Kanagawa 2300045, Japan.
[Takayanagi, Hiroshi] Japan Sci & Technol Agcy JST, Explorat Res Adv Technol ERATO Program, Takayanagi Osteonetwork Project, Bunkyo Ku, Tokyo 1138549, Japan.
RP Oh-hora, M (reprint author), Tokyo Med & Dent Univ, Grad Sch Med & Dent Sci, Dept Cell Signaling, Bunkyo Ku, 1-5-45 Yushima, Tokyo 1138549, Japan.
EM ohora.gcoe@tmd.ac.jp; arao@liai.org
RI Taniguchi, Masaru/N-7932-2015;
OI Taniguchi, Masaru/0000-0001-7821-7179; Feske, Stefan/0000-0001-5431-8178
FU Japan Society for the Promotion of Science (JSPS); PRESTO from the Japan
Science and Technology Agency (JST); Ministry of Education, Culture,
Sports, Science and Technology of Japan; ERATO; Takayanagi Osteonetwork
Project from the JST; NIH [AI 066128, AI40127, AI84167]; Takeda Life
Science Foundation; Mochida Memorial Foundation for Medical and
Pharmaceutical Research; JSPS Research Fellowships for Young Scientists
FX We thank T. Kitamura (The University of Tokyo) for providing Plat-E
packaging cell lines, as well as K. Okamoto, M. Guerrini, A. Terashima,
Y. Muratani, and T. Kato for discussion and assistance. This work was
supported in part by Grant-in-Aid for Scientific Research on Priority
Areas from the Japan Society for the Promotion of Science (JSPS), PRESTO
from the Japan Science and Technology Agency (JST) (to M.O.),
Grants-in-Aid for GCOE Program from the Ministry of Education, Culture,
Sports, Science and Technology of Japan (to M.O. and H. T.), ERATO,
Takayanagi Osteonetwork Project from the JST (to H. T.) and NIH grants
to S. F. (AI 066128) and A. R. (AI40127 and AI84167). M.O. was also
supported by grants from Takeda Life Science Foundation and the Mochida
Memorial Foundation for Medical and Pharmaceutical Research. N.K. is
supported by JSPS Research Fellowships for Young Scientists. S. F. and
A. R. are scientific founders of CalciMedica, a company that seeks to
identify novel treatments for immune-related diseases.
NR 60
TC 33
Z9 33
U1 2
U2 8
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD MAY 23
PY 2013
VL 38
IS 5
BP 881
EP 895
DI 10.1016/j.immuni.2013.02.008
PG 15
WC Immunology
SC Immunology
GA AA2RT
UT WOS:000330942500008
PM 23499491
ER
PT J
AU Py, BF
Gonzalez, SF
Long, K
Kim, MS
Kim, YA
Zhu, H
Yao, JH
Degauque, N
Villet, R
Ymele-Leki, P
Gadjeva, M
Pier, GB
Carroll, MC
Yuan, JY
AF Py, Benedicte F.
Gonzalez, Santiago F.
Long, Kai
Kim, Mi-Sung
Kim, Young-A.
Zhu, Hong
Yao, Jianhua
Degauque, Nicolas
Villet, Regis
Ymele-Leki, Patrick
Gadjeva, Mihaela
Pier, Gerald B.
Carroll, Michael C.
Yuan, Junying
TI Cochlin Produced by Follicular Dendritic Cells Promotes Antibacterial
Innate Immunity
SO IMMUNITY
LA English
DT Article
ID DEAFNESS DISORDER; DFNA9 DEAFNESS; LYMPH-NODE; A DOMAIN; IDENTIFICATION;
SYSTEM; MATRIX; GENE; AGGRECANASES; DEGRADATION
AB Cochlin, an extracellular matrix protein, shares homologies with the Factor C, a serine protease found in horseshoe crabs, which is critical for antibacterial responses. Mutations in the COCH gene are responsible for human DFNA9 syndrome, a disorder characterized by neurodegeneration of the inner ear that leads to hearing loss and vestibular impairments. The physiological function of cochlin, however, is unknown. Here, we report that cochlin is specifically expressed by follicular dendritic cells and selectively localized in the fine extracellular network of conduits in the spleen and lymph nodes. During inflammation, cochlin was cleaved by aggrecanases and secreted into blood circulation. In models of lung infection with Pseudomonas aeruginosa and Staphylococcus aureus, Coch (-/-) mice show reduced survival linked to defects in local cytokine production, recruitment of immune effector cells, and bacterial clearance. By producing cochlin, FDCs thus contribute to the innate immune response in defense against bacteria.
C1 [Py, Benedicte F.; Long, Kai; Kim, Mi-Sung; Zhu, Hong; Yao, Jianhua; Yuan, Junying] Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
[Gonzalez, Santiago F.; Kim, Young-A.; Carroll, Michael C.] Harvard Univ, Sch Med, Immune Dis Inst, Boston, MA 02115 USA.
[Degauque, Nicolas] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Transplant Immunol, Boston, MA 02115 USA.
[Degauque, Nicolas] Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Transplant Res Ctr, Boston, MA 02115 USA.
[Villet, Regis] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02115 USA.
[Ymele-Leki, Patrick] Harvard Univ, Sch Med, Childrens Hosp Boston, Div Infect Dis, Boston, MA 02115 USA.
[Gadjeva, Mihaela; Pier, Gerald B.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med,Channing Lab, Boston, MA 02115 USA.
RP Py, BF (reprint author), Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA 02115 USA.
EM benedicte.py@normalesup.org; junying_yuan@hms.harvard.edu
RI Py, Benedicte/M-6129-2014;
OI Degauque, Nicolas/0000-0003-2990-3513; Pier, Gerald/0000-0002-9112-2331
FU National Institutes of Health
FX We thank Colin L. Stewart (National Cancer Institute, Frederick, MD) for
providing Coch-/- mice; Bjorn R. Olsen and Rodrick Bronson
for scientific advices and discussions; Adeline Bernier and Melissa
Marinelli for technical assistance; James Kenny, Lisa A. Pitcher,
Caroline N. Herndon, Sloan Siegrist, Ying Li, and Michael Boyce for
technical advices; Stephanie Bedhomme for statistical analysis; Jennifer
Walters and the staff at the Nikon imaging center, Maria Ericsson, and
the staff at the electronic microscopy facility and the rodent histology
facility (Harvard Medical School) for help with image analysis. This
work was supported in part by the National Institutes of Health
Director's Pioneer Award (to J.Y.).
NR 41
TC 14
Z9 14
U1 0
U2 11
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-7613
EI 1097-4180
J9 IMMUNITY
JI Immunity
PD MAY 23
PY 2013
VL 38
IS 5
BP 1063
EP 1072
DI 10.1016/j.immuni.2013.01.015
PG 10
WC Immunology
SC Immunology
GA AA2RT
UT WOS:000330942500022
PM 23684986
ER
PT J
AU Biddinger, PD
Baggish, A
Harrington, L
d'Hemecourt, P
Hooley, J
Jones, J
Kue, R
Troyanos, C
Dyer, KS
AF Biddinger, Paul D.
Baggish, Aaron
Harrington, Lori
d'Hemecourt, Pierre
Hooley, James
Jones, Jerrilyn
Kue, Ricky
Troyanos, Chris
Dyer, K. Sophia
TI Be Prepared - The Boston Marathon and Mass-Casualty Events
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Editorial Material
C1 [Biddinger, Paul D.; Baggish, Aaron] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Biddinger, Paul D.; Baggish, Aaron] Harvard Univ, Sch Med, Boston, MA USA.
[Biddinger, Paul D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Harrington, Lori; Hooley, James; Jones, Jerrilyn; Kue, Ricky; Dyer, K. Sophia] Boston EMS Police & Fire, Boston, MA USA.
[Harrington, Lori; Jones, Jerrilyn; Kue, Ricky; Dyer, K. Sophia] Boston Med Ctr, Boston, MA USA.
[Harrington, Lori; Jones, Jerrilyn; Kue, Ricky; Dyer, K. Sophia] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Baggish, Aaron; d'Hemecourt, Pierre; Troyanos, Chris; Dyer, K. Sophia] Boston Athlet Assoc, Boston, MA USA.
[Hooley, James] Boston Publ Hlth Commiss, Boston, MA USA.
RP Biddinger, PD (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 4
TC 36
Z9 36
U1 0
U2 6
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 23
PY 2013
VL 368
IS 21
BP 1958
EP 1960
DI 10.1056/NEJMp1305480
PG 3
WC Medicine, General & Internal
SC General & Internal Medicine
GA 194KD
UT WOS:000322630700004
PM 23635020
ER
PT J
AU Wray, J
Williamson, EA
Singh, SB
Wu, YH
Cogle, CR
Weinstock, DM
Zhang, Y
Lee, SH
Zhou, DH
Shao, LJ
Hauer-Jensen, M
Pathak, R
Klimek, V
Nickoloff, JA
Hromas, R
AF Wray, Justin
Williamson, Elizabeth A.
Singh, Sudha B.
Wu, Yuehan
Cogle, Christopher R.
Weinstock, David M.
Zhang, Yu
Lee, Suk-Hee
Zhou, Daohong
Shao, Lijian
Hauer-Jensen, Martin
Pathak, Rupak
Klimek, Virginia
Nickoloff, Jac A.
Hromas, Robert
TI PARP1 is required for chromosomal translocations
SO BLOOD
LA English
DT Article
ID DOUBLE-STRAND BREAKS; END-JOINING PATHWAY; POLY(ADP-RIBOSE) POLYMERASE;
MAMMALIAN-CELLS; DNA-REPAIR; MECHANISMS; NHEJ; RECOMBINATION; LEUKEMIA;
ELEMENTS
AB Chromosomal translocations are common contributors to malignancy, yet little is known about the precise molecular mechanisms by which they are generated. Sequencing translocation junctions in acute leukemias revealed that the translocations were likely mediated by a DNA double-strand break repair pathway termed nonhomologous end-joining (NHEJ). There are major 2 types of NHEJ: (1) the classical pathway initiated by the Ku complex, and (2) the alternative pathway initiated by poly ADP-ribose polymerase 1 (PARP1). Recent reports suggest that classical NHEJ repair components repress translocations, whereas alternative NHEJ components were required for translocations. The rate-limiting step for initiation of alternative NHEJ is the displacement of the Ku complex by PARP1. Therefore, we asked whether PARP1 inhibition could prevent chromosomal translocations in 3 translocation reporter systems. We found that 2 PARP1 inhibitors or repression of PARP1 protein expression strongly repressed chromosomal translocations, implying that PARP1 is essential for this process. Finally, PARP1 inhibition also reduced both ionizing radiation-generated and VP16-generated translocations in 2 cell lines. These data define PARP1 as a critical mediator of chromosomal translocations and raise the possibility that oncogenic translocations occurring after high-dose chemotherapy or radiation could be prevented by treatment with a clinically available PARP1 inhibitor.
C1 [Wray, Justin; Williamson, Elizabeth A.; Singh, Sudha B.; Wu, Yuehan; Cogle, Christopher R.; Hromas, Robert] Univ Florida, Dept Med, Coll Med, Gainesville, FL 32610 USA.
[Weinstock, David M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Zhang, Yu] Mem Sloan Kettering Canc Ctr, Dept Med, New York, NY 10021 USA.
[Lee, Suk-Hee] Indiana Univ Sch Med, Dept Biochem & Mol Biol, Indianapolis, IN 46202 USA.
[Zhou, Daohong; Shao, Lijian; Hauer-Jensen, Martin; Pathak, Rupak] Univ Arkansas Med Sci, Dept Pharmaceut Sci, Little Rock, AR 72205 USA.
[Klimek, Virginia] Mem Sloan Kettering Canc Ctr, Dept Hematol, New York, NY 10021 USA.
[Nickoloff, Jac A.] Colorado State Univ, Dept Environm & Radiol Hlth Sci, Ft Collins, CO 80523 USA.
RP Hromas, R (reprint author), Univ Florida, Dept Med, Coll Med, 1600 Archer Rd SW, Gainesville, FL 32610 USA.
EM robert.hromas@medicine.ufl.edu
RI Cogle, Christopher/H-1746-2016
OI Cogle, Christopher/0000-0001-5422-6863
FU National Institutes of Health [CA151367, GM084020, CA122023, HL093606,
CA139429, CA140442]; Edward P. Evans Foundation; Leukemia and Lymphoma
Society Translational Research Award
FX This work was supported by the National Institutes of Health grants
CA151367 (S.-H. L.); GM084020 (J.A.N.); CA122023 (D.Z.); and HL093606,
CA139429, and CA140442 (R. H.); a grant from the Edward P. Evans
Foundation (D.Z.); and a Leukemia and Lymphoma Society Translational
Research Award (R.H.).
NR 27
TC 24
Z9 24
U1 0
U2 5
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 23
PY 2013
VL 121
IS 21
BP 4359
EP 4365
DI 10.1182/blood-2012-10-460527
PG 7
WC Hematology
SC Hematology
GA 184FS
UT WOS:000321873900020
PM 23568489
ER
PT J
AU Steensma, DP
Ebert, BL
AF Steensma, David P.
Ebert, Benjamin L.
TI Initial experience with L-leucine therapy in myelodysplastic syndromes
with associated chromosome 5q deletion
SO BLOOD
LA English
DT Letter
C1 [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Steensma, David P.; Ebert, Benjamin L.] Harvard Univ, Sch Med, Boston, MA USA.
[Ebert, Benjamin L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Steensma, DP (reprint author), Harvard Univ, Sch Med, Div Hematol Malignancies, Dana Farber Canc Inst, 450 Brookline Ave,Suite D1B30 Mayer 1B21, Boston, MA 02215 USA.
EM david_steensma@dfci.harvard.edu
OI Steensma, David/0000-0001-5130-9284
NR 5
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 23
PY 2013
VL 121
IS 21
BP 4428
EP 4428
DI 10.1182/blood-2013-03-493809
PG 1
WC Hematology
SC Hematology
GA 184FS
UT WOS:000321873900028
PM 23704049
ER
PT J
AU Sperandio, M
Quackenbush, EJ
Sushkova, N
Altstatter, J
Nussbaum, C
Schmid, S
Pruenster, M
Kurz, A
Margraf, A
Steppner, A
Schweiger, N
Borsig, L
Boros, I
Krajewski, N
Genzel-Boroviczeny, O
Jeschke, U
Frommhold, D
von Andrian, UH
AF Sperandio, Markus
Quackenbush, Elizabeth J.
Sushkova, Natalia
Altstaetter, Johannes
Nussbaum, Claudia
Schmid, Stephan
Pruenster, Monika
Kurz, Angela
Margraf, Andreas
Steppner, Alina
Schweiger, Natalie
Borsig, Lubor
Boros, Ildiko
Krajewski, Nele
Genzel-Boroviczeny, Orsolya
Jeschke, Udo
Frommhold, David
von Andrian, Ulrich H.
TI Ontogenetic regulation of leukocyte recruitment in mouse yolk sac
vessels
SO BLOOD
LA English
DT Article
ID CELL-ADHESION MOLECULE-1; P-SELECTIN; BONE-MARROW; TRANSENDOTHELIAL
MIGRATION; ENDOTHELIAL SELECTINS; NEONATAL NEUTROPHILS;
ACUTE-INFLAMMATION; PREMATURE-INFANTS; IN-VIVO; EXPRESSION
AB In adult mammals, leukocyte recruitment follows a well-defined cascade of adhesion events enabling leukocytes to leave the circulatory system and transmigrate into tissue. Currently, it is unclear whether leukocyte recruitment proceeds in a similar fashion during fetal development. Considering the fact that the incidence of neonatal sepsis increases dramatically with decreasing gestational age in humans, we hypothesized that leukocyte recruitment may be acquired only late during fetal ontogeny. To test this, we developed a fetal intravital microscopy model in pregnant mice and, using LysEGFP (neutrophil reporter) mice, investigated leukocyte recruitment during fetal development. We show that fetal blood neutrophils acquire the ability to roll and adhere on inflamed yolk sac vessels during late fetal development, whereas at earlier embryonic stages (before day E15), rolling and adhesion were essentially absent. Accordingly, flow chamber experiments showed that fetal EGFP(+) blood cells underwent efficient adhesion only when they were harvested on or after E15. Fluorescence-activated cell sorter analysis on EGFP(+) fetal blood cells revealed that surface expression of CXCR2 and less pronounced P-selectin glycoprotein ligand-1 (PSGL-1) begin to increase only late in fetal life. Taken together, our findings demonstrate that inflammation-induced leukocyte recruitment is ontogenetically regulated and enables efficient neutrophil trafficking only during late fetal life. (Blood. 2013;121(21):e118-e128)
C1 [Sperandio, Markus; Altstaetter, Johannes; Nussbaum, Claudia; Schmid, Stephan; Pruenster, Monika; Kurz, Angela; Margraf, Andreas; Schweiger, Natalie] Univ Munich, Walter Brendel Ctr Expt Med, D-81377 Munich, Germany.
[Quackenbush, Elizabeth J.; Sushkova, Natalia; von Andrian, Ulrich H.] Immune Dis Inst, Boston, MA USA.
[Steppner, Alina; Jeschke, Udo] Univ Munich, Univ Womens Hosp, D-81377 Munich, Germany.
[Borsig, Lubor] Univ Zurich, Inst Physiol, CH-8006 Zurich, Switzerland.
[Boros, Ildiko; Krajewski, Nele; Frommhold, David] Univ Childrens Hosp, Heidelberg, Germany.
[Genzel-Boroviczeny, Orsolya] Univ Munich, Von Haunerschen Kinderspital, D-81377 Munich, Germany.
[von Andrian, Ulrich H.] Harvard Univ, Sch Med, Dept Microbiol & Immunobiol, Boston, MA USA.
RP Sperandio, M (reprint author), Univ Munich, Walter Brendel Ctr Expt Med, Marchioninistr 27, D-81377 Munich, Germany.
EM markus.sperandio@med.uni-muenchen.de; uva@hms.harvard.edu
OI Kurz, Angela/0000-0002-5032-8026; Sperandio, Markus/0000-0002-7689-3613;
Borsig, Lubor/0000-0003-2263-9545
FU Pfizer; DFG Collaborative Research Center [SFB 914]; Ludwig Maximilians
University, Munich; National Institutes of Health, National Institute of
Allergy and Infectious Diseases [AI069259, AI078897, AI095261]; Amy
Potter Fellowship
FX This work was supported by the Pfizer Scholars Grant for New Faculty,
awarded to E.J.Q., by the DFG Collaborative Research Center grant SFB
914, project B1, and the FoFoLe program of Ludwig Maximilians
University, Munich, and by National Institutes of Health, National
Institute of Allergy and Infectious Diseases grants AI069259, AI078897,
and AI095261 to U. H. v. A. E.J.Q. was also supported by the Amy Potter
Fellowship, kindly granted to the Center for Blood Research by Mrs Nancy
Potter (Westin, MA).
NR 42
TC 6
Z9 6
U1 0
U2 3
PU AMER SOC HEMATOLOGY
PI WASHINGTON
PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA
SN 0006-4971
J9 BLOOD
JI Blood
PD MAY 23
PY 2013
VL 121
IS 21
BP E118
EP E128
DI 10.1182/blood-2012-07-447144
PG 11
WC Hematology
SC Hematology
GA 184FS
UT WOS:000321873900001
PM 23525796
ER
PT J
AU Frumm, SM
Fan, ZP
Ross, KN
Duvall, JR
Gupta, S
VerPlank, L
Suh, BC
Holson, E
Wagner, FF
Smith, WB
Paranal, RM
Bassil, CF
Qi, J
Roti, G
Kung, AL
Bradner, JE
Tolliday, N
Stegmaier, K
AF Frumm, Stacey M.
Fan, Zi Peng
Ross, Kenneth N.
Duvall, Jeremy R.
Gupta, Supriya
VerPlank, Lynn
Suh, Byung-Chul
Holson, Edward
Wagner, Florence F.
Smith, William B.
Paranal, Ronald M.
Bassil, Christopher F.
Qi, Jun
Roti, Giovanni
Kung, Andrew L.
Bradner, James E.
Tolliday, Nicola
Stegmaier, Kimberly
TI Selective HDAC1/HDAC2 Inhibitors Induce Neuroblastoma Differentiation
SO CHEMISTRY & BIOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; T-CELL LYMPHOMA; RETINOIC ACID; DRUG
DISCOVERY; STEM-CELLS; IN-VITRO; TARGET; CANCER; LEUKEMIA; GROWTH
AB While cytotoxic chemotherapy remains the hallmark of cancer treatment, intensive regimens fall short in many malignancies, including high-risk neuroblastoma. One alternative. strategy is to therapeutically promote tumor differentiation. We created a gene expression signature to measure neuroblast maturation, adapted it to a high-throughput platform, and screened a diversity oriented synthesis-generated small-molecule library for differentiation inducers. We identified BRD8430, containing a nine-membered lactam, an ortho-amino anilide functionality, and three chiral centers, as a selective class I histone deacetylase (HDAC) inhibitor (HDAC1 > 2 > 3). Further investigation demonstrated that selective HDAC1/HDAC2 inhibition using compounds or RNA interference induced differentiation and decreased viability in neuroblastoma cell lines. Combined treatment with 13-cis retinoic acid augmented these effects and enhanced activation of retinoic acid signaling. Therefore, by applying a chemical genomic screening approach, we identified selective HDAC1/HDAC2 inhibition as a strategy to induce neuroblastoma differentiation.
C1 [Frumm, Stacey M.; Fan, Zi Peng; Bassil, Christopher F.; Roti, Giovanni; Stegmaier, Kimberly] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Smith, William B.; Paranal, Ronald M.; Qi, Jun; Bradner, James E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Frumm, Stacey M.; Fan, Zi Peng; Bassil, Christopher F.; Roti, Giovanni; Stegmaier, Kimberly] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02215 USA.
[Ross, Kenneth N.; Duvall, Jeremy R.; Gupta, Supriya; VerPlank, Lynn; Suh, Byung-Chul; Holson, Edward; Wagner, Florence F.; Tolliday, Nicola; Stegmaier, Kimberly] Broad Inst Massachusetts Inst Technol & Harvard U, Cambridge, MA 02142 USA.
[Kung, Andrew L.] Columbia Univ, Med Ctr, Dept Pediat, New York, NY 10032 USA.
[Bradner, James E.] Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA.
RP Stegmaier, K (reprint author), Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
EM kimberly_stegmaier@dfci.harvard.edu
OI Kung, Andrew/0000-0002-9091-488X
FU Friends for Life Fellowship; Claudia Adams Barr Program in Cancer
Research; Howard Hughes Medical Institute Physician-Scientist Early
Career Award; National Cancer Institute's Initiative for Chemical
Genetics, National Institutes of Health (NIH) [N01-CO-12400]; NIGMS [P50
GM069721]; NIH [RL1CA133834, RL1HG004671, RL1GM084437, UL1DE019585]
FX We thank Rani George for providing neuroblastoma cell lines, Daniel G.
Tenen for providing the reporter plasmid, and Brian Crompton and Aaron
Thorner for their technical assistance. This work was funded by the
Friends for Life Fellowship (to K.S.), the Claudia Adams Barr Program in
Cancer Research (to K.S.), and a Howard Hughes Medical Institute
Physician-Scientist Early Career Award (to K.S.). The project has been
funded in part with federal funds from the National Cancer Institute's
Initiative for Chemical Genetics, National Institutes of Health (NIH),
under contract no. N01-CO-12400. The content of this publication does
not necessarily reflect the views or policies of the Department of
Health and Human Service, nor does mention of trade names, commercial
products, or organizations imply endorsement by the United States
government. This work was funded in part by the NIGMS-sponsored Center
of Excellence in Chemical Methodology and Library Development (Broad
Institute CMLD; P50 GM069721), as well as the NIH Genomics Based Drug
Discovery U54 grants Discovery Pipeline RL1CA133834 (administratively
linked to NIH Grants RL1HG004671, RL1GM084437, and UL1DE019585).
NR 47
TC 25
Z9 26
U1 0
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 1074-5521
J9 CHEM BIOL
JI Chem. Biol.
PD MAY 23
PY 2013
VL 20
IS 5
SI SI
BP 713
EP 725
DI 10.1016/j.chembiol.2013.03.020
PG 13
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA 161TN
UT WOS:000320216300010
PM 23706636
ER
PT J
AU Gifford, CA
Ziller, MJ
Gu, HC
Trapnell, C
Donaghey, J
Tsankov, A
Shalek, AK
Kelley, DR
Shishkin, AA
Issner, R
Zhang, XL
Coyne, M
Fostel, JL
Holmes, L
Meldrim, J
Guttman, M
Epstein, C
Park, H
Kohlbacher, O
Rinn, J
Gnirke, A
Lander, ES
Bernstein, BE
Meissner, A
AF Gifford, Casey A.
Ziller, Michael J.
Gu, Hongcang
Trapnell, Cole
Donaghey, Julie
Tsankov, Alexander
Shalek, Alex K.
Kelley, David R.
Shishkin, Alexander A.
Issner, Robbyn
Zhang, Xiaolan
Coyne, Michael
Fostel, Jennifer L.
Holmes, Laurie
Meldrim, Jim
Guttman, Mitchell
Epstein, Charles
Park, Hongkun
Kohlbacher, Oliver
Rinn, John
Gnirke, Andreas
Lander, Eric S.
Bernstein, Bradley E.
Meissner, Alexander
TI Transcriptional and Epigenetic Dynamics during Specification of Human
Embryonic Stem Cells
SO CELL
LA English
DT Article
ID DNA METHYLATION; MAMMALIAN DEVELOPMENT; HISTONE MODIFICATIONS;
REGULATORY REGIONS; HUMAN ES; DIFFERENTIATION; CHROMATIN; EXPRESSION;
GENERATION; ENHANCERS
AB Differentiation of human embryonic stem cells (hESCs) provides a unique opportunity to study the regulatory mechanisms that facilitate cellular transitions in a human context. To that end, we performed comprehensive transcriptional and epigenetic profiling of populations derived through directed differentiation of hESCs representing each of the three embryonic germ layers. Integration of whole-genome bisulfite sequencing, chromatin immunoprecipitation sequencing, and RNA sequencing reveals unique events associated with specification toward each lineage. Lineage-specific dynamic alterations in DNA methylation and H3K4me1 are evident at putative distal regulatory elements that are frequently bound by pluripotency factors in the undifferentiated hESCs. In addition, we identified germ-layer-specific H3K27me3 enrichment at sites exhibiting high DNA methylation in the undifferentiated state. A better understanding of these initial specification events will facilitate identification of deficiencies in current approaches, leading to more faithful differentiation strategies as well as providing insights into the rewiring of human regulatory programs during cellular transitions.
C1 [Gifford, Casey A.; Ziller, Michael J.; Gu, Hongcang; Trapnell, Cole; Donaghey, Julie; Tsankov, Alexander; Kelley, David R.; Shishkin, Alexander A.; Issner, Robbyn; Zhang, Xiaolan; Coyne, Michael; Fostel, Jennifer L.; Holmes, Laurie; Meldrim, Jim; Guttman, Mitchell; Epstein, Charles; Rinn, John; Gnirke, Andreas; Lander, Eric S.; Bernstein, Bradley E.; Meissner, Alexander] Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
[Gifford, Casey A.; Ziller, Michael J.; Donaghey, Julie; Tsankov, Alexander; Meissner, Alexander] Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
[Gifford, Casey A.; Ziller, Michael J.; Trapnell, Cole; Donaghey, Julie; Tsankov, Alexander; Kelley, David R.; Rinn, John; Meissner, Alexander] Harvard Univ, Dept Stem Cell & Regenerat Biol, Cambridge, MA 02138 USA.
[Shalek, Alex K.; Park, Hongkun] Harvard Univ, Dept Chem, Cambridge, MA 02138 USA.
[Kohlbacher, Oliver] Univ Tubingen, Ctr Bioinformat, D-72076 Tubingen, Germany.
[Kohlbacher, Oliver] Univ Tubingen, Quantitat Biol Ctr, D-72076 Tubingen, Germany.
[Rinn, John] Beth Israel Deaconess Med Ctr, Boston, MA 02115 USA.
[Lander, Eric S.] MIT, Dept Biol, Cambridge, MA 02139 USA.
[Bernstein, Bradley E.] Massachusetts Gen Hosp, Howard Hughes Med Inst, Boston, MA 02114 USA.
[Bernstein, Bradley E.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Bernstein, Bradley E.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Meissner, A (reprint author), Broad Inst MIT & Harvard, Cambridge, MA 02142 USA.
EM alexander_meissner@harvard.edu
RI Kohlbacher, Oliver/B-7310-2008;
OI Kohlbacher, Oliver/0000-0003-1739-4598; Shalek, Alex
K./0000-0001-5670-8778
FU Pew Charitable Trusts; US National Institutes of Health (NIH)
[U01ES017155, P01GM099117]; New York Stem Cell Foundation
FX We would like to thank Kendell Clement for support of the WGBS data
visualization and Loyal Goff for RNA-seq visualization, as well as
Zachary Smith and Jing Liao for critical reading of the manuscript, and
the SCRB FACS Core for advice regarding FACS analysis. We also thank
other members of the Meissner Lab and Epigenomics Platform at the Broad
Institute for helpful discussion. A. M. is supported by the Pew
Charitable Trusts and is a New York Stem Cell Foundation (NYSCF)
Robertson Investigator. The work was funded by the US National
Institutes of Health (NIH) grants (U01ES017155 and P01GM099117) and The
New York Stem Cell Foundation.
NR 48
TC 148
Z9 151
U1 8
U2 59
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0092-8674
J9 CELL
JI Cell
PD MAY 23
PY 2013
VL 153
IS 5
BP 1149
EP 1163
DI 10.1016/j.cell.2013.04.037
PG 15
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 151JN
UT WOS:000319456800020
PM 23664763
ER
PT J
AU Margolin, DH
Kousi, M
Chan, YM
Lim, ET
Schmahmann, JD
Hadjivassiliou, M
Hall, JE
Adam, I
Dwyer, A
Plummer, L
Aldrin, SV
O'Rourke, J
Kirby, A
Lage, K
Milunsky, A
Milunsky, JM
Chan, J
Hedley-Whyte, ET
Daly, MJ
Katsanis, N
Seminara, SB
AF Margolin, David H.
Kousi, Maria
Chan, Yee-Ming
Lim, Elaine T.
Schmahmann, Jeremy D.
Hadjivassiliou, Marios
Hall, Janet E.
Adam, Ibrahim
Dwyer, Andrew
Plummer, Lacey
Aldrin, Stephanie V.
O'Rourke, Julia
Kirby, Andrew
Lage, Kasper
Milunsky, Aubrey
Milunsky, Jeff M.
Chan, Jennifer
Hedley-Whyte, E. Tessa
Daly, Mark J.
Katsanis, Nicholas
Seminara, Stephanie B.
TI Ataxia, Dementia, and Hypogonadotropism Caused by Disordered
Ubiquitination
SO NEW ENGLAND JOURNAL OF MEDICINE
LA English
DT Article
ID GONADOTROPIN-RELEASING-HORMONE; BARDET-BIEDL-SYNDROME; FAMILIAL
CEREBELLAR-ATAXIA; TRIALLELIC INHERITANCE; PARKINSONS-DISEASE; HOLMES
TYPE; HYPOGONADISM; DEFICIENCY; PROTEIN; DEGENERATION
AB BACKGROUND
The combination of ataxia and hypogonadism was first described more than a century ago, but its genetic basis has remained elusive.
METHODS
We performed whole-exome sequencing in a patient with ataxia and hypogonadotropic hypogonadism, followed by targeted sequencing of candidate genes in similarly affected patients. Neurologic and reproductive endocrine phenotypes were characterized in detail. The effects of sequence variants and the presence of an epistatic interaction were tested in a zebrafish model.
RESULTS
Digenic homozygous mutations in RNF216 and OTUD4, which encode a ubiquitin E3 ligase and a deubiquitinase, respectively, were found in three affected siblings in a consanguineous family. Additional screening identified compound heterozygous truncating mutations in RNF216 in an unrelated patient and single heterozygous deleterious mutations in four other patients. Knockdown of rnf216 or otud4 in zebrafish embryos induced defects in the eye, optic tectum, and cerebellum; combinatorial suppression of both genes exacerbated these phenotypes, which were rescued by nonmutant, but not mutant, human RNF216 or OTUD4 messenger RNA. All patients had progressive ataxia and dementia. Neuronal loss was observed in cerebellar pathways and the hippocampus; surviving hippocampal neurons contained ubiquitin-immunoreactive intranuclear inclusions. Defects were detected at the hypothalamic and pituitary levels of the reproductive endocrine axis.
CONCLUSIONS
The syndrome of hypogonadotropic hypogonadism, ataxia, and dementia can be caused by inactivating mutations in RNF216 or by the combination of mutations in RNF216 and OTUD4. These findings link disordered ubiquitination to neurodegeneration and reproductive dysfunction and highlight the power of whole-exome sequencing in combination with functional studies to unveil genetic interactions that cause disease.
C1 [Margolin, David H.; Schmahmann, Jeremy D.] Massachusetts Gen Hosp, Dept Neurol, Harvard Reprod Sci Ctr, Boston, MA 02115 USA.
[Chan, Yee-Ming; Hall, Janet E.; Dwyer, Andrew; Plummer, Lacey; Aldrin, Stephanie V.; O'Rourke, Julia; Seminara, Stephanie B.] Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02115 USA.
[Lim, Elaine T.; Kirby, Andrew; Lage, Kasper; Daly, Mark J.] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02115 USA.
[Lage, Kasper] Massachusetts Gen Hosp, Dept Med, Pediat Surg Res Labs, Boston, MA 02115 USA.
[Hedley-Whyte, E. Tessa] Massachusetts Gen Hosp, Dept Neuropathol, Boston, MA 02115 USA.
[Chan, Yee-Ming] Boston Childrens Hosp, Div Endocrinol, Dept Med, Boston, MA USA.
[Chan, Jennifer] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Milunsky, Aubrey; Milunsky, Jeff M.] Ctr Human Genet, Cambridge, MA USA.
[Kousi, Maria; Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Cell Biol, Ctr Human Dis Modeling, Durham, NC 27710 USA.
[Katsanis, Nicholas] Duke Univ, Med Ctr, Dept Pediat, Durham, NC 27710 USA.
[Hadjivassiliou, Marios] Royal Hallamshire Hosp, Dept Neurol, Sheffield S10 2JF, S Yorkshire, England.
[Adam, Ibrahim] Specialty Hosp, Amman, Jordan.
Tech Univ Denmark, Ctr Biol Sequence Anal, DK-2800 Lyngby, Denmark.
[Lage, Kasper] Univ Copenhagen, Ctr Prot Res, Copenhagen, Denmark.
RP Seminara, SB (reprint author), Massachusetts Gen Hosp, Reprod Endocrine Unit, Boston, MA 02115 USA.
EM katsanis@cellbio.duke.edu; seminara.stephanie@mgh.harvard.edu
RI Dwyer, Andrew/D-8099-2012;
OI Dwyer, Andrew/0000-0002-7023-6794; Hall, Janet/0000-0003-4644-3061;
Katsanis, Nicholas/0000-0002-2480-0171
FU National Institutes of Health; Eunice K. Shriver National Institute for
Child Health and Human Development [K24 HD067388, R01 HD043341, R01
HD042601, U54 HD028138]; National Institute of Diabetes and Digestive
and Kidney Diseases [P50 DK096415]; Harvard Catalyst; Harvard Clinical
and Translational Science Center; National Center for Research
Resources; National Center for Advancing Translational Sciences
[UL1TR025758, M01RR01066]; Harvard University; National Human Genome
Research Institute to the Broad Institute [U54 HG003967]; National
Heart, Lung, and Blood Institute for the Exome Sequencing Project
[HL102923, HL102924, HL102925, HL102926, HL103010]; Charles A. King
Trust postdoctoral fellowship; Career Development Award from Boston
Children's Hospital
FX Funded by the National Institutes of Health and others.; Supported by
grants from the Eunice K. Shriver National Institute for Child Health
and Human Development (K24 HD067388, R01 HD043341, R01 HD042601, and U54
HD028138); from the National Institute of Diabetes and Digestive and
Kidney Diseases (P50 DK096415); by Harvard Catalyst and the Harvard
Clinical and Translational Science Center (funded by the National Center
for Research Resources and the National Center for Advancing
Translational Sciences [UL1TR025758 and M01RR01066] and Harvard
University and its affiliated academic health care centers); by a grant
from the National Human Genome Research Institute to the Broad Institute
(U54 HG003967); and by grants from the National Heart, Lung, and Blood
Institute for the Exome Sequencing Project (HL102923, HL102924,
HL102925, HL102926, and HL103010). Dr. Chan is the recipient of a
Charles A. King Trust postdoctoral fellowship and a Career Development
Award from Boston Children's Hospital.
NR 40
TC 53
Z9 56
U1 0
U2 12
PU MASSACHUSETTS MEDICAL SOC
PI WALTHAM
PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA
SN 0028-4793
EI 1533-4406
J9 NEW ENGL J MED
JI N. Engl. J. Med.
PD MAY 23
PY 2013
VL 368
IS 21
BP 1992
EP 2003
DI 10.1056/NEJMoa1215993
PG 12
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148TJ
UT WOS:000319270200001
PM 23656588
ER
PT J
AU Gardiner, D
Lalezari, J
Lawitz, E
DiMicco, M
Ghalib, R
Reddy, KR
Chang, KM
Sulkowski, M
O' Marro, S
Anderson, J
He, B
Kansra, V
McPhee, F
Wind-Rotolo, M
Grasela, D
Selby, M
Korman, AJ
Lowy, I
AF Gardiner, David
Lalezari, Jay
Lawitz, Eric
DiMicco, Michael
Ghalib, Rheem
Reddy, K. Rajender
Chang, Kyong-Mi
Sulkowski, Mark
O' Marro, Steven
Anderson, Jeffrey
He, Bing
Kansra, Vikram
McPhee, Fiona
Wind-Rotolo, Megan
Grasela, Dennis
Selby, Mark
Korman, Alan J.
Lowy, Israel
TI A Randomized, Double-Blind, Placebo-Controlled Assessment of BMS-936558,
a Fully Human Monoclonal Antibody to Programmed Death-1 (PD-1), in
Patients with Chronic Hepatitis C Virus Infection
SO PLOS ONE
LA English
DT Article
ID T-CELL EXHAUSTION; CHRONIC VIRAL-INFECTION; IMMUNE-RESPONSES; FUNCTIONAL
RESTORATION; UP-REGULATION; PHASE-I; B-VIRUS; BLOCKADE; EXPRESSION;
SAFETY
AB Expression of the programmed death 1 (PD-1) receptor and its ligands are implicated in the T cell exhaustion phenotype which contributes to the persistence of several chronic viral infections, including human hepatitis C virus (HCV). The antiviral potential of BMS-936558 (MDX-1106) - a fully human anti-PD-1 monoclonal immunoglobulin-G4 that blocks ligand binding - was explored in a proof-of-concept, placebo-controlled single-ascending-dose study in patients (N = 54) with chronic HCV infection. Interferon-alfa treatment-experienced patients (n = 42) were randomized 5:1 to receive a single infusion of BMS-936558 (0.03, 0.1, 0.3, 1.0, 3.0 mg/kg [n = 5 each] or 10 mg/kg [n = 10]) or of placebo (n = 7). An additional 12 HCV treatment naive patients were randomized to receive 10 mg/kg BMS-936558 (n = 10) or placebo (n = 2). Patients were followed for 85 days post-dose. Five patients who received BMS-936558 (0.1 [n = 1] or 10 mg/kg) and one placebo patient achieved the primary study endpoint of a reduction in HCV RNA >= 0.5 log(10) IU/mL on at least 2 consecutive visits; 3 (10 mg/kg) achieved a >4 log(10) reduction. Two patients (10 mg/kg) achieved HCV RNA below the lower limit of quantitation (25 IU/mL), one of whom (a prior null-responder) remained RNA-undetectable 1 year post-study. Transient reductions in CD4(+), CD8(+) and CD19(+) cells, including both naive and memory CD4(+) and CD8(+) subsets, were observed at Day 2 without evidence of immune deficit. No clinically relevant changes in immunoglobulin subsets or treatment-related trends in circulating cytokines were noted. BMS-936558 exhibited dose-related exposure increases, with a half-life of 20-24 days. BMS-936558 was mostly well tolerated. One patient (10 mg/kg) experienced an asymptomatic grade 4 ALT elevation coincident with the onset of a 4-log viral load reduction. Six patients exhibited immune-related adverse events of mild-to-moderate intensity, including two cases of hyperthyroidism consistent with autoimmune thyroiditis. Further investigation of PD-1 pathway blockade in chronic viral disease is warranted.
C1 [Gardiner, David; Anderson, Jeffrey; He, Bing; Grasela, Dennis] Bristol Myers Squibb Co, Pennington, NJ USA.
[Lalezari, Jay] Quest Clin Res, San Francisco, CA USA.
[Lawitz, Eric] Alamo Med Res, San Antonio, TX USA.
[DiMicco, Michael] Adv Clin Res Inst, Anaheim, CA USA.
[Ghalib, Rheem] Methodist Hosp, Liver Inst, Dallas, TX USA.
[Reddy, K. Rajender; Chang, Kyong-Mi] Univ Penn, Sch Med, Philadelphia, PA 19104 USA.
[Chang, Kyong-Mi] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA.
[Sulkowski, Mark] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[O' Marro, Steven] Springfield Clin Infect Dis, Springfield, IL USA.
[Kansra, Vikram; Wind-Rotolo, Megan] Bristol Myers Squibb Co, Princeton, NJ USA.
[McPhee, Fiona] Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
[Selby, Mark; Korman, Alan J.] Bristol Myers Squibb Co, Milpitas, CA USA.
[Lowy, Israel] Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA.
RP Gardiner, D (reprint author), Bristol Myers Squibb Co, Pennington, NJ USA.
EM david.gardiner@bms.com
FU Bristol-Myers Squibb
FX This study was wholly funded by Medarex, now Bristol-Myers Squibb. The
funders, Medarex (now BMS), had a primary role in study design, in
collaboration with clinical investigators and health authorities. In
addition, Medarex had a primary role in the data collection and
analysis, decision to publish, and publication of the manuscript.
NR 50
TC 53
Z9 57
U1 0
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e63818
DI 10.1371/journal.pone.0063818
PG 11
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700065
PM 23717490
ER
PT J
AU Thompson, G
Wang, SR
Bercovitch, R
Bolaris, M
Van Den Akker, D
Taylor, S
Lopez, R
Catanzaro, A
Cadena, J
Chin-Hong, P
Spellberg, B
AF Thompson, George, III
Wang, Sharon
Bercovitch, Robert
Bolaris, Michael
Van Den Akker, Dane
Taylor, Sandra
Lopez, Rodrigo
Catanzaro, Antonio
Cadena, Jose
Chin-Hong, Peter
Spellberg, Brad
TI Routine CSF Analysis in Coccidioidomycosis Is Not Required
SO PLOS ONE
LA English
DT Article
ID MENINGITIS; PULMONARY; THERAPY; DISEASE
AB Although routinely done, there has been no evaluation of the utility of performing routine cerebrospinal fluid (CSF) examination in patients with active coccidioidomycosis and high complement fixation (IgG) antibody titers or other risk factors for disseminated infection. In our review 100% of patients diagnosed with coccidioidal meningitis had at least one sign or symptom consistent with infection of the central nervous system, headache was present in 100% of those with meningitis, while no patients without signs/symptoms of CNS infection were found to have coccidioidal meningitis, irrespective of antibody titers or other risk factors. Thus routine lumbar puncture may be unnecessary for patients with coccidioidomycosis who lack suggestive clinical symptoms.
C1 [Thompson, George, III] Univ Calif Davis, Dept Med Microbiol & Immunol, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
[Thompson, George, III; Wang, Sharon] Univ Calif Davis, Med Ctr, Dept Internal Med, Div Infect Dis, Sacramento, CA 95817 USA.
[Bercovitch, Robert; Catanzaro, Antonio] Univ Calif San Diego, Dept Internal Med, Div Pulm & Crit Care Med, San Diego, CA 92103 USA.
[Bolaris, Michael] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Pediat Infect Dis, Torrance, CA 90509 USA.
[Van Den Akker, Dane; Spellberg, Brad] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Div Gen Internal Med, Torrance, CA 90509 USA.
[Taylor, Sandra] Univ Calif Davis, Dept Publ Hlth Sci, Div Biostat, Davis, CA 95616 USA.
[Lopez, Rodrigo; Cadena, Jose] Univ Texas Hlth Sci Ctr San Antonio, Dept Internal Med, Div Infect Dis, San Antonio, TX 78229 USA.
[Cadena, Jose] South Texas Vet Hlth Care Syst, Dept Internal Med, San Antonio, TX USA.
[Chin-Hong, Peter] Univ Calif San Francisco, Dept Interal Med, Div Infect Dis, San Francisco, CA 94143 USA.
[Spellberg, Brad] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
RP Thompson, G (reprint author), Univ Calif Davis, Dept Med Microbiol & Immunol, Coccidioidomycosis Serol Lab, Davis, CA 95616 USA.
EM grthompson@ucdavis.edu; bspellberg@LABioMed.org
FU Pfizer; National Center for Advancing Translational Sciences (NCATS),
National Institutes of Health (NIH) [UL1 TR000002]
FX Funding for this study was generously provided by Pfizer. The funders
had no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.; We wish to thank Stuart
Cohen MD for helpful comments during the writing of this manuscript and
we thank the research staff at each of the sites for invaluable
assistance. "The project described was supported by the National Center
for Advancing Translational Sciences (NCATS), National Institutes of
Health (NIH), through grant #UL1 TR000002.''
NR 15
TC 4
Z9 4
U1 0
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 22
PY 2013
VL 8
IS 5
AR e64249
DI 10.1371/journal.pone.0064249
PG 5
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163UP
UT WOS:000320362700124
PM 23717579
ER
PT J
AU Berdichevsky, Y
Dryer, AM
Saponjian, Y
Mahoney, MM
Pimentel, CA
Lucini, CA
Usenovic, M
Staley, KJ
AF Berdichevsky, Yevgeny
Dryer, Alexandra M.
Saponjian, Yero
Mahoney, Mark M.
Pimentel, Corrin A.
Lucini, Corrina A.
Usenovic, Marija
Staley, Kevin J.
TI PI3K-Akt Signaling Activates mTOR-Mediated Epileptogenesis in
Organotypic Hippocampal Culture Model of Post-Traumatic Epilepsy
SO JOURNAL OF NEUROSCIENCE
LA English
DT Article
ID TEMPORAL-LOBE EPILEPSY; MAMMALIAN TARGET; STATUS EPILEPTICUS; INTERICTAL
SPIKES; BRAIN-INJURY; MOUSE MODEL; CELL-DEATH; IN-VITRO; RAPAMYCIN;
SEIZURES
AB mTOR is activated in epilepsy, but the mechanisms of mTOR activation in post-traumatic epileptogenesis are unknown. It is also not clear whether mTOR inhibition has an anti-epileptogenic, or merely anticonvulsive effect. The rat hippocampal organotypic culture model of post-traumatic epilepsy was used to study the effects of long-term (four weeks) inhibition of signaling pathways that interact with mTOR. Ictal activity was quantified by measurement of lactate production and electrical recordings, and cell death was quantified with lactate dehydrogenase (LDH) release measurements and Nissl-stained neuron counts. Lactate and LDH measurements were well correlated with electrographic activity and neuron counts, respectively. Inhibition of PI3K and Akt prevented activation of mTOR, and was as effective as inhibition of mTOR in reducing ictal activity and cell death. A dual inhibitor of PI3K and mTOR, NVP-BEZ235, was also effective. Inhibition of mTOR with rapamycin reduced axon sprouting. Late start of rapamycin treatment was effective in reducing epileptic activity and cell death, while early termination of rapamycin treatment did not result in increased epileptic activity or cell death. The conclusions of the study are as follows: (1) the organotypic hippocampal culture model of post-traumatic epilepsy comprises a rapid assay of anti-epileptogenic and neuroprotective activities and, in this model (2) mTOR activation depends on PI3K-Akt signaling, and (3) transient inhibition of mTOR has sustained effects on epilepsy.
C1 [Berdichevsky, Yevgeny; Saponjian, Yero; Usenovic, Marija; Staley, Kevin J.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02129 USA.
[Berdichevsky, Yevgeny; Staley, Kevin J.] Harvard Univ, Sch Med, Boston, MA 02129 USA.
[Dryer, Alexandra M.] Lehigh Univ, Dept Elect & Comp Engn, Bethlehem, PA 18015 USA.
[Mahoney, Mark M.; Pimentel, Corrin A.; Lucini, Corrina A.] Lehigh Univ, Bioengn Program, Bethlehem, PA 18015 USA.
RP Staley, KJ (reprint author), MGH Neurol, CNY 114,Room 2600,114 16th St, Charlestown, MA 02129 USA.
EM Staley.Kevin@mgh.harvard.edu
FU National Institutes of Health [R21 NS072258, R01 NS077908]
FX This study was supported by National Institutes of Health Grants R21
NS072258 and R01 NS077908 (National Institute of Neurological Disorders
and Stroke).
NR 44
TC 27
Z9 29
U1 3
U2 18
PU SOC NEUROSCIENCE
PI WASHINGTON
PA 11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA
SN 0270-6474
J9 J NEUROSCI
JI J. Neurosci.
PD MAY 22
PY 2013
VL 33
IS 21
BP 9056
EP 9067
DI 10.1523/JNEUROSCI.3870-12.2013
PG 12
WC Neurosciences
SC Neurosciences & Neurology
GA 150LF
UT WOS:000319391200015
PM 23699517
ER
PT J
AU Gandy, S
Heppner, FL
AF Gandy, Sam
Heppner, Frank L.
TI Microglia as Dynamic and Essential Components of the Amyloid Hypothesis
SO NEURON
LA English
DT Editorial Material
ID ONSET ALZHEIMERS-DISEASE; PATHOLOGY; VARIANTS; MICE
C1 [Gandy, Sam] Icahn Sch Med, New York, NY 10029 USA.
[Gandy, Sam] James J Peters VA Med Ctr, New York, NY 10029 USA.
[Heppner, Frank L.] Charite, Dept Neuropathol, D-10117 Berlin, Germany.
RP Gandy, S (reprint author), Icahn Sch Med, New York, NY 10029 USA.
EM samuel.gandy@mssm.edu; frank.heppner@charite.de
FU NIA NIH HHS [U01 AG046170, P50 AG005138, R34 AG049649]
NR 15
TC 26
Z9 26
U1 1
U2 19
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD MAY 22
PY 2013
VL 78
IS 4
BP 575
EP 577
DI 10.1016/j.neuron.2013.05.007
PG 3
WC Neurosciences
SC Neurosciences & Neurology
GA 151WN
UT WOS:000319491200001
PM 23719156
ER
PT J
AU Griciuc, A
Serrano-Pozo, A
Parrado, AR
Lesinski, AN
Asselin, CN
Mullin, K
Hooli, B
Choi, SH
Hyman, BT
Tanzil, RE
AF Griciuc, Ana
Serrano-Pozo, Alberto
Parrado, Antonio R.
Lesinski, Andrea N.
Asselin, Caroline N.
Mullin, Kristina
Hooli, Basavaraj
Choi, Se Hoon
Hyman, Bradley T.
Tanzil, Rudolph E.
TI Alzheimer's Disease Risk Gene CD33 Inhibits Microglial Uptake of Amyloid
Beta
SO NEURON
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; A-BETA; APOLIPOPROTEIN-E; IDENTIFIES VARIANTS;
MYELOID-LEUKEMIA; COMMON VARIANTS; IN-VIVO; SIGLECS; HYPOTHESIS;
DEPOSITION
AB The transmembrane protein CD33 is a sialic acid-binding immunoglobulin-like lectin that regulates innate immunity but has no known functions in the brain. We have previously shown that the CD33 gene is a risk factor for Alzheimer's disease (AD). Here, we observed increased expression of CD33 in microglial cells in AD brain. The minor allele of the CD33 SNP rs3865444, which confers protection against AD, was associated with reductions in both CD33 expression and insoluble amyloid beta 42 (A beta 42) levels in AD brain. Furthermore, the numbers of CD33-immunoreactive microglia were positively correlated with insoluble A beta 42 levels and plaque burden in AD brain. CD33 inhibited uptake and clearance of A beta 42 in microglial cell cultures. Finally, brain levels of insoluble A beta 42 as well as amyloid plaque burden were markedly reduced in APP(Swe)/PS1(Delta E9)/CD33(-/-) mice. Therefore, CD33 inactivation mitigates A beta pathology and CD33 inhibition could represent a novel therapy for AD.
C1 [Griciuc, Ana; Parrado, Antonio R.; Lesinski, Andrea N.; Asselin, Caroline N.; Mullin, Kristina; Hooli, Basavaraj; Choi, Se Hoon; Tanzil, Rudolph E.] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
[Serrano-Pozo, Alberto; Hyman, Bradley T.] Massachusetts Gen Hosp, Dept Neurol, Alzheimers Dis Res Lab, Charlestown, MA 02129 USA.
[Serrano-Pozo, Alberto; Hyman, Bradley T.] Harvard Univ, Sch Med, Charlestown, MA 02129 USA.
RP Tanzil, RE (reprint author), Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA 02129 USA.
EM tanzi@helix.mgh.harvard.edu
OI SERRANO-POZO, ALBERTO/0000-0003-0899-7530
FU National Institutes of Health [5R37MH060009, 5P01AG15379, AG08487,
P50AG05134]; Cure Alzheimer's Fund; Deutsche Forschungsgemeinschaft
(Germany)
FX We thank Ronald B. Walter (Fred Hutchinson Cancer Research Center,
Seattle, WA, USA) for the CD33 plasmids and Linda Van Eldik (University
of Kentucky, Lexington, KY, USA) for the BV2 microglial cell line. We
thank Karlotta Fitch for assistance with tissue sectioning. We thank
Lars Bertram, Zhongcong Xie, Jaehong Suh, Can Zhang, and Doo Kim for
stimulating discussions. This work was supported by grants from the
National Institutes of Health (5R37MH060009 and 5P01AG15379 to R.E.T.
and AG08487 and P50AG05134 to B.T.H.), and Cure Alzheimer's Fund. A.G.
is supported by a fellowship from the Deutsche Forschungsgemeinschaft
(Germany). B.T.H. is on the Scientific Advisory Board of Neurophage,
which was not involved in this study.
NR 57
TC 200
Z9 208
U1 4
U2 63
PU CELL PRESS
PI CAMBRIDGE
PA 600 TECHNOLOGY SQUARE, 5TH FLOOR, CAMBRIDGE, MA 02139 USA
SN 0896-6273
J9 NEURON
JI Neuron
PD MAY 22
PY 2013
VL 78
IS 4
BP 631
EP 643
DI 10.1016/j.neuron.2013.04.014
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 151WN
UT WOS:000319491200008
PM 23623698
ER
PT J
AU Axelrod, L
Shah, DJ
Jena, AB
AF Axelrod, Lloyd
Shah, Deep J.
Jena, Anupam B.
TI Duty Hour Reforms in Europe and the United States Reply
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Letter
C1 [Axelrod, Lloyd] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Jena, Anupam B.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Shah, Deep J.] Harvard Univ, Sch Med, Boston, MA USA.
RP Axelrod, L (reprint author), Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
EM laxelrod@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 22
PY 2013
VL 309
IS 20
BP 2095
EP 2095
DI 10.1001/jama.2013.4096
PG 1
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148FU
UT WOS:000319229600021
PM 23695477
ER
PT J
AU Marcum, ZA
Sevick, MA
Handler, SM
AF Marcum, Zachary A.
Sevick, Mary Ann
Handler, Steven M.
TI Medication Nonadherence A Diagnosable and Treatable Medical Condition
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
ID ADHERENCE
C1 [Marcum, Zachary A.; Handler, Steven M.] Univ Pittsburgh, Sch Med, Div Geriatr Med, Pittsburgh, PA 15213 USA.
[Handler, Steven M.] Univ Pittsburgh, Sch Med, Dept Biomed Informat, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] Univ Pittsburgh, Sch Med, Dept Gen Internal Med, Pittsburgh, PA 15213 USA.
[Sevick, Mary Ann] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
RP Marcum, ZA (reprint author), Univ Pittsburgh, Sch Med, Div Geriatr Med, 3471 5th Ave,Ste 500, Pittsburgh, PA 15213 USA.
EM zam12@pitt.edu
OI Handler, Steven/0000-0002-3940-3224
FU AHRQ HHS [R01 HS018721, R01HS018721]; NIA NIH HHS [K07 AG033174,
K07AG033174, P30 AG024827, P30AG024827]; NIDDK NIH HHS [R01 DK100492,
R01-DK100492]; NINR NIH HHS [2R01-NR010135, K24 NR012226, K24-NR012226,
R01 NR010135]
NR 7
TC 43
Z9 43
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 22
PY 2013
VL 309
IS 20
BP 2105
EP 2106
DI 10.1001/jama.2013.4638
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148FU
UT WOS:000319229600024
PM 23695479
ER
PT J
AU Baggett, TP
AF Baggett, Travis P.
TI The Proud Paratrooper
SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
LA English
DT Editorial Material
C1 [Baggett, Travis P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med,Dept Med, Boston, MA 02114 USA.
[Baggett, Travis P.] Boston Hlth Care Homeless Program, Boston, MA USA.
RP Baggett, TP (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen Med,Dept Med, Boston, MA 02114 USA.
EM tbaggett@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 0098-7484
EI 1538-3598
J9 JAMA-J AM MED ASSOC
JI JAMA-J. Am. Med. Assoc.
PD MAY 22
PY 2013
VL 309
IS 20
BP 2109
EP 2110
DI 10.1001/jama.2013.3044
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 148FU
UT WOS:000319229600026
PM 23695481
ER
PT J
AU Bowman-Colin, C
Xia, B
Bunting, S
Klijn, C
Drost, R
Bouwman, P
Fineman, L
Chen, XX
Culhane, AC
Cai, H
Rodig, SJ
Bronson, RT
Jonkers, J
Nussenzweig, A
Kanellopoulou, C
Livingston, DM
AF Bowman-Colin, Christian
Xia, Bing
Bunting, Samuel
Klijn, Christiaan
Drost, Rinske
Bouwman, Peter
Fineman, Laura
Chen, Xixi
Culhane, Aedin C.
Cai, Hong
Rodig, Scott J.
Bronson, Roderick T.
Jonkers, Jos
Nussenzweig, Andre
Kanellopoulou, Chryssa
Livingston, David M.
TI Palb2 synergizes with Trp53 to suppress mammary tumor formation in a
model of inherited breast cancer
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE mouse model; familial breast cancer
ID EARLY EMBRYONIC LETHALITY; HOMOLOGOUS RECOMBINATION; SUSCEPTIBILITY
GENE; BRCA1 DEFICIENCY; FANCONI-ANEMIA; CELLULAR PROLIFERATION; GENOMIC
INSTABILITY; CRE RECOMBINASE; MOUSE MODELS; SOLID TUMORS
AB Germ-line mutations in PALB2 lead to a familial predisposition to breast and pancreatic cancer or to Fanconi Anemia subtype N. PALB2 performs its tumor suppressor role, at least in part, by supporting homologous recombination-type double strand break repair (HR-DSBR) through physical interactions with BRCA1, BRCA2, and RAD51. To further understand the mechanisms underlying PALB2-mediated DNA repair and tumor suppression functions, we targeted Palb2 in the mouse. Palb2-deficient murine ES cells recapitulated DNA damage defects caused by PALB2 depletion in human cells, and germline deletion of Palb2 led to early embryonic lethality. Somatic deletion of Palb2 driven by K14-Cre led to mammary tumor formation with long latency. Codeletion of both Palb2 and Tumor protein 53 (Trp53) accelerated mammary tumor formation. Like BRCA1 and BRCA2 mutant breast cancers, these tumors were defective in RAD51 focus formation, reflecting a defect in Palb2 HR-DSBR function, a strongly suspected contributor to Brca1, Brca2, and Palb2 mammary tumor development. However, unlike the case of Brca1-mutant cells, Trp53bp1 deletion failed to rescue the genomic instability of Palb2- or Brca2-mutant primary lymphocytes. Therefore, Palb2-driven DNA damage control is, in part, distinct from that executed by Brca1 and more similar to that of Brca2. The mechanisms underlying Palb2 mammary tumor suppression functions can now be explored genetically in vivo.
C1 [Bowman-Colin, Christian; Fineman, Laura; Chen, Xixi; Kanellopoulou, Chryssa; Livingston, David M.] Dana Farber Canc Inst, Dept Canc Biol, Boston, MA 02215 USA.
[Culhane, Aedin C.] Dana Farber Canc Inst, Boston, MA 02215 USA.
[Xia, Bing; Cai, Hong] Canc Inst New Jersey, New Brunswick, NJ 08901 USA.
[Bunting, Samuel] Rutgers State Univ, Dept Mol Biol & Biochem, Piscataway, NJ 08854 USA.
[Klijn, Christiaan; Drost, Rinske; Bouwman, Peter; Jonkers, Jos] Netherlands Canc Inst, Div Mol Pathol, NL-1066 CX Amsterdam, Netherlands.
[Culhane, Aedin C.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Rodig, Scott J.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Bronson, Roderick T.] Harvard Univ, Sch Med, Rodent Histol Core, Dana Farber Harvard Canc Ctr, Boston, MA 02115 USA.
[Nussenzweig, Andre] NCI, Lab Genome Integr, NIH, Bethesda, MD 20892 USA.
RP Kanellopoulou, C (reprint author), NIAID, Immunol Lab, NIH, 9000 Rockville Pike, Bethesda, MD 20892 USA.
EM chrysi.kanellopoulou@nih.gov; david_livingston@dfci.harvard.edu
OI Klijn, Christiaan/0000-0003-0878-4121
FU National Cancer Institute [P01CA80111]; Specialized Program of Research
Excellence grant in breast cancer research [2P50CA089393]; Susan G.
Komen Foundation for the Cure [SAC110022]; Breast Cancer Research
Foundation
FX We thank Drs. Ron DePinho and William Kaelin for Trp53fl/fl
mice and Dr. Bing Xia for openly exchanging information on PALB2 KO mice
with our laboratory. We also thank Drs. Kristine McKinney, Nana
Naetar-Kerenyi, Patricia Dahia, and Stefan Muljo for critical reading of
this manuscript; Dvora Ghitza and Dr. Klaus Rajewsky for help with the
tetraploid complementation assays; Dr. Rene Maehr for V6.5 ES cells; Dr.
Ronny Drapkin for the antibody developed against mouse BRCA1; and James
Horner for ES cell micro-injections. We also thank all members of the D.
M. L. laboratory for cooperation, expertise, and reagent sharing, as
well as fruitful discussions. Finally, we thank the staff from the
Dana-Farber Cancer Institute Animal Resources Facility for excellent
technical support and Anuradha Kohli and Nancy Gerard for outstanding
administrative support. This work was supported by National Cancer
Institute Grant P01CA80111, by a Specialized Program of Research
Excellence grant in breast cancer research (2P50CA089393 to the
Dana-Farber/Harvard Cancer Center), by the Susan G. Komen Foundation for
the Cure (SAC110022), and grants from the Breast Cancer Research
Foundation.
NR 53
TC 13
Z9 13
U1 1
U2 6
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 21
PY 2013
VL 110
IS 21
BP 8632
EP 8637
DI 10.1073/pnas.1305362110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163IE
UT WOS:000320328700071
PM 23657012
ER
PT J
AU Martinod, K
Demers, M
Fuchs, TA
Wong, SL
Brill, A
Gallant, M
Hu, J
Wang, YM
Wagner, DD
AF Martinod, Kimberly
Demers, Melanie
Fuchs, Tobias A.
Wong, Siu Ling
Brill, Alexander
Gallant, Maureen
Hu, Jing
Wang, Yanming
Wagner, Denisa D.
TI Neutrophil histone modification by peptidylarginine deiminase 4 is
critical for deep vein thrombosis in mice
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE histone citrullination; venous thromboembolism; inflammation; programmed
cell death; nuclear swelling
ID EXTRACELLULAR TRAP FORMATION; VON-WILLEBRAND-FACTOR; IN-VIVO; VENOUS
THROMBOEMBOLISM; PLATELET-ADHESION; INNATE IMMUNITY; MOUSE MODELS; DNA
TRAPS; PAD4; LOCALIZATION
AB Deep vein thrombosis and pulmonary embolism are major health problems associated with high mortality. Recently, DNA-based neutrophil extracellular traps (NETs) resulting from the release of decondensed chromatin, were found to be part of the thrombus scaffold and to promote coagulation. However, the significance of nuclear decondensation and NET generation in thrombosis is largely unknown. To address this, we adopted a stenosis model of deep vein thrombosis and analyzed venous thrombi in peptidylarginine deiminase 4 (PAD4)-deficient mice that cannot citrullinate histones, a process required for chromatin decondensation and NET formation. Intriguingly, less than 10% of PAD4(-/-) mice produced a thrombus 48 h after inferior vena cava stenosis whereas 90% of wild-type mice did. Neutrophils were abundantly present in thrombi formed in both groups, whereas extracellular citrullinated histones were seen only in thrombi from wild-type mice. Bone marrow chimera experiments indicated that PAD4 in hematopoietic cells was the source of the prothrombotic effect in deep vein thrombosis. Thrombosis could be rescued by infusion of wild-type neutrophils, suggesting that neutrophil PAD4 was important and sufficient. Endothelial activation and platelet aggregation were normal in PAD4(-/-) mice, as was hemostatic potential determined by bleeding time and platelet plug formation after venous injury. Our results show that PAD4-mediated chromatin decondensation in the neutrophil is crucial for pathological venous thrombosis and present neutrophil activation and PAD4 as potential drug targets for deep vein thrombosis.
C1 [Martinod, Kimberly] Harvard Univ, Immunol Grad Program, Sch Med, Div Med Sci, Boston, MA 02115 USA.
[Martinod, Kimberly; Demers, Melanie; Fuchs, Tobias A.; Wong, Siu Ling; Brill, Alexander; Gallant, Maureen; Wagner, Denisa D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Demers, Melanie; Fuchs, Tobias A.; Wong, Siu Ling; Brill, Alexander; Wagner, Denisa D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Hu, Jing; Wang, Yanming] Penn State Univ, Dept Biochem & Mol Biol, Ctr Eukaryot Gene Regulat, University Pk, PA 16802 USA.
[Wagner, Denisa D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
EM denisa.wagner@childrens.harvard.edu
OI Martinod, Kimberly/0000-0002-1026-6107
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01 HL095091, R01 HL041002, HL102101, R01 CA136856];
GlaxoSmithKline
FX We thank Tanya N. Mayadas for helpful discussions and for the method of
neutrophil infusion, Stephen M. Cifuni for expert technical assistance,
and Lesley Cowan for assistance in manuscript preparation. This work was
supported by the National Heart, Lung, and Blood Institute of the
National Institutes of Health Grants R01 HL095091, R01 HL041002, and
HL102101 (to D. D. W.), and R01 CA136856 (to Y.W.). K. M. was supported
in part by a research grant from GlaxoSmithKline.
NR 37
TC 88
Z9 90
U1 0
U2 14
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 21
PY 2013
VL 110
IS 21
BP 8674
EP 8679
DI 10.1073/pnas.1301059110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163IE
UT WOS:000320328700078
PM 23650392
ER
PT J
AU Jurado, KA
Wang, H
Slaughter, A
Feng, L
Kessl, JJ
Koh, Y
Wang, WF
Ballandras-Colas, A
Patel, PA
Fuchs, JR
Kvaratskhelia, M
Engelman, A
AF Jurado, Kellie A.
Wang, Hao
Slaughter, Alison
Feng, Lei
Kessl, Jacques J.
Koh, Yasuhiro
Wang, Weifeng
Ballandras-Colas, Allison
Patel, Pratiq A.
Fuchs, James R.
Kvaratskhelia, Mamuka
Engelman, Alan
TI Allosteric integrase inhibitor potency is determined through the
inhibition of HIV-1 particle maturation
SO PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF
AMERICA
LA English
DT Article
DE AIDS; antiretroviral therapy
ID IMMUNODEFICIENCY-VIRUS TYPE-1; SMALL-MOLECULE INHIBITORS; PREINTEGRATION
COMPLEXES; NUCLEAR-LOCALIZATION; DNA INTEGRATION; COACTIVATOR P75;
STRAND TRANSFER; IN-VITRO; REPLICATION; LEDGF/P75
AB Integration is essential for HIV-1 replication, and the viral integrase (IN) protein is an important therapeutic target. Allosteric IN inhibitors (ALLINIs) that engage the IN dimer interface at the binding site for the host protein lens epithelium-derived growth factor (LEDGF)/transcriptional coactivator p75 are an emerging class of small molecule antagonists. Consistent with the inhibition of a multivalent drug target, ALLINIs display steep antiviral dose-response curves ex vivo. ALLINIs multimerize IN protein and concordantly block its assembly with viral DNA in vitro, indicating that the disruption of two integration-associated functions, IN catalysis and the IN-LEDGF/p75 interaction, determines the multimode mechanism of ALLINI action. We now demonstrate that ALLINI potency is unexpectedly accounted for during the late phase of HIV-1 replication. The compounds promote virion IN multimerization and, reminiscent of class II IN mutations, block the formation of the electron-dense viral core and inhibit reverse transcription and integration in subsequently infected target cells. Mature virions are recalcitrant to ALLINI treatment, and compound potency during virus production is independent of the level of LEDGF/p75 expression. We conclude that cooperative multimerization of IN by ALLINIs together with the inability for LEDGF/p75 to effectively engage the virus during its egress from cells underscores the multimodal mechanism of ALLINI action. Our results highlight the versatile nature of allosteric inhibitors to primarily inhibit viral replication at a step that is distinct from the catalytic requirement for the target enzyme. The vulnerability of IN to small molecules during the late phase of HIV-1 replication unveils a pharmacological Achilles' heel for exploitation in clinical ALLINI development.
C1 [Jurado, Kellie A.; Wang, Hao; Koh, Yasuhiro; Wang, Weifeng; Ballandras-Colas, Allison; Engelman, Alan] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Jurado, Kellie A.; Wang, Hao; Koh, Yasuhiro; Wang, Weifeng; Ballandras-Colas, Allison; Engelman, Alan] Harvard Univ, Sch Med, Dept Med, Boston, MA 02215 USA.
[Slaughter, Alison; Feng, Lei; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Retrovirus Res, Columbus, OH 43210 USA.
[Slaughter, Alison; Feng, Lei; Kessl, Jacques J.; Kvaratskhelia, Mamuka] Ohio State Univ, Coll Pharm, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Patel, Pratiq A.; Fuchs, James R.] Ohio State Univ, Coll Pharm, Div Med Chem & Pharmacognosy, Columbus, OH 43210 USA.
RP Engelman, A (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
EM alan_engelman@dfci.harvard.edu
RI wang, weifeng/N-4140-2013; wang, hao/O-6217-2014; Kessl,
Jacques/J-6073-2015
FU National Institutes of Health [AI039394, AI062520, AI081581, GM103368,
AI097044, P30AI060354]; National Academies' Ford Foundation Predoctoral
Fellowship
FX We thank J. Kappes (University of Alabama) for pRL2P-Vpr-IN, M. D.
Miller (Merck Research Laboratories) for pMM310, E. Poeschla (Mayo
Clinic) for 293T-si1340/1428 and 293T-siScram cells, N. Landau (New York
University) for CEMx174 5.25 M7 cells, C. Tipper for advice on HIV-1
purification for microscopy, and P. Cherepanov for pCPH6P-HIV1-IN and
for critical review of the manuscript. This work was funded in part by
National Institutes of Health Grants AI039394 (to A. E.), AI062520 and
AI081581 (to M. K.), GM103368 (to A. E. and M. K.), AI097044 (to J. J.
K. and J. R. F.), and P30AI060354 (to the Harvard University Center for
AIDS Research). K. A. J. is a recipient of a National Academies' Ford
Foundation Predoctoral Fellowship.
NR 50
TC 66
Z9 66
U1 1
U2 15
PU NATL ACAD SCIENCES
PI WASHINGTON
PA 2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA
SN 0027-8424
J9 P NATL ACAD SCI USA
JI Proc. Natl. Acad. Sci. U. S. A.
PD MAY 21
PY 2013
VL 110
IS 21
BP 8690
EP 8695
DI 10.1073/pnas.1300703110
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 163IE
UT WOS:000320328700081
PM 23610442
ER
PT J
AU Majmudar, MD
Keliher, EJ
Heidt, T
Leuschner, F
Truelove, J
Sena, BF
Gorbatov, R
Iwamoto, Y
Dutta, P
Wojtkiewicz, G
Courties, G
Sebas, M
Borodovsky, A
Fitzgerald, K
Nolte, MW
Dickneite, G
Chen, JW
Anderson, DG
Swirski, FK
Weissleder, R
Nahrendorf, M
AF Majmudar, Maulik D.
Keliher, Edmund J.
Heidt, Timo
Leuschner, Florian
Truelove, Jessica
Sena, Brena F.
Gorbatov, Rostic
Iwamoto, Yoshiko
Dutta, Partha
Wojtkiewicz, Gregory
Courties, Gabriel
Sebas, Matt
Borodovsky, Anna
Fitzgerald, Kevin
Nolte, Marc W.
Dickneite, Gerhard
Chen, John W.
Anderson, Daniel G.
Swirski, Filip K.
Weissleder, Ralph
Nahrendorf, Matthias
TI Monocyte-Directed RNAi Targeting CCR2 Improves Infarct Healing in
Atherosclerosis-Prone Mice
SO CIRCULATION
LA English
DT Article
DE heart failure; inflammation; magnetic resonance imaging; molecular
imaging; monocytes; myocardial infarction; positron-emission tomography;
RNA, small interfering; ventricular remodeling
ID ACUTE MYOCARDIAL-INFARCTION; FACTOR-XIII; HEART-FAILURE;
MYELOPEROXIDASE; INFLAMMATION; PET/MRI; LESIONS; INJURY; AGENTS; PET
AB Background-Exaggerated and prolonged inflammation after myocardial infarction (MI) accelerates left ventricular remodeling. Inflammatory pathways may present a therapeutic target to prevent post-MI heart failure. However, the appropriate magnitude and timing of interventions are largely unknown, in part because noninvasive monitoring tools are lacking. Here, we used nanoparticle-facilitated silencing of CCR2, the chemokine receptor that governs inflammatory Ly-6C(high) monocyte subset traffic, to reduce infarct inflammation in apolipoprotein E-deficient (apoE(-/-)) mice after MI. We used dual-target positron emission tomography/magnetic resonance imaging of transglutaminase factor XIII (FXIII) and myeloperoxidase (MPO) activity to monitor how monocyte subset-targeted RNAi altered infarct inflammation and healing.
Methods and Results-Flow cytometry, gene expression analysis, and histology revealed reduced monocyte numbers and enhanced resolution of inflammation in infarcted hearts of apoE(-/-) mice that were treated with nanoparticle-encapsulated siRNA. To follow extracellular matrix cross-linking noninvasively, we developed a fluorine-18-labeled positron emission tomography agent (F-18-FXIII). Recruitment of MPO-rich inflammatory leukocytes was imaged with a molecular magnetic resonance imaging sensor of MPO activity (MPO-Gd). Positron emission tomography/magnetic resonance imaging detected anti-inflammatory effects of intravenous nanoparticle-facilitated siRNA therapy (75% decrease of MPO-Gd signal; P<0.05), whereas F-18-FXIII positron emission tomography reflected unimpeded matrix cross-linking in the infarct. Silencing of CCR2 during the first week after MI improved ejection fraction on day 21 after MI from 29% to 35% (P<0.05).
Conclusion-CCR2-targeted RNAi reduced recruitment of Ly-6C(high) monocytes, attenuated infarct inflammation, and curbed post-MI left ventricular remodeling.
C1 [Majmudar, Maulik D.; Keliher, Edmund J.; Heidt, Timo; Leuschner, Florian; Truelove, Jessica; Sena, Brena F.; Gorbatov, Rostic; Iwamoto, Yoshiko; Dutta, Partha; Wojtkiewicz, Gregory; Courties, Gabriel; Sebas, Matt; Chen, John W.; Swirski, Filip K.; Weissleder, Ralph; Nahrendorf, Matthias] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Borodovsky, Anna; Fitzgerald, Kevin] Alnylam Pharmaceut, Cambridge, MA USA.
[Nolte, Marc W.; Dickneite, Gerhard] CSL Behring GmbH, Marburg, Germany.
[Anderson, Daniel G.] MIT, David H Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Anderson, Daniel G.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
[Anderson, Daniel G.] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
RP Nahrendorf, M (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM mnahrendorf@mgh.harvard.edu
FU National Heart, Lung, and Blood Institute, National Institutes of
Health, Department of Health and Human Services [HHSN268201000044C,
R01-HL096576, R01-HL095629, T32-HL094301]; Deutsche
Forschungsgemeinschaft [HE-6382/1-1]
FX This project has been funded in part by federal funds from the National
Heart, Lung, and Blood Institute, National Institutes of Health,
Department of Health and Human Services under contract No.
HHSN268201000044C and grants R01-HL096576, R01-HL095629, and
T32-HL094301. Dr Heidt was funded by Deutsche Forschungsgemeinschaft
HE-6382/1-1.
NR 48
TC 72
Z9 74
U1 3
U2 30
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 21
PY 2013
VL 127
IS 20
BP 2038
EP +
DI 10.1161/CIRCULATIONAHA.112.000116
PG 21
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 149NG
UT WOS:000319326400012
PM 23616627
ER
PT J
AU Piccini, JP
White, JA
Mehta, RH
Lokhnygina, Y
Al-Khatib, SM
Tricoci, P
Califf, RM
Harrington, RA
Newby, LK
Pollack, CV
Montalescot, G
Van de Werf, F
Gibson, CM
Giugliano, RP
AF Piccini, Jonathan P.
White, Jennifer A.
Mehta, Rajendra H.
Lokhnygina, Yuliya
Al-Khatib, Sana M.
Tricoci, Pierluigi
Califf, Robert M.
Harrington, Robert A.
Newby, L. Kristin
Pollack, Charles V., Jr.
Montalescot, Gilles
Van de Werf, Frans
Gibson, C. Michael
Giugliano, Robert P.
TI Response to Letter Regarding Article, "Sustained Ventricular Tachycardia
and Ventricular Fibrillation Complicating Non-ST-Segment Elevation Acute
Coronary Syndromes"
SO CIRCULATION
LA English
DT Letter
C1 [Piccini, Jonathan P.; White, Jennifer A.; Mehta, Rajendra H.; Lokhnygina, Yuliya; Al-Khatib, Sana M.; Tricoci, Pierluigi; Califf, Robert M.; Harrington, Robert A.; Newby, L. Kristin] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA.
[Pollack, Charles V., Jr.] Penn Hosp, Dept Emergency Med, Philadelphia, PA 19107 USA.
[Montalescot, Gilles] Hop La Pitie Salpetriere, Inst Cardiol, Paris, France.
[Van de Werf, Frans] Univ Hosp Gasthuisberg, B-3000 Louvain, Belgium.
[Van de Werf, Frans] Leuven Coordinating Ctr, Louvain, Belgium.
[Gibson, C. Michael] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Boston, MA 02115 USA.
RP Piccini, JP (reprint author), Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC 27706 USA.
OI Van de Werf, Frans/0000-0001-9479-7767
NR 1
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0009-7322
J9 CIRCULATION
JI Circulation
PD MAY 21
PY 2013
VL 127
IS 20
BP E634
EP E634
DI 10.1161/CIRCULATIONAHA.112.147546
PG 1
WC Cardiac & Cardiovascular Systems; Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA 149NG
UT WOS:000319326400006
PM 23833786
ER
PT J
AU Bauman, WA
Spungen, AM
Collins, JF
Raisch, DW
Ho, C
Deitrick, GA
Nemchausky, BA
Goetz, LL
Park, JS
Schwartz, M
Merritt, JL
Jayawardena, V
Sandford, P
Sabharwal, S
Holmes, SA
Nasar, F
Sasaki, R
Punj, V
Zachow, KF
Chua, WC
Thomas, MD
Trincher, RC
AF Bauman, William A.
Spungen, Ann M.
Collins, Joseph F.
Raisch, Dennis W.
Ho, Chester
Deitrick, George A.
Nemchausky, Bernard A.
Goetz, Lance L.
Park, Jai S.
Schwartz, Michael
Merritt, John L.
Jayawardena, Vidya
Sandford, Paul
Sabharwal, Sunil
Holmes, Sally A.
Nasar, Fahima
Sasaki, Roy
Punj, Vandana
Zachow, Karin F.
Chua, Walter C.
Thomas, MaryKutty D.
Trincher, Rose C.
TI The Effect of Oxandrolone on the Healing of Chronic Pressure Ulcers in
Persons With Spinal Cord Injury A Randomized Trial
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID SURGICAL PATIENTS; NUTRITIONAL-STATUS; STATUS CLASSIFICATION; BURN
INJURY; MALNUTRITION; TESTOSTERONE; CYTOKINES; WEIGHT; INFECTION;
RESIDENTS
AB Background: Anabolic steroids have been reported to improve wound healing.
Objective: To determine whether oxandrolone increases the percentage of target pressure ulcers (TPUs) that heal compared with placebo and whether healed ulcers remain closed 8 weeks after treatment.
Design: Parallel-group, placebo-controlled, randomized trial conducted from 1 August 2005 to 30 November 2008. Patients, clinical care providers, study personnel, and statisticians were blinded to treatment assignment. (ClinicalTrials.gov: NCT00101361)
Setting: 16 inpatient spinal cord injury (SCI) services at Veterans Affairs medical centers.
Patients: 1900 prescreened, 779 screened, and 212 randomly assigned inpatients with SCI and stage III or IV TPUs.
Intervention: Oxandrolone, 20 mg/d (n = 108), or placebo (n = 104) until the TPU healed or 24 weeks.
Measurements: The primary outcome was healed TPUs. The secondary outcome was the percentage of TPUs that remained healed at 8-week follow-up.
Results: 24.1% (95% CI, 16.0% to 32.1%) of TPUs in oxandrolone recipients and 29.8% (CI, 21.0% to 38.6%) in placebo recipients healed (difference, -5.7 percentage points [CI, -17.5 to 6.8 percentage points]; P = 0.40). At 8-week follow-up, 16.7% (CI, 9.6% to 23.7%) of oxandrolone recipients and 15.4% (CI, 8.5% to 22.3%) of placebo recipients retained a healed TPU (difference, 1.3 percentage points [CI, -8.8 to 11.2 percentage points]; P = 0.70). No serious adverse events were related to oxandrolone. Liver enzyme levels were elevated in 32.4% (CI, 23.6% to 41.2%) of oxandrolone recipients and 2.9% (CI, 0.0% to 6.1%) of placebo recipients (P < 0.001).
Limitations: Selection of severe wounds may have reduced treatment response. Approximately one third of patients did not complete the study in the treatment and placebo groups. The study was terminated after a futility analysis showed a low probability of detecting a significant difference between the groups.
Conclusion: Oxandrolone showed no benefit over placebo for improving healing or the percentage of TPUs that remained closed after 8 weeks of treatment.
C1 James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Med Spinal Cord Injury & Res Serv, Bronx, NY 10468 USA.
Mt Sinai Sch Med, New York, NY USA.
Perry Point Vet Affairs Med Ctr, Vet Affairs Cooperat Studies Program, Coordinating Ctr, Perry Point, MD USA.
Univ New Mexico, Vet Affairs Cooperat Study Program, Clin Res Pharm Coordinating Ctr, Albuquerque, NM 87131 USA.
Univ New Mexico, Coll Pharm, Albuquerque, NM 87131 USA.
Louis Stokes Cleveland Vet Affairs Med Ctr, Cleveland, OH USA.
Univ Calgary, Calgary, AB, Canada.
Vet Affairs North Texas Hlth Care Syst, Dallas, TX USA.
Virginia Commonwealth Univ, Richmond, VA USA.
St Louis Vet Affairs Med Ctr, Spinal Cord Injury Serv, St Louis, MO 63125 USA.
Univ S Florida, James A Haley Vet Hosp, Tampa, FL USA.
Univ S Florida, Coll Med, Tampa, FL USA.
Hunter H McGuire Vet Affairs Med Ctr, Richmond, VA USA.
Tufts Univ, Sch Med, Boston, MA 02111 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Clement J Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Vet Affairs Boston Healthcare Syst, Boston, MA 02132 USA.
Michael E DeBakey VA Med Ctr, Houston, TX 77030 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Vet Affairs San Diego Healthcare Syst, San Diego, CA USA.
Vet Affairs Palo Alto Healthcare Syst, Palo Alto, CA USA.
Stanford Sch Med, Stanford, CA USA.
Miami Vet Affairs Healthcare Syst, Spinal Cord Injury Serv, Miami, FL USA.
Vet Affairs Long Beach Healthcare Syst, Long Beach, CA USA.
Charlie Norwood Vet Affairs Med Ctr, Augusta, GA 30904 USA.
Georgia Hlth Sci Univ, Augusta, GA USA.
RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Natl Ctr Excellence Med Consequences Spinal Cord, Suite 7A-13,130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM william.bauman@va.gov
FU By the Veterans Affairs Clinical Science Research and Development
Service, Cooperative Study [535]; Rehabilitation Research and
Development, National Center of Excellence for the Medical Consequences
of Spinal Cord Injury [B2648C, B4162C, B9212C]; Department of Veterans
Affairs, Spinal Cord Injury Services
FX Grant Support: By the Veterans Affairs Clinical Science Research and
Development Service, Cooperative Study #535; Rehabilitation Research and
Development, National Center of Excellence for the Medical Consequences
of Spinal Cord Injury (B2648C, B4162C, and B9212C); and Department of
Veterans Affairs, Spinal Cord Injury Services.
NR 51
TC 7
Z9 8
U1 2
U2 12
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 21
PY 2013
VL 158
IS 10
BP 718
EP 726
DI 10.7326/0003-4819-158-10-201305210-00006
PG 9
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154HY
UT WOS:000319666200014
PM 23689765
ER
PT J
AU Qaseem, A
Barry, MJ
Denberg, TD
Owens, DK
Shekelle, P
AF Qaseem, Amir
Barry, Michael J.
Denberg, Thomas D.
Owens, Douglas K.
Shekelle, Paul
CA Amer Coll Phys
TI Screening for Prostate Cancer: A Guidance Statement From the Clinical
Guidelines Committee of the American College of Physicians
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Article
ID RANDOMIZED PROSTATE; FOLLOW-UP; MORTALITY; STATISTICS; TRIAL; TIME; MEN
AB Description: Prostate cancer is an important health problem in men. It rarely causes death in men younger than 50 years; most deaths associated with it occur in men older than 75 years. The benefits of screening with the prostate-specific antigen (PSA) test are outweighed by the harms for most men. Prostate cancer never becomes clinically significant in a patient's lifetime in a considerable proportion of men with prostate cancer detected with the PSA test. They will receive no benefit and are subject to substantial harms from the treatment of prostate cancer. The American College of Physicians (ACP) developed this guidance statement for clinicians by assessing current prostate cancer screening guidelines developed by other organizations. ACP believes that it is more valuable to provide clinicians with a rigorous review of available guidelines rather than develop a new guideline on the same topic when several guidelines are available on a topic or when existing guidelines conflict. The purpose of this guidance statement is to critically review available guidelines to help guide internists and other clinicians in making decisions about screening for prostate cancer. The target patient population for this guidance statement is all adult men.
Methods: This guidance statement is derived from an appraisal of available guidelines on screening for prostate cancer. Authors searched the National Guideline Clearinghouse to identify prostate cancer screening guidelines in the United States and selected 4 developed by the American College of Preventive Medicine, American Cancer Society, American Urological Association, and U. S. Preventive Services Task Force. The AGREE II (Appraisal of Guidelines, Research and Evaluation in Europe) instrument was used to evaluate the guidelines.
Guidance Statement 1: ACP recommends that clinicians inform men between the age of 50 and 69 years about the limited potential benefits and substantial harms of screening for prostate cancer. ACP recommends that clinicians base the decision to screen for prostate cancer using the prostate-specific antigen test on the risk for prostate cancer, a discussion of the benefits and harms of screening, the patient's general health and life expectancy, and patient preferences. ACP recommends that clinicians should not screen for prostate cancer using the prostate-specific antigen test in patients who do not express a clear preference for screening.
Guidance Statement 2: ACP recommends that clinicians should not screen for prostate cancer using the prostate-specific antigen test in average-risk men under the age of 50 years, men over the age of 69 years, or men with a life expectancy of less than 10 to 15 years.
C1 [Qaseem, Amir] Amer Coll Physicians, Philadelphia, PA 19106 USA.
Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
West Los Angeles Vet Affairs Med Ctr, Los Angeles, CA USA.
Harvard Vanguard Med Associates, Auburndale, MA USA.
RP Qaseem, A (reprint author), Amer Coll Physicians, 190 N Independence Mall West, Philadelphia, PA 19106 USA.
EM aqaseem@acponline.org
FU ACP
FX Financial support for the development of this guideline comes
exclusively from the ACP operating budget.
NR 25
TC 98
Z9 100
U1 0
U2 17
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 21
PY 2013
VL 158
IS 10
BP 761
EP +
DI 10.7326/0003-4819-158-10-201305210-00633
PG 10
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154HY
UT WOS:000319666200018
PM 23567643
ER
PT J
AU Walensky, RP
Paltiel, AD
Schackman, BR
AF Walensky, Rochelle P.
Paltiel, A. David
Schackman, Bruce R.
TI Cost-Effectiveness of Generic Antiretroviral Therapy RESPONSE
SO ANNALS OF INTERNAL MEDICINE
LA English
DT Letter
C1 [Walensky, Rochelle P.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Paltiel, A. David] Yale Univ, Sch Med, New Haven, CT USA.
[Schackman, Bruce R.] Weill Cornell Med Coll, New York, NY USA.
RP Walensky, RP (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 4
Z9 4
U1 0
U2 1
PU AMER COLL PHYSICIANS
PI PHILADELPHIA
PA INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA
SN 0003-4819
EI 1539-3704
J9 ANN INTERN MED
JI Ann. Intern. Med.
PD MAY 21
PY 2013
VL 158
IS 10
BP 776
EP 777
DI 10.7326/0003-4819-158-10-201305210-00016
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA 154HY
UT WOS:000319666200022
PM 23689770
ER
PT J
AU Albacker, CE
Storer, NY
Langdon, EM
DiBiase, A
Zhou, Y
Langenau, DM
Zon, LI
AF Albacker, Colleen E.
Storer, Narie Y.
Langdon, Erin M.
DiBiase, Anthony
Zhou, Yi
Langenau, David M.
Zon, Leonard I.
TI The Histone Methyltransferase SUV39H1 Suppresses Embryonal
Rhabdomyosarcoma Formation in Zebrafish
SO PLOS ONE
LA English
DT Article
ID CELLULAR SENESCENCE; RAS GENES; CYCLIN B1; N-RAS; CELLS; TUMORS;
RECRUITMENT; MUTATIONS; DIFFERENTIATION; METHYLATION
AB Epigenetics, or the reversible and heritable marks of gene regulation not including DNA sequence, encompasses chromatin modifications on both the DNA and histones and is as important as the DNA sequence itself. Chromatin-modifying factors are playing an increasingly important role in tumorigenesis, particularly among pediatric rhabdomyosarcomas (RMS), revealing potential novel therapeutic targets. We performed an overexpression screen of chromatin-modifying factors in a KRAS(G12D)-driven zebrafish model for RMS. Here, we describe the identification of a histone H3 lysine 9 histone methyltransferase, SUV39H1, as a suppressor of embryonal RMS formation in zebrafish. This suppression is specific to the histone methyltransferase activity of SUV39H1, as point mutations in the SET domain lacked the effect. SUV39H1-overexpressing and control tumors have a similar proliferation rate, muscle differentiation state, and tumor growth rate. Strikingly, SUV39H1-overexpressing fish initiate fewer tumors, which results in the observed suppressive phenotype. We demonstrate that the delayed tumor onset occurs between 5 and 7 days post fertilization. Gene expression profiling at these stages revealed that in the context of KRAS(G12D) overexpression, SUV39H1 may suppress cell cycle progression. Our studies provide evidence for the role of SUV39H1 as a tumor suppressor.
C1 [Albacker, Colleen E.; Storer, Narie Y.; Langdon, Erin M.; DiBiase, Anthony; Zhou, Yi; Zon, Leonard I.] Boston Childrens Hosp, Stem Cell Program, Boston, MA USA.
[Albacker, Colleen E.; Storer, Narie Y.; Langdon, Erin M.; DiBiase, Anthony; Zhou, Yi; Zon, Leonard I.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Albacker, Colleen E.; Storer, Narie Y.; Langdon, Erin M.; DiBiase, Anthony; Zhou, Yi; Zon, Leonard I.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Harvard Stem Cell Inst,Dana Farber Canc Inst, Boston, MA 02115 USA.
[Langenau, David M.] Massachusetts Gen Hosp, Dept Pathol, Harvard Stem Cell Inst, Charlestown, MA USA.
RP Zon, LI (reprint author), Boston Childrens Hosp, Stem Cell Program, Boston, MA USA.
EM zon@enders.tch.harvard.edu
FU NIH grant [T32 HL07623]
FX The work was funded by NIH grant T32 HL07623. The funders had no role in
study design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 40
TC 12
Z9 12
U1 0
U2 5
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e64969
DI 10.1371/journal.pone.0064969
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200176
PM 23705022
ER
PT J
AU Hajjarian, Z
Nadkarni, SK
AF Hajjarian, Zeinab
Nadkarni, Seemantini K.
TI Evaluation and Correction for Optical Scattering Variations in Laser
Speckle Rheology of Biological Fluids
SO PLOS ONE
LA English
DT Article
ID DIFFUSING-WAVE-SPECTROSCOPY; DYNAMIC LIGHT-SCATTERING; POLARIZED-LIGHT;
COMPLEX FLUIDS; ATHEROSCLEROTIC PLAQUES; TRACKING MICRORHEOMETRY;
REFLECTION MEASUREMENTS; COHERENCE TOMOGRAPHY; MULTIPLE-SCATTERING;
VISCOELASTIC MODULI
AB Biological fluids fulfill key functionalities such as hydrating, protecting, and nourishing cells and tissues in various organ systems. They are capable of these versatile tasks owing to their distinct structural and viscoelastic properties. Characterizing the viscoelastic properties of bio-fluids is of pivotal importance for monitoring the development of certain pathologies as well as engineering synthetic replacements. Laser Speckle Rheology (LSR) is a novel optical technology that enables mechanical evaluation of tissue. In LSR, a coherent laser beam illuminates the tissue and temporal speckle intensity fluctuations are analyzed to evaluate mechanical properties. The rate of temporal speckle fluctuations is, however, influenced by both optical and mechanical properties of tissue. Therefore, in this paper, we develop and validate an approach to estimate and compensate for the contributions of light scattering to speckle dynamics and demonstrate the capability of LSR for the accurate extraction of viscoelastic moduli in phantom samples and biological fluids of varying optical and mechanical properties.
C1 [Hajjarian, Zeinab; Nadkarni, Seemantini K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02115 USA.
RP Nadkarni, SK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02115 USA.
EM snadkarni@partners.org
FU NIH grant [R21 HL 088306, U54 EB015408-01]; ARRA grant [R21 HL
088306-02S1]
FX This study was funded by the NIH grant No. R21 HL 088306 (SN), NIH grant
No. U54 EB015408-01 (SN), and the ARRA grant No. R21 HL 088306-02S1
(SN). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
NR 77
TC 10
Z9 10
U1 2
U2 16
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e65014
DI 10.1371/journal.pone.0065014
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200182
PM 23705028
ER
PT J
AU Kaida, A
Matthews, LT
Kanters, S
Kabakyenga, J
Muzoora, C
Mocello, AR
Martin, JN
Hunt, P
Haberer, J
Hogg, RS
Bangsberg, DR
AF Kaida, Angela
Matthews, Lynn T.
Kanters, Steve
Kabakyenga, Jerome
Muzoora, Conrad
Mocello, A. Rain
Martin, Jeffrey N.
Hunt, Peter
Haberer, Jessica
Hogg, Robert S.
Bangsberg, David R.
TI Incidence and Predictors of Pregnancy among a Cohort of HIV-Positive
Women Initiating Antiretroviral Therapy in Mbarara, Uganda
SO PLOS ONE
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; REPRODUCTIVE HEALTH-CARE; SUB-SAHARAN
AFRICA; SOUTH-AFRICA; INFECTED WOMEN; FERTILITY INTENTIONS; MALE
CIRCUMCISION; RURAL UGANDA; PREEXPOSURE PROPHYLAXIS; MISSED
OPPORTUNITIES
AB Objective: Many people living with HIV in sub-Saharan Africa desire biological children. Implementation of HIV prevention strategies that support the reproductive goals of people living with HIV while minimizing HIV transmission risk to sexual partners and future children requires a comprehensive understanding of pregnancy in this population. We analyzed prospective cohort data to determine pregnancy incidence and predictors among HIV-positive women initiating antiretroviral therapy (ART) in a setting with high HIV prevalence and fertility.
Methods: Participants were enrolled in the Uganda AIDS Rural Treatment Outcomes (UARTO) cohort of HIV-positive individuals initiating ART in Mbarara. Bloodwork (including CD4 cells/mm(3), HIV viral load) and questionnaires (including socio-demographics, health status, sexual behavior, partner dynamics, HIV history, and self-reported pregnancy) were completed at baseline and quarterly. Our analysis includes 351 HIV-positive women (18-49 years) who enrolled between 2005-2011. We measured pregnancy incidence by proximal and distal time relative to ART initiation and used multivariable Cox proportional hazards regression analysis (with repeated events) to identify baseline and time-dependent predictors of pregnancy post-ART initiation.
Results: At baseline (pre-ART initiation), median age was 33 years [IQR: 27-37] and median prior livebirths was four [IQR: 2-6]. 38% were married with 61% reporting HIV-positive spouses. 73% of women had disclosed HIV status to a primary sexual partner. Median baseline CD4 was 137 cells/mm(3) [IQR: 81-207]. At enrolment, 9.1% (31/342) reported current pregnancy. After ART initiation, 84 women experienced 105 pregnancies over 3.8 median years of follow-up, yielding a pregnancy incidence of 9.40 per 100 WYs. Three years post-ART initiation, cumulative probability of at least one pregnancy was 28% and independently associated with younger age (Adjusted Hazard Ratio (AHR): 0.89/year increase; 95% CI: 0.86-0.92) and HIV serostatus disclosure to primary sexual partner (AHR: 2.45; 95% CI: 1.29-4.63).
Conclusions: Nearly one-third of women became pregnant within three years of initiating ART, highlighting the need for integrated services to prevent unintended pregnancies and reduce periconception-related risks for HIV-infected women choosing to conceive. Association with younger age and disclosure suggests a role for early and couples-based safer conception counselling.
C1 [Kaida, Angela; Hogg, Robert S.] Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.
[Matthews, Lynn T.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Matthews, Lynn T.; Haberer, Jessica; Bangsberg, David R.] Harvard Univ, Sch Med, Boston, MA USA.
[Matthews, Lynn T.; Haberer, Jessica; Bangsberg, David R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kanters, Steve] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada.
[Kabakyenga, Jerome; Muzoora, Conrad; Bangsberg, David R.] Mbarara Univ Sci & Technol, Mbarara, Uganda.
[Mocello, A. Rain; Martin, Jeffrey N.; Hunt, Peter] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hogg, Robert S.] BC Ctr Excellence HIV AIDS, Vancouver, BC, Canada.
RP Kaida, A (reprint author), Simon Fraser Univ, Burnaby, BC V5A 1S6, Canada.
EM kangela@sfu.ca
OI Hogg, Robert/0000-0003-3463-5488
FU National Institute of Child Health and Human Development [NICHD
R21-HD069194]; National Institute of Mental Health [NIMH R01-MH54907];
Sullivan Family Foundation; [K-23 MH095655]; [K-24 MH87227]
FX Funding for this study was provided by grants from the National
Institute of Child Health and Human Development (NICHD R21-HD069194),
the National Institute of Mental Health (NIMH R01-MH54907), and the
Sullivan Family Foundation. LTM received support from K-23 MH095655 and
DRB received support from K-24 MH87227. The funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 90
TC 20
Z9 20
U1 1
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63411
DI 10.1371/journal.pone.0063411
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200036
PM 23704906
ER
PT J
AU Li, YJ
Xu, M
Gao, ZH
Wang, YQ
Yue, Z
Zhang, YX
Li, XX
Zhang, C
Xie, SY
Wang, PY
AF Li, You-Jie
Xu, Mei
Gao, Zong-Hua
Wang, Ya-Qi
Yue, Zhen
Zhang, Yan-Xia
Li, Xin-Xin
Zhang, Can
Xie, Shu-Yang
Wang, Ping-Yu
TI Alterations of Serum Levels of BDNF-Related miRNAs in Patients with
Depression
SO PLOS ONE
LA English
DT Article
ID NEUROTROPHIC FACTOR LEVELS; BRAIN; MICRORNAS; DISORDER; RISK;
ADENOCARCINOMA; SCHIZOPHRENIA; POLYMORPHISM; EXPRESSION; DISEASE
AB Depression is a serious and potentially life-threatening mental disorder with unknown etiology. Emerging evidence shows that brain-derived neurotrophic factor (BDNF) and microRNAs (miRNAs) play critical roles in the etiology of depression. Here this study was aimed to identify and characterize the roles of BDNF and its putative regulatory miRNAs in depression. First, we identified that miR-182 may be a putative miRNA that regulates BDNF levels by bioinformatic studies, and characterized the effects of miR-182 on the BDNF levels using cell-based studies, side by side with miR-132 (a known miRNA that regulates BDNF expression). We showed that treatment of miR-132 and miR-182 respectively decreased the BDNF protein levels in a human neuronal cell model, supporting the regulatory roles of miR-132 and miR-182 on the BDNF expression. Furthermore, we explored the roles of miR-132 and miR-182 on the BDNF levels in depression using human subjects by assessing their serum levels. Compared with the healthy controls, patients with depression showed lower serum BDNF levels (via the enzyme-linked immunosorbent assays) and higher serum miR-132 and miR-182 levels (via the real-time PCR). Finally, the Pearson's (or Spearman's) correlation coefficient was calculated to study whether there was a relationship among the Self-Rating Depression Scale score, the serum BDNF levels, and serum BDNF-related miRNA levels. Our results revealed that there was a significant negative correlation between the SDS scores and the serum BDNF levels, and a positive correlation between the SDS scores and miR-132 levels. In addition, we found a reverse relationship between the serum BDNF levels and the miR-132/miR-182 levels in depression. Collectively, we provided evidence supporting that miR-182 is a putative BDNF-regulatory miRNA, and suggested that the serum BDNF and its related miRNAs may be utilized as important biomarkers in the diagnosis or as therapeutic targets of depression.
C1 [Li, You-Jie; Wang, Ya-Qi; Yue, Zhen; Zhang, Yan-Xia; Li, Xin-Xin; Xie, Shu-Yang; Wang, Ping-Yu] Binzhou Med Univ, Dept Biochem & Mol Biol, Yantai, Shandong, Peoples R China.
[Xu, Mei] Yantai Fushan Dist Peoples Hosp, Dept Psychiat, Yantai, Shandong, Peoples R China.
[Gao, Zong-Hua] Binzhou Med Univ, Dept Chem, Yantai, Shandong, Peoples R China.
[Zhang, Can] Massachusetts Gen Hosp, Dept Neurol, Genet & Aging Res Unit, Charlestown, MA USA.
[Zhang, Can] Harvard Univ, Sch Med, Charlestown, MA USA.
[Wang, Ping-Yu] Binzhou Med Univ, Dept Epidemiol, Yantai, Shandong, Peoples R China.
RP Xie, SY (reprint author), Binzhou Med Univ, Dept Biochem & Mol Biol, Yantai, Shandong, Peoples R China.
EM shuyangxie@yahoo.com.cn; wpinggirl@163.com
FU 'Taishan scholar' position [NCET-10-0919]; National Natural Science
Foundation [30801324, 81141114, 81200601]; Shandong Science and
Technology Committee [ZR2009CQ033, ZR2009CL005]; Foundation of ShanDong
Educational Committee of China [J09LF11, J11LC01]
FX This study was supported by the NCET-10-0919, 'Taishan scholar' position
and National Natural Science Foundation (No. 30801324, 81141114,
81200601), the Shandong Science and Technology Committee (ZR2009CQ033,
ZR2009CL005) and the Foundation of ShanDong Educational Committee of
China (No. J09LF11, J11LC01). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 51
TC 13
Z9 15
U1 1
U2 14
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63648
DI 10.1371/journal.pone.0063648
PG 7
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200058
PM 23704927
ER
PT J
AU Liang, HY
Hussey, SE
Sanchez-Avila, A
Tantiwong, P
Musi, N
AF Liang, Hanyu
Hussey, Sophie E.
Sanchez-Avila, Alicia
Tantiwong, Puntip
Musi, Nicolas
TI Effect of Lipopolysaccharide on Inflammation and Insulin Action in Human
Muscle
SO PLOS ONE
LA English
DT Article
ID LPS-BINDING-PROTEIN; ENDOPLASMIC-RETICULUM STRESS; TYPE-2 DIABETIC
SUBJECTS; HUMAN SKELETAL-MUSCLE; ADIPOSE-TISSUE; RESISTANCE; GLUCOSE;
SENSITIVITY; ENDOTOXEMIA; OBESITY
AB Accumulating evidence from animal studies suggest that chronic elevation of circulating intestinal-generated lipopolysaccharide (LPS) (i.e., metabolic endotoxemia) could play a role in the pathogenesis of insulin resistance. However, the effect of LPS in human muscle is unclear. Moreover, it is unknown whether blockade/down regulation of toll-like receptor (TLR) 4 can prevent the effect of LPS on insulin action and glucose metabolism in human muscle cells. In the present study we compared plasma LPS concentration in insulin resistant [obese non-diabetic and obese type 2 diabetic (T2DM)] subjects versus lean individuals. In addition, we employed a primary human skeletal muscle cell culture system to investigate the effect of LPS on glucose metabolism and whether these effects are mediated via TLR4. Obese non-diabetic and T2DM subjects had significantly elevated plasma LPS and LPS binding protein (LBP) concentrations. Plasma LPS (r = -0.46, P = 0.005) and LBP (r = -0.49, P = 0.005) concentrations negatively correlated with muscle insulin sensitivity (M). In human myotubes, LPS increased JNK phosphorylation and MCP-1 and IL-6 gene expression. This inflammatory response led to reduced insulin-stimulated IRS-1, Akt and AS160 phosphorylation and impaired glucose transport. Both pharmacologic blockade of TLR4 with TAK-242, and TLR4 gene silencing, suppressed the inflammatory response and insulin resistance caused by LPS in human muscle cells. Taken together, these findings suggest that elevations in plasma LPS concentration found in obese and T2DM subjects could play a role in the pathogenesis of insulin resistance and that antagonists of TLR4 may improve insulin action in these individuals.
C1 [Liang, Hanyu; Hussey, Sophie E.; Sanchez-Avila, Alicia; Tantiwong, Puntip; Musi, Nicolas] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
[Liang, Hanyu; Hussey, Sophie E.; Tantiwong, Puntip; Musi, Nicolas] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Audie L Murphy Div, San Antonio, TX USA.
[Liang, Hanyu; Hussey, Sophie E.; Tantiwong, Puntip; Musi, Nicolas] Texas Diabet Inst, San Antonio, TX USA.
RP Musi, N (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Diabet Div, San Antonio, TX 78229 USA.
EM musi@uthscsa.edu
FU National Institutes of Health [RO1-DK80157, RO1- DK089229, TR000149,
1F32DK095565-01A1]; American Diabetes Association
FX This work was supported by grants from the National Institutes of Health
(RO1-DK80157 and RO1- DK089229 to N.M., TR000149 to UTHSCSA, and
1F32DK095565-01A1 to S.H.) and the American Diabetes Association. The
funders had no role in study design, data collection and analysis,
decision to publish, or preparation of the manuscript.
NR 39
TC 26
Z9 27
U1 2
U2 19
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63983
DI 10.1371/journal.pone.0063983
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200098
PM 23704966
ER
PT J
AU Mu, XX
Lin, S
Yang, JH
Chen, C
Chen, Y
Herzig, MC
Washburn, K
Halff, GA
Walter, CA
Sun, BC
Sun, LZ
AF Mu, Xiaoxin
Lin, Shu
Yang, Junhua
Chen, Chen
Chen, Yun
Herzig, Maryanne C.
Washburn, Kenneth
Halff, Glenn A.
Walter, Christi A.
Sun, Beicheng
Sun, Lu-Zhe
TI TGF-beta Signaling Is Often Attenuated during Hepatotumorigenesis, but
Is Retained for the Malignancy of Hepatocellular Carcinoma Cells
SO PLOS ONE
LA English
DT Article
ID GROWTH-FACTOR-BETA; PLASMA TRANSFORMING GROWTH-FACTOR-BETA-1;
RECEPTOR-TYPE-II; TUMOR-SUPPRESSOR; HUMAN CANCER; EXPRESSION; LIVER;
INHIBITOR; SURVIVAL; PROTEIN
AB The role of transforming growth factor-beta (TGF-beta) signaling in hepatocarcinogenesis remains controversial. We aimed to reveal TGF-beta signaling status in human and murine tissues of hepatocellular carcinoma (HCC) and the mechanisms that mediate TGF-beta's role in regulating HCC malignancy. Here, TGF-beta pathway component expression and activation in human and murine HCC tissues were measured with quantitative RT-PCR and Western blotting assays. The role of TGF-beta receptor and Smad signaling in the growth and survival of several HCC cell lines was determined with several in vitro and in vivo approaches. We found that TGF-beta receptor II (T beta RII) expression was downregulated in two different HCC patient cohorts. Consistently, Smad3 phosphorylation was also downregulated in HCC tissues in comparison to that in adjacent normal tissues. Interestingly, many HCC cell lines were sensitive to TGF-beta and growth-inhibited by exogenous TGF-beta. However, stable knockdown of T beta RII inhibited cell growth on plastic and in soft agar, and induced apoptosis resulting in suppressed subcutaneous tumor growth and metastatic potential in vivo. Furthermore, knockdown of Smad4 also led to a significant inhibition of growth on plastic and in soft agar with concomitant increase of apoptosis, PTEN expression, and reduced nuclear accumulation of linker region-phosphorylated Smad3. Taken together, TGF-beta signaling pathway plays a dichotomous role in hepatocellular carcinogenesis. It appears to suppress HCC development, but is retained for HCC cell survival and malignancy. Furthermore, Smad4 can mediate both growth inhibitory activity induced by exogenous TGF-beta and the survival activity induced by autocrine TGF-beta revealing a delicate selection of the two opposing activities of TGF-beta during HCC evolution.
C1 [Mu, Xiaoxin; Chen, Chen; Chen, Yun; Sun, Beicheng] Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.
[Mu, Xiaoxin; Lin, Shu; Yang, Junhua; Herzig, Maryanne C.; Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Washburn, Kenneth; Halff, Glenn A.] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.; Sun, Lu-Zhe] Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Canc Ctr, San Antonio, TX 78229 USA.
[Walter, Christi A.] Audie Murphy Hosp, South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Sun, BC (reprint author), Nanjing Med Univ, Affiliated Hosp 1, Liver Transplantat Ctr, Nanjing, Jiangsu, Peoples R China.
EM sunbc@njmu.edu.cn; sunl@uthscsa.edu
RI Lin, Shu/C-3790-2013; Washburn, William/Q-5677-2016
FU NIH [R01CA75253, R01CA79683]; Cancer Therapy and Research Center at the
University of Texas Health Science Center at San Antonio (UTHSCSA)
through the NCI Cancer Center Support Grant [2 P30 CA054174-17];
National Science Foundation for Distinguished Young Scholars of China
Grant [81225017]
FX This work was supported in part by NIH Grants R01CA75253 and R01CA79683,
the Cancer Therapy and Research Center at the University of Texas Health
Science Center at San Antonio (UTHSCSA) through the NCI Cancer Center
Support Grant 2 P30 CA054174-17, and the National Science Foundation for
Distinguished Young Scholars of China Grant No.81225017. The funders had
no role in study design, data collection and analysis, decision to
publish, or preparation of the manuscript.
NR 43
TC 14
Z9 15
U1 0
U2 11
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63436
DI 10.1371/journal.pone.0063436
PG 12
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200038
PM 23704908
ER
PT J
AU Wadia, PR
Cabaton, NJ
Borrero, MD
Rubin, BS
Sonnenschein, C
Shioda, T
Soto, AM
AF Wadia, Perinaaz R.
Cabaton, Nicolas J.
Borrero, Michael D.
Rubin, Beverly S.
Sonnenschein, Carlos
Shioda, Toshi
Soto, Ana M.
TI Low-Dose BPA Exposure Alters the Mesenchymal and Epithelial
Transcriptomes of the Mouse Fetal Mammary Gland
SO PLOS ONE
LA English
DT Article
ID XENOESTROGEN BISPHENOL-A; ESTROGEN-RECEPTORS ALPHA; ENVIRONMENTAL
ESTROGENS; ENDOCRINE DISRUPTION; PERINATAL EXPOSURE; FOCAL ADHESIONS;
BREAST-CANCER; IN-VITRO; EXPRESSION; CELLS
AB Exposure of rodent fetuses to low doses of the endocrine disruptor bisphenol A (BPA) causes subtle morphological changes in the prenatal mammary gland and results in pre-cancerous and cancerous lesions during adulthood. To examine whether the BPA-induced morphological alterations of the fetal mouse mammary glands are a) associated with changes in mRNA expression reflecting estrogenic actions and/or b) dependent on the estrogen receptor alpha (ER alpha), we compared the transcriptomal effects of BPA and the steroidal estrogen ethinylestradiol (EE2) on fetal mammary tissues of wild type and ER alpha knock-out mice. Mammary glands from fetuses of dams exposed to vehicle, 250 ng BPA/kg BW/d or 10 ng EE2/kg BW/d from embryonic day (E) 8 were harvested at E19. Transcriptomal analyses on the ductal epithelium and periductal stroma revealed altered expression of genes involved in the focal adhesion and adipogenesis pathways in the BPA-exposed stroma while genes regulating the apoptosis pathway changed their expression in the BPA-exposed epithelium. These changes in gene expression correlated with previously reported histological changes in matrix organization, adipogenesis, and lumen formation resulting in enhanced maturation of the fat-pad and delayed lumen formation in the epithelium of BPA-exposed fetal mammary glands. Overall similarities in the transcriptomal effects of BPA and EE2 were more pronounced in the epithelium, than in the stroma. In addition, the effects of BPA and EE2 on the expression of various genes involved in mammary stromal-epithelial interactions were suppressed in the absence of ER alpha. These observations support a model whereby BPA and EE2 act directly on the stroma, which expresses ER alpha, ER beta and GPR30 in fetal mammary glands, and that the stroma, in turn, affects gene expression in the epithelium, where ER alpha and ER beta are below the level of detection at this stage of development.
C1 [Wadia, Perinaaz R.; Cabaton, Nicolas J.; Borrero, Michael D.; Rubin, Beverly S.; Sonnenschein, Carlos; Soto, Ana M.] Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
[Shioda, Toshi] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
RP Soto, AM (reprint author), Tufts Univ, Sch Med, Dept Anat & Cellular Biol, Boston, MA 02111 USA.
EM ana.soto@tufts.edu
FU National Institute of Environmental Health Sciences [ES08314];
[FAS0703860]; [KG090515]
FX This work was supported by the National Institute of Environmental
Health Sciences grant ES08314 and its Supplement to Dr. Ana M. Soto and
by the Susan G. Komen for the Cure grants FAS0703860 and KG090515 to Dr.
Toshi Shioda. The funders had no role in study design, data collection
and analysis, decision to publish or preparation of the manuscript.
NR 50
TC 22
Z9 22
U1 1
U2 13
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 21
PY 2013
VL 8
IS 5
AR e63902
DI 10.1371/journal.pone.0063902
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 149OK
UT WOS:000319330200083
PM 23704952
ER
PT J
AU Johnson, EM
Traver, KL
Hoffman, SW
Harrison, CR
Herman, JP
AF Johnson, Erica M.
Traver, Kyle L.
Hoffman, Stuart W.
Harrison, Catherine R.
Herman, James P.
TI Environmental enrichment protects against functional deficits caused by
traumatic brain injury
SO FRONTIERS IN BEHAVIORAL NEUROSCIENCE
LA English
DT Article
DE environmental enrichment; traumatic brain injury; morris water maze;
controlled cortical impact; sensory neglect
ID EARLY-ONSET STIMULATION; ADULT-RAT; COGNITIVE FUNCTION; PREFRONTAL
CORTEX; DENTATE GYRUS; RECOVERY; MICE; EXPRESSION; PLASTICITY; INCREASES
AB Environmental enrichment (EE) increases cortical weight, neuronal density, dendritic branching, and angiogenesis, all of which may be critical for functional recovery following insult. Our study was designed to determine possible benefits of pre-exposure to EE in preventing functional deficits following traumatic brain injury (TBI) to the prefrontal cortex. To examine the benefit of EE, adult male rats were placed in an enriched environment for 15 days. Enrichment was provided through social interaction, exercise, olfactory stimulation, and new objects/toys to explore. Following enrichment, experimental and age-matched controls were subjected to a moderate medial prefrontal cortex injury via controlled cortical impact (CCI). After 1 week recovery, animals were behaviorally tested to assess memory, anxiety, and sensory neglect. Lesion-induced deficits in spatial memory [Morris water maze (MWM)] were significantly attenuated in EE pre-exposed rats 18-21 days following injury. In addition, TBI-induced sensory neglect was significantly reduced in EE rats relative to non-enriched animals. No differences in anxiety-like behavior on the elevated plus maze (EPM) were detected. The behavioral data suggest that EE is neuroprotective when applied prior to TBI, resulting in improved recovery following injury.
C1 [Johnson, Erica M.; Herman, James P.] Univ Cincinnati, Dept Psychiat & Behav Neurosci, Cincinnati, OH USA.
[Johnson, Erica M.; Traver, Kyle L.] USAF, Res Lab, Wright Patterson AFB, OH 45433 USA.
[Hoffman, Stuart W.] US Dept Vet Affairs, Off Res & Dev, Washington, DC USA.
[Harrison, Catherine R.] FAA, Washington, DC USA.
RP Johnson, EM (reprint author), USAF, Res Lab, 711th Human Performance Wing,2510 5th St, Wright Patterson AFB, OH 45433 USA.
EM erica.johnson.7@us.af.mil
RI Herman, James/D-4960-2015
OI Herman, James/0000-0003-3571-2406
FU Air Force Research Laboratory, Wright Patterson Air Force Base; Defense
and Veterans Brain Injury Center
FX This research was sponsored by the Air Force Research Laboratory, Wright
Patterson Air Force Base, and was funded in part by the Defense and
Veterans Brain Injury Center. The authors wish to thank Mr. Chuck
Goodyear for his invaluable assistance with statistical analysis, the
animal research support team for their excellent assistance with
enrichment housing and behavioral testing and the University of
Cincinnati Neuroscience graduate program for their generous support.
NR 51
TC 20
Z9 21
U1 4
U2 19
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5153
J9 FRONT BEHAV NEUROSCI
JI Front. Behav. Neurosci.
PD MAY 21
PY 2013
VL 7
AR 44
DI 10.3389/fnbeh.2013.00044
PG 7
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA 148NV
UT WOS:000319252700001
PM 23734108
ER
PT J
AU Das, J
Vo, TV
Wei, XM
Mellor, JC
Tong, V
Degatano, AG
Wang, XJ
Wang, LH
Cordero, NA
Kruer-Zerhusen, N
Matsuyama, A
Pleiss, JA
Lipkin, SM
Yoshida, M
Roth, FP
Yu, HY
AF Das, Jishnu
Vo, Tommy V.
Wei, Xiaomu
Mellor, Joseph C.
Tong, Virginia
Degatano, Andrew G.
Wang, Xiujuan
Wang, Lihua
Cordero, Nicolas A.
Kruer-Zerhusen, Nathan
Matsuyama, Akihisa
Pleiss, Jeffrey A.
Lipkin, Steven M.
Yoshida, Minoru
Roth, Frederick P.
Yu, Haiyuan
TI Cross-Species Protein Interactome Mapping Reveals Species-Specific
Wiring of Stress Response Pathways
SO SCIENCE SIGNALING
LA English
DT Article
ID YEAST SCHIZOSACCHAROMYCES-POMBE; FISSION YEAST;
SACCHAROMYCES-CEREVISIAE; INTERACTION NETWORK; INTERACTION DATASETS;
GLOBAL ANALYSIS; INTERACTION MAP; SEQUENCE; COEVOLUTION; PREDICTION
AB The fission yeast Schizosaccharomyces pombe has more metazoan-like features than the budding yeast Saccharomyces cerevisiae, yet it has similarly facile genetics. We present a large-scale verified binary protein-protein interactome network, "StressNet," based on high-throughput yeast two-hybrid screens of interacting proteins classified as part of stress response and signal transduction pathways in S. pombe. We performed systematic, cross-species interactome mapping using StressNet and a protein interactome network of orthologous proteins in S. cerevisiae. With cross-species comparative network studies, we detected a previously unidentified component (Snr1) of the S. pombe mitogen-activated protein kinase Sty1 pathway. Coimmunoprecipitation experiments showed that Snr1 interacted with Sty1 and that deletion of snr1 increased the sensitivity of S. pombe cells to stress. Comparison of StressNet with the interactome network of orthologous proteins in S. cerevisiae showed that most of the interactions among these stress response and signaling proteins are not conserved between species but are "rewired"; orthologous proteins have different binding partners in both species. In particular, transient interactions connecting proteins in different functional modules were more likely to be rewired than conserved. By directly testing interactions between proteins in one yeast species and their corresponding binding partners in the other yeast species with yeast two-hybrid assays, we found that about half of the interactions that are traditionally considered "conserved" form modified interaction interfaces that may potentially accommodate novel functions.
C1 [Das, Jishnu; Wang, Xiujuan; Yu, Haiyuan] Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
[Das, Jishnu; Vo, Tommy V.; Wei, Xiaomu; Tong, Virginia; Degatano, Andrew G.; Wang, Xiujuan; Wang, Lihua; Cordero, Nicolas A.; Kruer-Zerhusen, Nathan; Yu, Haiyuan] Cornell Univ, Weill Inst Cell & Mol Biol, Ithaca, NY 14853 USA.
[Vo, Tommy V.; Kruer-Zerhusen, Nathan; Pleiss, Jeffrey A.] Cornell Univ, Dept Mol Biol & Genet, Ithaca, NY 14853 USA.
[Wei, Xiaomu; Lipkin, Steven M.] Weill Cornell Coll Med, Dept Med, New York, NY 10021 USA.
[Mellor, Joseph C.; Roth, Frederick P.] Univ Toronto, Donnelly Ctr, Toronto, ON M5S 3E1, Canada.
[Matsuyama, Akihisa; Yoshida, Minoru] RIKEN Adv Sci Inst, Inst Gen Chem, Wako, Saitama 3510198, Japan.
[Matsuyama, Akihisa; Yoshida, Minoru] JST, CREST Res Project, Kawaguchi, Saitama 3320012, Japan.
[Yoshida, Minoru] Univ Tokyo, Grad Sch Agr & Life Sci, Dept Biotechnol, Bunkyo Ku, Tokyo 1138657, Japan.
[Roth, Frederick P.] Univ Toronto, Dept Mol Genet, Toronto, ON M5S 3E1, Canada.
[Roth, Frederick P.] Univ Toronto, Dept Comp Sci, Toronto, ON M5S 3E1, Canada.
[Roth, Frederick P.] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02115 USA.
[Roth, Frederick P.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Roth, Frederick P.] Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
[Roth, Frederick P.] Canadian Inst Adv Res, Genet Networks Program, Toronto, ON M5G 1Z8, Canada.
RP Yu, HY (reprint author), Cornell Univ, Dept Biol Stat & Computat Biol, Ithaca, NY 14853 USA.
EM haiyuan.yu@cornell.edu
RI Roth, Frederick/H-6308-2011; Das, Jishnu/C-6924-2015; Das,
Jayajit/E-2951-2011; Yoshida, Minoru/C-8049-2014; Matsuyama,
Akihisa/P-7805-2016;
OI Das, Jishnu/0000-0002-5747-064X; Matsuyama, Akihisa/0000-0002-6135-6276;
Roth, Frederick/0000-0002-6628-649X
FU Tata Graduate Fellowship; National Institute of General Medical Sciences
(NIGMS) [GM098634, R01 GM097358]; NIH [HG001715]; Canada Excellence
Research Chairs Program; Canadian Institute for Advanced Research
FX We thank A. Bretscher for providing budding yeast deletion strains, S.
Forsburg for providing fission yeast expression vectors, M. Smolka for
experimental advice, and A. Clark and E. Alani for critical reading of
our manuscript. Funding: J.D. was supported by the Tata Graduate
Fellowship. A.M. was supported by Grant-in-Aid for Scientific Research
(C). J.A.P. was supported by National Institute of General Medical
Sciences (NIGMS) grant GM098634. F.P.R. was supported by NIH grant
HG001715, by the Canada Excellence Research Chairs Program, and by the
Canadian Institute for Advanced Research. This work was funded by NIGMS
grant R01 GM097358 to H.Y.
NR 71
TC 11
Z9 11
U1 0
U2 20
PU AMER ASSOC ADVANCEMENT SCIENCE
PI WASHINGTON
PA 1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA
SN 1945-0877
J9 SCI SIGNAL
JI Sci. Signal.
PD MAY 21
PY 2013
VL 6
IS 276
AR ra38
DI 10.1126/scisignal.2003350
PG 13
WC Biochemistry & Molecular Biology; Cell Biology
SC Biochemistry & Molecular Biology; Cell Biology
GA 149RO
UT WOS:000319339000003
PM 23695164
ER
PT J
AU Wang, XL
Liu, MY
Sun, SM
Liu, XL
Yu, L
Wang, XR
Chu, LX
Rosenthal, B
Shi, HN
Boireau, P
Wang, F
Zhao, Y
Wu, XP
AF Wang, X. L.
Liu, M. Y.
Sun, S. M.
Liu, X. L.
Yu, L.
Wang, X. R.
Chu, L. X.
Rosenthal, B.
Shi, H. N.
Boireau, P.
Wang, F.
Zhao, Y.
Wu, X. P.
TI An anti-tumor protein produced by Trichinella spiralis induces apoptosis
in human hepatoma H7402 cells
SO VETERINARY PARASITOLOGY
LA English
DT Article; Proceedings Paper
CT 13th International Conference on Trichinellosis
CY AUG 01-06, 2011
CL Changchun, PEOPLES R CHINA
SP Int Commiss Trichinellosis, Jilin Univ, BioRad, Prionics, Paratest, Natl Nat Sci Fdn China
DE A200711; Apoptosis; Hepatocellular carcinomas; Phage display library;
Trichinella spiralis
ID PARASITES
AB Trichinella spiralis infection confers effective resistance to tumor cell expansion. In this study, a T7 phage cDNA display library was constructed to express genes encoded by T. spiralis. Organic phase multi-cell screening was used to sort through candidate proteins in a transfected human chronic myeloid leukemia cell line (K562) and a human hepatoma cell line (H7402) using the display library. The protein encoded by the A200711 gene was identified and analyzed using protein analysis software. To test the antitumor effects of A200711, variations in cell proliferation and apoptosis were monitored after recombinant pEGFP-N1-A200711 was transfected into H7402 cells. The results show that the expressed target gene successfully induced apoptosis in H7402 cells as measured by Hoechst-PI staining, MTT assay (p < 0.05). This study warrants further investigation into the therapeutic use of A200711 for anti-hepatocellular carcinomas. (C) 2013 Elsevier B.V. All rights reserved.
C1 [Wang, X. L.; Liu, M. Y.; Sun, S. M.; Liu, X. L.; Yu, L.; Wang, X. R.; Chu, L. X.; Wang, F.; Zhao, Y.; Wu, X. P.] Jilin Univ, Inst Zoonosis, Minist Educ, Key Lab Zoonosis Res, Changchun 130062, Peoples R China.
[Rosenthal, B.] USDA, Anim Parasit Dis Lab, Beltsville, MD 20705 USA.
[Shi, H. N.] Massachusetts Gen Hosp East, Pediat Gastroenterol Unit, Mucosal Immunol Lab, Charlestown, MA 02129 USA.
[Boireau, P.] ANSES, Hlth Anim Lab, Maisons Alfort, France.
RP Liu, MY (reprint author), Jilin Univ, Inst Zoonosis, Minist Educ, Key Lab Zoonosis Res, Changchun 130062, Peoples R China.
EM liumy@jlu.edu.cn; zhaoyingsohu@sohu.com; xpwu@jlu.edu.cn
OI Rosenthal, Benjamin/0000-0002-0224-3773
FU MOST [2011AA10A215]; NSFC [30825033, 31030064, 30972177, 30950110328,
81070311, 31072124]; CPSF [2011M500366]; NIH/NIDDK [R01 DK082427]
FX This study was supported by MOST 2011AA10A215; NSFC 30825033, 31030064,
30972177, 30950110328, 81070311, 31072124; CPSF 2011M500366 and
NIH/NIDDK R01 DK082427.
NR 9
TC 2
Z9 5
U1 0
U2 5
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0304-4017
EI 1873-2550
J9 VET PARASITOL
JI Vet. Parasitol.
PD MAY 20
PY 2013
VL 194
IS 2-4
SI SI
BP 186
EP 188
DI 10.1016/j.vetpar.2013.01.052
PG 3
WC Parasitology; Veterinary Sciences
SC Parasitology; Veterinary Sciences
GA 168CX
UT WOS:000320684400024
PM 23433602
ER
PT J
AU Kahn, I
Knoblich, U
Desai, M
Bernstein, J
Graybiel, AM
Boyden, ES
Buckner, RL
Moore, CI
AF Kahn, I.
Knoblich, U.
Desai, M.
Bernstein, J.
Graybiel, A. M.
Boyden, E. S.
Buckner, R. L.
Moore, C. I.
TI Optogenetic drive of neocortical pyramidal neurons generates fMRI
signals that are correlated with spiking activity
SO BRAIN RESEARCH
LA English
DT Article
DE fMRI; Hemodynamic response function; Somatosensory cortex; Barrel
cortex; Multi-unit activity; Cell-attached recording; Local field
potential
ID OPTICAL CONTROL; VISUAL-CORTEX; MILLISECOND-TIMESCALE; HEMODYNAMIC
SIGNALS; ASTROCYTE CONTROL; CORTICAL-NEURONS; NEURAL CIRCUITRY;
TRANSGENIC MICE; IN-VIVO; TELL US
AB Local fluctuations in the blood oxygenation level-dependent (BOLD) signal serve as the basis of functional magnetic resonance imaging (fMRI). Understanding the correlation between distinct aspects of neural activity and the BOLD response is fundamental to the interpretation of this widely used mapping signal. Analysis of this question requires the ability to precisely manipulate the activity of defined neurons. To achieve such control, we combined optogenetic drive of neocortical neurons with high-resolution (9.4 T) rodent fMRI and detailed analysis of neurophysiological data. Light-driven activation of pyramidal neurons resulted in a positive BOLD response at the stimulated site. To help differentiate the neurophysiological correlate(s) of the BOLD response, we employed light trains of the same average frequency, but with periodic and Poisson distributed pulse times. These different types of pulse trains generated dissociable patterns of single-unit, multi-unit and local field potential (LFP) activity, and of BOLD signals. The BOLD activity exhibited the strongest correlation to spiking activity with increasing rates of stimulation, and, to a first approximation, was linear with pulse delivery rate, while LFP activity showed a weaker correlation. These data provide an example of a strong correlation between spike rate and the BOLD response. This article is part of a Special Issue entitled Optogenetics (7th BRES) (C) 2013 Elsevier B.V. All rights reserved.
C1 [Kahn, I.; Buckner, R. L.] Harvard Univ, Ctr Brain Sci, Cambridge, MA 02138 USA.
[Kahn, I.; Buckner, R. L.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA USA.
[Knoblich, U.; Desai, M.; Bernstein, J.; Graybiel, A. M.; Boyden, E. S.; Moore, C. I.] MIT, McGovern Inst Brain Res, Cambridge, MA 02139 USA.
[Knoblich, U.; Desai, M.; Bernstein, J.; Graybiel, A. M.; Boyden, E. S.; Moore, C. I.] MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA.
[Bernstein, J.; Boyden, E. S.] MIT, Media Lab, Synthet Neurobiol Grp, Cambridge, MA 02139 USA.
[Buckner, R. L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Buckner, R. L.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
RP Kahn, I (reprint author), Technion Israel Inst Technol, Rappaport Fac Med, Dept Physiol & Biophys, IL-32000 Haifa, Israel.
EM kahn@technion.ac.il
RI Knoblich, Ulf/A-1762-2010
OI Knoblich, Ulf/0000-0002-0756-5587
FU National Science Foundation; National Institutes of Health; Howard
Hughes Medical Institute; McGovern Institute for Brain Research
FX This work was supported by the National Science Foundation, National
Institutes of Health, the Howard Hughes Medical Institute, and the
McGovern Institute for Brain Research.
NR 58
TC 24
Z9 25
U1 1
U2 14
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0006-8993
J9 BRAIN RES
JI Brain Res.
PD MAY 20
PY 2013
VL 1511
SI SI
BP 33
EP 45
DI 10.1016/j.brainres.2013.03.011
PG 13
WC Neurosciences
SC Neurosciences & Neurology
GA 159ZY
UT WOS:000320087000004
PM 23523914
ER
PT J
AU Hoffecker, BM
Raffield, LM
Kamen, DL
Nowling, TK
AF Hoffecker, Brett M.
Raffield, Laura M.
Kamen, Diane L.
Nowling, Tamara K.
TI Systemic Lupus Erythematosus and Vitamin D Deficiency Are Associated
with Shorter Telomere Length among African Americans: A Case-Control
Study
SO PLOS ONE
LA English
DT Article
ID DISEASE-ACTIVITY; IMMUNE-SYSTEM; REVISED CRITERIA; CELLS;
MANIFESTATIONS; CLASSIFICATION; AUTOIMMUNITY; POPULATION; PREVALENCE;
ANTIBODIES
AB Systemic lupus erythematosus (SLE) is a chronic systemic autoimmune disease that disproportionately affects African American females. The causes of SLE are unknown but postulated to be a combination of genetic predisposition and environmental triggers. Vitamin D deficiency is one of the possible environmental triggers. In this study we evaluated relationships between vitamin D status, cellular aging (telomere length) and anti-telomere antibodies among African American Gullah women with SLE. The study population included African American female SLE patients and unaffected controls from the Sea Island region of South Carolina. Serum 25-hydroxyvitamin D levels were measured using a nonchromatographic radioimmunoassay. Telomere length was measured in genomic DNA of peripheral blood mononuclear cells (PBMCs) by monochrome multiplex quantitative PCR. Anti-telomere antibody levels were measured by enzyme-linked immunosorbent assay (ELISA). Patients with SLE had significantly shorter telomeres and higher anti-telomere antibody titers compared to age-and gender-matched unaffected controls. There was a positive correlation between anti-telomere antibody levels and disease activity among patients and a significant correlation of shorter telomeres with lower 25-hydroxyvitamin D levels in both patients and controls. In follow-up examination of a subset of the patients, the patients who remained vitamin D deficient tended to have shorter telomeres than those patients whose 25-hydroxyvitamin D levels were repleted. Increasing 25-hydroxyvitamin D levels in African American patients with SLE may be beneficial in maintaining telomere length and preventing cellular aging. Moreover, anti-telomere antibody levels may be a promising biomarker of SLE status and disease activity.
C1 [Hoffecker, Brett M.; Raffield, Laura M.; Kamen, Diane L.; Nowling, Tamara K.] Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
[Nowling, Tamara K.] Ralph H Johnson Vet Affairs Med Ctr, Med Res Serv, Charleston, SC USA.
RP Kamen, DL (reprint author), Med Univ S Carolina, Dept Med, Charleston, SC 29425 USA.
EM kamend@musc.edu; nowling@musc.edu
FU Medical Research Service, Veterans Affairs Medical Center [BX000115];
National Institutes of Health (NIH) [AR053376, K23 AR052364]; South
Carolina Clinical & Translational Research (SCTR) Institute; Medical
University of South Carolina, (NIH/NCRR) [UL1 RR029882]; NIAMS [P60
AR062755]
FX This work was supported by VA Merit Review grant BX000115 from the
Medical Research Service, Veterans Affairs Medical Center and National
Institutes of Health (NIH) grant AR053376 awarded to TKN, NIH grant K23
AR052364 awarded to DLK and by the South Carolina Clinical &
Translational Research (SCTR) Institute, with an academic home at the
Medical University of South Carolina, (NIH/NCRR UL1 RR029882), and NIAMS
grant P60 AR062755 (DLK). The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 41
TC 8
Z9 9
U1 1
U2 4
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2013
VL 8
IS 6
AR UNSP e63725
DI 10.1371/journal.pone.0063725
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 158JQ
UT WOS:000319966400028
PM 23700431
ER
PT J
AU Tan, CS
Broge, TA
Seung, E
Vrbanac, V
Viscidi, R
Gordon, J
Tager, AM
Koralnik, IJ
AF Tan, Chen Sabrina
Broge, Thomas A., Jr.
Seung, Edward
Vrbanac, Vlad
Viscidi, Raphael
Gordon, Jennifer
Tager, Andrew M.
Koralnik, Igor J.
TI Detection of JC Virus-Specific Immune Responses in a Novel Humanized
Mouse Model
SO PLOS ONE
LA English
DT Article
ID PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; CYTOTOXIC T-LYMPHOCYTES;
DNA; MICE; PML; BK; INDIVIDUALS; REPLICATION; ASSOCIATION; EXPRESSION
AB Progressive Multifocal Leukoencephalopathy (PML) is an often fatal disease caused by the reactivation of the JC virus (JCV). Better understanding of viral-host interactions has been hampered by the lack of an animal model. Engrafting NOD/SCID/IL-2-Rg (null) mice with human lymphocytes and thymus, we generated a novel animal model for JCV infection. Mice were inoculated with either a PML isolate, JCV Mad-4, or with JCV CY, found in the kidney and urine of healthy individuals. While mice remained asymptomatic following inoculation, JCV DNA was occasionally detected in both the blood and the urine compartments. Mice generated both humoral and cellular immune responses against JCV. Expressions of immune exhaustion marker, PD-1, on lymphocytes were consistent with response to infection. Using this model we present the first in vivo demonstration of virological and immunological differences between JCV Mad-4 and CY. This model may prove valuable for studying JCV host immune responses.
C1 [Tan, Chen Sabrina] Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
[Tan, Chen Sabrina; Broge, Thomas A., Jr.; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Dept Med, Ctr Virol & Vaccine Res, Boston, MA 02215 USA.
[Tan, Chen Sabrina; Broge, Thomas A., Jr.; Koralnik, Igor J.] Beth Israel Deaconess Med Ctr, Dept Neurol, Div NeuroVirol, Boston, MA 02215 USA.
[Seung, Edward; Vrbanac, Vlad; Tager, Andrew M.] Massachusetts Gen Hosp, Ctr Immunol & Inflammatory Dis, Div Rheumatol Allergy & Immunol, Charlestown, MA USA.
[Viscidi, Raphael] Johns Hopkins Med Ctr, Baltimore, MD USA.
[Gordon, Jennifer] Temple Univ, Dept Neurosci, Ctr Neurovirol, Sch Med, Philadelphia, PA 19122 USA.
[Gordon, Jennifer] Harvard Univ, Sch Med, Boston, MA USA.
RP Tan, CS (reprint author), Beth Israel Deaconess Med Ctr, Div Infect Dis, Boston, MA 02215 USA.
EM ctan@bidmc.harvard.edu
FU National Institutes of Health (NIH) [R01 NS 047029, NS 074995, NS R56
041198, K24 NS 060950]; Harvard University Center for AIDS Research
(CFAR); NIH [P30 AI60354, K08 NS 064215-01]
FX This work was conducted with support from National Institutes of Health
(NIH) grants R01 NS 047029, NS 074995, NS R56 041198, and K24 NS 060950
to IJK; grants to CST and AMT from Harvard University Center for AIDS
Research (CFAR); an NIH-funded program (P30 AI60354), and NIH grant K08
NS 064215-01 to CST. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 27
TC 16
Z9 16
U1 0
U2 2
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1932-6203
J9 PLOS ONE
JI PLoS One
PD MAY 20
PY 2013
VL 8
IS 6
AR e64313
DI 10.1371/journal.pone.0064313
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA 158JQ
UT WOS:000319966400053
PM 23700470
ER
PT J
AU Fischer, MJ
Ho, PM
McDermott, K
Lowy, E
Parikh, CR
AF Fischer, Michael J.
Ho, P. Michael
McDermott, Kelly
Lowy, Elliott
Parikh, Chirag R.
TI Chronic kidney disease is associated with adverse outcomes among elderly
patients taking clopidogrel after hospitalization for acute coronary
syndrome
SO BMC NEPHROLOGY
LA English
DT Article
DE Kidney disease; Myocardial infarction; Hospitalization; Bleeding
ID ACUTE MYOCARDIAL-INFARCTION; CHRONIC RENAL-INSUFFICIENCY; ST-SEGMENT
ELEVATION; ANTIPLATELET THERAPY; STENT IMPLANTATION; PLATELET-FUNCTION;
ELUTING STENTS; MEDICATION USE; BLEEDING-TIME; SHORT-TERM
AB Background: Chronic kidney disease (CKD) is associated with worse outcomes among patients with acute coronary syndrome (ACS). Less is known about the impact of CKD on longitudinal outcomes among clopidogrel treated patients following ACS.
Methods: Using a retrospective cohort design, we identified patients hospitalized with ACS between 10/1/2005 and 1/10/10 at Department of Veterans Affairs (VA) facilities and who were discharged on clopidogrel. Using outpatient serum creatinine values, estimated glomerular filtration rate [eGFR (1.73 ml/min/m(2))] was calculated using the CKD-EPI equation. The association between eGFR and mortality, hospitalization for acute myocardial infarction (AMI), and major bleeding were examined using Cox proportional hazards models.
Results: Among 7413 patients hospitalized with ACS and discharged taking clopidogrel, 34.5% had eGFR 30-60 and 11.6% had eGFR < 30. During 1-year follow-up after hospital discharge, 10% of the cohort died, 18% were hospitalized for AMI, and 4% had a major bleeding event. Compared to those with eGFR > = 60, individuals with eGFR 30-60 (HR 1.45; 95% CI: 1.18-1.76) and < 30 (HR 2.48; 95% CI: 1.97-3.13) had a significantly higher risk of death. A progressive increased risk of AMI hospitalization was associated with declining eGFR: HR 1.20; 95% CI: 1.04-1.37 for eGFR 30-60 and HR 1.47; 95% CI: 1.22-1.78 for eGFR < 30. eGFR < 30 was independently associated with over a 2-fold increased risk in major bleeding (HR 2.09; 95% CI: 1.40-3.12) compared with eGFR > = 60.
Conclusion: Lower levels of kidney function were associated with higher rates of death, AMI hospitalization, and major bleeding among patients taking clopidogrel after hospitalization for ACS.
C1 [Fischer, Michael J.] Jesse Brown VAMC Univ Illinois Med Ctr, Chicago, IL USA.
[Fischer, Michael J.] Edward Hines Jr VA Hosp, Ctr Management Complex Chron Care, Hines, IL 60141 USA.
[Ho, P. Michael] Denver VA Med Ctr, Denver, CO USA.
[McDermott, Kelly] Univ Calif San Francisco, Osher Ctr Integrat Med, San Francisco, CA 94143 USA.
[Lowy, Elliott] Univ Washington, VA Puget Sound Healthcare System, Seattle, WA 98195 USA.
[Parikh, Chirag R.] Yale Univ, Clin Epidemiol Res Ctr, West Haven VA, New Haven, CT USA.
[Parikh, Chirag R.] Yale Univ, Dept Med, Program Appl Translat Res, New Haven, CT 06520 USA.
RP Fischer, MJ (reprint author), Jesse Brown VAMC Univ Illinois Med Ctr, Chicago, IL USA.
EM fischerm@uic.edu
FU Ischemic Heart Disease (IHD) Quality Enhancement Research Initiative
(QUERI); Department of Veterans Affairs; Office of Research and
Development; Health Services Research and Development Service (HSRD);
Career Development Award; National Institutes of Health (NIH), National
Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
[K24DK090203]
FX Funding support was provided by the Ischemic Heart Disease (IHD) Quality
Enhancement Research Initiative (QUERI). The authors also received
support from the Department of Veterans Affairs, Office of Research and
Development, Health Services Research and Development Service (HSR&D),
Career Development Award (MJF, PMH), and the National Institutes of
Health (NIH), National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK), K24DK090203 (CRP). The views expressed in this article
are those of the authors and do not necessarily represent the views of
the Department of Veterans Affairs or Health Services Research and
Development Service.
NR 50
TC 7
Z9 8
U1 2
U2 8
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1471-2369
J9 BMC NEPHROL
JI BMC Nephrol.
PD MAY 20
PY 2013
VL 14
AR 107
DI 10.1186/1471-2369-14-107
PG 8
WC Urology & Nephrology
SC Urology & Nephrology
GA 154IA
UT WOS:000319666400001
PM 23688069
ER
PT J
AU Porter, JB
Wood, J
Olivieri, N
Vichinsky, EP
Taher, A
Neufeld, E
Giardina, P
Thompson, A
Moore, B
Evans, P
Kim, HY
Macklin, EA
Trachtenberg, F
AF Porter, John B.
Wood, John
Olivieri, Nancy
Vichinsky, Elliott P.
Taher, Ali
Neufeld, Ellis
Giardina, Patricia
Thompson, Alexis
Moore, Blaine
Evans, Patricia
Kim, Hae-Young
Macklin, Eric A.
Trachtenberg, Felicia
TI Treatment of heart failure in adults with thalassemia major: response in
patients randomised to deferoxamine with or without deferiprone
SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE
LA English
DT Article
DE Thalassemia; Heart failure; Deferoxamine; Deferiprone; Combination
ID BETA-THALASSEMIA; CHELATION-THERAPY; MYOCARDIAL IRON;
MAGNETIC-RESONANCE; RENAL-FUNCTION; DEFERASIROX; SIDEROSIS; TRIAL
AB Background: Established heart failure in thalassaemia major has a poor prognosis and optimal management remains unclear.
Methods: A 1 year prospective study comparing deferoxamine (DFO) monotherapy or when combined with deferiprone (DFP) for patients with left ventricular ejection fraction (LVEF) <56% was conducted by the Thalassemia Clinical Research Network (TCRN). All patients received DFO at 50-60 mg/kg 12-24 hr/day sc or iv 7 times weekly, combined with either DFP 75 at mg/kg/day (combination arm) or placebo (DFO monotherapy arm). The primary endpoint was the change in LVEF by CMR.
Results: Improvement in LVEF was significant in both study arms at 6 and 12 months (p = 0.04), normalizing ventricular function in 9/16 evaluable patients. With combination therapy, the LVEF increased from 49.9% to 55.2% (+5.3% p = 0.04; n = 10) at 6 months and to 58.3% at 12 months (+8.4% p = 0.04; n = 7). With DFO monotherapy, the LVEF increased from 52.8% to 55.7% (+2.9% p = 0.04; n = 6) at 6 months and to 56.9% at 12 months (+4.1% p = 0.04; n = 4). The LVEF trend did not reach statistical difference between study arms (p = 0.89). In 2 patients on DFO monotherapy during the study and in 1 patient on combined therapy during follow up, heart failure deteriorated fatally. The study was originally powered for 86 participants to determine a 5% difference in LVEF improvement between treatments. The study was prematurely terminated due to slow recruitment and with the achieved sample size of 20 patients there was 80% power to detect an 8.6% difference in EF, which was not demonstrated. Myocardial T2* improved in both arms (combination +1.9 +/- 1.6 ms p = 0.04; and DFO monotherapy +1.9 +/- 1.4 ms p = 0.04), but with no significant difference between treatments (p = 0.65). Liver iron (p = 0.03) and ferritin (p < 0.001) both decreased significantly in only the combination group.
Conclusions: Both treatments significantly improved LVEF and myocardial T2*. Although this is the largest and only randomized study in patients with LV decompensation, further prospective evaluation is needed to identify optimal chelation management in these high-risk patients.
C1 [Porter, John B.; Evans, Patricia] UCL, London, England.
[Wood, John] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Olivieri, Nancy] Univ Hlth Network, Toronto Gen Hosp, Toronto, ON, Canada.
[Vichinsky, Elliott P.] Childrens Hosp & Res Ctr Oakland, Oakland, CA USA.
[Taher, Ali] Amer Univ Beirut, Beirut, Lebanon.
[Neufeld, Ellis] Childrens Hosp, Boston, MA 02115 USA.
[Giardina, Patricia] Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
[Thompson, Alexis] Childrens Mem Hosp, Chicago, IL 60614 USA.
[Moore, Blaine] NHLBI, Bethesda, MD 20892 USA.
[Kim, Hae-Young; Trachtenberg, Felicia] New England Res Inst, Watertown, MA 02172 USA.
[Macklin, Eric A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Porter, John B.] UCL, UCL Canc Inst, Dept Haematol, London WC1E 6BT, England.
RP Porter, JB (reprint author), UCL, London, England.
EM j.porter@ucl.ac.uk
OI Porter, John/0000-0003-3000-9359; Macklin, Eric/0000-0003-1618-3502
FU NIH-NHLBI [U01 HL065238, U01-HL65232, NIH/NCRR UL1-RR-024134,
U01-HL72291]; Harvard Catalyst CTSC [UL1-RR-025758, U01-HL65233,
U01-HL65239, U01-HL65244, CTSC UL1-RR024996, U01-HL65238]
FX This work was supported by the following NIH-NHLBI cooperative
agreements: U01 HL065238; U01-HL65232 and NIH/NCRR UL1-RR-024134 to the
Children's Hospital of Philadelphia; U01-HL72291 and by Harvard Catalyst
CTSC UL1-RR-025758 to Children's Hospital, Boston; U01-HL65233 to
University Health Network Toronto General Hospital; U01-HL65239 to
Children's Hospital & Research Center Oakland; U01-HL65244 and CTSC
UL1-RR024996 to Weill Medical College of Cornell University; and
U01-HL65238 to New England Research Institutes.
NR 21
TC 16
Z9 16
U1 4
U2 7
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1097-6647
J9 J CARDIOVASC MAGN R
JI J. Cardiov. Magn. Reson.
PD MAY 20
PY 2013
VL 15
AR 38
DI 10.1186/1532-429X-15-38
PG 10
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA 155IB
UT WOS:000319740100001
PM 23688265
ER
PT J
AU Garraway, LA
Verweij, J
Ballman, KV
AF Garraway, Levi A.
Verweij, Jaap
Ballman, Karla V.
TI Precision Oncology: An Overview
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Editorial Material
C1 [Garraway, Levi A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Garraway, Levi A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Garraway, Levi A.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
[Verweij, Jaap] Erasmus Univ, Med Ctr, Daniel den Hoed Canc Ctr, Rotterdam, Netherlands.
[Ballman, Karla V.] Mayo Clin, Rochester, MN USA.
RP Garraway, LA (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 14
TC 83
Z9 84
U1 1
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 1803
EP 1805
DI 10.1200/JCO.2013.49.4799
PG 3
WC Oncology
SC Oncology
GA 148OP
UT WOS:000319255100001
PM 23589545
ER
PT J
AU Garraway, LA
AF Garraway, Levi A.
TI Genomics-Driven Oncology: Framework for an Emerging Paradigm
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; ACUTE MYELOBLASTIC-LEUKEMIA; SQUAMOUS-CELL
CARCINOMA; CLINICAL TUMOR SAMPLES; ACUTE MYELOID-LEUKEMIA; SOMATIC
MUTATIONS; BREAST-CANCER; LUNG-CANCER; INHIBITOR 3-DEAZANEPLANOCIN;
CHROMOSOMAL-ABNORMALITIES
AB A majority of cancers are driven by genomic alterations that dysregulate key oncogenic pathways influencing cell growth and survival. However, the ability to harness tumor genetic information for its full clinical potential has only recently become manifest. Over the past several years, the convergence of discovery, technology, and therapeutic development has created an unparalleled opportunity to test the hypothesis that systematic knowledge of genomic information from individual tumors can improve clinical outcomes for many patients with cancer. Rigorous evaluation of this genomics-driven cancer medicine hypothesis will require many logistic innovations that are guided by overarching conceptual advances in tumor genomic profiling, data interpretation, clinical trial design, and the ethical return of genetic results to oncologists and their patients. The results of these efforts and the rigor with which they are implemented will determine whether and how comprehensive tumor genomic information may become incorporated into the routine care of patients with cancer.
C1 [Garraway, Levi A.] Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
[Garraway, Levi A.] Broad Inst Harvard & Massachusetts Inst Technol, Cambridge, MA USA.
RP Garraway, LA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM levi_garraway@dfci.harvard.edu
FU Novartis
FX Research Funding: Levi A. Garraway, Novartis
NR 74
TC 102
Z9 103
U1 0
U2 27
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 1806
EP 1814
DI 10.1200/JCO.2012.46.8934
PG 9
WC Oncology
SC Oncology
GA 148OP
UT WOS:000319255100002
PM 23589557
ER
PT J
AU MacConaill, LE
AF MacConaill, Laura E.
TI Existing and Emerging Technologies for Tumor Genomic Profiling
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID CELL LUNG-CANCER; ACUTE MYELOID-LEUKEMIA; TRANSVERSE ELECTRONIC
TRANSPORT; SOMATIC MUTATIONS; WHOLE-GENOME; PERSONALIZED MEDICINE;
NUCLEOTIDE RESOLUTION; SEQUENCING PLATFORMS; DRIVER MUTATIONS;
PROSTATE-CANCER
AB Ongoing global genome characterization efforts are revolutionizing our knowledge of cancer genomics and tumor biology. In parallel, information gleaned from these studies on driver cancer gene alterations-mutations, copy number alterations, translocations, and/or chromosomal rearrangements-can be leveraged, in principle, to develop a cohesive framework for individualized cancer treatment. These possibilities have been enabled, to a large degree, by revolutionary advances in genomic technologies that facilitate systematic profiling for hallmark cancer genetic alterations at increasingly fine resolutions. Ongoing innovations in existing genomics technologies, as well as the many emerging technologies, will likely continue to advance translational cancer genomics and precision cancer medicine.
C1 [MacConaill, Laura E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[MacConaill, Laura E.] Harvard Univ, Sch Med, Boston, MA USA.
[MacConaill, Laura E.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP MacConaill, LE (reprint author), Dana Farber Canc Inst, Ctr Canc Genome Discovery, 44 Binney St,Dana 1539, Boston, MA 02115 USA.
EM laura_macconaill@dfci.harvard.edu
FU Dana-Farber Cancer Institute; National Institutes of Health [R33
CA155554]
FX Supported by the Dana-Farber Cancer Institute and by Grant No. R33
CA155554 from the National Institutes of Health.
NR 110
TC 50
Z9 51
U1 2
U2 15
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 1815
EP 1824
DI 10.1200/JCO.2012.46.5948
PG 10
WC Oncology
SC Oncology
GA 148OP
UT WOS:000319255100003
PM 23589546
ER
PT J
AU Van Allen, EM
Wagle, N
Levy, MA
AF Van Allen, Eliezer M.
Wagle, Nikhil
Levy, Mia A.
TI Clinical Analysis and Interpretation of Cancer Genome Data
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID CELL LUNG-CANCER; GENERATION SEQUENCING DATA; COPY-NUMBER ALTERATIONS;
ACUTE MYELOID-LEUKEMIA; READ ALIGNMENT; GENE FUSIONS; SOMATIC MUTATIONS;
TUMOR SAMPLES; IDENTIFICATION; DISCOVERY
AB The scale of tumor genomic profiling is rapidly outpacing human cognitive capacity to make clinical decisions without the aid of tools. New frameworks are needed to help researchers and clinicians process the information emerging from the explosive growth in both the number of tumor genetic variants routinely tested and the respective knowledge to interpret their clinical significance. We review the current state, limitations, and future trends in methods to support the clinical analysis and interpretation of cancer genomes. This includes the processes of genome-scale variant identification, including tools for sequence alignment, tumor-germline comparison, and molecular annotation of variants. The process of clinical interpretation of tumor variants includes classification of the effect of the variant, reporting the results to clinicians, and enabling the clinician to make a clinical decision based on the genomic information integrated with other clinical features. We describe existing knowledge bases, databases, algorithms, and tools for identification and visualization of tumor variants and their actionable subsets. With the decreasing cost of tumor gene mutation testing and the increasing number of actionable therapeutics, we expect the methods for analysis and interpretation of cancer genomes to continue to evolve to meet the needs of patient-centered clinical decision making. The science of computational cancer medicine is still in its infancy; however, there is a clear need to continue the development of knowledge bases, best practices, tools, and validation experiments for successful clinical implementation in oncology.
C1 [Van Allen, Eliezer M.; Wagle, Nikhil] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Van Allen, Eliezer M.; Wagle, Nikhil] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Levy, Mia A.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA.
RP Levy, MA (reprint author), Vanderbilt Ingram Canc Ctr, 2220 Pierce Ave,691 Preston Res Bldg, Nashville, TN 37232 USA.
EM mia.levy@vanderbilt.edu
OI Van Allen, Eliezer/0000-0002-0201-4444
FU J. Kleberg, Jr. and Helen C. Kleberg Foundation; Dana-Farber Leadership
Council
FX Supported by Robert J. Kleberg, Jr. and Helen C. Kleberg Foundation and
the Dana-Farber Leadership Council.
NR 86
TC 48
Z9 48
U1 2
U2 18
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 1825
EP 1833
DI 10.1200/JCO.2013.48.7215
PG 9
WC Oncology
SC Oncology
GA 148OP
UT WOS:000319255100004
PM 23589549
ER
PT J
AU Janeway, KA
Place, AE
Kieran, MW
Harris, MH
AF Janeway, Katherine A.
Place, Andrew E.
Kieran, Mark W.
Harris, Marian H.
TI Future of Clinical Genomics in Pediatric Oncology
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Review
ID ACUTE LYMPHOBLASTIC-LEUKEMIA; REFRACTORY SOLID TUMORS; INTERNAL TANDEM
DUPLICATION; MAPK PATHWAY ACTIVATION; ACUTE MYELOID-LEUKEMIA; PHASE-I
CONSORTIUM; B-PROGENITOR; WILMS-TUMOR; STRUCTURAL VARIATION;
GENE-MUTATIONS
AB The somatic genomic alterations in pediatric cancers to some extent overlap with those seen in adult cancers, but the exact distribution throughout the genome and the types and frequency of alterations differ. The ultimate goal of genomic research in children, as with adults, is translation to the clinic to achieve more accurate diagnosis, more precise risk stratification, and more effective, less toxic therapy. The genomic features of pediatric malignancies and pediatric-specific issues in clinical investigation may make translating genomic discoveries to the clinic more difficult. However, through large-scale molecular profiling of pediatric tumors, continued coordinated efforts to evaluate novel therapies in the pediatric population, thoughtful phase II and III trial design, and continued drug development, genomically based therapies will become more common in the pediatric oncology clinic in the future.
C1 [Janeway, Katherine A.; Place, Andrew E.; Kieran, Mark W.] Dana Farber Childrens Hosp Canc Ctr, Boston, MA USA.
[Harris, Marian H.] Boston Childrens Hosp, Boston, MA USA.
RP Janeway, KA (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM katherine.janeway@childrens.harvard.edu
OI Kieran, Mark/0000-0003-2184-7692
FU Friends for Life Research Fund; Gilmore Research Fund; St Baldrick's
Foundation
FX Supported by the Friends for Life Research Fund, Gilmore Research Fund,
and St Baldrick's Foundation.
NR 121
TC 14
Z9 14
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
BP 1893
EP +
DI 10.1200/JCO.2012.46.8470
PG 12
WC Oncology
SC Oncology
GA 148OP
UT WOS:000319255100012
PM 23589558
ER
PT J
AU Hostin, R
McCarthy, I
O'Brien, M
Bess, S
Line, B
Boachie-Adjei, O
Burton, D
Gupta, M
Ames, C
Deviren, V
Kebaish, K
Shaffrey, C
Wood, K
Hart, R
AF Hostin, Richard
McCarthy, Ian
O'Brien, Michael
Bess, Shay
Line, Breton
Boachie-Adjei, Oheneba
Burton, Doug
Gupta, Munish
Ames, Christopher
Deviren, Vedat
Kebaish, Khaled
Shaffrey, Christopher
Wood, Kirkham
Hart, Robert
CA Int Spine Study Grp
TI Incidence, Mode, and Location of Acute Proximal Junctional Failures
After Surgical Treatment of Adult Spinal Deformity
SO SPINE
LA English
DT Article
DE acute proximal junctional failure; upper thoracic proximal junctional
failures; thoracolumbar proximal junctional failures
ID RISK-FACTOR ANALYSIS; PEDICLE SCREW CONSTRUCTS; IDIOPATHIC SCOLIOSIS;
KYPHOSIS; INSTRUMENTATION; FUSION; OUTCOMES; BALANCE
AB Study Design. Multicenter, retrospective series.
Objective. To analyze the incidence, mode, and location of acute proximal junctional failures (APJFs) after surgical treatment of adult spinal deformity.
Summary of Background Data. Early proximal junctional failures above adult deformity constructs are a serious clinical problem; however, the incidence and nature of early APJFs remain unclear.
Methods. A total of 1218 consecutive adult spinal deformity surgeries across 10 deformity centers were retrospectively reviewed to evaluate the incidence and nature of APJF, defined as any of the following within 28 weeks of index procedure: minimum 15 post-operative increase in proximal junctional kyphosis, vertebral fracture of upper instrumented vertebrae (UIV) or UIV + 1, failure of of UIV fixation, or need for proximal extension of fusion within 6 months of surgery.
Results. Sixty-eight APJF cases were identified out of 1218 consecutive surgeries (5.6%). Patients had a mean age of 63 years (range, 26-82 yr), mean fusion levels of 9.8 (range, 4-18), and mean time to APJF of 11.4 weeks (range, 1.5-28 wk). Fracture was the most common failure mode (47%), followed by soft-tissue failure (44%). Failures most often occurred in the thoracolumbar region (TL-APJF) compared with the upper thoracic region (UT-APJF), with 66% of patients experiencing TL-APJF compared with 34% experiencing UT-APJF. Fracture was significantly more common for TL-APJF relative to UT-APJF (P = 0.00), whereas soft-tissue failure was more common for UT-APJF (P < 0.02). Patients experiencing TL-APJF were also older (P = 0.00), had fewer fusion levels (P = 0.00), and had worse postoperative sagittal vertical axis (P < 0.01).
Conclusion. APJFs were identified in 5.6% of patients undergoing surgical treatment of adult spinal deformity, with failures occurring primarily in the TL region of the spine. There is evidence that the mode of failure differs depending on the location of UIV, with TL failures more likely due to fracture and UT failures more likely due to soft-tissue failures.
C1 [Hostin, Richard; O'Brien, Michael] Baylor Scoliosis Ctr, Dept Orthopaed Surg, Plano, TX USA.
[McCarthy, Ian] Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, Dallas, TX USA.
[McCarthy, Ian] So Methodist Univ, Dept Econ, Dallas, TX 75275 USA.
[Bess, Shay; Line, Breton] Rocky Mt Scoliosis & Spine, Dept Orthopaed Surg, Denver, CO USA.
[Boachie-Adjei, Oheneba] Hosp Special Surg, Dept Orthopaed Surg, New York, NY 10021 USA.
[Burton, Doug] Univ Kansas, Med Ctr, Dept Orthopaed Surg, Kansas City, KS 66103 USA.
[Gupta, Munish] Univ Calif Davis, Dept Orthopaed Surg, Sacramento, CA 95817 USA.
[Ames, Christopher] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA.
[Deviren, Vedat] Univ Calif San Francisco, Dept Orthopaed Surg, San Francisco, CA 94143 USA.
[Kebaish, Khaled] Johns Hopkins Univ, Dept Orthopaed Surg, Baltimore, MD USA.
[Shaffrey, Christopher] Univ Virginia, Dept Neurosurg, Charlottesville, VA USA.
[Wood, Kirkham] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Hart, Robert] Oregon Hlth & Sci Univ, Dept Orthopaed Surg, Portland, OR USA.
RP McCarthy, I (reprint author), Baylor Hlth Care Syst, Inst Hlth Care Res & Improvement, 4708 Alliance Blvd,Ste 800, Plano, TX 75093 USA.
EM ianmccarthy.econ@gmail.com
OI bess, shay/0000-0002-9697-8999
FU Baylor Health Care System Foundation; Seeger; Endowment Fund; Children's
Specialist Foundation, Inc.
FX Funding provided in part by the Baylor Health Care System Foundation,
Seeger, Endowment Fund, and the Children's Specialist Foundation, Inc.,
as administrator for the International Spine Study Group.
NR 14
TC 22
Z9 25
U1 0
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0362-2436
J9 SPINE
JI SPINE
PD MAY 20
PY 2013
VL 38
IS 12
BP 1008
EP 1015
DI 10.1097/BRS.0b013e318271319c
PG 8
WC Clinical Neurology; Orthopedics
SC Neurosciences & Neurology; Orthopedics
GA 148QR
UT WOS:000319261800017
PM 22986834
ER
PT J
AU Abbott, CH
Prigerson, HG
Maciejewski, PK
AF Abbott, Caroline H.
Prigerson, Holly Gwen
Maciejewski, Paul K.
TI Caregivers' perception of advanced cancer patients' quality of death:
Impact on caregiver suicidal ideation in bereavement
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9522
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603005
ER
PT J
AU Abel, GA
Cronin, A
Stroupe, A
Earles, K
Gray, SW
AF Abel, Gregory Alan
Cronin, Angel
Stroupe, Angela
Earles, Kristofer
Gray, Stacy W.
TI Quality and accessibility of oncology-related clinical trials
information: A content analysis of Internet media
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Abel, Gregory Alan; Cronin, Angel; Stroupe, Angela; Earles, Kristofer; Gray, Stacy W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6547
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602263
ER
PT J
AU Abernethy, AP
Temel, JS
Currow, D
Gleich, LL
Friend, J
AF Abernethy, Amy Pickar
Temel, Jennifer S.
Currow, David
Gleich, Lyon L.
Friend, John
TI Phase III clinical trials with anamorelin HCl, a novel oral treatment
for NSCLC cachexia.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Sch Med, Durham, NC USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Flinders Univ S Australia, Adelaide, SA 5001, Australia.
Medpace, Cincinnati, OH USA.
Helsinn Therapeut, Bridgewater, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS9649
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605532
ER
PT J
AU Abrantes, FL
Vergamini, LB
Rodriguez-Galindo, C
Hofmann, I
London, WB
Ribeiro, KB
Frazier, AL
Sun, PL
AF Abrantes, Fernanda L.
Vergamini, Lucas B.
Rodriguez-Galindo, Carlos
Hofmann, Inga
London, Wendy B.
Ribeiro, Karina Braga
Frazier, A. Lindsay
Sun, Pengling
TI Evaluation of the necessity of bilateral bone marrow aspirates and
biopsies for the diagnosis of metastatic disease in pediatric patients
with solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp, Dana Farber Canc Inst, Harvard Canc Care, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10054
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600212
ER
PT J
AU Aggarwal, C
Dahlberg, SE
Hanna, N
Kolesar, J
Hirsch, FR
Ramalingam, SS
Schiller, JH
AF Aggarwal, Charu
Dahlberg, Suzanne Eleanor
Hanna, Nasser
Kolesar, Jill
Hirsch, Fred R.
Ramalingam, Suresh S.
Schiller, Joan H.
TI Exploratory biomarker analyses from ECOG 4508: Three-arm randomized
phase II study of carboplatin (C) and paclitaxel (P) in combination with
cetuximab (CET), IMC-A12, or both for advanced non-small cell lung
cancer (NSCLC) patients (pts)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ Sch Med, Simon Canc Ctr, Indianapolis, IN 46202 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8106
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602585
ER
PT J
AU Ahn, DH
Dahlberg, SE
Sandler, A
Perry, MC
Schiller, JH
Brahmer, JR
Johnson, DH
Gerber, DE
AF Ahn, Daniel H.
Dahlberg, Suzanne Eleanor
Sandler, Alan
Perry, Michael C.
Schiller, Joan H.
Brahmer, Julie R.
Johnson, David H.
Gerber, David E.
CA Eastern Cooperative Oncology Grp
TI Association between baseline tumor dimensions and survival in advanced
non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Univ Missouri, Ellis Fischel Canc Ctr, Columbia, MO USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8046
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602527
ER
PT J
AU Aizer, AA
Phillips, J
Chen, MH
Zhang, DJ
Loffredo, M
D'Amico, AV
AF Aizer, Ayal A.
Phillips, John
Chen, Ming-Hui
Zhang, Danjie
Loffredo, Marian
D'Amico, Anthony Victor
TI Detecting lower in addition to the highest Gleason score prostate cancer
on core biopsy and the risk of prostate cancer-specific mortality.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Univ Connecticut, Storrs, CT USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5051
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601649
ER
PT J
AU Alexander, BM
Ramkissoon, S
Wen, PY
Reardon, DA
Lee, EQ
Rinne, M
Norden, AD
Nayak, L
Ruland, S
Doherty, LM
LaFrankie, DC
Brown, LE
Arvold, ND
Dunn, IF
Santagata, S
Rollins, BJ
Lindeman, NI
Beroukhim, R
Ligon, A
Ligon, KL
AF Alexander, Brian Michael
Ramkissoon, Shakti
Wen, Patrick Y.
Reardon, David A.
Lee, Eudocia Quant
Rinne, Mikael
Norden, Andrew David
Nayak, Lakshmi
Ruland, Sandra
Doherty, Lisa M.
LaFrankie, Debra C.
Brown, Loreal E.
Arvold, Nils D.
Dunn, Ian F.
Santagata, Sandro
Rollins, Barrett J.
Lindeman, Neal Ian
Beroukhim, Rameen
Ligon, Azra
Ligon, Keith L.
TI Combined whole genome copy number genotyping and multiplex somatic
mutation profiling of FFPE brain tumor specimens for clinical diagnosis
and trial selection
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Radiat Oncol Program, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2030
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600691
ER
PT J
AU Almhanna, K
Messersmith, WA
Ahnert, JR
Cruz, C
Ryan, DP
Jung, J
Fasanmade, A
Wyant, T
Kalebic, T
AF Almhanna, Khaldoun
Messersmith, Wells A.
Ahnert, Jordi Rodon
Cruz, Cristina
Ryan, David P.
Jung, JungAh
Fasanmade, Adedigbo
Wyant, Tim
Kalebic, Thea
TI MLN0264, an investigational, first-in-class antibody-drug conjugate
(ADC) targeting guanylyl cyclase C (GCC): Phase I, first-in-human study
in patients (pts) with advanced gastrointestinal (GI) malignancies
expressing GCC
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Vall dHebron Inst Oncol, Barcelona, Spain.
Inst Catala Oncol, Barcelona, Spain.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3646
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605424
ER
PT J
AU Alsina, M
Richardson, PGG
Schlossman, RL
Weber, DM
Coutre, SE
Gasparetto, C
Mukhopadhyay, S
Ondovik, MS
Khan, MH
Paley, CS
Lonial, S
AF Alsina, Melissa
Richardson, Paul Gerard Guy
Schlossman, Robert L.
Weber, Donna M.
Coutre, Steven E.
Gasparetto, Cristina
Mukhopadhyay, Sutapa
Ondovik, Michael S.
Khan, Mahmudul H.
Paley, Carole S.
Lonial, Sagar
TI Clinical response by baseline characteristics in patients (pts) with
relapsed and bortezomib (BTZ)-refractory multiple myeloma treated with
panobinostat (PAN), BTZ, and dexamethasone (DEX; PANORAMA 2)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Stanford Canc Inst, Stanford, CA USA.
Duke Univ, Med Ctr, Durham, NC USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Emory Univ, Sch Med, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8531
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602627
ER
PT J
AU Alumkal, JJ
Slottke, R
Mori, M
Schwartzman, J
Graff, JN
Beer, TM
Ryan, CW
Koop, DR
Cherala, G
Munar, M
Flamiatos, JF
Gao, L
Tucker, E
AF Alumkal, Joshi J.
Slottke, Rachel
Mori, Motomi
Schwartzman, Jacob
Graff, Julie Nicole
Beer, Tomasz M.
Ryan, Christopher W.
Koop, Dennis R.
Cherala, Ganesh
Munar, Myrna
Flamiatos, Jason Frederick
Gao, Lina
Tucker, Erin
TI Sulforaphane treatment in men with recurrent prostate cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5017
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601618
ER
PT J
AU Amin, A
Ernstoff, MS
Infante, JR
Heng, DYC
Rini, BI
Plimack, ER
McDermott, DF
Kollmannsberger, CK
Reaume, MN
Spratlin, JL
Knox, JJ
Voss, MH
Pal, SK
Shen, Y
Dhar, A
Hammers, HJ
AF Amin, Asirn
Ernstoff, Marc S.
Infante, Jeffrey R.
Heng, Daniel Yick Chin
Rini, Brian I.
Plimack, Elizabeth R.
McDermott, David F.
Kollmannsberger, Christian K.
Reaume, Martin Neil
Spratlin, Jennifer L.
Knox, Jennifer J.
Voss, Martin Henner
Pal, Sumanta Kumar
Shen, Yuri
Dhar, Arindarn
Hammers, Hans J.
TI A phase I study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) in
combination with sunitinib, pazopanib, or ipilimumab in patients (pts)
with metastatic renal cell carcinoma (mRCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Levine Canc Inst, Charlotte, NC USA.
Norris Cotton Canc Ctr, Geisel Sch Med, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Univ Calgary, Tom Baker Canc Ctr, Calgary, AB, Canada.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
BC Canc Agcy, Vancouver, BC, Canada.
Ottawa Hosp Canc Ctr, Ottawa, ON, Canada.
Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Sch Med, Baltimore, MD USA.
NR 0
TC 1
Z9 1
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS4593
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605453
ER
PT J
AU Anders, CK
Deal, AM
Abramson, VG
Liu, MC
Storniolo, AM
Carpenter, JT
Puhalla, S
Nanda, R
Melhem-Bertrandt, A
Lin, NU
Marcom, PK
Van Poznak, CH
Stearns, V
Melisko, ME
Smith, JK
Karginova, O
Winer, EP
Perou, CM
Wolff, AC
Carey, LA
AF Anders, Carey K.
Deal, Allison Mary
Abramson, Vandana Gupta
Liu, Minetta C.
Storniolo, Anna Maria
Carpenter, John T.
Puhalla, Shannon
Nanda, Rita
Melhem-Bertrandt, Amal
Lin, Nancy U.
Marcom, Paul K.
Van Poznak, Catherine H.
Stearns, Vered
Melisko, Michelle E.
Smith, J. Keith
Karginova, Olga
Winer, Eric P.
Perou, Charles M.
Wolff, Antonio C.
Carey, Lisa A.
CA Translational Breast Canc Res
TI TBCRC 018: Phase II study of iniparib plus chemotherapy to treat
triple-negative breast cancer (TNBC) central nervous system (CNS)
metastases (mets).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Univ N Carolina, Chapel Hill, NC USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ Pittsburgh, Med Ctr, Magee Womens Canc Program, Pittsburgh, PA USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Sidney Kimmel Comprehens Canc Ctr, Johns Hopkins Sch Med, Baltimore, MD USA.
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 515
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600020
ER
PT J
AU Arora, ML
Mistry, S
Shaik, M
Tyagi, N
Korant, AK
Saha, SK
Johnston, G
Abadeer, B
Dhar, VK
Wiese, D
Saha, S
AF Arora, Madan L.
Mistry, Shams
Shaik, Mohammed
Tyagi, Neha
Korant, Alpesh K.
Saha, Supriya Kumar
Johnston, Gregory
Abadeer, Benjamin
Dhar, Vikrom K.
Wiese, David
Saha, Sukamal
TI Comparative analysis of bone marrow micrometastases with sentinel lymph
node status in early-stage breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Michigan State Univ, Flint, MI USA.
Mclaren Reg Med Ctr, Flint, MI USA.
Michigan State Univ, Hurley Med Ctr, Flint, MI USA.
Michigan State Univ, McLaren Reg Med Ctr, Flint, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
McLaren Macomb Med Ctr, Mt Clemens, MI USA.
Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 570
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600075
ER
PT J
AU Bach, P
Zauderer, MG
Gucalp, A
Epstein, AS
Norton, L
Seidman, AD
Caroline, A
Grigorenko, A
Bartashnik, A
Wagner, I
Keesing, J
Kohn, M
Hsiao, F
Megerian, M
Stevens, RJ
Malin, J
Whitney, J
Kris, MG
AF Bach, Peter
Zauderer, Marjorie Glass
Gucalp, Ayca
Epstein, Andrew S.
Norton, Larry
Seidman, Andrew David
Caroline, Aryeh
Grigorenko, Alexander
Bartashnik, Aleksandra
Wagner, Isaac
Keesing, Jeffrey
Kohn, Martin
Hsiao, Franny
Megerian, Mark
Stevens, Rick J.
Malin, Jennifer
Whitney, John
Kris, Mark G.
TI Beyond Jeopardy!: Harnessing IBM's Watson to improve oncology decision
making
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
IBM Corp, Yorktown Hts, NY USA.
IBM Corp, Dublin, Ireland.
IBM Corp, Rochester, MN 55901 USA.
IBM Corp, Monkton, VT USA.
VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
Wellpoint Inc, Albany, NY USA.
NR 0
TC 0
Z9 0
U1 1
U2 18
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6508
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602228
ER
PT J
AU Bae, J
Carrasco, R
Daley, J
Dranoff, G
Anderson, KC
Munshi, NC
AF Bae, Jooeun
Carrasco, Ruben
Daley, John
Dranoff, Glen
Anderson, Kenneth Carl
Munshi, Nikhil C.
TI Novel heteroclitic XBP1 peptides evoking antigen-specific cytotoxic T
lymphocytes targeting various solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3067
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601199
ER
PT J
AU Bailey, AS
Cheng, SC
Kwon, ED
Leibovich, BC
Signoretti, S
Dutcher, JP
Appleman, LJ
Sosman, JA
Margolin, KA
Clark, J
Khushalani, NI
Curti, BD
Ernstoff, MS
Pantuck, AJ
Vaishampayan, UN
Logan, T
McDermott, DF
Atkins, MB
AF Bailey, Alexandra S.
Cheng, SuChun
Kwon, Eugene D.
Leibovich, Bradley C.
Signoretti, Sabina
Dutcher, Janice P.
Appleman, Leonard Joseph
Sosman, Jeffrey Alan
Margolin, Kim Allyson
Clark, Joseph
Khushalani, Nikhil I.
Curti, Brendan D.
Ernstoff, Marc S.
Pantuck, Allan J.
Vaishampayan, Ulka N.
Logan, Theodore
McDermott, David F.
Atkins, Michael B.
CA Cytokine Working Grp
TI Pdl-1/pdl-3 (programmed death ligand-1/3) tissue expression and response
to treatment with IL2 and antiangiogenic therapies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
Mayo Clin, Rochester, MN USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Columbia Univ, St Lukes Roosevelt Hosp Ctr, Continuum Canc Ctr New York, New York, NY USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Univ Washington, Seattle, WA 98195 USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Earle A Chiles Res Inst, Portland, OR USA.
Norris Cotton Canc Ctr, Dartmouth Hitchcock Med Ctr, Lebanon, NH USA.
Univ Calif Los Angeles, Inst Urol Oncol, Dept Urol, Los Angeles, CA USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4521
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601535
ER
PT J
AU Baird, K
Reinke, DK
Pressey, JG
Mascarenhas, L
Federman, N
Marina, N
Chawla, SP
Lagmay, JP
Goldberg, JM
Milhem, MM
Loeb, DM
Butrynski, JE
Janeway, KA
Turpin, B
Staddon, AP
Spunt, SL
Rodler, ET
Schuetze, S
Okuno, SH
Heiman, LJ
AF Baird, Kristin
Reinke, Denise K.
Pressey, Joseph Gerald
Mascarenhas, Leo
Federman, Noah
Marina, Neyssa
Chawla, Sant P.
Lagmay, Joanne Pigues
Goldberg, John M.
Milhem, Mohammed M.
Loeb, David Mark
Butrynski, James E.
Janeway, Katherine A.
Turpin, Brian
Staddon, Arthur P.
Spunt, Sheri L.
Rodler, Eve T.
Schuetze, Scott
Okuno, Scott H.
Heiman, Lee J.
TI A randomized, double-blinded, placebo-controlled, multi-institutional,
cross-over, phase II. 5 study of saracatinib (AZD0530), a selective Src
kinase inhibitor, in patients with recurrent osteosarcoma localized to
the lung.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Bethesda, MD 20892 USA.
Sarcoma Alliance Res Collaborat, Ann Arbor, MI USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
Univ Calif Los Angeles, Dept Pediat, Los Angeles, CA 90024 USA.
Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
Sarcoma Oncol Ctr, Santa Monica, CA USA.
Nationwide Childrens Hosp, Gainesville, FL USA.
Univ Miami, Miller Sch Med, Miami, FL 33136 USA.
Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
Univ Penn, Philadelphia, PA 19104 USA.
St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Mayo Clin, Rochester, MN USA.
NCI, Ctr Canc Res, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS10591
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605357
ER
PT J
AU Balboni, TA
Maciejewski, PK
Balboni, MJ
Enzinger, AC
Paulk, ME
Munoz, F
Rivera, L
Mutchler, J
Finlay, E
Marr, L
McCorkle, R
Temel, JS
Weeks, JC
Vanderweele, TJ
Prigerson, HG
AF Balboni, Tracy A.
Maciejewski, Paul K.
Balboni, Michael J.
Enzinger, Andrea Catherine
Paulk, M. Elizabeth
Munoz, Francisco
Rivera, Lorna
Mutchler, Jan
Finlay, Esme
Marr, Lisa
McCorkle, Ruth
Temel, Jennifer S.
Weeks, Jane C.
Vanderweele, Tyler J.
Prigerson, Holly Gwen
TI Racial/ethnic differences in end-of-life (EoL) treatment preferences:
The role of religious beliefs about care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Pomona Valley Hosp Med Ctr, Pomona, CA USA.
Univ Massachusetts, Boston, MA 02125 USA.
Univ New Mexico, Albuquerque, NM 87131 USA.
Yale Univ, Sch Nursing, New Haven, CT 06536 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6529
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602248
ER
PT J
AU Truong, B
Green, AL
Friedrich-Medina, P
Kamihara, J
Frazier, AL
Ribeiro, KB
Rodriguez-Galindo, C
AF Bao Truong
Green, Adam L.
Friedrich-Medina, Paola
Kamihara, Junne
Frazier, A. Lindsay
Ribeiro, Karina Braga
Rodriguez-Galindo, Carlos
TI Impact of socioeconomic status on extent of disease at diagnosis and
cancer and ocular outcomes in retinoblastoma: A population-based
analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
Childrens Hosp, Med Ctr, Boston, MA 02115 USA.
Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10011
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600165
ER
PT J
AU Bardia, A
Santa-Maria, CA
Jacobs, LK
Cimino-Mathews, A
Huang, P
Russell, S
Camp, M
Habibi, M
Lange, JR
Jeter, S
Powers, P
Slater, S
Gabrielson, E
Carducci, MA
Semenza, G
Stearns, V
AF Bardia, Aditya
Santa-Maria, Cesar Augusto
Jacobs, Lisa K.
Cimino-Mathews, Ashley
Huang, Peng
Russell, Stuart
Camp, Melissa
Habibi, Mehran
Lange, Julie R.
Jeter, Stacie
Powers, Penny
Slater, Shannon
Gabrielson, Edward
Carducci, Michael Anthony
Semenza, Gregg
Stearns, Vered
TI Digoxin as an inhibitor of global hypoxia inducible factor-1 alpha (HIF1
alpha) expression and downstream targets in breast cancer: Dig-HIF1
pharmacodynamic trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS1144
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605377
ER
PT J
AU Bardia, A
Isakoff, SJ
Juric, D
Borger, DR
Dias-Santagata, D
Iafrate, AJ
Flaherty, K
Moy, B
Ellisen, LW
AF Bardia, Aditya
Isakoff, Steven J.
Juric, Dejan
Borger, Darrell R.
Dias-Santagata, Dora
Iafrate, Anthony John
Flaherty, Keith
Moy, Beverly
Ellisen, Leif William
TI Impact of routine tumor genotyping on enrollment in targeted therapy
trials for metastatic breast cancer (MBC): 4-year review
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Bardia, Aditya; Isakoff, Steven J.; Juric, Dejan; Borger, Darrell R.; Dias-Santagata, Dora; Iafrate, Anthony John; Flaherty, Keith; Moy, Beverly; Ellisen, Leif William] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 533
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600038
ER
PT J
AU Barth, MJ
Goldman, S
Smith, L
Perkins, SL
Shiramizu, B
Gross, TG
Harrison, L
Sanger, W
Geyer, MB
Giulino, LB
Cairo, MS
AF Barth, Matthew John
Goldman, Stanton
Smith, Lynette
Perkins, Sherrie L.
Shiramizu, Bruce
Gross, Thomas G.
Harrison, Lauren
Sanger, Warren
Geyer, Mark B.
Giulino, Lisa B.
Cairo, Mitchell S.
TI Rituximab pharmacokinetics in children and adolescents with de novo
intermediate and advanced mature B-cell lymphoma/leukemia: A Children's
Oncology Group (COG) report.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Med City Childrens Hosp, Dallas, TX USA.
Univ Nebraska Med Ctr, Omaha, NE USA.
Univ Utah Hlth Sci, Dept Pathol, Salt Lake City, UT USA.
ARUP Inst Clin & Expt Pathol, Salt Lake City, UT USA.
Univ Hawaii, Honolulu, HI 96822 USA.
Nationwide Childrens Hosp, Dept Pediat Hematol Oncol, Columbus, OH USA.
New York Med Coll, Valhalla, NY 10595 USA.
Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3055
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601187
ER
PT J
AU Basch, EM
Pietanza, MC
Kris, MG
Shaw, M
Sima, CS
Rogak, LJ
Schrag, D
AF Basch, Ethan M.
Pietanza, Maria Catherine
Kris, Mark G.
Shaw, Mary
Sima, Camelia S.
Rogak, Lauren J.
Schrag, Deborah
TI Integration of patient-reported adverse events into a phase II
chemotherapy treatment trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Chapel Hill, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6583
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602299
ER
PT J
AU Bauman, JE
Gross, ND
Gooding, WE
Denq, W
Thomas, SM
Wang, L
Chiosea, SI
Hood, BL
Flint, MS
Sun, M
Conrads, TP
Ferris, RL
Johnson, JT
Kim, S
Argiris, A
Wirth, LJ
Siegfried, J
Grandis, JR
AF Bauman, Julie E.
Gross, Neil D.
Gooding, William E.
Denq, William
Thomas, Sufi M.
Wang, Lin
Chiosea, Simion I.
Hood, Brian L.
Flint, Melanie S.
Sun, Mai
Conrads, Thomas P.
Ferris, Robert L.
Johnson, Jonas Talmadge
Kim, Seungwon
Argiris, Athanassios
Wirth, Lori J.
Siegfried, Jill
Grandis, Jennifer R.
TI Neoadjuvant erlotinib, erlotinib-sulindac, or placebo: A randomized,
double-blind biomarker modulation study in operable head and neck
squamous cell carcinoma (HNSCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Pittsburgh Canc Inst, Pittsburgh, PA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Univ Pittsburgh Eye & Ear Inst, Pittsburgh, PA USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6051
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602174
ER
PT J
AU Beaver, JA
Balukrishna, S
Jelovac, D
Higgins, MJ
Jeter, S
Stearns, V
Wolff, AC
Kessler, J
VanDenBerg, D
Toro, PV
Argani, P
Park, BH
AF Beaver, Julia A.
Balukrishna, Sasidharan
Jelovac, Danijela
Higgins, Michaela Jane
Jeter, Stacie
Stearns, Vered
Wolff, Antonio C.
Kessler, Jill
VanDenBerg, Dustin
Toro, Patricia Valda
Argani, Pedram
Park, Ben Ho
TI Sensitivity for detecting PIK3CA mutations in early-stage breast cancer
with droplet digital PCR
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Christian Med Coll & Hosp, Vellore, Tamil Nadu, India.
Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Johns Hopkins Sch Med, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 11019
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600429
ER
PT J
AU Benson, DM
Kahl, BS
Furman, RR
Brown, JR
Wagner-Johnston, ND
Coutre, SE
Spurgeon, SEF
Byrd, JC
Leonard, J
Peterman, S
Johnson, DM
Cho, Y
Dansey, RD
Godfrey, WR
Flinn, I
AF Benson, Don M.
Kahl, Brad S.
Furman, Richard R.
Brown, Jennifer R.
Wagner-Johnston, Nina D.
Coutre, Steven E.
Spurgeon, Stephen Edward Forbes
Byrd, John C.
Leonard, John
Peterman, Sissy
Johnson, David Michael
Cho, Yoonjin
Dansey, Roger D.
Godfrey, Wayne R.
Flinn, Ian
TI Final results of a phase I study of idelalisib, a selective inhibitor of
PI3K delta, in patients with relapsed or refractory indolent non-Hodgkin
lymphoma (iNHL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ohio State Univ, Columbus, OH 43210 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Weill Cornell Med Coll, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Washington Univ, Sch Med, St Louis, MO USA.
Stanford Canc Inst, Stanford, CA USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Gilead Sci Inc, Seattle, WA USA.
Sarah Cannon Res Inst, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8526
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602622
ER
PT J
AU Berry, DL
Hong, FX
Blonquist, T
Halpenny, B
Siefert, ML
Partridge, AH
AF Berry, Donna Lynn
Hong, Fangxin
Blonquist, Traci
Halpenny, Barbara
Siefert, Mary Lou
Partridge, Ann H.
TI Self report assessment and support for cancer symptoms: Impact on
hospital admissions and emergency department visits.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Berry, Donna Lynn; Hong, Fangxin; Blonquist, Traci; Halpenny, Barbara; Siefert, Mary Lou; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20552
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604818
ER
PT J
AU Birrer, MJ
Bondarenko, I
Tjulandin, S
Vergote, I
Cibula, D
Ray-Coquard, I
Colombo, N
Allard, A
Oprea, C
Rey, AA
Sessa, C
Pujade-Lauraine, E
AF Birrer, Michael J.
Bondarenko, Igor
Tjulandin, Sergei
Vergote, Ignace
Cibula, David
Ray-Coquard, Isabelle
Colombo, Nicoletta
Allard, Aurore
Oprea, Corina
Rey, Augustin A.
Sessa, Cristiana
Pujade-Lauraine, Eric
TI Opsalin: A phase II placebo (Pbo)-controlled randomized study of
ombrabulin in patients with platinum-sensitive recurrent ovarian cancer
(OC) treated with carboplatin (Cb) and paclitaxel (P)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Dnipropetrovsk Med Acad, Dnepropetrovsk, Ukraine.
NN Blokhin Russian Canc Res Ctr, Moscow, Russia.
Katholieke Univ Leuven Hosp, Louvain, Belgium.
Charles Univ Prague, Fac Med 1, Prague, Czech Republic.
Ctr Leon Berard, F-69373 Lyon, France.
Ist Europeo Oncol, Milan, Italy.
Sanofi, Chilly Mazarin, France.
Sanofi, Vitry Sur Seine, France.
Ist Oncol Svizzera Italiana, Bellinzona, Switzerland.
Hop Hotel Dieu, F-75181 Paris, France.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5516
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602030
ER
PT J
AU Blakeley, JO
Fisher, JD
Lieberman, FS
Lupo, J
Nabors, LB
Crane, J
Wen, PY
Cote, A
Peereboom, DM
Wen, QT
Cloughesy, TF
Robins, HI
Desideri, S
Grossman, SA
Ye, XB
Nelson, S
AF Blakeley, Jaishri O'Neill
Fisher, Joy D.
Lieberman, Frank S.
Lupo, Janine
Nabors, Louis B.
Crane, Jason
Wen, Patrick Y.
Cote, Andre
Peereboom, David M.
Wen, Qiuting
Cloughesy, Timothy Francis
Robins, H. Ian
Desideri, Serena
Grossman, Stuart A.
Ye, Xiaobu
Nelson, Sarah
CA Adult Brain Tumor Consortium
TI Imaging biomarkers of ramucirumab and olaratumab in patients with
recurrent glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Univ Wisconsin Hosp & Clin, Madison, WI 53792 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2044
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600705
ER
PT J
AU Blay, JY
Shen, L
Kang, YK
Rutkowski, P
Qin, SK
Nosov, D
Novick, SC
Taningco, L
Mo, SY
Reichardt, P
Demetri, GD
AF Blay, Jean-Yves
Shen, Lin
Kang, Yoon-Koo
Rutkowski, Piotr
Qin, Shukui
Nosov, Dmitry
Novick, Steven C.
Taningco, Lilia
Mo, Shuyuan
Reichardt, Peter
Demetri, George D.
TI Phase III trial of nilotinib versus imatinib as first-line targeted
therapy of advanced gastrointestinal stromal tumors (GIST)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France.
Peking Univ, Canc Hosp, Minist Educ, Key Lab Carcinogenesis & Translat Res,Dept Gastro, Beijing 100871, Peoples R China.
Univ Ulsan, Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
PLA, Hosp 81, Nanjing, Jiangsu, Peoples R China.
Blokhin Oncol Res Ctr, Moscow, Russia.
Nova Pharmaceut Corp, E Hanover, NJ USA.
Novartis Pharmaceut, Oncol, Florham Pk, NJ USA.
HELIOS Klinikum Bad Saarow, Bad Saarow Pieskow, Germany.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10501
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600275
ER
PT J
AU Blumenschein, GR
Smit, EF
Planchard, D
Kim, DW
Cadranel, J
De Pas, T
Dunphy, F
Udud, K
Ahn, MJ
Hanna, NH
Kim, JH
Mazieres, J
Kim, SW
Baas, P
Rappold, E
Redhu, S
Bellew, KM
Streit, MRW
Wu, FS
Janne, PA
AF Blumenschein, George R.
Smit, Egbert F.
Planchard, David
Kim, Dong-Wan
Cadranel, Jacques
De Pas, Tommaso
Dunphy, Frank
Udud, Katalin
Ahn, Myung-Ju
Hanna, Nasser H.
Kim, Joo-Hang
Mazieres, Julien
Kim, Sang-We
Baas, Paul
Rappold, Erica
Redhu, Suman
Bellew, Kevin M.
Streit, Michael R. W.
Wu, Frank S.
Janne, Pasi A.
TI MEK114653: A randomized, multicenter, phase II study to assess efficacy
and safety of trametinib (T) compared with docetaxel (D) in KRAS-mutant
advanced non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA.
Vrije Univ Amsterdam, Med Ctr, Amsterdam, Netherlands.
Inst Gustave Roussy, Dept Med Oncol, Villejuif, France.
Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
Univ Paris 06, Hop Tenon, Serv Pneumol & GRC Theranoscan 04, Paris, France.
European Inst Oncol, Milan, Italy.
Duke Univ, Med Ctr, Durham, NC USA.
Koranyi Natl Inst Pulmonol, Budapest, Hungary.
Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Med,Div Hematol Oncol, Seoul, South Korea.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Yonsei Canc Ctr, Dept Internal Med Med Oncol, Yonsei Canc Res Inst, Seoul, South Korea.
CHU Toulouse, Hop Larrey, Toulouse, France.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Netherlands Canc Inst, Amsterdam, Netherlands.
GlaxoSmithKline, Collegeville, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI MAZIERES, JULIEN/M-3986-2014
NR 0
TC 3
Z9 3
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8029
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602510
ER
PT J
AU Bober, S
Garber, J
Recklitis, CJ
Patenaude, AF
AF Bober, Sharon
Garber, Judy
Recklitis, Christopher J.
Patenaude, Andrea Farkas
TI A pilot intervention addressing sexual dysfunction after risk-reducing
oophorectomy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Bober, Sharon; Garber, Judy; Recklitis, Christopher J.; Patenaude, Andrea Farkas] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9644
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603127
ER
PT J
AU Borowitz, MJ
Wood, BL
Devidas, M
Loh, ML
Raetz, EA
Larsen, E
Maloney, KW
Carroll, AJ
Friedmann, AM
Gastier-Foster, JM
Heerema, NA
Mattano, LA
Nachman, JB
Winick, NJ
Carroll, WL
Hunger, S
AF Borowitz, Michael J.
Wood, Brent L.
Devidas, Meenakshi
Loh, Mignon L.
Raetz, Elizabeth A.
Larsen, Eric
Maloney, Kelly W.
Carroll, Andrew J.
Friedmann, Alison M.
Gastier-Foster, Julie M.
Heerema, Nyla A.
Mattano, Leonard A.
Nachman, James B.
Winick, Naomi Joan
Carroll, William L.
Hunger, Stephen
TI Assessment of end induction minimal residual disease (MRD) in childhood
B precursor acute lymphoblastic leukemia (ALL) to eliminate the need for
day 14 marrow examination: A Children's Oncology Group study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
Univ Washington, Seattle, WA 98195 USA.
Childrens Oncol Grp, Gainesville, FL USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NYU, Langone Med Ctr, New York, NY USA.
Maine Childrens Canc Program, Scarborough, ME USA.
Childrens Hosp Colorado, Aurora, CO USA.
Childrens Hosp Alabama, Birmingham, AL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Nationwide Childrens Hosp, Columbus, OH USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Richard J Solove Res Inst, Columbus, OH USA.
MSU KCMS, Kalamazoo, MI USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Texas SW Med Ctr Dallas, Ctr Canc & Blood Disorders, Childrens Med Ctr Dallas, Dallas, TX 75390 USA.
Univ Colorado Denver, Hlth Sci Ctr, Aurora, CO USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10001
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600155
ER
PT J
AU Boucher, Y
Martin, JD
Tolaney, SM
Ancukiewicz, M
Seano, G
Goal, S
Yeh, E
Meyer, JE
Isakoff, SJ
Duda, DG
Winer, EP
Krop, IE
Jain, RK
AF Boucher, Yves
Martin, John D.
Tolaney, Sara M.
Ancukiewicz, Marek
Seano, Giorgio
Goal, Shom
Yeh, Eren
Meyer, Jack E.
Isakoff, Steven J.
Duda, Dan G.
Winer, Eric P.
Krop, Ian E.
Jain, Rakesh K.
TI Differential changes in tissue biomarkers after bevacizumab (REV) alone
in a neoadjuvant study of REV and chemotherapy in ER plus breast cancer
(BC) versus triple-negative breast cancer (TNBC) patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1065
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600374
ER
PT J
AU Bradford, LS
Rauh-Hain, JA
Clark, RM
Groeneweg, JW
Zhang, L
DiGloria, CM
Borger, DR
Growdon, WB
Schorge, JO
Foster, R
Rueda, BR
AF Bradford, Leslie Siriya
Rauh-Hain, Jose Alejandro
Clark, Rachel Marie
Groeneweg, Jolijn W.
Zhang, Ling
DiGloria, Celeste M.
Borger, Darrell R.
Growdon, Whitfield Board
Schorge, John O.
Foster, Rosemary
Rueda, Bo R.
TI Targeting the PI3K signaling cascade in PIK3CA mutated endometrial
cancer in a primary human xenograft model.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e13564
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603454
ER
PT J
AU Brahmer, JR
Horn, L
Antonia, SJ
Spigel, DR
Gandhi, L
Sequist, LV
Sankar, V
Ahlers, CM
Wigginton, JM
Kollia, G
Gupta, AK
Gettinger, SN
AF Brahmer, Julie R.
Horn, Leora
Antonia, Scott J.
Spigel, David R.
Gandhi, Leena
Sequist, Lecia V.
Sankar, Vindira
Ahlers, Christoph Matthias
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Gettinger, Scott N.
TI Survival and long-term follow-up of the phase I trial of nivolumab
(Anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with previously
treated advanced non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Yale Univ, New Haven, CT USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8030
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602511
ER
PT J
AU Brenner, AJ
Cohen, Y
Vredenburgh, JJ
Peters, KB
Breitbart, E
Bangio, L
Sher, N
Harats, D
Wen, PY
AF Brenner, Andrew Jacob
Cohen, Yael
Vredenburgh, James J.
Peters, Katherine B.
Breitbart, Eyal
Bangio, Livnat
Sher, Naamit
Harats, Dror
Wen, Patrick Y.
TI Phase I/II dose-escalation study of VB-111, an antiangiogenic gene
therapy, in patients with recurrent glioblastoma multiforme.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
VBL Therapeut, Or Yehuda, Israel.
St Francis Hosp & Med Ctr, Hartford, CT USA.
Duke Univ, Med Ctr, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS2102
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605384
ER
PT J
AU Brown, JR
Furman, RR
Flinn, I
Coutre, SE
Wagner-Johnston, ND
Kahl, BS
Spurgeon, SEF
Benson, DM
Peterman, S
Johnson, DM
Li, D
Dansey, RD
Jahn, TM
Byrd, JC
AF Brown, Jennifer R.
Furman, Richard R.
Flinn, Ian
Coutre, Steven E.
Wagner-Johnston, Nina D.
Kahl, Brad S.
Spurgeon, Stephen Edward Forbes
Benson, Don M.
Peterman, Sissy
Johnson, David Michael
Li, Daniel
Dansey, Roger D.
Jahn, Thomas Michael
Byrd, John C.
TI Final results of a phase I study of idelalisib (GSE1101) a selective
inhibitor of PI3K delta, in patients with relapsed or refractory CLL.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Weill Cornell Med Coll, New York, NY USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Stanford Canc Inst, Stanford, CA USA.
Washington Univ Sch Med St Louis, St Louis, MO USA.
Univ Wisconsin Carbone Canc Ctr, Madison, WI USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Gilead Sci Inc, Seattle, WA USA.
NR 0
TC 11
Z9 11
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7003
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602361
ER
PT J
AU Brown, V
Partridge, A
Chu, L
Szado, T
Trudeau, C
Andrews, EB
AF Brown, Vikki
Partridge, Ann
Chu, Laura
Szado, Tania
Trudeau, Caroline
Andrews, Elizabeth B.
TI MotHER: A registry for women with breast cancer who received trastuzumab
(T) with or without pertuzumab (P) during pregnancy or within 6 months
prior to conception.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 INC Res, Raleigh, NC USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Genentech Inc, San Francisco, CA 94080 USA.
RTI Int, Res Triangle Pk, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS658
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605488
ER
PT J
AU Burtness, B
Lee, JW
Yang, DH
Zhu, F
Garcia, JJ
Forastiere, AA
Chung, CH
AF Burtness, Barbara
Lee, Ju-Whei
Yang, Donghua
Zhu, Fang
Garcia, Joaquin J.
Forastiere, Arlene A.
Chung, Christine H.
TI Activity of cetuximab (C) in head and neck squamous cell carcinoma
(HNSCC) patients (pts) with PTEN loss or PIK3CA mutation treated on
E5397, a phase III trial of cisplatin (CDDP) with placebo (P) or C
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, MN USA.
Johns Hopkins Univ, Baltimore, MD USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6028
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602152
ER
PT J
AU Byrd, JC
Barrientos, JC
Devereux, S
Brown, JR
Kay, NE
Reddy, NM
O'Brien, SM
Kipps, TJ
Furman, RR
Schuster, SJ
Bloor, A
Gill, DS
Thornton, P
Dearden, CE
Jager, U
Barker, C
Lin, J
Kunkel, LA
James, DF
Hillmen, P
AF Byrd, John C.
Barrientos, Jacqueline Claudia
Devereux, Stephen
Brown, Jennifer R.
Kay, Neil E.
Reddy, Nishitha M.
O'Brien, Susan Mary
Kipps, Thomas J.
Furman, Richard R.
Schuster, Stephen J.
Bloor, Adrian
Gill, Devinder Singh
Thornton, Patrick
Dearden, Claire E.
Jaeger, Ulrich
Barker, Christine
Lin, Jennifer
Kunkel, Lori A.
James, Danelle Frances
Hillmen, Peter
TI A randomized, multicenter, open-label, phase III study of the Bruton
tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab
in patients (pts) with relapsed or refractory (RR) chronic lymphocytic
leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ohio State Univ, Columbus, OH 43210 USA.
Long Isl Jewish Med Ctr, Hyde Pk, NY USA.
Kings Coll London, London WC2R 2LS, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mayo Clin, Rochester, NY USA.
Vanderbilt Univ Sch Med, Nashville, TN USA.
Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Weill Cornell Med Coll, New York, NY USA.
Hosp Univ Penn, Philadelphia, PA 19104 USA.
Christie Hosp NHS Fdn Trust, Manchester, Lancs, England.
Princess Alexandra Hosp, Woodville, SA, Australia.
Hermitage Med Clin, Dublin, Ireland.
Royal Marsden Hosp NHS Fdn Trust, London, England.
Med Univ Vienna, Vienna, Austria.
Pharmacyclics Inc, Sunnyvale, CA USA.
Pharmacyclics, Sunnyvale, CA USA.
St James Univ Hosp, Leeds, W Yorkshire, England.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS8619
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605524
ER
PT J
AU Callander, NS
Jacobus, SJ
Weiss, M
Kumar, S
Fonseca, R
Siegel, DSD
Katz, MS
Abonour, R
Williams, ME
Greipp, PR
Rajkumar, V
AF Callander, Natalie Scott
Jacobus, Susanna J.
Weiss, Matthias
Kumar, Shaji
Fonseca, Rafael
Siegel, David Samuel DiCapua
Katz, Michael S.
Abonour, Rafat
Williams, Michael E.
Greipp, Philip R.
Rajkumar, Vincent
CA Eastern Cooperative Oncology Grp
TI Evaluation of protocol mandated testing in E4A03, a randomized phase III
study of CC-5013 plus dexamethasone versus CC-5013 plus low-dose
dexamethasone in multiple myeloma (MM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Wisconsin, Madison, WI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Marshfield CCOP, Marshfield, WI USA.
Mayo Clin, Rochester, MN USA.
Mayo Clin, Scottsdale, AZ USA.
Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
Int Myeloma Fdn, North Hollywood, CA USA.
Indiana Univ, Simon Canc Ctr, Indianapolis, IN 46204 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
RI Kumar, Shaji/A-9853-2008
OI Kumar, Shaji/0000-0001-5392-9284
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e19517
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604706
ER
PT J
AU Calvillo, KZ
Caragacianu, DL
Chun, YS
Caterson, S
Bellon, JR
Wong, JS
Troyan, S
Rhei, E
Dominici, LS
Economy, KE
Tung, NM
Schapira, L
Meisel, JL
Partridge, A
Mayer, EL
AF Calvillo, Katherina Zabicki
Caragacianu, Diana L.
Chun, Yoon S.
Caterson, Stephanie
Bellon, Jennifer Ruth
Wong, Julia S.
Troyan, Susan
Rhei, Esther
Dominici, Laura Stewart
Economy, Katherine E.
Tung, Nadine M.
Schapira, Lidia
Meisel, Jane L.
Partridge, Ann
Mayer, Erica L.
TI Immediate tissue expander breast reconstruction following mastectomy hi
pregnancy-associated breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1133
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600560
ER
PT J
AU Camidge, DR
Bazhenova, L
Salgia, R
Weiss, GJ
Langer, CJ
Shaw, AT
Narasimhan, NI
Dorer, DJ
Rivera, VM
Zhang, J
Clackson, T
Haluska, FG
Gettinger, SN
AF Camidge, D. Ross
Bazhenova, Lyudmila
Salgia, Ravi
Weiss, Glen J.
Langer, Corey J.
Shaw, Alice Tsang
Narasimhan, Narayana I.
Dorer, David J.
Rivera, Victor M.
Zhang, Joshua
Clackson, Tim
Haluska, Frank G.
Gettinger, Scott N.
TI First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in
patients with advanced malignancies: Updated results.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado, Ctr Canc, Aurora, CO USA.
UC San Diego Moores Canc Ctr, La Jolla, CA USA.
Univ Chicago, Chicago, IL 60637 USA.
Virginia G Piper Canc Ctr, Scottsdale Healthcare Program, Scottsdale, AZ USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
ARIAD Pharmaceut Inc, Cambridge, MA USA.
Yale Univ, Sch Med, New Haven, CT USA.
NR 0
TC 27
Z9 27
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8031
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602512
ER
PT J
AU Caragacianu, DL
Liu, XH
Norton, I
Ide, J
Richardson, A
Dillon, D
Jolesz, FA
Golshan, M
Agar, NYR
AF Caragacianu, Diana L.
Liu, Xiaohui
Norton, Isaiah
Ide, Jennifer
Richardson, Andrea
Dillon, Deborah
Jolesz, Ferenc A.
Golshan, Mehra
Agar, Nathalie Y. R.
TI Distinctive lipid profiles of human breast cancer and adjacent normal
tissues by desorption electrospray ionization mass spectrometry imaging
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 2
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1132
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600559
ER
PT J
AU Carey, LA
Berry, DA
Ollila, D
Harris, L
Krop, IE
Weckstein, D
Henry, NL
Anders, CK
Cirrincione, C
Winer, EP
Perou, CM
Hudis, C
AF Carey, Lisa A.
Berry, Donald A.
Ollila, David
Harris, Lyndsay
Krop, Ian E.
Weckstein, Douglas
Henry, Norah Lynn
Anders, Carey K.
Cirrincione, Constance
Winer, Eric P.
Perou, Charles M.
Hudis, Clifford
CA Alliance
TI Clinical and translational results of CALGB 40601: A neoadjuvant phase
III trial of weekly paclitaxel and trastuzumab with or without lapatinib
for HER2-positive breast cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Chapel Hill, NC USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Case Western Seidman Canc Ctr, Cleveland, OH USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
New Hampshire Oncol Hematol PA, Hooksett, NH USA.
Univ Michigan, Med Ctr, Ann Arbor, MI USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 16
Z9 16
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 500
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600007
ER
PT J
AU Cebon, JS
Flaherty, K
Weber, JS
Kim, K
Infante, JR
Daud, A
Hamid, O
Kefford, R
Schuchter, LM
Sosman, JA
Sznol, M
Sharfman, WH
Gonzalez, R
Andrews, MC
Dronca, RS
Long, G
Little, SM
Sun, P
Patel, K
McWilliams, RR
AF Cebon, Jonathan S.
Flaherty, Keith
Weber, Jeffrey S.
Kim, Kevin
Infante, Jeffrey R.
Daud, Adil
Hamid, Omid
Kefford, Richard
Schuchter, Lynn Mara
Sosman, Jeffrey Alan
Sznol, Mario
Sharfman, William Howard
Gonzalez, Rene
Andrews, Miles Cameron
Dronca, Roxana Stefania
Long, Georgina
Little, Shonda M.
Sun, Peng
Patel, Kiran
McWilliams, Robert R.
TI Comparison of BRAF inhibitor (BRAFi)-induced cutaneous squamous cell
carcinoma (cuSCC) and secondary malignancies in BRAF mutation-positive
metastatic melanoma (MM) patients (pts) treated with dabrafenib (D) as
monotherapy or in combination with MEK1/2 inhibitor (MEKi) trametinib
(T)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Ludwig Inst Canc Res, Melbourne, Vic 3050, Australia.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Comprehens Melanoma Res Ctr, Moffitt Canc Ctr, Tampa, FL USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Sarah Cannon Res Inst, Drug Dev Unit, Nashville, TN USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Westmead Hosp, Westmead, NSW 2145, Australia.
Melanoma Inst Australia, Westmead, NSW, Australia.
Univ Penn, Philadelphia, PA 19104 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Yale Univ, New Haven, CT USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Colorado Denver, Aurora, CO USA.
Ludwig Inst Canc Res, Austin Branch, Heidelberg, Vic, Australia.
Mayo Clin, Dept Med Oncol, Rochester, MN USA.
Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
GlaxoSmithKline, Collegeville, PA USA.
Mayo Clin, Rochester, MN USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9016
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602717
ER
PT J
AU Chandwani, KD
Zhao, FM
Morrow, GR
De Shields, T
Minasian, LM
Manola, J
Fisch, M
AF Chandwani, Kavita Dayal
Zhao, Fengmin
Morrow, Gary R.
De Shields, Teresa
Minasian, Lori M.
Manola, Judith
Fisch, Michael
TI Lack of patient-clinician concordance (LOC) across disease and treatment
status in cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Washington Univ, Sch Med St Louis, St Louis, MO USA.
NCI, Bethesda, MD 20892 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20520
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604791
ER
PT J
AU Chapman, JAW
Shepherd, LE
Ingle, JN
Muss, HB
Pritchard, KI
Gelmon, KA
Whelan, TJ
Elliott, C
Goss, PE
AF Chapman, Judy-Anne W.
Shepherd, Lois E.
Ingle, James N.
Muss, Hyman Bernard
Pritchard, Kathleen I.
Gelmon, Karen A.
Whelan, Timothy Joseph
Elliott, Catherine
Goss, Paul E.
TI Competing risks of death in NCIC CTG MA.27 adjuvant exemestane versus
anastrozole.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Queens Univ, NCIC Clin Trials Grp, Kingston, ON, Canada.
Mayo Clin, Rochester, MN USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
British Columbia Canc Agcy, Vancouver Ctr, Vancouver, BC V5Z 4E6, Canada.
McMaster Univ, Juravinski Canc Ctr Hamilton Hlth Sci, Hamilton, ON, Canada.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI Whelan, Timothy/D-3185-2017
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 564
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600069
ER
PT J
AU Chauhan, D
Ray, A
Brooks, C
Rowinsky, EK
Anderson, KC
AF Chauhan, Dharminder
Ray, Arghya
Brooks, Christopher
Rowinsky, Eric K.
Anderson, Kenneth Carl
TI Effect of a novel agent, SL-401, targeting interleukin-3 (IL-3)-receptor
on plasmacytoid dendritic cell (pDC)-induced myeloma cell growth and
drug resistance
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Stemline Therapeut Inc, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8582
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602677
ER
PT J
AU Chawla, N
Yabroff, KR
Mariotto, A
McNeel, TS
Schrag, D
Warren, JL
AF Chawla, Neetu
Yabroff, K. Robin
Mariotto, Angela
McNeel, Timothy S.
Schrag, Deborah
Warren, Joan L.
TI Accuracy and completeness of diagnosis codes for cancer metastasis on
Medicare claims
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Bethesda, MD 20892 USA.
IMS, Rockville, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6521
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602240
ER
PT J
AU Chawla, SP
Blay, JY
Italiano, A
Gutierrez, M
Le Cesne, A
Gomez-Roca, CA
Gouw, LG
von Mehren, M
Wagner, A
Maki, RG
Higgins, B
Middleton, S
Nichols, GL
Geho, D
Blotner, S
Zhi, JG
Chen, LC
AF Chawla, Sant P.
Blay, Jean-Yves
Italiano, Antoine
Gutierrez, Martin
Le Cesne, Axel
Gomez-Roca, Carlos Alberto
Gouw, Launce G.
von Mehren, Margaret
Wagner, Andrew
Maki, Robert G.
Higgins, Brian
Middleton, Steven
Nichols, Gwen L.
Geho, David
Blotner, Steven
Zhi, Jianguo
Chen, Lin Chi
TI Phase Ib study of RG7112 with doxorubicin (D) in advanced soft tissue
sarcoma (ASTS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarcoma Oncol Ctr, Santa Monica, CA USA.
Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France.
Inst Bergonie, Bordeaux, France.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Inst Gustave Roussy, Villejuif, France.
Inst Claudius Regaud, Toulouse, France.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mt Sinai Sch Med, New York, NY USA.
Hoffmann La Roche Inc, Translat Clin Res Ctr, Oncol Translat Med Grp, Nutley, NJ 07110 USA.
Hoffmann La Roche Inc, Translat Clin Res Ctr, Nutley, NJ 07110 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10514
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600286
ER
PT J
AU Chi, KN
Sweeney, C
Jacobs, C
Stewart, PS
Hahn, NM
AF Chi, Kim N.
Sweeney, Christopher
Jacobs, Cindy
Stewart, Patricia S.
Hahn, Noah M.
TI The Pacific trial: A randomized phase II study of OGX-427 in men with
metastatic castration-resistant prostate cancer (mCRPC) and PSA
progression while receiving abiraterone acetate (AA).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Dana Farber Canc Inst, Boston, MA 02115 USA.
OncoGenex Pharmaceut Inc, Bothell, WA USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS5101
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605464
ER
PT J
AU Chi, KN
San Kheoh, T
Ryan, CJ
Molina, A
Bellmunt, J
Vogelzang, NJ
Rathkopf, DE
Fizazi, K
Kantoff, PW
Li, JH
De Bono, JS
Scher, HI
AF Chi, Kim N.
San Kheoh, Thian
Ryan, Charles J.
Molina, Arturo
Bellmunt, Joaquim
Vogelzang, Nicholas J.
Rathkopf, Dana E.
Fizazi, Karim
Kantoff, Philip W.
Li, Jinhui
De Bono, Johann Sebastian
Scher, Howard I.
TI A prognostic model for predicting overall survival (OS) in patients
(pts) with metastatic castration-resistant prostate cancer (mCRPC)
treated with abiraterone acetate (AA) after docetaxel.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Janssen Res & Dev LLC, Los Angeles, CA USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Hosp del Mar, Barcelona, Spain.
Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Janssen Res & Dev LLC, Raritan, NJ USA.
Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5013
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601614
ER
PT J
AU Chinnaiyan, P
Won, M
Wen, PY
Rojiani, A
Wendland, MM
DiPetrillo, TA
Corn, BW
Mehta, MP
AF Chinnaiyan, Prakash
Won, Minhee
Wen, Patrick Y.
Rojiani, Amyn
Wendland, Merideth M.
DiPetrillo, Thomas A.
Corn, Benjamin W.
Mehta, Minesh P.
TI RTOG 0913: A phase I study of daily everolimus (RAD001) in combination
with radiation therapy and temozolomide in patients with newly diagnosed
glioblastoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Radiat Therapy Oncol Grp, Philadelphia, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgia Hlth Sci Univ, Augusta, GA USA.
Willamette Valley Canc Inst, Eugene, OR USA.
Rhode Isl Hosp, Dept Radiat Oncol, Providence, RI USA.
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
Univ Maryland, Baltimore, MD 21201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2047
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600708
ER
PT J
AU Chino, F
Peppercorn, JM
Tulsky, JA
Ubel, PA
Schrag, D
Rushing, C
Nicolla, J
Altomare, I
Samsa, G
Abernethy, AP
Zafar, Y
AF Chino, Fumiko
Peppercorn, Jeffrey M.
Tulsky, James A.
Ubel, Peter A.
Schrag, Deborah
Rushing, Christel
Nicolla, Jonathan
Altomare, Ivy
Samsa, Greg
Abernethy, Amy Pickar
Zafar, Yousuf
TI The financial burden of cancer care: Do patients know what to expect?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Sch Med, Durham, NC USA.
Duke Canc Inst, Durham, NC USA.
Duke Univ, Med Ctr, Ctr Palliat Care, Durham, NC USA.
Duke Univ, Fuqua Sch Business, Durham, NC 27706 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Med Ctr, Dept Biostat & Informat, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6516
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602235
ER
PT J
AU Chittoria, N
Zhu, H
Choueiri, TK
Kroeger, N
Lee, JL
Srinivas, S
Knox, J
Bjarnason, GA
MacKenzie, MJ
Wood, L
Vaishamayan, UN
Agarwal, N
Pal, SK
Tan, MH
Rha, SY
Yuasa, T
Donskov, F
North, SA
Rini, BI
Heng, DYC
AF Chittoria, Namita
Zhu, Hui
Choueiri, Toni K.
Kroeger, Nils
Lee, Jae-Lyun
Srinivas, Sandy
Knox, Jennifer
Bjarnason, Georg A.
MacKenzie, Mary J.
Wood, Lori
Vaishamayan, Ulka N.
Agarwal, Neeraj
Pal, Sumanta Kumar
Tan, Min-Han
Rha, Sun Young
Yuasa, Takeshi
Donskov, Frede
North, Scott A.
Rini, Brian I.
Heng, Daniel Yick Chin
TI Outcome of metastatic sarcomatoid renal cell carcinoma (sRCC): Results
from the International mRCC Database Consortium
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Stanford Med Ctr, Stanford, CA USA.
Univ Toronto, Princess Margaret Hosp, Toronto, ON, Canada.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
London Reg Canc Program, London, ON, Canada.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Natl Canc Ctr Singapore, Singapore, Singapore.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
Akita Univ, Sch Med, Dept Urol, Akita 010, Japan.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4565
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601579
ER
PT J
AU Chmielowski, B
Hamid, O
Minor, DR
D'Angelo, SP
Pennock, GK
Grossmann, K
Ascierto, PA
Daud, A
Dummer, R
Hodi, FS
Lebbe, C
Robert, C
Sosman, JA
Yang, A
Lambert, A
Weber, JS
AF Chmielowski, Bartosz
Hamid, Omid
Minor, David R.
D'Angelo, Sandra P.
Pennock, Gregory K.
Grossmann, Kenneth
Ascierto, Paolo Antonio
Daud, Adil
Dummer, Reinhard
Hodi, F. Stephen
Lebbe, Celeste
Robert, Caroline
Sosman, Jeffrey Alan
Yang, Arvin
Lambert, Alexandre
Weber, Jeffrey S.
TI A phase III open-label study of nivolumab (anti-PD-1; BMS-936558;
ONO-4538) versus investigator's choice in advanced melanoma patients
progressing post anti-CTLA-4 therapy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Calif Pacific Ctr Melanoma Res & Treatment, San Francisco, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Texas MD Anderson Canc Ctr, Orlando, FL USA.
Huntsman Canc Inst, Salt Lake City, UT USA.
Fdn Pascale, Ist Nazl Tumori, Naples, Italy.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Paris 07, Hop St Louis, Paris, France.
Inst Gustave Roussy, Villejuif, France.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Bristol Myers Squibb Co, Braine Lalleud, Belgium.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS9105
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605527
ER
PT J
AU Cho, DC
Sosman, JA
Sznol, M
Gordon, MS
Hollebecque, A
Hamid, O
McDermott, DF
Delord, JP
Rhee, IP
Mokatrin, A
Kowanetz, M
Funke, RP
Fine, GD
Powles, T
AF Cho, Daniel C.
Sosman, Jeffrey Alan
Sznol, Mario
Gordon, Michael S.
Hollebecque, Antoine
Hamid, Omid
McDermott, David F.
Delord, Jean-Pierre
Rhee, Ina Park
Mokatrin, Ahmad
Kowanetz, Marcin
Funke, Roel Peter
Fine, Gregg Daniel
Powles, Thomas
TI Clinical activity, safety, and biomarkers of MPDL3280A, an engineered
PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Yale Univ, New Haven, CT USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Inst Gustave Roussy, Villejuif, France.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Claudius Regaud, Toulouse, France.
Genentech Inc, San Francisco, CA 94080 USA.
Barts Hlth NHS Trust, QMUL, Barts Canc Inst, London, England.
RI DELORD, Jean-Pierre/I-8866-2014
NR 0
TC 0
Z9 0
U1 1
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4505
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601521
ER
PT J
AU Chong, CR
Wirth, LJ
Chen, AB
Sholl, LM
Janne, PA
Johnson, BE
AF Chong, Curtis Robert
Wirth, Lori J.
Chen, Aileen B.
Sholl, Lynette M.
Janne, Pasi Antero
Johnson, Bruce E.
TI Medical management of pulmonary carcinoid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e18512
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604496
ER
PT J
AU Choti, MA
Bobiak, S
Bloomston, M
Zornosa, CC
Bergsland, EK
Strosberg, JR
Benson, A
Kulke, M
Shah, MH
Nakakura, EK
Yao, JC
AF Choti, Michael A.
Bobiak, Sarah
Bloomston, Mark
Zornosa, Carrie C.
Bergsland, Emily K.
Strosberg, Jonathan R.
Benson, Al Bowen
Kulke, Matthew
Shah, Manisha H.
Nakakura, Eric K.
Yao, James C.
TI Treatment of liver metastases in patients with neuroendocrine tumors: A
National Comprehensive Cancer Network analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Natl Comprehens Canc Network, Ft Washington, PA USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Richard J Solove Res Inst, Columbus, OH USA.
Univ Calif San Francisco, Ctr Comprehens Canc, San Francisco, CA 94143 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
UCSF, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RI Bloomston, Mark/E-2767-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4143
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601516
ER
PT J
AU Cloughesy, TF
Mischel, PS
Omuro, AMP
Prados, M
Wen, PY
Wu, B
Rockich, K
Xu, Y
Lager, JJ
Mellinghoff, IK
AF Cloughesy, Timothy Francis
Mischel, Paul S.
Omuro, Antonio Marcilio Padula
Prados, Michael
Wen, Patrick Y.
Wu, Bin
Rockich, Kevin
Xu, Yi
Lager, Joanne J.
Mellinghoff, Ingo K.
TI Tumor pharmocokinetics (PK) and pharmocodynamics (PD) of SAR245409
(XL765) and SAR245408 (XL147) administered as single agents to patients
with recurrent glioblastoma (GBM): An Ivy Foundation early-phase
clinical trials consortium study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Ludwig Inst Canc Res, La Jolla, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Sanofi Aventis, Cambridge, MA USA.
Sanofi Aventis, Bridgewater, NJ USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2012
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600673
ER
PT J
AU Corcoran, C
Rani, S
Breslin, S
Ghobrial, IM
Crown, J
O'Driscoll, L
AF Corcoran, Claire
Rani, Sweta
Breslin, Susan
Ghobrial, Irene M.
Crown, John
O'Driscoll, Lorraine
TI The potential of miR-630, an IGF1R regulator, as a predictive biomarker
for HER2-targeted drugs.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Trinity Coll Dublin, Sch Pharm & Pharmaceut Sci, Dublin, Ireland.
Trinity Coll Dublin, Trinity Biomed Sci Inst, Dublin, Ireland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Irish Clin Oncol Res Grp & Mol Therapeut Canc Ire, Dublin, Ireland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 620
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600125
ER
PT J
AU Corcoran, RB
Falchook, GS
Infante, JR
Messersmith, OHWA
Daud, A
Kwak, EL
Ryan, DP
Kurzrock, R
Atreya, CE
Luan, J
Sun, P
Schaeffer, M
Motwani, M
Bleam, MR
Moy, CH
Patel, K
Orford, KW
Kopetz, S
Venook, AP
AF Corcoran, Ryan Bruce
Falchook, Gerald Steven
Infante, Jeffrey R.
Messersmith, Omid Hamid Wells A.
Daud, Adil
Kwak, Eunice Lee
Ryan, David P.
Kurzrock, Razelle
Atreya, Chloe Evelyn
Luan, Jennifer
Sun, Peng
Schaeffer, Megan
Motwani, Monica
Bleam, Maureen R.
Moy, Christopher H.
Patel, Kiran
Orford, Keith W.
Kopetz, Scott
Venook, Alan Paul
TI Pharmacodynamic and efficacy analysis of the BRAF inhibitor dabrafenib
(GSK436) in combination with the MEK inhibitor trametinib (GSK212) in
patients with BRAFV600 mutant colorectal cancer (CRC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
PLLC, SCRI Tennessee Oncol, Nashville, TN USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Univ Colorado, Dept Med Oncol, Aurora, CO USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
GlaxoSmithKline, Collegeville, PA USA.
GlaxoSmithKline, Oncol R&D, Collegeville, PA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3507
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601243
ER
PT J
AU D'Souza, G
Gross, ND
Pai, SI
Haddad, RI
Gillison, ML
Posner, MR
AF D'Souza, Gypsyamber
Gross, Neil D.
Pai, Sara I.
Haddad, Robert I.
Gillison, Maura L.
Posner, Marshall R.
TI Oral HPV infection in HPV-positive oropharyngeal cancer cases and their
spouses
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Bloomberg Sch Publ Hlth, Baltimore, MD USA.
Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Columbus, OH 43210 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA CRA6031
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603132
ER
PT J
AU Daud, A
Kluger, HM
Edelman, G
Gordon, MS
Schimmoller, F
Weitzman, A
Samuel, TA
Moussa, AH
Flaherty, K
Shapiro, G
AF Daud, Adil
Kluger, Harriet M.
Edelman, Gerald
Gordon, Michael S.
Schimmoller, Frauke
Weitzman, Aaron
Samuel, Thomas A.
Moussa, Ali H.
Flaherty, Keith
Shapiro, Geoffrey
TI Activity of cabozantinib in metastatic uveal melanoma: Updated results
from a phase II randomized discontinuation trial (RDT)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, San Francisco, CA 94143 USA.
Yale Univ, New Haven, CT USA.
Texas Oncol, Irving, TX USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Exelixis Inc, San Francisco, CA USA.
Georgia Regents Univ, Augusta, GA USA.
Canc Care Associates, Tulsa, OK USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9094
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602795
ER
PT J
AU Davids, MS
Seymour, JF
Gerecitano, JF
Kahl, BS
Pagel, JM
Wierda, WG
Anderson, MA
Darden, DE
Nolan, CE
Gressick, LA
Yang, JN
Chyla, BJ
Busman, TA
Graham, AM
Cerri, E
Enschede, SH
Humerickhouse, RA
Roberts, AW
AF Davids, Matthew Steven
Seymour, John Francis
Gerecitano, John F.
Kahl, Brad S.
Pagel, John M.
Wierda, William G.
Anderson, Mary Ann
Darden, David E.
Nolan, Cathy E.
Gressick, Lori A.
Yang, Jianning
Chyla, Brenda J.
Busman, Todd A.
Graham, Alison M.
Cerri, Elisa
Enschede, Sari H.
Humerickhouse, Rod A.
Roberts, Andrew W.
TI Updated results of a phase I first-in-human study of the BCL-2 inhibitor
ABT-199 (GDC-0199) in patients with relapsed/refractory non-Hodgkin
lymphoma (NHL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Univ Washington, Seattle, WA 98195 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Royal Melbourne Hosp, Walter & Eliza Hall Inst Med Res, Parkville, Vic 3050, Australia.
AbbVie Inc, N Chicago, IL USA.
Royal Melbourne Hosp, Parkville, Vic 3050, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8520
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602616
ER
PT J
AU De Azambuja, E
Procter, MJ
van Veldhuisen, D
Agbor-Tarh, D
Metzger, O
Steinseifer, J
Untch, M
Smith, IE
Gianni, L
Baselga, J
Jackisch, C
Cameron, DA
Bell, R
Leyland-Jones, B
Dowsett, M
Gelber, RD
Piccart-Gebhart, MJ
Suter, T
AF De Azambuja, Evandro
Procter, Marion Jennifer
van Veldhuisen, Dirk
Agbor-Tarh, Dominique
Metzger Filho, Otto
Steinseifer, Jutta
Untch, Michael
Smith, Ian E.
Gianni, Luca
Baselga, Jose
Jackisch, Christian
Cameron, David A.
Bell, Richard
Leyland-Jones, Brian
Dowsett, Mitchell
Gelber, Richard D.
Piccart-Gebhart, Martine J.
Suter, Thomas
TI Long-term (8 years) assessment of trastuzumab-related cardiac events in
the HERA trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
FSS, Kingussie, Scotland.
Univ Med Ctr Groningen, Dept Cardiol, NL-9713 AV Groningen, Netherlands.
FSS, Kincraig, Scotland.
Dana Farber Canc Inst, Boston, MA 02115 USA.
F Hoffmann La Roche Ltd, Basel, Switzerland.
Helios Klinikum Berlin Buch, Dept Gynecol & Obstet, Berlin, Germany.
Helios Klinikum Berlin Buch, Multidisciplinary Breast Canc Ctr, Berlin, Germany.
Royal Marsden Hosp NHS Fdn Trust, London, England.
Ist Sci San Raffaele, I-20132 Milan, Italy.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Klinikum Offenbach, Offenbach, Germany.
Univ Edinburgh, Edinburgh, Midlothian, Scotland.
Barwon Hlth, Geelong, Vic, Australia.
Edith Sanford Breast Canc Res Inst, Sioux Falls, SD USA.
Frontier Sci & Technol Res Fdn Inc, IBCSG, Dana Farber Canc Inst, Dept Biostat & Computat, Boston, MA USA.
Inst Jules Bordet, B-1000 Brussels, Belgium.
Univ Hosp Bern, Inselspital, Swiss Cardiovasc Ctr, CH-3010 Bern, Switzerland.
RI Steinseifer-Szabo, Jutta/A-2083-2014; Steinseifer-Szabo,
Jutta/A-4840-2013
OI Steinseifer-Szabo, Jutta/0000-0002-1358-6245
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 525
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600030
ER
PT J
AU Rodrigues, MCD
Rodriguez-Galindo, C
Ribeiro, KB
Frazier, AL
AF de Faria Soares Rodrigues, Maria Clarissa
Rodriguez-Galindo, Carlos
Ribeiro, Karina Braga
Frazier, A. Lindsay
TI Elevated risk of second malignant neoplasms in pediatric germ cell tumor
patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10010
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600164
ER
PT J
AU de Wit, D
van Erp, NP
Khosravan, R
Wiltshire, R
Allred, RU
Demetri, GD
Guchelaar, HJ
Gelderblom, H
AF de Wit, Djoeke
van Erp, Nielka P.
Khosravan, Reza
Wiltshire, Robin
Allred, Randy U.
Demetri, George D.
Guchelaar, Henk-Jan
Gelderblom, Hans
TI The influence of gastrointestinal resection on sunitinib exposure in
GIST patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Leiden Univ, Med Ctr, Dept Clin Pharm & Toxicol, Leiden, Netherlands.
Radboud Univ Nijmegen Med Ctr, Dept Clin Pharm, Nijmegen, Netherlands.
Pfizer Oncol, La Jolla, CA USA.
Pfizer Oncol, Tadworth, England.
Pfizer Inc, La Jolla, CA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
RI van Erp, Nielka/A-1907-2016
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10547
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600321
ER
PT J
AU Demetri, GD
Jeffers, M
Reichardt, P
Kang, YK
Blay, JY
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, MG
von Mehren, M
Joensuu, H
Badalamenti, G
Blackstein, ME
Le Cesne, A
Schoffski, P
Maki, RG
Xu, JM
Nishida, T
Kuss, I
Casali, PG
AF Demetri, George D.
Jeffers, Michael
Reichardt, Peter
Kang, Yoon-Koo
Blay, Jean-Yves
Rutkowski, Piotr
Gelderblom, Hans
Hohenberger, Peter
Leahy, Michael Gordon
von Mehren, Margaret
Joensuu, Heikki
Badalamenti, Giuseppe
Blackstein, Martin E.
Le Cesne, Axel
Schoffski, Patrick
Maki, Robert G.
Xu, Jian-Ming
Nishida, Toshirou
Kuss, Iris
Casali, Paolo Giovanni
TI Mutational analysis of plasma DNA from patients (pts) in the phase III
GRID study of regorafenib (REC) versus placebo (PL) in tyrosine kinase
inhibitor (TKI)-refractory GIST: Correlating genotype with clinical
outcomes.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Bayer HealthCare Pharmaceut, Montville, NJ USA.
HELIOS Klinikum Berlin Buch, Berlin, Germany.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Ctr Leon Berard, F-69373 Lyon, France.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
Leiden Univ, Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
Univ Mannheim, Med Ctr, Dept Surg, D-68131 Mannheim, Germany.
Christie Hosp NHS Fdn Trust, Manchester, Lancs, England.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Helsinki, Cent Hosp, Dept Oncol, Helsinki, Finland.
Univ Palermo, Dept Surg & Oncol Sci, Palermo, Italy.
Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
Inst Gustave Roussy, Villejuif, France.
Katholieke Univ Leuven, Louvain, Belgium.
Katholieke Univ Leuven Hosp, Leuven, Belgium.
Mt Sinai Sch Med, New York, NY USA.
Acad Mil Med Sci, Hosp 307, Beijing, Peoples R China.
Osaka Police Hosp, Dept Surg, Osaka, Japan.
Bayer HealthCare Pharmaceut, Berlin, Germany.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10503
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600276
ER
PT J
AU Dhimolea, E
Mitsiades, CS
AF Dhimolea, Eugen
Mitsiades, Constantine S.
TI Effect of nonmalignant accessory cells from the metastatic
microenvironment on breast cancer cell resistance to antiestrogens.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 11039
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600451
ER
PT J
AU Doebele, RC
Vaishnavi, A
Capelletti, M
Le, AT
Kako, S
Butaney, M
Mahale, S
Aisner, DL
Haas, J
Andrews, SW
Lipson, D
Stephens, PJ
Varella-Garcia, M
Janne, PA
Miller, VA
AF Doebele, Robert Charles
Vaishnavi, Aria
Capelletti, Marzia
Le, Anh T.
Kako, Severine
Butaney, Mohit
Mahale, Sakshi
Aisner, Dara L.
Haas, Julia
Andrews, Steven W.
Lipson, Doron
Stephens, Philip J.
Varella-Garcia, Marileila
Janne, Pasi Antero
Miller, Vincent A.
TI NTRK1 gene fusions as a novel oncogene target in lung cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado, Ctr Canc, Aurora, CO USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Array BioPharma, Boulder, CO USA.
Fdn Med Inc, Cambridge, MA USA.
Fdn Med, Cambridge, MA USA.
Univ Colorado, Sch Med, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8023
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602504
ER
PT J
AU Dougherty, DW
Kadlubek, P
Pham, T
Earle, C
Malin, J
Breathwaite, L
Jacobson, JO
AF Dougherty, David W.
Kadlubek, Pamela
Pham, Trang
Earle, Craig
Malin, Jennifer
Breathwaite, Larry
Jacobson, Joseph O.
TI Opportunities for improved end-of-life (EOL) care for adult patients
with advanced cancer: Results of a longitudinal assessment of care
provided by Quality Oncology Practice Initiative (QOPI) participants
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Rochester, Med Ctr, Rochester, NY 14642 USA.
Amer Soc Clin Oncol, Alexandria, VA USA.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
WellPoint Inc, Indianapolis, IN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9537
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603020
ER
PT J
AU Drabick, JJ
Lapsiwala, R
Talamo, G
Epner, EE
Supko, JG
Claxton, D
Ehmann, WC
Lander, M
Pierre, MS
Rybka, WB
AF Drabick, Joseph J.
Lapsiwala, Ritu
Talamo, Giampaolo
Epner, Elliot E.
Supko, Jeffrey G.
Claxton, David
Ehmann, W. Christopher
Lander, Mary
Pierre, Michelle St.
Rybka, Witold B.
TI A phase II pilot efficacy trial of the combination regimen peg
asparaginase/peg liposomal doxorubicin/dexamethasone (ODD) in patients
with refractory lymphoid malignancies (NCT00837200).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Penn State Hershey Canc Inst, Hershey, PA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e19502
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604691
ER
PT J
AU Drake, CG
McDermott, DF
Sznol, M
Choueiri, TK
Kluger, HM
Powderly, JD
Smith, DC
Sankar, V
Gutierrez, AA
Wigginton, JM
Kollia, G
Gupta, AK
Atkins, MB
AF Drake, Charles G.
McDermott, David F.
Sznol, Mario
Choueiri, Toni K.
Kluger, Harriet M.
Powderly, John D.
Smith, David C.
Sankar, Vindira
Gutierrez, Andres A.
Wigginton, Jon M.
Kollia, Georgia
Gupta, Ashok Kumar
Atkins, Michael B.
TI Survival, safety, and response duration results of nivolumab (Anti-PD-1;
BMS-936558; ONO-4538) in a phase I trial in patients with previously
treated metastatic renal cell carcinoma (mRCC): Long-term patient
follow-up
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Canc Ctr, New Haven, CT USA.
Yale Univ, New Haven, CT USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Georgetown Univ, Lombardi Comprehens Canc Ctr, Washington, DC USA.
NR 0
TC 19
Z9 19
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4514
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601528
ER
PT J
AU Drazer, M
Prasad, SM
Huo, DZ
Schonberg, MA
Szmulewitz, RZ
Dale, W
Eggener, SE
AF Drazer, Michael
Prasad, Sandip M.
Huo, Dezheng
Schonberg, Mara A.
Szmulewitz, Russell Zelig
Dale, William
Eggener, Scott E.
TI PSA screening rates in older men in the United States based on nine-year
estimated remaining life expectancy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Chicago, IL 60637 USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16006
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604199
ER
PT J
AU Dummer, R
Robert, C
Nyakas, M
McArthur, GA
Kudchadkar, RR
Gomez-Roca, C
Sullivan, RJ
Flaherty, K
Murer, C
Michel, D
Tang, ZW
De Parseval, LA
Delord, JP
AF Dummer, Reinhard
Robert, Caroline
Nyakas, Marta
McArthur, Grant A.
Kudchadkar, Ragini Reiney
Gomez-Roca, Carlos
Sullivan, Ryan J.
Flaherty, Keith
Murer, Carla
Michel, Daniela
Tang, Zhongwen
De Parseval, Laure A.
Delord, Jean-Pierre
TI Initial results from a phase I, open-label, dose escalation study of the
oral BRAF inhibitor LGX818 in patients with BRAF V600 mutant advanced or
metastatic melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Inst Gustave Roussy, Villejuif, France.
Oslo Univ Hosp, Oslo, Norway.
Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Inst Claudius Regaud, Toulouse, France.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Novartis Pharma AG, Basel, Switzerland.
Novartis Pharmaceut, E Hanover, NJ USA.
RI DELORD, Jean-Pierre/I-8866-2014
NR 0
TC 10
Z9 10
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9028
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602729
ER
PT J
AU Duquette, M
Sadow, PM
Priolo, C
Fischer, A
Hodin, R
Parangi, S
Lawler, J
Nucera, C
AF Duquette, Mark
Sadow, Peter M.
Priolo, Carmen
Fischer, Andrew
Hodin, Richard
Parangi, Sareh
Lawler, Jack
Nucera, Carmelo
TI Investigating an orally available small-molecule inhibitor (vemurafenib)
of BRAF(V600E) in a novel preclinical model of human papillary thyroid
cancer.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Med Ctr, Beth Israel Deaconess Med Ctr, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Univ Massachusetts, Worcester, MA 01605 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e17014
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604357
ER
PT J
AU Enzinger, AC
Zhang, BH
Balboni, TA
Schrag, D
Prigerson, HG
AF Enzinger, Andrea Catherine
Zhang, Baohui
Balboni, Tracy A.
Schrag, Deborah
Prigerson, Holly Gwen
TI Outcomes of prognostic disclosure: Effects on advanced cancer patients'
prognostic understanding, mental health, and relationship with their
oncologist
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9519
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603002
ER
PT J
AU Epstein, AS
Shuk, E
Gary, K
O'Reilly, EM
Volandes, AE
AF Epstein, Andrew S.
Shuk, Elyse
Gary, Kristen
O'Reilly, Eileen Mary
Volandes, Angelo E.
TI Advanced pancreas and hepatobiliary (PHB) cancer patients' impressions
regarding cardiopulmonary resuscitation (CPR).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20586
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604844
ER
PT J
AU Eradat, HA
Coutre, SE
Barrientos, JC
Rai, KR
Farber, CM
Hillmen, P
Sharman, JP
Ghia, P
Coiffier, B
Walewski, JA
Berneman, ZN
O'Brien, SM
Brown, JR
Peterman, S
Dansey, RD
Jahn, TM
Cramer, P
Hallek, MJ
AF Eradat, Herbert Aaron
Coutre, Steven E.
Barrientos, Jacqueline Claudia
Rai, Kanti Roop
Farber, Charles Michael
Hillmen, Peter
Sharman, Jeff Porter
Ghia, Paolo
Coiffier, Bertrand
Walewski, Jan Andrzej
Berneman, Zwi N.
O'Brien, Susan Mary
Brown, Jennifer R.
Peterman, Sissy
Dansey, Roger D.
Jahn, Thomas Michael
Cramer, Paula
Hallek, Michael J.
TI A phase III, randomized, double-blind, placebo-controlled study
evaluating the efficacy and safety of idelalisib (GS-1101) in
combination with bendamustine and rituximab for previously treated
chronic lymphocytic leukemia (CLL).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
Stanford Canc Inst, Stanford, CA USA.
Hofstra North Shore LIJ Sch Med, Hyde Pk, NY USA.
Morristown Mem Hosp, Carol G Simon Canc Ctr, Morristown, NJ USA.
St James Univ Hosp, Leeds, W Yorkshire, England.
US Oncol Res, Willamette Valley Canc Inst, Springfield, OR USA.
Univ Vita Salute San Raffaele, Milan, Italy.
Ist Sci San Raffaele, Milan, Italy.
Hosp Civils Lyon Sud, Pierre Benite, France.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
Univ Antwerp Hosp, Edegem, Belgium.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Gilead Sci Inc, Seattle, WA USA.
Univ Cologne, D-50931 Cologne, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS7133
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605505
ER
PT J
AU Farley, JH
Brady, WE
Birrer, MJ
Gershenson, DM
Fleming, GF
AF Farley, John H.
Brady, William E.
Birrer, Michael J.
Gershenson, David Marc
Fleming, Gini F.
CA Gynecologic Oncology Grp
TI An evaluation of survival of ovarian cancer patients with clear cell
carcinoma versus serous carcinoma treated with platinum therapy: A
Gynecologic Oncology Group experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Arizona, Sch Med, Phoenix, AZ USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Alliance Clin Trials Oncol, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5534
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602048
ER
PT J
AU Fletcher, KM
Prigerson, HG
Maciejewski, PK
AF Fletcher, Kalen Michele
Prigerson, Holly Gwen
Maciejewski, Paul K.
TI Patients' perceptions of caregivers' preference for comfort care at the
EOL: Impact on DNR completion
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9521
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603004
ER
PT J
AU Forero-Torres, A
Rugo, HS
Vaklavas, C
Lin, NU
Carey, LA
Liu, MC
Nanda, R
Puhalla, S
Storniolo, AM
Krontiras, H
Saleh, MN
Li, YF
LoBuglio, AF
De Los Santos, JF
AF Forero-Torres, Andres
Rugo, Hope S.
Vaklavas, Christos
Lin, Nancy U.
Carey, Lisa A.
Liu, Minetta C.
Nanda, Rita
Puhalla, Shannon
Storniolo, Anna Maria
Krontiras, Helen
Saleh, Mansoor N.
Li, Yufeng
LoBuglio, Albert F.
De Los Santos, Jennifer F.
CA Translational Breast Canc Res
TI TBCRC 002: A phase II, randomized, open label trial of preoperative
letrozole versus letrozole (LET) in combination with bevacizumab (BEV)
in post-menopausal women with newly diagnosed stage II/III breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Alabama Birmingham, Birmingham, AL USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ North Carolina Lineberger Comprehens Canc Ct, Chapel Hill, NC USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Pittsburgh Med Ctr, Magee Womens Canc Program, Pittsburgh, PA USA.
Indiana Univ Simon Canc Ctr, Indianapolis, IN USA.
Georgia Canc Specialists PC, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 527
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600032
ER
PT J
AU Freedman, RA
Luis, IMVD
Lin, N
Lii, J
Winer, EP
Keating, NL
AF Freedman, Rachel A.
Luis, Ines Maria Vaz Duarte
Lin, Nancy
Lii, Joyce
Winer, Eric P.
Keating, Nancy Lynn
TI Completion of adjuvant trastuzumab for older patients with early-stage
breast cancer (BC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Hosp Santa Maria, Dept Oncol, Lisbon, Portugal.
Univ Lisbon, Inst Mol Med, P-1699 Lisbon, Portugal.
Brigham & Womens Hosp, Div Pharmacoepidemiol & Pharmacoecon, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 616
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600121
ER
PT J
AU Funahashi, Y
Penson, RT
Powell, MA
Miller, DS
Fan, J
Ren, M
Meneses, N
Sachdev, P
Kadowaki, T
O'Brien, JP
Vergote, I
AF Funahashi, Yasuhiro
Penson, Richard T.
Powell, Matthew A.
Miller, David S.
Fan, Jean
Ren, Min
Meneses, Nicole
Sachdev, Pallavi
Kadowaki, Tadashi
O'Brien, James P.
Vergote, Ignace
TI Analysis of plasma biomarker and tumor genetic alterations from a phase
II trial of lenvatinib in patients with advanced endometrial cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Eisai Inc, Andover, MA USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Washington Univ, Sch Med, St Louis, MO USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Eisai Inc, Woodcliff Lake, NJ USA.
UZ Leuven, Louvain, Belgium.
RI Miller, David/H-4604-2011
OI Miller, David/0000-0002-8215-5887
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5591
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602104
ER
PT J
AU Gainor, JF
Varghese, AM
Ou, SHI
Kabraji, S
Awad, MM
Katayama, R
Pawlak, A
Mino-Kenudson, M
Yeap, BY
Riely, GJ
Iafrate, AJ
Arcila, ME
Ladanyi, M
Engelman, JA
Dias-Santagata, D
Shaw, AT
AF Gainor, Justin F.
Varghese, Anna M.
Ou, Sai-Hong Ignatius
Kabraji, Sheheryar
Awad, Mark M.
Katayama, Ryohei
Pawlak, Amanda
Mino-Kenudson, Mari
Yeap, Beow Y.
Riely, Gregory J.
Iafrate, Anthony John
Arcila, Maria E.
Ladanyi, Marc
Engelman, Jeffrey A.
Dias-Santagata, Dora
Shaw, Alice Tsang
TI A retrospective analysis of the prevalence of EGFR or KRAS mutations in
patients (pts) with crizotinib-naive and crizotinib-resistant,
ALK-positive non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Chao Family Comprehens Canc Ctr, Orange, CA USA.
Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8083
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602562
ER
PT J
AU Galanis, E
Sarkaria, JN
Anderson, SK
Wu, WT
Jaeckle, KA
Giannini, C
Buckner, JC
Wen, PY
AF Galanis, Evanthia
Sarkaria, Jann Nagina
Anderson, S. Keith
Wu, Wenting
Jaeckle, Kurt A.
Giannini, Caterina
Buckner, Jan C.
Wen, Patrick Y.
CA Alliance Clinical Trials Oncology
TI Phase I/II trial of vorinostat combined with temozolomide (TMZ) and
radiation therapy (RT) for newly diagnosed glioblastoma (GBM)
(N0874-ABTC0902, Alliance): Final results of the phase I trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
Mayo Clin, Jacksonville, FL 32224 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2046
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600707
ER
PT J
AU Galsky, MD
Chowdhury, S
Bellmunt, J
Wong, YN
Recine, F
Pal, SK
Moshier, EL
Ladoire, S
De Giorgi, U
Yu, EY
Niegisch, G
Crabb, SJ
Mardones, MA
Necchi, A
Golshayan, AR
Bamias, A
Mano, R
Harshman, LC
Powles, T
Rosenberg, JE
AF Galsky, Matt D.
Chowdhury, Simon
Bellmunt, Joaquim
Wong, Yu-Ning
Recine, Federica
Pal, Sumanta Kumar
Moshier, Erin L.
Ladoire, Sylvain
De Giorgi, Ugo
Yu, Evan Y.
Niegisch, Guenter
Crabb, Simon J.
Mardones, Mabel A.
Necchi, Andrea
Golshayan, Ali Reza
Bamias, Aristotelis
Mano, Roy
Harshman, Lauren Christine
Powles, Thomas
Rosenberg, Jonathan E.
CA RISC Investigators
TI Treatment patterns and outcomes in "real world" patients (pts) with
metastatic urothelial cancer (UC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mt Sinai Sch Med, Tisch Canc Inst, Div Hematol & Med Oncol, New York, NY USA.
Guys & St Thomas NHS Fdn Trust, London, England.
Univ Hosp del Mar, Barcelona, Spain.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
San Camillo Forlanini Hosp, Rome, Italy.
City Hope Natl Med Ctr, Duarte, CA USA.
Icahn Sch Med Mt Sinai, Dept Prevent Med, New York, NY USA.
Georges Francois Leclerc Canc Ctr, Dijon, France.
IRCCS Ist Sci Romagnolo Studio & Cura Tumori IRST, Meldola, Italy.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Univ Southampton, Fac Med, Southampton SO9 5NH, Hants, England.
Hunstman Canc Inst, Salt Lake City, UT USA.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Med Univ S Carolina, Charleston, SC 29425 USA.
HECOG, Athens, Greece.
Univ Athens, Athens, Greece.
Rabin Med Ctr, Tel Aviv, Israel.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Barts & London, London, England.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4525
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601539
ER
PT J
AU Gandhi, L
Soria, JC
Bryce, R
Besse, B
AF Gandhi, Leena
Soria, Jean-Charles
Bryce, Richard
Besse, Benjamin
TI Randomized phase II study of neratinib with or without temsirolimus in
patients (pts) with non-small cell lung cancer (NSCLC) carrying
HER2-activating mutations.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Inst Gustave Roussy, Villejuif, France.
Puma Biotechnol, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS8124
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605513
ER
PT J
AU Gao, J
Calkins, G
Birrer, MJ
Dizon, DS
AF Gao, Jennifer
Calkins, Geoffrey
Birrer, Michael J.
Dizon, Don S.
TI Achieving quality: Comparing recommendations for cancer care between
NCCN and ESMO
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
FlatIron Hlth, New York, NY USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6579
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602295
ER
PT J
AU George, DJ
McGowan, T
Daugaard, G
Flaig, TW
Geczi, L
Hotte, SJ
Mainwaring, PN
Saad, F
Smith, MR
Souza, C
Sternberg, CN
Tay, MH
Garrido, JMT
Londhe, A
Naini, V
Todd, MB
Molina, A
AF George, Daniel J.
McGowan, Tracy
Daugaard, Gedske
Flaig, Thomas W.
Geczi, Lajos
Hotte, Sebastien J.
Mainwaring, Paul N.
Saad, Fred
Smith, Matthew R.
Souza, Ciro
Sternberg, Cora N.
Tay, Miah Hiang
Garrido, Jose Manuel Tello
Londhe, Anil
Naini, Vahid
Todd, Mary Beth
Molina, Arturo
TI Interim safety results of a global early access protocol (EAP) of
abiraterone acetate (AA) in patients (pts) with metastatic
castration-resistant prostate cancer (mCRPC) progressing after
taxane-based chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Canc Inst, Durham, NC USA.
Janssen Biotech, Horsham, PA USA.
Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Natl Inst Oncol, Dept Chemotherapy & Clin Pharmacol, Budapest, Hungary.
McMaster Univ, Dept Oncol, Hamilton, ON, Canada.
Haematol Clin Australia, Brisbane, Qld, Australia.
Oncol Clin Australia, Brisbane, Qld, Australia.
Univ Montreal, Montreal, PQ, Canada.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Hosp Sirio Libanes, Ctr Oncol, Sao Paulo, Brazil.
San Camillo & Forlanini Hosp, Dept Med Oncol, Rome, Italy.
OncoCare Canc Ctr, Singapore, Singapore.
Ctr Oncol Belenus, Cuernavaca, Morelos, Mexico.
Janssen Res & Dev LLC, Raritan, NJ USA.
Janssen Res & Dev LLC, Los Angeles, CA USA.
Janssen Global Serv, Raritan, NJ USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5059
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601657
ER
PT J
AU George, S
Feng, Y
Von Mehren, M
Choy, E
Corless, CL
Hornick, JL
Butrynski, JE
Wagner, AJ
Solomon, S
Morgan, JA
Heinrich, MC
Demetri, GD
AF George, Suzanne
Feng, Yang
Von Mehren, Margaret
Choy, Edwin
Corless, Christopher L.
Hornick, Jason L.
Butrynski, James E.
Wagner, Andrew J.
Solomon, Sarah
Morgan, Jeffrey A.
Heinrich, Michael C.
Demetri, George D.
TI Prolonged survival and disease control in the academic phase II trial of
regorafenib in GIST: Response based on genotype.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Oregon Hlth & Sci Univ, Knight Diagnost Labs, Portland, OR 97201 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10511
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600283
ER
PT J
AU Gerstner, ER
Levine, M
Ye, XB
Mikkelsen, T
Nabors, LB
Olson, JJ
Kaley, TJ
Wen, PY
Batchelor, T
Grossman, SA
AF Gerstner, Elizabeth Robins
Levine, Mike
Ye, Xiaobu
Mikkelsen, Tom
Nabors, Louis B.
Olson, Jeffrey J.
Kaley, Thomas Joseph
Wen, Patrick Y.
Batchelor, Tracy
Grossman, Stuart A.
TI A phase I study of cediranib in combination with cilengitide in patients
with recurrent glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Martinos Ctr Biomed Imaging, Charlestown, MA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Emory Univ, Atlanta, GA 30322 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2054
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600715
ER
PT J
AU Ghobrial, IM
Laubach, J
Armand, P
Boswell, E
Hanlon, C
Chuma, S
Chu, ED
Handisides, D
Kroll, S
Hickingbottom, B
Anderson, KC
Richardson, PGG
AF Ghobrial, Irene M.
Laubach, Jacob
Armand, Philippe
Boswell, Erica
Hanlon, Courtney
Chuma, Stacey
Chu, Esther Dawn
Handisides, Damian
Kroll, Stew
Hickingbottom, Barbara
Anderson, Kenneth Carl
Richardson, Paul Gerard Guy
TI Phase I study of TH-302, an investigational hypoxia-targeted drug, and
dexamethasone in patients with relapsed/refractory multiple myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
Threshold Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8602
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602697
ER
PT J
AU Glisson, BS
Tseng, J
Marur, S
Shin, DM
Murphy, BA
Cohen, EEW
Thomas, CY
Willey, R
Cosaert, J
William, WN
Harun, N
Lee, JJ
Haddad, RI
AF Glisson, Bonnie S.
Tseng, Jennifer
Marur, Shanthi
Shin, Dong M.
Murphy, Barbara A.
Cohen, Ezra E. W.
Thomas, Christopher Y.
Willey, Richard
Cosaert, Jan
William, William Nassib
Harun, Nusrat
Lee, J. Jack
Haddad, Robert I.
TI Randomized phase II trial of cixutumumab (CIX) alone or with cetuximab
(CET) for refractory recurrent/metastatic squamous cancer of head and
neck (R/M-SCCHN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
MD Anderson Canc Ctr, Orlando, FL USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Vanderbilt Univ Sch Med, Deptartment Med, Nashville, TN USA.
Univ Chicago Med Ctr, Chicago, IL USA.
Wake Forest Baptist Med Ctr, Winston Salem, NC USA.
ImClone Syst LLC, Bridgewater, NJ USA.
Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6030
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602154
ER
PT J
AU Go, RS
Lee, SJ
Shin, D
Callister, SM
Jobe, DA
Conry, RM
Tarhini, AA
Kirkwood, JM
AF Go, Ronald S.
Lee, Sandra J.
Shin, Donghoon
Callister, Steven M.
Jobe, Dean A.
Conry, Robert Martin
Tarhini, Ahmad A.
Kirkwood, John M.
TI Phase II study of low-dose peginterferon alfa-2b antiangiogenic therapy
in patients with metastatic melanoma overexpressing basic fibroblast
growth factor: An Eastern Cooperative Oncology Group study (E2602)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Gundersen Lutheran Hlth Syst, La Crosse, WI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Alabama Birmingham, Birmingham, AL USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9038
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602739
ER
PT J
AU Gonzalez-Angulo, AM
Juric, D
Argiles, G
Schellens, JHM
Burris, HA
Berlin, J
Middleton, MR
Schuler, MH
Van Geel, R
Helgason, T
Bootle, D
Boehm, M
Goggin, TK
Demanse, D
Quadt, C
Baselga, J
AF Gonzalez-Angulo, Ana M.
Juric, Dejan
Argiles, Guillem
Schellens, Jan H. M.
Burris, Howard A.
Berlin, Jordan
Middleton, Mark R.
Schuler, Martin H.
Van Geel, Robin
Helgason, Thorunn
Bootle, Douglas
Boehm, Markus
Goggin, Timothy K.
Demanse, David
Quadt, Cornelia
Baselga, Jose
TI Safety, pharmacokinetics, and preliminary activity of the alpha-specific
PI3K inhibitor BYL719: Results from the first-in-human study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Vall dHebron Univ Hosp, Dept Med Oncol, Barcelona, Spain.
Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Churchill Hosp, Ctr Canc, Oxford OX3 7LJ, England.
Univ Hosp Essen, West German Canc Ctr, Essen, Germany.
Novartis Pharma AG, Basel, Switzerland.
Novartis Pharmaceut, E Hanover, NJ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2531
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601049
ER
PT J
AU Goodwin, PJ
Parulekar, W
Gelmon, KA
Shepherd, LE
Ligibel, JA
Hershman, DL
Rastogi, P
Mayer, IA
Hobday, TJ
Lemieux, J
Thompson, AM
Pritchard, KI
Whelan, TJ
Mukherjee, SD
Chalchal, HI
Oja, CD
Tonkin, KS
Bernstein, V
Chen, BSE
Stambolic, V
AF Goodwin, Pamela Jean
Parulekar, Wendy
Gelmon, Karen A.
Shepherd, Lois E.
Ligibel, Jennifer A.
Hershman, Dawn L.
Rastogi, Priya
Mayer, Ingrid A.
Hobday, Timothy J.
Lemieux, Julie
Thompson, Alastair Mark
Pritchard, Kathleen I.
Whelan, Timothy Joseph
Mukherjee, Som Dave
Chalchal, Haji I.
Oja, Conrad D.
Tonkin, Katia Sonia
Bernstein, Vanessa
Chen, Bingshu E.
Stambolic, Vuk
TI Effect of metformin versus placebo on weight and metabolic factors in
initial patients enrolled onto NCIC CTG MA.32, a multicenter adjuvant
randomized controlled trial in early-stage breast cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Toronto, Mt Sinai Hosp, Samuel Lunenfeld Res Inst, Toronto, ON M5G 1X5, Canada.
Queens Univ, NCIC Clin Trials Grp, Canc Res Inst, Kingston, ON, Canada.
Univ British Columbia, British Columbia Canc Agcy, NCIC Clin Trials Grp, Vancouver, BC, Canada.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Columbia Univ, Med Ctr, New York, NY USA.
Natl Surg Adjuvant Breast & Bowel Project, Pittsburgh, PA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Vanderbilt Univ, Sch Med, Vanderbilt Ingram Canc Ctr, Nashville, TN 37212 USA.
Mayo Clin, Coll Med, Rochester, MN USA.
Hop St Sacrement, CHU Quebec, Ctr Rech, Unite Rech Sante Populat, Quebec City, PQ, Canada.
Natl Inst Canc Res, Breast Clin Studies Grp, London, England.
Univ Toronto, Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON, Canada.
McMaster Univ, Hamilton Hlth Sci, Juravinski Canc Ctr, Hamilton, ON, Canada.
Allan Blair Canc Ctr, Regina, SK, Canada.
British Columbia Canc Agcy, Fraser Valley Ctr, Surrey, BC, Canada.
Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada.
Univ British Columbia, British Columbia Canc Agcy, Vancouver Isl Ctr, Vancouver, BC V5Z 1M9, Canada.
Univ Toronto, Ontario Canc Inst, Univ Hlth Network, Princess Margaret Hosp, Toronto, ON M5S 1A1, Canada.
RI Whelan, Timothy/D-3185-2017
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1033
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600256
ER
PT J
AU Gore, ME
Gruenwald, V
Motzer, RJ
Quinn, DI
Rini, BI
Lin, X
Perkins, JJ
Simantov, R
Choueiri, TK
AF Gore, Martin Eric
Gruenwald, Viktor
Motzer, Robert John
Quinn, David I.
Rini, Brian I.
Lin, Xun
Perkins, Julia Jane
Simantov, Ronit
Choueiri, Toni K.
TI Retrospective analysis of risk factors for fatigue in clinical trial
patients (pts) with metastatic renal cell carcinoma (mRCC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Royal Marsden NHS Fdn Trust, London, England.
Hannover Med Sch, Dept Hematol Hemostasis Oncol & Stem Cell Transpl, Hannover, Germany.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Pfizer Oncol, San Diego, CA USA.
Pfizer Oncol, New York, NY USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e15624
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604193
ER
PT J
AU Goss, PE
Barrios, CH
Chan, A
Finkelstein, DM
Iwata, H
Martin, M
Braun, A
Ding, BY
Maniar, T
Coleman, RE
AF Goss, Paul E.
Barrios, Carlos H.
Chan, Arlene
Finkelstein, Dianne M.
Iwata, Hiroji
Martin, Miguel
Braun, Ada
Ding, Beiying
Maniar, Tapan
Coleman, Robert E.
TI Denosumab versus placebo as adjuvant treatment for women with
early-stage breast cancer at high risk of disease recurrence (D-CARE):
An international, placebo-controlled, randomized, double-blind phase III
clinical trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
PUCRS Sch Med, Porto Alegre, RS, Brazil.
Curtin Univ, Mt Hosp, Perth, WA 6845, Australia.
Aichi Canc Ctr Hosp, Dept Breast Oncol, Nagoya, Aichi 464, Japan.
Univ Complutense, Inst Invest Sanitaria Gregario Maranon, E-28040 Madrid, Spain.
Amgen Inc, Thousand Oaks, CA 91320 USA.
YCR Sheffield Canc Res Ctr, Canc Res UK Inst Canc Studies, Sheffield, S Yorkshire, England.
RI Barrios, Carlos/G-8525-2015
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS662
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605492
ER
PT J
AU Goyal, L
Borger, DR
Yau, T
Poon, RTP
Ancukiewicz, M
Christiani, DC
Liebman, HM
Yen, K
Straley, K
Agresta, SV
Faris, JE
Kwak, EL
Clark, JW
Ryan, DP
Tanabe, K
Deshpande, V
Jain, RK
Iafrate, AJ
Duda, DG
Zhu, AX
AF Goyal, Lipika
Borger, Darrell R.
Yau, Thomas
Poon, Ronnie Tung Ping
Ancukiewicz, Marek
Christiani, David C.
Liebman, Hannah M.
Yen, Katharine
Straley, Kimberly
Agresta, Samuel V.
Faris, Jason Edward
Kwak, Eunice Lee
Clark, Jeffrey W.
Ryan, David P.
Tanabe, Kenneth
Deshpande, Vikram
Jain, Rakesh K.
Iafrate, Anthony John
Duda, Dan G.
Zhu, Andrew X.
TI Circulating oncometabolite 2-hydroxyglutarate (2HG) as a potential
surrogate biomarker in patients with isocitrate dehydrogenase mutant
(IDHm) intrahepatic cholangiocarcinoma (ICC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Univ Hong Kong, Queen Mary Hosp, Hong Kong, Hong Kong, Peoples R China.
Univ Hong Kong, Queen Mary Hosp, Div Hepatobiliary & Pancreat Surg, Hong Kong, Hong Kong, Peoples R China.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Agios Pharmaceut, Cambridge, MA USA.
Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4125
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601498
ER
PT J
AU Gray, PJ
Sher, D
Yeap, BY
Cryer, SK
Mak, RH
Weiss, SE
Alexander, BM
Jackman, DM
AF Gray, Phillip J.
Sher, David
Yeap, Beow Y.
Cryer, Sarah K.
Mak, Raymond H.
Weiss, Stephanie E.
Alexander, Brian Michael
Jackman, David Michael
TI Impact of aggressive therapy in patients with non-small cell lung
carcinoma presenting with brain-only oligometastatic disease
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8069
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602549
ER
PT J
AU Gray, SW
Janeway, KA
Weeks, JC
AF Gray, Stacy W.
Janeway, Katherine A.
Weeks, Jane C.
TI Personalized cancer tests and services on the Internet: A website
content analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Gray, Stacy W.; Janeway, Katherine A.; Weeks, Jane C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1553
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600612
ER
PT J
AU Green, AL
Langholz, B
Chintagumpala, MM
Cockburn, M
Chevez-Barrios, P
Albert, D
Eagle, R
Rodriguez-Galindo, C
AF Green, Adam L.
Langholz, Bryan
Chintagumpala, Murali M.
Cockburn, Myles
Chevez-Barrios, Patricia
Albert, Daniel
Eagle, Ralph
Rodriguez-Galindo, Carlos
TI Correlation of insurance status, ethnicity, and race with pathologic
risk in retinoblastoma: A Children's Oncology Group (COG) study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
Univ So Calif, Dept Prevent Med, Los Angeles, CA 90089 USA.
Baylor Coll Med, Houston, TX 77030 USA.
Methodist Hosp, Houston, TX 77030 USA.
Univ Wisconsin, Eye Res Inst, Madison, WI USA.
Wills Eye Inst, Philadelphia, PA USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e17573
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604442
ER
PT J
AU Groeneweg, JW
DiGloria, CM
Growdon, WB
Sathyanarayanan, S
Foster, R
Rueda, BR
AF Groeneweg, Jolijn W.
DiGloria, Celeste M.
Growdon, Whitfield Board
Sathyanarayanan, Sriram
Foster, Rosemary
Rueda, Bo R.
TI Inhibition of gamma-secretase activity in combination with paclitaxel to
reduce platinum-resistant ovarian tumor growth.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Merck & Co Inc, Merck Res Labs, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5578
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602092
ER
PT J
AU Gropper, A
Calvillo, KZ
Troyan, S
Dominici, LS
Rhei, E
Economy, KE
Schapira, L
Tung, NM
Meisel, JL
Partridge, AH
Mayer, EL
AF Gropper, Adrienne
Calvillo, Katherina Zabicki
Troyan, Susan
Dominici, Laura Stewart
Rhei, Esther
Economy, Katherine E.
Schapira, Lidia
Tung, Nadine M.
Meisel, Jane L.
Partridge, Ann H.
Mayer, Erica L.
TI Sentinel lymph node biopsy (SNB) in pregnancy-associated breast cancer
(PABC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1117
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600544
ER
PT J
AU Guddati, AK
Kumar, G
AF Guddati, Achuta Kumar
Kumar, Gagan
TI Trends and outcomes of severe sepsis in hematopoietic stem cell
transplant recipients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7127
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602484
ER
PT J
AU Guerra, YC
Chan, A
Finkelstein, DM
Chan, VF
Harvey, VJ
Lee, KS
Mahendra, M
Petrakova, JK
Raina, V
Xu, BH
Gomez, H
Rappold, E
Kaneko, T
Huang, YJ
Goss, PE
AF Guerra, Yanin Chavarri
Chan, Arlene
Finkelstein, Dianne M.
Chan, Valorie F.
Harvey, Vernon J.
Lee, Keun Seok
Mahendra, Minish
Petrakova, Jain Katarina
Raina, Vinod
Xu, Binghe
Gomez, Henry
Rappold, Erica
Kaneko, Tomomi
Huang, Yingjie
Goss, Paul E.
TI Lack of efficacy of adjuvant lapatinib in HER2-negative breast cancer
(HER2-ve BC): Analysis of patients in the TEACH trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Salvador Zubiran, Inst Nacl Ciencias Med & Nutr, Mexico City, DF, Mexico.
Curtin Univ, Mt Hosp, Perth, WA 6845, Australia.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Vet Mem Med Ctr, Quezon City, Philippines.
Auckland Hosp, Auckland, New Zealand.
Natl Canc Ctr, Ctr Breast Canc, Goyang, South Korea.
KEM Hosp & Res Ctr, Pune, Maharashtra, India.
Masaryk Mem Canc Inst, Brno, Czech Republic.
All India Inst Med Sci, Dr BR Ambedkar Inst Rotary Canc Hosp, New Delhi, India.
Chinese Acad Med Sci, Canc Inst & Hosp, Dept Med Oncol, Beijing 100730, Peoples R China.
Peking Union Med Coll, Beijing 100021, Peoples R China.
Inst Nacl Enfermedades Neoplas, Lima, Peru.
GlaxoSmithKline, Collegeville, PA USA.
GlaxoSmithKline, Uxbridge, Middx, England.
GlaxoSmithKline, London, England.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 628
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600133
ER
PT J
AU Hamid, O
Sosman, JA
Lawrence, DP
Sullivan, RJ
Ibrahim, N
Kluger, HM
Boasberg, PD
Flaherty, K
Hwu, P
Ballinger, M
Mokatrin, A
Kowanetz, M
Chen, DS
Hodi, FS
AF Hamid, Omid
Sosman, Jeffrey Alan
Lawrence, Donald P.
Sullivan, Ryan J.
Ibrahim, Nageatte
Kluger, Harriet M.
Boasberg, Peter D.
Flaherty, Keith
Hwu, Patrick
Ballinger, Marcus
Mokatrin, Ahmad
Kowanetz, Marcin
Chen, Daniel S.
Hodi, F. Stephen
TI Clinical activity, safety, and biomarkers of MPDL3280A, an engineered
PD-L1 antibody in patients with locally advanced or metastatic melanoma
(mM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Angeles Clin & Res Inst, Los Angeles, CA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Univ, New Haven, CT USA.
Angeles Clin & Res Inst, Santa Monica, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Genentech Inc, San Francisco, CA 94080 USA.
NR 0
TC 18
Z9 19
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9010
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602711
ER
PT J
AU Hanna, GJ
Haddad, RI
Barletta, JA
Posner, MR
Lorch, JH
AF Hanna, Glenn J.
Haddad, Robert I.
Barletta, Justine A.
Posner, Marshall R.
Lorch, Jochen H.
TI Squamous cell carcinoma of the oral cavity (SCCOC) in young patients:
The Dana Farber Cancer Institute experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6054
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602177
ER
PT J
AU Harshman, LC
Kroeger, N
Rha, SY
Donskov, F
Wood, L
Tantravahi, SK
Vaishampayan, UN
Rini, BI
Knox, JJ
North, SA
MacKenzie, MJ
Yuasa, T
Srinivas, S
Pal, SK
Heng, DYC
Choueiri, TK
AF Harshman, Lauren Christine
Kroeger, Nils
Rha, Sun Young
Donskov, Frede
Wood, Lori
Tantravahi, Srinivas Kiran
Vaishampayan, Ulka N.
Rini, Brian I.
Knox, Jennifer J.
North, Scott A.
MacKenzie, Mary J.
Yuasa, Takeshi
Srinivas, Sandy
Pal, Sumanta Kumar
Heng, Daniel Yick Chin
Choueiri, Toni K.
TI First-line mTOR inhibition in metastatic renal cell carcinoma (mRCC): An
updated analysis from the International mRCC Database Consortium (IMDC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Tom Baker Canc Clin, Calgary, AB, Canada.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
London Reg Canc Program, London, ON, Canada.
Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo 170, Japan.
Stanford Med Ctr, Stanford, CA USA.
City Hope Natl Med Ctr, Duarte, CA USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e15518
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604094
ER
PT J
AU Hassett, MJ
Schrag, D
Chen, K
Roohan, PR
Boscoe, FP
Schymura, MJ
AF Hassett, Michael J.
Schrag, Deborah
Chen, Kun
Roohan, Patrick R.
Boscoe, Francis P.
Schymura, Maria J.
TI Patterns of disparities in breast cancer care
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
New York State Dept Hlth, Albany, NY USA.
New York State Canc Registry, Albany, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6565
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602281
ER
PT J
AU Heinrich, MC
Fletcher, JA
Anjum, R
Serrano-Garcia, C
Vodala, S
Bauer, S
Town, A
Zhu, MJ
Ning, YY
Eilers, G
Griffith, D
Patterson, J
McKinley, A
Wang, FY
Garner, AP
Rivera, VM
AF Heinrich, Michael C.
Fletcher, Jonathan A.
Anjum, Rana
Serrano-Garcia, Cesar
Vodala, Sadanand
Bauer, Sebastian
Town, Ajia
Zhu, Meijun
Ning, Yaoyu
Eilers, Grant
Griffith, Diana
Patterson, Janice
McKinley, Arin
Wang, Frank Y.
Garner, Andrew P.
Rivera, Victor M.
TI Use of ponatinib to inhibit kinase mutations associated with
drug-resistant gastrointestinal stromal tumors (GIST).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Portland VA Med Ctr, Portland, OR USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
ARIAD Pharmaceut Inc, Cambridge, MA USA.
Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Dept Med Oncol, Essen, Germany.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10509
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600280
ER
PT J
AU Heist, RS
Gandhi, L
Shapiro, G
Rizvi, NA
Burris, HA
Bendell, JC
Baselga, J
Yerganian, SB
Hsu, K
Ogden, J
Vincent, L
von Richter, O
Locatelli, G
Asatiani, E
Infante, JR
AF Heist, Rebecca Suk
Gandhi, Leena
Shapiro, Geoffrey
Rizvi, Naiyer A.
Burris, Howard A.
Bendell, Johanna C.
Baselga, Jose
Yerganian, Scott B.
Hsu, Karl
Ogden, Janet
Vincent, Loic
von Richter, Oliver
Locatelli, Giuseppe
Asatiani, Ekatherine
Infante, Jeffrey R.
TI Combination of a MEK inhibitor, pimasertib (MSC1936369B), and a
PI3K/mTOR inhibitor, SAR245409, in patients with advanced solid tumors:
Results of a phase Ib dose-escalation trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Sanofi Aventis, Cambridge, MA USA.
EMD Serono Inc, Billerica, MA USA.
Sanofi Oncol, Vitry Sur Seine, France.
Merck KGaA, Darmstadt, Germany.
Merck Serono SA, Geneva, Switzerland.
RI von Richter, Oliver/O-6412-2016
OI von Richter, Oliver/0000-0002-5262-9922
NR 0
TC 2
Z9 2
U1 1
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2530
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601048
ER
PT J
AU Hendifar, AE
Chawla, SP
Leahy, MG
Italiano, A
Patel, S
Santoro, A
Staddon, AP
Penel, N
Piperno-Neumann, S
Demetri, GD
Hayward, L
White, J
Gouw, LG
De Miguel, B
Lardelli, P
Soto, A
Nieto, A
Blay, JY
AF Hendifar, Andrew Eugene
Chawla, Sant P.
Leahy, Michael Gordon
Italiano, Antoine
Patel, Shreyaskumar
Santoro, Armando
Staddon, Arthur P.
Penel, Nicolas
Piperno-Neumann, Sophie
Demetri, George D.
Hayward, Larry
White, Jeff
Gouw, Launce G.
De Miguel, Bernardo
Lardelli, Pilar
Soto, Arturo
Nieto, Antonio
Blay, Jean-Yves
TI Results of the randomized phase III trial of trabectedin (F) versus
doxorubicin-based chemotherapy (DXCT) as First-line therapy in patients
(pts) with translocation-related sarcoma (TRS).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Sarcoma Oncol Ctr, Santa Monica, CA USA.
Christie Hosp NHS Fdn Trust, Manchester, Lancs, England.
Inst Bergonie, Bordeaux, France.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Humanitas Canc Ctr, Rozzano, Italy.
Penn Hosp, Philadelphia, PA 19107 USA.
Ctr Oscar Lambert, Lille, France.
Inst Curie, Paris, France.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Western Gen Hosp, Edinburgh Canc Res UK Ctr, Edinburgh EH4 2XU, Midlothian, Scotland.
Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
PharmaMar, Madrid, Spain.
Univ Lyon 1, Ctr Leon Berard, F-69365 Lyon, France.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10517
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600289
ER
PT J
AU Heng, DYC
Rini, BI
Lee, JL
Kroeger, N
Srinivas, S
Harshman, LC
Knox, JJ
Bjarnason, GA
MacKenzie, MJ
Wood, L
Vaishampayan, UN
Agarwal, N
Pal, SK
Tan, MH
Rha, SY
Yuasa, T
Donskov, F
Bamias, A
North, SA
Choueiri, TK
AF Heng, Daniel Yick Chin
Rini, Brian I.
Lee, Jae-Lyun
Kroeger, Nils
Srinivas, Sandy
Harshman, Lauren Christine
Knox, Jennifer J.
Bjarnason, Georg A.
MacKenzie, Mary J.
Wood, Lori
Vaishampayan, Ulka N.
Agarwal, Neeraj
Pal, Sumanta Kumar
Tan, Min-Han
Rha, Sun Young
Yuasa, Takeshi
Donskov, Frede
Bamias, Aristotelis
North, Scott A.
Choueiri, Toni K.
TI First-, second-, third-line therapy for metastatic renal cell carcinoma
(mRCC): Benchmarks for trials design from the International mRCC
Database Consortium (IMDC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Stanford Med Ctr, Stanford, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
London Reg Canc Program, London, ON, Canada.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Inst Bioengn & Nanotechnol, Singapore, Singapore.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Alexandra Peripheral Gen Hosp, Athens, Greece.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4586
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601600
ER
PT J
AU Herbst, RS
Gordon, MS
Fine, GD
Sosman, JA
Soria, JC
Hamid, O
Powderly, JD
Burris, HA
Mokatrin, A
Kowanetz, M
Leabman, M
Anderson, M
Chen, DS
Hodi, FS
AF Herbst, Roy S.
Gordon, Michael S.
Fine, Gregg Daniel
Sosman, Jeffrey Alan
Soria, Jean-Charles
Hamid, Omid
Powderly, John D.
Burris, Howard A.
Mokatrin, Ahmad
Kowanetz, Marcin
Leabman, Maya
Anderson, Maria
Chen, Daniel S.
Hodi, F. Stephen
TI A study of MPDL3280A, an engineered PD-L1 antibody in patients with
locally advanced or metastatic tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Univ, New Haven, CT USA.
Pinnacle Oncol Hematol, Scottsdale, AZ USA.
Genentech Inc, San Francisco, CA 94080 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Inst Gustave Roussy, Villejuif, France.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Carolina BioOncol Inst, Huntersville, NC USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 43
Z9 44
U1 2
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3000
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601133
ER
PT J
AU Higano, CS
Armstrong, AJ
Cooperberg, MR
Kantoff, PW
Bailen, J
Concepcion, RS
Kassabian, V
Dakhil, SR
Finkelstein, SE
Vacirca, JL
Rifkin, RM
Sandler, A
McCoy, C
Whitmore, JB
Tyler, C
Sartor, AO
AF Higano, Celestia S.
Armstrong, Andrew J.
Cooperberg, Matthew R.
Kantoff, Philip W.
Bailen, James
Concepcion, Raoul S.
Kassabian, Vahan
Dakhil, Shaker R.
Finkelstein, Steven E.
Vacirca, Jeffrey L.
Rifkin, Robert M.
Sandler, Andrew
McCoy, Candice
Whitmore, James Boyd
Tyler, Claude
Sartor, A. Oliver
TI Impact of prior docetaxel (D) on sipuleucel-T (sip-T) product parameters
in PROCEED patients (pts).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
Duke Canc Inst, Durham, NC USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
First Urol PSC, Jeffersonville, IN USA.
Urol Associates, Nashville, TN USA.
Georgia Urol, Atlanta, GA USA.
Canc Ctr Kansas, Wichita, KS USA.
Translat Res Consortium TRC, Scottsdale, AZ USA.
North Shore Hematol Oncol Associates PC, East Setauket, NY USA.
US Oncol Res, Rocky Mt Canc Ctr, Denver, CO USA.
Dendreon Corp, Seattle, WA USA.
Tulane Canc Ctr, New Orleans, LA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5034
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601633
ER
PT J
AU Higgins, PC
Prigerson, HG
AF Higgins, Philip C.
Prigerson, Holly Gwen
TI Caregiver evaluation of the quality of end-of-life care (CEQUEL) scale:
The caregiver's perception of patient care near death
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Higgins, Philip C.; Prigerson, Holly Gwen] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6573
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602289
ER
PT J
AU Hirsch, FR
Yatabe, Y
Dietel, M
Sholl, LM
Tsao, MS
Schuuring, E
Tubbs, RR
AF Hirsch, Fred R.
Yatabe, Yasushi
Dietel, Manfred
Sholl, Lynette M.
Tsao, Ming Sound
Schuuring, Ed
Tubbs, Raymond R.
TI ALK-immunohistochemistry (IHC) standardization with D5F3 antibody in
non-small cell lung carcinoma (NSCLC): An international consensus study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado, Ctr Canc, Aurora, CO USA.
Aichi Canc Ctr Hosp, Dept Pathol & Mol Diagnost, Nagoya, Aichi 464, Japan.
Charite, Inst Pathol, D-13353 Berlin, Germany.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Toronto, Princess Margaret Hosp, Univ Hlth Network, Toronto, ON, Canada.
Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
Cleveland Clin, Pathol & Lab Med Inst, Cleveland, OH 44106 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e22042
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605181
ER
PT J
AU Hirsh, V
Blackhall, FH
Kim, DW
Besse, B
Nokihara, H
Han, JY
Tassell, VR
Reisman, A
Iyer, S
Shaw, AT
AF Hirsh, Vera
Blackhall, Fiona Helen
Kim, Dong-Wan
Besse, Benjamin
Nokihara, Hiroshi
Han, Ji-Youn
Tassell, Vanessa Roberts
Reisman, Arlene
Iyer, Shrividya
Shaw, Alice Tsang
TI Impact of crizotinib on patient-reported symptoms and quality of life
(QOL) compared with single-agent chemotherapy in a phase III study of
advanced ALK plus non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
Christie Natl Hlth Serv Fdn Trust, Manchester, Lancs, England.
Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea.
Inst Gustave Roussy, Villejuif, France.
Natl Canc Ctr, Div Thorac Oncol, Tokyo, Japan.
Natl Canc Ctr, Ctr Lung Canc, Goyang, South Korea.
Pfizer Oncol, La Jolla, CA USA.
Pfizer Specialty Care, New York, NY USA.
Pfizer Oncol, New York, NY USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
RI Blackhall, Fiona/N-2186-2015
OI Blackhall, Fiona/0000-0001-8716-3395
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8108
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602587
ER
PT J
AU Hodi, FS
Baudelet, C
Chen, AC
Weber, JS
AF Hodi, F. Stephen
Baudelet, Christine
Chen, Allen C.
Weber, Jeffrey S.
TI An open-label, randomized, phase II study of nivolumab (anti-PD-1;
BMS-936558; ONO-4538) given sequentially with ipilimumab in patients
(pts) with advanced or metastatic melanoma (MEL).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Bristol Myers Squibb Co, Braine Lalleud, Belgium.
Bristol Myers Squibb Co, Princeton, NJ USA.
Lee Moffitt Canc Ctr, Tampa, FL USA.
Res Inst, Tampa, FL USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS9107
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605529
ER
PT J
AU Hodi, FS
Amen, A
Saenger, YM
Pennock, GK
Guthrie, TH
Salama, AK
Flaherty, LE
Koon, HB
Lawson, DH
Shaheen, MF
Balogh, A
Konto, C
O'Day, S
AF Hodi, F. Stephen
Amen, Asim
Saenger, Yvonne M.
Pennock, Gregory K.
Guthrie, Troy H.
Salama, April K.
Flaherty, Lawrence E.
Koon, Henry B.
Lawson, David H.
Shaheen, Montaser F.
Balogh, Agnes
Konto, Cyril
O'Day, Steven
TI CA184-240: A single-arm, open-label phase II study of vemurafenib
followed by ipilimumab in patients with BRAF V600-mutated advanced
melanoma (AM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Levine Canc Inst, Charlotte, NC USA.
Mt Sinai Sch Med, New York, NY USA.
MD Anderson Canc Ctr, Orlando, FL USA.
Baptist Canc Inst, Jacksonville, FL USA.
Duke Canc Inst, Durham, NC USA.
Wayne State Univ Sch Med, Detroit, MI USA.
Univ Hosp Cleveland, Cleveland, OH 44106 USA.
Emory Univ Sch Med, Atlanta, GA USA.
Univ New Mexico Canc Ctr, Albuquerque, NM USA.
Bristol Myers Squibb Co, Braine Lalleud, Belgium.
Bristol Myers Squibb Co, Wallingford, CT USA.
Beverly Hills Canc Ctr, Beverly Hills, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS9103
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605525
ER
PT J
AU Hodi, FS
Lee, SJ
McDermott, DF
Rao, UNM
Butterfield, LH
Tarhini, AA
Leming, PD
Puzanov, I
Kirkwood, JM
AF Hodi, F. Stephen
Lee, Sandra J.
McDermott, David F.
Rao, Uma N. M.
Butterfield, Lisa H.
Tarhini, Ahmad A.
Leming, Philip D.
Puzanov, Igor
Kirkwood, John M.
CA Eastern Cooperative Oncology Grp
TI Multicenter, randomized phase II trial of GM-CSF (GM) plus ipilimumab
(Ipi) versus ipi alone in metastatic melanoma: E1608
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Pittsburgh Phys, Pittsburgh, PA USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA.
Cincinnati Hematol Oncol Inc, Cincinnati, OH USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA CRA9007
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603137
ER
PT J
AU Holdhoff, M
Grossman, SA
Supko, JG
Ye, XB
Fisher, JI
Desideri, S
Wahl, RL
Schiff, D
AF Holdhoff, Matthias
Grossman, Stuart A.
Supko, Jeffrey G.
Ye, Xiaobu
Fisher, Joy Id
Desideri, Serena
Wahl, Richard L.
Schiff, David
TI Sequential therapy with the selective T-type calcium channel blocker
mibefradil and temozolomide in patients with recurrent high-grade
gliomas: An Adult Brain Tumor Consortium phase I study (ABTC1101).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS2105
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605387
ER
PT J
AU Hong, TS
Deshpande, V
Ancukiewicz, M
Yeap, BY
Borger, DR
Wo, JYL
Boucher, Y
Kwak, EL
Clark, JW
Zhu, AX
Blaszkowsky, LS
Mamon, HJ
Jain, RK
Ryan, DP
DeLaney, TF
Fernandez-del Castillo, C
Duda, DG
AF Hong, Theodore S.
Deshpande, Vikram
Ancukiewicz, Marek
Yeap, Beow Y.
Borger, Darrell R.
Wo, Jennifer Yon-Li
Boucher, Yves
Kwak, Eunice Lee
Clark, Jeffrey W.
Zhu, Andrew X.
Blaszkowsky, Lawrence Scott
Mamon, Harvey J.
Jain, Rakesh K.
Ryan, David P.
DeLaney, Thomas F.
Fernandez-del Castillo, Carlos
Duda, Dan G.
TI Genetic, tissue, and plasma biomarkers of outcomes from a prospective
study of neoadjuvant short course proton-based chemoradiation for
resectable pancreatic ductal adenocarcinoma (PDAC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA USA.
Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4047
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601421
ER
PT J
AU Hourigan, CS
Goswami, M
Alkharouf, N
Bhagwat, M
Sardon, HM
Williams, AL
Mccoy, JP
Ito, S
Strickland, SA
Savanl, BN
Fraser, JW
Sadrzadeh, H
Fathi, AT
Qin, L
Hess, A
Smith, BD
Karp, JE
Barrett, AJ
AF Hourigan, Christopher Simon
Goswami, Meghali
Alkharouf, Nawal
Bhagwat, Medha
Sardon, Heidi May
Williams, Ann L.
Mccoy, J. Phillip
Ito, Sawa
Strickland, Stephen Anthony
Savanl, Bipin N.
Fraser, James W.
Sadrzadeh, Hossein
Fathi, Amir Tahmasb
Qin, Lu
Hess, Allan
Smith, B. Douglas
Karp, Judith E.
Barrett, A. John
TI Systematic analysis of potential targets for immunotherapy in acute
myeloid leukemia.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NHLBI, Hematol Branch, Myeloid Malignancies Sect, Bethesda, MD 20892 USA.
Natl Inst Hlth Lib, Bioinformat Program, Bethesda, MD USA.
NHLBI, Flow Cytometry Core Facil, Bethesda, MD 20892 USA.
NHLBI, Hematol Branch, Stem Cell Allogene Transplantat Sect, Bethesda, MD 20892 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Ctr Leukemia & Bone Marrow Transplant Unit, Div Hematology Oncol,Massachusetts Gen Hosp, Boston, MA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3104
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601236
ER
PT J
AU Huang, R
Rahman, R
Hamdan, A
Kane, C
Chen, C
Norden, AD
Reardon, DA
Mukundan, S
Wen, PY
AF Huang, Raymond
Rahman, Rifaquat
Hamdan, Alhafidz
Kane, Caroline
Chen, Christina
Norden, Andrew David
Reardon, David A.
Mukundan, Srinivasan
Wen, Patrick Y.
TI Recurrent glioblastoma: Stratification of patient survival using tumor
volume before and after antiangiogenic treatment
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2075
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600736
ER
PT J
AU Hurwitz, H
Cushman, S
Jiang, C
Shterev, I
Mahoney, MR
Niedzwiecki, D
Mayer, RJ
Venook, AP
Owzar, K
Nixon, AB
AF Hurwitz, Herbert
Cushman, Stephanie
Jiang, Chen
Shterev, Ivo
Mahoney, Michelle R.
Niedzwiecki, Donna
Mayer, Robert J.
Venook, Alan Paul
Owzar, Kouros
Nixon, Andrew B.
CA Alliance Clinical Trials Oncology
TI Tumor markers of efficacy and resistance to cetuximab (C) treatment in
metastatic colorectal cancer (mCRC): Results from CALGB 80203 (Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Duke Univ, Med Ctr, Durham, NC USA.
Duke Univ, Durham, NC USA.
Mayo Clin, Rochester, MN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 11011
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600422
ER
PT J
AU Hurwitz, M
Meyer, JE
Iozeffi, D
Ghanouni, P
Gianfelice, D
Fennessy, FM
Kuten, A
LeBlang, S
Roberts, AC
Choi, J
Napoli, A
Turkevich, V
Tempany, CM
Inbar, Y
Pfeffer, RM
Larner, JM
Kanaev, S
AF Hurwitz, Mark
Meyer, Joshua E.
Iozeffi, Dimitri
Ghanouni, Pejman
Gianfelice, David
Fennessy, Fiona M.
Kuten, Abraham
LeBlang, Suzanne
Roberts, Anne C.
Choi, Junsung
Napoli, Alessandro
Turkevich, Vladimir
Tempany, Clare M.
Inbar, Yael
Pfeffer, Raphael M.
Larner, James Mitchell
Kanaev, Sergy
TI Magnetic resonance guided focused ultrasound surgery for palliation of
painful bone metastasis: Results of a multicenter phase III trial.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Thomas Jefferson Univ & Hosp, Philadelphia, PA USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Rostov Sci Res Inst Oncol, Rostov Na Donu, Russia.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
Univ Hlth Network, Toronto, ON, Canada.
Harvard Univ, Brigham & Womens Hosp, Dana Farber Canc Inst, Sch Med, Boston, MA 02115 USA.
Rambam Hlth Care Campus, Haifa, Israel.
Univ MRI, Boca Raton, FL USA.
Univ Calif San Diego, San Diego, CA 92103 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Univ Rome, Rome, Italy.
NN Petrov Oncol Res Inst, St Petersburg, Russia.
Chaim Sheba Med Ctr, Ramat Gan, Israel.
Univ Virginia, Charlottesville, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9500
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602804
ER
PT J
AU Hussain, M
Corn, PG
Michaelson, MD
Hammers, HJ
Alumkal, JJ
Ryan, CJ
Bruce, JY
Moran, S
MacLean, D
Lee, SY
Lin, HM
Zhu, YY
Shi, HL
Mortimer, P
George, DJ
AF Hussain, Maha
Corn, Paul Gettys
Michaelson, M. Dror
Hammers, Hans J.
Alumkal, Joshi J.
Ryan, Charles J.
Bruce, Justine Yang
Moran, Susan
MacLean, David
Lee, Shih-Yuan
Lin, H. Mark
Zhu, Yanyan
Shi, Hongliang
Mortimer, Peter
George, Daniel J.
TI Safety, efficacy, and health-related quality of life (HRQoL) of the
investigational single agent orteronel (ortl) in nonmetastatic
castration-resistant prostate cancer (nmCRPC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Johns Hopkins Univ, Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
Millennium Pharmaceut Inc, Cambridge, MA USA.
Takeda Global Res & Dev Ctr Europe Ltd, London, England.
Duke Univ, Med Ctr, Durham, NC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5076
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601674
ER
PT J
AU Jackman, DM
Mach, SL
Heng, JC
Rabin, MS
Barbie, DA
Gandhi, L
Marcoux, JP
Costa, DB
AF Jackman, David Michael
Mach, Stacy L.
Heng, Jennifer C.
Rabin, Michael S.
Barbie, David Allen
Gandhi, Leena
Marcoux, J. Paul
Costa, Daniel Botelho
TI Pulsed dosing of erlotinib for central nervous system (CNS) progression
in EGFR-mutant non-small cell lung cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8116
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602595
ER
PT J
AU Jagannath, S
Hofmeister, CC
Baz, RC
Siegel, DSD
Vij, R
Chen, C
Lonial, S
Anderson, KC
Chen, M
Zaki, MH
Richardson, PGG
AF Jagannath, Sundar
Hofmeister, Craig C.
Baz, Rachid C.
Siegel, David Samuel DiCapua
Vij, Ravi
Chen, Christine
Lonial, Sagar
Anderson, Kenneth Carl
Chen, Min
Zaki, Mohamed H.
Richardson, Paul Gerard Guy
TI Pomalidomide (POM) with or without low-dose dexamethasone (LoDEX) in
patients (Pts) with relapsed and refractory multiple myeloma (RRMM):
MM-002 phase II age subgroup analysis
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mt Sinai Med Ctr, New York, NY 10029 USA.
Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
Washington Univ, St Louis, MO USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Emory Univ, Sch Med, Atlanta, GA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Celgene Corp, Summit, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8532
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602628
ER
PT J
AU Jimeno, A
Wirth, LJ
Posner, MR
Cohen, RB
Weiss, J
Popa, EC
Saba, NF
Grossmann, KF
Sukari, A
Cohen, EEW
Argiris, A
Condon, CH
Wilson, D
McClure, T
Alimzhanov, M
Pearsall, S
Attie, KM
Sherman, ML
Pandya, SS
AF Jimeno, Antonio
Wirth, Lori J.
Posner, Marshall R.
Cohen, Roger B.
Weiss, Jared
Popa, Elizabeta C.
Saba, Nabil F.
Grossmann, Kenneth F.
Sukari, Ammar
Cohen, Ezra E. W.
Argiris, Athanassios
Condon, Carolyn H.
Wilson, Dawn
McClure, Ty
Alimzhanov, Marat
Pearsall, Scott
Attie, Kenneth M.
Sherman, Matthew L.
Pandya, Shuchi Sumant
TI Phase II study of dalantercept, a novel inhibitor of ALK1-mediated
angiogenesis, in patients with recurrent or metastatic squamous cell
carcinoma of the head and neck.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado, Denver, CO 80202 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Univ N Carolina, Lineberger Canc Ctr, Chapel Hill, NC USA.
Weill Cornell Med Coll, New York, NY USA.
Emory Univ, Winship Canc Inst, Dept Hematol & Med Oncol, Atlanta, GA 30322 USA.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Univ Chicago Med & Biol Sci, Chicago, IL USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Acceleron Pharma, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS6098
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605474
ER
PT J
AU Joensuu, H
Casali, PG
Reichardt, P
Kang, YK
Blay, JY
Rutkowski, P
Gelderblom, H
Hohenberger, P
Leahy, MG
von Mehren, M
Badalamenti, G
Blackstein, ME
Le Cesne, A
Schoffski, P
Maki, RG
Xu, JM
Nishida, T
Kappeler, C
Kuss, I
Demetri, GD
AF Joensuu, Heikki
Casali, Paolo Giovanni
Reichardt, Peter
Kang, Yoon-Koo
Blay, Jean-Yves
Rutkowski, Piotr
Gelderblom, Hans
Hohenberger, Peter
Leahy, Michael Gordon
von Mehren, Margaret
Badalamenti, Giuseppe
Blackstein, Martin E.
Le Cesne, Axel
Schoffski, Patrick
Maki, Robert G.
Xu, Jian-Ming
Nishida, Toshirou
Kappeler, Christian
Kuss, Iris
Demetri, George D.
TI Results from a phase III trial (GRID) evaluating regorafenib (REG) in
metastatic gastrointestinal stromal tumour (GIST) Subgroup analysis of
outcomes based on pretreatment characteristics
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Helsinki Univ Cent Hosp, Dept Oncol, Helsinki, Finland.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
HELIOS Klinikum Berlin Buch, Berlin, Germany.
Univ Ulsan Coll Med, Dept Oncol, Asan Med Ctr, Seoul, South Korea.
Ctr Leon Berard, F-69373 Lyon, France.
Maria Sklodowska Curie Mem Canc Ctr, Warsaw, Poland.
Inst Oncol, Warsaw, Poland.
Leiden Univ Med Ctr, Dept Clin Oncol, Leiden, Netherlands.
Mannheim Univ Med Ctr, Dept Surg, Mannheim, Germany.
Christie Hosp NHS Fdn Trust, Manchester, Lancs, England.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Palermo, Div Med Oncol, Dept Oncol, Palermo, Italy.
Univ Toronto, Mt Sinai Hosp, Toronto, ON M5G 1X5, Canada.
Inst Gustave Roussy, Villejuif, France.
Katholieke Univ Leuven, Lab Expt Oncol, Leuven, Belgium.
Katholieke Univ Leuven, Dept Gen Med Oncol, Leuven, Belgium.
Univ Hosp, Louvain, Belgium.
Mt Sinai Sch Med, New York, NY USA.
Acad Mil Med Sci, Hosp 307, Ctr Canc, Beijing, Peoples R China.
Osaka Police Hosp, Dept Surg, Osaka, Japan.
Bayer Pharma AG, Berlin, Germany.
Bayer HealthCare Pharmaceut, Berlin, Germany.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10551
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600326
ER
PT J
AU Johnson, BE
Kris, MG
Berry, LD
Kwiatkowski, DJ
Iafrate, AJ
Varella-Garcia, M
Wistuba, II
Franklin, WA
Ladanyi, M
Su, PF
Sequist, LV
Khuri, FR
Garon, EB
Pao, W
Rudin, CM
Schiller, JH
Haura, EB
Giaccone, G
Minna, JD
Bunn, PA
AF Johnson, Bruce E.
Kris, Mark G.
Berry, Lynne D.
Kwiatkowski, David J.
Iafrate, Anthony John
Varella-Garcia, Marileila
Wistuba, Ignacio Ivan
Franklin, Wilbur A.
Ladanyi, Marc
Su, Pei-Fang
Sequist, Lecia V.
Khuri, Fadlo Raja
Garon, Edward B.
Pao, William
Rudin, Charles M.
Schiller, Joan H.
Haura, Eric B.
Giaccone, Giuseppe
Minna, John D.
Bunn, Paul A.
TI A multicenter effort to identify driver mutations and employ targeted
therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation
Consortium (LCMC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Univ Colorado, Sch Med, Aurora, CO USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Colorado, Denver, CO 80202 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Calif Los Angeles, Santa Monica, CA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NCI, Bethesda, MD 20892 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
NR 0
TC 15
Z9 16
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8019
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602500
ER
PT J
AU Johnson, DB
Lovly, CM
Flavin, M
Ayers, GD
Zhao, ZG
Iams, WT
Iafrate, AJ
Berry, EG
Terry, CR
Sullivan, RJ
Carvajal, RD
Sosman, JA
AF Johnson, Douglas Buckner
Lovly, Christine Marie
Flavin, Marisa
Ayers, Gregory Dan
Zhao, Zhiguo
Iams, Wade Thomas
Iafrate, Anthony John
Berry, Elizabeth Gates
Terry, Charles R.
Sullivan, Ryan J.
Carvajal, Richard D.
Sosman, Jeffrey Alan
TI NRAS mutation: A potential biomarker of clinical response to
immune-based therapies in metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Univ Virginia, Sch Med, Charlottesville, VA 22908 USA.
Vanderbilt Univ, Div Canc Biostat, Nashville, TN 37235 USA.
Vanderbilt Univ, Dept Biostat, Nashville, TN 37235 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 5
Z9 5
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9019
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602720
ER
PT J
AU Johnson, T
Xu, CF
Choueiri, TK
Deen, KC
Xue, ZY
Bartlett-Pandite, AN
Carpenter, C
Motzer, RJ
AF Johnson, Toby
Xu, Chun-fang
Choueiri, Toni K.
Deen, Keith C.
Xue, Zhengyu
Bartlett-Pandite, Arundathy N.
Carpenter, Christopher
Motzer, Robert John
TI Association of hyperbilirubinemia in pazopanib- or sunitinib-treated
patients in COMPARZ with UGT1A1 polymorphisms
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 GlaxoSmithKline, Uxbridge, Middx, England.
GlaxoSmithKline, Harlow, Essex, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
GlaxoSmithKline, Collegeville, PA USA.
GlaxoSmithKline, Res Triangle Pk, NC USA.
GlaxoSmithKline Res & Dev Ltd, Collegeville, PA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4569
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601583
ER
PT J
AU Ju, ZL
Westin, SN
Broaddus, R
Li, J
Pal, N
Lu, KH
Coleman, RL
Klempner, S
Cantley, L
Mills, GB
Myers, AP
AF Ju, Zhenlin
Westin, Shannon Neville
Broaddus, Russell
Li, Jie
Pal, Navdeep
Lu, Karen H.
Coleman, Robert L.
Klempner, Samuel
Cantley, Lewis
Mills, Gordon B.
Myers, Andrea P.
TI PTEN loss as a context-dependent determinant of patient outcomes in
obese and non-obese endometrioid endometrial cancer patients
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Div Canc Med, Houston, TX 77030 USA.
Univ Texas MD Anderson Canc Ctr, Dept Gynecol Oncol, Houston, TX 77030 USA.
BIDMC, Boston, MA USA.
Harvard Univ, Cambridge, MA 02138 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5521
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602035
ER
PT J
AU Judson, TJ
Bennett, AV
Rogak, LJ
Sit, L
Barz, A
Kris, MG
Hudis, C
Scher, HI
Sabbatini, P
Schrag, D
Basch, EM
AF Judson, Timothy J.
Bennett, Antonia V.
Rogak, Lauren J.
Sit, Laura
Barz, Allison
Kris, Mark G.
Hudis, Clifford
Scher, Howard I.
Sabbatini, Paul
Schrag, Deborah
Basch, Ethan M.
TI Feasibility of long-term patient reporting of toxicities from home via
the internet during routine chemotherapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Weill Cornell Med Coll, New York, NY USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Chicago, Chicago, IL 60637 USA.
Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6575
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602291
ER
PT J
AU Kang, YK
Ryu, MH
Ryoo, BV
Kim, HJ
Lee, JJ
Yoo, C
Nam, BH
Ramaiya, N
Jagannathan, JP
Demetri, GD
AF Kang, Yoon-Koo
Ryu, Min-Hee
Ryoo, Baek-Yeol
Kim, Hyun Jin
Lee, Jong Jin
Yoo, Changhoon
Nam, Byung-Ho
Ramaiya, Nikhil
Jagannathan, Jyothi Priya
Demetri, George D.
TI Randomized phase III trial of imatinib (IM) rechallenge versus placebo
in patients (pts) with metastatic and/or unresectable gastrointestinal
stromal tumor (GIST) after failure of at least both IM and sunitinib
(SU): Right study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Ulsan, Coll Med, Asan Med Ctr, Seoul, South Korea.
Natl Canc Ctr, Goyang, South Korea.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA LBA10502
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605331
ER
PT J
AU Kansal, KJ
Dominici, LS
Tolaney, SM
Isakoff, SJ
Krop, IE
Smith, BL
Jiang, W
Potler, H
Brock, JE
Winer, EP
Goishan, M
AF Kansal, Kari Joanne
Dominici, Laura Stewart
Tolaney, Sara M.
Isakoff, Steven J.
Krop, Ian E.
Smith, Barbara L.
Jiang, Wei
Potler, Hannah
Brock, Jane E.
Winer, Eric P.
Goishan, Mehra
TI Neoadjuvant bevacizumab: Surgical complications of mastectomy with and
without reconstruction
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brigham & Womens Hosp, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1100
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600409
ER
PT J
AU Kaufman, H
Lutzky, J
Clark, J
Margolin, KA
Lawson, DH
Amin, A
Collichio, FA
Pecora, A
Urba, WJ
Bennett, KL
McDermott, DF
AF Kaufman, Howard
Lutzky, Jose
Clark, Joseph
Margolin, Kim Allyson
Lawson, David H.
Amin, Asim
Collichio, Frances A.
Pecora, Andrew
Urba, Walter John
Bennett, Kelly L.
McDermott, David F.
TI Safety and efficacy of ipilimumab in melanoma patients who received
prior immunotherapy on phase III study MDX010-020
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Rush Univ, Med Ctr, Chicago, IL 60612 USA.
Mt Sinai Comprehens Canc Ctr, Miami Beach, FL USA.
Loyola Univ, Med Ctr, Maywood, IL 60153 USA.
Univ Washington, Seattle, WA 98195 USA.
Emory Univ, Sch Med, Atlanta, GA USA.
Levine Canc Inst, Charlotte, NC USA.
Univ N Carolina, Sch Med, Chapel Hill, NC USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA.
Bristol Myers Squibb Co, Plainsboro, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9050
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602751
ER
PT J
AU Keck, MK
Zuo, ZX
Khattri, A
Brown, CD
Stricker, T
Weichselbaum, RR
Lingen, MW
Cohen, EEW
White, KP
Vokes, EE
Hammerman, PS
Seiwert, TY
AF Keck, Michaela K.
Zuo, Zhixiang
Khattri, Arun
Brown, Christopher D.
Stricker, Thomas
Weichselbaum, Ralph R.
Lingen, Mark W.
Cohen, Ezra E. W.
White, Kevin P.
Vokes, Everett E.
Hammerman, Peter S.
Seiwert, Tanguy Y.
TI Genomic profiling of kinase genes in head and neck squamous cell
carcinomas to identify potentially targetable genetic aberrations in
FGFR1/2, DDR2, EPHA2, and PIK3CA
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Chicago, IL 60637 USA.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Univ Penn, Philadelphia, PA 19104 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Univ Chicago Hosp, Dept Radiat & Cellular Oncol, Chicago, IL 60637 USA.
Univ Chicago Med & Biol Sci, Chicago, IL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Zuo, Zhixiang/M-4441-2016
OI Zuo, Zhixiang/0000-0002-2492-2689
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6010
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602135
ER
PT J
AU Kefford, R
Miller, WH
Tan, DSW
Sullivan, RJ
Long, G
Dienstmann, R
Tai, WMD
Flaherty, K
Stutvoet, S
Schumacher, KM
Wandel, S
De Parseval, LA
Tabernero, J
AF Kefford, Richard
Miller, Wilson H.
Tan, Daniel Shao-Weng
Sullivan, Ryan J.
Long, Georgina
Dienstmann, Rodrigo
Tai, Wai Meng David
Flaherty, Keith
Stutvoet, Simone
Schumacher, Karl Maria
Wandel, Simon
De Parseval, Laure A.
Tabernero, Josep
TI Preliminary results from a phase Ib/II, open-label, dose-escalation
study of the oral BRAF inhibitor LGX818 in combination with the oral
MEK1/2 inhibitor MEK162 in BRAF V600-dependent advanced solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Sydney, Westmead Inst Canc Res, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
McGill Univ, Jewish Gen Hosp, Lady Davis Inst, Montreal, PQ H3T 1E2, Canada.
McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
Natl Canc Ctr, Singapore, Singapore.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Sydney, Westmead Hosp, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
Vall dHebron Inst Oncol, Barcelona, Spain.
Natl Canc Ctr Singapore, Singapore, Singapore.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Novartis Pharma AG, Basel, Switzerland.
NR 0
TC 10
Z9 10
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9029
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602730
ER
PT J
AU Kelly, KJ
Yoon, SS
Kuk, D
Qin, LX
Dukleska, K
Chang, K
DeLaney, TF
Brennan, MF
Singer, S
AF Kelly, Kaitlyn Jane
Yoon, Sam S.
Kuk, Deborah
Qin, Li-Xuan
Dukleska, Katerina
Chang, Kevin
DeLaney, Thomas F.
Brennan, Murray F.
Singer, Samuel
TI Association of perioperative radiation therapy with outcome in 204
patients with primary retroperitoneal sarcoma: A two-institution study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, Dept Surg, New York, NY 10021 USA.
Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10520
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600293
ER
PT J
AU Keohan, ML
Tap, WD
Dickson, MA
D'Angelo, SP
Carvajal, RD
Gounder, MM
Morales, RE
Condy, MM
Hameed, M
Ho, AL
Vasuveda, S
Qin, LX
Luke, JJ
Takebe, N
Schwartz, GK
AF Keohan, Mary Louise
Tap, William D.
Dickson, Mark Andrew
D'Angelo, Sandra P.
Carvajal, Richard D.
Gounder, Mrinal M.
Morales, Rita Elena
Condy, Mercedes M.
Hameed, M.
Ho, Alan Loh
Vasuveda, S.
Qin, Li-Xuan
Luke, Jason J.
Takebe, Naoko
Schwartz, Gary K.
TI A phase Ib/II study of imatinab and everolimus in patients with PDGFRA
plus synovial sarcoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mem Sloan Kettering Canc Ctr, Dept Biostat & Epidemiol, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Canc Therapy Evaluat Program, Invest Drug Branch, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10558
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600333
ER
PT J
AU Khera, N
Storer, AEB
Sandmaier, BM
Alyea, E
Lee, S
AF Khera, Nandita
Storer, Amy Emmert Barry
Sandmaier, Brenda M.
Alyea, Edwin
Lee, Stephanie
TI Costs of allogeneic hematopoietic cell transplantation using reduced
intensity conditioning regimens.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin Arizona, Div Hematol Oncol, Phoenix, AZ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7034
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602392
ER
PT J
AU Khoury, HJ
Cortes, JE
Kim, DW
Pinilla-Ibarz, J
Le Coutre, PD
Paquette, R
Chuah, C
Nicolini, FE
Apperley, J
Talpaz, M
DiPersio, JF
DeAngelo, DJ
Abruzzese, E
Rea, D
Baccarani, M
Muller, MC
Gambacorti-Passerini, C
Lustgarten, S
Yanase, K
Kantarjian, HM
AF Khoury, Hanna Jean
Cortes, Jorge E.
Kim, Dong-Wook
Pinilla-Ibarz, Javier
Le Coutre, Philipp D.
Paquette, Ronald
Chuah, Charles
Nicolini, Franck E.
Apperley, Jane
Talpaz, Moshe
DiPersio, John F.
DeAngelo, Daniel J.
Abruzzese, Elisabetta
Rea, Delphine
Baccarani, Michele
Mueller, Martin C.
Gambacorti-Passerini, Carlo
Lustgarten, Stephanie
Yanase, Kumiko
Kantarjian, Hagop M.
TI Analysis of the cardiovascular risk profile of Ph plus leukemia patients
treated with ponatinib
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Charite, Campus Virchow Klinikum, D-13353 Berlin, Germany.
Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore.
Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Washington Univ, Sch Med, St Louis, MO USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Osped S Eugenio, Rome, Italy.
Hop St Louis, Serv Malad Sang, Paris, France.
S Orsola Malpighi Univ Hosp, Bologna, Italy.
Heidelberg Univ, Med Klin 1, Med Fak Mannheim, Mannheim, Germany.
Univ Milano Bicocca, Azienda Osped San Gerardo, Unita Ric Clin, Monza, Italy.
ARIAD Pharmaceut Inc, Cambridge, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7048
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602406
ER
PT J
AU Kim, JW
Marte, JL
Singh, NK
Heery, CR
Madan, RA
Pazdur, M
McMahon, S
Rauckhorst, M
Schlom, J
Kantoff, PW
Gulley, JL
AF Kim, Joseph W.
Marte, Jennifer L.
Singh, Nishith K.
Heery, Christopher Ryan
Madan, Ravi Amrit
Pazdur, Mary
McMahon, Sheri
Rauckhorst, Myrna
Schlom, Jeffrey
Kantoff, Philip W.
Gulley, James L.
TI Safety profile of recombinant poxviral TRICOM vaccines.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 NCI, Med Oncol Branch, NIH, Bethesda, MD 20892 USA.
NCI, Bethesda, MD 20892 USA.
NCI, Lab Tumor Immunol & Biol, Med Oncol Branch, Bethesda, MD 20892 USA.
NCI, Med Oncol Branch, Bethesda, MD 20892 USA.
Ctr Canc Res, Lab Tumor Immunol & Biol, Bethesda, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Gulley, James/K-4139-2016
OI Gulley, James/0000-0002-6569-2912
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16036
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604226
ER
PT J
AU Kleinberg, L
Supko, JG
Mikkelsen, T
Blakeley, JO
Stevens, G
Ye, XB
Desideri, S
Ryu, S
Desai, B
Giranda, VL
Grossman, SA
AF Kleinberg, Lawrence
Supko, Jeffrey G.
Mikkelsen, Tom
Blakeley, Jaishri O'Neill
Stevens, Glen
Ye, Xiaobu
Desideri, Serena
Ryu, Samuel
Desai, Bhardwaj
Giranda, Vincent L.
Grossman, Stuart A.
TI Phase I adult brain tumor consortium (ARTC) trial of ABT-888
(veliparib), temozolomide (TMZ), and radiotherapy (RT) for newly
diagnosed glioblastoma multiforme (GBM) including pharmacokinetic (PK)
data
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Baltimore, MD USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Henry Ford Hlth Syst, Detroit, MI USA.
Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
Cleveland Clin Fdn, Cleveland, OH 44195 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Henry Ford Hosp, Detroit, MI 48202 USA.
Abbott Labs, Abbott Pk, IL 60064 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2065
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600726
ER
PT J
AU Kris, MG
Oxnard, GR
Johnson, BE
Berry, LD
Chen, HD
Kwiatkowski, DJ
Iafrate, AJ
Wistuba, II
Franklin, WA
Aisner, D
Sequist, LV
Khuri, FR
Garon, EB
Pao, W
Rudin, CM
Schiller, JH
Haura, EB
Minna, JD
Bunn, PA
AF Kris, Mark G.
Oxnard, Geoffrey R.
Johnson, Bruce E.
Berry, Lynne D.
Chen, Heidi
Kwiatkowski, David J.
Iafrate, Anthony John
Wistuba, Ignacio Ivan
Franklin, Wilbur A.
Aisner, Dara
Sequist, Lecia V.
Khuri, Fadlo Raja
Garon, Edward B.
Pao, William
Rudin, Charles M.
Schiller, Joan H.
Haura, Eric B.
Minna, John D.
Bunn, Paul A.
TI Incidence, characteristics, and survival of patients with EGFR-mutant
lung cancers with EGFR T790M at diagnosis identified in the lung cancer
mutation consortium (LCMC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Nashville, TN 37235 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Colorado Denver, Denver, CO USA.
Univ Colorado, Sch Med, Aurora, CO USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
Univ Calif Los Angeles, Santa Monica, CA USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8085
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602564
ER
PT J
AU Kristeleit, RS
Shapiro, G
LoRusso, P
Infante, JR
Flynn, M
Patel, MR
Tolaney, SM
Hilton, JF
Calvert, AH
Giordano, H
Isaacson, JD
Borrow, J
Allen, AR
Jaw-Tsai, SS
Burris, HA
AF Kristeleit, Rebecca Sophie
Shapiro, Geoffrey
LoRusso, Patricia
Infante, Jeffrey R.
Flynn, Michael
Patel, Manish R.
Tolaney, Sara M.
Hilton, John Frederick
Calvert, Alan Hilary
Giordano, Heidi
Isaacson, Jeffrey D.
Borrow, Jennifer
Allen, Andrew R.
Jaw-Tsai, Sarah S.
Burris, Howard A.
TI A phase I dose-escalation and PK study of continuous oral rucaparib in
patients with advanced solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UCL, London, England.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Sarah Cannon Res Inst, Tennessee Oncol, Nashville, TN USA.
Florida Canc Specialists, Sarah Cannon Res Inst, Sarasota, FL USA.
Clovis Oncol Inc, San Francisco, CA USA.
NR 0
TC 8
Z9 8
U1 0
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2585
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601102
ER
PT J
AU Kroeger, N
Lee, JL
Bjarnason, GA
Knox, JJ
MacKenzie, MJ
Vaishamayan, UN
Wood, L
Srinivas, S
Rha, SY
Pal, SK
Yuasa, T
Donskov, F
Agarwal, N
Tan, MH
Bamias, A
Kollmannsberger, CK
North, SA
Rini, BI
Choueiri, TK
Heng, DYC
AF Kroeger, Nils
Lee, Jae-Lyun
Bjarnason, Georg A.
Knox, Jennifer J.
MacKenzie, Mary J.
Vaishamayan, Ulka N.
Wood, Lori
Srinivas, Sandy
Rha, Sun Young
Pal, Sumanta Kumar
Yuasa, Takeshi
Donskov, Frede
Agarwal, Neeraj
Tan, Min-Han
Bamias, Aristotelis
Kollmannsberger, Christian K.
North, Scott A.
Rini, Brian I.
Choueiri, Toni K.
Heng, Daniel Yick Chin
TI Treatment response and survival outcome of patients with late relapse
(LR) from renal cell carcinoma (RCC) in the era of targeted therapy
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Tom Baker Canc Clin, Calgary, AB, Canada.
Univ Ulsan, Coll Med, Asan Med Ctr, Dept Oncol, Seoul, South Korea.
Univ Toronto, Sunnybrook Odette Canc Ctr, Toronto, ON, Canada.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
London Reg Canc Program, London, ON, Canada.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
Stanford Med Ctr, Stanford, CA USA.
Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea.
City Hope Comprehens Canc Ctr, Duarte, CA USA.
Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan.
Aarhus Univ Hosp, Dept Oncol, DK-8000 Aarhus, Denmark.
Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
Natl Canc Ctr Singapore, Singapore, Singapore.
Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece.
BC Canc Agcy, Vancouver, BC, Canada.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Cleveland Clin, Taussig Canc Inst, Cleveland, OH 44106 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4578
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601592
ER
PT J
AU Kumar, P
Sepucha, K
Chang, YC
Belkora, J
Lee, CN
Partridge, AH
Feibelmann, S
Moy, B
AF Kumar, Pallavi
Sepucha, Karen
Chang, Yuchiao
Belkora, Jeffrey
Lee, Clara N.
Partridge, Ann H.
Feibelmann, Sandra
Moy, Beverly
TI Risk perceptions in localized breast cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ N Carolina, Chapel Hill, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9534
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603017
ER
PT J
AU Kupfer, S
Guindalini, RSC
Gulden, C
Ukaegbu, CI
Koeppe, E
Conrad, P
Hampel, H
Stoffel, EM
Syngal, S
Olopade, OI
AF Kupfer, Sonia
Guindalini, Rodrigo Santa Cruz
Gulden, Cassandra
Ukaegbu, Chinedu I.
Koeppe, Erika
Conrad, Peggy
Hampel, Heather
Stoffel, Elena Martinez
Syngal, Sapna
Olopade, Olufunmilayo I.
TI Cancer risks and mutation spectrum of mismatch repair genes in African
American families with Lynch syndrome.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Michigan, Ann Arbor, MI 48109 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Ohio State Univ, Div Human Genet, Columbus, OH 43210 USA.
Univ Chicago, Chicago, IL 60637 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1530
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600589
ER
PT J
AU Kurkjian, C
LoRusso, P
Sankhala, KK
Birrer, MJ
Kirby, M
Ladd, S
Hawes, S
Running, KL
O'Leary, JJ
Moore, KN
AF Kurkjian, Carla
LoRusso, Patricia
Sankhala, Kamalesh Kumar
Birrer, Michael J.
Kirby, Maurice
Ladd, Sharron
Hawes, Susan
Running, Kelli Lynn
O'Leary, James J.
Moore, Kathleen N.
TI A phase I, first-in-human study to evaluate the safety, pharmacokinetics
(PK), and pharmacodynamics (PD) of IMGN853 in patients (Pts) with
epithelial ovarian cancer (EOC) and other FOLR1-positive solid tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Oklahoma, Oklahoma City, OK USA.
Wayne State Univ, Karmanos Canc Inst, Detroit, MI USA.
Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
ImmunoGen Inc, Waltham, MA USA.
Univ Oklahoma, Hlth Sci Ctr, Oklahoma City, OK USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2573
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601090
ER
PT J
AU Kwak, EL
Goyal, L
Abrams, TA
Carpenter, A
Wolpin, BM
Wadlow, RC
Allen, JN
Heist, RS
McCleary, NJ
Chan, JA
Goessling, W
Schrag, D
Evans, C
Ng, K
Enzinger, PC
Ryan, DP
AF Kwak, Eunice Lee
Goyal, Lipika
Abrams, Thomas Adam
Carpenter, Amanda
Wolpin, Brian M.
Wadlow, Raymond Couric
Allen, Jill N.
Heist, Rebecca Suk
McCleary, Nadine Jackson
Chan, Jennifer A.
Goessling, Wolfram
Schrag, Deborah
Evans, Colleen
Ng, Kimmie
Enzinger, Peter C.
Ryan, David P.
TI A phase II clinical trial of ganetespib (STA-9090) in previously treated
patients with advanced esophagogastric cancers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp Canc Ctr, Div Hematol & Oncol, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp Canc Ctr, Boston, MA USA.
Virginia Canc Specialists, Fairfax, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4090
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601463
ER
PT J
AU Ladanyi, M
Cagle, PT
Beasley, MB
Chitale, D
Dacic, S
Giaccone, G
Jenkins, RB
Kwiatkowski, DJ
Saldivar, JS
Squire, J
Thunnissen, E
Lindeman, NI
AF Ladanyi, Marc
Cagle, Phil T.
Beasley, Mary Beth
Chitale, Dhananjay
Dacic, Sanja
Giaccone, Giuseppe
Jenkins, Robert B.
Kwiatkowski, David J.
Saldivar, Juan-Sebastian
Squire, Jeremy
Thunnissen, Erik
Lindeman, Neal Ian
TI The CAP-IASLC-AMP molecular testing guideline for the selection of lung
cancer patients for EGFR and ALK tyrosine kinase inhibitors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Methodist Hosp, Houston, TX 77030 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Henry Ford Hlth Syst, Dept Pathol, Detroit, MI USA.
Univ Pittsburgh, Pittsburgh, PA USA.
NCI, Bethesda, MD 20892 USA.
Mayo Clin, Rochester, MN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA 91010 USA.
Queens Univ, Dept Pathol & Mol Med, Kingston, ON, Canada.
Vrije Univ Amsterdam Med Ctr, Amsterdam, Netherlands.
Harvard Univ, Sch Med, Brigham & Womens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 11085
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600502
ER
PT J
AU Langleben, A
Supko, JG
Hotte, SJ
Batist, G
Hirte, HW
Rogoff, H
Li, YZ
Li, W
Kerstein, D
Leggett, D
Hitron, MJ
Li, C
AF Langleben, Adrian
Supko, Jeffrey G.
Hotte, Sebastien J.
Batist, Gerald
Hirte, Hal W.
Rogoff, Harry
Li, Youzhi
Li, Wei
Kerstein, David
Leggett, David
Hitron, Matthew J.
Li, Chiang
TI A dose-escalation phase I study of a first-in-class cancer stemness
inhibitor in patients with advanced malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 McGill Univ, Dept Oncol, Montreal, PQ, Canada.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Juravinski Canc Ctr, Hamilton, ON, Canada.
McGill Univ, Montreal, PQ, Canada.
McGill Univ, Jewish Gen Hosp, Segal Canc Ctr, Montreal, PQ H3T 1E2, Canada.
Boston Biomed Inc, Cambridge, MA USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2542
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601060
ER
PT J
AU Lathan, C
Kumar, P
Gareen, IF
Gorelick, J
Sicks, J
Hyland, K
Park, ER
AF Lathan, Christopher
Kumar, Pallavi
Gareen, Ilana F.
Gorelick, Jeremy
Sicks, JoRean
Hyland, Kelly
Park, Elyse R.
TI Racial differences in perceived risk in participants enrolled in the
American College of Radiology (ACRIN-6654) arm of the National Lung
Screening Trial (NLST)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brown Univ, Ctr Stat Sci, Providence, RI 02912 USA.
Brown Univ, Providence, RI 02912 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
RI Gareen, Ilana/I-2816-2014
OI Gareen, Ilana/0000-0002-0457-5595
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1563
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600622
ER
PT J
AU Ledermann, JA
Harter, P
Gourley, C
Friedlander, M
Vergote, I
Rustin, GJS
Scott, CL
Meier, W
Shapira-Frommer, R
Safra, T
Matei, D
Fielding, A
Macpherson, E
Dougherty, B
Jurgensmeier, JM
Orr, M
Matulonis, U
AF Ledermann, Jonathan A.
Harter, Philipp
Gourley, Charlie
Friedlander, Michael
Vergote, Ignace
Rustin, Gordon J. S.
Scott, Clare L.
Meier, Werner
Shapira-Frommer, Ronnie
Safra, Tamar
Matei, Daniela
Fielding, Anitra
Macpherson, Euan
Dougherty, Brian
Juergensmeier, Juliane M.
Orr, Maria
Matulonis, Ursula
TI Olaparib maintenance therapy in patients with platinum-sensitive
relapsed serous ovarian cancer (SOC) and a BRCA mutation (BRCAm)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Coll London Canc Hosp, Univ Coll London Canc Inst, London, England.
Kliniken Essen Mitte, Essen, Germany.
Edinburgh Canc Res UK Ctr, Edinburgh, Midlothian, Scotland.
Prince Wales Hosp, Sydney, NSW, Australia.
UZ Leuven, Leuven, Belgium.
Mt Vernon Hosp, Northwood, Middx, England.
Royal Melbourne Hosp, Melbourne, Vic, Australia.
Evangel Hosp, Dusseldorf, Germany.
Sackler Fac Med Tel Aviv Univ, Sheba Med Ctr, Ella Inst Res & Treatment Melanoma, Tel Hashomer, Israel.
Tel Aviv Univ, Tel Aviv Sourasky Med Ctr, IL-69978 Tel Aviv, Israel.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
AstraZeneca, Macclesfield, Cheshire, England.
AstraZeneca, Waltham, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 10
Z9 10
U1 1
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5505
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602019
ER
PT J
AU Lee, EQ
Reardon, DA
Schiff, D
Drappatz, J
Muzikansky, A
Hammond, S
Grimm, SA
Norden, AD
Beroukhim, R
McCluskey, CS
Chi, AS
Batchelor, T
Smith, KH
Gaffey, SC
Gerard, M
Snodgrass, SM
Raizer, JJ
Wen, PY
AF Lee, Eudocia Quant
Reardon, David A.
Schiff, David
Drappatz, Jan
Muzikansky, Alona
Hammond, Samantha
Grimm, Sean Aaron
Norden, Andrew David
Beroukhim, Rameen
McCluskey, Christine Sceppa
Chi, Andrew S.
Batchelor, Tracy
Smith, Katrina H.
Gaffey, Sarah C.
Gerard, Mary
Snodgrass, Susan M.
Raizer, Jeffrey J.
Wen, Patrick Y.
TI Interim analysis of a phase I/II study of panobinostat in combination
with bevacizumab for recurrent glioblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Univ Minnesota, Minneapolis, MN USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2013
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600674
ER
PT J
AU Lesokhin, AM
Gutierrez, M
Halwani, AS
Ansell, SM
Armand, P
Borrello, I
Segota, ZE
Cohen, AD
Talpaz, M
Cattry, D
Turner, T
Mezes, M
Hartman, C
Gupta, AK
Kim, SY
Wigginton, JM
Timmerman, J
AF Lesokhin, Alexander M.
Gutierrez, Martin
Halwani, Ahmad Sami
Ansell, Stephen Maxted
Armand, Philippe
Borrello, Ivan
Segota, Zdenka E.
Cohen, Adam D.
Talpaz, Moshe
Cattry, Deepika
Turner, Tracy
Mezes, Maria
Hartman, Christina
Gupta, Ashok Kumar
Kim, Su Young
Wigginton, Jon M.
Timmerman, John
TI A phase I dose-escalation study evaluating the effects of nivolumab
(anti-PD-1; BMS-936558; ONO-4538) in patients (pts) with select relapsed
or refractory hematologic malignancies
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Cornell Univ, Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Cornell Univ, Weill Med Coll, New York, NY 10021 USA.
Hackensack Univ, Med Ctr, Hackensack, NJ USA.
Huntsman Canc Inst, Salt Lake City, UT USA.
Mayo Clin, Rochester, MN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Holy Cross Med Grp, Ft Lauderdale, FL USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3113
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605407
ER
PT J
AU Lichtman, SM
Cirrincione, C
Hurria, A
Jatoi, A
Theodoulou, M
Wolff, AC
Gralow, J
Morganstern, D
Magrinat, G
Cohen, HJ
Muss, H
AF Lichtman, Stuart M.
Cirrincione, Constance
Hurria, Arti
Jatoi, Aminah
Theodoulou, Maria
Wolff, Antonio C.
Gralow, Julie
Morganstern, Daniel
Magrinat, Gustav
Cohen, Harvey Jay
Muss, Hyman
CA Alliance Clinical Trials Oncology
TI Effect of renal function (RF) on outcomes in the adjuvant treatment of
older women with breast cancer (> 65 years): CALGB/CTSU 49907 (CC)
ancillary data study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Mayo Clin, Rochester, MN USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Seattle Canc Care Alliance, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Cone Hlth Canc Ctr, Greensboro, NC USA.
Duke Univ, Med Ctr, Durham, NC USA.
Univ N Carolina, Lineberger Comprehens Canc Ctr, Chapel Hill, NC 27599 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9515
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602818
ER
PT J
AU Ligibel, JA
Cirrincione, C
Liu, MC
Citron, ML
Ingle, JN
Gradishar, WJ
Martino, S
Sikov, WM
Michaelson, RA
Hudis, C
Winer, EP
Barry, WT
AF Ligibel, Jennifer A.
Cirrincione, Constance
Liu, Minetta C.
Citron, Marc L.
Ingle, James N.
Gradishar, William John
Martino, Silvana
Sikov, William M.
Michaelson, Richard Alan
Hudis, Clifford
Winer, Eric P.
Barry, William Thomas
TI Body mass index (BMI), tumor subtype, and relapse-free survival (RFS) in
CALGB 9741 (Alliance)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Mayo Clin, Rochester, MN USA.
ProHlth Care Assoc LLP, Lake Success, NY USA.
Northwestern Univ, Chicago, IL 60611 USA.
Angeles Clin & Res Inst, Santa Monica, CA USA.
Brown Univ, Dept Med, Warren Alpert Med Sch, Providence, RI 02912 USA.
St Barnabas Hosp, Livingston, NJ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1032
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600255
ER
PT J
AU Limaye, SA
Haddad, RI
Partridge, A
O'Neill, AM
Radossi, A
Shreenivas, AV
Lorente, D
Hanna, GJ
Sonis, ST
Shulman, LN
Posner, MR
Lorch, JH
AF Limaye, Sewanti Atul
Haddad, Robert I.
Partridge, Ann
O'Neill, Anne M.
Radossi, Andrea
Shreenivas, Aditya V.
Lorente, David
Hanna, Glenn J.
Sonis, Stephen T.
Shulman, Lawrence N.
Posner, Marshall R.
Lorch, Jochen H.
TI Long-term symptom burden and orodental health of oropharyngeal cancer
(OPC) survivors following treatment with chemoradiotherapy (CRT) or
sequential therapy (ST)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
RI Lorente Estelles, David/F-9728-2016
OI Lorente Estelles, David/0000-0001-7550-0657
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9530
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603013
ER
PT J
AU Lin, NU
Danso, MA
David, AK
Muscato, JJ
Rayson, D
Houck, WA
Ellis, CE
DeSilvio, M
Garofalo, A
Levin, J
Winer, EP
AF Lin, Nancy U.
Danso, Michael A.
David, Alice K.
Muscato, Joseph J.
Rayson, Daniel
Houck, William A.
Ellis, Catherine Elizabeth
DeSilvio, Michelle
Garofalo, Amanda
Levin, Jeremy
Winer, Eric P.
TI Human epidermal growth factor receptor 2 (HER2) suppression with the
addition of lapatinib to trastuzumab in HER2-positive metastatic breast
cancer (HALT: LPT112515).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Virginia Oncol Associates, US Oncol, Norfolk, VA USA.
Augusta Oncol Associates, Augusta, GA USA.
Missouri Canc Associates, Columbia, MO USA.
Dalhousie Univ, Dept Med, Halifax, NS, Canada.
Virginia Canc Specialists PC, Winchester, VA USA.
GlaxoSmithKline, Oncol, Collegeville, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS664
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605494
ER
PT J
AU Lin, NU
Gelman, RS
Brock, JE
Bardia, A
Mayer, EL
Overmoyer, B
Wang, V
Lannone, M
Krop, IE
Polyak, K
Winer, EP
AF Lin, Nancy U.
Gelman, Rebecca Sue
Brock, Jane E.
Bardia, Aditya
Mayer, Erica L.
Overmoyer, Beth
Wang, Vivian
Lannone, Marie
Krop, Ian E.
Polyak, Kornelia
Winer, Eric P.
TI Phase II study of ruxolitinib in patients with pStat3+breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS1134
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605367
ER
PT J
AU Lin, NU
Gelman, RS
Younger, WJ
Sohl, J
Freedman, RA
Sorensen, AG
Bullitt, E
Harris, GJ
Morganstern, D
Schneider, BP
Krop, IE
Winer, EP
AF Lin, Nancy U.
Gelman, Rebecca Sue
Younger, W. Jerry
Sohl, Jessica
Freedman, Rachel A.
Sorensen, A. Gregory
Bullitt, Elizabeth
Harris, Gordon J.
Morganstern, Daniel
Schneider, Bryan P.
Krop, Ian E.
Winer, Eric P.
TI Phase II trial of carboplatin (C) and bevacizumab (BEV) in patients
(pts) with breast cancer brain metastases (BCBM).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Siemens Healthcare North Amer, Malvern, PA USA.
Univ N Carolina, Chapel Hill, NC USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
NR 0
TC 10
Z9 10
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 513
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600018
ER
PT J
AU Loggers, ET
Prigerson, HG
AF Loggers, Elizabeth Trice
Prigerson, Holly Gwen
TI End-of-life experience of patients with rare cancers and their
caregivers
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Grp Hlth Res Inst, Seattle, WA USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9540
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603023
ER
PT J
AU Lokhorst, HM
Plesner, T
Gimsing, P
Nahi, H
Minnema, M
Lassen, UN
Krejcik, J
Laubach, J
Lisby, S
Basse, L
Richardson, PGG
AF Lokhorst, Henk M.
Plesner, Torben
Gimsing, Peter
Nahi, Hareth
Minnema, Monique
Lassen, Ulrik Niels
Krejcik, Jakub
Laubach, Jacob
Lisby, Steen
Basse, Linda
Richardson, Paul Gerard Guy
TI Phase I/II dose-escalation study of daratumumab in patients with
relapsed or refractory multiple myeloma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 UMC Utrecht, Utrecht, Netherlands.
Vejle Hosp, Vejle, Denmark.
Copenhagen Univ Hosp, Copenhagen, Denmark.
Karolinska Univ, Sjukhuset Huddinge, Huddinge, Sweden.
Rigshosp, DK-2100 Copenhagen, Denmark.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
Genmab AS, Copenhagen, Denmark.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 3
Z9 3
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8512
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602608
ER
PT J
AU Lonial, S
Jagannath, S
Moreau, P
Jakubowiak, AJ
Raab, MS
Facon, T
Vij, R
Bleickardt, E
Reece, DE
Benboubker, L
Zonder, JA
Deng, W
Singhal, AK
Richardson, PGG
AF Lonial, Sagar
Jagannath, Sundar
Moreau, Philippe
Jakubowiak, Andrzej J.
Raab, Marc S.
Facon, Thierry
Vij, Ravi
Bleickardt, Eric
Reece, Donna Ellen
Benboubker, Lotfi
Zonder, Jeffrey A.
Deng, Wei
Singhal, Anil K.
Richardson, Paul Gerard Guy
CA 1703 Study Investigators
TI Phase (Ph) I/II study of elotuzumab (Elo) plus
lenalidomide/dexamethasone (Len/dex) in relapsed/refractory multiple
myeloma (RR MM): Updated Ph II results and Ph I/II long-term safety
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Emory Univ, Sch Med, Atlanta, GA USA.
Multiple Myeloma Res Consortium, Norwalk, CT USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Univ Hosp Hotel Dieu, Nantes, France.
Univ Chicago, Chicago, IL 60637 USA.
Univ Klinikum Heidelberg, Heidelberg, Germany.
Hop Claude Huriez, Lille, France.
Washington Univ, Sch Med, St Louis, MO USA.
Bristol Myers Squibb Co, Wallingford, CT 06492 USA.
Princess Margaret Hosp, Toronto, ON M4X 1K9, Canada.
Hop Bretonneau, Ctr Hosp Univ Tours, Tours, France.
Karmanos Canc Inst, Detroit, MI USA.
AbbVie Biotherapeut Inc, Redwood City, CA USA.
AbbVie Biotherapeut Corp, Redwood City, CA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015
OI FACON, THIERRY/0000-0001-7705-8460;
NR 0
TC 2
Z9 2
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8542
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602638
ER
PT J
AU Lorch, JH
Busaidy, N
Ruan, DT
Janne, PA
Limaye, SA
Wirth, LJ
Barletta, JA
Rabinowits, G
Garraway, LA
Van Allen, EM
Wagle, N
Hanna, GJ
Misiukiewicz, K
Suda, M
Haddad, TC
Devine, CE
Williams, A
Warsi, G
Posner, MR
Haddad, RI
AF Lorch, Jochen H.
Busaidy, Naifa
Ruan, Daniel T.
Janne, Pasi A.
Limaye, Sewanti Atul
Wirth, Lori J.
Barletta, Justine A.
Rabinowits, Guilherme
Garraway, Levi A.
Van Allen, Eliezer Mendel
Wagle, Nikhil
Hanna, Glenn J.
Misiukiewicz, Krzysztof
Suda, Margaret
Haddad, Tyler C.
Devine, Catherine E.
Williams, Amy
Warsi, Ghulam
Posner, Marshall R.
Haddad, Robert I.
TI A phase II study of everolimus in patients with aggressive RAI
refractory (RAIR) thyroid cancer (TC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Mt Sinai Med Ctr, Dept Med, New York, NY 10029 USA.
Novartis, E Hanover, NJ USA.
Novartis Pharmaceut, E Hanover, NJ USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6023
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602147
ER
PT J
AU Love, N
Anderson, KC
Flaherty, K
Kantarjian, HM
Lynch, TJ
O'Shaughnessy, J
Sartor, AO
Venook, AP
Zelenetz, AD
Moss, J
Kelly, G
Ziel, K
AF Love, Neil
Anderson, Kenneth Carl
Flaherty, Keith
Kantarjian, Hagop M.
Lynch, Thomas James
O'Shaughnessy, Joyce
Sartor, A. Oliver
Venook, Alan Paul
Zelenetz, Andrew David
Moss, Jonathan
Kelly, Gloria
Ziel, Kathryn
TI Medical oncologists' clinical experiences and comfort levels with 20
recently approved agents.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Res To Practice, Miami, FL USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
Tulane Canc Ctr, New Orleans, LA USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e17570
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604439
ER
PT J
AU Lu, WD
Lorch, JH
Wayne, PM
Davis, RB
Tishler, RB
Posner, MR
Goguen, LA
Li, HL
Macklin, E
Burke, E
Jaffa, Z
Dreyer, NJ
Haddad, TC
Buring, JE
Rosenthal, DS
Haddad, RI
AF Lu, Weidong
Lorch, Jochen H.
Wayne, Peter M.
Davis, Roger B.
Tishler, Roy B.
Posner, Marshall R.
Goguen, Laura A.
Li, Hailun
Macklin, Eric
Burke, Elaine
Jaffa, Zachary
Dreyer, Nicholas J.
Haddad, Tyler C.
Buring, Julie E.
Rosenthal, David S.
Haddad, Robert I.
TI Acupuncture for dysphagia after chemoradiation therapy in head and neck
cancer: A randomized sham-controlled study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Osher Ctr Integrat Med, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Brigham & Womens Hosp, Dept Surg, Div Otolaryngol, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Biostat, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI Lu, Weidong/C-3844-2008
OI Lu, Weidong/0000-0003-2838-6307
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6058
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602181
ER
PT J
AU Luis, IMVD
Ottesen, RA
Hughes, ME
Mamet, R
Burstein, HJ
Edge, SB
Gonzalez-Angulo, AM
Javid, SH
Moy, B
Rugo, HS
Theriault, RL
Weeks, JC
Lin, NU
AF Luis, Ines Maria Vaz Duarte
Ottesen, Rebecca A.
Hughes, Melissa E.
Mamet, Rizvan
Burstein, Harold J.
Edge, Stephen B.
Gonzalez-Angulo, Ana M.
Javid, Sara H.
Moy, Beverly
Rugo, Hope S.
Theriault, Richard L.
Weeks, Jane C.
Lin, Nancy U.
TI Time trends in the use of adjuvant chemotherapy (CTX) and outcomes in
women with T1N0 breast cancer (BC) in the National Comprehensive Cancer
Network (NCCN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
City Hope Natl Med Ctr, Duarte, CA USA.
Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Washington, Seattle, WA 98195 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1006
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600218
ER
PT J
AU Lynch, JA
Fiore, L
Kelley, MJ
Borzecki, A
Lathan, CS
Hassett, M
Rugo, HS
Khoury, MJ
Freedman, AN
AF Lynch, Julie Ann
Fiore, Louis
Kelley, Michael J.
Borzecki, Ann
Lathan, Christopher S.
Hassett, Michael
Rugo, Hope S.
Khoury, Muin J.
Freedman, Andrew N.
TI Current status of the implementation of gene expression testing in
breast cancer management in the United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Vet Hlth Adm, Bedford, MA USA.
Vet Hlth Adm, Boston, MA USA.
Vet Hlth Adm, Durham, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
UCSF Helen Diller Family Comprehens Canc Ctr, San Francisco, CA USA.
Ctr Dis Control & Prevent, Off Publ Hlth Genom, Atlanta, GA USA.
NCI, Epidemiol & Genom Res Program, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6562
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602278
ER
PT J
AU Macy, M
Kieran, MW
Chi, SN
Cohen, KJ
MacDonald, T
Smith, AA
Etzl, MM
Narendran, A
Gore, L
DiRenzo, J
Trippett, TM
Foreman, NK
Dunkel, IJ
AF Macy, Margaret
Kieran, Mark W.
Chi, Susan N.
Cohen, Kenneth J.
MacDonald, Tobey
Smith, Amy A.
Etzl, Michael Matthew
Narendran, Aru
Gore, Lia
DiRenzo, Jennifer
Trippett, Tanya M.
Foreman, Nicholas K.
Dunkel, Ira J.
TI A phase II trial of radiation and cetuximab followed by
irinotecan/cetuximab for children with newly diagnosed diffuse pontine
tumors and high-grade astrocytomas
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Colorado Denver, Aurora, CO USA.
Childrens Hosp Colorado, Aurora, CO USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Sch Med, Baltimore, MD USA.
Emory Univ, Atlanta, GA 30322 USA.
Univ Texas MD Anderson Canc Ctr, Orlando, FL USA.
Phoenix Childrens Hosp, Phoenix, AZ USA.
Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10030
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600186
ER
PT J
AU Mailhot, R
Kim, J
Hollander, A
Michalski, JM
Tarbell, N
Yock, TI
MacDonald, SM
AF Mailhot, Raymond
Kim, Jane
Hollander, Abby
Michalski, Jeff M.
Tarbell, Nancy
Yock, Torunn I.
MacDonald, Shannon M.
TI Cost-effectiveness analysis of proton versus photon therapy with respect
to risk of growth hormone deficiency
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Washington Univ, Sch Med St Louis, St Louis, MO USA.
Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Washington Univ, St Louis Childrens Hosp, Sch Med, St Louis, MO 63110 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e17553
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604423
ER
PT J
AU Marak, CP
Guddati, AK
AF Marak, Creticus Petrov
Guddati, Achuta Kumar
TI Elimination of both cancer stem cells and progenitor cells as essential
for tumor eradication.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Montefiore Hosp, Albert Einstein Coll Med, New York, NY USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e22179
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605298
ER
PT J
AU Margolin, KA
Hamid, O
Weber, JS
Pavlick, AC
Hodi, FS
Amin, A
Bennett, K
Michener, T
Minor, DR
AF Margolin, Kim Allyson
Hamid, Omid
Weber, Jeffrey S.
Pavlick, Anna C.
Hodi, F. Stephen
Amin, Asim
Bennett, Kelly
Michener, Tracy
Minor, David R.
TI Ipilimumab retreatment following induction therapy: The expanded access
program (EAP) experience
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Seattle, WA 98195 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA.
NYU, Dept Med, Langone Med Ctr, New York, NY 10016 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Levine Canc Inst, Charlotte, NC USA.
Bristol Myers Squibb, Plainsboro, NJ USA.
Calif Pacific Ctr Melanoma Res & Treatment, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9041
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602742
ER
PT J
AU Marur, S
Li, SL
Cmelak, A
Gillison, ML
Ferris, RL
Bauman, JE
Zhao, WQ
Westra, WH
Chung, CH
Wagner, LI
Trevarthen, DR
Jahagirdar, BN
Colevas, AD
AF Marur, Shanthi
Li, Shuli
Cmelak, Anthony
Gillison, Maura L.
Ferris, Robert L.
Bauman, Julie E.
Zhao, Weiqiang
Westra, William H.
Chung, Christine H.
Wagner, Lynne I.
Trevarthen, David R.
Jahagirdar, Balkrishna N.
Colevas, A. Dimitrios
CA Barbara Burtness Eastern Cooperati
TI E 1308: A phase II trial of induction chemotherapy (IC) followed by
cetuximab with low dose versus standard dose IMRT in patients with human
papilloma virus (HPV)-associated resectable squamous cell carcinoma of
the oropharynx (OPSCC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Johns Hopkins Univ, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Ohio State Univ, Columbus, OH 43210 USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Ohio State Univ, Ctr Comprehens Canc, Dept Pathol, Columbus, OH 43210 USA.
Johns Hopkins Sch Med, Baltimore, MD USA.
Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Colorado Canc Res Program, Denver, CO USA.
HealthPartners & Reg Canc Care Ctr, St Paul, MN USA.
Stanford Univ, Stanford, CA 94305 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 7
Z9 7
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6005
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602130
ER
PT J
AU Matsumoto, AM
Getzenberg, RH
Coss, C
Hancock, ML
Si, XM
Dalton, JT
Steiner, MS
AF Matsumoto, Alvin M.
Getzenberg, Robert H.
Coss, Christopher
Hancock, Michael L.
Si, Xuemei
Dalton, James T.
Steiner, Mitchell S.
TI The free hormone hypothesis: Correlation of decreases in PSA with free
testosterone rather than total testosterone in men with advanced
prostate cancer treated with GTx-758.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, GRECC, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA.
Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
GTx Inc, Memphis, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16015
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604207
ER
PT J
AU Mattano, LA
Devidas, M
Friedmann, AM
Raetz, EA
Hunger, S
Winick, NJ
Carroll, WL
Maloney, KW
AF Mattano, Leonard A.
Devidas, Meenakshi
Friedmann, Alison M.
Raetz, Elizabeth A.
Hunger, Stephen
Winick, Naomi Joan
Carroll, William L.
Maloney, Kelly W.
CA Children's Oncology Grp
TI Effect of dexamethasone (DEX) dose modification on osteonecrosis (ON)
risk associated with intensified therapies for standard risk acute
lymphoblastic leukemia (SR-ALL): A report from the Children's Oncology
Group (COG) study AALL0331.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Bronson Methodist Hosp, Kalamazoo, MI USA.
Childrens Oncol Grp, Gainesville, FL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NYU, Langone Med Ctr, New York, NY USA.
Univ Colorado Denver, Hlth Sci Ctr, Aurora, CO USA.
Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
Childrens Med Ctr Dallas, Ctr Canc & Blood Disorders, Dallas, TX USA.
Childrens Hosp Colorado, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10002
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600156
ER
PT J
AU Mckay, RR
Lin, X
Perkins, JJ
Simantov, R
Choueiri, TK
AF Mckay, Rana R.
Lin, Xun
Perkins, Julia Jane
Simantov, Ronit
Choueiri, Toni K.
TI Prognostic significance of bone metastases (BM) and bisphosphonate (BIS)
therapy in patients with metastatic renal cell carcinoma (mRCC) treated
with molecularly targeted agents (MTAs)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Pfizer Oncol, San Diego, CA USA.
Pfizer Oncol, New York, NY USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4572
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601586
ER
PT J
AU Mehra, R
Egloff, AM
Li, SL
Yang, DH
Wang, L
Zhu, F
Forastiere, AA
Burtness, B
Argiris, A
AF Mehra, Ranee
Egloff, Ann Marie
Li, Shuli
Yang, Donghua
Wang, Lin
Zhu, Fang
Forastiere, Arlene A.
Burtness, Barbara
Argiris, Athanassios
CA Eastern Cooperative Oncology Grp
TI Analysis of HPV and ERCC1 in recurrent or metastatic squamous cell
carcinoma of the head and neck (R/M SCCHN)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Univ Pittsburgh, Pittsburgh, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Univ Texas Hlth Sci Ctr San Antonio, Canc Therapy & Res Ctr, San Antonio, TX 78229 USA.
NR 0
TC 2
Z9 2
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6006
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602131
ER
PT J
AU Meier, FE
Niessner, H
Schmitz, J
Schmid, A
Calaminus, C
Pichler, B
Forschner, A
Flaherty, K
Honegger, JB
Dummer, R
Tabatabai, G
Weide, B
Eigentler, TK
Schadendorf, D
Quintanilla-Fend, L
Garbe, C
AF Meier, Friedegund Elke
Niessner, Heike
Schmitz, Jennifer
Schmid, Andreas
Calaminus, Carsten
Pichler, Bernd
Forschner, Andrea
Flaherty, Keith
Honegger, Juergen Bernd
Dummer, Reinhard
Tabatabai, Ghazaleh
Weide, Benjamin
Eigentler, Thomas K.
Schadendorf, Dirk
Quintanilla-Fend, Leticia
Garbe, Claus
TI The PI3K inhibitor BKM120 has potent antitumor activity in melanoma
brain metastases in vitro and in vivo
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Tubingen, Tubingen, Germany.
Univ Tubingen, Dept Dermatol & Oncol, Tubingen, Germany.
Univ Tubingen, Dept Radiol, Tubingen, Germany.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Univ Zurich Hosp, Dept Neurol, CH-8091 Zurich, Switzerland.
Univ Tubingen, Dept Dermatol, Tubingen, Germany.
Univ Klinikum Essen, Essen, Germany.
RI Pichler, Bernd/B-4483-2012; Eigentler, Thomas/K-8570-2015
OI Eigentler, Thomas/0000-0003-0019-2770
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e20050
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604770
ER
PT J
AU Melero, I
Gangadhar, TC
Kohrt, HE
Segal, NH
Logan, T
Urba, WJ
Hodi, FS
Ott, PA
Perez-Gracia, JL
Wolchok, JD
Shah, A
Kurland, JF
Cohen, LJ
Levy, R
Wigginton, JM
Goldberg, SM
AF Melero, Ignacio
Gangadhar, Tara C.
Kohrt, Holbrook Edwin
Segal, Neil Howard
Logan, Theodore
Urba, Walter John
Hodi, F. Stephen
Ott, Patrick Alexander
Perez-Gracia, Jose Luis
Wolchok, Jedd D.
Shah, Aadhar
Kurland, John F.
Cohen, Lewis J.
Levy, Ronald
Wigginton, Jon M.
Goldberg, Stacie M.
TI A phase I study of the safety, tolerability, pharmacokinetics, and
immunoregulatory activity of urelumab (BMS-663513) in subjects with
advanced and/or metastatic solid tumors and relapsed/refractory B-cell
non-Hodgkin's lymphoma (B-NHL)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Navarra Clin, Pamplona, Spain.
CIBEREHD, Pamplona, Spain.
Univ Penn, Philadelphia, PA 19104 USA.
Stanford Canc Inst, Stanford, CA USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Providence Canc Ctr, Earle A Chiles Res Inst, Portland, OR USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Navarra Clin, Dept Med Oncol, Pamplona, Spain.
Bristol Myers Squibb Co, Princeton, NJ USA.
Stanford Univ, Sch Med, Stanford, CA 94305 USA.
NR 0
TC 1
Z9 1
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3107
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605401
ER
PT J
AU Melnyk, N
Xie, XQ
Koh, DJY
Rajpal, M
Moss, RA
Gibbon, D
Cleary, JM
Tran, MT
Scott, P
Stein, MN
Tan, AR
Adams, S
Lindquist, DC
Harris, PJ
Takebe, N
Lin, HX
Aisner, J
White, E
DiPaola, RS
Mehnert, JM
AF Melnyk, Nataliya
Xie, Xiaoqi
Koh, Danny Ju Yong
Rajpal, Megha
Moss, Rebecca Anne
Gibbon, Darlene
Cleary, James M.
Minh-Thu Tran
Scott, Pamela
Stein, Mark N.
Tan, Antoinette R.
Adams, Shari
Lindquist, Diana C.
Harris, Pamela Jo
Takebe, Naoko
Lin, Hongxia
Aisner, Joseph
White, Eileen
DiPaola, Robert S.
Mehnert, Janice M.
TI CTEP #8342 autophagy modulation with antiangiogenic therapy: A phase I
trial of sunitinib (Su) and hydroxychloroquine (HCQ)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Med & Dent New Jersey, New Brunswick, NJ USA.
Univ Med & Dent New Jersey, Piscataway, NJ 08854 USA.
Robert Wood Johnson Med Sch, Piscataway, NJ USA.
UMDNJ Robert Wood Johnson Med Sch, Canc Inst New Jersey, New Brunswick, NJ USA.
Canc Inst New Jersey, New Brunswick, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Bethesda, MD 20892 USA.
Canc Therapy Evaluat Program, Invest Drug Branch, Rockville, MD USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2553
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601071
ER
PT J
AU Metzger, O
Giobbie-Hurder, A
Mallon, EA
Viale, G
Winer, EP
Thurlimann, BJK
Gelber, RD
Regan, MM
Colleoni, M
Ejlertsen, B
Bonnefoi, H
Forbes, JF
Neven, P
Wardley, AM
Lang, I
Smith, IE
Price, KN
Coates, AS
Goldhirsch, A
AF Metzger Filho, Otto
Giobbie-Hurder, Anita
Mallon, Elizabeth A.
Viale, Giuseppe
Winer, Eric P.
Thurlimann, Beat J. K.
Gelber, Richard D.
Regan, Meredith M.
Colleoni, Marco
Ejlertsen, Bent
Bonnefoi, Herve
Forbes, John F.
Neven, Patrick
Wardley, Andrew M.
Lang, Istvan
Smith, Ian E.
Price, Karen N.
Coates, Alan S.
Goldhirsch, Aron
CA Int Breast Canc Study Grp
TI Relative effectiveness of letrozole alone or in sequence with tamoxifen
for patients diagnosed with invasive lobular carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
IBCSG Stat Ctr, Boston, MA USA.
NHS Greater Glasgow & Clyde, Glasgow, Lanark, Scotland.
European Inst Oncol, Milan, Italy.
Kantonsspital St Gallen, St Gallen, Switzerland.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.
Inst Bergonie, Bordeaux, France.
Univ Newcastle, Australian New Zealand Breast Canc Trials Grp, Newcastle, NSW 2300, Australia.
Catholic Univ Louvain, Hosp Gasthuisberg, B-3000 Louvain, Belgium.
Christie Hosp NHS Fdn Trust, Manchester, Lancs, England.
Natl Inst Oncol, Budapest, Hungary.
Royal Marsden Hosp NHS Fdn Trust, London, England.
Univ Sydney, Sydney, NSW 2006, Australia.
European Inst Oncol, Div Med Oncol, Milan, Italy.
RI Wardley, ANdrew/N-8135-2015
OI Wardley, ANdrew/0000-0002-9639-0888
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 529
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600034
ER
PT J
AU Michaelson, MD
McDermott, DF
Atkins, MB
Cho, DC
Olivier, KM
Schwarzberg, AB
Choueiri, TK
AF Michaelson, M. Dror
McDermott, David F.
Atkins, Michael B.
Cho, Daniel C.
Olivier, Kara M.
Schwarzberg, Abraham B.
Choueiri, Toni K.
TI Combination of antiangiogenic therapy and cytotoxic chemotherapy for
sarcomatoid renal cell carcinoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Canc Ctr South Florida, Lake Worth, FL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4512
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601526
ER
PT J
AU Morgenstern, DA
London, WB
Stephens, D
Volchenboum, SL
Hero, B
Di Cataldo, A
Nakagawara, A
Shimada, H
Ambros, PF
Matthay, KK
Cohn, SL
Pearson, ADJ
Irwin, M
AF Morgenstern, Daniel Alexander
London, Wendy B.
Stephens, Derek
Volchenboum, Samuel Louis
Hero, Barabara
Di Cataldo, Andrea
Nakagawara, Akira
Shimada, Hiroyuki
Ambros, Peter F.
Matthay, Katherine K.
Cohn, Susan Lerner
Pearson, Andrew D. J.
Irwin, Meredith
TI Metastatic neuroblastoma confined to distant lymph nodes (stage 4N) to
predict outcome in patients with stage 4 disease: A study from the
International Neuroblastoma (NB) Risk Group (INRG) Database.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
Childrens Hosp, Dana Farber Canc Inst, Harvard Canc Care, Boston, MA 02115 USA.
Univ Chicago, Chicago, IL 60637 USA.
Univ Childrens Hosp, Cologne, Germany.
Univ Catania, Catania, Italy.
Chiba Canc Res Inst, Chiba, Japan.
Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
St Anna Childrens Hosp, Childrens Canc Res Inst, Vienna, Austria.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Inst Canc Res, Sutton, Surrey, England.
Royal Marsden Hosp, Sutton, Surrey, England.
RI Di Cataldo, Andrea/M-2509-2016
OI Di Cataldo, Andrea/0000-0002-4509-3066
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10015
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600169
ER
PT J
AU Morris, MJ
Hammers, HJ
Sweeney, C
Antonarakis, ES
Cho, SY
Pandit-Taskar, N
Jacene, H
Bloma, M
Aksnes, AK
O'Bryan-Tear, CG
Carrasquillo, JA
AF Morris, Michael J.
Hammers, Hans J.
Sweeney, Christopher
Antonarakis, Emmanuel S.
Cho, Steve Y.
Pandit-Taskar, Neeta
Jacene, Heather
Bloma, Marianne
Aksnes, Anne-Kirsti
O'Bryan-Tear, C. Gillies
Carrasquillo, Jorge A.
TI Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients
with bone metastases from castration-resistant prostate cancer (CRPC): A
phase I Prostate Cancer Clinical Trials Consortium Study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Johns Hopkins Univ, Baltimore, MD USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Algeta ASA, Oslo, Norway.
RI Antonarakis, Emmanuel/E-4550-2011
NR 0
TC 2
Z9 2
U1 1
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5021
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601622
ER
PT J
AU Morris, PG
Iyengar, NM
Patil, S
Chen, C
Abbruzzi, A
Lehman, RJ
Steingart, R
Oeffinger, KC
Lin, N
Moy, B
Come, SE
Winer, EP
Norton, L
Hudis, C
Dang, CT
AF Morris, Patrick Glyn
Iyengar, Neil M.
Patil, Sujata
Chen, Carol
Abbruzzi, Alyson
Lehman, Robert James
Steingart, Richard
Oeffinger, Kevin C.
Lin, Nancy
Moy, Beverly
Come, Steven E.
Winer, Eric P.
Norton, Larry
Hudis, Clifford
Dang, Chau T.
TI Longer-term cardiac safety and outcomes of dose dense (dd) doxorubicin
and cyclophosphamide (AC) followed by paclitaxel (T) and trastuzumab (H)
with and without lapatinib (L) in patients (pts) with early breast
cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 630
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600135
ER
PT J
AU Moy, B
Tu, DS
Richardson, H
Maunsell, E
Goss, PE
AF Moy, Beverly
Tu, Dongsheng
Richardson, Harriet
Maunsell, Elizabeth
Goss, Paul E.
TI NCIC CTG MAP.3: Symptoms and quality of life (QoL) among racial/ethnic
minority women taking the aromatase inhibitor (AI) exemestane (EXE) for
breast cancer risk reduction
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Canc, Boston, MA USA.
NCIC Clin Trials Grp, Kingston, ON, Canada.
Univ Laval, Unite Rech Sante Populat, Quebec City, PQ, Canada.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6557
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602273
ER
PT J
AU Mucci, LA
Siddiqui, MM
Wilson, KM
Epstein, MM
Rider, JR
Martin, NE
Kantoff, PW
Stampfer, MJ
Giovannucci, EL
AF Mucci, Lorelei A.
Siddiqui, Mohummad Minhaj
Wilson, Kathryn M.
Epstein, Mara Meyer
Rider, Jennifer R.
Martin, Neil E.
Kantoff, Philip W.
Stampfer, Meir J.
Giovannucci, Edward L.
TI Vasectomy and risk of lethal prostate cancer: A 24-year prospective
study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Sch Publ Hlth, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
RI Martin, Neil/E-2193-2014
OI Martin, Neil/0000-0002-8164-8516
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5086
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602009
ER
PT J
AU Murphy, JE
Russo, AL
Szymonifka, J
Kwak, EL
Allen, JN
Zhu, AX
Blaszkowsky, LS
Clark, JW
Ryan, DP
Hong, TS
Borger, DR
AF Murphy, Janet E.
Russo, Andrea Lyn
Szymonifka, Jackie
Kwak, Eunice Lee
Allen, Jill N.
Zhu, Andrew X.
Blaszkowsky, Lawrence Scott
Clark, Jeffrey W.
Ryan, David P.
Hong, Theodore S.
Borger, Darrell R.
TI DNA mutation frequencies in metastatic small bowel adenocarcinoma (mSBA)
in comparison to gastric (mGC), colon (mCC), and rectal cancer (mRC):
Continuum or cutpoint?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Harvard Radiat Oncol Program, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Massachusetts Gen Hosp, Ctr Canc, Div Hematol & Oncol, Boston, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e14636
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603590
ER
PT J
AU Myers, AP
Broaddus, R
Makker, V
Konstantinopoulos, PA
Drapkin, R
Horowitz, NS
Liu, J
Van Hummelen, P
Meric-Bernstam, F
Birrer, MJ
Doyle, LA
Coleman, RL
Aghajanian, C
Mills, GB
Cantley, L
Matulonis, UA
Westin, SN
AF Myers, Andrea P.
Broaddus, Russell
Makker, Vicky
Konstantinopoulos, Panagiotis A.
Drapkin, Ronny
Horowitz, Neil S.
Liu, Joyce
Van Hummelen, Paul
Meric-Bernstam, Funda
Birrer, Michael J.
Doyle, L. Austin
Coleman, Robert L.
Aghajanian, Carol
Mills, Gordon B.
Cantley, Lewis
Matulonis, Ursula A.
Westin, Shannon Neville
CA SU2C Dream Team PI3K Womens Canc
TI Phase II, two-stage, two-arm, PIK3CA mutation stratified trial of
MK-2206 in recurrent endometrial cancer (EC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Ctr Canc Genome Discovery, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Natl Canc Inst CTEP, Rockville, MD USA.
Harvard Univ, Cambridge, MA 02138 USA.
RI Drapkin, Ronny/E-9944-2016
OI Drapkin, Ronny/0000-0002-6912-6977
NR 0
TC 2
Z9 2
U1 2
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5524
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602038
ER
PT J
AU Nau, PN
Meireles, O
AF Nau, Peter N.
Meireles, Ozanan
TI Gastric malignancy presenting after elective Roux-en-Y gastric bypass
for treatment of morbid obesity.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Nau, Peter N.; Meireles, Ozanan] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e12559
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603338
ER
PT J
AU Naughton, MJ
Schrag, D
Venook, AP
Niedzwiecki, D
Anderson, RT
Lenz, HJ
Grubbs, SS
AF Naughton, Michelle Joy
Schrag, Deborah
Venook, Alan Paul
Niedzwiecki, Donna
Anderson, Roger T.
Lenz, Heinz-Josef
Grubbs, Stephen S.
TI Quality of life (QOL) and toxicity among patients in CALGB 80405
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Duke Univ, Durham, NC USA.
Penn State Coll Med, Hershey, PA USA.
Univ So Calif, Kenneth Norris Jr Comprehens Canc Ctr, Los Angeles, CA 90033 USA.
Helen F Graham Canc Ctr Christiana Care, Newark, DE USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3611
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601346
ER
PT J
AU Navid, F
Chishoim, JC
Ferrari, A
Herzog, CE
Rodriguez-Galindo, C
Hauschild, A
Krishnan, K
Pappo, AS
AF Navid, Fariba
Chishoim, Julia C.
Ferrari, Andrea
Herzog, Cynthia E.
Rodriguez-Galindo, Carlos
Hauschild, Axel
Krishnan, Kartik
Pappo, Alberto S.
TI Open-label, multicenter, single-arm, phase I, dose-dscalation with
efficacy tail extension study of vemurafenib in pediatric patients with
surgically incurable and unresectable stage IIIc or IV melanoma
harboring BRAF(V600) mutations (NCT01519323).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 St Jude Childrens Res Hosp, Memphis, TN 38105 USA.
Royal Marsden NHS Fdn Trust, Sutton, Surrey, England.
Ist Nazl Studio Cura Tumori, Milan, Italy.
Univ Texas MD Anderson Canc Ctr, Div Pediat, Houston, TX 77030 USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Kiel, Kiel, Germany.
Genentech Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS9104
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605526
ER
PT J
AU Nimeiri, HS
Feng, Y
Catalano, PJ
Meropol, NJ
Giantonio, BJ
Sigurdson, ER
Martenson, JA
Whitehead, RP
Sinicrope, FA
Mayer, RJ
O'Dwyer, PJ
Benson, A
AF Nimeiri, Halla Sayed
Feng, Yang
Catalano, Paul J.
Meropol, Neal J.
Giantonio, Bruce J.
Sigurdson, Elin R.
Martenson, James A.
Whitehead, Robert P.
Sinicrope, Frank A.
Mayer, Robert J.
O'Dwyer, Peter J.
Benson, Al Bowen
CA Eastern Cooperative Oncology Grp
TI Intergroup randomized phase III study of postoperative irinotecan,
5-fluorouracil, and leucovorin versus oxaliplatin, 5-fluorouracil, and
leucovorin versus 5-fluorouracil and leucovorin for patients with stage
II or III rectal cancer receiving either preoperative radiation and
5-fluorouracil or postoperative radiation and 5-fluorouracil: ECOG
E3201-An updated survival analysis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Northwestern Univ, Feinberg Sch Med, Chicago, IL 60611 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Case Western Reserve Univ, Case Comprehens Canc Ctr, Univ Hosp Seidman Canc Ctr, Cleveland, OH 44106 USA.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Mayo Clin, Rochester, MN USA.
Med Univ S Carolina, Charleston, SC 29425 USA.
Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
NR 0
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e14711
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603661
ER
PT J
AU Norden, AD
Schiff, D
Ahluwalia, MS
Lesser, GJ
Nayak, L
Lee, EQ
Muzikansky, A
Dietrich, J
Smith, KH
Gaffey, SC
McCluskey, CS
Ligon, KL
Reardon, DA
Wen, PY
AF Norden, Andrew David
Schiff, David
Ahluwalia, Manmeet Singh
Lesser, Glenn Jay
Nayak, Lakshmi
Lee, Eudocia Quant
Muzikansky, Alona
Dietrich, Jorg
Smith, Katrina H.
Gaffey, Sarah C.
McCluskey, Christine Sceppa
Ligon, Keith L.
Reardon, David A.
Wen, Patrick Y.
TI Phase II trial of triple-receptor tyrosine kinase receptor inhibitor
nintedanib (BIBF 1120) in recurrent high-grade gliomas.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Virginia, Med Ctr, Charlottesville, VA USA.
Cleveland Clin, Cleveland, OH 44106 USA.
Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Boston Childrens Hosp, Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS2104
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605386
ER
PT J
AU O'Day, S
Gonzalez, R
Kim, K
Chmielowski, B
Kefford, R
Long, G
Loquai, C
Cowey, CL
Hauschild, A
Hainsworth, JD
Hersey, P
Boyle, F
Evans, TRJ
Hamid, O
Meneses, N
Andresen, C
Ren, M
O'Brien, JP
Flaherty, K
AF O'Day, Steven
Gonzalez, Rene
Kim, Kevin
Chmielowski, Bartosz
Kefford, Richard
Long, Georgina
Loquai, Carmen
Cowey, Charles Lance
Hauschild, Axel
Hainsworth, John D.
Hersey, Peter
Boyle, Frances
Evans, T. R. Jeffry
Hamid, Omid
Meneses, Nicole
Andresen, Corina
Ren, Min
O'Brien, James P.
Flaherty, Keith
TI A phase II study of the multitargeted kinase inhibitor lenvatinib in
patients with advanced BRAF wild-type melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Beverly Hills Canc Ctr, Beverly Hills, CA USA.
UCHSC, Aurora, CO USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Westmead Hosp, Westmead, NSW 2145, Australia.
Univ Sydney, Sydney, NSW 2006, Australia.
Johannes Gutenberg Univ Mainz, Univ Med, D-55122 Mainz, Germany.
Texas Oncol, Dallas, TX USA.
Univ Klinikum Schleswig Holstein, Kiel, Germany.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Calvary Mater Newcastle, Waratah, Australia.
Melanoma Inst Australia, Sydney, NSW, Australia.
Beatson West Scotland Canc Ctr, Glasgow, Lanark, Scotland.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Eisai Inc, Woodcliff Lake, NJ USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9026
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602727
ER
PT J
AU O'Donnell, E
Gray, KP
Hirsch, MS
Kantoff, PW
Beard, C
Sweeney, C
AF O'Donnell, Elizabeth
Gray, Kathryn P.
Hirsch, Michelle S.
Kantoff, Philip W.
Beard, Clair
Sweeney, Christopher
TI Smoking history and disease outcomes in patients with malignant germ
cell tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4561
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601575
ER
PT J
AU O'Neill, AF
Steinberger, A
Voss, SD
Root, EJ
Garber, JE
Diller, L
AF O'Neill, Allison Frances
Steinberger, Allie
Voss, Stephan D.
Root, Elizabeth J.
Garber, Judy Ellen
Diller, Lisa
TI Screening with whole-body MRI (WB-MRI) in pediatric patients with Li
Fraumeni syndrome (LFS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp Boston, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10071
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600231
ER
PT J
AU O'Reilly, EM
Lowery, MA
Yu, KH
Capanu, M
Stadler, ZK
Epstein, AS
Golan, T
Segal, A
Segal, M
Salo-Mullen, EE
Tang, LH
Hollywood, E
Moynahan, ME
Do, KG
Moore, MJ
Kindler, HL
Mayer, RJ
Chen, AP
Kelsen, DP
AF O'Reilly, Eileen Mary
Lowery, Maeve Aine
Yu, Kenneth H.
Capanu, Marinela
Stadler, Zsofia Kinga
Epstein, Andrew S.
Golan, Talia
Segal, Amiel
Segal, Michal
Salo-Mullen, Erin E.
Tang, Laura H.
Hollywood, Ellen
Moynahan, Mary Ellen
Do, Kinh G.
Moore, Malcolm J.
Kindler, Hedy Lee
Mayer, Robert J.
Chen, Alice P.
Kelsen, David Paul
TI Randomized phase II study of gemcitabine (G), cisplatin (C) with or
without veliparib (V) (arms A, B) and a phase II single-arm study of
single-agent veliparib (arm C) in patients with BRCA or PALB2-mutated
pancreas adenocarcinoma (PC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
Shaare Zedek Med Ctr, Jerusalem, Israel.
Mem Sloan Kettering Canc Ctr, Dept Med, Clin Genet Serv, New York, NY 10021 USA.
Univ Toronto, Dept Med, Princess Margaret Canc Ctr, Univ Hlth Network,Div Med Oncol & Hematol, Toronto, ON, Canada.
Univ Chicago, Med Ctr, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NCI, Bethesda, MD 20892 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS4144
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605428
ER
PT J
AU Ollila, DW
Berry, DA
Cirrincione, C
Carey, LA
Amos, KD
Henry, NL
Winer, EP
Hudis, C
Golshan, M
AF Ollila, David W.
Berry, Donald A.
Cirrincione, Constance
Carey, Lisa A.
Amos, Keith D.
Henry, Nora Lynn
Winer, Eric P.
Hudis, Clifford
Golshan, Mehra
CA Alliance Clinical Trials Oncology
TI Impact of neoadjuvant chemotherapy plus HER2-targeting on breast
conservation rates: Surgical results from CALGB 40601 (Alliance).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ N Carolina, Chapel Hill, NC USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Univ Michigan, Med Ctr, Ann Arbor, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 501
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600008
ER
PT J
AU Ou, SHI
Bang, YJ
Camidge, DR
Riely, GJ
Salgia, R
Shapiro, G
Solomon, BJ
Engelman, JA
Kwak, EL
Clark, JW
Tye, L
Wilner, KD
Stephenson, P
Varella-Garcia, M
Bergethon, K
Iafrate, AJ
Shaw, AT
AF Ou, Sai-Hong Ignatius
Bang, Yung-Jue
Camidge, D. Ross
Riely, Gregory J.
Salgia, Ravi
Shapiro, Geoffrey
Solomon, Benjamin J.
Engelman, Jeffrey A.
Kwak, Eunice Lee
Clark, Jeffrey W.
Tye, Lesley
Wilner, Keith D.
Stephenson, Patricia
Varella-Garcia, Marileila
Bergethon, Kristin
Iafrate, Anthony John
Shaw, Alice Tsang
TI Efficacy and safety of crizotinib in patients with advanced
ROS1-rearranged non-small cell lung cancer (NSCLC).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Chao Family Comprehens Canc Ctr, Orange, CA USA.
Seoul Natl Univ Hosp, Seoul 110744, South Korea.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Chicago, Chicago, IL 60637 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Peter MacCallum Canc Ctr, Dept Med Oncol, Melbourne, Vic, Australia.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Div Hematol & Oncol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Pfizer Oncol, La Jolla, CA USA.
Rho Inc, Chapel Hill, NC USA.
Univ Colorado, Sch Med, Aurora, CO USA.
Duke Univ, Sch Med, Durham, NC USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 17
Z9 17
U1 3
U2 7
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8032
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602513
ER
PT J
AU Oxnard, GR
Heng, JC
Rainville, IR
Dahlberg, SE
Sable-Hunt, AL
Wiesner, GL
Taylor, KA
Jackman, DM
Janne, PA
Garber, JE
AF Oxnard, Geoffrey R.
Heng, Jennifer C.
Rainville, Irene R.
Dahlberg, Suzanne Eleanor
Sable-Hunt, Alicia L.
Wiesner, Georgia L.
Taylor, Kelly A.
Jackman, David Michael
Janne, Pasi A.
Garber, Judy Ellen
TI Investigating hereditary risk from T790M (inherit): A prospective
multicentered study of risk associated with germline EGFR T790M.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Addario Lung Canc Med Inst, San Carlos, CA USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS1606
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605379
ER
PT J
AU Oxnard, GR
Heng, JC
Mach, SL
Lo, PC
Butaney, M
Jackman, DM
Janne, PA
AF Oxnard, Geoffrey R.
Heng, Jennifer C.
Mach, Stacy L.
Lo, Peter C.
Butaney, Mohit
Jackman, David Michael
Janne, Pasi A.
TI The spectrum of genomic alterations in young adult non-small cell lung
cancer (NSCLC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Oxnard, Geoffrey R.; Heng, Jennifer C.; Mach, Stacy L.; Lo, Peter C.; Butaney, Mohit; Jackman, David Michael; Janne, Pasi A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8077
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602557
ER
PT J
AU Papai, Z
Tolcher, AW
Italiano, A
Cupissol, D
Lopez-Pousa, A
Chawla, SP
Bompas, E
Penel, N
Isambert, N
Staddon, AP
Thyss, A
Santoro, A
Franke, FA
Cohen, P
Le-Guennec, S
Demetri, GD
Blay, JY
AF Papai, Zsuzsanna
Tolcher, Anthony W.
Italiano, Antoine
Cupissol, Didier
Lopez-Pousa, Antonio
Chawla, Sant P.
Bompas, Emmanuelle
Penel, Nicolas
Isambert, Nicolas
Staddon, Arthur P.
Thyss, Antoine
Santoro, Armando
Franke, Fabio A.
Cohen, Patrick
Le-Guennec, Solenn
Demetri, George D.
Blay, Jean-Yves
TI A randomized, double-blind, placebo (Pbo)-controlled phase III study of
ombrabulin plus cisplatin in patients (pts) with advanced-stage
soft-tissue sarcoma after failure of anthracycline and ifosfamide
chemotherapies.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Allami Egeszsegugyi Kozpont, Budapest, Hungary.
START, San Antonio, TX USA.
Inst Bergonie, Bordeaux, France.
Ctr Val dAurelle, Montpellier, France.
Hosp Santa Creu & Sant Pau, Barcelona, Spain.
St Johns Hosp, Santa Monica, CA USA.
Ctr Rene Gauducheau, F-44035 Nantes, France.
Ctr Oscar Lambret, F-59020 Lille, France.
Ctr Georges Francois Leclerc, Dijon, France.
Penn Oncol Hematol Associates, Philadelphia, PA USA.
Ctr Antoine Lacassagne, F-06054 Nice, France.
Ist Clin Humanitas IRCCS, Milan, Italy.
CACON Hosp Caridade Ijui, Ijui, Brazil.
Sanofi, Vitry Sur Seine, France.
Dana Farber Canc Inst, Ludwig Ctr, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Boston, MA USA.
Ctr Leon Berard, F-69373 Lyon, France.
RI Blay, Jean-Yves/N-3966-2016
OI Blay, Jean-Yves/0000-0001-7190-120X
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10506
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600278
ER
PT J
AU Parikh, R
Cronin, A
Kozono, DE
Oxnard, GR
Mak, RH
Jackman, DM
Lo, PC
Baldini, EH
Johnson, BE
Chen, AB
AF Parikh, Ravi
Cronin, Angel
Kozono, David E.
Oxnard, Geoffrey R.
Mak, Raymond H.
Jackman, David Michael
Lo, Peter C.
Baldini, Elizabeth H.
Johnson, Bruce E.
Chen, Aileen B.
TI Factors associated with survival in non-small cell lung cancer (NSCLC)
patients with a solitary metastasis.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Med, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e19121
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604650
ER
PT J
AU Partridge, AH
Sepucha, K
O'Neill, A
Miller, K
Baker, E
Dang, CT
Northfelt, DW
Sledge, GW
Schneider, BP
AF Partridge, Ann H.
Sepucha, Karen
O'Neill, Anne
Miller, Kathy
Baker, Emily
Dang, Chau T.
Northfelt, Donald W.
Sledge, George W.
Schneider, Bryan P.
TI Does biomarker information impact patients' preferences for therapy?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mayo Clin, Scottsdale, AZ USA.
Stanford Univ, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6527
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602246
ER
PT J
AU Pashtan, IM
Neuberg, DS
Beroukhim, R
Salvesen, HB
Cherniack, A
AF Pashtan, Itai Max
Neuberg, Donna S.
Beroukhim, Rameen
Salvesen, Helga B.
Cherniack, Andrew
TI Distinct copy number alteration patterns as prognostic of endometrial
cancer outcomes
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Bergen, Haukeland Univ Hosp, Bergen, Norway.
Broad Inst, Cambridge, MA USA.
RI salvesen, Helga/C-1187-2017
OI salvesen, Helga/0000-0002-4438-8831
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5511
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602025
ER
PT J
AU Pereira, GA
Rodriguez-Galindo, C
Frazier, AL
Boffetta, P
Ribeiro, KB
AF Pereira, Guilherme Abreu
Rodriguez-Galindo, Carlos
Frazier, A. Lindsay
Boffetta, Paolo
Ribeiro, Karina Braga
TI Birth and maternal characteristics, and childhood cancer in the United
States: An ecological study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Icahn Sch Med Mt Sinai, New York, NY USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Int Prevent Res Inst, Lyon, France.
Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10061
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600220
ER
PT J
AU Silva, RAP
Pace-Emerson, TP
Rodriguez-Galindo, C
Frazier, AL
Ribeiro, KB
AF Peres Silva, Raquel Ataide
Pace-Emerson, Tamara P.
Rodriguez-Galindo, Carlos
Lindsay Frazier, A.
Ribeiro, Karina Braga
TI Socioeconomic status and incidence of pediatric embryonal tumors in the
United States
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Fac Ciencias Med Santa Casa Sao Paulo, Sao Paulo, Brazil.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Childrens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10036
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600192
ER
PT J
AU Perez, AT
Rugo, HS
Baselga, J
Hart, L
Pritchard, KI
Arena, FP
Eakle, JF
Geberth, M
Hortobagyi, GN
Csoszi, T
Gnant, M
Chouinard, EE
Noguchi, S
Srimuninnimit, V
Puttawibul, P
Heng, DYC
Panneerselvam, A
Taran, T
Sahmoud, T
Burris, HA
AF Perez, Alejandra T.
Rugo, Hope S.
Baselga, Jose
Hart, Lowell
Pritchard, Kathleen I.
Arena, Francis P.
Eakle, J. F.
Geberth, M.
Hortobagyi, Gabriel N.
Csoszi, Tibor
Gnant, Michael
Chouinard, Edmond Emilien
Noguchi, Shinzaburo
Srimuninnimit, Vichien
Puttawibul, Puttisak
Heng, Daniel Yick Chin
Panneerselvam, Ashok
Taran, Tanya
Sahmoud, Tarek
Burris, Howard A.
TI Clinical management and resolution of stomatitis in BOLERO-2.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Canc Inst, Hollywood, FL USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Florida Canc Specialists, Ft Myers, FL USA.
Sunnybrook Hlth Sci Ctr, Odette Canc Ctr, Toronto, ON M4N 3M5, Canada.
Univ Toronto, Toronto, ON, Canada.
Arena Oncol Associates, Lake Success, NY USA.
SPGO Mannheim, Mannheim, Germany.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Jasz Nagykun Szolnok Megyei Hetenyi Geza Korhaz R, Szolnok, Hungary.
Med Univ Vienna, Dept Surg, Ctr Comprehens Canc, Vienna, Austria.
Cambridge Mem Hosp, Cambridge, ON, Canada.
Osaka Univ, Osaka, Japan.
Mahidol Univ, Fac Med, Siriraj Hosp, Bangkok 10700, Thailand.
Prince Songkla Univ, Fac Med, Dept Surg, Hat Yai, Thailand.
Tom Baker Canc Clin, Calgary, AB, Canada.
Novartis Pharmaceut, Florham Pk, NJ USA.
Novartis Pharmaceut, Global Oncol Dev, Florham Pk, NJ USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 558
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600063
ER
PT J
AU Petrylak, DP
Kantoff, PW
Mega, AE
Vogelzang, NJ
Stephenson, J
Fleming, MT
Stambler, N
Petrini, M
Blattman, S
Israel, RJ
AF Petrylak, Daniel Peter
Kantoff, Philip W.
Mega, Anthony E.
Vogelzang, Nicholas J.
Stephenson, Joe
Fleming, Mark T.
Stambler, Nancy
Petrini, Michaela
Blattman, Sara
Israel, Robert Joseph
TI Prostate-specific membrane antigen antibody drug conjugate (PSMA ADC): A
phase I trial in metastatic castration-resistant prostate cancer (mCRPC)
previously treated with a taxane
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Yale Univ, Med Ctr, New Haven, CT USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brown Univ, Oncol Grp, Providence, RI 02912 USA.
US Oncol Network, Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Canc Ctr Carolina, Greenville, SC USA.
Virginia Oncol Associates, Norfolk, VA USA.
Progen Pharmaceut Inc, Tarrytown, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5018
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601619
ER
PT J
AU Phan, AT
Wolin, EM
Chan, JA
Huang, JM
Hudson, M
Hughes, G
Shen, GX
Strosberg, JR
AF Phan, Alexandria T.
Wolin, Edward M.
Chan, Jennifer A.
Huang, Jerry M.
Hudson, Michelle
Hughes, Gareth
Shen, Guoxiang
Strosberg, Jonathan R.
TI Phase I dose-escalation study of pasireotide LAR in patients with
advanced neuroendocrine tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Novartis Pharmaceut, Florham Pk, NJ USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e15126
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604008
ER
PT J
AU Phillips, JG
Aizer, AA
Chen, MH
Hirsch, MS
Richie, JP
Tempany, CM
Hegde, J
Loffredo, M
D'Amico, AV
AF Phillips, John G.
Aizer, Ayal A.
Chen, Ming-Hui
Hirsch, Michelle S.
Richie, Jerome P.
Tempany, Clare M.
Hegde, John
Loffredo, Marian
D'Amico, Anthony Victor
TI Detecting lower in addition to the highest Gleason score prostate cancer
on core biopsy and the odds of upgrading at radical prostatectomy.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Radiat Oncol Program, Boston, MA USA.
Massachusetts Gen Hosp, Brigham & Womens Hosp, Boston, MA 02114 USA.
Univ Connecticut, Storrs, CT USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA e16026
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419604218
ER
PT J
AU Planchard, D
Mazieres, J
Riely, GJ
Rudin, CM
Barlesi, F
Quoix, EA
Souquet, PJ
Socinski, MA
Switzky, J
Ma, B
Goodman, VL
Carson, SW
Curtis, CM
Streit, MRW
Johnson, BE
AF Planchard, David
Mazieres, Julien
Riely, Gregory J.
Rudin, Charles M.
Barlesi, Fabrice
Quoix, Elisabeth A.
Souquet, Pierre Jean
Socinski, Mark A.
Switzky, Julie
Ma, Bo
Goodman, Vicki L.
Carson, Stanley W.
Curtis, C. Martin
Streit, Michael R. W.
Johnson, Bruce E.
TI Interim results of phase II study BRF113928 of dabrafenib in BRAF V600E
mutation-positive non-small cell lung cancer (NSCLC) patients.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Gustave Roussy, Dept Med Oncol, Villejuif, France.
CHU Toulouse, Hop Larrey, Toulouse, France.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Aix Marseille Univ, Hop Nord, Assistance Publ Hop Marseille, Marseille, France.
Hop Univ Strasbourg, Strasbourg, France.
Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
Univ Pittsburgh, Pittsburgh, PA USA.
GlaxoSmithKline, Collegeville, PA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
RI MAZIERES, JULIEN/M-3986-2014
NR 0
TC 13
Z9 14
U1 3
U2 9
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8009
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602491
ER
PT J
AU Polite, BN
Allred, JB
Rugo, HS
Cipriano, TM
Cirrincione, C
Gehlert, SJ
Paskett, ED
Hudis, C
Winer, EP
AF Polite, Blase N.
Allred, Jacob B.
Rugo, Hope S.
Cipriano, Toni Marie
Cirrincione, Constance
Gehlert, Sarah J.
Paskett, Electra D.
Hudis, Clifford
Winer, Eric P.
TI Differences in psychosocial factors among diverse women enrolled in a
phase III cooperative group metastatic breast cancer trial (CALGB
40502/Alliance).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Chicago, Chicago, IL 60637 USA.
Mayo Clin, Rochester, MN USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Duke Univ, Alliance Stat Ctr, Durham, NC USA.
Washington Univ, Brown Sch, St Louis, MO USA.
Ohio State Univ, Ctr Comprehens Canc, Arthur G James Canc Hosp, Columbus, OH 43210 USA.
Ohio State Univ, Ctr Comprehens Canc, Richard J Solove Res Inst, Columbus, OH 43210 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9581
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603064
ER
PT J
AU Pond, GR
Bellmunt, J
Fougeray, R
Choueiri, TK
Qu, AQ
Salhi, Y
Niegisch, G
Albers, P
Di Lorenzo, G
Galsky, MD
Necchi, A
Sonpavde, G
AF Pond, Gregory Russell
Bellmunt, Joaquim
Fougeray, Ronan
Choueiri, Toni K.
Qu, Angela Q.
Salhi, Yacine
Niegisch, Guenter
Albers, Peter
Di Lorenzo, Giuseppe
Galsky, Matt D.
Necchi, Andrea
Sonpavde, Guru
TI Impact of response to prior chemotherapy (RTPC) on outcomes in
second-line therapy for advanced urothelial carcinoma (UC): Implications
for trial design.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 McMaster Univ, Hamilton, ON, Canada.
Univ Hosp Mar, Barcelona, Spain.
Inst Rech Pierre Fabre, Boulogne, France.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Dusseldorf, Dept Urol, Dusseldorf, Germany.
Univ Dusseldorf, Dusseldorf, Germany.
Univ Naples Federico II, Dept Clin Oncol, Naples, Italy.
Univ Naples Federico II, Endocrinol & Rare Tumors Reference Ctr Campania R, Naples, Italy.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Fdn IRCCS Ist Nazl Tumori, Milan, Italy.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4539
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601553
ER
PT J
AU Powderly, JD
Koeppen, H
Hodi, FS
Sosman, JA
Gettinger, SN
Desai, R
Tabernero, J
Soria, JC
Hamid, O
Fine, GD
Xiao, YY
Mokatrin, A
Wu, J
Anderson, M
Irving, BA
Chen, DS
Kowanetz, M
AF Powderly, John D.
Koeppen, Hartmut
Hodi, F. Stephen
Sosman, Jeffrey Alan
Gettinger, Scott N.
Desai, Rupal
Tabernero, Josep
Soria, Jean-Charles
Hamid, Omid
Fine, Gregg Daniel
Xiao, Yuanyuan
Mokatrin, Ahmad
Wu, Jenny
Anderson, Maria
Irving, Bryan A.
Chen, Daniel S.
Kowanetz, Marcin
TI Biomarkers and associations with the clinical activity of PD-L1 blockade
in a MPDL3280A study.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Carolina BioOncol Inst, Huntersville, NC USA.
Genentech Inc, San Francisco, CA 94080 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
Yale Univ, Sch Med, New Haven, CT USA.
Vall dHebron Univ Hosp, Barcelona, Spain.
Inst Gustave Roussy, Villejuif, France.
Angeles Clin & Res Inst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3001
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601134
ER
PT J
AU Psyrri, A
Lee, JW
Vasilakopoulou, M
Pectasides, E
Burtness, B
Rimm, D
Wanebo, HJ
Forastiere, AA
AF Psyrri, Amanda
Lee, Ju-Whei
Vasilakopoulou, Maria
Pectasides, Eirini
Burtness, Barbara
Rimm, David
Wanebo, Harold J.
Forastiere, Arlene A.
TI Predictive biomarkers in a phase II trial of weekly carboplatin (CBDCA),
paclitaxel (P), and cetuximab (C) induction and chemoradiation (CRT) in
patients (pts) with resectable stage III/IVa,b head and neck squamous
cell carcinoma (HNSCC): Eastern Cooperative Oncology Group E2303.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Athens, Athens, Greece.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Yale Univ, New Haven, CT USA.
Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
Yale Univ, Sch Med, Dept Pathol, New Haven, CT 06510 USA.
Landmark Med Ctr, Woonsocket, RI USA.
Eviti Inc, Philadelphia, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6081
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602204
ER
PT J
AU Pugliano, L
Zardavas, D
Paesmans, M
Sestak, I
Gelber, RD
Cuzick, JM
Dowsett, M
Awada, A
Piccart-Gebhart, MJ
De Azambuja, E
AF Pugliano, Lina
Zardavas, Dimitrios
Paesmans, Marianne
Sestak, Ivana
Gelber, Richard D.
Cuzick, Jack M.
Dowsett, Mitchell
Awada, Ahmad
Piccart-Gebhart, Martine J.
De Azambuja, Evandro
TI A meta-analysis of endocrine therapy trials in early breast cancer (BC)
evaluating the impact of obesity: Are aromatase inhibitors (AIs) optimal
therapy in obese ER plus BC?
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Inst Jules Bordet, Breast Int Grp, B-1000 Brussels, Belgium.
Univ Libre Brussels, Inst Jules Bordet, Brussels, Belgium.
Univ London, London, England.
Dana Farber Canc Inst, Dept Biostat & Computat Biol, IBCSG, Frontier Sci & Technol Res Fdn, Boston, MA 02115 USA.
Wolfson Inst Prevent Med, Ctr Canc Prevent, London, England.
Royal Marsden Hosp NHS Fdn Trust, London, England.
Inst Jules Bordet, Med Oncol Clin, B-1000 Brussels, Belgium.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 575
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600080
ER
PT J
AU Qu, AQ
Jacobus, SJ
Signoretti, S
Stack, EC
Krajewski, KM
Rosenberg, JE
Choueiri, TK
AF Qu, Angela Q.
Jacobus, Susanna J.
Signoretti, Sabina
Stack, Edward C.
Krajewski, Katherine Maragaret
Rosenberg, Jonathan E.
Choueiri, Toni K.
TI Phase II study of neoadjuvant dose-dense methotrexate, vinblastine,
doxorubicin, and cisplatin (ddMVAC) chemotherapy in patients with
muscle-invasive urothelial cancer (MI-UC): Pathologic and radiologic
response, serum tumor markers, and DNA excision repair pathway
biomarkers in relation to disease-free survival (DFS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4530
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601544
ER
PT J
AU Rabinowits, G
Flores, L
O'Neill, AM
Stevenson, K
Ghobrial, IM
Vergara, V
Jo, VY
Verselis, SJ
Chau, NG
Lorch, JH
Haddad, RI
AF Rabinowits, Guilherme
Flores, Ludmila
O'Neill, Anne M.
Stevenson, Kristen
Ghobrial, Irene M.
Vergara, Victoria
Jo, Vickie Y.
Verselis, Sigitas Jonas
Chau, Nicole Grace
Lorch, Jochen H.
Haddad, Robert I.
TI miRNA analysis between malignant and benign tissue and circulating
exosomes (CE) in patients (pts) with tongue squamous cell carcinoma.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6088
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602211
ER
PT J
AU Raje, NS
Willenbacher, W
Hungria, V
Spencer, A
Alexeeva, Y
Facon, T
Stewart, AK
Roodman, D
Terpos, E
Feng, A
Braun, A
Balakumaran, A
AF Raje, Noopur S.
Willenbacher, Wolfgang
Hungria, Vania
Spencer, Andrew
Alexeeva, Yulia
Facon, Thierry
Stewart, A. Keith
Roodman, David
Terpos, Evangelos
Feng, Amy
Braun, Ada
Balakumaran, Arun
TI Evaluating results from the multiple myeloma subset of patients treated
with denosumab or zoledronic acid (ZA) in a randomized phase III study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA USA.
Med Univ Innsbruck, A-6020 Innsbruck, Austria.
Irmandade Santa Casa Misericordia Sao Paulo, Sao Paulo, Brazil.
Alfred Hosp, Melbourne, Vic, Australia.
City Hosp 31, St Petersburg, Russia.
Hop Claude Huriez, Lille, France.
Mayo Clin, Scottsdale, AZ USA.
Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
Univ Athens, Sch Med, Alexandra Gen Hosp, GR-11527 Athens, Greece.
Amgen Inc, Thousand Oaks, CA 91320 USA.
RI FACON, THIERRY/M-9736-2014
OI FACON, THIERRY/0000-0001-7705-8460
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8589
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602684
ER
PT J
AU Rathkopf, DE
Smith, MR
De Bono, JS
Logothetis, C
Shore, N
De Souza, PL
Fizazi, K
Mulders, P
Mainwaring, PN
Hainsworth, JD
Beer, TM
North, SA
Fradet, Y
Griffin, TW
Park, YC
Kheoh, TS
Small, EJ
Scher, HI
Molina, A
Ryan, CJ
AF Rathkopf, Dana E.
Smith, Matthew R.
De Bono, Johann Sebastian
Logothetis, Christopher
Shore, Neal
De Souza, Paul L.
Fizazi, Karim
Mulders, Peter
Mainwaring, Paul N.
Hainsworth, John D.
Beer, Tomasz M.
North, Scott A.
Fradet, Yves
Griffin, Thomas W.
Park, Youn Choi
Kheoh, Thian San
Small, Eric Jay
Scher, Howard I.
Molina, Arturo
Ryan, Charles J.
TI Long-term safety and efficacy analysis of abiraterone acetate (AA) plus
prednisone (P) in metastatic castration-resistant prostate cancer
(mCRPC) without prior chemotherapy (COU-AA-302)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Carolina Urol Res Ctr, Myrtle Beach, SC USA.
Univ Western Sydney, Sch Med, Ingham Inst, Liverpool, Australia.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands.
Haematol Clin Australia, Brisbane, Qld, Australia.
Oncol Clin Australia, Brisbane, Qld, Australia.
Sarah Cannon Res Inst, Nashville, TN USA.
Oregon Hlth & Sci Univ, Knight Canc Inst, Portland, OR 97201 USA.
Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
Univ Laval, Quebec City, PQ, Canada.
Janssen Res & Dev LLC, Los Angeles, CA USA.
Janssen Res & Dev LLC, Raritan, NJ USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
RI Mulders, Peter/H-8076-2014
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5009
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601610
ER
PT J
AU Rauh-Hain, JA
del Carmen, MG
Schorge, JO
Boruta, DM
Growdon, WB
Goodman, A
Clark, RM
Bradford, LS
Clemmer, J
AF Rauh-Hain, Jose Alejandro
del Carmen, Marcela G.
Schorge, John O.
Boruta, David M.
Growdon, Whitfield Board
Goodman, Annekathryn
Clark, Rachel Marie
Bradford, Leslie Siriya
Clemmer, Joel
TI Racial disparities in cervical cancer mortality over time
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 [Rauh-Hain, Jose Alejandro; del Carmen, Marcela G.; Schorge, John O.; Boruta, David M.; Growdon, Whitfield Board; Goodman, Annekathryn; Clark, Rachel Marie; Bradford, Leslie Siriya; Clemmer, Joel] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5604
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602117
ER
PT J
AU Recklitis, CJ
Zhou, E
Zwemer, E
Hu, JC
Kantoff, PW
AF Recklitis, Christopher J.
Zhou, Eric
Zwemer, Eric
Hu, Jim C.
Kantoff, Philip W.
TI Prevalence and predictors of suicidal ideation in long-term prostate
cancer survivors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Boston Childrens Hosp, Boston Med Ctr, Boston, MA USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9529
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603012
ER
PT J
AU Reynolds, KL
Bhatia, A
Cheng, XX
Smith, BL
Specht, MC
Moy, B
Bardia, A
AF Reynolds, Kerry Lynn
Bhatia, Ashmeet
Cheng, XingXing
Smith, Barbara Lynn
Specht, Michelle Connolly
Moy, Beverly
Bardia, Aditya
TI Impact of single and dual neoadjuvant HER2-directed therapy on clinical
outcomes among patients with HER2-positive breast cancer (BC)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
North Shore Med Ctr, Salem, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 647
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600152
ER
PT J
AU Ribas, A
Robert, C
Daud, A
Hodi, FS
Wolchok, JD
Kefford, R
Patnaik, A
Hwu, WJ
Weber, JS
Joshua, A
Hersey, P
Gangadhar, TC
Joseph, RW
Dronca, RS
Zarour, HM
Ebbinghaus, S
Gergich, K
Li, XY
Kang, SP
Hamid, O
AF Ribas, Antoni
Robert, Caroline
Daud, Adil
Hodi, F. Stephen
Wolchok, Jedd D.
Kefford, Richard
Patnaik, Amita
Hwu, Wen-Jen
Weber, Jeffrey S.
Joshua, Anthony
Hersey, Peter
Gangadhar, Tara C.
Joseph, Richard Wayne
Dronca, Roxana Stefania
Zarour, Hassane M.
Ebbinghaus, Scot
Gergich, Kevin
Li, Xiaoyun (Nicole)
Kang, Soonmo Peter
Hamid, Omid
TI Clinical efficacy and safety of lambrolizumab (MK-3475, Anti-PD-1
monoclonal antibody) in patients with advanced melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif Los Angeles, Los Angeles, CA USA.
Inst Gustave Roussy, Villejuif, France.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Sydney, Westmead Hosp, Sydney, NSW 2006, Australia.
Univ Sydney, Melanoma Inst Australia, Sydney, NSW 2006, Australia.
START Ctr Canc Care, San Antonio, TX USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
H Lee Moffitt Canc Ctr & Res Inst, Comprehens Melanoma Res Ctr, Tampa, FL USA.
Princess Margaret Canc Ctr, Toronto, ON, Canada.
Calvary Mater Newcastle, Waratah, NSW, Australia.
Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
Mayo Clin, Ctr Canc, Jacksonville, FL 32224 USA.
Mayo Clin, Dept Med Oncol, Rochester, MN USA.
Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA.
Merck & Co Inc, N Wales, PA USA.
Merck & Co Inc, Rahway, NJ 07065 USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9009
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602710
ER
PT J
AU Richardson, PGG
Hofmeister, CC
Siegel, DSD
Lonial, S
Laubach, J
Efebera, YA
Vesole, DH
Nooka, AK
Rosenblatt, J
Raje, NS
Zaki, MH
Hua, Y
Shah, S
Wang, JM
Anderson, KC
AF Richardson, Paul Gerard Guy
Hofmeister, Craig C.
Siegel, David Samuel DiCapua
Lonial, Sagar
Laubach, Jacob
Efebera, Yvonne Adeduni
Vesole, David H.
Nooka, Ajay K.
Rosenblatt, Jacalyn
Raje, Noopur S.
Zaki, Mohamed H.
Hua, Ye
Shah, Sheetal
Wang, Jianming
Anderson, Kenneth Carl
TI MM-005: A phase I trial of pomalidomide, bortezomib, and low-dose
dexamethasone (PVD) in relapsed and/or refractory multiple myeloma
(RRMM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Ohio State Univ, Dept Internal Med, Div Hematol, Columbus, OH 43210 USA.
Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Hackensack, NJ USA.
Emory Univ, Sch Med, Atlanta, GA USA.
Harvard Univ, Sch Med, Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Boston, MA 02115 USA.
Emory Univ, Div BMT, Winship Canc Inst, Atlanta, GA 30322 USA.
Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Boston, MA 02215 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Celgene Corp, Summit, NJ USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 8584
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602679
ER
PT J
AU Rider, JR
Wilson, KM
Kantoff, PW
Giovannucci, EL
Mucci, LA
AF Rider, Jennifer R.
Wilson, Kathryn M.
Kantoff, Philip W.
Giovannucci, Edward L.
Mucci, Lorelei A.
TI Ejaculation frequency and prostate cancer: A large, prospective study
with 16 years of follow-up
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Harvard Univ, Sch Med, Sch Publ Hlth, Boston, MA USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 6
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5078
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602001
ER
PT J
AU Riedemann, L
Snuderl, M
Batista, A
Kirkpatrick, ND
de Almodovar, CR
Hasselblatt, M
Rossig, C
Duda, GD
Xu, L
Fukumura, D
Carmeliet, P
Jain, RK
AF Riedemann, Lars
Snuderl, Matija
Batista, Ana
Kirkpatrick, Nathaniel David
de Almodovar, Carmen Ruiz
Hasselblatt, Martin
Rossig, Claudia
Duda, Gabriel Dan
Xu, Lei
Fukumura, Dai
Carmeliet, Peter
Jain, Rakesh K.
TI Neuropilin-1 (Nrp-1) as a prognostic biomarker and potential drug target
for pediatric medulloblastoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Katholieke Univ Leuven, Louvain, Belgium.
Univ Hosp Munster, Munster, Germany.
RI Riedemann, Lars/J-5725-2014
OI Riedemann, Lars/0000-0002-9510-1845
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 2056
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600717
ER
PT J
AU Rieder, RJ
Zhao, ZH
Chalmers, A
Stone, RM
Galinski, I
AF Rieder, Ronald J.
Zhao, Zhihui
Chalmers, Alex
Stone, Richard M.
Galinski, Ilene
TI Rapid identification of drug-resistant BCR-ABL(+) leukemia
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 BioSense Technol Inc, Woburn, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 7050
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602408
ER
PT J
AU Rizvi, NA
Infante, JR
Gibney, GT
Begin, EM
Cooley, SA
Lekatis, K
Wigginton, JM
Gutierrez, AA
Gupta, AK
Kim, SY
Hodi, FS
AF Rizvi, Naiyer A.
Infante, Jeffrey R.
Gibney, Geoffrey Thomas
Begin, Erin Marie
Cooley, Sarah A.
Lekatis, Kiki
Wigginton, Jon M.
Gutierrez, Andres A.
Gupta, Ashok Kumar
Kim, Su Young
Hodi, F. Stephen
TI A phase I study of lirilumab (BMS-986015), an anti-KIR monoclonal
antibody, administered in combination with ipilimumab, an anti-CTLA4
monoclonal antibody, in patients (Pts) with select advanced solid
tumors.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
SCRI Tennessee Oncol PLLC, Nashville, TN USA.
H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
Ohio State Univ, Wexner Med Ctr, Columbus, OH 43210 USA.
Univ Minnesota, Minneapolis, MN USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 4
U2 4
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3106
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605400
ER
PT J
AU Robison, K
Stuckey, A
Dizon, DS
Rogers, M
Ott, M
Miller, S
Politi, MC
Clark, M
AF Robison, Katina
Stuckey, Ashley
Dizon, Don S.
Rogers, Michelle
Ott, Miles
Miller, Susan
Politi, Mary C.
Clark, Melissa
TI Effect of female-dominant support networks on end-of-life decision
making among women with advanced or recurrent cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Women & Infants Hosp Rhode Isl, Providence, RI 02908 USA.
Massachusetts Gen Hosp, Dana Farber Harvard Canc Ctr, Boston, MA 02114 USA.
Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
Publ Hlth Program, Providence, RI USA.
Washington Univ, St Louis, MO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6590
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602306
ER
PT J
AU Rollins, BJ
MacConaill, LE
Wagle, N
Garcia, E
Kuo, FC
Longtine, JA
Garber, JE
Janeway, KA
Fuchs, CS
Bertagnolli, MM
Soiffer, R
Matulonis, U
Lin, NU
Hahn, WC
Garraway, LA
Kantoff, PW
Lindeman, NI
AF Rollins, Barrett J.
MacConaill, Laura E.
Wagle, Nikhil
Garcia, Elizabeth
Kuo, Frank C.
Longtine, Janina A.
Garber, Judy Ellen
Janeway, Katherine A.
Fuchs, Charles S.
Bertagnolli, Monica M.
Soiffer, Robert
Matulonis, Ursula
Lin, Nancy U.
Hahn, William C.
Garraway, Levi A.
Kantoff, Philip W.
Lindeman, Neal Ian
TI PROFILE: Broadly based genomic testing for all patients at a major
cancer center.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Mt Sinai Med Cener, New York, NY USA.
Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 1531
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600590
ER
PT J
AU Rosenberg, AR
Bradford, M
Shaffer, M
Wolfe, J
Baker, KS
AF Rosenberg, Abby R.
Bradford, Miranda
Shaffer, Michele
Wolfe, Joanne
Baker, Kevin Scott
TI Psychosocial outcomes among bereaved and non-bereaved parents of
children with cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Washington, Dept Pediat, Seattle Childrens Hosp, Seattle, WA 98195 USA.
Seattle Childrens Hosp, Seattle, WA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9526
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419603009
ER
PT J
AU Rosenberg, JE
Hahn, NM
Regan, MA
Jacobs, C
Stewart, PS
Choueiri, TK
AF Rosenberg, Jonathan E.
Hahn, Noah M.
Regan, Meredith A.
Jacobs, Cindy
Stewart, Patricia S.
Choueiri, Toni K.
TI The Borealis-2 clinical trial: A randomized phase II study of OGX-427
plus docetaxel versus docetaxel alone in relapsed/refractory metastatic
urothelial cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Indiana Univ Melvin & Bren Simon Canc Ctr, Indianapolis, IN USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
OncoGenex Pharmaceut Inc, Bothell, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS4588
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605448
ER
PT J
AU Rosenberg, SM
Sepucha, K
Ruddy, KJ
Tamimi, RM
Gelber, SI
Meyer, ME
Schapira, L
Come, SE
Borges, VF
Winer, EP
Partridge, AH
AF Rosenberg, Shoshana M.
Sepucha, Karen
Ruddy, Kathryn Jean
Tamimi, Rulla M.
Gelber, Shari I.
Meyer, Meghan E.
Schapira, Lidia
Come, Steven E.
Borges, Virginia F.
Winer, Eric P.
Partridge, Ann H.
TI Choosing mastectomy over lumpectomy: Factors associated with surgical
decisions in young women with breast cancer
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Brigham & Womens Hosp, Boston, MA 02115 USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Univ Colorado Denver, Aurora, CO USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6507
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602227
ER
PT J
AU Rosenthal, AN
Fraser, L
Philpott, S
Manchanda, R
Badman, P
Hadwin, R
Evans, DG
Eccles, D
Skates, SJ
Mackay, J
Menon, U
Jacobs, I
AF Rosenthal, Adam N.
Fraser, Lindsay
Philpott, Susan
Manchanda, Ranjit
Badman, Philip
Hadwin, Richard
Evans, D. Gareth
Eccles, Diana
Skates, Steven James
Mackay, James
Menon, Usha
Jacobs, Ian
TI Final results of 4-monthly screening in the UK Familial Ovarian Cancer
Screening Study (UKFOCSS Phase 2)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Barts Canc Inst, London, England.
UCL EGA Inst Womens Hlth, Dept Womens Canc, London, England.
St Marys Hosp, Manchester M13 0JH, Lancs, England.
Southampton Gen Hosp, Southampton SO9 4XY, Hants, England.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
UCL, London, England.
Univ Manchester, Fac Med & Human Sci, Manchester, Lancs, England.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5507
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602021
ER
PT J
AU Rothenberg, SM
McFadden, DG
Palmer, E
Daniels, GH
Wirth, LJ
AF Rothenberg, Stephen M.
McFadden, David G.
Palmer, Edwin
Daniels, Gilbert H.
Wirth, Lori J.
TI Re-differentiation of radioiodine-refractory BRAF V600E-mutant thyroid
carcinoma with dabrafenib: A pilot study
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Massachusetts Gen Hosp, Thyroid Unit, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 6025
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602149
ER
PT J
AU Ruddy, KJ
O'Neill, AM
Miller, K
Schneider, BP
Baker, E
Sparano, JA
Dang, CT
Northfelt, DW
Sledge, GW
AF Ruddy, Kathryn Jean
O'Neill, Anne M.
Miller, Kathy
Schneider, Bryan P.
Baker, Emily
Sparano, Joseph A.
Dang, Chau T.
Northfelt, Donald W.
Sledge, George W.
TI Biomarker prediction of chemotherapy-related amenorrhea.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Dana Farber Canc Inst, Boston, MA 02115 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Montefiore Med Ctr, Bronx, NY 10467 USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Mayo Clin, Scottsdale, AZ USA.
Stanford Univ, Stanford, CA 94305 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9508
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602812
ER
PT J
AU Ryan, CJ
Londhe, A
Molina, A
Smith, MR
De Bono, JS
Mulders, P
Rathkopf, DE
Saad, F
Logothetis, C
Fizazi, K
Scher, HI
Small, EJ
Matheny, S
Kheoh, TS
Griffin, TW
AF Ryan, Charles J.
Londhe, Anil
Molina, Arturo
Smith, Matthew R.
De Bono, Johann Sebastian
Mulders, Peter
Rathkopf, Dana E.
Saad, Fred
Logothetis, Christopher
Fizazi, Karim
Scher, Howard I.
Small, Eric Jay
Matheny, Shannon
Kheoh, Thian San
Griffin, Thomas W.
TI Relationship of baseline PSA and degree of PSA decline to radiographic
progression-free survival (rPFS) in patients with chemotherapy-naive
metastatic castration-resistant prostate cancer (mCRPC): Results from
COU-AA-302
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
Janssen Res & Dev LLC, Raritan, NJ USA.
Janssen Res & Dev LLC, Los Angeles, CA USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
Radboud Univ Nijmegen Med Ctr, Nijmegen, Netherlands.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Montreal, Montreal, PQ, Canada.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Paris 11, Inst Gustave Roussy, Villejuif, France.
RI Mulders, Peter/H-8076-2014
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5010
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601611
ER
PT J
AU Saad, F
Fizazi, K
Smith, MR
Griffin, TW
Londhe, A
Rathkopf, DE
Molina, A
Ryan, CJ
AF Saad, Fred
Fizazi, Karim
Smith, Matthew R.
Griffin, Thomas W.
Londhe, Anil
Rathkopf, Dana E.
Molina, Arturo
Ryan, Charles J.
TI Impact of concomitant bone-targeted therapies (BTT) on outcomes in
metastatic castration-resistant prostate cancer (mCRPC) patients (pts)
without prior chemotherapy (ctx) treated with abiraterone acetate (AA)
or prednisone (P).
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Montreal, Montreal, PQ, Canada.
Univ Paris Sud, Inst Gustave Roussy, Villejuif, France.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Janssen Res & Dev LLC, Los Angeles, CA USA.
Janssen Res & Dev LLC, Raritan, NJ USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5037
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601635
ER
PT J
AU Sachdev, P
Hamid, O
Kim, K
Hauschild, A
O'Day, S
Andresen, C
Funahashi, Y
Kadowaki, T
O'Brien, JP
Flaherty, K
AF Sachdev, Pallavi
Hamid, Omid
Kim, Kevin
Hauschild, Axel
O'Day, Steven
Andresen, Corina
Funahashi, Yasuhiro
Kadowaki, Tadashi
O'Brien, James P.
Flaherty, Keith
TI Analysis of serum biomarkers and tumor genetic alterations from a phase
II study of lenvatinib in patients with advanced BRAF wild-type melanoma
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Eisai Inc, Woodcliff Lake, NJ USA.
Angeles Clin & Res Inst, Los Angeles, CA USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
Univ Klinikum Schleswig Holstein, Kiel, Germany.
Beverly Hills Canc Ctr, Beverly Hills, CA USA.
Eisai Inc, Andover, MA USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9058
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602759
ER
PT J
AU Saenger, YM
Magidson, J
Liaw, BCH
Wassmann, K
Barker, W
Harcharik, S
Fisher, D
Oh, WK
Friedlander, P
AF Saenger, Yvonne M.
Magidson, Jay
Liaw, Bobby Chi-Hung
Wassmann, Karl
Barker, William
Harcharik, Sara
Fisher, David
Oh, William K.
Friedlander, Philip
TI Blood mRNA signature to predict survival in patients with metastatic
melanoma treated with tremelimumab
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mt Sinai Sch Med, New York, NY USA.
Stat Innovat Inc, Belmont, MA USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
GeneNews, Boston, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Icahn Sch Med Mt Sinai, Tisch Canc Inst, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9080
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602781
ER
PT J
AU Saha, S
Shaik, M
Saha, SK
Korant, AK
Johnston, G
Dhar, VK
Wiese, D
Singh, T
Arora, ML
Stewart, A
AF Saha, Sukamal
Shaik, Mohammed
Saha, Supriya Kumar
Korant, Alpesh K.
Johnston, Gregory
Dhar, Vikrom K.
Wiese, David
Singh, Trevor
Arora, Madan L.
Stewart, Andrew
TI Use of tumor size to predict long-term survival in colon cancer
patients: Analysis of National Cancer Data Base (NCDB)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Michigan State Univ, McLaren Reg Med Ctr, Flint, MI USA.
Michigan State Univ, Hurley Med Ctr, Flint, MI USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
McLaren Macomb Med Ctr, Mt Clemens, MI USA.
Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
McLaren Reg Med Ctr, Flint, MI USA.
Michigan State Univ, Flint, MI USA.
Amer Coll Surg, Commiss Canc, Chicago, IL USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3583
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601318
ER
PT J
AU Sanbom, RE
Sharfman, WH
Segal, NH
Hodi, FS
Wolchok, JD
Urba, WJ
Fox, BA
Topalian, SL
Pardoll, DM
Covello, KL
McDonald, D
Kim, SY
Gupta, AK
Wigginton, JM
Gajewski, T
AF Sanbom, Rachel E.
Sharfman, William Howard
Segal, Neil Howard
Hodi, F. Stephen
Wolchok, Jedd D.
Urba, Walter John
Fox, Bernard A.
Topalian, Suzanne Louise
Pardoll, Drew M.
Covello, Kelly L.
McDonald, Dan
Kim, Su Young
Gupta, Ashok Kumar
Wigginton, Jon M.
Gajewski, Thomas
TI A phase I dose-escalation and cohort expansion study of lirilumab
(anti-KIR; BMS-986015) administered in combination with nivolumab
(anti-PD-1; BMS-936558; ONO-4538) in patients (Pts) with advanced
refractory solid tumors
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Earle A Chiles Res Inst, Portland, OR USA.
Providence Canc Ctr, Portland, OR USA.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Bristol Myers Squibb Co, Princeton, NJ USA.
Univ Chicago, Ctr Comprehens Canc, Chicago, IL 60637 USA.
NR 0
TC 3
Z9 3
U1 4
U2 5
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA TPS3110
PG 2
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419605404
ER
PT J
AU Sarantopoulos, J
Dang, LH
Lauer, RC
Starodub, A
Hauke, RJ
Galsky, MD
Bylow, KA
Cowey, CL
Bibby, DC
Kremmidiotis, G
Doolin, EE
Lavranos, TC
Iglesias, JL
Sonpavde, G
Logan, T
Hahn, NM
Sweeney, C
Hutson, TE
AF Sarantopoulos, John
Dang, Long H.
Lauer, Richard C.
Starodub, Alexander
Hauke, Ralph J.
Galsky, Matt D.
Bylow, Kathryn A.
Cowey, Charles Lance
Bibby, David C.
Kremmidiotis, Gabriel
Doolin, Elizabeth E.
Lavranos, Tina C.
Iglesias, Jose Luis
Sonpavde, Guru
Logan, Theodore
Hahn, Noah M.
Sweeney, Christopher
Hutson, Thomas E.
CA Hoosier Oncology Grp
TI A phase I/II trial of BNC105P with everolimus in metastatic renal cell
carcinoma (mRCC) patients: Updated phase I results of the Disruptor-1
trial
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Texas Hlth Sci Ctr San Antonio, Inst Drug Dev, San Antonio, TX 78229 USA.
Univ Florida, Gainesville, FL USA.
Univ New Mexico, Ctr Canc, Albuquerque, NM 87131 USA.
Indiana Univ, Hlth Goshen Ctr Canc Care, Goshen, IN USA.
Nebraska Canc Specialists, Omaha, NE USA.
Mt Sinai Sch Med, Tisch Canc Inst, New York, NY USA.
Med Coll Wisconsin, Milwaukee, WI 53226 USA.
Texas Oncol, Dallas, TX USA.
Bionomics Ltd, Thebarton, Australia.
Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL 35294 USA.
Indiana Univ, Melvin & Bren Simon Canc Ctr, Indianapolis, IN 46204 USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
McKesson Specialty Hlth, Dallas, TX USA.
Texas Oncol Baylor Charles A Sammons Canc Ctr, Dallas, TX USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 4563
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601577
ER
PT J
AU Sargent, DJ
Shi, Q
Gill, S
Louvet, C
Everson, RB
Kellner, U
Clancy, TE
Pipas, JM
Resnick, MB
Meyers, MO
Huntsman, D
Validire, P
Farooq, U
Pavey, ES
Haince, JF
Beaudry, G
Fradet, Y
AF Sargent, Daniel J.
Shi, Qian
Gill, Sharlene
Louvet, Christophe
Everson, Richard Bernard
Kellner, Udo
Clancy, Thomas E.
Pipas, J. Marc
Resnick, Murray B.
Meyers, Michael O.
Huntsman, David
Validire, Pierre
Farooq, Umar
Pavey, Emily S.
Haince, Jean-Francois
Beaudry, Guillaume
Fradet, Yves
TI Guanylyl cyclase C (GCC) expression in lymph nodes (LNs) as a
determinant of recurrence in stage II colon cancer (CC) patients (pts)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mayo Clin, Rochester, MN USA.
British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada.
Inst Mutualiste Montsouris, Dept Oncol, Paris, France.
Univ Connecticut, Ctr Hlth, Farmington, CT USA.
Johannes Wessling Klinikum Minden, Minden, Germany.
Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
Dartmouth Hitchcock Med Ctr, Norris Cotton Canc Ctr, Lebanon, NH 03766 USA.
Brown Univ, Rhode Isl Hosp, Providence, RI 02903 USA.
Univ N Carolina, Sch Med, Div Surg Oncol & Endocrine Surg, Chapel Hill, NC USA.
Inst Mutualiste Montsouris, Dept Pathol, Paris, France.
DiagnoCure Inc, Quebec City, PQ, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 3639
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601374
ER
PT J
AU Schadendorf, D
Flaherty, K
Hersey, P
Nathan, PD
Garbe, C
Milhem, MM
Demidov, LV
Hassel, JC
Rutkowski, P
Mohr, P
Dummer, R
Trefzer, U
Larkin, JMG
Utikal, J
Casey, M
Santiago-Walker, A
Sherman, LJ
Martin, AM
Wu, FS
Robert, C
AF Schadendorf, Dirk
Flaherty, Keith
Hersey, Peter
Nathan, Paul D.
Garbe, Claus
Milhem, Mohammed M.
Demidov, Lev V.
Hassel, Jessica Cecile
Rutkowski, Piotr
Mohr, Peter
Dummer, Reinhard
Trefzer, Uwe
Larkin, James M. G.
Utikal, Jochen
Casey, Michelle
Santiago-Walker, Ademi
Sherman, Laurie Jill
Martin, Anne-Marie
Wu, Frank S.
Robert, Caroline
TI Tumor-specific circulating cell-free DNA (cfDNA) to predict clinical
outcome in BRAF V600 mutation-positive melanoma patients (pts) treated
with the MEK inhibitor trametinib (T) or chemotherapy (C)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Klinikum Essen, Essen, Germany.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
Univ Sydney, Sydney, NSW 2006, Australia.
Mt Vernon Canc Ctr, Northwood, Middx, England.
Univ Med Ctr, Tubingen, Germany.
Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA.
NN Blokhin Russian Canc Res Ctr, Moscow, Russia.
Univ Heidelberg Hosp, Hauttumorzentrum, Univ Hautklin, Heidelberg, Germany.
Maria Sklodowska Curie Mem Canc Ctr & Inst Oncol, Warsaw, Poland.
Elbeklinikum Buxtehude, Buxtehude, Germany.
Univ Zurich Hosp, CH-8091 Zurich, Switzerland.
Charite, Melanoma Ctr, D-13353 Berlin, Germany.
Royal Marsden Hosp NHS Fdn Trust, London, England.
Heidelberg Univ, German Canc Res Ctr DKFZ, Heidelberg, Germany.
Heidelberg Univ, Univ Med Ctr Mannheim, Heidelberg, Germany.
GlaxoSmithKline, Collegeville, PA USA.
Inst Gustave Roussy, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9020
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602721
ER
PT J
AU Scher, HI
Smith, MR
Sweeney, C
Corn, PG
Logothetis, C
Vogelzang, NJ
Smith, DC
Hussain, M
George, DJ
De Bono, JS
Higano, CS
Small, EJ
Goldin, J
Brown, MS
Aftab, DT
Noursalehi, M
Weitzman, A
Basch, EM
AF Scher, Howard I.
Smith, Matthew R.
Sweeney, Christopher
Corn, Paul Gettys
Logothetis, Christopher
Vogelzang, Nicholas J.
Smith, David C.
Hussain, Maha
George, Daniel J.
De Bono, Johann Sebastian
Higano, Celestia S.
Small, Eric Jay
Goldin, Jonathan
Brown, Matthew S.
Aftab, Dana T.
Noursalehi, Mojtaba
Weitzman, Aaron
Basch, Ethan M.
TI An exploratory analysis of bone scan lesion area (BSLA), circulating
tumor cell (CTC) change, pain reduction, and overall survival (OS) in
patients (pts) with castration-resistant prostate cancer (CRPC) treated
with cabozantinib (cabo): Updated results of a phase II nonrandomized
expansion (NRE) cohort.
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
US Oncol Network, Comprehens Canc Ctr Nevada, Las Vegas, NV USA.
Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
Duke Canc Inst, Durham, NC USA.
Royal Marsden NHS Fdn Trust, Inst Canc Res, Sutton, Surrey, England.
Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Univ Calif Los Angeles, Los Angeles, CA USA.
Univ Calif Los Angeles, Ctr Comp Vis & Imaging Biomarkers, Los Angeles, CA USA.
Exelixis Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 5026
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419601626
ER
PT J
AU Schuchter, LM
Kudchadkar, RR
Gonzalez, R
Lawrence, DP
Sosman, JA
Infante, JR
Daud, A
Kefford, R
Cebon, JS
Sharfman, WH
Amaravadi, RK
Boasberg, PD
Lewis, KD
Flaherty, K
Ouellet, D
Little, SM
Clark, J
Gibney, GT
Patel, K
Hamid, O
AF Schuchter, Lynn Mara
Kudchadkar, Ragini Reiney
Gonzalez, Rene
Lawrence, Donald P.
Sosman, Jeffrey Alan
Infante, Jeffrey R.
Daud, Adil
Kefford, Richard
Cebon, Jonathan S.
Sharfman, William Howard
Amaravadi, Ravi K.
Boasberg, Peter D.
Lewis, Karl D.
Flaherty, Keith
Ouellet, Danielle
Little, Shonda M.
Clark, Jennifer
Gibney, Geoffrey Thomas
Patel, Kiran
Hamid, Omid
TI Efficacy, safety, and pharmacokinetics (PK) of the BRAF inhibitor
dabrafenib (D) hydroxypropyl methylcellulose (HPMC) capsule formulation
in combination with the MEK1/2 inhibitor trametinib (T) in patients
(pts) with BRAF mutation-positive metastatic melanoma (MM)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Univ Penn, Philadelphia, PA 19104 USA.
Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
UCHSC, Aurora, CO USA.
Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
Vanderbilt Univ, Med Ctr, Nashville, TN USA.
Sarah Cannon Res Inst, Nashville, TN USA.
Tennessee Oncol, Nashville, TN USA.
Univ Calif San Francisco, San Francisco, CA 94143 USA.
Westmead Hosp, Westmead, NSW 2145, Australia.
Melanoma Inst Australia, Westmead, NSW, Australia.
Austin Hlth, Melbourne, Vic, Australia.
Johns Hopkins Univ, Sidney Kimmel Comprehens Canc Ctr, Baltimore, MD USA.
Angeles Clin & Res Inst, Santa Monica, CA USA.
Univ Colorado, Ctr Canc, Aurora, CO USA.
Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
GlaxoSmithKline, Res Triangle Pk, NC USA.
GlaxoSmithKline, Collegeville, PA USA.
Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 9066
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419602767
ER
PT J
AU Schwartz, CL
Hirway, P
Ader, J
Bradeen, HA
Grewal, SS
Huang, MS
Kadan-Lottick, N
Usmani, N
Kenney, LB
AF Schwartz, Cindy L.
Hirway, Priay
Ader, Jeremy
Bradeen, Heather Appleton
Grewal, Satkiran S.
Huang, Mary S.
Kadan-Lottick, Nina
Usmani, Naheed
Kenney, Lisa Brazzamano
TI Barriers to survivorship care in the Consortium for New England
Childhood Cancer Survivors (CONNECCS)
SO JOURNAL OF CLINICAL ONCOLOGY
LA English
DT Meeting Abstract
CT Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)
CY MAY 31-JUN 04, 2013
CL Chicago, IL
SP Amer Soc Clin Oncol
C1 Brown Univ, Hasbro Childrens Hosp, Providence, RI 02912 USA.
Brown Univ, Sch Publ Hlth, Providence, RI 02912 USA.
Brown Univ, Providence, RI 02912 USA.
Univ Vermont, Burlington, VT USA.
Baystate Med Ctr, Springfield, MA USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Yale Univ, Sch Med, New Haven, CT USA.
Univ Massachusetts, Med Ctr, Worcester, MA USA.
Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC CLINICAL ONCOLOGY
PI ALEXANDRIA
PA 2318 MILL ROAD, STE 800, ALEXANDRIA, VA 22314 USA
SN 0732-183X
EI 1527-7755
J9 J CLIN ONCOL
JI J. Clin. Oncol.
PD MAY 20
PY 2013
VL 31
IS 15
SU S
MA 10035
PG 1
WC Oncology
SC Oncology
GA AG4VY
UT WOS:000335419600191
ER
EF